,rank,nct number,title,acronym,status,study results,conditions,interventions,outcome measures,sponsor/collaborators,gender,age,phases,enrollment,funded bys,study type,study designs,other ids,start date,primary completion date,completion date,first posted,results first posted,last update posted,locations,study documents,url,duration,ftype2,cond1,allocation,interv_mod2,mask1,purp1
0,1,NCT03415399,"Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma",,Completed,No Results Available,"Lymphoma, B-Cell",Biological: ET190L1 ARTEMIS™ T cells,Maximum Tolerated Dose|Toxicity profile of ET190L1 ARTEMIS™ T-cell treatment|Tmax of serum cytokine levels|Time to baseline for serum cytokine levels|AUC of serum cytokine levels|Duration of in vivo engraftment of ET190L1 ARTEMIS™ T cells|Rate of disease response|Anti-tumor responses|B cell depletion,Eureka Therapeutics Inc.|Peking University,All,"18 Years and older   (Adult, Older Adult)",Phase 1,4.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ETCH17CD19AR103,2017-09-09,"December 31, 2020",2020-12-31,"January 30, 2018",,"March 16, 2021","Peking University Cancer Hospital, Beijing, China",,https://ClinicalTrials.gov/show/NCT03415399,1209.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1,2,NCT01334502,"Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma",,Completed,No Results Available,Lymphoma,Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: everolimus|Drug: prednisone|Drug: vincristine sulfate,"MTD of everolimus in combination with R-CHOP|Adverse events profile|Toxicity profile|Proportion of patients who have a significant toxicity|Rate of EFS|Overall response rate, CR rate, overall survival, PFS, and duration of response",Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,26.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCCTG-N1085|CDR0000698584|NCI-2011-02643,2012-03-01,February 2015,2017-08-01,"April 13, 2011",,"August 10, 2017","Mayo Clinic Cancer Center, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01334502,1979.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
2,3,NCT03039114,Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102),,Completed,No Results Available,Lymphoma,Drug: Parsaclisib|Drug: Hexal|Drug: Gazyvaro,"Safety and tolerability of parsaclisib in combination with bendamustine and obinutuzumab in relapsed or refractory FL, assessed by number of subjects with adverse events (AEs)|Objective response rate based on Lugano classification criteria|Complete response rate based on Lugano classification criteria|Duration of response|Progression-free survival|Overall survival",Incyte Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 1,26.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INCB 50465-102 (CITADEL-102)|Parsaclisib,2017-02-15,"March 30, 2021",2021-03-30,"February 1, 2017",,"December 2, 2021","Banner Health, Gilbert, Arizona, United States|University of California, San Diego, La Jolla, California, United States|University of Kansas Cancer Center, Fairway, Kansas, United States|Center for Cancer and Blood Disorders (CCBD) - Bethesda, Bethesda, Maryland, United States|Clinical Research Alliance, Lake Success, New York, United States|Froedtert & Medical College of Wisconsin & Affiliated Hospitals, Milwaukee, Wisconsin, United States|FN Ostrava / Ostrava, Ostrava, Czechia|Aarhus University Hospital, Aarhus, Denmark|Rigshospitalet, Copenhagen, Denmark|The Finsen Centre, National Hospital, Copenhagen, Denmark|Semmelweis Egyetem, Budapest, Hungary|Centro di Riferimento Oncologico, Aviano, Italy|Azienda Ospedaliero Universitaria Di Bologna, Bologna, Italy|Policlinico S. Orsola-Ematologia LA Seragnoli, Bologna, Italy|A.O. Spedali Civili, Brescia, Italy|UO Ematologia ASST Spedali Civili, Brescia, Italy|Hospital Germans Trias Pujol, Barcelona, Spain|Hospital Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain",,https://ClinicalTrials.gov/show/NCT03039114,1504.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
3,4,NCT04103905,A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas,,Completed,No Results Available,CD20-positive B Cell Non-Hodgkin Lymphoma,Drug: Recombinant Humanized Monoclonal Antibody MIL62 Injection,Percentage of Participants Who Experienced a Dose-limiting Toxicity in Dose Escalation Period of the Study|Percentage of Participants With Best Overall Response|Maximum Observed Plasma Concentration (Cmax) Under Steady State of MIL62|Area Under the Plasma Concentration Versus Time Curve (AUC) of MIL62 Under Steady State|Systemic Clearance of MIL62 Under Steady State|Volume of Distribution Under Steady State (Vss) of MIL62|Terminal Plasma Half-Life (t1/2) of MIL62 Under Steady State|Change in Cluster of Differentiation 19 (CD19+) B Cells|Change in Cluster of Differentiation 20 (CD20+) B Cells|Percentage of Participants with Positive Anti-Drug Antibodies to MIL62|Progression-free Survival (PFS) in the Study|Overall Survival (OS) in the Study|Duration of response (DoR)|Disease control rate (DCR)|Participants With Event-Free Survival (EFS),"Beijing Mabworks Biotech Co., Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,27.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MIL62-CT01,2017-02-10,"May 30, 2019",2020-05-29,"September 26, 2019",,"June 16, 2021","Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT04103905,1204.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
4,5,NCT02741388,A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP,SELINDA,Completed,No Results Available,B-cell Lymphoma,Drug: selinexor|Drug: Rituximab|Drug: Dexamethasone|Drug: Oxaliplatin|Drug: Cisplatin|Drug: Cytarabine|Drug: Gemcitabine,"Incidence rate of dose-limiting toxicities (DLTs) observed during the DLT assessment period (cycle 1) at each dose level examined|Response rates|Duration of response|Progression-free survival (PFS)|Time to next anti-lymphoma treatment (TTNLT)|Overall survival (OS)|Incidence of grade ≥ 2 renal toxicities, grade ≥ 2 neuropathy, and grade ≥ 3 toxicities",The Lymphoma Academic Research Organisation|Karyopharm Therapeutics Inc,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,39.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SELINDA,2016-10-01,"September 29, 2021",2021-09-29,"April 18, 2016",,"December 7, 2021","Institut Jules Bordet, Bruxelles, Belgium|CHU Dijon, Dijon, France|CHRU de Lille - Hôpital Claude Huriez, Lille, France|CHU Montpellier - Hôpital Saint Eloi, Montpellier, France|CHU Nancy - Hôpital de Brabois, Nancy, France|Hôpital Saint-Louis, Paris, France|CHU Bordeaux - Centre François Magendie, Pessac, France|Centre Henri Becquerel, Rouen, France",,https://ClinicalTrials.gov/show/NCT02741388,1824.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
5,6,NCT02395601,A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas,,Completed,No Results Available,B-Cell Lymphoma,Drug: CPI-1205,"Frequency of Dose-limiting toxicities (DLTs)|Frequency of adverse events|Pharmacokinetic parameters of CPI-1205: AUC(0-t), AUC(0-inf), AUCtau,ss, Tmax, Cmax, Ctrough, T1/2, Vd/F, CL/F|Pharmacodynamic effects of CPI-1205 in lymphoma tissue: changes in levels of the trimethylated form of lysine residue 27 on histone 3; changes in the expression of genes whose transcription may be altered by EZH2 inhibition|Pharmacodynamic effects of CPI-1205 in bone marrow and in skin: changes in global levels of the trimethylated form of lysine residue 27 on histone 3 (H3K27me3)|Disease response assessment will be performed using the 2014 Lugano Response Criteria for Hodgkin and Non-Hodgkin Lymphoma",Constellation Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 1,41.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1205-01,2015-03-01,December 2018,2018-12-01,"March 23, 2015",,"May 18, 2022","Horizon Oncology Center, Lafayette, Indiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|The Ohio State University James Cancer Hospital, Columbus, Ohio, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02395601,1371.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
6,7,NCT02598570,Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma,,Completed,No Results Available,Lymphoma,Drug: duvelisib,Number of participants reporting Treatment-emergent Adverse Events|Maximum Observed Plasma Concentration (Cmax) of Duvelisib|Time to Maximum Observed Concentration (Tmax) of Duvelisib|Area Under the Plasma Concentration-time Curve (AUC) of Duvelisib|Overall Response Rate|Overall Survival|Progression Free Survival,"AbbVie|Infinity Pharmaceuticals, Inc.",All,"20 Years to 99 Years   (Adult, Older Adult)",Phase 1,7.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M15-460,2015-11-01,December 2016,2017-02-01,"November 6, 2015",,"February 6, 2017","Site Reference ID/Investigator# 141826, Aichi, Japan|Site Reference ID/Investigator# 141595, Fukuoka, Japan|Site Reference ID/Investigator# 141594, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT02598570,458.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
7,8,NCT01926665,"Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)",,Completed,No Results Available,Lymphoma,Drug: Carfilzomib|Drug: Dexamethasone,Maximum Tolerated Dose (MTD) of Carfilzomib (CFZ) After Autologous Stem Cell Transplantation (ASCT)|Efficacy of Carfilzomib (CFZ) After Autologous Stem Cell Transplantation (ASCT),M.D. Anderson Cancer Center|Amgen,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,2.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012-1070|NCI-2014-00994,2014-06-17,"September 17, 2017",2017-09-17,"August 21, 2013",,"September 19, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01926665,1188.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
8,9,NCT00787969,"Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",,Completed,No Results Available,Lymphoma,Biological: rituximab|Drug: cladribine|Drug: temsirolimus|Biological: Filgrastim|Biological: Pegfilgrastim,"Number of dose limiting toxicity incidents as per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 3.0 (Phase I)|Proportion of complete tumor responses defined as complete remission (CR) as the objective status (Phase II)|Overall survival|Progression-free survival (PFS)|Time to disease progression|Duration of response, defined as date at which the patient's objective status is first noted to be either a CR or partial remission to the date progression is documented|Survival time|Frequency and severity of adverse events assessed by CTCAE v3.0",Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,74.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCCTG-N078D|NCI-2009-00669|CDR0000619329,2009-04-01,April 2012,2017-06-15,"November 10, 2008",,"January 9, 2018","Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Illinois CancerCare - Bloomington, Bloomington, Illinois, United States|St. Joseph Medical Center, Bloomington, Illinois, United States|Graham Hospital, Canton, Illinois, United States|Illinois CancerCare - Canton, Canton, Illinois, United States|Illinois CancerCare - Carthage, Carthage, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Eureka Community Hospital, Eureka, Illinois, United States|Illinois CancerCare - Eureka, Eureka, Illinois, United States|Galesburg Clinic, PC, Galesburg, Illinois, United States|Illinois CancerCare - Galesburg, Galesburg, Illinois, United States|Illinois CancerCare - Havana, Havana, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Illinois CancerCare - Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare - Macomb, Macomb, Illinois, United States|McDonough District Hospital, Macomb, Illinois, United States|Illinois CancerCare - Monmouth, Monmouth, Illinois, United States|OSF Holy Family Medical Center, Monmouth, Illinois, United States|BroMenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center, Normal, Illinois, United States|Illinois CancerCare - Community Cancer Center, Normal, Illinois, United States|Community Hospital of Ottawa, Ottawa, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, Illinois, United States|Cancer Treatment Center at Pekin Hospital, Pekin, Illinois, United States|Illinois CancerCare - Pekin, Pekin, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF St. Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare - Peru, Peru, Illinois, United States|Illinois Valley Community Hospital, Peru, Illinois, United States|Illinois CancerCare - Princeton, Princeton, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|Illinois CancerCare - Spring Valley, Spring Valley, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Michiana Hematology-Oncology, PC - Elkhart, Elkhart, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|Howard Community Hospital, Kokomo, Indiana, United States|Center for Cancer Therapy at LaPorte Hospital and Health Services, La Porte, Indiana, United States|Michiana Hematology-Oncology, PC - South Bend, Mishawaka, Indiana, United States|Saint Joseph Regional Medical Center, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC - Plymouth, Plymouth, Indiana, United States|CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Michiana Hematology Oncology PC - La Porte, Westville, Indiana, United States|McFarland Clinic, PC, Ames, Iowa, United States|Cedar Rapids Oncology Associates, Cedar Rapids, Iowa, United States|Mercy Regional Cancer Center at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates - West Des Moines, Clive, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Lutheran Hospital, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - North Iowa, Mason City, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas, PA - Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas, PA - Liberal, Liberal, Kansas, United States|Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States|Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas, PA - Salina, Salina, Kansas, United States|Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States|Associates in Womens Health, PA - North Review, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States|Battle Creek Health System Cancer Care Center, Battle Creek, Michigan, United States|Mecosta County Medical Center, Big Rapids, Michigan, United States|Green Bay Oncology, Limited - Escanaba, Escanaba, Michigan, United States|Butterworth Hospital at Spectrum Health, Grand Rapids, Michigan, United States|CCOP - Grand Rapids, Grand Rapids, Michigan, United States|Lacks Cancer Center at Saint Mary's Health Care, Grand Rapids, Michigan, United States|Dickinson County Healthcare System, Iron Mountain, Michigan, United States|Mercy General Health Partners, Muskegon, Michigan, United States|Michiana Hematology Oncology PC - Niles, Niles, Michigan, United States|Lakeland Regional Cancer Care Center - St. Joseph, Saint Joseph, Michigan, United States|Lakeside Cancer Specialists, PLLC, Saint Joseph, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States|Duluth Clinic Cancer Center - Duluth, Duluth, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller - Dwan Medical Center, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Mercy and Unity Cancer Center at Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|HealthEast Cancer Care at St. John's Hospital, Maplewood, Minnesota, United States|Minnesota Oncology Hematology, PA - Maplewood, Maplewood, Minnesota, United States|Virginia Piper Cancer Institute at Abbott - Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center - Minneapolis, Minneapolis, Minnesota, United States|Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Park Nicollet Cancer Center, Saint Louis Park, Minnesota, United States|Regions Hospital Cancer Care Center, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|St. Francis Cancer Center at St. Francis Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Willmar Cancer Center at Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology, PA - Woodbury, Woodbury, Minnesota, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|St. Vincent Healthcare Cancer Care Services, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Billings Clinic - Downtown, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|St. James Healthcare Cancer Care, Butte, Montana, United States|Great Falls Clinic - Main Facility, Great Falls, Montana, United States|Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Glacier Oncology, PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|Bismarck Cancer Center, Bismarck, North Dakota, United States|Medcenter One Hospital Cancer Care Center, Bismarck, North Dakota, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, United States|St. Alexius Medical Center Cancer Center, Bismarck, North Dakota, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Green Bay Oncology, Limited at St. Mary's Hospital, Green Bay, Wisconsin, United States|St. Mary's Hospital Medical Center - Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Holy Family Memorial Medical Center Cancer Care Center, Manitowoc, Wisconsin, United States|Bay Area Cancer Care Center at Bay Area Medical Center, Marinette, Wisconsin, United States|Green Bay Oncology, Limited - Oconto Falls, Oconto Falls, Wisconsin, United States|St. Nicholas Hospital, Sheboygan, Wisconsin, United States|Green Bay Oncology, Limited - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Welch Cancer Center at Sheridan Memorial Hospital, Sheridan, Wyoming, United States",,https://ClinicalTrials.gov/show/NCT00787969,2997.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
9,10,NCT03424122,"INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)",,Completed,No Results Available,B-cell Lymphoma,Drug: Parsaclisib|Drug: Rituximab|Drug: Bendamustine|Drug: Ibrutinib,"Number of treatment-emergent adverse events (TEAEs)|Apparent clearance of parsaclisibin combination with rituximab, bendamustine and rituximab, or ibrutinib|Apparent volume of distribution of parsaclisib in combination with rituximab, bendamustine and rituximab, or ibrutinib",Incyte Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 1,50.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INCB 50465-112 (CITADEL-112)|Parsaclisib,2018-07-02,"June 27, 2022",2022-06-27,"February 6, 2018",,"June 29, 2022","University of Arizona Cancer Center - Out Pt., Tucson, Arizona, United States|Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States|Comprehensive Cancer Center of Nevada, Las Vegas, Nevada, United States|Texas Oncology, Austin, Texas, United States|Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Smith Clinic, Houston, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Texas Oncology San Antonio, San Antonio, Texas, United States|Asst Spedali Civili Di Brescia, Brescia, Italy|Azienda Ospedaliera San Gerardo Di Monza, Monza, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Ospedale Delle Croci - Ematologia Ravenna, Ravenna, Italy|Hospital Germans Trias I Pujol, Badalona, Spain|Hospital General Universitari Vall D Hebron, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Fundacion Jimenez Diaz University Hospital, Madrid, Spain|Hospital Universitario Hm Sanchinarro, Madrid, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Hospital Universitario Y Politecnic La Fe, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT03424122,1456.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
10,11,NCT02877550,Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients,,Completed,No Results Available,Follicular Lymphoma,Drug: Obinutuzumab|Drug: Venetoclax,Dose limiting toxicities (DLT) during the first cycle|Adverse events (AEs)|Laboratory safety variables|Complete response (CR)|Overall response (OR) based on best response observed during combination therapy.|Duration of response|Progression free survival (PFS),Swiss Group for Clinical Cancer Research,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,25.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SAKK 35/15|2017-001175-23,2017-02-15,"April 28, 2020",2022-05-04,"August 24, 2016",,"June 10, 2022","Universitaetsspital Basel, Basel, Switzerland|Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland|Inselspital, Bern, Bern, Switzerland|Kantonsspital Graubünden, Chur, Switzerland|Hopital Cantonal Universitaire de Geneve, Geneva, Switzerland|Kantonsspital - St. Gallen, St. Gallen, Switzerland",,https://ClinicalTrials.gov/show/NCT02877550,1904.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
11,12,NCT01561833,A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients,,Completed,Has Results,T Cell Lymphoma,Drug: Sorafenib,Overall Response Rate,Yale University,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,12.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0901004690,2009-10-01,May 2013,2013-06-01,"March 23, 2012","August 13, 2020","August 13, 2020","Yale Cancer Center, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01561833,1339.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
12,13,NCT01504776,Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL),BUS48T,Completed,No Results Available,Mantle Cell Lymphoma,Drug: Panobinostat|Drug: Bortezomib,Dose-Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD)|Observe the activity of the combination against Mantle Cell Lymphoma (MCL) in patients treated in this Phase I study.,Anand Jillella|Novartis Pharmaceuticals|Augusta University,All,"18 Years and older   (Adult, Older Adult)",Phase 1,3.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLBH589BUS48T,2011-04-01,September 2014,2014-09-01,"January 5, 2012",,"September 19, 2014","Georgia Regents University, Augusta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT01504776,1249.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
13,14,NCT04260932,CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients,,Completed,No Results Available,B-cell Lymphoma,Biological: CD19/CD20 Dual-CAR-T cells,Percentage of participants with adverse events.|Objective remission rate(ORR)|Relapse-Free Survival(RFS )|Overall-Survival(OS)|Persistence of CAR-T cells in vivo,"Hebei Yanda Ludaopei Hospital|China Immunotech (Beijing) Biotechnology Co., Ltd.",All,"1 Year to 80 Years   (Child, Adult, Older Adult)",Phase 1,12.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HXYT-006,2020-03-01,"May 10, 2021",2021-09-10,"February 7, 2020",,"March 8, 2022","Hebei Yanda Ludaopei Hospital, Sanhe, Hebei, China",,https://ClinicalTrials.gov/show/NCT04260932,558.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
14,15,NCT00028613,Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell Lymphoma,,Completed,No Results Available,Lymphoma,Radiation: iodine I 131 monoclonal antibody Lym-1,,Case Comprehensive Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,2.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BRLX1400|CWRU-BRLX-1400|BRLX-303680|CWRU-090036|NCI-G01-2038,2001-03-01,October 2001,2001-10-01,"June 30, 2003",,"January 9, 2014","Ireland Cancer Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00028613,214.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
16,17,NCT01831505,Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents,,Completed,No Results Available,Lymphoma,"Drug: Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them",Evaluation of the response to locally injected drugs|Evaluate the safety profile of multiple simultaneous microinjections using custom syringe,Presage Biosciences|National Institutes of Health (NIH)|National Cancer Institute (NCI)|Fred Hutchinson Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1,4.0,Industry|NIH|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,PRS-1|R42CA144104-02,2012-11-01,July 2013,2013-07-01,"April 15, 2013",,"February 27, 2017","Seattle Cancer Care Alliance, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01831505,242.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
17,18,NCT00003741,Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma,,Completed,No Results Available,Lymphoma,Biological: monoclonal antibody HeFi-1,,Beth Israel Deaconess Medical Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,,Other,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,BIDMC-97127|CDR0000066859|NEDH-97127|NCI-870|NCI-V99-1515,1999-02-01,,2007-12-01,"January 27, 2003",,"June 26, 2013","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00003741,3225.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
18,19,NCT00561756,Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma,,Completed,No Results Available,Lymphoma,Biological: plasmid DNA vaccine therapy|Other: flow cytometry|Other: immunoenzyme technique,Safety and immunogenicity|Antibody and T-cell responses against CD20|Antitumor response,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,8.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,07-100|MSKCC-07100,2007-10-01,November 2015,2015-11-01,"November 21, 2007",,"November 17, 2015","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00561756,2953.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
19,20,NCT03381768,Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma,,Completed,No Results Available,Follicular Lymphoma,Biological: PD-L2 peptide|Biological: PD-L2 and PD-L1 peptide,Adverse events evaluated by CTCAE 4.03|Immune responses,Lars Møller Pedersen|Herlev Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 1,8.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FL1701|2017-002000-28,2017-12-12,"February 12, 2020",2020-02-12,"December 22, 2017",,"February 24, 2021","Herlev Hospital, Herlev, RegionH, Denmark",,https://ClinicalTrials.gov/show/NCT03381768,792.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
20,21,NCT00182650,Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma,,Completed,No Results Available,Lymphoma,Biological: aldesleukin|Biological: rituximab|Biological: therapeutic autologous lymphocytes|Drug: fludarabine phosphate,,City of Hope Medical Center|National Cancer Institute (NCI),All,"16 Years to 70 Years   (Child, Adult, Older Adult)",Phase 1,5.0,Other|NIH,Interventional,Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000438797|R21CA105824|P30CA033572|CHNMC-IRB-01160,2004-06-01,March 2008,2008-03-01,"September 16, 2005",,"December 29, 2009","City of Hope Comprehensive Cancer Center, Duarte, California, United States",,https://ClinicalTrials.gov/show/NCT00182650,1369.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
22,23,NCT03707093,Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma,,Completed,No Results Available,"Solid Tumors, Non-Hodgkin Lymphoma",Drug: ADG106,Number of participants experiencing dose-limiting toxicities|Number of participants experiencing clinical and laboratory adverse events (AEs)|The area under the curve (AUC) of plasma concentration of drug|Maximum concentration (Cmax)|Time at which maximum concentration (Tmax)|Lowest plasma concentration (C[trough]),Adagene Inc,All,"18 Years and older   (Adult, Older Adult)",Phase 1,49.0,Industry,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ADG106-1001,2018-09-17,"January 24, 2022",2022-09-30,"October 16, 2018",,"October 18, 2022","Horizon Oncology Research, Lafayette, Indiana, United States|NEXT Oncology, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT03707093,1474.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
23,24,NCT03836768,BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma,,Completed,No Results Available,Mantle Cell Lymphoma,Drug: DTRMWXHS-12,Safety: Incidence and severity of (serious) adverse events n each patient according to the NCI-CTCAE4.03 grading|concentration of drug in plasma,Zhejiang DTRM Biopharma,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,20.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DTRM_DTRMWXHS-12_004,2019-01-11,"November 17, 2021",2021-11-17,"February 11, 2019",,"February 15, 2023","Peking University Cancer Hospital, Beijing, China",,https://ClinicalTrials.gov/show/NCT03836768,1041.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
24,25,NCT01804335,CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL),,Completed,No Results Available,Lymphoma,Drug: CD5789 0.01% Cream,Tolerance Score of CD5789 0.01% Cream,M.D. Anderson Cancer Center|Galderma R&D,All,"18 Years and older   (Adult, Older Adult)",Phase 1,11.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012-0710|NCI-2014-01377,2013-02-01,March 2015,2015-03-01,"March 5, 2013",,"April 13, 2016","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01804335,758.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
25,26,NCT00777114,Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy,,Completed,No Results Available,Non-Hodgkin's Lymphoma,"Drug: bortezomib, tositumomab",The primary objectives of this study are to determine: a) The appropriate doses of bortezomib and 131I-tositumomab when used in combination. b) Toxicities of the combination treatment.,"Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc.|GlaxoSmithKline",All,"18 Years and older   (Adult, Older Adult)",Phase 1,31.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0806009862,2007-04-01,"December 18, 2012",2012-12-18,"October 22, 2008",,"August 13, 2018","University of Michigan, Ann Arbor, Michigan, United States|Weill Cornell Medical College, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00777114,2088.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
26,27,NCT01022255,Autologous Vaccine for Follicular Lymphoma,,Completed,No Results Available,"Lymphoma, Follicular",Biological: Autologous FL vaccine,Proportion of patients with toxicities as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI/CTCAE) version 3.0 grade >/= 3 to the magnICON generated idiotype (Id) vaccine|Assessment of humoral idiotype-specific immune responses|Assessment of cellular idiotype-specific immune responses|Long-term safety/tolerability as determined by the proportion of patients with toxicities as assessed by the FDA CBER Guidance for Industry Toxicity Grading Scale in Preventive Vaccine Clinical Trials and the NCI/CTCAE version 4.02 grade >/= 3,Icon Genetics GmbH,All,"18 Years and older   (Adult, Older Adult)",Phase 1,28.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PMP0025-01,2010-01-01,October 2013,2013-10-01,"December 1, 2009",,"January 30, 2014","Burbank, California, United States|Dallas, Texas, United States|Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01022255,1369.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
27,28,NCT03316144,"Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma",,Completed,No Results Available,Malignant Lymphoma,Biological: Toripalimab,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|correlation analysis of PD-L1 expression of tumor|Objective Response Rate (ORR) by irRC and RECIST 1.1,"Shanghai Junshi Bioscience Co., Ltd.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,13.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Junshi-JS001-011,2017-07-12,"September 15, 2018",2019-12-30,"October 20, 2017",,"September 30, 2020","Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China",,https://ClinicalTrials.gov/show/NCT03316144,901.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
28,29,NCT01275209,Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma,LIFT,Completed,No Results Available,Follicular Lymphoma,Drug: HCD122,Incidence rate of dose-limiting toxicities and adverse events|Response rate,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,1.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHCD122A2104|2010-022350-17,2011-02-01,May 2012,2012-05-01,"January 12, 2011",,"December 8, 2020","Dana Farber Cancer Institute SC-5, Boston, Massachusetts, United States|Wayne State University/Karmanos Cancer Institute Dept.of KarmanosCancerInst (6), Detroit, Michigan, United States|Duke University Medical Center Duke Hem & Onc, Durham, North Carolina, United States|Sarah Cannon Research Institute SC - 2, Chattanooga, Tennessee, United States|Novartis Investigative Site, Prahran, Victoria, Australia|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT01275209,455.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
29,30,NCT00389051,A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma,,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: bendamustine hydrochloride,"Non-Hematological toxicity; > grade three(CTCAE v.3.0), during the treatment cycle (twenty one days)|All adverse events or adverse reactions, during the treatment cycle (twenty one days)|Pharmacokinetics profile",SymBio Pharmaceuticals,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 1,9.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2006001,2006-10-31,"July 5, 2007",2007-10-26,"October 17, 2006",,"October 22, 2020","Kanagawa, Japan|Kyoto, Japan|Nagoya, Japan|Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00389051,360.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
30,31,NCT02776813,Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma,,Completed,No Results Available,Lymphoma,Biological: ACTR087|Biological: rituximab,"Safety as assessed by dose limiting toxicities (DLTs)|Safety as assessed by determination of the maximum tolerated dose (MTD)|Safety as assessed by determination of the recommended phase 2 dose (RP2D)|Safety as assessed by and adverse events, laboratory assessments and physical examinations|Safety as assessed by mini-mental state examination (MMSE)|Overall response rate|Duration of response|Progression free survival|Overall survival","Cogent Biosciences, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,34.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UT-201501|ATTCK-20-2,2016-08-01,"February 12, 2020",2020-02-12,"May 18, 2016",,"March 31, 2020","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Yale University, New Haven, Connecticut, United States|Loyola University Chicago, Maywood, Illinois, United States|Indiana Bone and Marrow Transplantation, Indianapolis, Indiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02776813,1290.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
31,32,NCT01644799,Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma,,Completed,No Results Available,Recurrent Follicular Lymphoma,Drug: idelalisib|Drug: lenalidomide,MTD based on the incidence of dose-limiting toxicity (DLT) assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Toxicity profile assessed by NCI CTCAE version 4.0|OR rate assessed up to 10 years|CR rate assessed up to 10 years|PFS assessed up to 10 years,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Gilead Sciences|Celgene Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 1,8.0,Other|NIH|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A051202|CDR0000736814|NCI-2012-01988|U10CA031946,2013-07-01,August 2014,2017-05-01,"July 19, 2012",,"January 30, 2018","MedStar Georgetown University Hospital, Washington, District of Columbia, United States|University of Chicago, Chicago, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Weill Medical College of Cornell University, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Ohio State University Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01644799,1400.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
32,33,NCT03189524,A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma,,Completed,Has Results,B-cell Lymphoma,Drug: Zanubrutinib,"Part I: Number Of Participants Experiencing Treatment-emergent Adverse Events And Treatment-emergent Serious Adverse Events|Part II: Overall Response Rate (ORR) Of Zanubrutinib In Participants With FL And MZL|Part II: Complete Response Rate (CRR) Of Zanubrutinib In Participants With FL And MZL|Part II: Partial Response Rate (PRR) Of Zanubrutinib In Participants With FL And MZL|Part II: Duration of Response (DOR) Of Zanubrutinib In Participants With FL And MZL|Part II: Progression Free Survival (PFS) Of Zanubrutinib In Participants With FL And MZL|Part I and Part II: Area Under The Plasma Concentration-time Curve From Zero To The Last Measurable Concentration (AUClast) For Single-dose Zanubrutinib|Part I and Part II: Area Under The Plasma Concentration-time Curve Zero To Infinity (AUC0-inf) For Single-dose Zanubrutinib|Part I And Part II: Maximum Plasma Concentration (Cmax) For Single-dose Zanubrutinib|Part I and Part II: Time To Maximum Plasma Concentration (Tmax) For Single-dose Zanubrutinib|Part I and Part II: Apparent Terminal Half Life (t1/2) For Single-dose Zanubrutinib|Part I and Part II: Apparent Plasma Clearance (CL/F) For Single-dose Zanubrutinib|Part I and Part II: Terminal Apparent Volume Of Distribution (Vz/F) For Single-dose Zanubrutinib|Part I and Part II: Area Under The Plasma Concentration-time Curve For Steady State (AUCss) Zanubrutinib|Part I and Part II: Maximum Plasma Concentration At Steady State (Cmax,ss) For Zanubrutinib|Part I and Part II: Time To Steady Plasma Concentration (Tmax,ss) For Zanubrutinib|Part I: Percentage of BTK Occupied In Peripheral Blood Mononuclear Cells In Participants Who Received Zanubrutinib|Part II: Number Of Participants Experiencing Treatment-emergent Adverse Events And Treatment-emergent Serious Adverse Events",BeiGene,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,44.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BGB-3111-1002|CTR20160204,2016-07-05,"August 26, 2020",2020-08-26,"June 16, 2017","October 22, 2021","October 22, 2021","Beijing Cancer Hospital, Beijing, Beijing, China|Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|Tianjin Hematonosis Hospital, Tianjin, Tianjin, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03189524/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03189524/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03189524,1513.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
34,35,NCT04292626,Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose,,Completed,No Results Available,"Hodgkin Lymphoma, Adult|Non-Hodgkin Lymphoma, Adult",Diagnostic Test: SPECT with 99mTc-1-thio-D-glucose,Gamma camera-based whole-body 99mTc-1-thio-D-glucose uptake value (percent)|SPECT-based 99mTc-1-thio-D-glucose value in tumor lesions (counts)|SPECT-based 99mTc-1-thio-D-glucose uptake value (counts)|Tumor-to-background ratio (SPECT)|Safety attributable to 99mTc-1-thio-D-glucose injections (physical findings)|Safety attributable to 99mTc-1-thio-D-glucose injections (laboratory tests)|Safety attributable to 99mTc-1-thio-D-glucose injections (incidence and severity of adverse events)|Safety attributable to 99mTc-1-thio-D-glucose injections,Tomsk National Research Medical Center of the Russian Academy of Sciences|Uppsala University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,16.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,Lymphoma-Tc-99m,2020-01-19,"February 19, 2021",2021-03-19,"March 3, 2020",,"April 1, 2021","TomskNRMC, Tomsk, Russian Federation",,https://ClinicalTrials.gov/show/NCT04292626,425.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
35,36,NCT04089527,"Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma",,Completed,No Results Available,"Lymphoma, Non-Hodgkin",Drug: CC-95775,Dose Limiting Toxicity (DLT)|Maximum Tolerated Dose (MTD)|Non-tolerated Dose (NTD)|Adverse Events (AEs)|Pharmacokinetics - Cmax of CC-95775|Pharmacokinetics - AUC of CC-95775|Pharmacokinetics - Tmax of CC-95775|Pharmacokinetics - t1/2 of CC-95775|Pharmacokinetics - CL/F of CC-95775|Pharmacokinetics - Vz/F of CC-95775|Evaluate the pharmacodynamic (PD) effects of CC-95775 on gene expression in peripheral blood and in tumor tissue.,Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CC-95775-ST-001|U1111-1238-6062|2019-001092-36,2019-10-24,"October 25, 2021",2021-10-25,"September 13, 2019",,"February 1, 2022","Institut Curie, Paris, France|Hopital Saint Louis, Paris, France|Centre Eugene Marquis, Rennes, France|Hospital de Madrid Norte- Sanchinarro, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Spain",,https://ClinicalTrials.gov/show/NCT04089527,732.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
36,37,NCT00667329,"Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab",,Completed,No Results Available,Lymphoma,Drug: 2CdA|Drug: Cyclophosphamide|Drug: Rituximab,"Response Rate|After these drugs are given for 2 courses, a second goal is to see how long a remission lasts.|A third goal is to see how often repeat remissions can be achieved when the lymphoma returns later and the same drugs are restarted.",M.D. Anderson Cancer Center,All,"Child, Adult, Older Adult",Phase 1,14.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DM99-070|NCI-2020-00334,1999-07-09,"February 10, 2022",2022-02-10,"April 28, 2008",,"March 7, 2022","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00667329,8252.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
37,38,NCT01949883,A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma,,Completed,No Results Available,Lymphoma,Drug: CPI-0610,"Frequency of dose-limiting toxicities (DLTs) associated with CPI-0610 administration during the first cycle (first 21 days) of treatment|Safety and tolerability of CPI-0610 as assessed by: frequency of adverse events and serious adverse events; changes in hematology and clinical chemistry values; changes in physical examination, vital signs, electrocardiogram, ECHO and ECOG score|Pharmacokinetic parameters of CPI-0610: AUC(0-t), AUC(0-inf), AUCtau,ss, Tmax, Cmax, Ctrough, T1/2, Vd/F, CL/F|Pharmacodynamic effects of CPI-0610: Changes in the expression of MYC and other genes in tumor tissue; changes in cellular proliferation and in the extent of apoptosis; changes in tumor metabolism|Changes in the expression of a set of genes in peripheral blood mononuclear cells (PBMCs) that are sensitive to BET inhibition|Anti-lymphoma activity associated with CPI-0610 treatment",Constellation Pharmaceuticals|The Leukemia and Lymphoma Society,All,"18 Years and older   (Adult, Older Adult)",Phase 1,64.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0610-01,2013-09-01,December 2017,2018-02-01,"September 25, 2013",,"May 18, 2022",,,https://ClinicalTrials.gov/show/NCT01949883,1614.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
38,39,NCT03218072,"A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas",,Completed,No Results Available,B-cell Lymphomas,Drug: HLX01,AEs|SAEs|AUC0-inf|Cmax|t1/2|CD19 positive B cells|CD20 positive B cells|Antidrug antibodies of HLX01,Shanghai Henlius Biotech,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,12.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HLX01-NHL01,2014-05-04,"January 31, 2015",2015-01-31,"July 14, 2017",,"May 9, 2022",,,https://ClinicalTrials.gov/show/NCT03218072,272.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
39,40,NCT01055496,Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma,,Completed,Has Results,"Lymphoma, B-Cell",Drug: inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone|Drug: inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone,"Participants Reporting Dose Limiting Toxicity (DLT) Adverse Events (AEs) for Participants in the DE Cohort and the MTD Confirmation Cohort for Arm 1|Participants Reporting DLT AEs for Participants in the DE Cohort and the MTD Confirmation Cohort for Arm 2|Percentage of Participants With Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) According to International Response Criteria for NHLs in the MTD and EE Cohorts|Percentage of Participants With a Treatment Emergent AE|Percentage of Participants With Any Grade 3/4 Chemistry Abnormality During Therapy|Percentage of Participants With Any Grade 3/4 Hematology Abnormality During Therapy|Percentage of Participants With a Best OR of CR or PR According to International Response Criteria for NHLs in the DE Cohorts|Kaplan-Meier Estimate of the Progression-Free Survival (PFS) in the DE Cohorts|Kaplan-Meier Estimates of the Probability of Being Alive and Free From PD or New Anticancer Therapy at 6, 12, and 24 Months in the DE Cohorts|Kaplan-Meier Estimate of the PFS in the MTD Confirmation/EE Cohorts|Kaplan-Meier Estimates of the Probability of Being Alive and Free From PD or New Anticancer Therapy at 6, 12, and 24 Months in the MTD Confirmation/EE Cohorts.|Kaplan-Meier Estimate of the Overall Survival (OS) in the DE Cohorts|Kaplan-Meier Estimates of the Probability of Being Alive at 6, 12, and 24 Months in the DE Cohorts|Kaplan-Meier Estimate of the OS in the MTD Confirmation/EE Cohorts|Kaplan-Meier Estimates of the Probability of Being Alive at 6, 12, and 24 Months in the MTD Confirmation/EE Cohorts|Mean Inotuzumab Ozogamicin Serum Concentrations",Pfizer|UCB Pharma,All,"18 Years and older   (Adult, Older Adult)",Phase 1,103.0,Industry,Interventional,Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,3129K2-1105|B1931003|2009-015497-35,2010-03-01,July 2013,2014-03-01,"January 25, 2010","August 2, 2019","August 2, 2019","Davis Cancer Pavillion and Shands Medical Plaza, Gainesville, Florida, United States|Shands Cancer Hospital At The University Of Florida, Gainesville, Florida, United States|Shands Hospital at the University of Florida, Gainesville, Florida, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Northwest Medical Specialties, PLLC, Federal Way, Washington, United States|Northwest Medical Specialties, PLLC, Gig Harbor, Washington, United States|Northwest Medical Specialties, PLLC, Lakewood, Washington, United States|Rainier Physicians, PC, Puyallup, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|UZ Gent, Gent, Belgium|UZ Gasthuisberg, Leuven, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|Queen Elizabeth Health Sciences Centre, Halifax, Nova Scotia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Hospital Saint-Louis - Service d'Hemato-Oncologie, Paris Cedex 10, France|Hopital Saint-Louis -Universite Paris VII, Paris, France|Centre Hospitalier Lyon Sud - Service d'Hematologie, Pierre Benite, France|Prince of Wales Hospital, Hong Kong, Hong Kong|Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Cancer Institute Hospital, Japanese Foundation For Cancer Research, Koto-Ku, Tokyo, Japan|Samsung Medical Center, Seoul, Korea, Republic of|Singapore General Hospital, Singapore, Singapore|Nuffield Hospital, Eastleigh, Hants, United Kingdom|Spire Southampton Hospital, Southampton, Hants, United Kingdom|Cancer Sciences Division, Somers Cancer Research Building, Southampton, Hants, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01055496,1461.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
40,41,NCT03925935,Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation,,Completed,No Results Available,Hodgkin Lymphoma|Non-hodgkin Lymphoma,Biological: AB-205,"Occurrence of adverse events grade ≥ 3 as assessed by CTCAEv5|Severity and duration of grade ≥ 3 mucosal toxicities including oropharyngeal mucositis, nausea, vomiting, and/or diarrhea.|Time to neutrophil engraftment|Time to platelet engraftment|Time to lymphoid recovery|Progression-free survival|Non-relapse mortality|Overall survival",Angiocrine Bioscience|California Institute for Regenerative Medicine (CIRM),All,"18 Years and older   (Adult, Older Adult)",Phase 1,42.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AB-205-001,2019-05-07,"November 18, 2020",2021-11-08,"April 24, 2019",,"March 3, 2022","City of Hope Comprehensive Cancer Center, Duarte, California, United States|UC Davis Comprehensive Cancer Center, Sacramento, California, United States|UC San Diego Moores Cancer Center, San Diego, California, United States|The University of California San Francisco, San Francisco, California, United States|University of Michigan, Ann Arbor, Michigan, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|MD Anderson, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03925935,916.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
41,42,NCT03003039,A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma,,Completed,No Results Available,B-Cell Lymphoma,Biological: GB241|Biological: Rituximab,"Area under the curve (AUC) for GB241 and rituximab concentrations|AUC for GB241 and rituximab concentrations|Maximum observed concentration of the GB241 and rituximab|Degree of clearance from baseline of CD19+ , CD20+ B-cells between the two study arms|Comparison of AEs between the two study arms|Comparison of the incidence rate of HACA（host anti-chimeric antibody） between the two study arms","Nanjing Yoko Biomedical Co., Ltd.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,85.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GB241NHL1,2017-06-05,"May 20, 2019",2019-05-20,"December 26, 2016",,"March 23, 2021","Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT03003039,714.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
42,43,NCT02679196,"The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma",,Completed,No Results Available,"Lymphoma, B Cell",Drug: KA2237,The occurrence of dose limiting toxicity (DLT);|Concentration (mg/ml) of KA2237 in serum/plasma over time (hours)|Concentration (mg/ml) of KA2237 in urine over time (hours)|Concentration (ng/ml) of key cytokine and intracellular signalling markers in immune cell subsets|Frequency of KA2237 related adverse events and laboratory abnormalities,Karus Therapeutics Limited,All,"18 Years and older   (Adult, Older Adult)",Phase 1,23.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KTP-002,2016-07-01,"December 24, 2018",2018-12-24,"February 10, 2016",,"February 6, 2019","MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02679196,906.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
43,44,NCT00334438,"Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma",,Completed,No Results Available,Lymphoma,Biological: rituximab|Drug: bortezomib|Radiation: yttrium Y 90 ibritumomab tiuxetan|Radiation: Indium 111 ibritumomab tiuxetan,Maximum tolerated dose of bortezomib|Dose-limiting toxicity|Response rate,UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1,12.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LCCC 0525|CDR0000550130,2006-07-01,October 2008,2011-10-01,"June 7, 2006",,"December 23, 2016","Hackensack University Medical Center Cancer Center, Hackensack, New Jersey, United States|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00334438,1918.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
44,45,NCT00574509,BEAM+131I-Anti-B1 & Autologous Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma,,Completed,No Results Available,Lymphoma,Radiation: 131Iodine-Anti-B1 Radioimmunotherapy,Safety of 131I-anti-B1 radioimmunotherapy when combined with high-dose BEAM or BEAC chemotherapy & HSCT|Difference in response rates & time to tx failure between historical control patients receiving high-dose BEAM or BEAC chemo. with autologous HSCT and pateints receiving radioimmunotherapy and high-dose BEAM or BEAC chemo. with autologous HSCT,University of Nebraska,All,"19 Years to 70 Years   (Adult, Older Adult)",Phase 1,34.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,165-96,1996-03-01,November 2014,2014-12-01,"December 17, 2007",,"May 4, 2017","University of Nebraska Medical Center, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT00574509,6849.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
45,46,NCT00779337,Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas,EPL,Completed,No Results Available,Lymphoma,Biological: Autologous AdE1- Latent Membrane Protein CTLs,"Feasibility (generation of autologous clinical grade AdE1-LMP-specific CTL from the blood of EBV-positive lymphoma patients)|Safety as assessed by adverse event monitoring. Patients will be questioned and toxicities recorded according to the International Common Toxicity Criteria.|Reconstitution of EBV-specific CTL immunity with anti-viral efficacy measured by immunological & virological assessment of blood samples including immunophenotyping, intracellular cytokine assays, CD107 cytotoxicity assays and EBV DNA load analysis.|Optimal dose intensity of the intervention. Clinical efficacy (radiological assessment by CT), biological efficacy (reconstitution of EBV-specific CTL immunity & anti-viral efficacy), safety & efficacy of the 1st treatment schedule vs the 2nd schedule|Clinical efficacy","Queensland Institute of Medical Research|The Atlantic Philanthropies|Australian Department of Industry, Tourism and Resources|British Society for Haematology|National Health and Medical Research Council, Australia",All,"18 Years and older   (Adult, Older Adult)",Phase 1,8.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QIMR P1167|ANZCTR12608000521325,2008-10-01,January 2012,2012-05-01,"October 24, 2008",,"May 22, 2012","Princess Alexandra Hospital, Brisbane, Queensland, Australia",,https://ClinicalTrials.gov/show/NCT00779337,1308.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
46,47,NCT02220842,A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma,,Completed,No Results Available,Lymphoma,Drug: Atezolizumab|Drug: Obinutuzumab|Drug: Tazemetostat,Percentage of Participants With Dose Limiting Toxicities (DLTs)|Recommended Phase 2 Dose (RP2D) of Atezolizumab|Obinutuzumab Minimum Serum Concentration (Cmin)|Percentage of Participants With Adverse Events (AEs) Graded According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)|Percentage of Participants With Anti-therapeutic Antibody Response to Atezolizumab and Obinutuzumab|Atezolizumab Maximum Serum Concentration (Cmax)|Atezolizumab Minimum Serum Concentration (Cmin)|Obinutuzumab Maximum Serum Concentration (Cmax)|Percentage of Participants With Best Overall Response According to Lugano Classification|Percentage of Participants With Objective Response (Complete Response or Partial Response) According to Lugano Classification|Progression Free Survival (PFS) According to Lugano Classification|Overall Survival (OS)|Duration of Objective Response (DOR) According to Lugano Classification|Tazemetostat Plasma Concentrations,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1,96.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GO29383|2014-001812-21,2014-12-18,"January 21, 2020",2020-01-21,"August 20, 2014",,"January 27, 2020","City of Hope National Medical Center, Duarte, California, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Sloan Kettering Cancer Center, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States|UW- Fred Hutchinson Cancer Center, Seattle, Washington, United States|Hopital Claude Huriez - CHU Lille; Service des maladies du sang, Lille, France|Hopital Saint Eloi, Montpellier, France|Hôpital Saint-Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Institut Gustave Roussy, Villejuif, France|Universitaetsklinikum Freiburg, Freiburg, Germany|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Piemonte, Italy|Barts Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02220842,1860.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
48,49,NCT00569985,Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma,,Completed,No Results Available,Lymphoma,Biological: lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Drug: carmustine|Drug: cyclophosphamide|Drug: etoposide|Procedure: autologous hematopoietic stem cell transplantation,"Safety of treatment using the National Cancer Institute (NCI) hematologic Common Terminology Criteria for Adverse Events (CTCAE) version 3.0|Survival of shI-TAR-CCR5RZ-marked cells in the peripheral blood, demonstrated by presence of transgene by Q-PCR using primers specific for rHIV7-shI-TAR-CCR5RZ in serial samples of peripheral blood|Determination of RNA transgene expression in samples of peripheral blood mononuclear cells (PBMCs) or marrow before and after infusion, analyzed by Northern blotting/hybridization|Analysis of vector rescue by HIV|Ability to obtain suitable numbers of lentiviral vector treated HPC-A|Determination of replication competent lentivirus (RCL) and HIV-1/vector recombination",City of Hope Medical Center|National Cancer Institute (NCI),All,18 Years to 60 Years   (Adult),Phase 1,5.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,04047|CHNMC-04047|NCI-2012-00437,2007-06-01,"November 12, 2019",2019-11-12,"December 10, 2007",,"November 15, 2019","City of Hope Medical Center, Duarte, California, United States",,https://ClinicalTrials.gov/show/NCT00569985,4547.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
49,50,NCT01226849,Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma,SGH652,Completed,No Results Available,Diffuse Large B-Cell Lymphoma,"Drug: bortezomib, rituximab, ifosphamide, etoposide, carboplatin",To evaluate number of participants with adverse events with R-ICE plus bortezomib (VR-ICE)|Response rate,Singapore General Hospital|Janssen-Cilag Ltd.,All,"21 Years and older   (Adult, Older Adult)",Phase 1,6.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SGH652,2010-11-01,November 2014,2014-11-01,"October 22, 2010",,"April 27, 2017","Singapore General Hospital, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT01226849,1461.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
50,51,NCT02187133,Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,,Completed,No Results Available,"Lymphoma, Non-Hodgkin|Lymphoma",Drug: Carfilzomib|Drug: Bendamustine|Drug: Rituximab,Maximally tolerated dose (MTD)|Number of participants with Dose Limiting Toxicities (DLT)|Overall Response Rate (ORR)|Median Duration of Response|Median Progression Free Survival (PFS)|Median Time to Next Therapy,"University of California, San Francisco|National Comprehensive Cancer Network",All,"18 Years and older   (Adult, Older Adult)",Phase 1,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14251|NCI-2015-00775,2015-05-05,"March 31, 2021",2021-03-31,"July 10, 2014",,"April 23, 2021","University of California, Davis, Davis, California, United States|University of California, San Diego, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT02187133,2157.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
51,52,NCT02945215,A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients,,Completed,No Results Available,B-Cell Lymphoma,Drug: IBI301|Drug: Rituximab,AUC0-inf of IBI301 and rituximab|Peak Plasma Concentration (Cmax)|Percentage and absolute value of CD19+|Percentage and absolute value of CD20+ B-cell|Positive rate of ADA|Positive rate of NAb|Safety profiles|Area under the plasma concentration versus time curve (AUC)|AUC（0-t） of IBI301 and rituximab,Innovent Biologics (Suzhou) Co. Ltd.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,181.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CIBI301A201,2016-12-13,"March 21, 2019",2019-10-16,"October 26, 2016",,"September 1, 2020","Beijing cancer hospital, Beijing, Beijing, China|Peking University third hospital, Beijing, Beijing, China|The 307th Hospital of Military Medical Sciences, Beijing, Beijing, China|Harbin Medical University Cancer Hospital, Haerbin, Heilongjiang, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|The Third Xiangya Hospital of Central South University, Changsha, Hunan, China|Xiangya Hospital of Central South University, Changsha, Hunan, China|Jiangsu province people's hospital, Nanjing, Jiangsu, China|West China Hospital,Sichuan University, Chengdu, Sichuan, China|Tianjin People's Hospital, Tianjin, Tianjin, China|The First Affiliated Hospital Zhejiang University, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT02945215,1037.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,Not Open Label,Treatment/Diagnostic
52,53,NCT01276717,Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma,,Completed,No Results Available,Lymphoma,Drug: Drug: Carfilzomib|Drug: Vorinostat,Number of Participants who experience Adverse Events as a Measure of Safety and Tolerability|Number of Participants who Respond to Treatment,University of Rochester|Massey Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,32833,2011-01-01,July 2013,2015-01-01,"January 13, 2011",,"December 3, 2015","University of Rochester, Rochester, New York, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01276717,1461.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
53,54,NCT00598169,"Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma",,Completed,No Results Available,Lymphoma,Biological: rituximab|Drug: bortezomib|Drug: carboplatin|Drug: dexamethasone|Drug: etoposide|Drug: ifosfamide|Genetic: polymerase chain reaction|Genetic: western blotting,"Maximum tolerated dose of bortezomib|Overall lymphoma response rate|Safety as assessed using the CTCAE|Median overall survival at 1 year|Impact of bortezomib alone and in combination with rituximab, ifosfamide, carboplatin, and etoposide ([R]ICE) on serum HIV viral loads and APOBEC3G levels|Impact of bortezomib alone and in combination with (R)ICE on EBV and HHV-8 lytic activation using serum viral loads|Safety of bortezomib alone in patients with relapsed or refractory AIDS-associated lymphomas|Correlation of EBV/HHV-8 viral load changes with lymphoma response|Comparison of above outcomes to a parallel protocol employing ICE +/- rituximab in patients with EBV/HHV-8-negative AIDS-NHL to assess whether bortezomib has additional effects beyond (R)ICE alone","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC",All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1,23.0,Other|NIH|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AMC-053|U01CA121947|CDR0000581078,2007-11-01,October 2014,2014-11-01,"January 18, 2008",,"August 10, 2020","Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States|University of California at Davis Center for Aids Research and Education Services, Sacramento, California, United States|University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States|Emory Winship Cancer Institute, Atlanta, Georgia, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Northwestern Cancer Center, Chicago, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Montefiore Medical Center, Bronx, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Pennsylvania Oncology Hematology Associates, Incorporated - Philadelphia, Philadelphia, Pennsylvania, United States|Thomas Street Health Center, Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00598169,2557.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
54,55,NCT01854606,Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma,COEB071X2103,Completed,No Results Available,CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma,Drug: AEB071|Drug: Everolimus,"Phase Ib- Incidence of dose limiting toxicities (DLT) during the first cycle|Phase II- Overall response rate (ORR) = complete response (CR) + partial response (PR) according to the non-Hodgkin's Lymphoma International Working Group criteria|Occurrence of Adverse Events (AEs), Serious Adverse Events (SAEs) assessments of clinical laboratory values and vital sign measurements.|Best Overall Response (BOR)|Duration of Response (DOR)|Progression Free survival (PFS)|Overall Survival (OS)|Concentration-time profiles of Pharmacokinetics (PK) parameters - Phase Ib",Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,31.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COEB071X2103,2013-12-05,"June 1, 2016",2016-06-01,"May 15, 2013",,"December 19, 2020","Washington University School of Medicine Dept of Oncology., Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center Onc. Dept., New York, New York, United States|Sarah Cannon Research Institute Dept of Onc, Nashville, Tennessee, United States|Novartis Investigative Site, Rouen Cedex 1, France|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, New Territories, Hong Kong|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT01854606,909.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
55,56,NCT01950273,Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma,,Completed,Has Results,"Lymphoma, Follicular",Drug: BI 695500|Drug: MabThera,Area Under the Concentration (AUC) Time Curve of BI 695500 and Rituximab (MabThera®) Over the First Dosing Interval (Pre-infusion on Day 1 to Pre-infusion on Day 8)|AUC of BI 695500 and Rituximab (MabThera®) Over the Fourth Dosing Interval (Pre-infusion on Day 22 to Day 29) (AUC Day 22-Day 29)|Maximum Measured Concentration of BI 695500 and Rituximab (MabThera®) in Plasma (Cmax) Following Dose 1|Maximum Measured Concentration of Rituximab (MabThera®) and BI 695500 in Plasma (Cmax) Following Dose 4|Area Under the Depletion-time Curve of the Cluster of Differentiation (CD)19+ B-cell Count (% Change From Baseline (CFB)) in Peripheral Blood From Pre-infusion on Day 1 Until Last Measurement on Day 8 (Pre-infusion)|Change From Baseline (%) of CD19+ B-cells in Peripheral Blood Measured After Seven Days on Day 8 (Day 8 Pre-infusion Time Point)|Overall Response Rate (ORR) (Complete Response (CR) Plus Partial Response (PR)) Evaluated Approximately One Month After Last Dose of BI 695500 or Rituximab (MabThera®)|Percentage of Patients With Treatment Emergent Adverse Events (TEAEs) Selected for Comparability Assessment of BI 695500 and Rituximab (MabThera®),Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 1,95.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,1301.5|2013-001904-12,2013-09-27,"December 22, 2015",2015-12-22,"September 25, 2013","September 5, 2018","September 5, 2018","The Canberra Hospital, Canberra, Migration Data, Australia|AKH - Medical University of Vienna, Wien, Austria|Brussels - UNIV St-Luc, Bruxelles, Belgium|UZ Leuven, Leuven, Belgium|Namur - HOSP Ste-Elisabeth, Namur, Belgium|Clinical Hospital Centre Zagreb, Zagreb, Croatia|University Hospital Brno, Brno, Czechia|University Hospital Ostrava, Ostrava-Poruba, Czechia|Vseobecna fakultni nemocnice V Praze, Praha 2, Czechia|INS Bergonié, Bordeaux cedex, France|HOP Morvan, Brest, France|Centre Hospitalier Départemental Les Oudairies, La Roche sur Yon, France|HOP Haut-Lévêque, Pessac, France|Hôpital la Milétrie - CHU Poitiers, Poitiers, France|Gesundheitszentrum Wetterau gGmbH, Bad Nauheim, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Haemato-Onkologie Hamburg, Hamburg, Germany|Klinikum Kassel GmbH, Kassel, Germany|General Hospital of Athens ""G. Gennimatas"", Athens, Greece|Semmelweis University, 1st Dept. Internal Medicine, Budapest, Hungary|Auckland Clinical Studies Ltd, Auckland, New Zealand|Oncol Centre M Sklodowska-Curie, Dept of Lung & Chest Cancer, Warszawa, Poland|BHI of Omsk region - Clinical Oncology Dispensary, Omsk, Russian Federation|St. Petersburg GUZ City Clinical Oncology Dispensary, St. Petersburg, Russian Federation|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Puerta del Mar, Cádiz, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Virgen del Rocío, Sevilla, Spain",,https://ClinicalTrials.gov/show/NCT01950273,816.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,Not Open Label,Treatment/Diagnostic
56,57,NCT00004260,Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma,,Completed,No Results Available,Lymphoma,Biological: recombinant interleukin-12|Biological: rituximab,,Mayo Clinic|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000067514|U01CA069912|980112,1999-10-01,June 2003,2003-06-01,"June 18, 2004",,"August 3, 2011","Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00004260,1339.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
57,58,NCT00893464,A Study of IXAZOMIB in Adult Patients With Lymphoma,,Completed,Has Results,Lymphoma,Drug: IXAZOMIB,Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Number of Participants Reporting at Least 1 TEAE Related to Laboratory Assessments|Number of Participants With Clinically Significant Change From Baseline in Vital Signs|Maximum Tolerated Dose (MTD)|Recommended Phase 2 Dose (RP2D)|C0: Initial Plasma Concentration After Bolus Intravenous Administration|AUC(0-168): Area Under the Plasma Concentration-Time Curve From Time 0 to 168 Hours Postdose for Ixazomib|Terminal Phase Elimination Half-life (T1/2) for Ixazomib|Rac: Accumulation Ratio for Ixazomib|Ae (0-4): Amount of Drug Excreted in Urine From 0 to 4 Hours Postdose|Fe (0-4): Fraction of Dose Excreted Unchanged in Urine From 0 to 4 Hours Postdose|CLr: Renal Clearance|Emax: Maximum Observed Effect for Ixazomib|TEmax: Time to Maximum Observed Effect (Emax) for Ixazomib|Overall Best Response,"Millennium Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,31.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C16002|U1111-1166-8981,2009-08-01,October 2014,2014-10-01,"May 6, 2009","November 11, 2015","November 11, 2015","Tower Cancer Research Center, Beverly Hills, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Kansas University Medical Center, Westwood, Kansas, United States|Cornell University, New York City, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Wisconsin Madison, Madison, Wisconsin, United States|Jewish General Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00893464,1887.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
58,59,NCT00004162,Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma,,Completed,No Results Available,Lymphoma,Biological: sargramostim|Drug: methotrexate|Drug: pegylated liposomal doxorubicin hydrochloride|Drug: vincristine sulfate,Determine the toxicity and maximum tolerated dose of doxorubicin HCl liposome when administered with combination chemotherapy in patients with AIDS-associated non-Hodgkin's lymphoma.|Determine the optimal phase II dose of doxorubicin HCl liposome to be administered with the combination chemotherapy regimen.|Determine the effect of this regimen on HIV viral load in these patients|Determine the clinical response to this regimen by these patients,University of Alabama at Birmingham|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,48.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000067402|UAB-9708|UAB-F970529007|NCI-G99-1627,1997-06-01,January 2001,2001-01-01,"August 5, 2004",,"April 12, 2013","University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT00004162,1310.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
59,60,NCT02086604,Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma,,Completed,No Results Available,"Lymphoma, Large B-Cell, Diffuse",Drug: Brentuximab vedotin|Drug: Lenalidomide,Safety as measured by grade and frequency of adverse events|Maximum Tolerated Dose (MTD) as measured by the number of dose-limiting toxicities in each dose level (cohort)|Objective response rate as measured by CD30 expression|Overall response rate|Duration of response|Progression-free survival (PFS),Washington University School of Medicine|Celgene|Seagen Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,37.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201404056,2014-09-18,"June 9, 2017",2022-01-12,"March 13, 2014",,"February 17, 2022","Washington University School of Medicine, Saint Louis, Missouri, United States|Ohio State University, James Cancer Hospital, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02086604,2673.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
61,62,NCT00420056,"An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.",,Completed,Has Results,"Lymphoma, Mantle-Cell",Drug: PD-0332991,Correlation Coefficient Between Change From Baseline in Fluoro-L-thymidine Positron Emission Tomography (FLT-PET) Maximum Standard Uptake Value (SUVmax) and in Phosphorylated Retinoblastoma (Phospho-Rb) Percent Positive Cells at Cycle 1 Day 21|Correlation Coefficient Between Change From Baseline in Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Maximum Standard Uptake Value (SUVmax) and in Phosphorylated Retinoblastoma (Phospho-Rb) Percent Positive Cells at Cycle 1 Day 21|Change From Baseline in Maximum Standard Uptake Value (SUVmax) at Cycle 1 Day 21|Correlation Between Positron Emission Tomography (PET) Response and Progression-Free Survival (PFS)|Correlation Between Positron Emission Tomography (PET) Response and Objective Response (OR)|Phosphorylated Retinoblastoma (Phospho-Rb) Percent Positive Cells at Baseline|Phosphorylated Retinoblastoma (Phospho-Rb) Percent Positive Cells at Cycle 1 Day 21|Ki-67 Composite Score at Baseline|Ki-67 Composite Score at Cycle 1 Day 21|Cyclin D1 Composite Score at Baseline|Cyclin D1 Composite Score at Cycle 1 Day 21|Number of Participants With Laboratory Test Abnormalities|Number of Participants With Treatment-Emergent Adverse Events by Severity|Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)|Progression-Free Survival (PFS)|Percentage of Participants With Objective Response|Duration of Response (DR)|Time to Tumor Progression (TTP)|Correlation Coefficient Between Plasma PD 0332991 Concentration and Change From Baseline in Biomarkers and SUVmax at Cycle 1 Day 21,Pfizer,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1,17.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A5481002,2007-05-01,March 2010,2012-03-01,"January 9, 2007","June 9, 2015","October 28, 2015","Brigham & Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|New York Presbyterian Hospital, New York, New York, United States|Weill Medical College of Cornell University - New York Presbyterian Hospital, New York, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00420056,1766.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
63,64,NCT00622258,A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma,,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: Everolmus,To assess the safety and tolerability of RAD001 in Japanese patients with relapsed or refractory non-Hodgkin's lymphoma|To assess the pharmacokinetics in Japanese patients|To seek preliminary evidence of efficacy in this population,Novartis Pharmaceuticals|Novartis,All,"20 Years and older   (Adult, Older Adult)",Phase 1,13.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CRAD001C1104,2008-03-01,January 2014,2014-01-01,"February 22, 2008",,"December 21, 2020","Novartis Investigative Site, Nagoya-city, Aichi, Japan|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Kashiwa, Chiba, Japan|Novartis Investigative Site, Isehara-city, Kanagawa, Japan|Novartis Investigative Site, Sendai-city, Miyagi, Japan|Novartis Investigative Site, Chuo-ku, Tokyo, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Kyoto, Japan",,https://ClinicalTrials.gov/show/NCT00622258,2132.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
64,65,NCT01536561,Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma,,Completed,Has Results,"Lymphoma, Non-Hodgkin",Biological: Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab),"Number of Participants (Par.) During Initial Treatment Exposed to the Indicated Dose Levels of the Therapeutic Dose (TD), Re-dose, and Total Dose (TD + Re-dose)|Number of Participants During Retreatment Exposed to the Indicated Dose Levels of the TD, Re-dose, and Total Dose (TD + Re-dose)|Maximum Tolerated Dose (MTD) of TST/I 131 TST Evaluated in the Study|Tumor/Organ Dosimetry of TST/I 131 TST for All Predoses (Initial Treatment)|Tumor/Organ Dosimetry at the Indicated Predoses of 475 mg, 95 mg, and 0 mg (Initial Treatment)|Number of Participants (Par.) With the Indicated Response as Assessed by the Investigator|Number of Participants (Par.) With Confirmed Response as Assessed by the Investigator|Duration of Response for All Unconfirmed Responders (CR, CCR, or PR) as Assessed by the Investigator|Time to Progression of Disease or Death|Overall Survival|Half-life: Initial Half-life (t1/2 Alpha) and Terminal Half-life (t1/2 Beta) of I 131 TST for the Antibody Predose Levels of 0 mg, 95 mg, and 475 mg|Clearance (CL) of I 131 TST for the Indicated Antibody Predose Levels|Area Under the Concentration Time Curve (AUC) of I 131 TST for the Indicated Antibody Predose Levels|Maximum Blood Concentration (Cmax) of I 131 TST for the Indicated Antibody Predose Levels|Volume of Distribution at Steady State (Vss) of I 131 TST for the Indicated Antibody Predose Levels|Number of Participants Who Developed Human Anti-mouse Antibodies (HAMA Postivitiy) After Receiving Tositumomab|Time to HAMA Positivity From the First Dosimetric Dose (Time From Baseline [Dosimetric Dose] to the First Reported Presence of HAMA)|Number of Participants With the Indicated Type of Infection|Time to Nadir for the Indicated Hematologic Laboratory Parameters|Time to Recovery to Baseline for the Indicated Hematologic Laboratory Parameters|Nadir Values for the Hematologic Parameters ANC, Platelets, and WBC Count|Nadir Values for Hemoglobin, a Hematologic Parameter",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,59.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,104728,1990-04-24,"July 2, 1997",2009-10-16,"February 22, 2012","March 30, 2012","August 31, 2017",,,https://ClinicalTrials.gov/show/NCT01536561,7115.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
65,66,NCT00047164,Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy,,Completed,No Results Available,Lymphoma,Biological: ipilimumab,Toxicity after every 3 courses of treatment and every month for up to a year after completion of study treatment|T-cell response after every 3 courses of treatment and every month for up to a year after completion of study treatment,National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1,89.0,NIH,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,020284|02-C-0284|NCI-5744|CDR0000257563,2002-09-01,September 2010,2010-11-01,"January 27, 2003",,"September 26, 2016","Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00047164,2983.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
66,67,NCT00323323,CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas,,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: CHOP|Drug: Alemtuzumab|Procedure: Plasma Samples,Toxicity and safety of concurrent CHOP and Alemtuzumab|Determine pharmacokinetics of Alemtuzumab|Determine immunosuppressive properties of Alemtuzumab + CHOP|Determine if Fc Receptor-gamma (FcγR) polymorphism is predictive of response or toxicity with Alemtuzumab treatment.,Ohio State University Comprehensive Cancer Center|Bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSU-0303,2004-03-01,August 2012,2016-10-01,"May 9, 2006",,"January 20, 2017","Ohio State University, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00323323,4597.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
67,68,NCT00244946,"Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma",,Completed,No Results Available,Lymphoma,Biological: therapeutic autologous lymphocytes|Drug: carmustine|Drug: cytarabine|Drug: etoposide|Drug: melphalan|Procedure: peripheral blood stem cell transplantation (PBSCT),To perform a dose escalation trial of ATC armed with CD20Bi immunotherapy after PBSCT to determine the maximum tolerated dose (MTD) of ATC armed with CD20BI.|Evaluate the toxicities of ATC infusions armed with CD20Bi|Evaluate immune B-cell recovery after ATC infusion|Evaluate response rates of infusions and compare relapse rates and overall survival to historical controls,Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI),All,"15 Years to 70 Years   (Child, Adult, Older Adult)",Phase 1,15.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000446079|P30CA022453|WSU-2007-023|RWMC-0639446,2004-03-01,January 2010,2013-03-01,"October 27, 2005",,"March 26, 2015","Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00244946,3287.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
69,70,NCT01969695,An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma,,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: ABT-199,"Change in cardiac assessment findings|Percentage of subjects with adverse events|Change in clinical laboratory test results|Number of subjects with adverse events|Change in physical exam finding, including vital signs","AbbVie|Genentech, Inc.",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1,11.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M13-835,2013-12-20,"December 16, 2019",2019-12-16,"October 25, 2013",,"December 19, 2019","University of Arizona Arthritis Center /ID# 101359, Tucson, Arizona, United States|Dartmouth-Hitchcock Med Ctr /ID# 92596, Lebanon, New Hampshire, United States|Hackensack Univ Med Ctr /ID# 101417, Hackensack, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT01969695,2187.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
70,71,NCT02809573,Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients,,Completed,No Results Available,Peripheral T-cell Lymphoma,Drug: Chidamide|Drug: cyclophosphamide|Drug: adriacin|Drug: vincristine|Drug: prednisone,dose-limiting toxicity (DLT)|Adverse events|complete response rate|Duration of response|Progression free survival|Objective response rate|Overall survival|Area under the concentration versus time curve (AUC)|Peak plasma concentration (Cmax)|Time of Cmax (Tmax),"Chipscreen Biosciences, Ltd.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,30.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDM103,2016-08-11,"January 8, 2019",2019-01-08,"June 22, 2016",,"July 24, 2019","Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT02809573,880.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
71,72,NCT02613598,Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma,,Completed,No Results Available,"Hodgkin's Lymphoma|Lymphoma, Non-Hodgkin",Drug: Bortezomib|Drug: Ruxolitinib,The Maximum Tolerated Dose (MTD) of Ruxolitinib in Combination with Standard Dose Bortezomib,University of Michigan Rogel Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1,15.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UMCC 2014.066|HUM00104716,2016-05-12,"June 7, 2021",2021-06-07,"November 24, 2015",,"December 20, 2021","University of Michgan Comprehensive Cancer Center, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02613598,1852.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
72,73,NCT00392691,"Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment",,Completed,No Results Available,Lymphoma,Drug: ibritumomab tiuxetan|Drug: rituximab|Drug: melphalan|Drug: vinorelbine tartrate / G-CSF|Procedure: autologous hematopoietic stem cell harvesting and transplantation,Dose-limiting toxicity of high-dose melphalan in combination with yttrium Y 90 ibritumomab tiuxetan|Toxicity|Event occurrence up to 100 days after transplantation|Complete remission 100 days after transplantation,Swiss Group for Clinical Cancer Research,All,65 Years to 120 Years   (Older Adult),Phase 1,20.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SAKK 37/05|SWS-SAKK-37/05|EU-20648|SPRI-SWS-SAKK-37/05|CDR0000511915,2006-10-01,December 2012,2013-05-01,"October 26, 2006",,"May 15, 2019","Kantonsspital Aarau, Aarau, Switzerland|Saint Claraspital AG, Basel, Switzerland|Universitaetsspital-Basel, Basel, Switzerland|Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland|Inselspital Bern, Bern, Switzerland|Kantonsspital Liestal, Bern, Switzerland|Kantonsspital Bruderholz, Bruderholz, Switzerland|Hopital Cantonal Universitaire de Geneve, Geneva, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kantonsspital - St. Gallen, St. Gallen, Switzerland",,https://ClinicalTrials.gov/show/NCT00392691,2404.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
73,74,NCT03630159,Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients,PORTIA,Completed,No Results Available,Diffuse Large B-cell Lymphoma,Biological: Tisagenlecleucel|Drug: Pembrolizumab,"Percent of participants recieving pembrolizumab per protocol schedule|Dose Timing part: Incidence of dose limiting toxicities (DLTs)|Expansion part: Overall response rate (ORR)|Duration of Response (DOR)|Progression Free Survival (PFS)|Overall Survival (OS)|In vivo cellular kinetics of tisagenlecleucel in blood, bone marrow, lymph nodes and other tissues by qPCR and flow cytometry|Impact of pembrolizumab dosing strategy on the cellular kinetics of tisagenlecleucel by qPCR and flow cytometry|Immunogenicity measured by antibody titres specific to tisagenlecleucel molecule and by the presence of T lymphocytes activated by the tisagenlecleucel protein",Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,12.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CCTL019J2101|2018-000973-57,2018-10-09,"July 20, 2021",2021-07-20,"August 14, 2018",,"August 15, 2022","Emory University School of Medicine SC CTL019, Atlanta, Georgia, United States|University of Chicago Medical Center Hematology and Oncology, Chicago, Illinois, United States|University of Kansas Hospital and Medical Center U of Kansas Cancer Center, Kansas City, Kansas, United States|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT03630159,1015.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
74,75,NCT02578316,"A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.",,Completed,Has Results,Advanced Solid Tumors|Lymphomas,Drug: Lenvatinib,Maximum Plasma Concentration (Cmax) of Radiolabeled 14^C-Lenvatinib and Non-Radiolabeled Lenvatinib|Time of Maximum Plasma Concentration (Tmax) of Radiolabeled 14^C-Lenvatinib and Non-Radiolabeled Lenvatinib|Terminal Phase Rate Constant (λz) of Radiolabeled 14^C-Lenvatinib and Non-Radiolabeled Lenvatinib in Plasma|Terminal Exponential Half-life (t1/2) of Radiolabeled 14^C-Lenvatinib and Non-Radiolabeled Lenvatinib in Plasma|Area Under the Plasma Concentration-Time Curve From Time Zero to Time t (AUC(0-t))|Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC(0-inf))|Percentage of Area Under the Plasma Concentration Curve Extrapolated to Infinity (%AUC(Extra))|Apparent Clearance (CL/F) of Lenvatinib From Plasma|Apparent Terminal Volume of Distribution in the Terminal Phase of Lenvatinib (Vz/F)|Renal Clearance of Lenvatinib (CLr)|Percentage Recovery of 14^C- Lenvatinib Related Material in the Urine|Percentage Recovery of 14^C- Lenvatinib Related Material in the Feces|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Objective Tumor Response,Eisai Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,6.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E7080-E044-104,2009-06-01,June 2010,2010-10-01,"October 16, 2015","June 20, 2017","June 20, 2017","Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT02578316,487.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
75,76,NCT00930514,A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma,,Completed,No Results Available,"Lymphoma, Follicular",Drug: Rituximab,Minimum Observed Plasma Trough Concentration (C trough)|Area Under the Curve From Time Zero to end of Dosing Interval (AUCtau)|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Plasma Decay Half-Life (t1/2)|Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs),Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1,281.0,Industry,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP22333|2008-008490-60,2009-09-01,July 2013,2013-07-01,"June 30, 2009",,"November 2, 2016","Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Córdoba, Argentina|Rosario, Argentina|Kogarah, New South Wales, Australia|Sydney, New South Wales, Australia|Kurralta Park, South Australia, Australia|Fitzroy, Victoria, Australia|Porto Alegre, RS, Brazil|Barretos, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Calgary, Alberta, Canada|St. John's, Newfoundland and Labrador, Canada|Halifax, Nova Scotia, Canada|Montreal, Quebec, Canada|Quebec, Canada|Brno, Czech Republic|Hradec Kralove, Czech Republic|Praha 2, Czech Republic|Herlev, Denmark|Guayaquil, Ecuador|Quito, Ecuador|Helsinki, Finland|Tampere, Finland|Turku, Finland|Marseille, France|Montpellier, France|Reims, France|Haifa, Israel|Jerusalem, Israel|Petach Tikva, Israel|Ramat Gan, Israel|Bergamo, Lombardia, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Pisa, Toscana, Italy|Seoul, Korea, Republic of|Aguascalientes, Mexico|Mexico City, Distrito Federal, Mexico|Monterrey, Mexico|Oslo, Norway|Lima, Peru|Lima, Peru|Warszawa, Poland|Wroclaw, Poland|Moscow, Russian Federation|Bratislava, Slovakia|Barcelona, Spain|Barcelona, Spain|Salamanca, Spain|Sevilla, Spain|Huddinge, Sweden|Sundsvall, Sweden|Umea, Sweden|Uppsala, Sweden|Basel, Switzerland|Cambridge, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT00930514,1399.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
76,77,NCT03688152,A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma,,Completed,No Results Available,Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma,Drug: INCB053914|Drug: INCB050465,Number of treatment-emergent adverse events (TEAEs)|Cmax of INCB053914 in combination with INCB050465|Tmax of INCB053914 in combination with INCB050465|Cmin of INCB053914 in combination with INCB050465|AUC0-t of INCB053914 in combination with INCB050465|Cl/F of INCB053914 in combination with INCB050465|Overall response rate|Duration of response|Progression-free survival,Incyte Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 1,9.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INCB 53914-102,2018-12-03,"September 1, 2020",2020-09-01,"September 28, 2018",,"November 10, 2020","University of Arizona Cancer Center, Tucson, Arizona, United States|UCLA Healthcare Hematology-Oncology, Santa Monica, California, United States|Clinical Research Alliance, Lake Success, New York, United States",,https://ClinicalTrials.gov/show/NCT03688152,638.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
77,78,NCT00771472,Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1),,Completed,Has Results,Lymphoma,Drug: vorinostat,"Parts I & II: Number of Participants Experiencing Clinical or Laboratory Adverse Experiences (AE)|Part I: Number of Participants Experiencing Dose Limiting Toxicity (DLT)|Part I: Total Drug Exposure (Area Under the Concentration Curve, AUC[0-24 Hours])|Part I: Maximum Drug Concentration (Cmax)|Part I: Time at Which Cmax Occurs (Tmax)|Part I: The Amount of Time it Takes for the Drug Concentration to Decrease by Half (T1/2)",Merck Sharp & Dohme LLC,All,"20 Years and older   (Adult, Older Adult)",Phase 1,10.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0683-089|2008_565,2008-08-01,July 2011,2011-07-01,"October 13, 2008","July 4, 2012","April 21, 2015",,,https://ClinicalTrials.gov/show/NCT00771472,1064.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
78,79,NCT00098332,"Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma",,Completed,No Results Available,Lymphoma,Drug: forodesine hydrochloride,,BioCryst Pharmaceuticals|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,,Industry,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,BIOCRYST-BCX1777-C-04-105|CDR0000405886,2004-11-01,December 2010,2011-07-01,"December 8, 2004",,"July 10, 2013","Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham, Birmingham, Alabama, United States|Burke Pharmaceutical Research, Hot Springs, Arkansas, United States|Stanford Comprehensive Cancer Center - Stanford, Stanford, California, United States|University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Cancer and Blood Disease Center, Lecanto, Florida, United States|Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Charles M. Barrett Cancer Center at University Hospital, Cincinnati, Ohio, United States|M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00098332,2433.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
79,80,NCT00717925,Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL),,Completed,No Results Available,"Lymphoma, B-Cell",Drug: Inotuzumab Ozogamicin (CMC-544),"Incidence and severity of adverse events, dose-limiting toxicities, and changes in laboratory test results.|Tumor response (according to the International Response Criteria for Non-Hodgkin's Lymphomas).",Wyeth is now a wholly owned subsidiary of Pfizer,All,"20 Years to 74 Years   (Adult, Older Adult)",Phase 1,13.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3129K1-103,2007-03-01,July 2008,2008-07-01,"July 18, 2008",,"December 9, 2015",,,https://ClinicalTrials.gov/show/NCT00717925,488.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
80,81,NCT00698243,Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma,,Completed,No Results Available,Any Solid Tumor or Lymphoma,Drug: OSI-027,Maximum tolerated dose|Safety profile of OSI-027|Pharmacokinetic profile of OSI-027|Preliminary pharmacodynamic relationship with OSI-027 systemic exposure|Preliminary antitumor activity of OSI-027,Astellas Pharma Inc,All,"18 Years and older   (Adult, Older Adult)",Phase 1,128.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSI-027-101|2007-006158-25,2008-06-01,February 2013,2013-02-01,"June 17, 2008",,"April 15, 2013","Karmanos Cancer Institute, Detroit, Michigan, United States|University Hospitals Leuven, Leuven, Belgium|Royal Mardsen Hospital, Sutton, Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT00698243,1706.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
81,82,NCT00040950,Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma,,Completed,No Results Available,Lymphoma,Biological: rituximab|Drug: agatolimod sodium,,Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000069423|UCLA-0112032|CPGI-C004-CPG7909|NCI-G02-2086,2002-03-01,,2007-10-01,"January 27, 2003",,"December 19, 2013","Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00040950,2040.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
82,83,NCT00221325,A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma,,Completed,No Results Available,Central Nervous System Lymphoma|Intraocular Lymphoma,Drug: Intraventricular Rituximab Plus MTX,"whether intra-CSF administration of rituximab in combination with MTX in patients with recurrent CNS and intraocular lymphoma is associated with neurotoxicity|To define the rate of tumor response (CR plus PR) in the brain, spine, eye, or CSF.","University of California, San Francisco",All,"18 Years and older   (Adult, Older Adult)",Phase 1,14.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CC05254|H9414-29670,2007-04-01,January 2012,2013-03-01,"September 22, 2005",,"February 16, 2015","University of California, San Francisco, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00221325,2161.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
83,84,NCT00438802,Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma,,Completed,Has Results,Lymphoma,Drug: Alefacept,Dose Limiting Toxicity (DLT)|Maximum Tolerated Dose (MTD)|Clinical Response,Mayo Clinic|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1,23.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000530071|P50CA097274|P30CA015083|LS058C|06-002246,2006-03-01,"August 24, 2010",2019-07-25,"February 22, 2007","October 2, 2017","August 13, 2019","City of Hope Comprehensive Cancer Center, Duarte, California, United States|Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00438802,4894.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
84,85,NCT00127140,A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030),,Completed,No Results Available,Lymphoma,Drug: vorinostat,Number of participants Experiencing Dose-Limiting Toxicities (DLTs)|Area Under the Curve (AUC) of Vorinostat After Single Oral Dosing,Merck Sharp & Dohme LLC,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 1,10.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0683-030|2005_041,2005-06-01,April 2012,2012-04-01,"August 5, 2005",,"September 28, 2015",,,https://ClinicalTrials.gov/show/NCT00127140,2496.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
85,86,NCT04313608,A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma,,Completed,No Results Available,B-cell Lymphoma,Drug: Glofitamab|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Mosunetuzumab|Drug: Obinutuzumab|Drug: Tocilizumab,"Percentage of Participants with Adverse Events (AEs)|Tolerability of Study Treatment as Measured by Dose Interruptions, Dose Reductions, Dose Intensity, and Treatment Discontinuation due to AEs|Complete Response (CR) Based on PET/CT as Determined by the Investigator According to the 2014 Lugano Response Criteria|Objective Response Rate (ORR), Defined as the Proportion of Participants with a Best Overall Response of Partial Response (PR) or CR, as Determined by the Investigator According to the 2014 Lugano Response Criteria|Minimum Serum Concentration (Cmin) of the CD20-CD3 Bispecific Antibody|Maximum Serum Concentration (Cmax) of the CD20-CD3 Bispecific Antibody|Area Under the Concentration-Time Curve (AUC) of the CD20-CD3 Bispecific Antibody|Proportion of Participants with Anti-Drug Antibodies (ADAs) to Glofitamab|Proportion of Participants with ADAs to Mosunetuzumab",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1,23.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GO41943,2020-06-04,"October 26, 2021",2021-10-26,"March 18, 2020",,"November 24, 2021","Prince of Wales Hospital; Haematology, Randwick, New South Wales, Australia|Monash Health Monash Medical Centre, Clayton, Victoria, Australia|St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT04313608,509.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
86,87,NCT02697552,Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma,,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: HBI-8000,"Maximum tolerated dose (MTD) of HBI-8000 in adult Japanese patients with non Hodgkin's lymphoma (NHL) for whom no other standard therapy is suitable based on the frequency of dose-limiting toxicities (DLTs) which occur within 28 days.|Pharmacokinetic parameter: area under the plasma concentration-time curve (AUC) measurement at 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 12, 24, 48, and 72 hours.|Pharmacokinetic parameter: maximum observed plasma concentration (Cmax) measurement at 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 12, 24, 48, and 72 hours.|Pharmacokinetic parameter: time of maximum observed plasma concentration (Tmax) at 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 12, 24, 48, and 72 hours.|Pharmacokinetic parameter: apparent terminal half-life (T1/2) at 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 12, 24, 48, and 72 hours.|Anti-tumor activity of HBI-8000 by overall response status based on Cheson's response criteria for NHL and Japan Clinical Oncology Group (JCOG) response criteria for Adult T-Cell Lymphoma (ATL)|Safety of HBI-8000 in Japanese patients with NHL for whom no other standard therapy is suitable with incidence and severity of adverse events graded according to the NCI-CTCAE version 4.03","HUYABIO International, LLC.",All,"20 Years and older   (Adult, Older Adult)",Phase 1,13.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HBI-8000-201,2014-03-01,October 2016,2016-10-01,"March 3, 2016",,"January 12, 2017","Nagoya City University Hospital, Aichi, Japan|Fukuoka University Hospital, Fukuoka, Japan|NHO Kyushu Cancer Center, Fukuoka, Japan|Kagoshima University Medical and Dental Hospital, Kagoshima, Japan|Tokai University Hospital, Kanagawa, Japan|NHO Kumamoto Medical Center, Kumamoto, Japan|NHO Nagasaki Medical Center, Nagasaki, Japan|National Cancer Center Hospital, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT02697552,945.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
87,88,NCT00058292,Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma,,Completed,No Results Available,Lymphoma,Biological: filgrastim|Biological: rituximab|Drug: Carmustine|Drug: cytarabine|Drug: etoposide|Drug: melphalan|Procedure: peripheral blood stem cell transplantation|Radiation: yttrium Y 90 ibritumomab tiuxetan,Determine the maximum tolerated dose of absorbed radiation to critical organs delivered with this combination of study treatments,Northwestern University|National Cancer Institute (NCI),All,"17 Years and older   (Child, Adult, Older Adult)",Phase 1,44.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NU 99H11|NU-99H11|IDEC-NU99H11,2000-04-01,June 2006,2009-03-01,"April 9, 2003",,"June 1, 2012","Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States|Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00058292,3256.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
88,89,NCT01237236,A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.,,Completed,No Results Available,Advanced Solid Tumor|Lymphomas,Drug: LEE011,"Primary Outcome Measures: Maximum tolerated dose of LEE011 when administered orally once daily, as assessed by Frequency of DLTs as a function of LEE011 dose|Safety and tolerability of LEE011, as assessed by grade and frequency of Adverse events, serious adverse events, and changes in lab values, vital signs and ECGs.|The pharmacokinetics (PK) of LEE011 (AUC inf, Cmax, Tmax, T1/2)|Any pharmacodynamic activity of LEE011 treatment, as assessed by changes from baseline in biomarkers associated with the pharmacologic activity of LEE011|Antitumor activity that may be associated with LEE011 treatment, as assessed by CT/MRI Response Evaluation Criteria for Solid Tumors (RECIST) Criteria v1.0 or Cheson Criteria 2007 for lymphomas.|Relationship between QTc prolongation and exposure to LEE011 and/or any of its relevant metabolites.",Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,156.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLEE011X2101|2009-017017-30,2010-12-21,"March 9, 2017",2017-03-09,"November 9, 2010",,"December 17, 2020","Dana Farber Cancer Institute DFCI, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center SC, Ann Arbor, Michigan, United States|Memorial Sloan Kettering MSKCC (2), New York, New York, United States|Sarah Cannon Research Institute DeptofSarahCannonRes.Inst. (2), Nashville, Tennessee, United States|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT01237236,2270.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
89,90,NCT00396864,Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma,,Completed,No Results Available,Cancer|Lymphomas,Drug: NPI-0052,Safety|Maximum Tolerated Dose (MTD)|Pharmacokinetics|Pharmacodynamics|Response,Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 1,51.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NPI-0052-100,2006-05-01,March 2010,2010-03-01,"November 8, 2006",,"November 22, 2017","Premiere Oncology of America, Scottsdale, Arizona, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Univ. of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00396864,1400.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
90,91,NCT00935844,Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma,,Completed,No Results Available,Advanced Solid Tumors|Lymphoma,Drug: TAK-901,To identify the MTD of TAK-901 administered as either a 3-hour or 1-hour infusion.|To adaptively adjust the estimate of the MTD of TAK-901 from the escalation phase in an expansion cohort of subjects.|To evaluate the pharmacokinetic profile of TAK-901 and its primary metabolite (M-I).|To evaluate disease response.|To investigate the effect of TAK-901 on tumor proliferation.,"Millennium Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C19001,2009-10-01,August 2011,2011-11-01,"July 9, 2009",,"December 8, 2011","The University of Michigan, Ann Arbor, Michigan, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Fox Chase Cancer Center, Rockledge, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00935844,761.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
91,92,NCT00347971,Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma,,Completed,No Results Available,"Lymphoma, Non-Hodgkin",Drug: recombinant human interleukin 21 and rituximab,Incidence and severity of adverse events through 1 month after completing treatment|Incidence and grade of clinical laboratory abnormalities through 1 month after treatment|Disease response by the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas 2 weeks after completion of the first treatment cycle|Immunogenicity by incidence of anti-rIL-21 antibodies up to 1 month after treatment,ZymoGenetics,All,"18 Years and older   (Adult, Older Adult)",Phase 1,23.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,494E03,2006-06-01,April 2008,2008-04-01,"July 4, 2006",,"September 5, 2008","University of California, Los Angeles, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00347971,670.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
92,93,NCT03730363,Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma,,Completed,No Results Available,Hodgkin Lymphoma|Refractory Hodgkin Lymphoma,Drug: Pentamidine,Maximum tolerated dose (MTD)|Determine Efficacy: best overall response|Define the Duration of Response|Identify Immunohistochemistry Biomarkers|Polymerase Chair Reaction (PCR) analysis of Biomarkers|Identify Phosphorylation Biomarkers|Identify sCD30 and TARC Biomarkers,Reinhold Munker|University of Kentucky,All,"18 Years and older   (Adult, Older Adult)",Phase 1,1.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MCC-18-HEM-13,2018-12-19,"May 23, 2019",2019-05-23,"November 5, 2018",,"July 7, 2021","University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT03730363,155.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
93,94,NCT02658968,Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05),,Completed,No Results Available,"Relapsed, Diffuse Large B-cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma",Drug: Betalutin,Determine the Maximum Tolerated Dose|The best overall tumour response rate|Dosimetry,Nordic Nanovector,All,"18 Years and older   (Adult, Older Adult)",Phase 1,18.0,Industry,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EudraCT: 2015-001933-26,2017-03-02,"June 4, 2021",2021-07-10,"January 20, 2016",,"September 2, 2021","University of California, San Diego (UCSD) - Moores Cancer Center, San Diego, California, United States|University of California, San Francisco (UCSF) - Innovation, Technology & Alliances, San Francisco, California, United States|Sylvester Comprehensive Cancer Centre, Miami, Florida, United States|Klinikum rechts der Isar der TU München, Munich, Germany|Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi, Bologna, Italy|Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy|Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento, Verona, Italy|Hospital Universitari i Politècnic La Fe, Valencia, Spain|University Hospitals Bristol NHS Foundation Trust - Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Christie NHS Foundation Trust, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT02658968,1591.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
94,95,NCT02611323,"A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: Obinutuzumab|Drug: Rituximab|Drug: Polatuzumab Vedotin|Drug: Venetoclax,"Percentage of Participants with CR, Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography (CT) Scans|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Percentage of Participants with Dose-Limiting Toxicities (DLTs)|Recommended Phase 2 Dose (RP2D) of Polatuzumab Vedotin|Recommended Phase 2 Dose (RP2D) of Venetoclax|Percentage of Participants with CR, Determined by the Investigator on the basis of PET and CT Scans|Percentage of Participants with CR, Determined by the Investigator on the Basis of CT Scans Alone|Percentage of Participants with CR, Determined by the IRC on the Basis of CT Scans Alone|Percentage of Participants with Objective Response, Determined by an IRC on the Basis of PET and CT Scans|Percentage of Participants with Objective Response, Determined by the Investigator on the Basis of PET and CT Scans|Percentage of Participants with Objective Response, Determined by an IRC on the Basis of CT Scans Alone|Percentage of Participants with Objective Response, Determined by the Investigator on the Basis of CT Scans Alone|Percentage of Participants with Best Response of CR or PR, Determined by the Investigator on the Basis of CT Scans Alone|Observed Serum Obinutuzumab Concentration|Observed Serum Rituximab Concentration|Observed Serum Polatuzumab Vedotin Concentration|Observed Plasma Polatuzumab Vedotin Concentration|Observed Serum Concentration of Total Antibody to Polatuzumab Vedotin|Observed Plasma Concentration of Polatuzumab Vedotin Antibody-Conjugated Mono-Methyl Auristatin E (MMAE) (acMMAE)|Observed Plasma Concentration of Polatuzumab Vedotin Unconjugated MMAE|Observed Plasma Venetoclax Concentration|Percentage of Participants with Human Anti-Human Antibodies (HAHAs) to Obinutuzumab|Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) to Polatuzumab Vedotin",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1,133.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GO29833|2015-001998-40,2016-03-09,"August 4, 2022",2022-08-04,"November 20, 2015",,"August 8, 2022","University of Arizona Cancer Center, Tucson, Arizona, United States|Yale Cancer Center, New Haven, Connecticut, United States|Memorial Healthcare System, Pembroke, Florida, United States|Emory Univ Winship Cancer Inst, Atlanta, Georgia, United States|University of Louisville Hospital; The James Graham Brown Cancer Center, Louisville, Kentucky, United States|University of Michigan, Ann Arbor, Michigan, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Roswell Park Cancer Inst., Buffalo, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Scott and White, Temple, Texas, United States|Royal North Shore Hospital; Haematology Department, St. Leonards, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Peter MacCallum Cancer Center, North Melbourne, Victoria, Australia|Papa Giovanni Hospital XXIII, Bergamo, Emilia-Romagna, Italy|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Emilia-Romagna, Italy|UO Ematologia, Ospedale S.Maria delle Croci, Ravenna, Emilia-Romagna, Italy|Ospedale Infermi U.O. Ematologia, Rimini, Emilia-Romagna, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy|SCDU Ematologia, Novara, Piemonte, Italy|A.O.U. Citta' Della Salute E Della Scienza-P.O. Molinette;S.C. Ematologia, Torino, Piemonte, Italy",,https://ClinicalTrials.gov/show/NCT02611323,2339.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
95,96,NCT02961881,A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma,,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: blinatumomab,Subject grade of dose limiting toxicities (DLTs)|Incidence of dose limiting toxicities (DLTs)|Severity of dose limiting toxicities (DLTs)|Number of subjects who experience an adverse event (AE)|Blinatumomab PK parameters (clearance of blinatumomab) under cIV|Blinatumomab PK parameters (volume of distribution of blinatumomab) under cIV|Blinatumomab PK parameters (clearance of blinatumomab) under SC administrations|Blinatumomab PK parameters (volume of distribution of blinatumomab) under SC administrations|Maximum Tolerated Dose|Incidence of anti-blinatumomab antibodies|Overall Response Rate (ORR)|Complete Response (CR)|Partial Response (PR) as determined by best overall response (ORR) using Cheson criteria,Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 1,36.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20140286|2016-002034-76,2017-09-18,"September 2, 2021",2021-09-02,"November 11, 2016",,"January 11, 2022","City of Hope National Medical Center, Duarte, California, United States|Rush University Medical Center, Chicago, Illinois, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Epworth Healthcare, East Melbourne, Victoria, Australia|St Vincents Hospital Melbourne, Fitzroy, Victoria, Australia|Hopital Henri Mondor, CrÃ©teil Cedex, France|Hopital Saint Louis, Paris Cedex 10, France|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|UniversitÃ¤tsklinikum Frankfurt/Main, Frankfurt am Main, Germany|Universitatsklinikum Ulm, Ulm, Germany|Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy|Azienda Ospedaliera Universitaria di Bologna Policlinico S Orsola Malpighi, Bologna, Italy|Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|IRCCS Istituto Clinico Humanitas, Rozzano MI, Italy|Leicester Royal Infirmary, Leicester, United Kingdom",,https://ClinicalTrials.gov/show/NCT02961881,1445.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
96,97,NCT00354926,Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma,,Completed,No Results Available,Non-Hodgkin's Lymphoma,Biological: AME-133v (LY2469298),Adverse Events,Applied Molecular Evolution,All,"18 Years and older   (Adult, Older Adult)",Phase 1,67.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AME 06.133v.A,2006-07-01,January 2009,2009-01-01,"July 20, 2006",,"January 7, 2016","University of Alabama Medical Center, Birmingham, Alabama, United States|UCLA Medical Hematology and Oncology, Los Angeles, California, United States|Stanford University Medical Center, Stanford, California, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|University of Virginia Health System, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00354926,915.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
97,98,NCT01594229,A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma,,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: ABT-199|Drug: Rituximab|Drug: Bendamustine,"Determination of the maximum tolerated dose of ABT-199 when administered with Bendamustine and Rituximab in subjects with relapsed or refractory non-Hodgkin's lymphoma|Determination of peak concentration (Cmax), trough concentration (Ctrough) and/or area under the concentration versus time curve (AUC) of ABT-199, Bendamustine and Rituximab in the dose escalation cohort|Number of participants with adverse events as a measure of safety and tolerability|Determination of the recommended Phase 2 dose of ABT-199 when administered with Bendamustine and Rituximab in subjects with relapsed or refractory non-Hodgkin's lymphoma|Evaluate preliminary data regarding progression-free survival when ABT-199 is administered in combination with Bendamustine and Rituximab|Evaluate preliminary data regarding overall survival and duration of overall response when ABT-199 is administered in combination with Bendamustine and Rituximab.|Evaluate preliminary data regarding objective response rate when ABT-199 is administered in combination with Bendamustine and Rituximab|Evaluate preliminary data regarding time to tumor progression when ABT-199 is administered in combination with Bendamustine and Rituximab.","AbbVie|Genentech, Inc.",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1,60.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M12-630,2012-05-21,"July 14, 2020",2020-07-14,"May 9, 2012",,"August 2, 2021","Ucsd /Id# 67350, La Jolla, California, United States|University of California, Los Angeles /ID# 67343, Los Angeles, California, United States|Emory University Hospital /ID# 67349, Atlanta, Georgia, United States|Georgia Regents University /ID# 67342, Augusta, Georgia, United States|Ingalls Memorial Hosp /ID# 67344, Harvey, Illinois, United States|Johns Hopkins University /ID# 67345, Baltimore, Maryland, United States|Henry Ford Health System /ID# 67346, Detroit, Michigan, United States|University of Texas MD Anderson Cancer Center /ID# 69222, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01594229,2976.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
98,99,NCT02581878,Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma,,Completed,No Results Available,"Lymphoma, Non-Hodgkin",Drug: BAY1862864,Maximum tolerated dose assessed by the number of subjects with dose-limiting toxicities (DLTs),Bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,21.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17845|2014-004140-36,2015-11-20,"November 11, 2019",2019-11-26,"October 21, 2015",,"November 25, 2020","Skanes Universitetssjukhus, Lund, Sweden|Southampton General Hospital, Southampton, Hampshire, United Kingdom|Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom|Royal Free Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02581878,1467.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
99,100,NCT01433731,"Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)",,Completed,Has Results,"Lymphoma, T-Cell, Cutaneous",Drug: placebo for SHAPE (SHP-141)|Drug: SHAPE (SHP-141) 0.1% BID|Drug: SHAPE (SHP-141) 0.5% BID|Drug: SHAPE (SHP-141) 1.0% BID,Percentage of Patients With Complete or Partial Response as Measured by Change in Lesion Severity Using CAILS (Composite Assessment of Index Lesion Severity),"TetraLogic Pharmaceuticals|The Leukemia and Lymphoma Society|Therapeutics, Inc.|Veristat, Inc.|PPD",All,"18 Years and older   (Adult, Older Adult)",Phase 1,18.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SHP-141-001,2011-11-01,September 2013,2013-09-01,"September 14, 2011","March 24, 2016","March 24, 2016","Stanford University, Stanford, California, United States|Northwestern University Dept of Dermatology, Chicago, Illinois, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Gahanna, Ohio, United States|MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01433731,670.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,Not Open Label,Treatment/Diagnostic
100,101,NCT00338494,Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma,,Completed,No Results Available,B-Cell Lymphoma,Drug: Clofarabine,"tolerated dose (MTD) of clofarabine|characterize and quantify the toxicity profile associated with clofarabine|determine the overall response rate, plus partial response of clofarabine","Yale University|Genzyme, a Sanofi Company",All,"18 Years and older   (Adult, Older Adult)",Phase 1,16.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0506000158,2005-10-01,March 2010,2011-04-01,"June 20, 2006",,"January 29, 2015","Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00338494,2008.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
101,102,NCT00439361,Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma,,Completed,No Results Available,Hodgkin Lymphoma|Lymphoma,Drug: Bortezomib|Drug: Carboplatin|Drug: Etoposide|Drug: Ifosfamide|Drug: Mesna,Maximum Tolerable Dose (MTD) of Bortezomib when given in combination with ICE chemotherapy in participants with relapsed and refractory classical Hodgkin lymphoma (HL),"M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc.",All,"16 Years and older   (Child, Adult, Older Adult)",Phase 1,14.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2006-0527,2007-02-01,June 2012,2012-06-01,"February 23, 2007",,"July 9, 2012","UT MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00439361,1947.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
102,103,NCT01768338,Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma,,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: Ofatumumab combined with SB-485232,To evaluate the the number of subjects with adverse events who receive SB-485232 when given in combination with ofatumumab|To evaluate the biologic effects of SB-485232 given in combination with ofatumumab,Michael John Robertson|Novartis|Indiana University,All,"18 Years and older   (Adult, Older Adult)",Phase 1,9.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IUCRO-0397|1210009882,2013-02-01,March 2016,2017-08-03,"January 15, 2013",,"February 10, 2023","Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT01768338,1644.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
103,104,NCT00466583,Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma,,Completed,No Results Available,Carcinoma|Lymphoma,Drug: Intravenous EZN-2968 (anti-HIF-1α LNA AS-ODN),Determine the maximum tolerated dose (MTD) of EZN-2968.|Determine the pharmacokinetic (PK) profile; Determine the PD profile.,"Enzon Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,52.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EZN-2968-01,2007-03-01,June 2011,2011-06-01,"April 27, 2007",,"July 7, 2011","Duke University Medical Center, Durham, North Carolina, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States",,https://ClinicalTrials.gov/show/NCT00466583,1553.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
104,105,NCT02594267,A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL),,Completed,No Results Available,Peripheral T-Cell Lymphoma (PTCL),Drug: Pralatrexate Injection,Maximum Tolerated Dose|Number of participants with treatment emergent adverse events (TEAEs) using CTCAE version 4.03|Objective Response Rate|Plasma concentration of pralatrexate in combination with CHOP|Pharmacokinetics: Area Under the Curve (AUC)|Pharmacokinetics: Maximum Concentration (Cmax)|Pharmacokinetics: Time to Maximum concentration (Tmax)|Pharmacokinetics: Clearance (CL),Acrotech Biopharma Inc.|Axis Clinicals Limited,All,"18 Years and older   (Adult, Older Adult)",Phase 1,48.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SPI-FOL-101,2015-11-10,"April 7, 2017",2020-10-08,"November 3, 2015",,"July 27, 2021","Mayo Clinic, Rochester, Minnesota, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|MD Anderson, Houston, Texas, United States|Seattle Cancer Care Alliance/University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02594267,1794.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
105,106,NCT00916630,Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed),,Completed,No Results Available,Central Nervous System Lymphoma,Drug: pemetrexed,To assess the safety and to determine the maximum tolerated dose of pemetrexed given intravenously for the treatment of recurrent lymphoma invading the CNS.|To determine the plasma pharmacokinetics of pemetrexed and assess drug penetration into the CSF.|To provide preliminary evidence of pemetrexed activity against brain lymphoma my MRI criteria of clearance of CSF lymphoma cells.|To identify the time to complete response.|To provide a measure of reduction of enhancing tumor volume as compared to our nomogram of reduction of tumor volume for methotrexate recipients with brain lymphoma.,Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Eli Lilly and Company|Dana-Farber Cancer Institute,All,"18 Years and older   (Adult, Older Adult)",Phase 1,18.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,06-097|H3-US-X059,2009-01-01,September 2015,2015-09-01,"June 9, 2009",,"September 23, 2015","Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00916630,2434.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
106,107,NCT01401530,E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma,,Completed,Has Results,Peripheral T-Cell Lymphoma,Biological: denileukin diftitox (E7777),Maximum Tolerated Dose (MTD) and Recommended Dose (RD)|Number of Participants With Non-Serious Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Denileukin Diftitox|Maximum Serum Concentration (Cmax) of Denileukin Diftitox|Time to Cmax (Tmax) of Denileukin Diftitox in Serum|Area Under the Serum Concentration-Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC(0-t))|Area Under the Serum Concentration-Time Curve From Time 0 to Infinity (AUC(0-inf))|Terminal Phase Rate Constant (λz)|Terminal Elimination Phase Half-life (t1/2)|Volume of Distribution at Terminal Phase (Vz)|Volume of Distribution at Steady State (Vss)|Total Clearance (CL)|Recommended Dose,"Eisai Co., Ltd.|Eisai Inc.",All,"20 Years to 79 Years   (Adult, Older Adult)",Phase 1,13.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E7777-J081-101,2011-07-01,August 2015,2016-01-01,"July 25, 2011","November 23, 2018","November 23, 2018","Nagoya, Aichi, Japan|Kashiwa, Chiba, Japan|Isehara, Kanagawa, Japan|Chuo-ku, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01401530,1645.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
107,108,NCT00103779,A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma,,Completed,No Results Available,Non-Hodgkin Lymphoma,Drug: SGN-40 (anti-huCD40 mAb),Adverse events and lab abnormalities.,"Seagen Inc.|Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,50.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SG040-0002,2004-12-01,March 2007,2007-03-01,"February 15, 2005",,"December 18, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Stanford, California, United States|University of Miami, Miami, Florida, United States|Cornell University, New York, New York, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00103779,820.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
108,109,NCT01345357,Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma,,Completed,No Results Available,Solid Tumors or Mantle Cell Lymphoma,Drug: CEP-9722|Drug: Gemcitabine|Drug: Cisplatin,Determination of the maximum tolerated dose (MTD) of CEP-9722 in combination with gemcitabine and cisplatin in patients with advanced solid tumors or mantle cell lymphoma.|Evaluate the safety and tolerability of CEP-9722 in combination with gemcitabine and cisplatin|Cmax pharmacokinetics parameter|AUC pharmacokinetics parameter|Pharmacodynamics assessment|Efficacy - will be assessed by Tumor response evaluation of each patient,"Cephalon|Teva Branded Pharmaceutical Products R&D, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C9722/1092|2010-023658-36,2011-05-01,December 2012,2013-01-01,"May 2, 2011",,"January 18, 2013","Teva Investigational Site 3, Bruxelles, Belgium|Teva Investigational Site 1, Nantes, France|Teva Investigational Site 2, Villejuif, France",,https://ClinicalTrials.gov/show/NCT01345357,611.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
109,110,NCT00992758,Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement,,Completed,No Results Available,"Lymphoma, Non-Hodgkin",Biological: Iodine-131 Anti-B1 Antibody,"The maximum tolerated dose of Iodine-131 Anti B-1 Antibody in patients with previously treated NHL having more than 25% bone marrow involvement with lymphoma.|response rate|duration of response|relapse-free survival|time to treatment failure|Safety as measured by adverse events, severity of hematologic toxicity, the use of supportive care and the percentage of human anti-murine antibody positivity",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,11.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,104512,1999-05-28,"June 7, 2012",2012-06-07,"October 9, 2009",,"July 25, 2017",,,https://ClinicalTrials.gov/show/NCT00992758,4759.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
110,111,NCT01567475,The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas,(RAD001-R),Completed,No Results Available,Non-Hodgkin's Lymphomas,Drug: Everolimus and rituximab,Phase I part: Determination of the Recommended Dose of RAD001 in combination with rituximab.|Phase II part: Complete Response Rate (CR+CRu)|OVERALL RESPONSE RATE|PROGRESSION-FREE SURVIVAL|OVERALL SURVIVAL|DURATION OF RESPONSE,The Lymphoma Academic Research Organisation,All,"18 Years and older   (Adult, Older Adult)",Phase 1,21.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RAD001-R,2011-12-01,June 2013,2015-12-01,"March 30, 2012",,"March 15, 2016","Service des Maladies du Sang - CHRU de Lille, Lille, France|Service Hématologie - Hôtel Dieu de NANTES, Nantes, France|Service Hématologie - CHU Lyon Sud, Pierre-Bénite, France|Service Hématologie - Centre Henri Becquerel, Rouen, France|Service Hématologie - Institut Gustave Roussy, Villejuif, France",,https://ClinicalTrials.gov/show/NCT01567475,1461.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
111,112,NCT01950364,A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma,,Completed,Has Results,Hodgkin Lymphoma|Anaplastic Large-cell Lymphoma,Drug: brentuximab vedotin|Drug: Brentuximab vedotin and rifampicin,"Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, Predose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 2, Predose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, Predose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 0.5 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 2, 0.5 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 0.5 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 4 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 4 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 24 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 24 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 48 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 48 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 72 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 72 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 96 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 96 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 144 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 144 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 336 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 336 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 480 Hour Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, Predose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 0-24 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 24-48 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 48-72 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 72-96 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 96-120 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 120-144 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 144-168 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 336-360 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 480-504 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, Predose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 0-24 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 24-48 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 48-72 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 72-96 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 96-120 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 120-144 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 144-168 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 336-360 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 480-504 Hours Postdose|Serum Concentrations of Antibody-drug Conjugate (ADC)|Serum Concentration of Total Antibody (TAb)|Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Number of Participants With Anti-therapeutic Antibodies (ATA) to Brentuximab Vedotin|Number of Participants With Markedly Abnormal Laboratory Values|Number of Participants With Clinically Significant Change From Baseline in Vital Signs","Millennium Pharmaceuticals, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,20.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C25005|2013-000193-29|U1111-1174-1958,2013-11-01,October 2014,2015-06-01,"September 25, 2013","February 9, 2016","May 11, 2016","Brussels, Belgium|Gent, Belgium|Vilnius, Lithuania|Barcelona, Spain|Madrid, Spain|Salamanca, Spain",,https://ClinicalTrials.gov/show/NCT01950364,577.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
112,113,NCT01766583,A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma,CLEAR,Completed,No Results Available,Relapsed/Refractory B-cell Lymphoma,Drug: CC-292 + lenalidomide,Determination of the recommended dose of CC-292 and lenalidomide in patients with relapsed/refractory B-cell lymphoma|preliminary efficacy signals of the CC-292 + Lenalidomide combination|Observed maximum plasma concentration|time to reach maximum observed plasma concentration (Tmax)|Terminal phase rate constant (λz)|plasma decay half-life (t1/2)|Area under the curve from time zero to the last quantifiable concentration [AUC(0-t)]|Area under the curve from time zero to extrapolated infinity [AUC(0-∞)]|BTk receptor occupancy,The Lymphoma Academic Research Organisation|Celgene Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 1,18.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLEAR,2013-02-01,November 2014,2018-01-01,"January 11, 2013",,"March 7, 2018","Hopital henri mondor, Créteil, France|CHU de Lille, Lille, France|Institut Paoli Calmette, Marseille, France|CHU de Nantes, Nantes, France|CHU Lyon Sud, Pierre Bénite, France|CHU de Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01766583,1795.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
113,114,NCT00644124,Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma,,Completed,No Results Available,"Lymphoma, Non-Hodgkin",Drug: aflibercept,selected dose of aflibercept based on Dose Limiting Toxicities observed|Adverse events|Response rate|Progression free survival|Biomarkers,Sanofi|Regeneron Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 1,25.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TCD10173|EudraCT 2007-003737-16,2008-03-01,October 2011,2011-10-01,"March 26, 2008",,"May 6, 2016","Sanofi-Aventis Administrative Office, Paris, France",,https://ClinicalTrials.gov/show/NCT00644124,1309.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
114,115,NCT01838434,Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma,,Completed,No Results Available,Relapsed/Refractory Mantle Cell Lymphoma,Drug: lenalidomide|Drug: idelalisib,"Maximum tolerated dose (MTD) of idelalisib and lenalidomide, determined according to incidence of dose-limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)|Progression Free Survival (PFS) of the combination of lenalidomide, with or without idelalisib (Phase II)|Overall survival (OS) (Phase II)|Overall response rate (partial or complete response) (Phase II)","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Celgene Corporation|Gilead Sciences|Biologics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,106.0,Other|NIH|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A051201|NCI-2012-01734|U10CA031946,2013-07-01,"September 30, 2014",2017-05-01,"April 24, 2013",,"January 30, 2018","University of Chicago, Chicago, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Ohio State University Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01838434,1400.0,Not Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
115,116,NCT00073749,Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma,,Completed,Has Results,"Lymphoma, B-Cell",Drug: Inotuzumab ozogamicin [CMC-544],Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Grade 3 or Higher Grades Treatment-Emergent Adverse Events (TEAEs) Based on Severity|Maximum Tolerated Dose (MTD): Part 1 (Dose Escalation Cohorts)|Number of Participants With Dose-limiting Toxicity (DLT)|Progression-Free Survival (PFS): Evaluable Population- Part 2 (Lead-in + Expanded Cohorts)|Progression-Free Survival (PFS): Intent-to-treat Population-Part 2 (Lead-in + Expanded Cohorts)|Overall Survival (OS): Evaluable Population- Part 2 (Lead-in + Expanded Cohorts)|Overall Survival (OS): Intent-to-treat Population: Part 2 (Lead-in + Expanded Cohorts)|Number of Participants With Best Overall Response (BOR): Part 2 (Expanded Cohorts)|Duration of Overall Response (DoR): Part 2 (Lead-in + Expanded Cohorts)|Time-to-Tumor Progression: Part 2 (Expanded Cohorts),Pfizer,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1,79.0,Industry,Interventional,Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,3129K1-100|B1931002,2003-08-01,December 2010,2010-12-01,"December 5, 2003","October 26, 2018","December 17, 2018","UAB CCC Clinical Studies Unit, Birmingham, Alabama, United States|University of Alabama at Birmingham Kirklin Clinic, Birmingham, Alabama, United States|UAB Russell Ambulatory Pharmacy, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|M.D. Anderson Cancer Center, Houston, Texas, United States|Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium|Hopital Saint Louis, Paris, France|Centre Hospitalier Lyon-Sud, Pierre Benite Cedex, France|Universitätsklinikum Bonn, Bonn, NRW, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet, Mainz, Germany|Medizinische Klinik und Poliklinik III, Klinikum der Universitat Muenchen-Grosshadern, Muenchen, Germany|Universitaet Muenchen Klinikum Grosshadern, Muenchen, Germany|Hospital de la Santa Creu I Sant Pau, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|St Bartholomew's Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00073749,2679.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
116,117,NCT00634452,Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma,MDX1401-01,Completed,No Results Available,Hodgkin's Lymphomas,Biological: MDX-1401,Safety and Tolerability Profile|Objective Response Rate (ORR)|Tumor response assessment,Bristol-Myers Squibb,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 1,22.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MDX1401-01|CA213-001,2008-02-01,January 2010,2010-01-01,"March 13, 2008",,"December 6, 2012","Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|ClinWorks Cancer Research Center, Charlotte, North Carolina, United States|Scott and White Memorial Hospital and Clinic, Temple, Texas, United States|West Virginia University, Morgantown, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT00634452,700.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
117,118,NCT02343536,"A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma",,Completed,No Results Available,"Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular",Drug: Oral Azacitidine|Drug: Rituximab|Drug: cyclophosphamide|Drug: Vincristine|Drug: Prednisone,Maximum Tolerated Dose (MTD)|Maximal Administered Dose (MAD)|Adverse Event (AE)|Pharmacokinetics- Cmax|Pharmacokinetics - AUC|Pharmacokinetics - Tmax|Pharmacokinetics - t1/2|Pharmacokinetics CL/F|Pharmacokinetics - Vz/F|Overall response rate (ORR)|Complete response (CR) rate|Progression free survival (PFS),Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 1,59.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CC-486-DLBCL-001,2015-04-29,"January 29, 2020",2020-01-29,"January 22, 2015",,"August 28, 2020","Moffitt Cancer Center, Tampa, Florida, United States|University of Chicago, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Weill Cornell Medicine, New York, New York, United States|Rhode Island Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT02343536,1736.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
118,119,NCT01403948,BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL),,Completed,Has Results,"Lymphoma, Non-Hodgkin",Drug: BI 836826,Determination of the Maximum Tolerated Dose (MTD) Based on the Occurrence of Dose-limiting Toxicity (DLT) in First Cycle in Caucasian Patients|Number of Subjects With Dose Limiting Toxicities (DLT) in First Cycle in Caucasian Patients|Tumour Size Reduction|Best Overall Response Based on All Assessment|Best Overall Response Based on Imaging Data|Progression Free Survival (PFS)|Failure Free Survival (FFS),Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 1,48.0,Industry,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1270.2|2010-024456-29,2011-08-01,"November 14, 2017",2018-02-28,"July 27, 2011","August 11, 2020","August 11, 2020","INS Paoli-Calmettes, Marseille Cedex 09, France|HOP Lyon Sud, Pierre Bénite, France|Charité - Universitätsmedizin Berlin, Berlin, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany|Universitätsklinikum Frankfurt, Frankfurt am Main, Germany|Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Ulm, Ulm, Germany|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT01403948/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT01403948/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01403948,2403.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
119,120,NCT00536835,Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma,,Completed,No Results Available,"Lymphoma, Non-Hodgkin",Drug: GSK461364,"Plasma levels for GSK461364 will be taken at:Schedule 1:Day 1, 8, 15, & 22 for Cycle 1 and Day 1, 8 & 15 for subsequent cycles.Schedule 2:Day 1, 2, 8, 9, 15, & 16 for all cycles.Schedule 3:Day 1 to 5 for all cycles.|Safety will be evaluated by: - Physical exam at screen & then D1 for each cycle - 12 lead ECG & telemetry at screen & Wk 1 to 3 for Schedule 1 & 2, & Wk 1 & 2 (ECG only) for Schedule 3. - Lab tests & AE monitoring throughout the study.",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,41.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PLK107427,2007-08-16,"September 29, 2009",2009-09-29,"September 28, 2007",,"June 26, 2017","GSK Investigational Site, Sutton, Surrey, United Kingdom|GSK Investigational Site, Belfast, Northern Ireland, United Kingdom|GSK Investigational Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00536835,775.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
120,121,NCT01703481,"A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma",,Completed,No Results Available,Tumor or Lymphoma,Drug: JNJ-42756493: Part 1|Drug: JNJ-42756493: Part 2|Drug: JNJ-42756493: Part 3|Drug: JNJ-42756493: Part 4,Part 1: Maximum Tolerated Dose (MTD) of JNJ-42756493|Maximum Observed Plasma Concentration (Cmax) of JNJ-42756493|Minimum Observed Plasma Concentration (Cmin) of JNJ-42756493|Time to Reach Maximum Observed Plasma Concentration (Tmax) of JNJ-42756493|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)|Elimination Half Life of JNJ-42756493|Apparent Volume of Distribution at Steady-State (Vss) of JNJ-42756493|Total Clearance of JNJ-42756493|Accumulation Index (AI) of JNJ-42756493|Number of Participants With Objective Tumor Response|Progression Free Survival (PFS)|Duration of Objective Response|Number of Participants With an Adverse Event,"Janssen Research & Development, LLC",All,"18 Years and older   (Adult, Older Adult)",Phase 1,188.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR100845|42756493EDI1001|2012-000697-34,2012-06-15,"July 5, 2017",2017-07-05,"October 10, 2012",,"May 29, 2019","Birmingham, Alabama, United States|Tucson, Arizona, United States|La Jolla, California, United States|Los Angeles, California, United States|Sacramento, California, United States|Santa Monica, California, United States|Denver, Colorado, United States|Tampa, Florida, United States|Augusta, Georgia, United States|Chicago, Illinois, United States|Goshen, Indiana, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Saint Louis, Missouri, United States|New Brunswick, New Jersey, United States|Albuquerque, New Mexico, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|Tyler, Texas, United States|Fairfax, Virginia, United States|Bordeaux, France|Caen Cedex 05, France|Dijon, France|Lyon, France|Marseille, France|Saint Herblain Cedex, France|Villejuif, France|Badalona, Spain|Barcelona, Spain|Madrid, Spain|Málaga, Spain|Pamplona, Spain|Sevilla, Spain|Valencia, Spain",,https://ClinicalTrials.gov/show/NCT01703481,1846.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
121,122,NCT03212937,"Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma",,Completed,No Results Available,Peripheral T-cell Lymphoma,Drug: Selinexor|Drug: ICE Chemotherapy,Number of participants with treatment related dose limiting toxicity as assessed by NCI CTCAE v4.0|Overall response rate|Progression-free survival|Overall survival,"National Cancer Centre, Singapore",All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 1,11.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Karyopharm001,2016-07-01,November 2020,2020-11-01,"July 11, 2017",,"April 28, 2021","National Cancer Centre Singapore, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT03212937,1584.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
122,123,NCT01564251,A Study of GDC-0575 Alone and in Combination With Gemcitabine in Participants With Refractory Solid Tumors or Lymphoma,,Completed,No Results Available,"Lymphoma, Solid Tumor",Drug: GDC-0575|Drug: Gemcitabine,Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Dose-Limiting Toxicities (DLTs)|Maximum Tolerated Dose (MTD) of GDC-0575|Recommended Phase II Dose of GDC-0575|Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC0-inf) of GDC-0575|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)|Maximum Observed Plasma Concentration (Cmax) GDC-0575|Minimum Observed Plasma Trough Concentration (Cmin) of GDC-0575|Time to Reach Maximum Observed Plasma Concentration (Tmax) of GDC-0575|Apparent Terminal Half-Life (t1/2) of GDC-0575|Apparent Oral Clearance (CL/F) of GDC-0575|Accumulation Ratio (Rac) of GDC-0575|PK-dose Proportionality as Assessed With Cmax of GDC-0575|PK-dose Proportionality as Assessed With AUC of GDC-0575|Phospho-Cyclin-Dependent Kinase 2 (pCdk2) Levels in Fresh Tumor|Phospho-Cyclin-Dependent Kinase 2 (pCdk2) Levels in Skin Tissue|Gamma-H2Ax (γ-H2Ax) Levels in Fresh Tumor|Gamma-H2Ax (γ-H2Ax) Levels in Skin Tissue|Percentage of Participants With Objective Response as Determined Using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1|Progression-Free Survival (PFS) as Determined Using RECIST v1.1|Duration of Objective Response as Determined Using RECIST v1.1,"Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,104.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GP28153|2011-005602-30,2012-03-23,"January 11, 2018",2018-01-11,"March 27, 2012",,"February 25, 2020","Yale Cancer Center, New Haven, Connecticut, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|The Sarah Cannon Research Inst, Nashville, Tennessee, United States|Institut Bergonie; Oncologie, Bordeaux, France|Institut Gustave Roussy; Departement Oncologie Medicale, Villejuif, France",,https://ClinicalTrials.gov/show/NCT01564251,2120.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
123,124,NCT03036904,Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas,V+DA-EPOCH-R,Completed,No Results Available,Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma,Drug: Venetoclax|Drug: Rituximab|Drug: Etoposide|Drug: Vincristine Sulfate|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Doxorubicin Hydrochloride,"Determination of the maximal tolerated dose (MTD)|Determination of dose limiting toxicity (DLT)|Define incidence and severity of adverse events, defined according to CTCAE v 4.0.|Overall response rate|Complete response rate|Event-free survival|Progression Free Survival|Overall survival","Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,31.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1607017413,2017-02-06,"November 11, 2021",2021-11-11,"January 30, 2017",,"August 24, 2022","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Weill Cornell Medicine, New York, New York, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03036904,1739.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
124,125,NCT00001271,A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma,,Completed,No Results Available,B Cell Lymphoma,Drug: IgG-RFB4-SMPT-dgA,,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",Phase 1,24.0,NIH,Interventional,Primary Purpose: Treatment,910176|91-C-0176,1991-07-01,,2001-04-01,"December 10, 2002",,"March 4, 2008","National Cancer Institute (NCI), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00001271,3562.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
125,126,NCT02665650,Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,,Completed,No Results Available,Hodgkin Lymphoma,Biological: AFM13|Biological: Pembrolizumab,Number of participants experiencing dose limiting toxicity (DLT) during combination treatment|Number and frequency of adverse events|Objective response rate (ORR),Affimed GmbH|Merck Sharp & Dohme LLC|The Leukemia and Lymphoma Society,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AFM13-103,2016-05-01,January 2019,2019-03-01,"January 28, 2016",,"May 16, 2019","University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States|Mayo Clinic, Scottsdale, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|University of Miami Sylvester Comprehensive Cancer Center, Coral Gables, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University Medical Center, Saint Louis, Missouri, United States|Providence Portland Medical Center, Providence Cancer Center, Portland, Oregon, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Institut Catala d'Oncologia (ICO) L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Fundacion Privada Instituto de Investigacion Oncologica de Vall Hebron, Barcelona, Spain|Hospital Universitario 12 de Octubre, Servicio de Hematologia, Madrid, Spain|Salamanca University Hospital, Salamanca, Spain",,https://ClinicalTrials.gov/show/NCT02665650,1034.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
126,127,NCT04144140,Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101,,Completed,No Results Available,Lymphoma|Advanced Solid Tumors,Drug: E7766,Dose Escalation Part: Number of Participants with Dose-limiting Toxicities (DLTs)|Dose Escalation and Expansion Part: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Dose Expansion Part: Percentage of Participants With Objective Response|Dose Expansion Part: Duration of Response (DOR)|Dose Expansion Part: Percentage of Participants With Disease Control|Dose Escalation Part: Percentage of Participants With Objective Response|Dose Escalation Part: DOR|Dose Escalation Part: Percentage of Participants With Disease Control|Cmax: Maximum Observed Plasma Concentration for E7766|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for E7766|AUC: Area Under the Plasma Concentration Versus Time Curve for E7766|t1/2: Terminal Elimination Half-life for E7766|CL/F: Apparent Total Body Clearance for E7766|Vd/F: Apparent Volume of Distribution for E7766|CLr: Renal Clearance for E7766|R: Accumulation Ratio for E7766|Dose Escalation Part: Fraction Excreted (fe) in Urine for E7766|Dose Escalation Part: Fraction Excreted (fe) in Feces for E7766|Dose Escalation and Dose Expansion: Progression Free Survival (PFS)|Dose Escalation and Dose Expansion: Overall Survival (OS)|Dose escalation and Dose Expansion: Change in Tumor Size in Injected lesions and in Distant Non-injected Lesions,Eisai Inc.|H3 Biomedicine Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E7766-G000-101|2019-000160-17,2020-02-24,"July 26, 2022",2022-07-26,"October 30, 2019",,"March 24, 2023","Yale New Haven Hospital, New Haven, Connecticut, United States|University of Miami Hospital Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Pittsburgh Medical Center and Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Institut Gustave Roussy, Villejuif, France|Samsung Medical Center, Seoul, Korea, Republic of|Hospital Universitario Vall d'Hebrón, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|START Madrid, Madrid, Spain|INCLIVA Hospital Clínico Universitario de Valencia, Valencia, Spain|Imperial College Healthcare NHS Trust, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT04144140,883.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
127,128,NCT02812875,"A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas",,Completed,No Results Available,Advanced Solid Tumors or Lymphomas,Drug: CA-170,The number of patients with a dose-limiting toxicity (DLT) in the first treatment cycle|Maximum tolerated dose (MTD) of CA-170|Recommended Phase 2 Dose (RP2D) of CA-170|Pharmacokinetic (PK) Profile of CA-170|Preliminary Anti-tumor Activity of CA-170 based on RECIST and Immune Related Response Criterion (irRC) for Solid Tumors or Cheson for Lymphoma,"Curis, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,71.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA-170-101,2016-05-01,"May 7, 2020",2020-05-07,"June 24, 2016",,"June 26, 2020","University of California San Francisco, San Francisco, California, United States|Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States|Sarah Cannon Research Institute, Sarasota, Florida, United States|Northwestern University, Chicago, Illinois, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Icahn School of Medicine at Mt. Sinai, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Carolina BioOncology Institute, Huntersville, North Carolina, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Yonsei University Health System - Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Hospital Clinic i Provincial, Barcelona, Spain|Catalan Institute of Oncology, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02812875,1467.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
128,129,NCT00947739,Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma,,Completed,No Results Available,Advanced Solid Tumors|Lymphomas,Drug: Camptothecin-20-O-Propionate Hydrate (CZ48),"To describe the dose limiting toxicities, adverse event profile, and Phase II recommended dose of Camptothecin-20-O-Propionate hydrate (CZ48).|To perform a pharmacokinetic study of orally administered CZ48 in the plasma. To assess responses by RECIST criteria and to follow patients for survival.",New Mexico Cancer Care Alliance|Christus Stehlin Foundation for Cancer Research,All,"18 Years and older   (Adult, Older Adult)",Phase 1,43.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INST CZ48-01|NCI-2011-02688,2008-09-01,December 2012,2014-03-01,"July 28, 2009",,"June 18, 2015","University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|University of Texas Health Sciences Center, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00947739,2007.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
129,130,NCT02935907,APG-115 in Patients With Advanced Solid Tumors or Lymphomas,APG-115,Completed,No Results Available,Patients With Advanced Solid Tumor or Lymphoma,Drug: APG-115,"Maximum Tolerated Dose (MTD)|Response will be evaluated every 2 cycles (8 weeks), according to the revised RECIST Guideline, Version 1.1|Maximum plasma concentration (Cmax) of APG-115 on Day 1-3 and Day 21-23 post APG-115 treatment on cycle 1|Area under the plasma concentration versus time curve (AUC) of APG-115 on Day 1 -3 and Day 21 - 23 post APG-115 treatment on cycle 1",Ascentage Pharma Group Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,50.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APG-115-US-001,2016-10-01,"June 28, 2019",2019-06-28,"October 18, 2016",,"July 12, 2022","START Midwest, Grand Rapids, Michigan, United States|The START Center for Cancer Care, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02935907,1000.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
130,131,NCT00955786,Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas,,Completed,No Results Available,Advanced Solid Tumors|Lymphoma,Drug: CX-3543,Maximum tolerated dose (MTD) and Dose limiting toxicity (DLT)|Recommended Phase 2 dose|Pharmacokinetics (PK) in humans of intravenously administered CX-3543.|Evaluate evidence of antitumor activity of CX-3543 by objective radiographic assessment.|Pharmacodynamic evaluation of antitumor activity,Cylene Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 1,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C3-05-001,2005-07-01,July 2007,2008-12-01,"August 10, 2009",,"August 10, 2009","Scottsdale, Arizona, United States|San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00955786,1249.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
131,132,NCT02992483,"Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma",,Completed,No Results Available,"Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma",Drug: MIK665,"Incidence and severity of AEs and SAEs, incl. changes in laboratory parameters, vital signs and ECGs.|Incidence of DLTs during the first cycle of treatment with single agent MIK665 during the dose escalation phase only|Tolerability: Dose interruptions|Tolerability: Dose reductions|Tolerability: Dose intensity|Best Overall response (BOR) per International Myeloma Working Group (IMWG) criteria for Myeloma; and per revised criteria for staging of the International Working Group (IWG) guidelines for Lymphoma|Area Under Curve (AUC)|Maximum Plasma Concentration (Cmax)|Terminal elimination half-life (T1/2)|Apparent volume of distribution (Vz)|Clearance (CL)|Duration of Response (DOR)per International Myeloma Working Group (IMWG) criteria for Myeloma; and per revised criteria for staging of the International Working Group (IWG) guidelines for Lymphoma|Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) criteria for Myeloma; and per revised criteria for staging of the International Working Group (IWG) guidelines for Lymphoma",Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,31.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CMIK665X2101|2016-003624-22,2017-07-12,"June 7, 2019",2019-06-07,"December 14, 2016",,"August 3, 2021","MD Anderson Cancer Center/University of Texas MD Anderson CC, Houston, Texas, United States|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Nantes Cedex 1, France|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Fukuoka-city, Fukuoka, Japan|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain",,https://ClinicalTrials.gov/show/NCT02992483,695.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
132,133,NCT02432235,Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma,,Completed,Has Results,Hodgkin Lymphoma|Non-Hodgkin Lymphoma,Drug: Camidanlumab tesirine,Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)|Recommended Dose of Camidanlumab Tesirine for Part 2|Number of Participants Reporting at Least One Treatment Emergent Adverse Event (TEAE)|Number of Participants Reporting at Least One Treatment Emergent Serious Adverse Event (SAE)|Overall Response Rate (ORR)|Duration of Response (DoR)|Progression-Free Survival (PFS)|Overall Survival (OS)|Maximum Observed Serum Concentration (Cmax) for Camidanlumab Tesirine|Time to Reach the Maximum Serum Concentration (Tmax) for Camidanlumab Tesirine|Area Under the Serum Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) for Camidanlumab Tesirine|Area Under the Serum Concentration-time Curve From Time 0 to the End of the Dosing Interval (AUC0-t) for Camidanlumab Tesirine|Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUC∞) for Camidanlumab Tesirine|Accumulation Index (AI) for Camidanlumab Tesirine|Volume of Distribution for Camidanlumab Tesirine|Apparent Terminal Half-life (T1/2) of Camidanlumab Tesirine|Clearance of Camidanlumab Tesirine|Number of Participants With Anti-drug Antibody Response (ADA) Against Camidanlumab Tesirine,ADC Therapeutics S.A.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,133.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ADCT-301-001|2015-005272-25|199948,2015-10-05,"October 24, 2019",2019-10-24,"May 4, 2015","July 13, 2021","July 13, 2021","City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|The University of Texas/MD Anderson Cancer Center, Houston, Texas, United States|Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Froedtert Hospital/Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Guy's and St. Thomas' Hospital NHS Trust, London, England, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom|Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, England, United Kingdom|The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom|Southampton General Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02432235/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02432235/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02432235,1480.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
133,134,NCT03255096,"A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6",,Completed,No Results Available,Diffuse Large B-cell Lymphoma|High-Grade B-cell Lymphoma,Drug: RO6870810|Drug: Venetoclax|Drug: Rituximab,"Percentage of Participants With Dose-Limiting Toxiciities (DLT)- Part 1|Percentage of Participants With Adverse Events (AEs) - Part 1|Percentage of Participants With Clinically Significant Changes in Vital Signs, Physical Examination, Clinical Laboratory Results and Electrocardiogram (ECG) Findings- Part 1|Complete Response (CR) Rate as Determined by Independent Radiological Central Review (ICR) Using Modified Lugano Response Criteria- Recommended Dose (RD) Expansion - Part 2|Overall Response (OR) Rate as Determined by Independent Radiological Central Review (ICR) Using Modified Lugano Response Criteria- RD Expansion - Part 2|Percentage of Participants With Adverse Events (AEs) - Part 2|Percentage of Participants With Clinically Significant Changes in Vital Signs, Physical Examination, Clinical Laboratory Results and Electrocardiogram (ECG) Findings- Part 2|Maximum Concentration (Cmax) of RO6870810 and its Potential Metabolites- Part 1 and Part 2|Trough Serum Concentration (Cmin) of RO6870810 and its Potential Metabolites- Part 1 and Part 2|Time of Maximum Concentration (tmax) of RO6870810 and its Potential Metabolites- Part 1 and Part 2|Clearance (CL) of RO6870810 and its Potential Metabolites- Part 1 and Part 2|Volume of Distribution (Vd) of RO6870810 and its Potential Metabolites- Part 1 and Part 2|Area Under the Curve (AUC) of RO6870810 and its Potential Metabolites- Part 1 and Part 2|Complete Response (CR) Rate as Determined by the Investigator Based on the Modified Lugano Response Criteria- Part 1 and Part 2|Complete Response (CR) Rate, as Determined by the ICR and by the Investigator on the Basis of CT Scans Alone- Part 1 and Part 2|Objective Response Rate, as Determined by the ICR and by the Investigator on the Basis of Modified Lugano Response Criteria- Part 1 and Part 2|Objective Response Rate, as Determined by the ICR and by the Investigator on the Basis of CT Scans Alone- Part 1 and Part 2|Duration of Response (DoR)- Part 1 and Part 2|Progression-Free Survival (PFS)- Part 1 and Part 2|Event-Free Survival (EFS)- Part 1 and Part 2|Disease-Free Survival (DFS)- Part 1 and Part 2|Overall Survival (OS)- Part 1 and Part 2|Half-Life (t1/2) of RO6870810 and its Potential Metabolites- Part 1 and Part 2|Percentage of Ant-Drug Antibodies (ADA) Against Rituximab - Part 1 and Part 2",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1,39.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NP39461|2017-000357-39,2017-08-28,"July 3, 2019",2019-07-03,"August 21, 2017",,"January 24, 2022","City of Hope National Medical Center, Duarte, California, United States|Stanford Cancer Center, Stanford, California, United States|Weill Cornell Medical College, New York, New York, United States|Levine Cancer Institute - Blythe, Charlotte, North Carolina, United States|Peter MacCallum Cancer Centre-East Melbourne, Melbourne, Victoria, Australia|Rigshospitalet; Hæmatologisk Klinik, København Ø, Denmark|Hospital de la Santa Creu i Sant Pau; Servicio de Hematologia, Barcelona, Spain|Hospital Duran i Reynals; Servicio de Hematologia, Barcelona, Spain|START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03255096,674.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
134,135,NCT02164006,"Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients",,Completed,No Results Available,Hodgkin's Lymphoma,Drug: TGR-1202 + brentuximab vedotin,Maximum Tolerated Dose acceptable for participants|Overall Response Rate,"TG Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,16.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TGR-BV-107,2014-06-11,May 2016,2016-05-01,"June 16, 2014",,"October 2, 2019","TG Therapeutics Investigational Trial Site, Duarte, California, United States|TG Therapeutics Investigational Trial Site, San Diego, California, United States|TG Therapeutics Investigational Trial Site, Sarasota, Florida, United States|TG Therapeutics Investigational Trial Site, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02164006,690.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
135,136,NCT01212341,Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor,MG4101,Completed,No Results Available,Malignant Lymphomas|Solid Tumors,Biological: Allogeneic NK cells,To determine the MTD of allogenetic NK cells|To determine the overall response rate|To evaluate the safety|To evaluate the pharmacokinetics of allogeneic NK cells,Seoul National University Hospital|GC Biopharma Corp,All,"18 Years and older   (Adult, Older Adult)",Phase 1,18.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MG4101_P1,2010-09-01,August 2012,2013-03-01,"September 30, 2010",,"August 19, 2013","Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01212341,912.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
136,137,NCT05173545,Clinical Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Recurrent/Refractory Lymphoma Subjects,,Completed,No Results Available,Recurrent/Refractory Lymphoma,Drug: Mitoxantrone Hydrochloride Liposome Injection,"Pharmacokinetic indexes, Cmax Maximum concentration (Cmax)|Pharmacokinetic indexes, Tmax|Pharmacokinetic indexes, Maximum concentration (Cmax,u)|progression-free survival(PFS)","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,24.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PLM60-PK,2019-07-29,"October 28, 2020",2020-10-28,"December 30, 2021",,"December 30, 2021","Guizhou Cancer Hospita, Guiyang, Guizhou, China",,https://ClinicalTrials.gov/show/NCT05173545,457.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
137,138,NCT03009344,A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma,,Completed,Has Results,Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma,Drug: Tazemetostat,"Number of Participants With Dose-limiting Toxicities (DLTs)|Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Cmax: Maximum Plasma Concentration of Tazemetostat and Its Metabolite ER-897387|Tmax: Time to Reach Maximum Plasma Concentration (Cmax) of Tazemetostat and Its Metabolite ER-897387|AUC(0-12 Hours): Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post-dose of Tazemetostat and Its Metabolite ER-897387|AUC(0-t Hours): Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration of Tazemetostat and Its Metabolite ER-897387|AUC(0-infinity): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity of Tazemetostat and Its Metabolite ER-897387|Lambda z: Terminal Phase Elimination Rate Constant of Tazemetostat and Its Metabolite ER-897387|T1/2: Terminal Half-life of Tazemetostat and Its Metabolite ER-897387|CL/F: Apparent Total Body Clearance of Tazemetostat|Vz/F: Apparent Volume of Distribution at Terminal Phase of Tazemetostat|MRT: Mean Residence Time of Tazemetostat and Its Metabolite ER-897387|AUC(0-tau): Area Under the Plasma Concentration-time Curve Over the Dosing Interval of Tazemetostat and Its Metabolite ER-897387|Css,Av: Average Steady State Plasma Concentration of Tazemetostat and Its Metabolite ER-897387|Css,Max: Maximum Steady State Plasma Concentration of Tazemetostat and Its Metabolite ER-897387|Css,Min: Minimum Steady State Plasma Concentration of Tazemetostat and Its Metabolite ER-897387|PTF: Peak-trough Fluctuation Ratio of Tazemetostat and Its Metabolite ER-897387|Tss,Max: Time to Reach the Maximum Plasma Concentration (Cmax) at Steady State of Tazemetostat and Its Metabolite ER-897387|CLss/F: Apparent Total Body Clearance of Tazemetostat at Steady State|Rac (Cmax): Accumulation Ratio of Cmax for Tazemetostat and Its Metabolite ER-897387|Rac (AUC): Accumulation Ratio of AUC for Tazemetostat and Its Metabolite ER-897387|Rss: Steady State Accumulation Ratio of Tazemetostat and Its Metabolite ER-897387|Ae: Amount of Unchanged Drug Tazemetostat Excreted in Urine|Fe: Fraction of Tazemetostat Dose Excreted in Urine|CLR: Renal Clearance of Tazemetostat|Percentage of Participants With Objective Response","Eisai Co., Ltd.|Eisai Inc.",All,"20 Years and older   (Adult, Older Adult)",Phase 1,7.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E7438-J081-106,2017-01-10,"July 12, 2017",2020-06-17,"January 4, 2017","November 10, 2022","November 10, 2022","Eisai Trial Site, Isehara, Kanagawa, Japan|Eisai Trial Site, Chuo-ku, Tokyo, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03009344/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03009344/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03009344,1254.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
138,139,NCT02392611,"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer",,Completed,Has Results,Solid Tumors and Lymphomas,Drug: Alobresib|Drug: Exemestane|Drug: Fulvestrant,Number of Participants Experiencing Dose Limiting Toxicities (DLTs)|Pharmacokinetic (PK) Parameter: Cmax of Alobresib|PK Parameter: Ctau of Alobresib|PK Parameter: AUC0-24 of Alobresib|PK Parameter: AUCtau of Alobresib|PK Parameter: Tmax of Alobresib|PK Parameter: t1/2 of Alobresib,Gilead Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 1,33.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-350-1599|2016-001912-39,2015-03-16,"October 11, 2017",2017-10-11,"March 19, 2015","December 29, 2020","December 29, 2020","Scottsdale, Arizona, United States|Fort Wayne, Indiana, United States|Goshen, Indiana, United States|San Antonio, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02392611/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02392611/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02392611,940.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
139,140,NCT01689220,A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea,,Completed,No Results Available,Peripheral T-cell Lymphoma,Drug: SP-02L (darinaparsin for injection),Incidence of dose-limiting toxicity and adverse events|Tumor response (overall response)|Plasma concentration-time profile,Solasia Pharma K.K.|Synex Consulting Korea Ltd.,All,"20 Years and older   (Adult, Older Adult)",Phase 1,6.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SP-02L03,2012-09-01,January 2014,2014-09-01,"September 21, 2012",,"September 4, 2014","Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01689220,730.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
140,141,NCT01839097,Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL),,Completed,No Results Available,Peripheral T-cell Lymphoma,Drug: Belinostat|Drug: CHOP,Maximum Tolerated Dose (MTD)|Safety and tolerance|Overall Response Rate|Effectiveness of study drug,Acrotech Biopharma Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,23.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SPI-BEL-12-104,2013-05-01,January 2016,2016-01-01,"April 24, 2013",,"January 3, 2020","Yale University, New Haven, Connecticut, United States|Northeast Georgia Cancer Care, LLC, Athens, Georgia, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Hematology - Oncology Associates of Northern NJ P.A, Morristown, New Jersey, United States|Columbia University Medical Center/Center for Lymphiod Malignancies, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01839097,975.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
141,142,NCT00271050,External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma,,Completed,No Results Available,"Lymphoma, B-Cell",Other: external beam radiotherapy plus 90-Y ibritumomab tiuxetan,PET and CT (w/oral and IV contrast),The Cleveland Clinic,All,"18 Years and older   (Adult, Older Adult)",Phase 1,12.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB 7883|CCF IRB 7883|Case 1405,2005-12-01,December 2007,2010-06-01,"December 29, 2005",,"December 21, 2010","Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00271050,1643.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
142,143,NCT00533728,Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma,,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: Soluble beta-glucan (SBG),,Biotec Pharmacon ASA,All,"18 Years and older   (Adult, Older Adult)",Phase 1,12.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SBG-2-02,2007-09-01,February 2009,2009-03-01,"September 21, 2007",,"March 4, 2009","Rikshospitalet, Kreftklinikken Radiumhospitalet, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT00533728,547.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
143,144,NCT01435863,A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL),,Completed,No Results Available,Peripheral T-cell Lymphoma,Drug: SP-02L (darinaparsin for injection),Incidence of dose-limiting toxicity and adverse events|Tumor response (overall response)|Plasma concentration-time profile,Solasia Pharma K.K.,All,"20 Years and older   (Adult, Older Adult)",Phase 1,17.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SP-02L01,2011-09-01,April 2015,2015-07-01,"September 19, 2011",,"August 13, 2015","Nagoya, Aichi, Japan|Sendai, Miyagi, Japan|Fukuoka, Japan|Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01435863,1399.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
144,145,NCT00486135,Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma,,Completed,No Results Available,Cancer|Lymphoma,Drug: XL147 (SAR245408),"Safety, tolerability, and maximum tolerated dose of oral administration of two formulations of XL147 in two treatment schedules|Safety and tolerability of oral dosing with XL147 capsules in subjects with lymphoma, and of XL147 capsules and tablets in subjects with solid tumors|Plasma pharmacokinetics of daily oral administration of XL147 in two treatment schedules|Pharmacodynamic effects of XL147 on tumor tissue when administered at the maximum tolerated dose in two treatment schedules|Plasma pharmacokinetics of XL147 capsule and tablet formulations",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 1,118.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TED11433|XL147-001,2007-06-01,October 2012,2012-10-01,"June 13, 2007",,"February 1, 2013","Investigational Site Number 1241, Augusta, Georgia, United States|Investigational Site Number 1503, Boston, Massachusetts, United States|Investigational Site Number 1401, Dallas, Texas, United States|Investigational Site Number 3412, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT00486135,1949.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
145,146,NCT00434629,Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant,,Completed,No Results Available,B-cell Lymphoma|Non-Hodgkin's Lymphoma,Drug: Bexxar,dose-limiting toxicity|maximum tolerated dose|overall response rate|progression-free survival|time to treatment failure,University of Pennsylvania|GlaxoSmithKline,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,16.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UPCC 18406|UPenn IRB#805353|GSK 106665,2007-02-01,May 2015,2015-05-01,"February 13, 2007",,"August 17, 2016","Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00434629,3011.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
146,147,NCT01221571,A Study to Assess AFM13 in Patients With Hodgkin Lymphoma,,Completed,No Results Available,Hodgkin Lymphoma,Drug: AFM 13,To determine the safety and tolerability of AFM13 monotherapy.|To determine the OBD (Optimal Biological Dose) or MTD (Maximum Tolerated Dose) of AFM13|To define the pharmacokinetic profile of AFM13.|To analyse immunological markers of activity|To assess the immunogenicity of AFM13.|To assess the activity of AFM13,Affimed GmbH,All,"18 Years and older   (Adult, Older Adult)",Phase 1,28.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AFM13-101|2010-019232-13,2010-10-01,May 2013,2013-06-01,"October 15, 2010",,"June 26, 2013","The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University Hosptial Cologne, Koln, Köln, Germany|University Hospital Würzburg, Würzburg, Germany",,https://ClinicalTrials.gov/show/NCT01221571,974.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
147,148,NCT01056679,"Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients",AVD-Rev,Completed,No Results Available,Hodgkin Lymphoma,Drug: Doxorubicine|Drug: DTIC|Drug: Lenalidomide|Drug: Vinblastine,Dose limiting toxicities (DLT)|Overall response rate (ORR)|Progression free survival (PFS),University of Cologne,All,"60 Years to 75 Years   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVD-Rev,2010-04-01,April 2014,2016-02-01,"January 26, 2010",,"March 22, 2018","1st Dept. of Medicine, Cologne University Hospital, Cologne, NRW, Germany",,https://ClinicalTrials.gov/show/NCT01056679,2132.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
148,149,NCT01572519,A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma,,Completed,No Results Available,Relapsed or Refractory Hodgkin Lymphoma,"Drug: Phase 1, Cohort 1|Drug: Phase 1, Cohort 2|Drug: Phase 1, Cohort 3|Drug: Phase 1, Cohort 4|Drug: Phase 2",Phase 1 maximum tolerated dose (MTD) for JNJ-40346527|Phase 2 overall response rate|Duration of response (DOR)|Progression-free survival (PFS)|The number of participants affected by an adverse event|Maximum observed plasma concentration of JNJ-40346527|Trough plasma concentration of JNJ-40346527|Minimum observed plasma concentration of JNJ-40346527|Time of maximum observed plasma concentration of JNJ-40346527|Area under the plasma concentration-time curve of JNJ-40346527|Total drug clearance of JNJ-40346527|Accumulation index of JNJ-40346527,"Janssen Research & Development, LLC",All,"18 Years and older   (Adult, Older Adult)",Phase 1,21.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR100813|40346527HKL1001|2011-005795-42,2012-07-17,"August 13, 2013",2013-08-13,"April 6, 2012",,"November 20, 2020","Lille, France|Villejuif, France|Köln, Germany|Würzburg, Germany",,https://ClinicalTrials.gov/show/NCT01572519,392.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
149,150,NCT02567656,Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma,,Completed,Has Results,"Lymphoma, T-Cell, Peripheral|Lymphoma, T-Cell, Cutaneous",Drug: RP6530,Safety of RP6530|Overall Response Rate (ORR) With RP6530|Duration of Response (DOR) With RP6530|Peak Plasma Concentration (Cmax),Rhizen Pharmaceuticals SA,All,"18 Years and older   (Adult, Older Adult)",Phase 1,58.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RP6530-1401|124584,2015-09-01,March 2018,2018-12-10,"October 5, 2015","January 13, 2020","January 13, 2020","City of Hope, Duarte, California, United States|Chao Family Comprehensive Cancer Center University of California Irvine, Orange, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Emory University School of Medicine, Atlanta, Georgia, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|MD Anderson Cancer Center, Houston, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02567656/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02567656/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02567656,1196.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
150,151,NCT02740270,Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas,,Completed,No Results Available,Solid Tumors|Lymphomas,Drug: GWN323|Drug: PDR001,"Incidence of Dose Limiting Toxicities (DLTs) - Single Agent|Incidence of Dose Limiting Toxicities (DLTs) - Combination Agents|Best Overall Response (BOR),|Progression Free Survival (PFS)|Serum concentration profiles of GWN323 as a single agent: Cmax|Serum concentration profiles of GWN323 in combination with PDR001 and derived PK parameters: Cmax|Presence and titer of anti-GWN323 antibodies|Measurement of the effector/regulatory T cell ratio|Serum concentration profiles of GWN323 as a single agent: AUC|Serum concentration profiles of GWN323 in combination with PDR001 and derived PK parameters: AUC|Presence and titer of anti-PDR001 antibodies",Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,92.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CGWN323X2101|2015-004206-42,2016-07-22,"March 3, 2020",2020-03-03,"April 15, 2016",,"February 21, 2021","Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Kashiwa, Chiba, Japan|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Barcelona, Catalunya, Spain",,https://ClinicalTrials.gov/show/NCT02740270,1320.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
151,152,NCT01317901,A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma,,Completed,Has Results,B-cell Small Lymphocytic Lymphoma Recurrent,Drug: TRU-016|Drug: Bendamustine|Drug: Rituximab,Response,Aptevo Therapeutics,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1,12.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16011,2011-05-01,April 2013,2013-06-01,"March 17, 2011","October 6, 2016","June 28, 2017","Site Reference ID/Investigator# 61543, Birmingham, Alabama, United States|Site Reference ID/Investigator# 61542, Augusta, Georgia, United States|Site Reference ID/Investigator# 61523, Omaha, Nebraska, United States|Site Reference ID/Investigator# 61522, Hackensack, New Jersey, United States|Site Reference ID/Investigator# 61544, Chapel Hill, North Carolina, United States|Site Reference ID/Investigator# 61524, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01317901,762.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
152,153,NCT02453087,A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma,,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: DCDS0780A|Drug: Rituximab|Drug: Obinutuzumab,Number of Participants with Adverse Events|Percentage of Participants with Dose-Limiting Toxicities|Maximum Tolerated Dose (MTD) of DCDS0780A|Recommended Phase 2 Dose (RP2D) of DCDS0780A|Area Under the Serum Concentration-Time Curve (AUC) for DCDS0780A Total Antibody|Maximum Observed Serum Concentration (Cmax) for DCDS0780A Total Antibody|Total Clearance (CL) of DCDS0780A Total Antibody|Half-life (t1/2) of DCDS0780A Total Antibody|Volume of Distribution Under Steady-State Conditions (Vss) of DCDS0780A Total Antibody|Area Under the Plasma Concentration-Time Curve (AUC) for DCDS0780A Conjugate (Antibody-Conjugated Monomethyl Auristatin E [acMMAE])|Maximum Observed Plasma Concentration (Cmax) for acMMAE|Total Clearance (CL) of acMMAE|Half-life (t1/2) of acMMAE|Volume of Distribution Under Steady-State Conditions (Vss) of acMMAE|Area Under the Plasma Concentration-Time Curve (AUC) for Unconjugated Monomethyl Auristatin E (MMAE)|Maximum Observed Plasma Concentration (Cmax) for Unconjugated MMAE|Total Clearance (CL) of Unconjugated MMAE|Half-life (t1/2) of Unconjugated MMAE|Volume of Distribution Under Steady-State Conditions (Vss) of Unconjugated MMAE|Obinutuzumab Serum Concentration|Rituximab Serum Concentration|Percentage of Participants with Anti-DCDS0780A Antibodies|Absolute Lymphocyte Count|Change from Baseline in Intra-Patient Absolute Lymphocyte Counts|Time to CD19+ B-Cell Count Recovery to Baseline Value|Percentage of Participants with Best Overall Response of Complete Response (CR) or Partial Response (PR) Assessed According to Lugano Classification|Duration of Response Assessed According to Lugano Classification|Progression-Free Survival (PFS) Assessed According to Lugano Classification|Relative Dose Intensity (DI) Calculated as Ratio of Amount of Drug Actually Administered to the Amount Planned,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1,66.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GO29687,2015-08-04,"July 12, 2019",2019-07-12,"May 25, 2015",,"August 29, 2019","City of Hope National Medical Center, Duarte, California, United States|Stanford Cancer Center, Stanford, California, United States|Medical Center of Aurora; Rocky Mountain Cancer Centers, Aurora, Colorado, United States|Georgetown University Medical Center Lombardi Cancer Center, Washington, District of Columbia, United States|Florida Cancer Specialists - Sarasota (North Catttlemen Rd), Sarasota, Florida, United States|New York University Cancer Cen, New York, New York, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States",,https://ClinicalTrials.gov/show/NCT02453087,1438.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
153,154,NCT00677105,A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma.,,Completed,No Results Available,Lymphoma|Neoplasms,Drug: JNJ-26481585,"Determine the safety and the maximum tolerated dose of JNJ-26481585. Determine how JNJ-26481585 and its metabolite, JNJ-26395018, are absorbed, broken down and eliminated after oral administration|Investigate the effect of food on the absorption, break down and elimination of JNJ-26481585 and its metabolite, JNJ-26395018. Monitor the antitumor activity of JNJ-26481585.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Janssen Pharmaceutica N.V., Belgium",All,"18 Years and older   (Adult, Older Adult)",Phase 1,92.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR013924,2007-08-01,September 2011,2011-09-01,"May 13, 2008",,"September 17, 2012","Glasgow, United Kingdom|Leeds, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Newcastel Upon Tyne, United Kingdom|Sutton, United Kingdom",,https://ClinicalTrials.gov/show/NCT00677105,1492.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
154,155,NCT03809767,A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas,,Completed,No Results Available,Solid Tumor|Lymphoma,Drug: CS1003 monoclonal antibody,Number of participants with adverse events,CStone Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 1,107.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CS1003-102,2018-10-29,"August 30, 2021",2022-06-13,"January 18, 2019",,"November 30, 2022","Beijing Cancer Hospital, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Peking University Third Hospital, Beijing, China|The First Hospital of Jilin University, Changchun, China|Hunan Cancer Hospital, Changsha, China|West China Hospital Sichuan University, Chengdu, China|Guangdong Provincial People's Hospital, Guangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Yunnan Cancer Hospital, Kunming, China|The First Affiliated Hospital of Nanchang University, Nanchang, China|Huashan Hospital Fudan University, Shanghai, China|Shanghai East Hospital, Shanghai, China|Shanghai pulmonary hospital, Shanghai, China|Zhongshan Hospital, Shanghai, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|Henan Cancer Hospital, Zhengzhou, China",,https://ClinicalTrials.gov/show/NCT03809767,1323.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
155,156,NCT03168035,Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma,,Completed,No Results Available,Advanced Cancer|Lymphoma,Drug: NC-4016,Maximum Tolerated Dose (MTD) of NC-4016|Cmax|Tmax|AUC|T1/2|CL|Vss|Vz|Excretion Profile of Total and Free (Ultrafiltrate) Platinum (Pt),"NanoCarrier Co., Ltd.|M.D. Anderson Cancer Center",All,"18 Years and older   (Adult, Older Adult)",Phase 1,34.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NC-4016-001,2013-11-01,April 2017,2017-04-01,"May 30, 2017",,"February 23, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03168035,1247.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
156,157,NCT01786096,A Safety Study of SGN-CD19A for Leukemia and Lymphoma,,Completed,No Results Available,Burkitt Lymphoma|Precursor B-cell Lymphoblastic Leukemia-Lymphoma,Drug: SGN-CD19A,Incidence of adverse events|Incidence of laboratory abnormalities|Objective response according to modified response criteria for acute myeloid leukemia (Cheson 2003) or revised response criteria for malignant lymphoma (Cheson 2007)|Duration of response|Overall survival|Blood concentrations of SGN-CD19A and metabolites|Incidence of antitherapeutic antibodies,Seagen Inc.,All,"1 Year and older   (Child, Adult, Older Adult)",Phase 1,92.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SGN19A-001,2013-02-01,"May 30, 2017",2017-05-30,"February 7, 2013",,"July 2, 2017","Children's Hospital of Alabama / University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Children's Healthcare of Atlanta / Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01786096,1579.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
157,158,NCT01356173,Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma,,Completed,No Results Available,"Non-Hodgkin's Lymphoma, Solid Tumor",Drug: GDC-0349,Incidence of dose limiting toxicities (DLTs) by NCI CTCAE v4.0 grade and associated dose of GDC-0349|Incidence of adverse events by NCI CTCAE v4.0 grade and associated dose of GDC-0349|Incidence of Grade 3 and 4 abnormalities in safety related laboratory parameters and associated dose of GDC-0349,"Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,10.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MKI4956g|MP00807,2011-06-01,December 2012,2012-12-01,"May 19, 2011",,"November 2, 2016","Scottsdale, Arizona, United States|Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01356173,549.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
158,159,NCT00796731,SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma,,Completed,No Results Available,Lymphoma|Non-Hodgkin,Drug: SAR3419,"Incidence of DLT(s) at each dose level|Cumulative DLT(s)|Incidence of Adverse Events and laboratory abnormalities|Tumor response (complete response, partial response) and duration of the response|Pharmacokinetics parameters",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 1,77.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TED6829|EudraCT 2007-004868-41,2008-10-01,June 2012,2012-06-01,"November 24, 2008",,"July 17, 2012","Sanofi-Aventis Investigational Site Number 250004, Creteil Cedex, France|Sanofi-Aventis Investigational Site Number 250006, Lille Cedex, France|Sanofi-Aventis Investigational Site Number 250001, Pierre Benite Cedex, France|Sanofi-Aventis Investigational Site Number 250005, Rennes, France|Sanofi-Aventis Investigational Site Number 250003, Rouen Cedex, France|Sanofi-Aventis Investigational Site Number 250002, Villejuif Cedex, France",,https://ClinicalTrials.gov/show/NCT00796731,1339.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
159,160,NCT01846390,"Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma",,Completed,No Results Available,Peripheral T-Cell Lymphoma|Diffuse Large B-Cell Lymphoma,Drug: Gemcitabine|Drug: Dexamethasone|Drug: Cisplatin|Drug: Romidepsin,"Maximum tolerated dose of combined romidepsin, gemcitabine, dexamethasone and cisplatin.|Number of patients with adverse events",Canadian Cancer Trials Group|Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 1,21.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LY15,2013-04-30,"July 6, 2016",2018-09-19,"May 3, 2013",,"November 27, 2019","Tom Baker Cancer Centre, Calgary, Alberta, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Regional Health Authority B, Zone 2, Saint John, New Brunswick, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Odette Cancer Centre, Toronto, Ontario, Canada|Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01846390,1968.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
160,161,NCT00788099,Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas,,Completed,No Results Available,Advanced Solid Tumors|Lymphomas,Drug: Plitidepsin and Sorafenib|Drug: Gemcitabine and Plitidepsin,"To determine the maximum tolerated dose (MTD) and the recommended dose (RD) of plitidepsin in combination with sorafenib or gemcitabine in patients with advanced solid tumors or lymphomas.|To characterize safety profile and feasibility, pharmacokinetics, drug-drug interactions. To obtain information on antitumor activity.",PharmaMar,All,"18 Years and older   (Adult, Older Adult)",Phase 1,45.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APL-A-010-08,2008-12-01,June 2011,2011-06-01,"November 10, 2008",,"June 7, 2011","The Cancer Institute of New Jersey (CINJ), New Brunswick, New Jersey, United States|Institut Gustave Roussy, Villejuif, France",,https://ClinicalTrials.gov/show/NCT00788099,912.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
161,162,NCT01491841,"IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma",BRP,Completed,Has Results,Non-Hodgkin's Lymphoma,Drug: Bendamustine + Rituximab + Pixantrone|Drug: Pegfilgrastim,Maximum Tolerated Dose|Overall Response|Progression Free Survival|Toxicity|Overall Survival,"Anne Beaven, MD|CTI BioPharma|Duke University",All,"18 Years and older   (Adult, Older Adult)",Phase 1,33.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00030834,2011-11-01,"November 22, 2016",2017-02-17,"December 14, 2011","June 14, 2019","March 4, 2020","Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01491841,1935.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
163,164,NCT02593045,Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL),,Completed,No Results Available,Cutaneous T-Cell Lymphoma,Biological: IPH4102,Occurrence of Dose Limiting Toxicities (DLT),Innate Pharma,All,"18 Years and older   (Adult, Older Adult)",Phase 1,44.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IPH4102-101,2015-10-01,April 2020,2020-04-01,"October 30, 2015",,"January 20, 2021","Stanford Cancer Center, Stanford, California, United States|Ohio State University, Columbus, Ohio, United States|Hôpital Saint-Louis, Paris, France|Leiden University Medical Center, Leiden, Netherlands|Guy's Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02593045,1644.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
164,165,NCT00854126,A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma,,Completed,No Results Available,"Non-Hodgkin's Lymphoma, Solid Cancers",Drug: GDC-0980,"Occurrence of adverse events|Occurrence of dose-limiting toxicities|Occurrence of Grade 3 and 4 abnormalities in safety-related laboratory parameters and associated dose of GDC-0980|PK parameters after doses of GDC-0980|Best overall response, duration of objective response, and progression-free survival for patients with measurable disease according to RECIST|PET response for patients with detectable FDG tumor uptake at baseline","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,38.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PIM4605g|MP00881,2009-05-01,July 2012,2012-07-01,"March 3, 2009",,"November 2, 2016","Boston, Massachusetts, United States|Villejuif, France|Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT00854126,1157.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
165,166,NCT00554827,Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma,,Completed,No Results Available,Cutaneous T-cell Lymphoma,Dietary Supplement: Vitamin B12|Dietary Supplement: Folic Acid|Drug: Pralatrexate,Determine an Effective and Well-tolerated Dose and Schedule of Pralatrexate with Vitamin B12 and Folic Acid Supplementation for Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma (CTCL)|Characterize the Safety Profile of Pralatrexate in Patients with Relapsed or Refractory CTCL.,Acrotech Biopharma Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,55.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PDX-010,2007-08-01,January 2012,2012-02-01,"November 7, 2007",,"January 3, 2020","City of Hope National Medical Center, Duarte, California, United States|Stanford University School of Medicine, Redwood City, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Fred Hutchinson Cancer Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00554827,1645.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
166,167,NCT01240577,"An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and Lymphomas",,Completed,No Results Available,Neoplasms|Lymphoma,Drug: IPdR,"-Measure plasma concentrations of IPdR, IdUrd, and IdUrd metabolites after a single oral dose of IPdR.-Determine the safety of administering a single oral dose of IPdR.",National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years to 110 Years   (Adult, Older Adult)",Phase 1,10.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,110026|11-C-0026,2010-10-26,"July 30, 2012",2012-07-30,"November 15, 2010",,"October 18, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01240577,643.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
167,168,NCT00644072,SNX-5422 to Treat Solid Tumor Cancers and Lymphomas,,Completed,No Results Available,Lymphoma|Neoplasms,Drug: SNX-5422,Determine the maximum tolerated dose (MTD) of SNX-5422 when administered twice a week for 28 days.|Investigate the effects of SNX-5422 on Hsp90 client proteins using pharmacodynamic (PD) assays.,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",Phase 1,33.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,080091|08-C-0091,2008-03-07,"June 30, 2009",2011-06-16,"March 26, 2008",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00644072,1196.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
168,169,NCT00854152,A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma,,Completed,No Results Available,"Non-Hodgkin's Lymphoma, Solid Cancers",Drug: GDC-0980,"Occurrence of adverse events|Occurrence of dose-limiting toxicities|PK parameters after doses of GDC-0980|Occurrence of Grade 3 and 4 abnormalities in safety-related laboratory parameters and associated dose of GDC-0980|Best overall response, duration of objective response, and progression-free survival for patients with measurable disease","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,121.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PIM4604g|MP00880,2009-03-01,November 2014,2014-11-01,"March 3, 2009",,"November 2, 2016","Chicago, Illinois, United States|Boston, Massachusetts, United States|New York, New York, United States|Nashville, Tennessee, United States|Sutton, United Kingdom",,https://ClinicalTrials.gov/show/NCT00854152,2071.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
169,170,NCT00606645,Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma,,Completed,No Results Available,Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma,Biological: XmAb2513,"Identification of the maximum tolerated dose and identification of the recommended dose of XmAb®2513 for evaluation in future studies.|Safety and tolerability|Assessment of immunogenicity|Objective response rate, disease control rate, and progression free survival.|Change in solCD30","Xencor, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,23.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XmAb2513-01,2007-12-01,April 2010,2010-04-01,"February 4, 2008",,"April 21, 2014","Rush University Medical Center, Chicago, Illinois, United States|Ohio State University, Columbus, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00606645,852.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
170,171,NCT01512758,A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas,,Completed,Has Results,Advanced Solid Tumors|Lymphomas,Drug: Alisertib,"Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)|Number of Participants With Adverse Events and Serious Adverse Events|Number of Participants With Abnormal Clinical Laboratory Values Reported as Adverse Events|Number of Participants With Clinically Significant Changes in Vital Signs Reported as Adverse Events|Cmax: Maximum Observed Concentration for Alisertib|Tmax: Time to First Occurrence of Cmax for Alisertib|AUCτ: Area Under the Concentration-Time Curve From Time 0 to End of Dosing Interval (τ) for Alisertib|Dose Normalized AUCτ: Area Under the Concentration-Time Curve From Time 0 to Time t for Alisertib|T1/2: Terminal Half-Life for Alisertib|Rac: Accumulation Ratio for Alisertib|PTR: Peak Trough Ratio During a Dosing Interval, at Steady State for Alisertib|CLss/F: Apparent Clearance After Extravascular Administration, at Steady State, Calculated Using AUCτ for Alisertib|Best Overall Response Rate Based on Investigator Assessment|Duration of Response|Concentrations of Relevant Tumor Markers","Millennium Pharmaceuticals, Inc.|Takeda",All,"18 Years and older   (Adult, Older Adult)",Phase 1,36.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C14013|1015004128|U1111-1187-6744,2012-02-06,"October 8, 2013",2013-10-08,"January 19, 2012","March 15, 2019","March 15, 2019","National Cancer Centre, Tiong Bahru, Singapore",,https://ClinicalTrials.gov/show/NCT01512758,610.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
171,172,NCT01273155,Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction,,Completed,Has Results,Neoplasms|Lymphomas,Drug: Belinostat,Dose Limiting Toxicity (DLTs)|Maximum Tolerated Dose (MTD) of Belinostat According to Degree of Liver Dysfunction|Number of Participants Experiencing Adverse Events Considered to be at Least Possibly Related to the Study Drug|Pharmacokinetics (PK) of a Single-dose Belinostat (400 mg/m^2)) According to Degree of Liver Dysfunction: Maximum Plasma Concentrations (Cmax)|Pharmacokinetics (PK) of Single-dose Belinostat (400 mg/m^2) According to Degree of Liver Dysfunction: Area Under the Plasma Concentration Time Curve Extrapolated to Infinity(AUC0-inf)|Pharmacokinetics (PK) of Single-dose Belinostat (400 mg/m^2) According to Degree of Liver Dysfunction: Area Under the Plasma Concentration Time Curve Extrapolated to Infinity(AUC0-inf) of Belinostat|Pharmacokinetics (PK) of Single-dose Belinostat (400 mg/m^2) According to Degree of Liver Dysfunction: Half-Life (t1/2)|Pharmacokinetics (PK) of Single-dose Belinostat (400 mg/m^2) According to Degree of Liver Dysfunction: Clearance (CL)|Pharmacokinetics (PK) of Single-dose Belinostat (400 mg/m^2) According to Degree of Liver Dysfunction: Volume of Distribution at Steady State (Vss)|Pharmacokinetics (PK) of Single-dose Belinostat (400 mg/m^2) According to Degree of Liver Dysfunction: Metabolic Ratios of Maximum Plasma Concentrations (Cmax) for the Belinostat Metabolic Pathway|Pharmacokinetics (PK) of Single-dose Belinostat (400 mg/m^2) According to Degree of Liver Dysfunction: Metabolic Ratios of Area Under the Plasma Concentration Time Curve Extrapolated to Infinity (AUC0-inf) for the Belinostat Metabolic Pathway|Best Response|Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0).,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years to 110 Years   (Adult, Older Adult)",Phase 1,72.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,110060|11-C-0060,2011-01-10,"October 25, 2017",2017-10-25,"January 10, 2011","March 26, 2019","March 26, 2019","University of California, Davis, Davis, California, United States|City of Hope National Medical Center, Duarte, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|Emory University, Atlanta, Georgia, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Albert Einstein College of Medicine, Bronx, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT01273155/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT01273155/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01273155,2480.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
172,173,NCT00589381,Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma,,Completed,No Results Available,"Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",Drug: fenretinide lipid matrix,Maximum tolerated dose of 4-HPR/LXS oral powder|Safety|Toxicity|Level of fenretinide in normal peripheral blood mononuclear cells,National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,NIH,Interventional,Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,080030|08-C-0030|NCI-P07187|CDR0000580777,2007-08-01,December 2010,2011-03-01,"January 9, 2008",,"March 8, 2012","Childrens Hospital Los Angeles, Los Angeles, California, United States|USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital, Fort Lauderdale, Florida, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00589381,1308.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
173,174,NCT00315731,"A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma",,Completed,Has Results,"Lymphoma, Follicular",Biological: Follicular Lymphoma,"Area Under the Curve (AUC) at 0 to 120, 0 to 168, and 0 to Infinity Hours|Maximum Concentration (Cmax) Values|Terminal Phase Half-life (t½)|Clearance (CL) Values|Volume of Distribution at Steady State (Vss)|Area Under the Curve (AUC) at 0 to 120 Hours|Area Under the Curve (AUC) at 0 to 168 Hours|Area Under the Curve (AUC) at 0 to Infinity (Extrapolated)|Mean Residence Times From Day 0 to Day 7|Mean Absorbed Dose in the Source Organs and the Target Organs|Number of Participants With Expected Distribution of Radioactivity in the Circulatory System Compared With Uptake by Other Organs.|Percentage of Participants Evaluable for Confirmed Response With Complete Response (CR), CR Unconfirmed (CRu), Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD)|Duration of Response|Progression-free Survival|Overall Survival",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,15.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,393229/027,2003-03-31,"December 4, 2006",2013-06-30,"April 19, 2006","April 23, 2012","July 11, 2017",,,https://ClinicalTrials.gov/show/NCT00315731,3744.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
174,175,NCT01933516,GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma,,Completed,No Results Available,Indolent B-cell Non-Hodgkin's Lymphoma,Drug: GP2013,To evaluate safety of GP2013|Area under the curve calculated from start of dose to the end of the dosing interval (tau) of GP2013|Maximum observed concentration of GP2013|Time to reach maximum concentration of GP2013|Minimum (trough) observed concentration during each dosing interval of GP2013|Terminal elimination rate constant calculated as the slope of the linear regression of the terminal phase of the logarithmic concentration-time profile of GP2013|Elimination half-life associated with the terminal slope of GP2013|To evaluate efficacy of GP2013|To evaluate the incidence of immunogenicity (ADA formation) against GP2013|To evaluate peripheral CD19+ B-cell count,Sandoz|Novartis Pharmaceuticals,All,"20 Years and older   (Adult, Older Adult)",Phase 1,6.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GP13-101,2013-05-01,August 2014,2014-08-01,"September 2, 2013",,"July 26, 2018","Investigative Site, Tachikawa, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01933516,457.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
175,176,NCT01588678,"A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas",,Completed,No Results Available,Advanced Solid Tumor|Lymphoma,Drug: DS-3078a,Maximum tolerated dose|determine the Cmax profile of DS 3078a|effect on glucose metabolism|assess pharmacodynamic effects tumor glucose uptake|assess tumor response|assess pharmacodynamic effects v-akt murine thymoma viral oncogene|determine the AUC of DS 3078a|determine the Tmax of DS 3078a|determine the terminal half-life of DS 3078a,"Daiichi Sankyo, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,32.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DS3078-A-U101,2012-04-01,June 2014,2014-06-01,"May 1, 2012",,"February 12, 2019","South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01588678,791.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
176,177,NCT00322140,CDDO to Treat Solid Tumors and Lymphomas,,Completed,No Results Available,Solid Tumors|Lymphoma,Drug: CDDO,"To determine the dose limiting toxicities, toxicity profile, and maximum tolerated dose of CDDO when administered in adult patients with solid tumors and lymphomas.|To obtain preliminary evidence of anti-tumor activity of CDDO in this population.",National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",Phase 1,7.0,NIH,Interventional,Primary Purpose: Treatment,060151|06-C-0151,2006-05-01,"January 14, 2008",2008-01-14,"May 5, 2006",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00322140,623.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
177,178,NCT01588548,Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma,,Completed,Has Results,Advanced Solid Malignancies|Malignant Lymphoma,Drug: AZD1208,Best Objective Response Based on RECIST Criteria (Evaluable for Response Analysis Set for RECIST Criteria),AstraZeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 1,43.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D4510C00005,2012-07-01,July 2014,2014-07-01,"May 1, 2012","August 19, 2015","November 4, 2015","Research Site, Chuo-ku, Japan|Research Site, Manchester, United Kingdom|Research Site, Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT01588548,730.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
178,179,NCT02963389,"A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients",,Completed,No Results Available,Solid Tumor|Lymphoma,Drug: Tripegfilgrastim,PK parameter|PD parameter,"Dong-A ST Co., Ltd.",All,"6 Years to 19 Years   (Child, Adult)",Phase 1,27.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,DA3031_PNP_I,2016-10-04,November 2018,2018-11-01,"November 15, 2016",,"January 15, 2019","Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02963389,758.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
179,180,NCT01794104,Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas,,Completed,No Results Available,Neoplasm|Lymphoma,Drug: LMP400,"To establish the safety and tolerability of weekly (days 1, 8, 15 q28-day cycle) LMP400 in patients with refractory solid tumors and lymphomas|Evaluate the level of Top1 in tumor biopsies pre and post- administration of LMP400",National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1,21.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,130080|13-C-0080,2013-02-15,"May 19, 2016",2017-10-27,"February 18, 2013",,"September 27, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01794104,1715.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
180,181,NCT00876122,A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable,,Completed,No Results Available,"Non-Hodgkin's Lymphoma, Solid Cancers",Drug: GDC-0941,"Occurrence of adverse events by NCI CTCAE grade and associated dose of GDC-0941|Occurrence of dose-limiting toxicities (DLTs) by NCI CTCAE grade and associated dose of GDC-0941|Occurrence of Grade 3 or 4 abnormalities in safety-related laboratory parameters and associated dose of GDC-0941|PK parameters after single and multiple doses of GDC-0941|Positron emission tomography (PET) response for patients with detectable FDG tumor uptake at baseline|Best overall response, duration of objective response, and progression-free survival (PFS) for patients with measurable disease according to RECIST","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,60.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GDC4254g|GO01299,2008-03-01,June 2012,2012-07-01,"April 6, 2009",,"November 2, 2016","Sutton, United Kingdom",,https://ClinicalTrials.gov/show/NCT00876122,1583.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
182,183,NCT03010176,Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001),,Completed,No Results Available,Solid Tumors|Lymphoma,Drug: Ulevostinag|Biological: Pembrolizumab,"Part 1: Percentage of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 4.0 (CTCAE 4.0)|Parts 1 and 2: Percentage of Participants Who Discontinue Study Drug Due to an Adverse Event (AE)|Parts 1 and 2: Ulevostinag Area Under the Plasma Drug Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24)|Parts 1 and 2: Ulevostinag Minimum Plasma Concentration (Cmin)|Parts 1 and 2: Ulevostinag Maximum Plasma Concentration (Cmax)|Parts 1 and 2: Pembrolizumab Minimum Plasma Concentration (Cmin)|Part 2: Objective Response Rate (ORR) As Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)",Merck Sharp & Dohme LLC,All,"18 Years and older   (Adult, Older Adult)",Phase 1,157.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1454-001|MK-1454-001|2016-003160-40,2017-02-03,"April 21, 2022",2022-04-21,"January 4, 2017",,"June 13, 2022","University of Alabama ( Site 0009), Birmingham, Alabama, United States|University of California San Francisco ( Site 0007), San Francisco, California, United States|UCSF ( Site 0015), San Francisco, California, United States|UCLA Medical Center ( Site 0005), Santa Monica, California, United States|Henry Ford Health System ( Site 0014), Detroit, Michigan, United States|Mount Sinai Hospital ( Site 0002), New York, New York, United States|Columbia University ( Site 0003), New York, New York, United States|UPMC Hillman Cancer Center ( Site 0013), Pittsburgh, Pennsylvania, United States|Mary Crowley Cancer Research Center ( Site 0001), Dallas, Texas, United States|Huntsman Cancer Institute ( Site 0004), Salt Lake City, Utah, United States|Institut Claudius Regaud ( Site 0051), Toulouse Cedex 9, Haute-Garonne, France|Institut Gustave Roussy ( Site 0049), Villejuif, Val-de-Marne, France|Institut Curie ( Site 0050), Paris, France|Rambam Medical Center ( Site 0041), Haifa, Israel|Sheba Medical Center ( Site 0040), Ramat Gan, Israel|Severance Hospital ( Site 0103), Seoul, Korea, Republic of|Asan Medical Center ( Site 0104), Seoul, Korea, Republic of|The Royal Marsden Foundation Trust ( Site 0031), London, London, City Of, United Kingdom|The Royal Marsden NHS Foundation Trust. ( Site 0032), Sutton, Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT03010176,1903.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
183,184,NCT01569750,"A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma",,Completed,No Results Available,CD20-positive B-cell Non-Hodgkin Lymphoma,"Drug: Part 1, Cohort 1|Drug: Part 1, Cohort 2|Drug: Part 1, Cohort 3|Drug: Part 2, Cohort 1|Drug: Part 2, Cohort 2",Part 1 maximum tolerated dose of ibrutinib|The number of participants affected by a dose-limiting toxicity|Number of participants with potential drug-drug interactions between ibrutinib and vincristine|Overall response rate|Duration of response|Progression-free survival|Mean plasma concentrations of ibrutinib|Maximum observed plasma concentration of ibrutinib|Time to reach the maximum plasma concentration of ibrutinib|Area under the plasma concentration-time curve from time 0 to 24 hours of ibrutinib|Elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of ibrutinib|Elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of vincristine|Partial area under the plasma concentration versus time curve of vincristine|The number of participants with pharmacodynamic markers of ibrutinib in peripheral blood mononuclear cells|The number of participants with biomarkers predictive of clinical response|The number of participants affected by an adverse event,"Janssen Research & Development, LLC|Pharmacyclics LLC.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,33.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR100844|PCI-32765DBL1002|2012-000546-35,2012-06-14,"September 4, 2014",2014-09-04,"April 3, 2012",,"August 22, 2017","New York, New York, United States|Rochester, New York, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Lille Cedex, France|Paris, France|Vandoeuvre Les Nancy, France",,https://ClinicalTrials.gov/show/NCT01569750,812.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
184,185,NCT02471911,KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma,KPT-330+RICE,Completed,No Results Available,Diffuse Large B-Cell Lymphoma,Drug: KPT-330|Drug: Rituximab|Drug: Etoposide|Drug: Carboplatin|Drug: Ifosfamide|Drug: Dexamethasone,Maximum Tolerated Dosage (MTD) of Selinexor/KPT-330 when combined with RICE chemo in a relapsed/refractory aggressive b-cell lymphoma setting.|Survival of subjects treated with KPT-330 + RICE|Progression-Free Survival of subjects treated with KPT-330 + RICE|Number of patients who demonstrate a Response to KPT-330+RICE|Number of patients who undergo stem cell collection after induction therapy with KPT-330 + RICE,Weill Medical College of Cornell University|Karyopharm Therapeutics Inc|The Leukemia and Lymphoma Society|FDA Office of Orphan Products Development,All,"18 Years and older   (Adult, Older Adult)",Phase 1,22.0,Other|Industry|U.S. Fed,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1502015891,2015-12-11,"October 31, 2019",2021-10-14,"June 15, 2015",,"April 12, 2022","Weill Cornell Medical College, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02471911,2134.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
185,186,NCT01877382,A Phase 1 Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas,,Completed,No Results Available,Advanced Solid Tumor|Lymphoma,Drug: Milademetan,"Number of Participants With Treatment-emergent Adverse Events by Frequency and Grade in Each Cohort of Dose and Dosing Schedule and the Total Number of Participants With the Treatment-emergent Adverse Events|Maximum Tolerated Dose(s) (MTD) Identified at Different Dosing Schedules|Number of Participants With Dose-Limiting Toxicities at Each Dose Level [level/cohort] and the Total Number of Participants With Dose-limiting Toxicities|Number of Participants With Melanoma and Diffuse Large B Cell Lymphoma in Dose Expansion Cohorts Who Achieved Objective Response per RECIST v1.1 and International Working Group, Respectively|Summary of Milademetan PK Parameter Maximum Plasma Concentration (Cmax)|Summary of Milademetan PK Parameter Area Under the Curve (AUC)|Summary of Milademetan PK Parameter Time to Reach Maximum Plasma concentration (Tmax)|Summary of Milademetan PK Parameter Apparent Clearance (CL/F)|Summary of Milademetan PK Parameter Elimination Terminal Half Life Half-Life (T1/2)|Pharmacodynamic Effect of Milademetan Assessed by Increase in Serum MIC-1 Levels Over Baseline","Daiichi Sankyo, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,108.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DS3032-A-U101,2013-07-01,"October 8, 2020",2020-12-03,"June 13, 2013",,"December 8, 2020","Karmanos Cancer Institute, Detroit, Michigan, United States|Columbia University College of Physicians and Surgeons, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Tennessee Oncology, Nashville, Tennessee, United States|UT MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01877382,2712.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
186,187,NCT00825149,A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma,GAUDI,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: Bendamustine|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Fludarabine|Drug: Obinutuzumab|Drug: Prednisone|Drug: Vincristine,"Percentage of Participants With Adverse Events (AEs) - Relapsed/Refractory Population|Percentage of Participants With AEs - First-line Population|Percentage of Participants With End of Induction Response, According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - Relapsed/Refractory Population|Percentage of Participants With End of Induction Response, According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - First-line Population|Percentage of Participants With Best Overall Response, According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - Relapsed/Refractory Population|Percentage of Participants With Best Overall Response, According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - First-line Population|Percentage of Participants With Best Overall Response of Complete Response, According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - Relapsed/Refractory Population|Percentage of Participants With Best Overall Response of Complete Response, According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - First-line Population|Number of Participants With Progression-Free Survival (PFS) Events (Disease Progression/Relapse or Death), According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - Relapsed/Refractory Population|Number of Participants With PFS Events (Disease Progression/Relapse or Death), According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - First-line Population|PFS, According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - Relapsed/Refractory Population|PFS, According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - First-line Population|Number of Participants With Event-Free Survival (EFS) Event (Disease Progression, Death, or Initiation of a New Anti-Lymphoma Therapy), According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - Relapsed/Refractory Population|Number of Participants With EFS Event (Disease Progression, Death, or Initiation of a New Anti-Lymphoma Therapy), According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - Relapsed/Refractory Population|EFS, According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - Relapsed/Refractory Population|EFS, According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - First-line Population|Pharmacokinetics of Obinutuzumab: Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) - Relapsed/Refractory Population|Pharmacokinetics of Obinutuzumab: AUClast - First-line Population|Pharmacokinetics of Obinutuzumab: Maximum Observed Plasma Concentration (Cmax) - Relapsed/Refractory Population|Pharmacokinetics of Obinutuzumab: Cmax - First-line Population|Pharmacokinetics of Obinutuzumab: Systemic Clearance at Steady State (CLss) - Relapsed/Refractory Population|Pharmacokinetics of Obinutuzumab: CLss - First-line Population|Pharmacokinetics of Obinutuzumab: AUC From Time Zero to 7 Days (AUC7d) - Relapsed/Refractory Population|Pharmacokinetics of Obinutuzumab: AUC7d - First-line Population|Pharmacokinetics of Obinutuzumab: Volume of Distribution at Steady State (Vss) - Relapsed/Refractory Population|Pharmacokinetics of Obinutuzumab: Vss - First-line Population|Pharmacokinetics of Obinutuzumab: Plasma Half-life (t1/2) - Relapsed/Refractory Population|Pharmacokinetics of Obinutuzumab: t1/2 - First-line Population|Pharmacokinetics of Obinutuzumab: Plasma Trough Concentration (Ctrough) - Relapsed/Refractory Population|Pharmacokinetics of Obinutuzumab: Ctrough - First-line Population|Pharmacodynamics of Obinutuzumab: Number of Participants With Peripheral Blood B-cell Depletion - Relapsed/Refractory Population|Pharmacodynamics of Obinutuzumab: Number of Participants With Peripheral Blood B-cell Depletion - First-line Population|Pharmacodynamics of Obinutuzumab: Time From End of Treatment to B-Cell Recovery - Relapsed/Refractory Population|Pharmacodynamics of Obinutuzumab: Time From End of Treatment to B-Cell Recovery - First-line Population",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1,137.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BO21000|2008-001643-19,2009-02-01,November 2015,2015-11-01,"January 19, 2009",,"November 4, 2016","Kogarah, New South Wales, Australia|Sydney, New South Wales, Australia|Greenslopes, Queensland, Australia|Woolloongabba, Queensland, Australia|Kurralta Park, South Australia, Australia|Frankston, Victoria, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Lille, France|Montpellier, France|Pierre Benite, France|Aschaffenburg, Germany|Freiburg, Germany|Göttingen, Germany|Heidelberg, Germany|Kiel, Germany|Köln, Germany|Muenchen, Germany|Ulm, Germany|Würzburg, Germany|Roma, Lazio, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Salamanca, Spain|Valencia, Spain|Leicester, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Plymouth, United Kingdom|Southampton, United Kingdom|Truro, United Kingdom",,https://ClinicalTrials.gov/show/NCT00825149,2464.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
187,188,NCT03249792,Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001),,Completed,No Results Available,Solid Tumor|Lymphoma,Drug: MK-2118 (IT)|Drug: MK-2118 (SC)|Biological: Pembrolizumab,Dose-limiting Toxicities (DLTs)|Adverse Events (AEs)|Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)|MK-2118 Minimum Plasma Concentration (Cmin)|MK-2118 Maximum Plasma Concentration (Cmax)|MK-2118 Area Under the Concentration-time Curve from 0 to 24 hours (AUC 0-24hr)|Pembrolizumab Cmin,Merck Sharp & Dohme LLC,All,"18 Years and older   (Adult, Older Adult)",Phase 1,140.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2118-001|MK-2118-001,2017-09-20,"December 28, 2022",2022-12-28,"August 15, 2017",,"January 25, 2023","University of California San Diego Moores Cancer Center ( Site 0004), La Jolla, California, United States|UCLA ( Site 0003), Los Angeles, California, United States|University of Chicago ( Site 0002), Chicago, Illinois, United States|New York Presbyterian Hospital/Columbia University ( Site 0001), New York, New York, United States|UPMC Hillman Cancer Centers ( Site 0007), Pittsburgh, Pennsylvania, United States|Mary Crowley Cancer Research Center ( Site 0005), Dallas, Texas, United States|MD Anderson Cancer Centr. ( Site 0006), Houston, Texas, United States|Sheba Medical Center ( Site 0301), Ramat-Gan, Israel",,https://ClinicalTrials.gov/show/NCT03249792,1925.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
188,189,NCT01898078,Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas,,Completed,Has Results,Advanced Solid Tumors|Lymphoma,Drug: Alisertib,Cmax: Maximum Observed Plasma Concentration of Alisertib|AUC(Last): Area Under the Plasma Concentration Curve From Time 0 to the Time of the Last Quantifiable Concentration of Alisertib|AUC∞: Area Under the Plasma Concentration Curve From Time 0 to Infinity of Alisertib|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Change in Laboratory Parameters Reported as AEs|Number of Participants With Clinically Significant Change in Vital Sign Reported as AEs,"Millennium Pharmaceuticals, Inc.|Takeda",All,"18 Years and older   (Adult, Older Adult)",Phase 1,26.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C14017,2013-07-16,"March 5, 2014",2017-01-24,"July 12, 2013","June 21, 2019","June 21, 2019","Bronx, New York, United States|Nashville, Tennessee, United States|San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01898078,1288.0,Industry Lead,Less than three Conditions,Randomized,Crossover Assignment,None (Open Label),Treatment/Diagnostic
190,191,NCT02076451,"Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas",,Completed,No Results Available,Advanced Solid Tumor|Lymphoma,Drug: DS-8273a,number of adverse events|maximum tolerated dose|tumor response|incidence of human anti-human antibody (HAHA) formation|determine the pharmacokinetics of DS-8273a,"Daiichi Sankyo, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,32.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DS8273-A-U101,2014-02-01,December 2015,2015-12-01,"March 3, 2014",,"February 12, 2019","Sarah Cannon Research Institute / Tennesee Oncology, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02076451,668.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
191,192,NCT02206308,"Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.",,Completed,No Results Available,B-cell Non Hodgkin's Lymphoma,Biological: Chimeric anti-CD20 monoclonal antibody,Number of participants with infusion-related reaction and with drug-related adverse events.|Area Under the plasma concentration versus time curve (AUC) of SCT400,Sinocelltech Ltd.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,15.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCT400NHLI,2012-05-01,July 2013,2013-07-01,"August 1, 2014",,"August 1, 2014",,,https://ClinicalTrials.gov/show/NCT02206308,426.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
192,193,NCT01169532,Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma,,Completed,Has Results,"Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",Drug: ridaforolimus|Drug: vorinostat|Procedure: biopsy|Other: pharmacological study|Other: laboratory biomarker analysis,Maximum Tolerated Dose (MTD)|Progression Free Survival|Overall Survival,Fox Chase Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,16.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,09-034|NCI-2010-01907,2010-10-01,March 2014,2014-03-01,"July 26, 2010","February 21, 2021","February 21, 2021","Fox Chase Cancer Center, Rockledge, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01169532,1247.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
193,194,NCT00553189,Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas,,Completed,No Results Available,Solid Tumors|Lymphomas,Drug: ABT-888|Drug: Topotecan,Safety and tolerability of the combination of ABT-888 with topotecan hydrochloride in patients with refractory solid tumors and lymphomas; Establish the maximum tolerated dose of ABT-888 with topotecan hydrochloride.|Evaluate the pharmacokinetic of each agent alone and in combination; determine the effects of the study treatment on the level of PARP inhibition and DNA damage in PBMCs and tumor samples.,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",Phase 1,31.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,070203|07-C-0203,2007-08-09,"February 1, 2008",2011-09-28,"November 4, 2007",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00553189,1511.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
194,195,NCT00001512,Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines,,Completed,No Results Available,B Cell Lymphoma|Follicular Lymphoma|Lymphoma,Drug: Id-KLH Vaccine|Drug: GM-CSF,,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",Phase 1,42.0,NIH,Interventional,Primary Purpose: Treatment,960133|96-C-0133,1996-09-09,"March 5, 2010",2010-03-05,"November 4, 1999",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00001512,4925.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
195,196,NCT03029338,CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma,,Completed,No Results Available,Lymphomas Non-Hodgkin's B-Cell|Relapse,Biological: CD19 CAR T cells,Number of patients with adverse events|Severity of the adverse events|Response rate|Progression-free survival(PFS)|Persistence of CAR T cells in vivo,Institute of Hematology & Blood Diseases Hospital|Juventas Cell Therapy Ltd.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,20.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XH-CD19CART-002,2017-06-08,"May 22, 2019",2021-06-22,"January 24, 2017",,"January 26, 2022","Institute of Hematology & Blood Diseases Hospital, Tianjin, China",,https://ClinicalTrials.gov/show/NCT03029338,1475.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
197,198,NCT00556699,"A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma",,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: rituximab|Drug: SGN-40,"Incidence and nature of dose-limiting toxicities in order to determine the maximum tolerated dose|Changes in vital signs, physical examination findings, and clinical laboratory results|Incidence, nature, and severity of adverse events|Pharmacokinetic parameters|Patient's best response as assessed by the investigator|Duration of response|Event-free survival","Genentech, Inc.|Seagen Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,22.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ACF4325g,2007-12-01,November 2010,2010-11-01,"November 12, 2007",,"March 20, 2014",,,https://ClinicalTrials.gov/show/NCT00556699,1066.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
198,199,NCT02057445,3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma,,Completed,No Results Available,Non-Hodgkins Lymphoma|Hodgkins Lymphoma|Lymphoproliferative Disorder,Drug: EBV CTL's|Other: Peripheral Blood Donor,To determine the safety of giving 3rd party EBV-CTLs|To develop a third party bank of LMP-specific CTL|To measure the response rate,New York Medical College|Children's National Research Institute|Baylor College of Medicine|M.D. Anderson Cancer Center|University of Michigan|University of Utah|City of Hope Medical Center|Ohio University|Johns Hopkins University,All,"1 Year and older   (Child, Adult, Older Adult)",Phase 1,1.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NYMC-561,2014-01-01,December 2016,2017-12-01,"February 7, 2014",,"December 22, 2017","Children's National Medical Center, Washington, District of Columbia, United States|New York Medical College, Valhalla, New York, United States",,https://ClinicalTrials.gov/show/NCT02057445,1430.0,Not Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
199,200,NCT02000934,A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies,,Completed,No Results Available,Advanced Solid Tumor and Lymphoma Malignancies,Drug: TAK-659,"Percentage of Participants with Dose Limiting toxicities (DLTs) in Cycle 1|Number of participants with Adverse events (AEs), Grade 3 and 4 AEs, Serious Adverse events (SAEs), Discontinuations for AEs|Overall response rate (ORR) in the CLL, DLBCL, iNHL, MCL, and PTLD Cohorts|Duration of response (DOR), time to progression (TTP) and progression-free survival (PFS) in the CLL, DLBCL, iNHL, MCL, PTLD Cohorts|Overall Survival (OS) Rate in the CLL, DLBCL, iNHL, MCL, PTLD Cohorts|Cmax: Maximum Observed Plasma Concentration for TAK-659|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-659|AUC(0-24): Area under the Plasma Concentration-Time Curve from Time 0 to Time 24 hour for TAK-659|AUClast: Area under the Plasma Concentration-Time Curve from Time 0 to Time of the Last Quantifiable Concentration for TAK-659|T1/2: Terminal Disposition Half-life","Calithera Biosciences, Inc",All,"18 Years and older   (Adult, Older Adult)",Phase 1,143.0,Industry,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C34001|U1111-1165-3590|15/LO/0302,2013-12-31,"June 29, 2021",2021-06-29,"December 4, 2013",,"February 8, 2023","Florida Cancer Specialists, Sarasota FL, Sarasota, Florida, United States|Northwestern University, Chicago, Illinois, United States|SCRI, Nashville, Tennessee, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy|Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi, Bologna, Italy|Ospedale San Raffaele U.O. di Ematologia e Trapianto di midollo osseo, Milano, Italy|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma, Italy|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Avda. Reyes Catolicos, 2, Madrid, Spain|Centro Integral Oncologico Clara Campal, Madrid, Spain|University College London Hospitals, London, Greater London, United Kingdom|The Christie, Manchester, Greater Manchester, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT02000934,2737.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
200,201,NCT01051635,A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas,,Completed,No Results Available,Neoplasms|Lymphoma,Drug: LMP400|Drug: LMP776,Safety|Pharmacodynamic effects,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",Phase 1,55.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,100056|10-C-0056,2010-01-25,"June 21, 2017",2017-06-21,"January 18, 2010",,"February 13, 2023","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01051635,2704.0,Not Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
202,203,NCT01169298,"A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma",,Completed,No Results Available,Adult T-cell Leukemia-Lymphoma|Peripheral T-cell Lymphoma,Drug: Lenalidomide,The safety of lenalidomide evaluated based on the severity of adverse events and their causality|Response|PK-Time to Maximum Plasma Concentration (Tmax)|PK-Apparent Total Body Clearance (CL/F)|PK-Apparent Volume of Distribution (Vz/F)|PK-Terminal half-life (T1/2)|PK-Area under the Plasma concentration time curve (AUC)|Accumulation ratio (Cmax)|Accumulation ratio (AUCτ)|PK-Maximum Concentration in Plasma (Cmax),Celgene,All,"20 Years and older   (Adult, Older Adult)",Phase 1,13.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CC-5013-ATLL-001,2010-07-01,"December 1, 2013",2013-12-20,"July 26, 2010",,"November 8, 2019","National Kyusyu Cancer Center, Fukuoka, Japan|Imamura Bun-in Hospital, Kagoshima, Japan|Kumamoto University Hospital, Kumamoto, Japan|Nagasaki University Hospital, Nagasaki, Japan|Nagoya Daini Red Cross Hospital, Nagoya, Japan|National Cancer Center Hospital, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01169298,1268.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
203,204,NCT01902225,Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma,,Completed,No Results Available,Lymphoma|T-Cell Lymphoma|Cutaneous Lymphoma,Drug: Istodax|Drug: Doxil,Maximum Tolerated Dose|Complete response (CR) rate|Overall response rate (CR + PR)|Time to response (TTR)|Duration of response (DOR)|Time to progression (TTP)|Changes in degree of pruritus|Quality of life during therapy|Changes in skin related symptoms,"Weiyun Ai|Celgene Corporation|University of California, San Francisco",All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,112516|NCI-2014-01722,2014-03-04,"July 13, 2018",2020-04-11,"July 18, 2013",,"June 9, 2020","University of California, San Francisco, San Francisco, California, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01902225,2230.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
204,205,NCT00012207,Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma,,Completed,No Results Available,Leukemia|Lymphoma,Biological: aldesleukin|Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide|Drug: prednisone|Drug: vincristine sulfate|Procedure: adjuvant therapy,"Safety and toxicity by NCI CTC toxicity scale in patients w/ recurr. or refract. CD20+ follicular lymphoma who are not candidates for high dose chemoradiotx and stem cell transplant during each infusion, weekly for 4 wks and then monthly for a yr|Duration of in vivo persistence of adoptively transferred CD20-specific CD8+ T cell clones by flow cytometry and quantitative polymerase chain reaction (qPCR) during each infusion, weekly for 4 weeks, and then monthly for a year|Trafficking of CD8+ CD20-specific T cell clones to lymph nodes by Gamma camera imaging during each infusion, weekly for 4 weeks, and then monthly for a year|Development of host anti-scFvFc:zeta (and anti-NeoR) immune responses by ELISA and chromium release assays during each infusion, weekly for 4 weeks, and then monthly for a year|Tumor responses to cyclophosphamide, vincristine, and prednisone (CVP) and to cytotoxic T-lymphocyte (CTL) infusions by Cheson criteria during each infusion, weekly for 4 weeks, and then monthly for a year",Fred Hutchinson Cancer Center|National Cancer Institute (NCI),All,"Child, Adult, Older Adult",Phase 1,12.0,Other|NIH,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,1503.00|FHCRC-1503.00|NCI-G01-1921|CDR0000068494,2000-09-01,,2010-07-01,"January 27, 2003",,"August 24, 2010","City of Hope Comprehensive Cancer Center, Duarte, California, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|University of Washington School of Medicine, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00012207,3590.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
205,206,NCT00323934,Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma,,Completed,No Results Available,Tumors|Non Hodgkin's Lymphoma,Drug: MGCD0103,Safety and tolerability|Clinical response|Pharmacokinetics|Pharmacodynamics (histone acetylation; biomarkers),Mirati Therapeutics Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,42.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0103-002,2004-04-01,October 2007,2008-10-01,"May 10, 2006",,"January 8, 2015","The Johns Hopkins Hospital, Baltimore, Maryland, United States|Princess Margaret Hospital, Toronto, Ontario, Canada|Hopital Charles LeMoyne, Greenfield Park, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00323934,1644.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
206,207,NCT00978523,Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma,,Completed,No Results Available,Solid Tumors|Lymphoma,Drug: AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide),"The primary objective of this study in adults with advanced or recurrent solid tumors or lymphoma is to evaluate the safety and tolerability of AR-12.|Evaluate PK samples during C1, identify and use biomarkers to characterize the PD effects in surrogate and tumor tissue, establish a biologically active dose range, assess preliminary anti-tumor activity in cancer patients.",Arno Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1,35.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ARN-AR12-CT101,2009-08-01,November 2013,2013-11-01,"September 17, 2009",,"January 29, 2014","TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona, United States|The Ohio State University - Comprehensive Cancer Center, Columbus, Ohio, United States|Royal Marsden Hospital, Sutton, Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT00978523,1553.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
207,208,NCT01432951,A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma,,Completed,Has Results,"Solid Tumor|Lymphoma, Malignant",Drug: Enzastaurin,"Pharmacokinetics (PK): Area Under the Concentration -Time Curve Over a Dosing Interval at Steady State (AUCt,ss) of Enzastaurin, It's Metabolites and Total Analytes in Plasma|PK: Maximum Observed Drug Concentration at Steady State (Cmax,ss) of Enzastaurin, It's Metabolites and Total Analytes in Plasma|PK: Time of Maximal Plasma Concentration at Steady State (Tmax, ss) of Enzastaurin, It's Metabolites and Total Analytes in Plasma|PK: Average Concentration During a Dosing Interval at Steady State (Cav,ss) of Enzastaurin, It's Metabolites and Total Analytes in Plasma|PK: Terminal Elimination Half-Life of Enzastaurin, It's Metabolites and Total Analytes in Plasma",Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 1,26.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,13322|H6Q-FW-JCCC,2011-11-01,"January 11, 2013",2018-01-05,"September 13, 2011","September 2, 2020","October 12, 2020","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changsha, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guang Zhou, China",,https://ClinicalTrials.gov/show/NCT01432951,2257.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
208,209,NCT00889408,"DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma",,Completed,No Results Available,Leukemia|Lymphoma,Biological: DT2219ARL,Maximum tolerated dose|Therapeutic activity of DT2219ARL,"Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI)",All,"12 Years and older   (Child, Adult, Older Adult)",Phase 1,25.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012LS075|MT2013-16|DT2219ARL,2013-12-02,"July 21, 2014",2014-07-21,"April 28, 2009",,"December 2, 2017","Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States|Scott and White Cancer Institute, Temple, Texas, United States",,https://ClinicalTrials.gov/show/NCT00889408,231.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
209,210,NCT00561418,Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma,,Completed,Has Results,Lymphoma|Small Intestine Cancer,Drug: vorinostat|Other: Correlative studies,Safety and Tolerability of Vorinostat (SAHA) After Autologous Stem Cell Transplantation|Clinical Benefit|Duration of Response|Time to Progression,Ohio State University Comprehensive Cancer Center|Merck Sharp & Dohme LLC,All,"18 Years and older   (Adult, Older Adult)",Phase 1,23.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSU-07047|NCI-2011-03145,2007-11-01,November 2012,2013-05-01,"November 21, 2007","July 16, 2015","July 16, 2015","Ohio State University Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00561418,2008.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
210,211,NCT02891590,"Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas",,Completed,No Results Available,Chronic Lymphocytic Leukemia|B-cell Lymphomas,Drug: DTRMWXHS-12,Number of participants with adverse events|Plasma concentrations of DTRMWXHS-12,Zhejiang DTRM Biopharma,All,"18 Years and older   (Adult, Older Adult)",Phase 1,13.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DTRM_DTRMWXHS-12_001,2016-09-01,February 2019,2019-02-01,"September 7, 2016",,"April 14, 2020","Peking University Cancer Hospital, Beijing, China",,https://ClinicalTrials.gov/show/NCT02891590,883.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
212,213,NCT01878890,Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.,ESCALE,Completed,Has Results,Solid Tumors|Non-Hodgkin's Lymphoma,Drug: Efavirenz 600mg|Drug: Efavirenz 1200 mg|Drug: Efavirenz 1800 mg|Drug: Efavirenz 2200 mg,Maximum Tolerated Dose (MTD) of Efavirenz|Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)|12-week Objective Response Rate|12-week Non-progression Rate,Institut Bergonié,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,25.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IB2011-01,2011-09-05,"September 16, 2014",2016-12-31,"June 17, 2013","January 27, 2021","January 27, 2021","Institut Bergonié, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT01878890,1944.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
213,214,NCT03357627,A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma,,Completed,No Results Available,"Lymphoma, Non-Hodgkin|Lymphoma, Large B-cell, Diffuse|Lymphoma, Follicular",Drug: TAK-659|Drug: Venetoclax,"Number of Participants with a Dose Limiting Toxicity (DLT)|Percentage of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs), Grade 3 or Higher Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Discontinuation|Cmax: Maximum Observed Plasma Concentration for TAK-659 and Venetoclax|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-659 and Venetoclax|AUCτ: Area Under the Plasma Concentration-time Curve from Time 0 to Time Over the Dosing Interval for TAK-659 and Venetoclax|Oral Clearance (CL/F) for TAK-659 and Venetoclax|Peak-trough Ratio (PTR) for TAK-659 and Venetoclax|Accumulation Ratio (Rac) for TAK-659 and Venetoclax|Trough Concentration (C trough) for TAK-659 and Venetoclax|Overall Response Rate (ORR)|Duration of Overall Response|CR Rate|Duration of CR|Time to Progression (TTP)|Progression-free Survival (PFS)","Calithera Biosciences, Inc",All,"18 Years and older   (Adult, Older Adult)",Phase 1,43.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other,C34008|2017-002872-14|U1111-1203-9951,2018-02-16,"August 3, 2021",2021-08-03,"November 30, 2017",,"February 8, 2023","University of Alabama at Birmingham, Birmingham, Alabama, United States|Emory University, Atlanta, Georgia, United States|NorthShore Medical Group - Evanston, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Norton Cancer Institute - Shelbyville, Shelbyville, Kentucky, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Universitatsklinikum Heidelberg, Heidelberg, Baden-wuerttemberg, Germany|Universitatsklinikum Ulm, Ulm, Baden-wuerttemberg, Germany|Universitatklinikum der Ludwig-Maximilians-Universitat Munchen, Munchen, Bayern, Germany|Universitatsklinikum Frankfurt, Frankfurt am Main, Hessen, Germany|Universitatsmedizin der Johannes Gutenberg Universitat, Mainz, Rheinland-pfalz, Germany",,https://ClinicalTrials.gov/show/NCT03357627,1264.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
214,215,NCT01542918,Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma,,Completed,No Results Available,Recurrent/Refractory CNS|Intraocular Lymphoma,Drug: Lenalidomide|Drug: Rituximab,"To establish the maximal tolerated dose (MTD) of Lenalidomide in patients with recurrent CNS NHL and intraocular NHL|To define the extent of cerebrospinal fluid (CSF) penetration of lenalidomide.|To assess the clinical efficacy Lenalidomide monotherapy as measured by cytologic, neurologic, radiographic, and ocular (for patients with intraocular lymphoma) response criteria.|To define the immunological effects of lenalidomide using flow-cytometry CSF as well as genomic markers of recurrent/refractory CNS lymphoma.|To assess the clinical efficacy of combined intraventricular plus systemic rituximab administration in combination with lenalidomide as measured by cytologic, neurologic, and radiographic response criteria.|To determine a potential impact of intravenous rituximab administration on the rate of rituximab clearance from the CSF after intraventricular rituximab administration.","James Rubenstein|Celgene|Genentech, Inc.|University of California, San Francisco",All,"18 Years and older   (Adult, Older Adult)",Phase 1,14.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,112530|NCI-2013-00056,2012-12-17,"April 7, 2016",2016-08-30,"March 2, 2012",,"August 11, 2020","University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT01542918,1352.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
215,216,NCT01471210,"Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma",,Completed,No Results Available,Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma,Drug: Urelumab (BMS-663513),"Safety assessments will be based on medical review of adverse event reports and the results of vital sign measurements, physical examinations, and clinical laboratory tests|Dose-limiting toxicity and maximum tolerated dose of Urelumab (BMS-663513) as determined by the incidence of dose-limiting toxicities|Maximum observed serum concentrations (Cmax) of Urelumab (BMS-663513)|Minimum observed serum concentrations (Cmin) of Urelumab (BMS-663513)|Time of maximum observed serum concentration (Tmax) of Urelumab (BMS-663513)|Area under the concentration-time curve in 1 dosing interval [AUC(TAU)] of Urelumab (BMS-663513)|Plasma half-life (T-HALF) of Urelumab (BMS-663513)|Total body clearance (CLT) of Urelumab (BMS-663513)|Volume of distribution at steady-state (Vss) of Urelumab (BMS-663513)|Human Anti-human Antibodies|Tumor response and progression as determined by proportion of patients with best overall response (BOR), progression-free survival (PFS), objective response rate (ORR), time to response, and duration of response",Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 1,124.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA186-011|2012-000170-28,2012-02-01,April 2016,2016-04-01,"November 15, 2011",,"April 19, 2017","Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States|Stanford University Medical Center, Stanford, California, United States|University Of Chicago, Chicago, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Hospital Of The University Of Pennsylvania, Philadelphia, Pennsylvania, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|Local Institution, Creteil Cedex, France|Local Institution, Lille Cedex, France|Local Institution, Paris, France|Local Institution, Pessac, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Rennes Cedex 9, France|Local Institution, Rouen, France|Local Institution, Villejuif Cedex, France|Local Institution, Essen, Germany|Hospital Universitari Vall D'Hebron, Barcelona, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Local Institution, Pamplona, Spain",,https://ClinicalTrials.gov/show/NCT01471210,1521.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
216,217,NCT02383368,A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma,,Completed,No Results Available,Lymphoma|Refractory Solid Tumors|Advanced Cancer,Drug: ASP4132,Safety as assessed by adverse events|Safety as assessed by clinical laboratory tests|Safety as assessed by vital signs|Safety as assessed by electrocardiograms (ECG)|Objective response rate to ASP4132|Duration of response to ASP4132|Disease control rate to ASP4132|Maximum concentration (Cmax) of ASP4132|Time of the maximum concentration (Tmax) of ASP4132|Area under the concentration-time curve from time of dosing to the last measurable concentration (AUClast) of ASP4132|AUC from the time of dosing to 24 hours (AUC24) of ASP4132|AUC from the time of dosing extrapolated to time infinity (AUCinf) of ASP4132|Apparent terminal elimination half-life (T1/2) of ASP4132|Accumulation ratio of ASP4132|Apparent total systemic clearance after single or multiple extravascular dosing (CL/F) of ASP4132|Apparent volume of distribution during the terminal elimination phase after single or multiple extravascular dosing (Vz/F) of ASP4132|Progression-free survival,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",All,"18 Years and older   (Adult, Older Adult)",Phase 1,39.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4132-CL-0001,2015-03-23,"April 27, 2018",2018-04-27,"March 9, 2015",,"June 4, 2019","Site US10001, New Haven, Connecticut, United States|Site US10004, Chicago, Illinois, United States|Site US10002, Rochester, Minnesota, United States|Site US10003, Houston, Texas, United States|Site US10005, Fairfax, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02383368,1131.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
219,220,NCT02600897,"A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",,Completed,No Results Available,"Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma",Drug: Lenalidomide|Drug: Obinutuzumab|Drug: Polatuzumab Vedotin|Drug: Rituximab,"Percentage of Participants with CR, Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography (CT) Scans|Percentage of Participants with Adverse Events (AEs)|Percentage of Participants with Dose-Limiting Toxicities (DLTs)|Percentage of participants with CR, determined by the investigator on the basis of PET and CT scans|Percentage of Participants with CR, Determined by the Independent Review Committee (IRC) and Investigator on the Basis of CT Scans Alone|Percentage of Participants with Objective Response, Determined by the IRC and Investigator on the Basis of PET and CT Scans|Percentage of Participants with Objective Response, Determined by the IRC and Investigator on the Basis of CT Scans Alone|Percentage of Participants With Objective Response, Determined by the Investigator on the Basis of CT Scans Alone|Percentage of Participants With Best Response of Clinical Response (CR) or Partial Response (PR), Determined by the Investigator on the Basis of CT Scans Alone|Observed Serum Obinutuzumab Concentration|Observed Serum Rituximab Concentration|Observed Serum and Plasma Polatuzumab Vedotin Concentration|Observed Plasma Lenalidomide Concentration|Percentage of Participants with Human Anti-human Antibodies (HAHAs) to Obinutuzumab|Percentage of Participants with Human Anti-chimeric Antibodies (HACAs) to Rituximab|Percentage of Participants with Anti-therapeutic Antibodies (ATAs) to Polatuzumab Vedotin",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1,114.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GO29834|2015-001999-22,2016-03-23,"December 15, 2021",2021-12-15,"November 9, 2015",,"February 7, 2022","Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital, Marietta, Georgia, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University of Missouri/Ellis Fischel, Columbia, Missouri, United States|Washington University; Wash Uni. Sch. Of Med, Saint Louis, Missouri, United States|NYU School of Medicine, New York, New York, United States|Rocky Mountain Cancer Centers, LLP, Irving, Texas, United States|Texas Oncology-Tyler, Irving, Texas, United States|Texas Oncology San Antonio Medical Center, San Antonio, Texas, United States|Insititut Catala D'Oncologia, Hospitalet de Llobregat, Barcelona, Spain|Hospital Clínico Málaga, Málaga, Malaga, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clínic. Barcelona, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Gregorio Marañon, Madrid, Spain|H. Universitario Leonor, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz., Madrid, Spain|Hospital La Fe, Valencia, Spain|St James University Hospital, Leeds, United Kingdom|University Hospitals of Leicester NHS Trust - Leicester Royal Infirmary, Leicester, United Kingdom|Royal Liverpool University Hospital, Liverpool, United Kingdom|Barts Hospital; Institute of Cancer, London, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|Maidstone & Tonbridge Wells Hospital; Kent Oncology Center, Maidstone, United Kingdom|Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, United Kingdom|Barking, Havering and Redbridge University Hospitals NHS Trust - Queen's Hospital, Romford, United Kingdom|The Royal Wolverhampton Hospitals NHS Trust; Department of Haematology, Wolverhampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT02600897,2093.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
220,221,NCT00406757,Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma,,Completed,No Results Available,"Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic",Drug: Nelarabine injection 400mg/m2|Drug: Nelarabine injection 650mg/m2|Drug: Nelarabine injection 1000mg/m2|Drug: Nelarabine injection 1500mg/m2,"Adverse events, changes from baseline in physical examination and clinical laboratory parameters12-lead ECGAssessment of pharmacokinetic endpoints of 506U78, ara-G and intracellular ara-GTP concentration.|Evaluation of response (e.g., CR, CR*) in patients with bone marrow involvement.",GlaxoSmithKline,All,"up to 64 Years   (Child, Adult)",Phase 1,13.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PGA105446,2006-08-30,"July 15, 2009",2009-07-15,"December 4, 2006",,"November 13, 2017","GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00406757,1050.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
221,222,NCT00001572,Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype,,Completed,No Results Available,B Cell Lymphoma|Follicular Lymphoma|Neoplasm,Drug: Id-KLH Vaccine|Drug: QS-21 (Stimulation-QS-21) Drug,,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",Phase 1,21.0,NIH,Interventional,Primary Purpose: Treatment,970077|97-C-0077,1997-01-30,"July 31, 1999",2010-11-02,"November 4, 1999",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00001572,5024.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
223,224,NCT02214147,Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function,,Completed,Has Results,Advanced Solid Tumors|Relapsed/Refractory Lymphoma,Drug: Alisertib,Unbound Cmax: Maximum Observed Plasma Concentration for Alisertib|Unbound AUClast: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib|Unbound AUC0-∞: Area Under the Concentration-Time Curve From Time 0 to Infinity for Alisertib|Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event|Percentage of Participants Who Experienced at Least 1 Serious Adverse Event|Percentage of Participants With Clinically Significant Laboratory Values|Percentage of Participants With Clinically Significant Vital Signs|Cmax: Maximum Observed Plasma Concentration for Alisertib Metabolites M1 and M2|Tmax: Time of First Occurrence of Cmax for Alisertib Metabolites M1 and M2|AUClast: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib Metabolites M1 and M2|Dose-normalized Trough Concentration of Alisertib on Cycle 1 Day 14,"Millennium Pharmaceuticals, Inc.|Takeda",All,"18 Years and older   (Adult, Older Adult)",Phase 1,36.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C14019|U1111-1155-6072,2014-08-21,"April 5, 2016",2016-07-18,"August 12, 2014","November 15, 2018","November 15, 2018","Miami, Florida, United States|Chicago, Illinois, United States|Ann Arbor, Michigan, United States|Saint Louis, Missouri, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02214147,697.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
225,226,NCT04702503,Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL),,Completed,No Results Available,Cutaneous T-Cell Lymphoma/Mycosis Fungoides,Drug: WP1220,Evaluation of the safety profile of WP1220 applied topically (adverse events)|Evaluation of WP1220 applied topically to index lesions via standard measurement scale,"Moleculin Biotech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,5.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MB-201,2019-03-08,"November 15, 2019",2020-11-15,"January 11, 2021",,"January 11, 2021","Medical University of Gdansk, Gdansk, Poland",,https://ClinicalTrials.gov/show/NCT04702503,618.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
226,227,NCT00006009,Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma,,Completed,No Results Available,Lymphoma|Small Intestine Cancer,Biological: visilizumab,,Stanford University|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,,Other|NIH,Interventional,Primary Purpose: Treatment,SUMC-NCI-102|CDR0000068017|NCI-102,2001-04-01,,2003-10-01,"October 8, 2003",,"May 15, 2013","Stanford University Medical Center, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT00006009,913.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
227,228,NCT02259010,A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma,,Completed,Has Results,Advanced Solid Tumors|Relapsed/Refractory Lymphoma,Drug: Alisertib|Drug: Itraconazole,Cmax: Maximum Observed Concentration of Alisertib in Presence and Absence of Itraconazole in Part A|AUC(Last): Area Under the Plasma Concentration Curve From Time 0 to the Time of the Last Quantifiable Concentration of Alisertib in Presence and Absence of Itraconazole in Part A|AUC∞: Area Under the Plasma Concentration Curve From Time 0 to Infinity of Alisertib in Presence and Absence of Itraconazole in Part A|CL/F: Oral Clearance of Alisertib in Presence and Absence of Itraconazole in Part A|Tmax: Time to Reach Maximum Plasma Concentration of Alisertib in Presence and Absence of Itraconazole in Part A|Terminal Phase Elimination Half-Life of Alisertib in Presence and Absence of Itraconazole in Part A|Cmax: Maximum Observed Plasma Concentration for Alisertib Metabolites M1 and M2 in Presence and Absence of Itraconazole in Part A|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib Metabolites M1 and M2 in Presence and Absence of Itraconazole in Part A|AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib Metabolites M1 and M2 in Presence and Absence of Itraconazole in Part A|Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Number of Participants With Abnormal Laboratory Values Reported as AEs|Number of Participants With Clinically Significant Change in Weight Reported as AEs|Number of Participants With Clinically Significant Change in Vital Sign Reported as AEs,"Millennium Pharmaceuticals, Inc.|Takeda",All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C14020|U1111-1161-5039,2014-10-22,"March 27, 2015",2016-10-21,"October 8, 2014","September 20, 2019","September 20, 2019","Saint Louis, Missouri, United States|Oklahoma City, Oklahoma, United States|Germantown, Tennessee, United States|Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT02259010,730.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
229,230,NCT03498430,Copanlisib Chinese PK Study,,Completed,No Results Available,"Lymphoma, Non-Hodgkin","Drug: Copanlisib (Aliqopa, BAY80-6946)","Cmax (Cycle 1 Day 1) of Copanlisib|AUC(0-24) (Cycle 1 Day 1) of Copanlisib|AUC(0-tlast) (Cycle 1 Day 1) of Copanlisib|Cmax (Cycle 1 Day 15) of Copanlisib|AUC(0-24) (Cycle 1 Day 15) of Copanlisib|Overall response rate: proportion of patients with confirmed complete response (CR) and partial response (PR)|Overall disease control rate: proportion of patients who have a best response rating of CR, PR or stable disease (SD)|The number of serious drug-related TEAEs (treatment-emergent adverse events)|The number of non-serious drug-related TEAEs|Cmax (Cycle 1 Day 1) of M-1 metabolite|AUC(0-24) (Cycle 1 Day 1) of M-1 metabolite|AUC(0-tlast) (Cycle 1 Day 1) of M-1 metabolite|Cmax (Cycle 1 Day 15) of M-1 metabolite|AUC(0-24) (Cycle 1 Day 15) of M-1 metabolite",Bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,13.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,16866,2018-04-27,"August 6, 2019",2020-06-02,"April 13, 2018",,"May 19, 2021","Beijing Cancer Hospital, Beijing, China",,https://ClinicalTrials.gov/show/NCT03498430,767.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
230,231,NCT03489369,Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas,,Completed,Has Results,Metastatic Cancer|Solid Tumor|Lymphoma,Drug: Sym022,Assessment of Treatment Related Adverse Events (AEs).|Evaluation of the Immunogenicity of Sym022.|Evaluation of Objective Response (OR) or Stable Disease (SD).|Time to Progression (TTP) of Disease.|Area Under the Concentration-time Curve in a Dosing Interval (AUC).|Maximum Concentration (Cmax)|Time to Reach Maximum Concentration (Tmax)|Trough Concentration (Ctrough)|Terminal Elimination Half-life (T½)|Clearance (CL),Symphogen A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 1,15.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Sym022-01,2018-05-08,"January 6, 2020",2020-01-06,"April 5, 2018","February 18, 2021","February 18, 2021","South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03489369/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03489369/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03489369,608.0,Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
231,232,NCT03489343,Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas,,Completed,Has Results,Metastatic Cancer|Solid Tumor|Lymphoma,Drug: Sym023,Assessment of Treatment Emergent Adverse Events (AEs) Meeting Dose-limiting Toxicity (DLT) Criteria.|Evaluation of the Immunogenicity of Sym023.|Evaluation of Objective Response (OR) or Stable Disease (SD) by RECIST v1.1|Evaluation of Objective Response (OR) or Stable Disease (SD) by iRECIST|Evaluation of Objective Response (OR) or Stable Disease (SD) by RECIL 2017.|Time to Progression (TTP) of Disease.|Area Under the Concentration-time Curve in a Dosing Interval (AUC).|Maximum Concentration (Cmax)|Time to Reach Maximum Concentration (Tmax)|Trough Concentration (Ctrough)|Terminal Elimination Half-life (T½)|Clearance (CL),Symphogen A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Sym023-01,2018-05-24,"June 3, 2020",2020-06-03,"April 5, 2018","October 12, 2021","October 12, 2021","South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|NEXT Oncology, San Antonio, Texas, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03489343/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03489343/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03489343,741.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
232,233,NCT01454076,Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma,,Completed,Has Results,Nonhematologic Malignancies|Lymphoma,Drug: Ixazomib 2.5 mg|Drug: Ixazomib 4 mg Capsule A|Drug: Ixazomib 4 mg Capsule B|Drug: Ketoconazole|Drug: Rifampin|Drug: Clarithromycin,Cmax: Maximum Observed Plasma Concentration for Ixazomib|AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Ixazomib|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Ixazomib|Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant TEAEs Related to Laboratory Abnormalities|Number of Participants With Clinically Significant Vital Sign Abnormalities|Percentage of Participants With Best Overall Response,"Millennium Pharmaceuticals, Inc.|Takeda",All,"18 Years and older   (Adult, Older Adult)",Phase 1,112.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C16009|U1111-1183-0218,2011-11-10,"April 1, 2015",2016-06-16,"October 18, 2011","November 1, 2017","November 1, 2017","Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01454076,1680.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
233,234,NCT00572637,Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas,,Completed,No Results Available,"Solid Tumors|Lymphoma, Non-Hodgkin",Drug: CEP-18770,Dose Limiting Toxicities (DLT) and Maximum Tolerated Dose (MTD) of CEP 18770|Pharmacokinetics of CEP-18770 following single and multiple dose administration.|Profile and time course of inhibition and recovery of proteasome activity|Antineoplastic activity evaluated with internationally accepted response criteria,Ethical Oncology Science,All,"18 Years and older   (Adult, Older Adult)",Phase 1,55.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E-CEP\I\01,2007-11-01,March 2010,2010-03-01,"December 13, 2007",,"May 20, 2010","Europen Institute of Oncology, Milano, Italy|IOSI - Oncology Institute of Southern Switzerland - Ospedale S. Giovanni, Bellinzona, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland",,https://ClinicalTrials.gov/show/NCT00572637,851.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
234,235,NCT00742144,Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia,,Completed,No Results Available,"Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular",Drug: ofatumumab,"tolerability|Adverse event,Clinical laboratory tests,Immunoglobulin,HAHA,Objective response rate,Duration of response,Progression free survival,CD5,19,20,CD23 positive cells,Complement (CH50),PK parameters,",GlaxoSmithKline,All,"20 Years to 79 Years   (Adult, Older Adult)",Phase 1,6.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OMB111148,2008-09-19,"November 18, 2009",2009-11-18,"August 27, 2008",,"November 17, 2017","GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00742144,425.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
235,236,NCT01296555,A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer,,Completed,No Results Available,Solid Cancers|Non-Hodgkin's Lymphoma,Drug: Fulvestrant|Drug: GDC-0032|Drug: Letrozole|Drug: Midazolam,"Phase I Stage I: Percentage of Participants With Adverse Events and Serious Adverse Events|Phase 1 Stage 1: Percentage of Participants With Dose-Limiting Toxicities|Phase I Stage 1: Maximum Tolerated Dose of GDC-0032|Phase I: Area Under the Concentration-Time Curve (AUC) From Zero to Infinity of GDC-0032|Phase I: AUC From Zero to tau (AUCtau) of GDC-0032|Phase I: Maximum Observed Concentration (Cmax) of GDC-0032|Phase I: Minimum Observed Concentration (Cmin) of GDC-0032|Phase I: Time to Reach Cmax (tmax) of GDC-0032|Phase I: Half-life (t1/2) of GDC-0032|Phase I: Apparent Clearance (CL/F) of GDC-0032|Phase I: Accumulation Ratio (AR) (Area Under the Concentration Time Curve at Steady-State Divided by Area Under the Concentration Time Curve for First Dose) of GDC-0032|Phase I: Recommended Dose of Single-Agent GDC-0032|Phase II: Percentage of Participants With Clinical Benefit, as Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1|Phase II: Percentage of Participants With Objective Response, as Assessed Using RECIST Version 1.1|Phase I: Fraction Dose Excreted (fe) of GDC-0032|Phase I: Renal Clearance (CLr) of GDC-0032|Phase I: Time to Achieve Steady State of GDC-0032|Phase I All Cohorts (Except Cohorts T and T2): Percentage of Participants With Best Overall Response, as Assessed Using RECIST Version 1.1|Phase I All Cohorts (Except Cohorts T and T2): Duration of Objective Response, as Assessed Using RECIST Version 1.1|Phase I All Cohorts (Except Cohorts T and T2): Progression Free Survival, as Assessed Using RECIST Version 1.1|Phase I Cohort T: Percentage of Participants With Best Overall Response, as Assessed Using 2007 Revised International Working Group (IWG) Response Criteria in Malignant Lymphoma|Phase I Cohort T: Duration of Objective Response, as Assessed Using 2007 Revised IWG Response Criteria in Malignant Lymphoma|Phase I Cohort T: Progression Free Survival, as Assessed Using 2007 Revised IWG Response Criteria in Malignant Lymphoma|Phase I Cohort T2: Percentage of Participants With Best Overall Response, as Assessed Using Modified Version of 2014 Lugano Response Criteria in Malignant Lymphoma|Phase I Cohort T2: Duration of Objective Response, as Assessed Using Modified Version of 2014 Lugano Response Criteria in Malignant Lymphoma|Phase I Cohort T2: Progression Free Survival, as Assessed Using Modified Version of 2014 Lugano Response Criteria in Malignant Lymphoma|Phase I Stage 2 Food Effect: Cmax of GDC-0032 Under Fed Condition|Phase I Stage 2 Food Effect: Cmax of GDC-0032 Under Fasted Condition|Phase I Stage 2 Food Effect: AUC of GDC-0032 Under Fed Condition|Phase I Stage 2 Food Effect: AUC of GDC-0032 Under Fasted Condition|Phase I Stage 2 Cohort C: AUC from Time Zero to 24 Hours (AUC0-24) of Midazolam Prior to and After 14 Days Continuous GDC-0032 Dosing|Phase I Stage 2 Cohort C: Cmax of Midazolam Prior to and After 14 Days Continuous GDC-0032 Dosing|Phase I Stage 2 Cohort C: Tmax of Midazolam Prior to and After 14 Days Continuous GDC-0032 Dosing|Phase I Stage 2 Cohorts E, N, P, Q, R, S: AUC0-24 of Letrozole|Phase I Stage 2 Cohorts E, N, P, Q, R, S: Cmax of Letrozole|Phase I Stage 2 Cohorts E, N, P, Q, R, S: tmax of Letrozole|Phase I Stage 2 Cohorts F, J, K, L, M and Phase II: AUC0-24 of Fulvestrant|Phase I Stage 2 Cohorts F, J, K, L, M and Phase II: Cmin of Fulvestrant|Phase I Stage 2 Cohorts F, J, K, L, M and Phase II: tmax of Fulvestrant|Phase I Stage 2 Cohort C: AUC0-24 of GDC-0032 in Combination with Midazolam|Phase I Stage 2 Cohort C: Cmax of GDC-0032 in Combination with Midazolam|Phase I Stage 2 Cohort C: Tmax of GDC-0032 in Combination with Midazolam|Phase I Stage 2 Cohorts E, N, P, Q, R, S: AUC0-24 of GDC-0032 in Combination with Letrozole|Phase I Stage 2 Cohorts E, N, P, Q, R, S: Cmax of GDC-0032 in Combination with Letrozole|Phase I Stage 2 Cohorts E, N, P, Q, R, S: Tmax of GDC-0032 in Combination with Letrozole|Phase I Stage 2 Cohorts F, J, K, L, M and Phase II: AUC0-24 of GDC-0032 in Combination with Fulvestrant|Phase I Stage 2 Cohorts F, J, K, L, M and Phase II: Cmin of GDC-0032 Fulvestrant|Phase I Stage 2 Cohorts F, J, K, L, M and Phase II: Tmax of GDC-0032 Fulvestrant|Phase II: Duration of Objective Response, as Assessed Using RECIST Version 1.1|Phase II: Progression Free Survival, as Assessed Using RECIST Version 1.1|Overall Survival, as Assessed Using RECIST Version 1.1|Phase II: Plasma Concentration of GDC-0032","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,686.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PMT4979g|GO00886|2012-002042-21,2011-03-16,"June 25, 2021",2021-06-25,"February 15, 2011",,"September 5, 2021","TGen Clinical Research Srvs, Scottsdale, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|University of California Irvine Medical Center, Orange, California, United States|UC Davis; Comprehensive Cancer Center, Sacramento, California, United States|Sutter Health, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|Florida Cancer Specialists - Fort Myers (New Hampshire Ct), Fort Myers, Florida, United States|Sarah Cannon Res Inst; FL, Sarasota, Florida, United States|Univ of Chicago, Chicago, Illinois, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana Farber Cancer Inst., Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University; Division of Oncology, Saint Louis, Missouri, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Sarah Cannon Res Inst; OK, Oklahoma City, Oklahoma, United States|West Cancer Center, Germantown, Tennessee, United States|Sarah Cannon Res Inst; TN Onc, Nashville, Tennessee, United States|Vanderbilt Breast Center; Vanderbilt Health Pharmacy, Nashville, Tennessee, United States|Vanderbilt, Nashville, Tennessee, United States|Texas Cancer Center, Abilene, Texas, United States|Mary Crowley Cancer Rsch Ctr, Dallas, Texas, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|USO - Tyler Cancer Ctr, Tyler, Texas, United States|Northwest Cancer Specialists - Vancouver, Vancouver, Washington, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|Institut Gustave Roussy, Villejuif, France|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT01296555,3754.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
236,237,NCT00549185,Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma,,Completed,No Results Available,Lymphoma|Non-Hodgkin,Drug: SAR3419,"Incidence of Dose Limiting Toxicity(ies) at each tested dose level|Tumor response (complete response, partial response, stable disease) according to Cheson criteria and duration of response|Incidence of Adverse Events",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 1,39.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TED6828,2007-10-01,January 2012,2012-01-01,"October 25, 2007",,"February 14, 2012","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00549185,1553.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
237,238,NCT00724971,Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab,,Completed,Has Results,"Lymphoma, B-Cell",Drug: Inotuzumab Ozogamicin (CMC-544)|Drug: Rituximab (Rituxan),Number of Participants With Dose-limiting Toxicities (DLT)|Number of Participants With Objective Response: Evaluable Population|Number of Participants With Objective Response: Intent-to-treat (ITT) Population|Progression-Free Survival (PFS),Pfizer,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 1,10.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3129K3-1104|B1931005,2008-07-04,"March 10, 2010",2010-03-10,"July 30, 2008","March 15, 2019","March 15, 2019","Nagoya Daini Red Cross Hospital, Aichi, Japan|Tokai University Hospital, Kanagawa, Japan|National Cancer Center Hospital, Tokyo, Japan|Cancer Inst. Hp. of Japanese Foundation for Cancer Research, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00724971,614.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
238,239,NCT04572308,Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells,,Completed,No Results Available,T-cell Acute Lymphoblastic Leukemia/Lymphoma,Biological: CD7 CAR-T,Safety: Incidence and severity of adverse events|Efficacy: Remission Rate|duration of response (DOR)|Efficacy: progression-free survival (PFS)|CAR-T proliferation|Cytokine release|Pharmacokinetics (PK) indicators:|Pharmacodynamic (PD) indicators:,"Hebei Senlang Biotechnology Inc., Ltd.",All,"2 Years to 65 Years   (Child, Adult, Older Adult)",Phase 1,20.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CD7 CAR-T for T-ALL/T-LBL,2020-10-01,"May 30, 2021",2021-05-30,"October 1, 2020",,"June 29, 2021","Hebei yanda Ludaopei Hospital, Yanda, Hebei, China",,https://ClinicalTrials.gov/show/NCT04572308,241.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
239,240,NCT02219737,Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,,Completed,No Results Available,CD20 Positive|Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma,Drug: Carboplatin|Drug: Etoposide|Drug: Ibrutinib|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Biological: Rituximab,"Maximum tolerated dose of the combination of ibrutinib with standard dosing R-ICE, graded using the Common Terminology Criteria for Adverse Events 4.0|Toxicity of the combination of ibrutinib with standard dosing R-ICE, graded using the CTCAE 4.0|Overall response rate, defined as the sum of partial and complete responses as determined by revised International Working Group Criteria for Malignant Lymphoma|PK parameters of ibrutinib in the presence of R-ICE as a measure of potential drug-drug interaction",National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,26.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2014-00571|14-145|9588|P30CA008748,2014-09-12,"May 11, 2017",2017-05-11,"August 19, 2014",,"January 26, 2018","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02219737,972.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
240,241,NCT00416923,Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma,,Completed,No Results Available,Brain and Central Nervous System Tumors|Lymphoma,Biological: rituximab,Adverse events as a measure of safety of intrathecal administration of Rituximab|Serum concentration of Rituximab|Cerebrospinal Fluid (CSF) concentration of Rituximab,"University of California, San Francisco",All,"17 Years and older   (Child, Adult, Older Adult)",Phase 1,10.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000454842|UCSF-01302|UCSF-H9414-19588-04|UCSF-U2337S|GENENTECH-UCSF-01302,2002-08-01,November 2005,2007-04-01,"December 28, 2006",,"February 16, 2015",,,https://ClinicalTrials.gov/show/NCT00416923,1704.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
241,242,NCT03302728,Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma,EpiBrentlen,Completed,No Results Available,"Lymphoma, T-Cell, Cutaneous|Lymphoma, T-Cell, Peripheral|Hodgkin Lymphoma",Drug: Lenalidomide 15mg|Drug: Brentuximab Vedotin 1.8 mg/Kg,"Determination of the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended phase 2 dose (RP2D) of the combination of lenalidomide and brentuximab vedotin|Safety profile of the combination of lenalidomide and brentuximab vedotin|Treatment intensity.|Objective response rate|Cytostatic response.|Event free survival.|Overall survival","Peter MacCallum Cancer Centre, Australia",All,"18 Years and older   (Adult, Older Adult)",Phase 1,6.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17/34,2018-08-30,"August 2, 2021",2021-08-02,"October 5, 2017",,"May 19, 2022","Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT03302728,1068.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
242,243,NCT01800630,Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas,,Completed,No Results Available,Advanced Solid Malignancies|Malignant Lymphomas,Drug: Gemcitabine HCl Oral Formulation,"To determine MTD and DLT of Gemcitabine Oral formulation|AE/SAE incidences|Changes from baseline in clinical laboratory test (hematology, biochemistry, coagulation factors and urinalysis) results, vital sign measurements, physical examination findings, and ECG and 2D echocardiogram/multiple-gated acquisition (MUGA) scan results|characterize the PK of D07001-F4|ORR(Objective Response Rate) and tumor response",InnoPharmax Inc.,All,"20 Years and older   (Adult, Older Adult)",Phase 1,37.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,HR-12-001,2013-04-01,November 2015,2016-03-01,"February 28, 2013",,"July 8, 2019","National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT01800630,1065.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
243,244,NCT03283202,Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors,,Completed,No Results Available,Diffuse B-Cell Lymphoma,Drug: Avadomide (CC-122)|Drug: Rituximab|Drug: Cyclophosphamide 750mg/m2 by IV infusion|Drug: Vincristine|Drug: Prednisone,Maximum Tolerated Dose/Maximum Administered Dose (MTD/MAD) (Phase 1)|Complete Response Rate (CRR); Percentage of participants experiencing positron emission tomography (PET)-negative complete response (CR) (Phase 2)|Overall Response Rate (ORR); Percentage of participants who achieve a PR or CR according to the Lugano criteria.|ORR by Predictive Gene Signature|Progression-free Survival (PFS)|Event-free Survival (EFS)|Overall Survival (OS)|Adverse Events (AEs),Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 1,35.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CC-122-DLBCL-002|U1111-1201-1994|2016-003778-42,2017-10-04,"July 30, 2019",2020-12-16,"September 14, 2017",,"April 29, 2021","George Washington University, Washington, District of Columbia, United States|Moffitt Cancer Center, Tampa, Florida, United States|Washington University, Saint Louis, Missouri, United States|UZ Gent, Gent, Belgium|University Hospital Gasthuisberg, Lueven, Belgium|Tom Baker Cancer Center, Calgary, Alberta, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Hospital Germans Trias I Pujol, Badalona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital de San Pedro de Alcantara, Caceres, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain",,https://ClinicalTrials.gov/show/NCT03283202,1169.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
244,245,NCT03311412,"Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas",,Completed,No Results Available,Metastatic Cancer|Solid Tumor|Lymphoma,Drug: Sym021|Drug: Sym022|Drug: Sym023,Part 1: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria.|Part 2: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria.|Part 3: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria.|Evaluation of the immunogenicity of Sym021 as a single agent and in combination with Sym022 and Sym023.|Evaluation of objective response (OR) or stable disease (SD).|Time to progression (TTP) of disease.|Area under the concentration-time curve in a dosing interval (AUC)|Maximum concentration (Cmax)|Time to reach maximum concentration (Tmax)|Trough concentration (Ctrough)|Terminal elimination half-life (T½)|Clearance (CL),Symphogen A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 1,91.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Sym021-01,2017-12-07,"March 23, 2022",2022-03-23,"October 17, 2017",,"October 26, 2022","South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|NEXT Oncology, San Antonio, Texas, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03311412,1567.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
245,246,NCT00901069,"Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma",,Completed,No Results Available,"Lymphoma|Hodgkin Disease|Lymphoma, Non-Hodgkin","Drug: Azacitidine with rituximab, vincristine, and cyclophosphamide","Determine the maximal tolerated dose (MTD) of azacitidine in combination with rituximab, vincristine, and cyclophosphamide in patients with lymphoma",Shams Shakil|Celgene|University of Kentucky,All,"18 Years and older   (Adult, Older Adult)",Phase 1,12.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,07-NHL-06-UK/CC,2009-05-01,January 2012,2012-11-01,"May 13, 2009",,"October 17, 2016","University of Kentucky, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT00901069,1280.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
246,247,NCT00963274,Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,,Completed,No Results Available,Leukemia|Lymphoma,Drug: Bortezomib|Drug: Romidepsin,Maximum tolerated dose|Pharmacodynamic responses,Virginia Commonwealth University|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,18.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MCC-12215|P30CA016059|R21CA137823|CDR0000652509,2010-04-26,"July 17, 2014",2018-04-13,"August 21, 2009",,"April 23, 2018","Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00963274,2909.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
247,248,NCT01699152,Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma,,Completed,No Results Available,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: TG02 citrate,Maximum Tolerated Dose|Adverse Events,"Tragara Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,16.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TG02-102,2012-09-01,July 2015,2016-05-01,"October 3, 2012",,"July 25, 2019","GRU, Augusta, Georgia, United States|DFCI, Boston, Massachusetts, United States|OSU, Columbus, Ohio, United States|SCRI, Nashville, Tennessee, United States|MDACC, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01699152,1338.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
248,249,NCT00003217,Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia,,Completed,No Results Available,Leukemia|Lymphoma,Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: methotrexate|Drug: vincristine sulfate,Event Free Survival,Children's Oncology Group|National Cancer Institute (NCI),All,"up to 21 Years   (Child, Adult)",Phase 1,20.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9517|POG-9517|CDR0000066078,1998-03-01,October 2004,2006-09-01,"September 6, 2004",,"July 25, 2014","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States|Children's Memorial Hospital, Chicago, Chicago, Illinois, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|University of Rochester Cancer Center, Rochester, New York, United States|State University of New York - Upstate Medical University, Syracuse, New York, United States|Oklahoma Memorial Hospital, Oklahoma City, Oklahoma, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States|Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States|Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States|Alberta Children's Hospital, Calgary, Alberta, Canada|Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00003217,3106.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
251,252,NCT01991184,A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.,,Completed,No Results Available,"Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma",Drug: GDC-0853,Safety: Incidence of dose-limiting toxicities (DLTs) of GDC-0853|Safety: Maximum tolerated dose (MTD) of GDC-0853|Safety: Incidence of adverse events|Pharmacokinetics: Area under the concentration-time curve (AUC) of GDC-0853|Pharmacokinetics: Maximum concentration (Cmax) of GDC-0853|Objective response to GDC-0853|Progression-free survival,"Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GO29089,2013-12-16,"March 8, 2022",2022-03-08,"November 25, 2013",,"June 21, 2022","Stanford Cancer Center, Stanford, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Oregon Health Sciences Uni, Portland, Oregon, United States|Sarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville, Tennessee, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba, Queensland, Australia|Peter MacCallum Cancer Centre; Department of Haematology, Melbourne, Victoria, Australia|Linear Clinical Research Limited, Nedlands, Western Australia, Australia",,https://ClinicalTrials.gov/show/NCT01991184,3004.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
252,253,NCT02374333,Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy,,Completed,No Results Available,Acute Lymphocytic Leukemia|Diffuse Large Cell Lymphoma,Biological: huCART19,"Occurrence of study related adverse events defined as NCI CTCAE 4.0 > grade 3 possibly, probably, or definitely related to study treatment.",University of Pennsylvania,All,"1 Year to 24 Years   (Child, Adult)",Phase 1,81.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"13BT022, 819851",2014-03-25,"September 2, 2021",2021-09-02,"February 27, 2015",,"September 23, 2021","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02374333,2718.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
253,254,NCT00849654,Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma,PCYC-04753,Completed,No Results Available,B-Cell Lymphoma|B-Cell Leukemia,Drug: PCI-32765,Dose limiting toxicity assessment for each patient.|Adverse events|Pharmacokinetic/ Pharmacodynamic assessments|Tumor response,Pharmacyclics LLC.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,66.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PCYC-04753,2009-02-01,July 2012,2012-07-01,"February 24, 2009",,"May 22, 2013","Stanford University School of Medicine, Palo Alto, California, United States|University of Chicago, Chicago, Illinois, United States|National Cancer Institute, Bethesda, Maryland, United States|New York Prebyterian Hospital Cornell Medical Center, New York, New York, United States|Willamette Valley Cancer Institute/Research Ctr, Eugene, Oregon, United States|University of Texas, MD Anderson, Houston, Texas, United States|University of Vermont College of Medicine, Burlington, Vermont, United States|Northwest Cancer Specialists, Vancouver Cancer Center, Vancouver, Washington, United States|Yakima Valley Memorial Hospital/North Star Lodge Cancer Ctr, Yakima, Washington, United States",,https://ClinicalTrials.gov/show/NCT00849654,1246.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
254,255,NCT03571828,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma",,Completed,No Results Available,Diffuse Large B-cell Lymphoma(DLBCL)|Mantle Cell Lymphoma (MCL)|Follicular Lymphoma (FL),Drug: AMG 562,Incidence of dose limiting toxicities (DLTs)|Incidence of treatment-emergent adverse events|Incidence of treatment-related adverse events|Incidence of disease-related events|Incidence of clinically-significant changes in vital signs|Incidence of clinically-significant changes in physical examinations|Incidence of clinically-significant changes in electrocardiograms (ECG)s|Incidence of clinically-significant changes in clinical laboratory tests|Maximum observed concentration (Cmax) of AMG 562|minimum concentration (Cmin)|time of maximum concentration (Tmax)|area under the concentration-time curve (AUC)|Half Life (t1/2)|Efficacy-Overall Response|Efficacy-Objective Response Rate (ORR)|Efficacy-Duration of Response (DOR)|Efficacy-Progression Free Survival (PFS)|Efficacy-Overall Survival (OS),Amgen,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 1,10.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20170533,2018-10-29,"January 13, 2022",2022-01-13,"June 28, 2018",,"February 23, 2022","City of Hope National Medical Center, Duarte, California, United States|University of California Los Angeles, Los Angeles, California, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|Washington University, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven, Belgium|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Klinikum der UniversitÃ¤t MÃ¼nchen Campus GroÃŸhadern, MÃ¼nchen, Germany|Universitatsklinikum Ulm, Ulm, Germany|UniversitÃ¤tsklinikum WÃ¼rzburg, WÃ¼rzburg, Germany",,https://ClinicalTrials.gov/show/NCT03571828,1172.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
255,256,NCT00052416,"Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",,Completed,No Results Available,Leukemia|Lymphoma,Drug: thalidomide,,Beth Israel Deaconess Medical Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,,Other,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,BIDMC-W-01-0384-FB|CDR0000258419|NEDH-W-01-0384-FB|BIDMC-2001-P-001950|NCI-V02-1714,2002-10-01,,2003-01-01,"January 27, 2003",,"June 26, 2013","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Fletcher Allen Health Care - University Health Center Campus, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00052416,92.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
256,257,NCT00962507,Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,,Completed,No Results Available,Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm,Drug: everolimus|Drug: panobinostat|Other: laboratory biomarker analysis|Other: pharmacological study,Maximum tolerated dose|Toxicity|Pharmacokinetic and correlative studies,City of Hope Medical Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,11.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,08099|P30CA033572|CHNMC-08099|NOVARTIS-CHNMC-08099|CDR0000652208|NCI-2010-00259,2009-07-01,January 2013,2013-01-01,"August 20, 2009",,"February 15, 2013","City of Hope Medical Center, Duarte, California, United States|City of Hope Medical Group, Pasadena, California, United States",,https://ClinicalTrials.gov/show/NCT00962507,1280.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
257,258,NCT01729806,Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma,,Completed,No Results Available,CD20 Positive|Recurrent B-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma,Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Rituximab,"Incidence of toxicities according to the Common Terminology Criteria for Adverse Events version 4|Immune response as measured by the frequency of activated T-cells, absolute lymphocyte count, antibody dependent cell-mediated cytotoxicity, and kinetics and magnitude of B-cell depletion|Clinical anti-tumor response (complete response and partial response as per international workshop lymphoma response criteria [Cheson 2007])|Progression-free survival",National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,32.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2012-02213|PHI-69|CDR0000743246|NCI# 9197|9197|P30CA033572|U01CA062505|UM1CA186704|UM1CA186717,2012-11-19,"March 30, 2018",2018-03-30,"November 20, 2012",,"April 11, 2018","City of Hope Comprehensive Cancer Center, Duarte, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|City of Hope South Pasadena, South Pasadena, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01729806,1957.0,Not Industry Lead,Three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
258,259,NCT01535989,Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma,IOSI-LND-001,Completed,No Results Available,B-cell Lymphoma Refractory,Drug: Inotuzumab Ozogamicin|Drug: Temsirolimus,number of participants with adverse events based on the CTCAE v.4|Antitumor activity based on Cheson criteria,Cristiana Sessa|Oncology Institute of Southern Switzerland,All,"18 Years and older   (Adult, Older Adult)",Phase 1,25.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IOSI-LND-001,2011-12-01,June 2016,2016-06-01,"February 20, 2012",,"June 7, 2016","Oncology Institute of Southern Switzerland, Bellinzona, Ticino, Switzerland|InselSpital, Universitätsspital Bern, Bern, Switzerland|Kantonsspital St.Gallen, San Gallen, Switzerland",,https://ClinicalTrials.gov/show/NCT01535989,1644.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
259,260,NCT02900716,"Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas",,Completed,No Results Available,Chronic Lymphocytic Leukemia|B-Cell Lymphoma,Drug: DTRMWXHS-12|Drug: DTRM-505|Drug: DTRM-555,Number of patients with adverse events|Plasma concentration over time,Zhejiang DTRM Biopharma,All,"18 Years and older   (Adult, Older Adult)",Phase 1,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D15-11094,2016-09-01,"November 23, 2020",2020-11-23,"September 14, 2016",,"November 27, 2020","Mayo Clinic, Phoenix, Arizona, United States|Yale Cancer Center, New Haven, Connecticut, United States|Mayo Clinic, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02900716,1544.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
260,261,NCT00126646,"BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma",,Completed,No Results Available,Leukemia|Lymphoma,Drug: BL22 immunotoxin|Procedure: antibody-drug conjugate therapy|Procedure: immunotoxin therapy,,MedImmune LLC,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000438672|NCI-05-C-0171|NCI-P6620|NCI-5336,2005-06-01,March 2009,2009-06-01,"August 4, 2005",,"June 22, 2010","Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00126646,1461.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
261,262,NCT02419560,Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL,,Completed,No Results Available,"Lymphoma, Mantle-Cell|Recurrent Lymphoma, Mantle-Cell",Drug: ABT-199 and Ibrutinib Combination,Incidence of Dose Limiting Toxicities|Incidence and Severity of Adverse Events|Overall Response Rate|Complete Response Rate|Progression-Free Survival|Overall Survival,"Craig Portell, MD|AbbVie|University of Virginia",All,"18 Years and older   (Adult, Older Adult)",Phase 1,37.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17983|ABT199-MCL-UVA-001,2015-04-01,May 2021,2021-05-01,"April 17, 2015",,"May 24, 2022","City of Hope, Duarte, California, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02419560,2222.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
262,263,NCT01445535,Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas,,Completed,Has Results,T-Cell Peripheral Lymphoma|Gamma Delta Hepatosplenic T-Cell Lymphoma|Subcutaneous Panniculitis-Like T-Cell Lymphoma|NK T-Cell Lymphoma,Biological: Rituximab|Drug: Etoposide|Biological: Siplizumab|Drug: Prednisone|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Doxorubicin,Number of Participants With Serious and Non-serious Adverse Events|Maximum Tolerated Dose (MTD) of Siplizumab|Number of Participants With a Response to Therapy|Overall Progression Free Survival (PFS)|Overall Survival (OS),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1,15.0,NIH,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,090065|09-C-0065,2009-01-13,"April 1, 2011",2020-10-22,"October 3, 2011","August 18, 2020","November 3, 2021","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT01445535/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT01445535/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01445535,4300.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
263,264,NCT01015911,A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma,,Completed,No Results Available,"Carcinoma, Renal Cell|Lymphoma, Non-Hodgkin",Drug: SGN-75,"Incidence of adverse events and laboratory abnormalities|Best clinical response|Duration of response, progression-free survival|Blood concentrations of SGN-75 and metabolites|Incidence of antitherapeutic antibodies",Seagen Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,58.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SGN75-001,2009-11-01,November 2011,2012-03-01,"November 18, 2009",,"December 18, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States|City of Hope National Medical Center, Duarte, California, United States|UCLA Medical Center / University of California at Los Angeles, Los Angeles, California, United States|Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer Center / University of Texas, Houston, Texas, United States|Seattle Cancer Care Alliance / University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01015911,851.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
264,265,NCT02976857,A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects,C-CAR011,Completed,No Results Available,Refractory Diffuse Large B-Cell Lymphoma,Biological: C-CAR-011,Dose-limiting toxicity (DLT)|Overall response rate|Disease control rate,Cellular Biomedicine Group Ltd.|The First Affiliated Hospital with Nanjing Medical University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,15.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CBMG2016002,2016-12-01,"September 11, 2018",2019-01-09,"November 29, 2016",,"January 17, 2019","Hematological Department, People's Hospital of Jiangsu Province, Nanjing City, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT02976857,769.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
265,266,NCT03527147,Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study),PRISM,Completed,No Results Available,NHL|DLBCL|Non-hodgkin's Lymphoma|Diffuse Large B Cell Lymphoma,Drug: AZD9150|Drug: Acalabrutinib|Drug: AZD6738|Drug: Hu5F9-G4|Drug: Rituximab|Drug: AZD5153,Safety of the study treatments when given in combination [Incidence of adverse events]|Assessment of the efficacy of each treatment by evaluation of overall response rate using RECIL 2017 response criteria|Duration of response (DOR) using RECIL 2017 response criteria for the anti-tumour activity of each therapy.|Progression free survival (PFS) using RECIL 2017 response criteria for the anti-tumour activity of each therapy.|Overall Survival (OS)|Peak plasma concentration (Cmax) of Study Drug A (Arm 1)|Peak plasma concentration (Cmax) of Study Drug B (Arm 2)|Area under the plasma concentration versus time curve (AUC) of Study Drug A (Arm 1)|Area under the plasma concentration versus time curve (AUC) of Study Drug B (Arm 2)|Presence of Anti-Drug Antibody (ADA) titres in subjects treated with Study Drug A|Peak plasma concentration (Cmax) of acalabrutinib (Arm 1)|Area under the plasma concentration versus time curve (AUC) for acalabrutinib (Arm 1)|Peak plasma concentration (Cmax) of acalabrutinib (Arm 2)|Area under the plasma concentration versus time curve (AUC) for acalabrutinib (Arm 2),Acerta Pharma BV|AstraZeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 1,30.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ACE-LY-111|2017-004191-63|D9820C00001|LYM 138,2018-06-19,"March 31, 2021",2021-03-31,"May 17, 2018",,"August 15, 2022","Research Site, Los Angeles, California, United States|Research Site, Sarasota, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Bethesda, Maryland, United States|Research Site, Omaha, Nebraska, United States|Research Site, Rochester, New York, United States|Research Site, Nashville, Tennessee, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, London, United Kingdom|Research Site, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT03527147,1016.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
266,267,NCT00005580,Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma,,Completed,No Results Available,Leukemia|Lymphoma,Drug: bryostatin 1|Drug: fludarabine phosphate,,Virginia Commonwealth University|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,54.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000066433|P30CA016059|MCV-CCHR-9801-2C|NCI-T97-0116,1998-09-01,August 2006,2006-08-01,"January 27, 2003",,"February 24, 2010","New York Presbyterian Hospital - Cornell Campus, New York, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Massey Cancer Center, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00005580,2891.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
267,268,NCT00477945,Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL,,Completed,No Results Available,Non Hodgkin's Lymphoma,Drug: clofarabine,"Determine the maximum tolerated dose (MTD) of clofarabine in association with high-dose etoposide and cyclophosphamide followed by ASCT in patients with refractory lymphoma malignancies.|Assessment of the toxicity of the combination of clofarabine, and high-dose etoposide and cyclophosphamide-- Describe engraftment kinetics-- Describe the response rate-- Describe relapse rate and event-free survival-- Assess clofarabine p","Indiana University School of Medicine|Genzyme, a Sanofi Company|Indiana University",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,18.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0704-29 IUCRO-0187,2007-05-01,November 2010,2010-11-01,"May 24, 2007",,"September 11, 2014","Indiana University Cancer Center, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00477945,1280.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
268,269,NCT01209130,A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma,,Completed,No Results Available,"Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia",Drug: DCDT2980S|Drug: rituximab,"Incidence and nature of dose-limiting toxicities (DLTs)|Objective response, defined as a partial response (PR) or complete response (CR)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,91.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCT4862g|GO01295,2010-10-01,March 2015,2015-03-01,"September 27, 2010",,"November 2, 2016","Stanford, California, United States|Denver, Colorado, United States|Washington, District of Columbia, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Hackensack, New Jersey, United States|Portland, Oregon, United States|Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01209130,1612.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
269,270,NCT02756247,A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma,,Completed,No Results Available,Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma,Drug: Buparlisib|Drug: Ibrutinib,Maximum tolerated dose (MTD),"Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs, LLC|Novartis Pharmaceuticals",All,"18 Years and older   (Adult, Older Adult)",Phase 1,37.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-009,2016-05-09,"October 6, 2022",2022-10-06,"April 29, 2016",,"October 10, 2022","Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States",,https://ClinicalTrials.gov/show/NCT02756247,2341.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
270,271,NCT03181126,A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma,,Completed,No Results Available,Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma,Drug: Navitoclax|Drug: Chemotherapy|Drug: Venetoclax,Cmax of Venetoclax + Navitoclax|AUC of Venetoclax + Navitoclax|Tmax of Venetoclax + Navitoclax|CL/F of Venetoclax + Navitoclax|Number of participants with dose-limiting toxicities (DLT)|Progression-free survival (PFS)|Partial Response (PR) rate|Number of Participant who Proceed to Stem Cell Transplantation or Chimeric antigen receptor T-cell (CAR-T) Therapy|Overall survival (OS)|Objective response rate (ORR)|Complete Response (CR) rate,AbbVie,All,"4 Years and older   (Child, Adult, Older Adult)",Phase 1,69.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M16-106,2017-11-27,"November 11, 2020",2020-11-14,"June 8, 2017",,"October 14, 2021","City of Hope /ID# 169029, Duarte, California, United States|LPCH Stanford /ID# 163337, Palo Alto, California, United States|University of Chicago /ID# 163369, Chicago, Illinois, United States|Washington University-School of Medicine /ID# 165689, Saint Louis, Missouri, United States|Univ NC Chapel Hill /ID# 163509, Chapel Hill, North Carolina, United States|Cincinnati Children's Hospital /ID# 164619, Cincinnati, Ohio, United States|Nationwide Childrens Hospital /ID# 163372, Columbus, Ohio, United States|Oregon Health and Science University /ID# 165690, Portland, Oregon, United States|St Jude Children's Research Hospital /ID# 163335, Memphis, Tennessee, United States|UT Southwestern Medical Center /ID# 163346, Dallas, Texas, United States|MD Anderson Cancer Center at Texas Medical Center /ID# 163327, Houston, Texas, United States|University of Wisconsin-Madiso /ID# 165691, Madison, Wisconsin, United States|Alfred Hospital /ID# 169576, Melbourne, Victoria, Australia|Victorian Comprehensive Cancer /ID# 165710, Melbourne, Victoria, Australia|Royal Children's Hospital /ID# 163322, Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT03181126,1083.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
271,272,NCT01473095,Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma,,Completed,No Results Available,Solid Tumor|Malignant Lymphoma|Tumor,Drug: ARQ 092,"Assess the safety and tolerability of ARQ 092 in subjects with advanced solid tumors and recurrent malignant lymphoma by monitoring frequency and severity of adverse events|Assess the pharmacokinetic profile (Cmax, AUC, and half-life) of ARQ 092|Assess pharmacodynamic activity|Determine preliminary evidence of activity as defined by RECIST v 1.1|Determine recommended Phase 2 dose","ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)",All,"18 Years and older   (Adult, Older Adult)",Phase 1,120.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ARQ 092-101,2011-11-01,"July 6, 2017",2017-08-07,"November 17, 2011",,"October 23, 2017","Birmingham, Alabama, United States|Scottsdale, Arizona, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Lafayette, Indiana, United States|San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01473095,2106.0,Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
272,273,NCT00088868,17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma,,Completed,No Results Available,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: alvespimycin hydrochloride,,National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,40.0,NIH,Interventional,Primary Purpose: Treatment,040218|04-C-0218|NCI-6544|CDR0000377488,2004-06-01,March 2010,2010-12-01,"August 5, 2004",,"March 15, 2012","Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00088868,2374.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
273,274,NCT01168752,Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma,,Completed,No Results Available,Cancer|Neoplasms|Solid Tumors|Lymphoma,Drug: Debio 0932,"Occurence of DLTs for both schedules|Incidence of AEs, change in safety and efficacy parameters",Debiopharm International SA,All,"18 Years and older   (Adult, Older Adult)",Phase 1,81.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Debio 0932-101|2009-017720-11,2010-04-01,April 2013,2013-04-01,"July 23, 2010",,"February 3, 2014","Centre Georges-François Leclerc, Dijon, France|Institut Claudius Regaud, Toulouse, France|Institut Gustave Roussy, Villejuif, France",,https://ClinicalTrials.gov/show/NCT01168752,1096.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
274,275,NCT01682616,A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma,,Completed,No Results Available,Small Lymphocytic Lymphoma|Chronic Lymphocytic Leukemia,Drug: ABT-199|Drug: Rituximab,"Assess the safety profile, to determine the maximum tolerated dose and Recommended Phase Two Dose of ABT-199 when administered in combination with rituximab (R) in subjects with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.|Determination of peak concentration (Cmax) of ABT-199 and/or Rituximab.|Assess the exploratory efficacy of the combination ABT-199 and rituximab.|Determination of trough concentration (Ctrough) of ABT-199 and/or Rituximab|Determination of area under the concentration versus time curve (AUC) of ABT-199 and/or Rituximab|Assess the exploratory efficacy of the combination ABT-199 and rituximab","AbbVie|Genentech, Inc.",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1,50.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M13-365,2012-07-25,"June 23, 2022",2022-06-23,"September 11, 2012",,"July 12, 2022","Moores Cancer Center at UC San Diego /ID# 70398, La Jolla, California, United States|Northwestern University Feinberg School of Medicine /ID# 71593, Chicago, Illinois, United States|North Shore University Hospital /ID# 71813, New Hyde Park, New York, United States|Duke Cancer Center /ID# 71393, Durham, North Carolina, United States|Peter MacCallum Cancer Ctr /ID# 70394, Melbourne, Victoria, Australia|The Royal Melbourne Hospital /ID# 70393, Parkville, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT01682616,3620.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
275,276,NCT03305445,Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL,,Completed,No Results Available,Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma,Drug: Ipilimumab|Drug: Nivolumab,Dose Limiting Toxicities (DLTs)|Completion Remission (CR) Rate|Progression Free Survival (PFS)|Overall Survival (OS)|IgVH level|Delayed CR|Overall Response Rate (ORR),Icahn School of Medicine at Mount Sinai|Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 1,6.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GCO 17-2164,2018-05-14,"April 1, 2021",2021-04-01,"October 10, 2017",,"February 15, 2023","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03305445,1053.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
276,277,NCT02130869,A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,,Completed,No Results Available,Neuroblastoma|Lymphoma|High-risk Tumor,Biological: CD133+ selected autologous stem cell infusion|Biological: IL-2|Biological: hu14.18K322A|Drug: Busulfan|Drug: Melphalan|Biological: GM-CSF|Drug: Bendamustine|Drug: Etoposide|Drug: Cytarabine|Drug: Carboplatin|Device: Haploidentical natural killer cell infusion|Biological: G-CSF|Drug: Etoposide phosphate|Device: CliniMACS,Percent of participants with positive ANC engraftment|Overall survival|Disease-free survival|Incidence of relapse|Lymphocyte and hematopoietic reconstitution|Characteristics of the stem cell grafts|Characteristics of the natural killer cell grafts.|Overall survival of patients treated without stem cell manipulation or NK cell infusion due to off therapy criteria,St. Jude Children's Research Hospital,All,"up to 21 Years   (Child, Adult)",Phase 1,8.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ASCIST|NCI-2014-00275,2014-10-10,"December 20, 2017",2017-12-20,"May 6, 2014",,"December 22, 2017","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02130869,1167.0,Not Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
277,278,NCT01614197,A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma,,Completed,No Results Available,"Lymphoblastic Leukemia, Acute, Childhood|Lymphoblastic Lymphoma|Peripheral T-cell Lymphoma",Drug: Temsirolimus|Drug: Etoposide|Drug: Cyclophosphamide|Drug: Methotrexate|Drug: Hydrocortisone|Drug: Cytarabine,The dose of temsirolimus that can be safely given with etoposide and cyclophosphamide.|The response rate after treatment.|Responsiveness of patient lymphoblasts to mTOR inhibition using in-vitro and in-vivo pharmacodynamic (PD) assessments.|Minimal residual disease (MRD) levels present at end of cycle 1 therapy in patients with bone marrow involvement.,Therapeutic Advances in Childhood Leukemia Consortium|Pfizer,All,"1 Year to 21 Years   (Child, Adult)",Phase 1,16.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,T2014-001,2015-03-01,"December 15, 2019",2020-05-31,"June 7, 2012",,"July 7, 2020","Childrens Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital Orange County, Orange, California, United States|UCSF School of Medicine, San Francisco, California, United States|The Children's Hospital, University of Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Miami Cancer Center, Miami, Florida, United States|Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, United States|Lurie Children's Hospital, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber, Boston, Massachusetts, United States|C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States|Childrens Hospital & Clinics of Minnesota, Minneapolis, Minnesota, United States|Children's Hospital New York-Presbyterian, New York, New York, United States|Levine Children's Hospital at Carolinas Medical Center, Charlotte, North Carolina, United States|Rainbow Babies, Cleveland, Ohio, United States|Nationwide Childrens Hospital, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude, Memphis, Tennessee, United States|University of Texas at Southwestern, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|Primary Children's, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Children's Hospital at Westmead, Westmead, New South Wales, Australia|Royal Children's Hospital, Brisbane, Queensland, Australia|Royal Children's Hospital, Melbourne, Melbourne, Victoria, Australia|Sydney Children's Hospital, Sydney, Australia|Hospital for Sick Kids, Toronto, Ontario, Canada|Sainte Justine University Hospital, Montreal, Quebec, Canada|British Columbia Children's Hospital, Vancouver, Canada",,https://ClinicalTrials.gov/show/NCT01614197,1918.0,Not Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
279,280,NCT04152148,"A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients",,Completed,No Results Available,Non-Hodgkin's Lymphoma,Biological: 500mg BAT4306F|Biological: 750mg BAT4306F|Biological: 900mg BAT4306F|Biological: 1000mg BAT4306F,Dose-limiting toxicity（DLT）|Maximum tolerated dosed (MTD)|pharmacokinetics (PK)|CD19+ B lymphocyte ratio|anti drug antibodies (ADA)|ORR,Bio-Thera Solutions,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,16.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BAT4306F-001-CR,2018-09-04,"January 13, 2021",2021-01-13,"November 5, 2019",,"February 8, 2023","Beijing Cancer Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT04152148,862.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
280,281,NCT01328626,A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma,,Completed,No Results Available,Chronic Lymphocytic Leukemia|Non-Hodgkin Lymphoma,Drug: ABT-199,"Determination of dose limiting toxicity (DLT), maximum tolerated dose (MTD), recommended phase two dose (RPTD), and lead-in period regimen|Number of subjects with adverse events|Determination of plasma peak concentration (Cmax) of ABT-199|Determination of trough concentration (Ctrough) of ABT-199|Determination of area under the concentration versus time curve (AUC) of ABT-199|Food Effect - Cmax|Preliminary efficacy assessment|Minimal residual disease collection (MRD)|Food Effect - Tmax|Food Effect - AUC","AbbVie|Genentech, Inc.",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1,222.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M12-175,2011-05-23,"May 8, 2020",2020-05-08,"April 5, 2011",,"February 23, 2022","University of Arizona Cancer Center - North Campus /ID# 52902, Tucson, Arizona, United States|Ucsd /Id# 48325, La Jolla, California, United States|Dana-Farber Cancer Institute /ID# 48324, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center /ID# 56810, New York, New York, United States|University of Texas MD Anderson Cancer Center /ID# 48326, Houston, Texas, United States|Swedish Medical Center /ID# 135853, Seattle, Washington, United States|Fred Hutchinson Cancer Research /ID# 52882, Seattle, Washington, United States|Univ of Wisconsin Hosp/Clinics /ID# 56811, Madison, Wisconsin, United States|Peter MacCallum Cancer Ctr /ID# 48323, Melbourne, Victoria, Australia|Royal Melbourne Hospital /ID# 48322, Parkville, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT01328626,3273.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
281,282,NCT02343718,Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours,,Completed,No Results Available,Recurrent Lymphoma|Refractory Lymphoma|Solid Tumours|Central Nervous System,Drug: Vinblastine|Drug: Temsirolimus,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Canadian Cancer Trials Group|Pfizer,All,"1 Year to 18 Years   (Child, Adult)",Phase 1,7.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,I218,2015-06-02,"September 28, 2017",2019-01-16,"January 22, 2015",,"April 9, 2020","Children's and Women's Health Centre of BC Branch, Vancouver, British Columbia, Canada|Izaak Walton Killam (IWK) Health Centre, Halifax, Nova Scotia, Canada|McMaster Children's Hospital, Hamilton, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|CHU Sainte-Justine, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02343718,1324.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
282,283,NCT01032681,"EMD 521873 in Advanced Solid Tumors, MTD Finding",,Completed,No Results Available,Non-Hodgkin Lymphoma,Biological: EMD 521873,"Assess the safety and tolerability of EMD 521873|To determine whether the MTD is reached with EMD 521873 doses of up to 1.5 mg/kg given alone or in combination with fixed, low-dose CPA in patients with metastatic or locally advanced solid tumors or B-cell non-Hodgkin lymphoma|Characterize the PK profile of EMD 521873 alone or in combination with fixed lowdose CPA|Evaluate the immunogenicity of EMD 521873 alone or in combination with CPA measured by the induction of o Specific antibodies against the genetically modified IL-2 o Fc-IL2-specific antibodies o Anti-idiotype antibodies|Collect evidence of best overall response, changes in serum tumor marker levels and best clinical response after treatment with EMD 521873 alone or in combination with CPA|Evaluate survival|Evaluate biological responses to EMD 521873 alone or in combination with CPA as measured by o Absolute cell numbers and ratios of lymphocyte subsets in defined combinations o Change in serum level of sIL2R and neopterin","Merck KGaA, Darmstadt, Germany",All,"18 Years and older   (Adult, Older Adult)",Phase 1,66.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EMR62235_001,2006-12-01,February 2011,2012-01-01,"December 15, 2009",,"July 31, 2014","Universitäts-Klinikum Mainz III.Medizinische Klinik, Mainz, Germany|Medizinische Klinik Universitätsklinikum Mannheim Medizinische Fakultät Mannheim, Mannheim, Germany|Istituto Oncologico della Svizzera Italiana Ospedale Regionale Bellinzona e Valli (IOSI), Bellinzona, Switzerland|University of Lausanne Hospitals (CHUV) and Hospitals of Riveria-Chablais, Lausanne, Switzerland|Kantonsspital St. Gallen, St.Gallen, Switzerland",,https://ClinicalTrials.gov/show/NCT01032681,1857.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
283,284,NCT02603445,Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL,,Completed,No Results Available,"Follicular Lymphoma, Mantle Cell Lymphoma",Drug: BCL201|Drug: Idelalisib,"Number of participants with adverse events (AEs)|Incidence rate of dose limiting toxicities (DLTs)|Exposure to BCL201 and idelalisib as measured by AUC0-24h at C1D15|Plasma concentration of BCL201, idelalisib and GS-563117 (metabolite of idelalisib)|AUC pharmacokinetics (PK) parameter for BCL201, idelalisib and GS-563117|Objective Response Rate (ORR)|Best Overall Response (BOR)|Duration of Response (DOR)|Complete Response (CR)|Partial Response (PR)|Stable disease (SD)|Cmax pharmacokinetics (PK) parameter for BCL201, idelalisib and GS-563117",Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CBCL201X2102C,2015-11-16,"July 10, 2018",2018-07-10,"November 11, 2015",,"February 24, 2020","Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Pierre Benite Cedex, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Mainz, Germany",,https://ClinicalTrials.gov/show/NCT02603445,967.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
284,285,NCT00655837,"Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL",,Completed,No Results Available,"Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin",Drug: SGN-40|Drug: rituximab|Drug: gemcitabine,"Determine the safety and adverse-event profile for combination therapy of SGN-40 with gemcitabine and rituximab.|Estimate progression free survival, clinical response rates to treatment, and overall survival to determine efficacy.","Seagen Inc.|Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,33.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SG040-0008,2008-04-01,February 2010,2010-02-01,"April 10, 2008",,"December 18, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|University of Colorado, Aurora, Colorado, United States|Oncology Specialists, Park Ridge, Illinois, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00655837,671.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
285,286,NCT01534715,IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia,,Completed,No Results Available,"Lymphoma, Non-Hodgkin|Chronic Lymphocytic Leukemia",Drug: IMGN529,Occurrence of dose limiting toxicities,"ImmunoGen, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,49.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IMGN0301,2012-01-01,July 2016,2016-07-01,"February 17, 2012",,"December 29, 2017","Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Ohio State University, Columbus, Ohio, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|CTRC at UTHSCSA, San Antonio, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Oncology Institute of Southern Switzerland, Bellinzona, Switzerland",,https://ClinicalTrials.gov/show/NCT01534715,1643.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
286,287,NCT00614042,Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma,,Completed,No Results Available,Chronic Lymphocytic Leukemia (CLL)|Non-Hodgkin's Lymphoma (NHL),Drug: TRU-016 (anti-CD37 protein therapeutic),Safety and tolerability of TRU-016 administered IV in patients with CLL or NHL|Preliminary indication of response as defined by NCI 1996 criteria,Aptevo Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1,96.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16007,2008-01-01,December 2011,2012-03-01,"February 13, 2008",,"June 28, 2017","For additional information regarding sites for this trial call 919-319-9374, Birmingham, Alabama, United States|For additional information regarding sites for this trial call 919-319-9374, Augusta, Georgia, United States|For additional information regarding sites for this trial call 919-319-9374, Boston, Massachusetts, United States|For additional information regarding sites for this trial call 919-319-9374, Las Vegas, Nevada, United States|For additional information regarding sites for this trial call 919-319-9374, Durham, North Carolina, United States|For additional information regarding sites for this trial call 919-319-9374, Portland, Oregon, United States|For additional information regarding sites for this trial call 919-319-9374, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00614042,1521.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
287,288,NCT01078649,Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas,,Completed,No Results Available,Cancer|Solid Tumors|Lymphoma|Malignancy,Drug: Debio 1143 (AT-406),Maximally Tolerated Dose|Pharmacokinetic|Pharmacodynamic|Efficacy|Correlation of Efficacy to Pharmacokinetic and/or Pharmacodynamic Effects of Debio 1143 (AT-406),Debiopharm International SA,All,"18 Years and older   (Adult, Older Adult)",Phase 1,51.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Debio 1143-101 (AT-406-CS-001),2010-03-29,April 2014,2014-04-01,"March 2, 2010",,"December 27, 2018","University of Michigan Cancer Center, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01078649,1464.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
288,289,NCT01429025,"Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma",,Completed,No Results Available,Refractory/Relapsed Indolent Non-Hodgkin Lymphoma,Biological: rituximab|Drug: bendamustine|Drug: lenalidomide,Maximum-tolerated dose of lenalidomide in combination with bendamustine hydrochloride and rituximab|Toxicity profile|Progression-free survival|Overall response rate|Complete response rate,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Celgene Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 1,26.0,Other|NIH|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCCTG-N1088|CDR0000710726|NCI-2011-03535,2012-05-01,November 2014,2019-07-01,"September 5, 2011",,"October 8, 2019","Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Iowa Oncology Research Association CCOP, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|Siouxland Hematology-Oncology, Sioux City, Iowa, United States|Mercy Medical Center-Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Mayo Clinic, Rochester, Minnesota, United States|Mid Dakota Clinic, Bismarck, North Dakota, United States|Saint Alexius Medical Center, Bismarck, North Dakota, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States",,https://ClinicalTrials.gov/show/NCT01429025,2617.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
289,290,NCT03483688,A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects,,Completed,No Results Available,B-cell Non-Hodgkin Lymphoma,Biological: CD19-directed CAR-T cells,AE|Overall response rate (ORR)|Duration of remission (DOR)|Progression free survival (PFS)|Overall survival rate（OSR）,Peking Union Medical College Hospital|Cellular Biomedicine Group Ltd.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,6.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CBMG-C2017007,2018-03-06,"December 10, 2019",2020-01-10,"March 30, 2018",,"March 5, 2020","Peking Union Medical College Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT03483688,675.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
290,291,NCT01650727,A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974),,Completed,No Results Available,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: Dinaciclib|Biological: Rituximab,Number of Participants Experiencing a Dose Limiting Toxicity (DLT),Merck Sharp & Dohme LLC,All,"18 Years and older   (Adult, Older Adult)",Phase 1,5.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P07974|2012-001437-14|MK-7965-011,2012-10-01,October 2013,2013-10-01,"July 26, 2012",,"February 10, 2015",,,https://ClinicalTrials.gov/show/NCT01650727,365.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
291,292,NCT02155582,Copanlisib Pharmacodynamic Study,,Completed,No Results Available,Non Hodgkin Lymphoma,Drug: Copanlisib (BAY80-6946),"Maximum change from baseline in expression of pathway inhibition (pAKT) in surrogate tissue (platelet rich plasma) during copanlisib monotherapy|Maximum change from baseline in plasma glucose during 2 cycles of copanlisib monotherapy|AUC(0-168) of copanlisib after each copanlisib IV infusion during 2 cycles of copanlisib monotherapy|AEs as characterized by type, frequency, severity (as graded by CTCAE) and relationship to study drug|Maximum change from baseline in insulin during 2 cycles of copanlisib|Maximum change from baseline in C-peptide during 2 cycles of copanlisib|FDG PET early response (decreased SUVmax compared to baseline) after dosing with copanlisib for non-diabetic patients with detectable FDG tumor uptake at baseline|Change from baseline in expression and / or phosphorylation of PI3K pathway proteins in paired tumor biopsies",Bayer,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 1,63.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,16790|2013-004746-42,2014-08-12,"October 4, 2016",2017-03-16,"June 4, 2014",,"June 16, 2017","Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Gent, Belgium|Caen Cedex 5, France|Lille, France|Nice Cedex 2, France|Pierre Benite, France|Sutton, Surrey, United Kingdom|London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02155582,947.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
292,293,NCT00694590,Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,,Completed,No Results Available,Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL),Drug: plerixafor,The maximum tolerated dose of plerixafor when combined with rituximab as treatment for previously treated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)|The principal toxicities and dose limiting toxicities of plerixafor when combined with rituximab|Time to maximal plasma concentration (Tmax) when plerixafor is combined with rituximab|Area under the concentration-time curve from time zero to the last observed concentration (AUC 0-last) when plerixafor is combined with rituximab|Area under the concentration-time curve over the dosing interval (τ) (AUC 0-τ) when plerixafor is combined with rituximab|Area under the concentration-time curve from time zero to infinity (AUC 0-∞ ) when plerixafor is combined with rituximab|Half-life (T½) when plerixafor is combined with rituximab|Volume of distribution (Vz/F for subcutaneous (SC) administration; Vz for intravenous (IV) administration);,"Genzyme, a Sanofi Company|Sanofi",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,24.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MOZ00207,2008-06-01,November 2010,2011-09-01,"June 10, 2008",,"March 20, 2015","UCSD Moores Cancer Center, La Jolla, California, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|UTMD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00694590,1187.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
293,294,NCT00693602,Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma,,Completed,No Results Available,Acute Lymphoblastic Leukemia|Non Hodgkins Lymphoma,Drug: Erwinase,To provide Erwinase to patients with acute lymphoblastic leukemia (ALL) or non-Hodgkins lymphoma who are intolerant or have developed hypersensitivity to E. coli asparaginase and/or PEG-asparaginase,St. Jude Children's Research Hospital|Jazz Pharmaceuticals|Parexel,All,"Child, Adult, Older Adult",Phase 1,87.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,ERWASE,2006-06-01,December 2011,2011-12-01,"June 9, 2008",,"April 26, 2017","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00693602,2009.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Supportive Care
294,295,NCT01088048,"Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia",,Completed,Has Results,Indolent Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma,Drug: Idelalisib|Drug: Rituximab|Drug: Bendamustine|Drug: Ofatumumab|Drug: Fludarabine|Drug: Everolimus|Drug: Bortezomib|Drug: Chlorambucil|Drug: Lenalidomide,"Duration of Exposure to IDELA|Toxicity of Administration of IDELA|Overall Response Rate|Duration of Response|Time to Response|Progression-free Survival|Overall Survival|Plasma Concentration of IDELA (Cohort 1, Cohorts 2 and 3, Cohort 5)|Plasma Concentration of IDELA (Cohort 4)|Plasma Concentration of IDELA (Cohort 6)|Plasma Concentration of IDELA (Cohort 7)|Sub-study: Plasma Concentration of IDELA (Cohorts 1-4)|Plasma Concentration of Bendamustine|Plasma Concentration of Everolimus|Plasma Concentration of Lenalidomide",Gilead Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 1,241.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,101-07,2010-03-25,"April 28, 2015",2015-04-28,"March 17, 2010","March 18, 2021","March 18, 2021","Clearview Cancer Institute, Huntsville, Alabama, United States|UCLA, Los Angeles, California, United States|Stanford Cancer Center, Palo Alto, California, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|Weill Medical College of Cornell, New York, New York, United States|Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer, Houston, Texas, United States|North Star Lodge Cancer Center, Yakima, Washington, United States",,https://ClinicalTrials.gov/show/NCT01088048,1860.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
295,296,NCT03798314,Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma,,Completed,No Results Available,Recurrent Nervous System Lymphoma|Recurrent Primary Vitreoretinal DLBCL|Refractory Nervous System Lymphoma|Refractory Primary Vitreoretinal DLBCL,Biological: Nivolumab|Drug: Pomalidomide,Maximum-tolerated dose (MTD) of pomalidomide|Incidence of adverse events|Percentage of Participants With Grade 3 or Higher Adverse Events Considered At Least Possibly Related to Treatment|Overall response rate (ORR)|Progression-free survival (PFS),Mayo Clinic|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,3.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MC178A|NCI-2018-03661,2019-01-30,"December 30, 2020",2021-09-15,"January 9, 2019",,"January 6, 2023","Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03798314,959.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
296,297,NCT00647764,Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas,,Completed,No Results Available,Solid Tumor Malignancy|Lymphoid Malignancy (Lymphoma and CLL)|Leukemia|Lymphoma,Drug: SNX-5422 Mesylate Hsp90 inhibitor,"MTD, safety and toxicity|pharmacokinetic profile of SNX-5422|tumor response measured by X-rays or scans",Esanex Inc.|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,32.0,Industry|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B1311003|PO7318,2008-03-01,September 2010,2010-09-01,"April 1, 2008",,"May 17, 2012","Pfizer Investigational Site, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00647764,914.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
297,298,NCT00058617,"Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL",,Completed,No Results Available,Epstein-Barr Virus-Related Hodgkin Lymphoma|Epstein-Barr Virus-Related Non-Hodgkin Lymphoma|EBV Positive Plasma Cell Neoplasm,Biological: Injection of EBV Specific CTLs,"The safety of two IV injections of auto EBV specific CTLs will be determined through adverse event measurement. These CTLs may be marked with the neomycin resistance gene introduced by a retroviral vector.|To determine the feasibility of generating EBV specific cytotoxic T cell lines from patients with active EBV positive Lymphoma including Hodgkin Disease (HD) or Non-Hodgkin Lymphoma (NHL).|To determine the survival, immunological efficacy and anti-tumor effects of EBV specific cytotoxic T-lymphocyte lines.","Baylor College of Medicine|The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",All,"Child, Adult, Older Adult",Phase 1,13.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6423-ANGEL|ANGEL,1996-01-01,August 2011,2014-07-01,"April 9, 2003",,"February 15, 2017","Houston Methodist Hospital, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00058617,6756.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
298,299,NCT00944905,Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL),,Completed,No Results Available,Renal Cell Carcinoma|Non-hodgkin's Lymphoma,Biological: MDX-1203,Safety profile of MDX-1203 and determine the maximum tolerated dose (MTD)|Biomarker: Incidence of CD70+ tumors in target population,Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 1,46.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MDX1203-01|CA211-001,2009-07-01,November 2012,2012-11-01,"July 23, 2009",,"May 22, 2013","Yale University School of Medicine, New Haven, Connecticut, United States|Emory University Winship Cancer Center, Atlanta, Georgia, United States|The University of Chicago, Chicago, Illinois, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|The University of Michigan Health System, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00944905,1219.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
299,300,NCT00659425,"CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma",,Completed,Has Results,Acute Lymphoblastic Leukemia|Non-Hodgkin's Lymphoma,Drug: CAT-8015 (Moxetumomab Pasudotox),"Number of Participants With Dose Limiting Toxicities (DLTs)|Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)|Number of Participants With Vital Signs Abnormalities Recorded as Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Clinically Significant Laboratory Abnormalities Recorded as Treatment-Emergent Adverse Events (TEAEs)|Treatment-Emergent Adverse Events (TEAEs) Related to Chemistry Abnormalities Occurring in Greater Than (>) 5 Percent of Participants|Number of Participants With Abnormalities in Ophthalmologic Examination at End of Treatment That Were Not Present at Baseline|Number of Participants With Change From Baseline in Normal Sinus Rhythm Findings in ECG|Change From Baseline to End of Treatment in Clinical Findings in Electrocardiogram (ECG) QT, QTC Interval and Ventricular Rate|Best Overall Tumor Response|Objective Response Rate (ORR)|Percentage of Participants With Relapse of Disease|Time to Disease Response|Duration of Response (DR)|Time to Disease Progression (TDP)|Progression-Free Survival (PFS)|Overall Survival (OS)|Maximum Observed Serum Concentration (Cmax) for Moxetumomab Pasudotox|Area Under the Serum Concentration Time Curve From Time Zero to Infinity (AUC [0 to Infinity]) for Moxetumomab Pasudotox|Systemic Clearance (CL) for Moxetumomab Pasudotox|Terminal Phase Elimination Half Life (t1/2) for Moxetumomab Pasudotox|Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibody|CD22 Expression Cells in Peripheral Blood by Best Response|Number of Participants With Potential Biomarkers of Predicting Capillary Leak Syndrome (CLS)",MedImmune LLC|National Cancer Institute (NCI),All,"6 Months to 25 Years   (Child, Adult)",Phase 1,57.0,Industry|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CAT-8015-1004,2008-09-01,December 2014,2014-12-01,"April 16, 2008","October 2, 2017","October 2, 2017","Research Site, Los Angeles, California, United States|Research Site, Bethesda, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Memphis, Tennessee, United States|Research Site, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00659425,2282.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
300,301,NCT00364676,"Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease",,Completed,No Results Available,Tumors|Hodgkins Disease|Non-Hodgkins Lymphoma,Drug: VLI,Evaluate the safety and tolerability of VLI.|To determine the maximum tolerated dose (MTD),"Spectrum Pharmaceuticals, Inc",All,"18 Years and older   (Adult, Older Adult)",Phase 1,67.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HBS501,2006-07-01,June 2015,2015-08-01,"August 16, 2006",,"September 22, 2015","Cancer Therapy and Research Center, San Antonio, Texas, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States|McGill Centre for Translational Research in Cancer-Jewish General Hospital Clinical Research Unit, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00364676,3318.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
301,302,NCT00850057,Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),,Completed,No Results Available,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Biological: Intranodal injection of Ad-ISF35,Determine the safety and maximum tolerated dose (MTD) of Adenovirus-CD154 (Ad-ISF35) when injected directly into lymph nodes of patients with CLL/SLL.|Determine and monitor clinical and biological responses in patients treated with intranodal injections of Ad-ISF35.|Determine pharmacodynamic (PD) parameters in patients treated with intranodal injections of ISF35.,"University of California, San Diego|Memgen, LLC",All,"18 Years and older   (Adult, Older Adult)",Phase 1,16.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UCSD-060201,2006-02-01,October 2009,2009-10-01,"February 24, 2009",,"July 12, 2019","University of California, San Diego Moores Cancer Center, La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT00850057,1338.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
302,303,NCT00725634,"A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma",P05538,Completed,No Results Available,Malignant Solid Tumor|Lymphomas|Multiple Myeloma,Biological: AV-299|Biological: AV-299 + erlotinib,"Dose Limiting Toxicity and Recommended Phase 2 dose|Pharmacokinetic (PK) profile of AV-299, and erlotinib (for subjects enrolled in the Phase 1b only).|Evaluate the effects of AV-299 and combination of AV-299 and erlotinib on exploratory biomarkers in blood, body fluid, tumor tissue, and/or bone marrow.|Study the preliminary antineoplastic activity of AV-299 in subjects with advanced solid tumors, lymphoma, or multiple myeloma, and the preliminary antineoplastic activity of AV 299 in combination with erlotinib in subjects with advanced solid tumor.|Investigate the effect of AV-299 and of the combination of AV-299 and erlotinib on gene expression patterns in peripheral blood mononuclear cells and/or bone marrow.|Assess dosing schedules of AV-299 (e.g. every 2-week and every 3-week schedules).|Assess safety and tolerability of the RP2D of AV-299 in expansion cohort(s).","AVEO Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,41.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P05538,2008-09-01,December 2010,2013-12-01,"July 30, 2008",,"January 27, 2014","Investigational Site 2, Scottsdale, Arizona, United States|Investigational Site 3, Columbus, Ohio, United States|Investigational Site 1, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00725634,1917.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
303,304,NCT00001249,Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac,,Completed,No Results Available,"Leukemia, T-Cell|Lymphoma, T-Cell, Cutaneous",Drug: Yttrium-90 radiolabeled anti-Tac antibody,,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",Phase 1,30.0,NIH,Interventional,Primary Purpose: Treatment,900043|90-C-0043,1989-12-01,,2000-10-01,"December 10, 2002",,"March 4, 2008","National Cancer Institute (NCI), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00001249,3957.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
304,305,NCT00522652,Phase I Trial of PX-478,,Completed,No Results Available,Advanced Solid Tumors|Lymphoma,Drug: PX-478,"To determine the MTD of PX-478 administered orally on days one to five of a 21 day cycle|To evaluate the safety profile of PX-478 when administered orally on days one to five of a 21 day cycle|To evaluate pharmacodynamic measures of the effects of PX 478 on the HIF 1-alpha pathway, and related tumor markers|To determine the PK profile of PX 478 when administered orally on days one to five of a 21 day cycle|To evaluate the effects of PX 478 on tumor blood flow and vascular permeability as measured by DCE MRI|To evaluate the anti-tumor activity of PX 478 in patients with advanced malignancies",Cascadian Therapeutics Inc.|Seagen Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,45.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PX-478-001,2007-08-01,May 2010,2010-05-01,"August 30, 2007",,"May 17, 2018","TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona, United States|The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00522652,1004.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
305,306,NCT03806179,Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL,LYMRIT-37-07,Completed,No Results Available,Non Hodgkin Lymphoma|Follicular Lymphoma|Relapsed Follicular Lymphoma,Drug: Betalutin,Safety and Tolerability: frequency and severity of adverse events (CTCAE v4.03)|Preliminary Anti-tumour Activity,Nordic Nanovector|ICON Clinical Research,All,"18 Years and older   (Adult, Older Adult)",Phase 1,7.0,Industry,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LYMRIT -37-07(Archer-1)|2017-004506-18,2018-10-04,"August 8, 2022",2022-08-08,"January 16, 2019",,"October 3, 2022","Klinika Hematoonkologie, Ostrava-, Porubá, Czechia|Oslo University Hospital, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT03806179,1404.0,Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
306,307,NCT01606878,Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,,Completed,No Results Available,Childhood Solid Neoplasm|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Neuroblastoma,Drug: Crizotinib|Drug: Cyclophosphamide|Drug: Dexrazoxane Hydrochloride|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Questionnaire Administration|Drug: Topotecan Hydrochloride|Drug: Vincristine Sulfate,Incidence of adverse events|Maximum tolerated dose (MTD) of crizotinib|Time to maximum plasma concentration (Tmax)|Peak concentration (Cmax)|Terminal phase half-life (t1/2)|Area under the concentration|Plasma Clearance (CI/F)|Response rate,Children's Oncology Group|National Cancer Institute (NCI),All,"13 Months to 21 Years   (Child, Adult)",Phase 1,46.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ADVL1212|NCI-2012-01968|CDR0000734059|UM1CA097452,2013-04-29,"December 31, 2018",2018-12-31,"May 28, 2012",,"February 26, 2019","Children's Hospital of Alabama, Birmingham, Alabama, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01606878,2072.0,Not Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
307,308,NCT03057418,"Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim",,Completed,No Results Available,"Lymphoma, Non-Hodgkin|Lymphoma, Follicular",Drug: Aurixim,Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)|Maximum tolerated dose (MTD) of Aurixim|Area under the plasma concentration versus time curve (AUC)|CD19+|Peak Plasma Concentration (Cmax)|Elimination half-life (T1/2),Biointegrator LLC,All,"18 Years and older   (Adult, Older Adult)",Phase 1,7.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONC-CON4619-01,2013-06-01,December 2016,2016-12-01,"February 20, 2017",,"May 23, 2017","State Budgetary Public Healthcare Institution of the Nizhni Novgorod Region ""Hospital of Ambulance of Dzerzhinsk city"", Dzerzhinsk, Russian Federation|Federal State Budgetary Institution ""National Medical-Surgical Center n.a. N.I.Pirogov"" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation|Federal State Budgetary Institution ""Russian Oncological Scientific Center n.a. N.N.Blokhin"" of the Russian Academy of Medical Sciences, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT03057418,1279.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
308,309,NCT04134936,Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL,,Completed,No Results Available,Diffuse Large B-cell Lymphoma,Drug: Tafasitamab|Drug: Tafasitamab plus lenalidomide,"Incidence and severity of treatment-emergent adverse events (TEAEs)|Objective Response Rate (ORR) at the end of treatment|Metabolic, PET-negative complete response (CR) rate at the end of treatment|Incidence and severity of adverse events (AEs) in the follow-up period|Best Objective Response Rate (ORR) until the end of study|Metabolic, PET-negative complete response (CR) rate until the end of study|Progression-free survival (PFS) at 12 and 24 months|Event-free survival (EFS) at 12 and 24 months|Time to next anti-lymphoma treatment (TTNT)|Overall survival at 12 and 24 months|Anti-tafasitamab antibodies formation",MorphoSys AG,All,"18 Years and older   (Adult, Older Adult)",Phase 1,66.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MOR208C107,2019-12-11,"February 11, 2021",2022-08-10,"October 22, 2019",,"March 15, 2023","MorphoSys Research Site, Tucson, Arizona, United States|MorphoSys Research Site, Anaheim, California, United States|MorphoSys Research Site, Duarte, California, United States|MorphoSys Research Site, Encinitas, California, United States|MorphoSys Research Site, Aurora, Colorado, United States|MorphoSys Research Site, New Haven, Connecticut, United States|MorphoSys Research Site, Washington, District of Columbia, United States|MorphoSys Research Site, Urbana, Illinois, United States|MorphoSys Research Site, Louisville, Kentucky, United States|MorphoSys Research Site, Covington, Louisiana, United States|MorphoSys Research Site, Rockville, Maryland, United States|MorphoSys Research Site, Ann Arbor, Michigan, United States|MorphoSys Research Site, Rochester, Minnesota, United States|MorphoSys Research Site, Cincinnati, Ohio, United States|MorphoSys Research Site, Cleveland, Ohio, United States|MorphoSys Research Site, Eugene, Oregon, United States|MorphoSys Research Site, Charleston, South Carolina, United States|MorphoSys Research Site, Austin, Texas, United States|MorphoSys Research Site, Dallas, Texas, United States|MorphoSys Research Site, Houston, Texas, United States|MorphoSys Research Site, San Antonio, Texas, United States|MorphoSys Research Site, Tyler, Texas, United States|MorphoSys Research Site, Vancouver, Washington, United States|MorphoSys Research Site, Graz, Austria|Medizinische Universtät Innsbruck, Innsbruck, Austria|MorphoSys Research Site, Linz, Austria|MorphoSys Research Site, Salzburg, Austria|MorphoSys Research Site, St. Poelten, Austria|MorphoSys Research Site, Vienna, Austria|MorphoSys Research Site, Wels, Austria|MorphoSys Research Site, Antwerpen, Belgium|MorphoSys Research Site, Antwerpen, Belgium|MorphoSys Research Site, Brussel, Belgium|MorphoSys Research Site, Gent, Belgium|MorphoSys Research Site, Roeselare, Belgium|MorphoSys Research Site, Yvoir, Belgium|MorphoSys Research Site, Hradec Králové, Czechia|MorphoSys Research Site, Ostrava, Czechia|MorphoSys Research Site, Prague, Czechia|MorphoSys Research Site, Prague, Czechia|MorphoSys Research Site, Prague, Czechia|MorphoSys Research Site, Bordeaux 33076, France|MorphoSys Research Site, Brest 29609, France|MorphoSys Research Site, Nantes 44093, France|MorphoSys Research Site, Pierre Benite 69310, France|MorphoSys Research Site, Aachen, Germany|MorphoSys Research Site, Augsburg, Germany|MorphoSys Research Site, Bonn, Germany|MorphoSys Research Site, Dortmund, Germany|MorphoSys Research Site, Gießen, Germany|MorphoSys Research Site, Göttingen, Germany|MorphoSys Research Site, Halle, Germany|MorphoSys Research Site, Mutlangen, Germany|MorphoSys Research Site, München, Germany|MorphoSys Research Site, München, Germany|MorphoSys Research Site, Nürnberg, Germany|MorphoSys Research Site, Würzburg, Germany|MorphoSys Research Site, Bologna 40138, Italy|MorphoSys Research Site, Ravenna 48100, Italy|MorphoSys Research Site, Lisboa, Portugal|MorphoSys Research Site, Lisbon, Portugal|MorphoSys Research Site, Porto, Portugal|MorphoSys Research Site, Porto, Portugal|MorphoSys Research Site, Barcelona 8003, Spain|MorphoSys Research Site, Caceres 10003, Spain|MorphoSys Research Site, Girona 17007, Spain|MorphoSys Research Site, Madrid 28041, Spain|MorphoSys Research Site, Sabadell 8208, Spain|MorphoSys Research Site, Sevilla 41013, Spain|MorphoSys Research Site, Vitoria-Gasteiz 1009, Spain",,https://ClinicalTrials.gov/show/NCT04134936,973.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
309,310,NCT00470405,Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma,,Completed,No Results Available,Lymphoma|Solid Tumor,Drug: oxaliplatin|Drug: pemetrexed disodium,Maximum tolerated dose|Recommended phase II dose|Toxicity|Efficacy,Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,25.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VICC PHI0367|VU-VICC-PHI-0367|LILLY-H3E-US-S053A|VU-IRB-031027,2004-05-01,May 2007,2007-11-01,"May 7, 2007",,"April 18, 2011","Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00470405,1279.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
310,311,NCT00779584,A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248),,Completed,Has Results,"Hodgkin Disease|Lymphoma, Non-Hodgkin|Neoplasms",Drug: MK-8776|Drug: Gemcitabine,Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) During Cycle 0 and Cycle 1 Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE v 3.0)|Number of Participants Who Experienced an Adverse Event (AE)|Number of Participants Who Discontinued Study Treatment Due to an AE|MK-8776 Maximum Plasma Concentration (Cmax)|MK-8776 Area Under the Curve of the Plasma Concentration Versus Time From Time Zero to the Time of the Last Analytically Quantifiable Concentration (AUC0-last)|Time of MK-8776 Cmax (Tmax)|MK-8776 Terminal Phase Half-Life (t1/2),Merck Sharp & Dohme LLC,All,"18 Years and older   (Adult, Older Adult)",Phase 1,45.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P05248|MK-8776-002,2008-10-17,"May 28, 2011",2011-05-28,"October 24, 2008","June 20, 2017","August 27, 2018",,,https://ClinicalTrials.gov/show/NCT00779584,953.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
311,312,NCT00060684,Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma,,Completed,No Results Available,"Lymphoma, Low-Grade|Lymphoma, Small Lymphocytic|Lymphoma, Mixed-Cell, Follicular|Lymphoma, Small Cleaved-Cell, Follicular",Drug: Pixantrone (BBR 2778)|Drug: fludarabine|Drug: dexamethasone|Drug: rituximab,Determine MTD|Establish safety profile,CTI BioPharma,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AZA I-06,2001-12-01,January 2005,2007-05-01,"May 12, 2003",,"January 19, 2015","Arizona Clinical Research Center, Tucson, Arizona, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|New Mexico Onc/Hem Consultants, Inc., Albuquerque, New Mexico, United States|MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00060684,1977.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
312,313,NCT01962532,"A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma",,Completed,No Results Available,Neoplasms|Lymphoma|Adenocarcinoma|Esophagogastric Junction,Drug: Part 1: JNJ-42756493|Drug: Part 2: JNJ-42756493,Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT)|Maximum observed plasma concentration of JNJ-42756493|Minimum observed plasma concentration of JNJ-42756493|Time correspondent to the maximum observed plasma concentration of JNJ-42756493|Area under the plasma concentration-time curve from time 0 to 24 hours of JNJ-42756493|Half-life of JNJ-42756493|Apparent volume of distribution of JNJ-42756493|Total clearance of drug of JNJ-42756493|Accumulation index of JNJ-42756493|Number of participants with complete response|Number of participants with partial response|Number of participants with stable disease|Number of participants with progressive disease,"Janssen Research & Development, LLC",All,"20 Years and older   (Adult, Older Adult)",Phase 1,19.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR102388|42756493GAC1001,2013-08-21,"January 28, 2016",2016-01-28,"October 14, 2013",,"May 15, 2019","Kashiwa, Japan|Matsuyama, Japan|Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01962532,890.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
313,314,NCT00413075,Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma,,Completed,No Results Available,Solid Tumor|Lymphoma,Drug: oral belinostat,"Safety, tolerability and maximum tolerated dose of orally administered PXD101 for each cohort|Determine the pharmacokinetics of oral PXD101 when dosed once or twice daily at various dose levels|Explore anti-tumor activity|Determine the safety, tolerability, and anti-tumor activity of orally administered PXD101 to patients with lymphoma","Onxeo|Spectrum Pharmaceuticals, Inc",All,"18 Years and older   (Adult, Older Adult)",Phase 1,121.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PXD101-CLN-9,2006-06-01,August 2011,2011-08-01,"December 19, 2006",,"July 8, 2015","Yale New Haven Hospital, New Haven, Connecticut, United States|Columbia University - Herbert Irving Cancer Center, New York, New York, United States|New York University Cancer Institute, New York, New York, United States|M.D. Anderson Cancer Center, Houston, Texas, United States|Research Facility, Copenhagen, Denmark|Research Facility, London, Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT00413075,1887.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
314,315,NCT00390117,AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma,,Completed,No Results Available,"Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",Drug: CDKI AT7519|Other: laboratory biomarker analysis,"Maximum tolerated dose as assessed by NCI CTCAE v.30|Safety, tolerability, toxicity profile, and dose-limiting toxicities as assessed by NCI CTCAE v.30|Pharmacokinetic profile as measured on days 1, 2, and 4 in course 1|Correlation of toxicity profile with pharmacokinetics|Preliminary antitumor activity of treatment in patients with measurable disease|Overall response (complete and partial response) rate|Response duration (median and range)",NCIC Clinical Trials Group|Canadian Cancer Trials Group,All,"18 Years and older   (Adult, Older Adult)",Phase 1,34.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,I177|CAN-NCIC-IND177|CDR0000507621,2006-08-22,"March 13, 2012",2013-01-10,"October 19, 2006",,"April 8, 2020","Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00390117,2333.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
316,317,NCT00352443,S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma,,Completed,No Results Available,"Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",Drug: everolimus|Drug: lapatinib ditosylate,Maximum tolerated dose of lapatinib and everolimus (Part I)|Pharmacokinetics (Part II),Southwest Oncology Group|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,66.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,S0528|U10CA032102,2006-09-01,August 2007,2013-09-01,"July 14, 2006",,"March 6, 2015","USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|University of California Davis Cancer Center, Sacramento, California, United States|University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado, United States|Lucille P. Markey Cancer Center at University of Kentucky, Lexington, Kentucky, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00352443,2557.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
317,318,NCT01290549,A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma,,Completed,No Results Available,Non-Hodgkins Lymphoma|Chronic Lymphocytic Leukemia,Drug: Polatuzumab Vedotin|Drug: Rituximab,"Percentage of Participants With Dose-Limiting Toxicities (DLTs)|Maximum Tolerated Dose|Proposed Phase II Dose of Polatuzumab Vedotin|Percentage of Participants With Adverse Events (AEs)|Percentage of Paticipants with Anti Therapeutic Antibodies (ATAs) Against Polatuzumab Vedotin|Progression Free Survival (PFS), as Assessed by Using Modified Response Criteria for Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)|Percentage of Participants With Objective Response [Complete Response (CR) or Partial Response (PR)], as Assessed by Using Modified Response Criteria for NHL or CLL|Duration of Response, as Assessed by Using Modified Response Criteria for NHL or CLL|Percentage of Participants with Best Overall Response (BOR), as Assessed by Using Modified Response Criteria for NHL or CLL|Area Under the Curve (AUC) from Time 0 to The Last Quantifiable Time Point (AUClast)-Polatuzumab Vedotin Monotherapy|AUC Extrapolating to Time of Infinity (AUCinf)-Polatuzumab Vedotin Monotherapy|Percentage of AUCinf (AUCextrap)-Polatuzumab Vedotin Monotherapy|Maximum Plasma Concentration (Cmax)-Polatuzumab Vedotin Monotherapy|Clearance-Polatuzumab Vedotin Monotherapy|Volume of Distribution at Steady State-Polatuzumab Vedotin Monotherapy|AUClast - Polatuzumab Vedotin Combined with Rituximab|AUCinf-Polatuzumab Vedotin Combined with Rituximab|AUCextrap-Polatuzumab Vedotin Combined with Rituximab|Cmax-Polatuzumab Vedotin Combined with Rituximab|Clearance-Polatuzumab Vedotin Combined with Rituximab|Volume of Distribution at Steady State-Polatuzumab Vedotin Combined with Rituximab|AUClast of Rituximab When Given in Combination With Polatuzumab Vedotin|AUCinf of Rituximab When Given in Combination With Polatuzumab Vedotin|AUCextrap of Rituximab When Given in Combination With Polatuzumab Vedotin|Cmax of Rituximab When Given in Combination With Polatuzumab Vedotin|Clearance of Rituximab When Given in Combination With Polatuzumab Vedotin|Volume of Distribution at Steady State-of Rituximab When Given in Combination With Polatuzumab Vedotin","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,95.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCS4968g|GO01294|2011-002330-39,2011-03-22,"June 29, 2012",2014-11-18,"February 7, 2011",,"June 16, 2017","Stanford Cancer Center, Stanford, California, United States|Stanford Cancer Institute Pharmacy, Stanford, California, United States|Florida Cancer Specialists; Sarasota, Sarasota, Florida, United States|Roswell Park Cancer Inst., Buffalo, New York, United States|Sarah Cannon Cancer Center, Germantown, Tennessee, United States|M.D Anderson Cancer Center; Oncology, Houston, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|CHU Dijon - SCE Hemato, Dijon, France|Centre Hospitalier Regional Universitaire de Lille, Lille, France|CHU Lapeyronie, Hematologie, Montpellier, France|Centre Hospitalier Lyon Sud; Hematolgie, Pierre Benite, France|Centre Henri Becquerel; Hematologie, Rouen, France|Academisch Medisch Centrum; Hematologie, Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT01290549,1337.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
319,320,NCT00794638,A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma,,Completed,No Results Available,Non-Hodgkin's Lymphoma|Diffuse Large B-Cell Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma,Drug: SyB L-0501|Drug: Rituximab,"Dose-limiting toxicity|CR rate and the overall response rate, determination by Independent Review Committee",SymBio Pharmaceuticals,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 1,9.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2008002,2008-11-01,March 2010,2010-05-01,"November 20, 2008",,"July 2, 2021","Nagoya-city, Aichi, Japan|Isehara-city, Kanagawa, Japan|Kyoto-city, Kyoto, Japan|Chuo-ku, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00794638,546.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
320,321,NCT01634763,Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK),,Completed,No Results Available,Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK),Drug: LDK378,"Maximum tolerated dose (MTD) and/or Recommended dose (RD) of LDK378|The safety and tolerability of LDK378, including both acute and chronic toxicities|Plasma concentration of LDK378|Preliminary anti-tumor activity of LDK378|PK parameter: AUClast|PK parameter: AUCtau|PK parameter: Cmax|PK parameter: Tmax|PK parameter: the apparent elimination half-life (T1/2)|PK parameter: accumulation ratio (Racc)",Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,22.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,CLDK378X1101,2012-06-01,January 2016,2016-01-01,"July 6, 2012",,"December 19, 2020","Novartis Investigative Site, Sunto-gun, Shizuoka, Japan|Novartis Investigative Site, Koto, Tokyo, Japan|Novartis Investigative Site, Fukuoka, Japan",,https://ClinicalTrials.gov/show/NCT01634763,1309.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
321,322,NCT01786135,A Safety Study of SGN-CD19A for B-Cell Lymphoma,,Completed,No Results Available,"Burkitt Lymphoma|Lymphoma, Follicular|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Mantle-Cell|Precursor B-cell Lymphoblastic Leukemia-Lymphoma",Drug: SGN-CD19A,Incidence of adverse events|Incidence of laboratory abnormalities|Objective response according to revised response criteria for malignant lymphoma (Cheson 2007)|Duration of response|Overall survival|Blood concentration of SGN-CD19A and metabolites|Incidence of antitherapeutic antibodies,Seagen Inc.,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 1,64.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SGN19A-002,2013-02-01,August 2015,2017-02-16,"February 7, 2013",,"October 19, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|City of Hope National Medical Center, Duarte, California, United States|Stanford Cancer Center, Stanford, California, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|MD Anderson Cancer Center / University of Texas, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01786135,1476.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
322,323,NCT00274742,Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL,,Completed,Has Results,"Non-Hodgkin's Lymphoma, Relapsed",Biological: Blinatumomab (MT103),Number of Participants With Adverse Events|Serum Concentration of Blinatumomab|Objective Tumor Response According to the Cheson Criteria (Without Minimal Response)|Objective Tumor Response According to the Cheson Criteria (With Minimal Response),Amgen Research (Munich) GmbH,All,"18 Years and older   (Adult, Older Adult)",Phase 1,76.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MT103-104,2004-06-01,August 2011,2012-04-01,"January 11, 2006","January 16, 2015","January 16, 2015","Medizinische Klinik 5, Hämatologie & Internistische Onkologie, Universitätsklinikum Erlangen, Erlangen, Germany|Universitätsklinikum Essen, Klinik für Hämatologie, Medizinische Klinik und Poliklinik, Essen, Germany|Universtätsklinkum Tübingen, Tübingen, Germany|Universitätsklinikum Ulm, Abteilung Innere Medizin III, Ulm, Germany|Medizinische Poliklinik der Julius-Maximilians-Universität Würzburg, Würzburg, Germany",,https://ClinicalTrials.gov/show/NCT00274742,2861.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
323,324,NCT02549651,MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023),,Completed,No Results Available,Diffuse Large B-Cell Lymphoma,Drug: MEDI4736|Drug: tremelimumab|Drug: AZD9150,Number of subjects reporting adverse events and number (percentage) of subjects reporting serious adverse events|Number of subjects experiencing dose-limiting toxicities|Number of subjects who develop anti-drug antibodies (ADA)|Time to Response|Duration of Response|Progression Free survival|Time to progression|Event free survival|Overall survival|MEDI4736 Maximum Plasma Concentration (Cmax)|Tremelimumab Maximum Plasma Concentration (Cmax)|AZD9150 Maximum Plasma Concentration (Cmax)|MEDI4736 Minimum Plasma Concentration (Cmin)|Tremelimumab Minimum Plasma Concentration (Cmin)|AZD9150 Minimum Plasma Concentration (Cmin)|Individual MEDI4736 Concentrations|Individual tremelimumab Concentrations|Individual AZD9150 Concentrations|Change from baseline of STAT3 RNA (signal transducer and activator of transcription)|Baseline PD-L1 protein expression within the tumor,MedImmune LLC,All,"18 Years and older   (Adult, Older Adult)",Phase 1,32.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D4190C00023,2016-07-13,"February 4, 2019",2019-02-04,"September 15, 2015",,"February 27, 2019","Research Site, La Jolla, California, United States|Research Site, Baltimore, Maryland, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Durham, North Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Marseille, France|Research Site, Villejuif, France|Research Site, Dublin 8, Ireland|Research Site, Galway, Ireland|Research Site, Leicester, United Kingdom",,https://ClinicalTrials.gov/show/NCT02549651,936.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
324,325,NCT00004057,"Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas",,Completed,No Results Available,"Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific","Drug: L-778,123|Drug: paclitaxel",,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,40.0,Other|NIH,Interventional,Primary Purpose: Treatment,98-116|CDR0000067254|MERCK-003-04|NCI-G99-1572,1998-12-01,December 2000,2000-12-01,"September 13, 2004",,"June 21, 2013","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00004057,731.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
325,326,NCT01742988,"Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma",,Completed,No Results Available,Lymphoma|Relapsed Lymphoma|Refractory Lymphoma|Relapsed and/or Refractory Lymphoma|Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL)|Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Double-hit Lymphoma (DHL)|Triple-hit Lymphoma (THL)|Double-expressor Lymphoma (DEL)|High-grade B-cell Lymphoma (HGBL),Drug: fimepinostat|Drug: Rituximab|Drug: venetoclax,"To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of oral fimepinostat (CUDC-907) in combination with venetoclax and rituximab|To assess the safety and tolerability of fimepinostat in combination with anti-cancer regimens by evaluating the number of participants with adverse events assessed using the NCI Common Terminology Criteria for Adverse Events (CTCAE, v4.0).|To evaluate the efficacy of fimepinostat in combination with anti-cancer regimens by evaluating ORR|To evaluate the efficacy of fimepinostat in combination with anti-cancer regimens by evaluating DOR|To assess pharmacokinetics (PK) of fimepinostat when administered in combination with anti-cancer regimens as measured by area under the concentration-time curve (AUC).|To assess pharmacokinetics (PK) of fimepinostat when administered in combination with anti-cancer regimens as measured by maximum plasma concentration (Cmax).|To assess pharmacokinetics (PK) of fimepinostat when administered in combination with anti-cancer regimens as measured by half-life (T1/2).|To assess pharmacokinetics (PK) of fimepinostat when administered in combination with anti-cancer regimens as measured by clearance (Cl).|To assess pharmacokinetics (PK) of fimepinostat when administered in combination with anti-cancer regimens as measured by volume of distribution (Vd).|To assess PK of venetoclax when administered in combination with fimepinostat as measured by area under the concentration-time curve (AUC).|To assess PK of venetoclax when administered in combination with fimepinostat as measured by maximum plasma concentration (Cmax).|To assess PK of venetoclax when administered in combination with fimepinostat as measured by half-life (T1/2).|To assess PK of venetoclax when administered in combination with fimepinostat as measured by clearance (Cl).|To assess PK of venetoclax when administered in combination with fimepinostat as measured by volume of distribution (Vd).|To evaluate the efficacy of fimepinostat in combination with anti-cancer regimens as measured by OS.|To evaluate the efficacy of fimepinostat in combination with anti-cancer regimens as measured by PFS.|To evaluate the efficacy of fimepinostat in combination with anti-cancer regimens as measured by ORR.|To evaluate the efficacy of fimepinostat in combination with anti-cancer regimens as measured by DOR.|To evaluate biomarkers of fimepinostat activity","Curis, Inc.|The Leukemia and Lymphoma Society",All,"18 Years and older   (Adult, Older Adult)",Phase 1,106.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CUDC-907-101,2012-12-01,"October 9, 2020",2020-10-09,"December 6, 2012",,"May 6, 2021","USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|University of Chicago Medicine, Chicago, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01742988,2869.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
326,327,NCT01410513,"Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia",,Completed,No Results Available,Indolent Non-Hodgkin Lymphoma|Mantle Cell Lymphoma|Chronic Lymphocytic Leukemia,Drug: SAR245409,Identification Of Dose-Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD)|Number of subjects with treatment emergent adverse events|Pharmacokinetics (Cmax) of SAR245409|Pharmacokinetics (tmax) of SAR245409|Pharmacokinetics (AUC0-12h) of SAR245409|Pharmacokinetics (Ctrough) of SAR245409|Pharmacokinetics (AUC) of bendamustine|Pharmacokinetics (AUClast) of bendamustine|Pharmacokinetics (Ceoi) of bendamustine|Pharmacokinetics (tmax) of bendamustine|Pharmacokinetics (Cl) of bendamustine|Pharmacokinetics (Vss) of bendamustine|Pharmacokinetics (AUC0-7h) of rituximab|Pharmacokinetics (Ceoi) of rituximab|Pharmacokinetics (tmax) of rituximab|Efficacy as determined by objective response rate (ORR),Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 1,37.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TCD12012|U1111-1119-2906,2011-12-01,May 2014,2014-05-01,"August 5, 2011",,"April 1, 2016","Investigational Site Number 840004, Aurora, Colorado, United States|Investigational Site Number 840006, Augusta, Georgia, United States|Investigational Site Number 840002, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT01410513,882.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
327,328,NCT03451825,Phase I/II Study of Avelumab in Pediatric Cancer Subjects,,Completed,No Results Available,Refractory or Relapsed Solid Tumors|Lymphoma,Drug: Avelumab,"Phase 1: Occurrence and Severity of Grade 3 or Higher Treatment Emergent Adverse Events (TEAEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v4.03)|Phase 1: Occurrence of Dose Limiting Toxicity|Phase 2: Confirmed Best Overall Response (BOR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) and as Adjudicated by the Investigator|Phase 1: Confirmed Best Overall Response (BOR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) and as Adjudicated by the Investigator|Phase 1 and Phase 2: Duration of Response (DOR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) and as Adjudicated by the Investigator|Phase 1 and Phase 2: Time to Response According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) and as Adjudicated by the Investigator|Phase 1 and Phase 2: Progression-Free Survival According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) and as Adjudicated by the Investigator|Phase 1 and Phase 2: Overall Survival (OS) Time|Phase 1 and Phase 2: Occurrence and Severity of Treatment Emergent Adverse Events (TEAEs), AEs of Special Interest, and Treatment-Related AEs, According to the NCI-CTCAE Version 4.03|Phase 1 and Phase 2: Incidence of Laboratory Abnormalities as Graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03|Phase 1 and Phase 2: Maximum Observed Plasma Concentration (Cmax) of Single and Multiple Dose of Avelumab|Phase 1 and Phase 2: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of Avelumab|Phase 1 and Phase 2: Half life (t1/2) of Single and Multiple Dose of Avelumab|Phase 1 and Phase 2: Minimum Post-dose Trough Concentration of Single and Multiple Dose of Avelumab|Phase 1 and Phase 2: Immunogenicity as measured by Incidence of Antidrug Antibody (ADA) and Neutralizing Antibody (Nabs)|Phase 1 and Phase 2: Tumor Programmed Death Ligand 1 (PD-L1) Expression Levels|Phase 1 and Phase 2: Tumor-Infiltrating T-cell Levels|Phase 1 and Phase 2: T-cell Population in Blood|Phase 1 and Phase 2: Number of T-cell, B-cell and NK-cell in Blood|Phase 1 and Phase 2: Vaccination-Related Antibody Concentrations|Phase 1 and Phase 2: Body Temperature|Phase 1 and Phase 2: Heart Rate|Phase 1 and Phase 2: Respiratory Rate|Phase 1 and Phase 2: Systolic and Diastolic Blood Pressure","EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono",All,"0 Years to 18 Years   (Child, Adult)",Phase 1,26.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MS100070-0306|2017-002985-28,2018-03-07,"July 27, 2021",2021-07-27,"March 2, 2018",,"December 6, 2021","Children's Hospital Colorado, Aurora, Colorado, United States|The Children's Hospital at Montefiore (CHAM), Bronx, New York, United States|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|UZ Leuven, Leuven, Belgium|Children's Hospital - London Health Sciences Centre, London, Canada|CHU Sainte-Justine, Montréal, Canada|The Hospital for Sick Children, Toronto, Canada|Rigshospitalet, Copenhagen, Denmark|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03451825,1238.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
328,329,NCT02181218,"Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas",,Completed,No Results Available,"Lymphoma, T-Cell, Cutaneous|Lymphoma, T-Cell, Peripheral|Hodgkin Disease|Lymphoma, Large B-Cell, Diffuse",Drug: Romidepsin|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Dexamethasone|Drug: Pegfilgrastim,Maximum tolerated dose (recommended Phase II dose)|Complete response rate|Partial response rate|Overall response rate|Progression free survival|Duration of response,Washington University School of Medicine|Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201407160,2015-02-04,"March 28, 2019",2020-06-26,"July 3, 2014",,"November 17, 2020","University of Chicago, Chicago, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT02181218,1969.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
329,330,NCT03332121,B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma,,Completed,No Results Available,CD20 Positive B Cell Non-Hodgkin's Lymphoma,Biological: B001,Safety of B001 as assessed by adverse reactions and events|Concentration-time curve of B001|PD results of B001|Immunogenicity of B001|ORR of B001,"Shanghai Pharmaceuticals Holding Co., Ltd",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,30.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B001-101,2018-03-22,"November 30, 2020",2021-02-28,"November 6, 2017",,"November 15, 2021","The second affiliated hospital of Guangzhou medical university, Guangzhou, Guangdong, China|Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, Tianjin, China",,https://ClinicalTrials.gov/show/NCT03332121,1074.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
330,331,NCT03049449,T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas,,Completed,Has Results,"Lymphoma, Large-Cell, Anaplastic|Enteropathy-Associated T-Cell Lymphoma|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Extranodal NK-T-Cell|Lymphoma, T-Cell, Peripheral",Biological: Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells|Drug: Cyclophosphamide|Drug: Fludarabine,"Maximum Tolerated Dose of Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) in Participants With Advanced CD30-expressing Lymphomas|Peak Percentage and Persistence at 1 Month of Peripheral Blood Mononuclear Cells (PBMC) That Expressed the Chimeric Antigen Receptor (CAR) T-cells|Number of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progression as Their Best Response",National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years to 73 Years   (Adult, Older Adult)",Phase 1,26.0,NIH,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,170048|17-C-0048,2017-03-17,"January 26, 2022",2022-01-26,"February 10, 2017","May 25, 2022","January 18, 2023","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT03049449/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT03049449/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03049449,1776.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
331,332,NCT00003541,"Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma",,Completed,No Results Available,Lymphoma,Biological: filgrastim|Drug: CHOP regimen|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: prednisone|Drug: vincristine sulfate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,24.0,Other|NIH,Interventional,Primary Purpose: Treatment,98-045|CDR0000066595|NCI-H98-0021,1998-06-01,July 2006,2006-07-01,"January 23, 2004",,"June 24, 2013","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00003541,2952.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
332,333,NCT00987493,"Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma",,Completed,No Results Available,Lymphoma,Biological: rituximab|Drug: bendamustine hydrochloride|Drug: lenalidomide,"Dose-limiting toxicity (phase I)|Maximum-tolerated dose (phase I)|Objective response (complete and partial response) (phase II)|Adverse events according to NCI CTCAE v. 3.0|Event-free survival (phase II)|Response duration (phase II)|Time to progression (phase II)|Overall survival (phase II)|Quality of life|Usefulness and feasibility of the SAKK C-SGA|Association between WHO performance status, QOL indicators, and SAKK C-SGA scores|Progression Free Survival (PFS)",Swiss Group for Clinical Cancer Research,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,49.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SAKK 38/08|SWS-SAKK-38/08|2009-012559-67|EU-20976|CDR0000652127,2009-09-01,April 2014,2016-04-01,"October 1, 2009",,"May 15, 2019","Kantonsspital Baden, Baden, Switzerland|Universitaetsspital Basel, Basel, Switzerland|St. Claraspital AG, Basel, Switzerland|Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland|Inselspital Bern, Bern, Switzerland|Kantonsspital Bruderholz, Bruderholz, Switzerland|Kantonsspital Graubünden, Chur, Switzerland|Hopital Fribourgeois, Fribourg, Switzerland|Hôpitaux Universitaires de Genève HUG, Geneva 14, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kantonsspital Liestal, Liestal, Switzerland|Kantonsspital Olten, Olten, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Stadtspital Triemli, Zürich, Switzerland|Universitäts Spital Zürich, Zürich, Switzerland",,https://ClinicalTrials.gov/show/NCT00987493,2404.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
333,334,NCT01363817,Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma,,Completed,No Results Available,"Lymphoblastic Leukemia, Acute T-cell|Precursor T-Cell Lymphoblastic Lymphoma",Drug: BMS-906024|Drug: Dexamethasone,Number of subjects with adverse events as a measure of safety and tolerability|Disease assessments in bone marrow & by computed tomography (CT)/ magnetic resonance imaging (MRI)|Pharmacokinetics of BMS-906024 and its metabolite BMS-911557: maximum observed concentration (Cmax)|Pharmacokinetics of BMS-906024 and its metabolite BMS-911557: minimum observed concentration (Cmin)|Pharmacokinetics of BMS-906024 and its metabolite BMS-911557: area under the concentration-time curve (AUC)|Pharmacokinetics of BMS-906024 and its metabolite BMS-911557: time to reach maximum observed concentration (Tmax)|Pharmacokinetics of BMS-906024 and its metabolite BMS-911557: terminal phase elimination half-life (T-Half)|Pharmacokinetics of BMS-906024 and its metabolite BMS-911557: accumulation index (ratio of AUC at steady state to AUC after first dose)|Pharmacodynamics (percent change from baseline in mRNA expression of Notch pathway-related genes in blood cells),Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 1,31.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA216-002|2010-022727-29,2011-09-28,"February 7, 2018",2018-02-07,"June 2, 2011",,"July 30, 2019","Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Local Institution, Marseille Cedex 9, France|Local Institution, Paris Cedex 10, France|Johann Wolfgang Goethe Universitaet, Frankfurt/main, Germany",,https://ClinicalTrials.gov/show/NCT01363817,2324.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
334,335,NCT00634179,A Phase I/II Trial of VR-CHOP in Lymphoma Patients,,Completed,Has Results,"Lymphoma, B-Cell|Follicular Lymphoma",Drug: Bortezomib|Biological: Rituximab|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisone,"Maximal Tolerated Doses of Bortezomib and Vincristine When Used in Combination of Bortezomib, Rituximab and the CHOP Chemotherapy Regimen (Phase I)|An Estimate of the Overall Response Rate (ORR)(Complete Response [CR] + CR Unconfirmed [CRu] + Partial Response [PR]) to Bortezomib and Rituximab (VR)-CHOP According to International Workshop to Standardize Response Criteria (IWRC) Criteria","Emory University|Millennium Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,37.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00002996|X05215,2008-02-01,November 2015,2015-11-01,"March 12, 2008","March 15, 2016","October 27, 2016","Emory University Winship Cancer Institute, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT00634179,2830.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
335,336,NCT00004212,DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas,,Completed,No Results Available,"Brain and Central Nervous System Tumors|Lymphoma|Unspecified Childhood Solid Tumor, Protocol Specific",Biological: filgrastim|Drug: exatecan mesylate,,"Daiichi Sankyo, Inc.",All,"up to 21 Years   (Child, Adult)",Phase 1,,Industry,Interventional,Primary Purpose: Treatment,CDR0000067330|DAIICHI-8951A-PRT013|MSKCC-99071|UTHSC-9895011445|NCI-V99-1573,1999-09-01,April 2004,2004-04-01,"January 27, 2003",,"May 16, 2012","Memorial Sloan-Kettering Cancer Center, New York, New York, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Children's Medical Center of Dallas, Dallas, Texas, United States|Institute for Drug Development, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00004212,1674.0,Industry Lead,Three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
336,337,NCT04418141,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1",,Completed,No Results Available,Advanced Solid Tumor|B Cell Lymphoma,Drug: CN1,"To determine dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and/or recommended Phase II dose (RP2D) of CN1 administered to patients with advanced solid tumor or B-cell lymphoma.|To assess the safety and tolerability of CN1 in patients with advanced solid tumor or B-cell lymphoma through Physical Exam|To assess the safety and tolerability of CN1 in patients with advanced solid tumor or B-cell lymphoma through Adverse Events/Serious Adverse Events|To assess the pharmacokinetic (PK) profile of CN1 in patients with advanced solid tumor or B-cell lymphoma through Area under the plasma concentration-time curve|To assess the pharmacokinetic (PK) profile of CN1 in patients with advanced solid tumor or B-cell lymphoma through Tmax|To assess the pharmacokinetic (PK) profile of CN1 in patients with advanced solid tumor or B-cell lymphoma through Apparent volume of distribution at steady state|To assess the pharmacokinetic (PK) profile of CN1 in patients with advanced solid tumor or B-cell lymphoma through Accumulation factor based on AUC 0-τ|To assess the immunogenicity to CN1 in patients with advanced solid tumor or B-cell lymphoma through ADA testing|To explore the anti-tumor efficacy of CN1 in patients with advanced solid tumor or B-cell lymphoma through ORR analysis|To explore the anti-tumor efficacy of CN1 in patients with advanced solid tumor or B-cell lymphoma through DCR analysis.|To explore the anti-tumor efficacy of CN1 in patients with advanced solid tumor or B-cell lymphoma through DoR analysis.",Curon Biopharmaceutical (Australia) Co Pty Ltd|Novotech (Australia) Pty Limited,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,13.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CN1-101,2020-07-02,"October 7, 2021",2021-10-07,"June 5, 2020",,"October 18, 2021","Mater Medical Centre, Brisbane, Queensland, Austria",,https://ClinicalTrials.gov/show/NCT04418141,462.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
337,338,NCT01354392,AZD1152 in Diffuse Large B-cell Lymphoma,,Completed,No Results Available,Lymphoma,Drug: AZD1152,Overall response rate (ORR; Cheson 2007 criteria)|Progression free survival at 1 year|Percentage change in tumour size|Safety of AZD1152,"Oxford University Hospitals NHS Trust|The Christie NHS Foundation Trust|University of Manchester|Early Phase Cancer Research Hub, Oxford",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,15.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORH/PID/6265,2011-09-01,September 2013,2013-09-01,"May 16, 2011",,"July 2, 2014","Christie NHS Foundation Trust (Christie Hospital), Machester, Lancashire, United Kingdom|Oxford Radcliffe NHS Trust (Cancer & Haematology Centre, Churchill Hospital), Oxford, Oxfordshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT01354392,731.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
338,339,NCT03028103,"Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients",,Completed,Has Results,Diffuse Large B Cell Lymphoma|Primary Mediastinal Lymphoma|Mantle Cell Lymphoma|Advanced Solid Tumor|Marginal Zone Lymphoma,Drug: Tazemetostat|Drug: Fluconazole|Drug: Omeprazole|Drug: Repaglinide,"Part A: Effect of CYP3A Inhibition by Fluconazole on the PK of Tazemetostat (AUC0-t, AUC0-8)|Part A: Cmax of Tazemetostat During Co-administration With Fluconazole|Part B: The Potential of Tazemetostat to Inhibit or Induce CYP2C8 Using Repaglinide as a Probe Substrate (AUC0-t, AUC0-∞)|Part B: Cmax of Repaglinide During Co-administration With Tazemetostat|Part B: The Potential of Tazemetostat to Inhibit or Induce CYP2C19 Using Omeprazole as Probe a Substrate (AUC0-t, AUC0-∞)|Part B: Cmax of Omeprazole During Co-administration With Tazemetostat|Part B: Effect of Increased Gastric pH by Omeprazole on the PK of Tazemetostat (AUC0-t, AUC0-8)|Part B: Cmax of Tazemetostat During Co-administration With Omeprazole|Incidence of Treatment-emergent Adverse Events as a Measure of Safety|Part A: PK of Tazemetostat and Its Metabolites After Administration Alone and With Fluconazole (AUC0-t, AUC0-8)|Part A: Tmax of Tazemetostat After Administration Alone and With Fluconazole|Part A: t1/2 of Tazemetostat After Administration Alone and With Fluconazole|Part A: Cmax of Tazemetostat Metabolites After Administration Alone and With Fluconazole|Part A: Tmax of Tazemetostat Metabolites After Administration Alone and With Fluconazole|Part A: t1/2 of Tazemetostat Metabolites After Administration Alone and With Fluconazole|Part A: Exposure of Fluconazole After Administration of 400 mg Once Daily for 4 Days (AUC0-8)|Part A: Cmax of Fluconazole After Administration of 400mg Once Daily for 4 Days|Part A: Tmax of Fluconazole After Administration of 400mg Once Daily for 4 Days|The Antitumor Activity of Tazemetostat Will be Assessed in Patients With Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL) or Advanced Solid Tumors .","Epizyme, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,32.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EZH-105,2017-03-27,"October 31, 2019",2019-11-29,"January 23, 2017","April 19, 2021","April 19, 2021","University of Arizona Cancer Center, Tucson, Arizona, United States|Moffitt Cancer Center, Tampa, Florida, United States|Columbia University Medical Center, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03028103/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03028103,977.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
340,341,NCT02529852,A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma,,Completed,No Results Available,Lymphoma,Drug: Lenalidomide|Drug: Obinutuzumab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone,"Maximum Tolerated Dose (MTD) of Lenalidomide, Obinutuzumab, and CHOP|Overall Response Rate","M.D. Anderson Cancer Center|Celgene|Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,59.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015-0069|NCI-2015-01517,2015-11-04,"October 31, 2022",2022-10-31,"August 20, 2015",,"November 3, 2022","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02529852,2553.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
341,342,NCT02257567,A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma,,Completed,Has Results,Lymphoma,Drug: Bendamustine|Drug: Obinutuzumab|Drug: Polatuzumab vedotin (Liquid)|Drug: Rituximab|Drug: Polatuzumab vedotin (Lyophilized),"Phase Ib: Percentage of Participants With Adverse Events (AEs)|Arm G+H (Phase II NF Cohort): Percentage of Participants With AEs|Cohort 1a (Phase Ib): Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (ADAs) to Polatuzumab Vedotin|Cohort 1b (Phase Ib): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab|Arms G+H: (Phase II NF Cohorts): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin (Lyophilized)|Phase II Randomized and NF Cohorts: Percentage of Participants With Complete Response (CR) at Primary Response Assessment (PRA) Based on Positron Emission Tomography (PET)-Computed Tomography (CT) Scan as Determined by Independent Review Committee (IRC)|Arm H (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC|Arm G (Phase II NF Cohort): Area Under Concentration-Time Curve (AUC) of Polatuzumab Vedotin (Lyophilized)|Arm G (Phase II NF Cohort): Maximum Concentration (Cmax) of Polatuzumab Vedotin (Lyophilized)|Arm G (Phase II NF Cohort): Systemic Clearance (CL) of Polatuzumab Vedotin (Lyophilized)|Arm G (Phase II NF Cohort): Steady-State Volume of Distribution (Vss) of Polatuzumab Vedotin (Lyophilized)|Phase II: Percentage of Participants With AEs|Arms A and C (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin|Arms E and F (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab|Phase II: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator|Phase II Expansion Cohorts and Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC|Phase II: Percentage of Participants With Objective Response (OR) at PRA Based on PET-CT as Determined by Investigator|Phase II: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC|Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator|Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC|Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator|Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC|Phase II: Percentage of Participants With Best Objective Response (BOR) Based on PET-CT or CT Only as Determined by the Investigator|DLBCL Cohorts: Percentage of Participants With BOR Based PET-CT or CT Only as Determined by IRC|DLBCL Cohorts: Duration of Response (DOR) Based on PET-CT or CT Only as Determined by the Investigator|DLBCL Cohorts: DOR Based on PET-CT or CT Only as Determined by the IRC|DLBCL Cohorts: Progression Free Survival (PFS) Based on PET-CT or CT Only as Determined by the Investigator|DLBCL Cohorts: PFS Based on PET-CT or CT Only as Determined by the IRC|Phase II NF Cohort: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator|Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by Investigator|Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC|Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the Investigator|Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the IRC|Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the Investigator|Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the IRC|Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the Investigator|Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the IRC|Phase II NF Cohort: Event-Free Survival (EFS) Based on PET-CT or CT Only, as Determined by the Investigator|Phase II NF Cohorts: Overall Survival (OS)|Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC|Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator|Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC|Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator|Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC|Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE|Arm G+H (Phase II NF Cohorts): Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE|Serum Concentration of of Polatuzumab Vedotin Analyte: Total Ab|Arm G+H (Phase II NF Cohorts): Plasma Concentration of Polatuzumab Vedotin Analyte: Total Ab|Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE|Arm G+H (Phase II NF Cohorts): Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE|Plasma Concentration of Bendamustine|Serum Concentration of Rituximab|Serum Concentration of Obinutuzumab|Phase Ib: Cmax of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a|Phase Ib: Cmax of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b|Phase II: Cmax of Polatuzumab Vedotin, Bendamustine, and Rituximab in Arms A and C|Phase II: Cmax of Bendamustine and Rituximab in Arms B and D|Phase II: Cmax of Polatuzumab Vedotin, Obinutuzumab and Bendamustine in Arms E and F|Arm H (Phase II NF Cohort): Cmax of Polatuzumab Vedotin (Lyophilized)|Phase Ib: AUC From Time Zero to Infinity (AUCinf) of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a|Phase Ib: AUCinf of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b|Phase II: AUCinf of Polatuzumab Vedotin, Bendamustine, and Rituximab in Arms A and C|Phase II: AUCinf of Bendamustine and Rituximab in Arms B and D|Phase II: AUCinf of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Arms E and F|Arm H (Phase II NF Cohort): AUC of Polatuzumab Vedotin (Lyophilized)|Phase Ib: CL of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a|Phase Ib: CL of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b|Phase II: CL of Polatuzumab Vedotin, Bendamustine and Rituximab in Arms A and C|Phase II: CL of Bendamustine and Rituximab in Arms B and D|Phase II: CL of Polatuzumab Vedotin, Bendamustine and Obinutuzumab in Arms E and F|Arm H (Phase II NF Cohort): CL of Polatuzumab Vedotin (Lyophilized)|Phase Ib: Vss of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1a|Phase Ib: Vss of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b|Phase II: Vss of Polatuzumab Vedotin, Bendamustine and Rituximab in Arms A and C|Phase II: Vss of Bendamustine and Rituximab in Arms B and D|Phase II: Vss of Polatuzumab Vedotin, Bendamustine and Obinutuzumab in Arms E and F|Arm H (Phase II NF Cohort): Vss of Polatuzumab Vedotin (Lyophilized)|Symptom Severity and Interference According to Therapy-Induced Neuropathy Assessment Score (TINAS) in Arms A-F",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,331.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GO29365|2014-001361-28,2014-10-15,"October 21, 2021",2021-10-21,"October 6, 2014","November 14, 2022","November 14, 2022","University of Alabama at Birmingham, Birmingham, Alabama, United States|Clearview Cancer Institute, Huntsville, Alabama, United States|City of Hope National Medical Center, Duarte, California, United States|Univ of Colorado Canc Ctr, Aurora, Colorado, United States|Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, United States|Emory Univ Winship Cancer Inst, Atlanta, Georgia, United States|Joliet Oncology-Hematology; Associates, Ltd., Joliet, Illinois, United States|Horizon Oncology Research, Inc., Lafayette, Indiana, United States|Weinberg CA Inst Franklin Sq, Baltimore, Maryland, United States|Regional Cancer Care Associates LLC - Morristown, Morristown, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|West Clinic, Germantown, Tennessee, United States|Swedish Cancer Inst., Seattle, Washington, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Prince of Wales Hospital; Oncology, Randwick, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Adelaide Cancer Centre, Kurralta Park, South Australia, Australia|Monash Medical Centre; Haematology Research, Clayton, Victoria, Australia|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre; Oncology, Halifax, Nova Scotia, Canada|Hopital Maisonneuve- Rosemont; Oncology, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultní nemocnice Ostrava Klinika hematoonkologie, Ostrava, Czechia|I Interni klinika; Vseobecna fakultni nemocnice, Prague 2, Czechia|Chu Site Du Bocage;Hematologie Clinique, Dijon, France|Centre Hospitalier Departemental Les Oudairies, La Roche Sur Yon, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|CHU Saint Eloi; Service d'Hématologie Clinique, Montpellier, France|CHU Lyon Sud - Service Hématologie, Pierre Benite, France|Centre Henri Becquerel; Hematologie, Rouen, France|HELIOS Klinikum Erfurt - Innere Medizin - 4. Medizinische Klinik, Hämatologie, Erfurt, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Abt. für Hämatologie und Onkologie, Mainz, Germany|Joh. Wesling Klinikum Minden; Klinik fuer Hämatologie und Onkologie, Minden, Germany|Gemeinschaftspraxis für Hämatologie und Onkologie, Münster, Germany|Klinik der Uni Regensburg; Hämatologie/Onkologie, Studienzentrale, Regensburg, Germany|Semmelweis University, First Dept of Medicine, Budapest, Hungary|National Institute of Oncology, A Dept of Internal Medicine, Budapest, Hungary|University of Debrecen Medical and Health Science Center, Institute of Internal medicine Building B, Debrecen, Hungary|Istituto Nazionale Tumori Irccs Fondazione g. Pascale;s.c. Ematologia Oncologica, Napoli, Campania, Italy|A.O. Spedali Civili Di Brescia-P.O. Spedali Civili;U.O. Ematologia, Brescia, Lombardia, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Emato-Oncologia, Milano, Lombardia, Italy|Ospedale Civile SS. Antonio E Biagio DI Alessandria; Ematologia, Alessandria, Piemonte, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|UMC St. Radboud; Hematology, Nijmegen, Netherlands|Hospital Universitari Vall d'Hebron; Servicio de Hematologia, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona; Hematology, Barcelona, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain|Hospital Universitario Virgen del Rocio; Servicio de Hematologia, Sevilla, Spain|Ankara University; Hematology, Ankara, Turkey|Dokuz Eylul Uni ; Hematology, Izmir, Turkey|Ondokuzmayis University Medical Faculty Heamatology Department, Samsun, Turkey|Karadeniz Technical Uni School of Medicine; Hematology, Trabzon, Turkey|KINGS COLLEGE HOSPITAL; Commercial R&D Amendments, Kings Health Partners Clinical Trials Office, London, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom|Nottingham City Hospital; Dept of Haematology, Nottingham, United Kingdom|Southampton General Hospital; Somers Cancer Research Building, Southampton, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT02257567/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02257567,2563.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
342,343,NCT01788189,"Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas",LeMLAR,Completed,No Results Available,B-cell Lymphoma,Drug: Lenalidomide,Dose-limiting toxicity|Progression-free survival,"University Hospital, Essen|Celgene",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,37.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EudraCT No. 2012-001891-13,2013-01-01,"February 20, 2020",2020-02-20,"February 11, 2013",,"February 26, 2020","Klinik für Hämatologie, Universitätsklinikum Essen, Essen, Germany",,https://ClinicalTrials.gov/show/NCT01788189,2606.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
343,344,NCT02760485,A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,,Completed,No Results Available,Lymphoma,Drug: itacitinib|Drug: ibrutinib,Phase 1: Safety and tolerability as assessed by adverse events and changes in clinical and laboratory assessments|Phase 2: Efficacy as assessed by objective response rate (ORR)|Phase 1: Efficacy as assessed by objective response rate (ORR)|Phase 2: Efficacy as assessed by duration of response (DOR)|Phase 2: Durable response rate|Phase 2: Efficacy as assessed by progression-free survival (PFS)|Phase 2: Efficacy as assessed by overall survival (OS)|Phase 2: Number of treatment-emergent adverse events,Incyte Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,33.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INCB 39110-206,2016-12-29,"June 6, 2022",2022-06-06,"May 3, 2016",,"November 15, 2022","Mayo Clinic Arizona, Scottsdale, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|LAC-USC Medical Center/Kenneth Norris Jr Cancer Hospital, Los Angeles, California, United States|Moores UC San Diego Cancer Center, San Diego, California, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Georgia Regents Research Institute, Augusta, Georgia, United States|University of Maryland Cancer Center, Baltimore, Maryland, United States|University of Michigan Cancer Center, Ann Arbor, Michigan, United States|Michigan State University Breslin Cancer Center, Lansing, Michigan, United States|St Vincent Frontier Cancer Center, Billings, Montana, United States|Comprehensive Cancer Center of Nevada, Las Vegas, Nevada, United States|Regional Cancer Center Associates, LLC, Little Silver, New Jersey, United States|Roswell Cancer Center, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Toledo Clinic Cancer Centers, Toledo, Ohio, United States|Tulsa Cancer Center, Tulsa, Oklahoma, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|Houston Methodist Cancer Center, Houston, Texas, United States|Northwest Medical Specialists & Research Institute, Puyallup, Washington, United States",,https://ClinicalTrials.gov/show/NCT02760485,1985.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
344,345,NCT00004075,17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery,,Completed,No Results Available,"Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",Drug: tanespimycin,,Mayo Clinic|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000067283|U01CA069912|P30CA015083|990102,1999-08-01,January 2007,2007-01-01,"January 27, 2003",,"August 3, 2011","Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00004075,2710.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
345,346,NCT01359982,Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects,DINAMIC,Completed,No Results Available,Malignant Solid Tumor|Lymphomas,Drug: RRx-001,"Number, frequency and type of adverse events","EpicentRx, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,26.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RRx001-11-01,2011-09-01,February 2015,2015-02-01,"May 25, 2011",,"May 20, 2015","Moores University of California San Diego Cancer Center, La Jolla, California, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT01359982,1249.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
346,347,NCT02902237,tTF-NGR Phase I Study,,Completed,Has Results,Malignant Solid Tumors|Lymphomas,Biological: tTF-NGR,Maximum Tolerated Dose (MTD) and Dose-limiting Toxicity (DLT)|1: Assessment of Anti-tumor Activity: MRI K-trans in [ 10^-3/Min] and/or CEUS in [Arbitrary Units]; 2: Pharmacokinetic Profile: AUC in [ng*h/mL],"University Hospital Muenster|Deutsche Krebshilfe e.V., Bonn (Germany)",All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UKM12_0018|2016-003042-85,2017-03-01,"November 5, 2019",2019-11-05,"September 15, 2016","December 8, 2020","December 8, 2020","University Hospital Muenster, Muenster, NRW, Germany","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02902237/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02902237,979.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
347,348,NCT00443976,Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma,,Completed,No Results Available,"Non-Hodgkins Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",Drug: Aurora kinase inhibitor AT9283,"Maximum tolerated dose of Aurora kinase inhibitor AT9283 (AT9283)|Recommended phase II dose of AT9283|Safety, tolerability, toxicity profile, and dose-limiting toxicity of AT9283|Pharmacokinetic profile of AT9283|Efficacy of AT9283","NCIC Clinical Trials Group|Astex Pharmaceuticals, Inc.|Canadian Cancer Trials Group",All,"18 Years and older   (Adult, Older Adult)",Phase 1,35.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,I181|CDR0000523837|CAN-NCIC-IND181|ASTEX-CAN-NCIC-IND181,2007-01-04,"April 9, 2010",2012-01-06,"March 7, 2007",,"April 8, 2020","BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Ottawa Health Research Institute - General Division, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00443976,1828.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
348,349,NCT00791011,Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat,,Completed,No Results Available,Hodgkin's Lymphoma|Low Grade Lymphoma|Lymphoma|Mantle Cell Lymphoma|Non-Hodgkin's Lymphoma|Diffuse Large Cell Lymphoma,Drug: AMG 655|Other: Vorinostat|Other: Bortezomib,"Part 1: Safety: Subject incidence of treatment emergent adverse events, Dose Limiting Toxicities, the severity of adverse events and clinically significant changes in safety laboratory tests, physical examinations, or vital signs.|Part 2: Objective response rate of AMG 655 Therapy as determined by using IWG criteria at the dose selected in Part 1, in combination with Bortezomib in subjects with mantle cell lymphoma|Part 2: Overall survival (OS).|Part 2: Progression-Free Survival (PFS).|Part 2: PK parameters for AMG 655 on a 3 week dosing schedule.|Part 2: Subject incidence of anti-AMG 655 antibody formation.|Part 2: Duration of response.|Part 1: Subject incidence of anti-AMG 655 antibody formation.|Part 1: Best tumor response, objective response rate and duration of response.|Part 1: Maximum tolerated dose of AMG 655 administered with bortezomib or vorinostat, if reached.|Part 1: PK parameters for AMG 655 on a 3 week dosing schedule.",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 1,33.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20060340,2008-02-01,July 2010,2011-08-01,"November 14, 2008",,"March 5, 2014",,,https://ClinicalTrials.gov/show/NCT00791011,1277.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
349,350,NCT00446095,Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma,,Completed,Has Results,Lymphoma,Drug: fostamatinib,"Overall Response Rate as Assessed According to the""Revised Response Criteria for Malignant Lymphoma"" (Cheson 2007).|Clinical Benefit Rate as Assessed According to the ""Revised Response Criteria for Malignant Lymphoma"" (Cheson 2007).|Progression Free Survival (PFS)|Overall Survival (OS)",Rigel Pharmaceuticals,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,81.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D4300C00023|C-935788-009,2007-04-01,April 2010,2010-10-01,"March 12, 2007","December 18, 2014","September 19, 2016","Research Site, Los Angeles, California, United States|Research Site, Stanford, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Rochester, Minnesota, United States|Research Site, Omaha, Nebraska, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00446095,1279.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
350,351,NCT01538472,Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma,,Completed,Has Results,Lymphoma,Drug: Y Zevalin|Drug: In Zevalin|Drug: Rituxan|Drug: BCNU|Drug: VP -16|Drug: Ara-C|Drug: Melphalan|Procedure: Stem Cell Infusion|Drug: G-CSF,Overall Survival Median|3-Year Overall Survival,M.D. Anderson Cancer Center|Biogen,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,40.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ID03-0123,2003-09-01,November 2011,2011-11-01,"February 24, 2012","September 11, 2014","September 11, 2014","UT MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01538472,2983.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
351,352,NCT00426855,Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL),,Completed,Has Results,"Lymphoma, Non-Hodgkin",Drug: Bendamustine|Drug: Bortezomib,Optimal Bendamustine Dosage for Further Studies,Peter Moosmann|Kantonsspital Aarau,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,12.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ZOHT-01/07,2007-01-01,February 2009,2009-06-01,"January 25, 2007","April 3, 2015","April 3, 2015",,,https://ClinicalTrials.gov/show/NCT00426855,882.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
352,353,NCT01953783,"Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB",,Completed,Has Results,Advanced Solid Tumors|Lymphoma,Drug: IXAZOMIB,Part A: Cmax: Maximum Observed Plasma Concentration for Ixazomib|Part A: Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Ixazomib|Part A: AUC(0-312): Area Under the Plasma Concentration-time Curve From Time 0 to 312 Hrs Post-dose for Ixazomib|Part A: Cmax: Maximum Observed Plasma Concentration of TRA|Part A: Tmax: Time to Reach the Cmax for TRA|Part A: AUC(0-816): Area Under the Plasma Concentration-time Curve From Time 0 to 816 Hrs Post-dose for TRA|Part A: Cmax: Maximum Observed Whole Blood Concentration of TRA|Part A: Tmax: Time to Reach the Maximum Observed Whole Blood Concentration (Cmax) for TRA|Part A: AUC(0-816): Area Under the Whole Blood Concentration-time Curve From Time 0 to 816 Hrs Post-dose for TRA|Part A: Cumulative Percentage of Ixazomib Dose Recovered in the Urine|Part A: Cumulative Percentage of the Total Radioactivity Dose Excreted in Feces|Part A: Cumulative Percentage of the Total Radioactivity Dose Excreted in Urine|Part A: Renal Clearance of Ixazomib|Ixazomib and Metabolites as Percent of Total Radioactivity in Plasma|Ixazomib and Metabolites as Percent of Total Dose Administered in Urine|Ixazomib and Metabolites as Percent of Total Dose Administered in Feces|Number of Participants Reporting One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Number of Participants With TEAEs Related to Investigations System Organ Class for Laboratory Values|Number of Participants With TEAEs Related to Vital Signs,"Millennium Pharmaceuticals, Inc.|Takeda",All,"18 Years and older   (Adult, Older Adult)",Phase 1,7.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C16016,2014-03-19,"December 17, 2014",2016-02-09,"October 1, 2013","August 26, 2020","August 26, 2020","Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01953783,692.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
353,354,NCT00294632,Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma,,Completed,Has Results,Lymphoma,Drug: Lenalidomide|Drug: Rituximab,Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab|Response of Participants Treated at Lenalidomide 20 mg|Objective Response Rate of Participants Treated With Lenalidomide 20 mg: Overall Response as % of Participants With Complete or Partial Response,M.D. Anderson Cancer Center|Celgene Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,54.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2005-0461|NCI-2012-01356,2006-02-01,February 2016,2016-02-01,"February 22, 2006","February 24, 2020","February 24, 2020","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00294632,3652.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
354,355,NCT03770000,Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma,,Completed,Has Results,T Cell Lymphoma,Drug: Tenalisib|Drug: Romidepsin,Number of Participants With and Without Dose Limiting Toxicities (DLTs)|Overall Response Rate (ORR) With Tenalisib and Romidepsin Combination|Duration of Response (DoR) With Tenalisib and Romidepsin Combination|Maximum Observed Plasma Concentration (Cmax),Rhizen Pharmaceuticals SA,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,33.0,Industry,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RP6530+Romidepsin-1805,2019-03-12,"May 14, 2021",2021-05-14,"December 10, 2018","October 28, 2022","October 28, 2022","USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of California, Hellen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|University of Miami-Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Rush University Cancer Center, Chicago, Illinois, United States|The University of Kansas Cancer Center, Fairway, Kansas, United States|Norton Cancer Institute, St Matthews Campus, Louisville, Kentucky, United States|University of Michigan, Ann Arbor, Michigan, United States|John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States|Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States|The University of Texas MD Anderson Cancer Center,, Houston, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT03770000/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT03770000/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03770000,794.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
355,356,NCT02518958,"A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab",PRIMETIME,Completed,No Results Available,Malignant Solid Tumor|Lymphoma,Drug: RRx-001|Drug: Nivolumab,"Number, frequency and type of adverse events|Time to Tumor Progression (TTP)|Overall Survival|Clinical benefit Rate|Progression-Free Survival (PFS)","EpicentRx, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,12.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RRx001-14-02,2015-07-21,"May 17, 2016",2016-09-12,"August 10, 2015",,"November 18, 2019","Walter Reed National Military Medical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02518958,419.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
356,357,NCT01714947,"Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib",,Completed,Has Results,Advanced Solid Tumors|Lymphoma,Drug: [^14C]-alisertib|Drug: alisertib,"Cmax: Maximum Observed Plasma Concentration for Alisertib and Drug-Related Material Following a Single Dose of [^14C]-Alisertib Oral Solution|Tmax: Time of First Occurrence of Cmax for Alisertib and Drug-Related Material in Plasma Following a Single Dose of [^14C]-Alisertib Oral Solution|AUClast: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Plasma Concentration for Alisertib and Drug-Related Material Following a Single Dose of [^14C]-Alisertib Oral Solution|AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Plasma Concentration for Alisertib and Drug-Related Material Following a Single Dose of [^14C]-Alisertib Oral Solution|T1/2: Terminal Half Life for Alisertib and Drug-Related Material in Plasma Following a Single Dose of [^14C]-Alisertib Oral Solution|CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Plasma Concentration for Alisertib Following a Single Dose of [^14C]-Alisertib Oral Solution|Ratio of Whole Blood Total Radioactivity (TRA) Cmax to Plasma TRA Cmax|Ratio of Alisertib Plasma Cmax to Drug-Related Material TRA Plasma Cmax|Ratio of Whole Blood TRA AUClast to Plasma TRA AUClast|Ratio of Alisertib Plasma AUClast to Drug-Related Material TRA Plasma AUClast|Ratio of Whole Blood TRA AUC∞ to Plasma TRA AUC∞|Ratio of Alisertib Plasma AUC∞ to Drug-Related Material TRA Plasma AUC∞|Fe: Fraction of Administered Dose of [^14C]-Alisertib Excreted in Urine|Fe: Fraction of Administered Dose of [^14C]-Alisertib Excreted in Feces|Ae: Amount of [^14C]-Alisertib Excreted in Urine|Ae: Amount of [^14C]-Alisertib Excreted in Feces|Percent of Total Radioactivity (TRA) in Urine and Feces|Fe: Fraction of Administered Dose of Alisertib Excreted in Urine|Ae: Amount of Alisertib Excretion in Urine|Renal Clearance (CLR) of Alisertib|Percentage of Alisertib Metabolites in Plasma Following a Single Dose of [^14C]-Alisertib Oral Solution|Percentage of Alisertib Metabolites in Urine Following a Single Dose of [^14C]-Alisertib Oral Solution|Percentage of Alisertib Metabolites in Feces Following a Single Dose of [^14C]-Alisertib Oral Solution|Number of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events|Number of Participants With Clinically Significant Changes or Abnormalities in Clinical Laboratory Values Reported as AEs|Number of Participants With Clinically Significant Changes or Abnormalities in Vital Sign Measurements","Millennium Pharmaceuticals, Inc.|Takeda",All,"18 Years and older   (Adult, Older Adult)",Phase 1,3.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C14014|U1111-1187-6760,2013-01-24,"April 4, 2013",2013-06-14,"October 26, 2012","October 31, 2018","October 31, 2018","Comprehensive Clinical Development, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT01714947,141.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
357,358,NCT02401048,A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas,,Completed,Has Results,Diffuse Large B-Cell Lymphoma|Follicular Lymphoma,Drug: Ibrutinib|Drug: MEDI4736,"Phase 1b/2 : Overall Response Rate of Number of Participants|Phase 1b/ 2: Duration of Response|Phase 1b/ 2: Progression-free Survival (PFS)|Phase 1b/2: Overall Survival|Phamacokinetics: Mean Maximum Observed Plasma Concentration (Cmax) for Ibrutinib|Pharmacokinetics: Mean Time to Maximum Observed Plasma Concentration (Tmax) for Ibrutinib|Pharmacokinetics: Mean Area Under the Plasma Concentration-Time Curve From Time 0-24 Hours (AUC0-24h) for Ibrutinib|Pharmacokinetics: Mean Terminal Elimination Half-Life (t1/2,Term) for Ibrutinib|Pharmacokinetics: Mean Peak Plasma Concentration (Cmax) for MEDI4736|Pharmacokinetics: Mean Trough Plasma Concentration (Ctrough) for MEDI4736|Pharmacokinetics: MEDI4736 Accumulation Ratio for Cmax|Pharmacokinetics: MEDI4736 Accumulation Ratio for Ctrough|Bruton Tyrosine Kinase (BTK) Occupancy|Pharmacodynamics of Ibrutinib in Subjects With Relapsed or Refractory Lymphomas|Pharmacodynamics of MEDI4736 in Subjects With Relapsed or Refractory Lymphomas","Pharmacyclics LLC.|AstraZeneca|Janssen Research & Development, LLC",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,61.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PCYC-1136-CA,2015-05-01,November 2017,2017-11-01,"March 27, 2015","June 27, 2019","June 27, 2019","Site-0397, Birmingham, Alabama, United States|Site-0047, Duarte, California, United States|Site-0038, Stanford, California, United States|Site-0388, Miami, Florida, United States|Site-0126, Chicago, Illinois, United States|Site-0020/0173, Boston, Massachusetts, United States|Site-0729, Ann Arbor, Michigan, United States|Site-0130, Detroit, Michigan, United States|Site-0343, Hackensack, New Jersey, United States|Site-0402, Philadelphia, Pennsylvania, United States|Site-0114, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT02401048/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT02401048/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02401048,915.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
358,359,NCT00134082,Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma,,Completed,Has Results,Lymphoma,Biological: KGEL vaccine|Biological: Filgrastim|Biological: Rituximab|Drug: Cyclophosphamide,Number of Participants With Grade 3-5 Adverse Events|Percentage of Participants With an Increase in Frequency of LMP2-specific CD8+ T Cells|Survival|Days to Neutrophil and Platelet Engraftment,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1|Phase 2,31.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,J0528|P50CA096888|P30CA006973|NA_00035358,2005-11-01,January 2013,2013-01-01,"August 24, 2005","February 26, 2019","February 26, 2019","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00134082,2618.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
359,360,NCT00967044,Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma,,Completed,Has Results,Lymphoma,Drug: Panobinostat|Drug: Everolimus,Maximum Tolerated Dose (MTD) of Everolimus With Panobinostat,M.D. Anderson Cancer Center|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,31.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2008-0805|NCI-2011-03023,2009-11-01,March 2014,2014-03-01,"August 27, 2009","September 10, 2014","February 26, 2015","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00967044,1581.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
360,361,NCT00003079,Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma,,Completed,No Results Available,Leukemia|Lymphoma,Drug: bryostatin 1|Drug: cytarabine,,Virginia Commonwealth University|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000065773|P30CA016059|MCV-MCC-9612-2E|NCI-T97-0011,1997-09-01,May 2001,2001-05-01,"May 27, 2004",,"February 17, 2010","New York Presbyterian Hospital - Cornell Campus, New York, New York, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Massey Cancer Center, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00003079,1338.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
361,362,NCT03343652,A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma,NB001,Completed,No Results Available,Hodgkin's Lymphoma,Drug: Nivolumab|Drug: Bendamustine Hydrochloride,Overall Response Rate (ORR) of Nivolumab in combination with Bendamustine Hydrochloride in patients with Hodgkin's lymphoma|Frequency of grade 3 or higher treatment-related adverse events by CTCAE 4.03|Duration of Response (DOR)|Time to Progression (TTP)|Progression-Free Survival (PFS)|Overall Survival (OS),St. Petersburg State Pavlov Medical University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,30.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10/17-n,2017-05-27,"March 27, 2019",2020-03-27,"November 17, 2017",,"May 28, 2020","First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation",,https://ClinicalTrials.gov/show/NCT03343652,1035.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
362,363,NCT01445522,ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer,,Completed,No Results Available,Neoplasms|Lymphoma,Drug: ABT-888|Drug: Cyclophosphamide,Establish the safety and tolerability of the combination of ABT-888 with metronomic cyclophosphamide in patients with refractory solid tumors and lymphomas. Establish the MTD of the combination of ABT-888 with metronomic cyclophosphamide.|Evaluate the pharmacokinetics of ABT-888 when administered combination with cyclophosphamide. Evaluate for anti-tumor response.,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years to 110 Years   (Adult, Older Adult)",Phase 1,35.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,090048|09-C-0048,2008-12-03,"July 3, 2012",2012-07-03,"October 3, 2011",,"December 17, 2019","City of Hope National Medical Center, Duarte, California, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01445522,1308.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
363,364,NCT01844583,"Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib",,Completed,Has Results,Solid Tumors|Lymphoma,Drug: Alisertib|Drug: Esomeprazole|Drug: Rifampin,Cmax: Maximum Observed Concentration for Alisertib in Presence and Absence of Esomeprazole|AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib in Presence and Absence of Esomeprazole|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Alisertib in Presence and Absence of Esomeprazole|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib in Presence and Absence of Esomeprazole|Terminal Phase Elimination Half-life (T1/2) for Alisertib in Presence and Absence of Esomeprazole|Cmax: Maximum Observed Concentration for Alisertib in Presence and Absence of Rifampin|AUC(Last): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib in Presence and Absence of Rifampin|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Alisertib in Presence or Absence of Rifampin|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib in Presence and Absence of Rifampin|Phase Elimination Half-life (T1/2) for Alisertib in Presence and Absence of Rifampin|Change From the Time-matched Baseline in the Individually Corrected QTc Interval (QTcI)|Change From the Time-matched Baseline in the Fridericia Correction of QTc (QTcF)|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),"Millennium Pharmaceuticals, Inc.|Takeda",All,"18 Years and older   (Adult, Older Adult)",Phase 1,55.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C14015,2013-06-25,"August 4, 2014",2016-09-06,"May 1, 2013","March 25, 2019","March 25, 2019","Sarasota, Florida, United States|Saint Louis, Missouri, United States|Oklahoma City, Oklahoma, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01844583,1169.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
364,365,NCT01129180,Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma,,Completed,No Results Available,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Prolymphocytic Leukemia|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Small Intestine Lymphoma|T-cell Large Granular Lymphocyte Leukemia,Drug: azacitidine|Drug: bortezomib|Procedure: Correlative studies,Maximum tolerable dose (MTD) of bortezomib in combination with azacitidine|Specific toxicities and the dose limiting toxicity (DLT) of bortezomib in combination with azacitidine as assessed by NCI CTCAE (Common Toxicity Criteria for Adverse Effects) v4.0|Overall response rate|Correlation of the biological activity of Azacitidine as a demethylating agent with clinical endpoints and plasma pharmacokinetics|Biological activity of bortezomib as a potential demethylating agent|Correlation of intracellular concentration of azacitidine-triphosphate with global DNA methylation and other biological endpoints as well as clinical response|Biologic role of microRNAs in determining clinical response to the bortezomib plus azacitidine combination and achievement of the other pharmacodynamic endpoints,"Pierluigi Porcu|Millennium Pharmaceuticals, Inc.|Celgene Corporation|Ohio State University Comprehensive Cancer Center",All,"18 Years and older   (Adult, Older Adult)",Phase 1,8.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSU-08067|NCI-2010-01081,2010-05-01,May 2012,2012-12-01,"May 24, 2010",,"December 3, 2013","Ohio State University Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01129180,945.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
365,366,NCT01132911,"A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas",,Completed,No Results Available,Lymphoma|Sarcoma|WilmsTumor|Neuroblastoma,"Drug: Vorinostat (SAHA)|Drug: Velcade (PS-341, Bortezomib)","To determine the maximum tolerated dose and Phase 2 dose of combination vorinostat and bortezomib to children with refractory or recurrent solid tumors.|Define toxicities and pharmacokinetics.|To define antitumor activity, assess biological activity of bortezomib by measuring NF-kb activity in PBMC and to assess the biologic activity of bortezomib by measuring endoplasmic reticulum stress response using GRP78 molecular chaperone marke...",National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"1 Year to 21 Years   (Child, Adult)",Phase 1,5.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,100119|10-C-0119,2010-05-10,"April 13, 2011",2011-04-13,"May 28, 2010",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01132911,338.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
366,367,NCT00299494,Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL),,Completed,Has Results,B-Cell Lymphoma,Drug: inotuzumab ozogamicin|Drug: Rituximab,"Maximum Tolerated Dose (MTD) of Inotuzumab Ozogamicin in Combination With Rituximab (375 mg/m^2 )|Percentage of Participants With a Treatment Emergent Adverse Event (TEAE) (Safety Population)|Percentage of Participants With Complete Response (CR), Unconfirmed CR (CRu), or Partial Response (PR)|Kaplan-Meier Estimates of Progression Free Survival (PFS)|Kaplan-Meier Estimates of the Probability of Being Progression Free at 6 Months|Kaplan-Meier Estimates of Overall Survival (OS)|Kaplan-Meier Estimates of the Probability of Survival at 6 Months|Kaplan-Meier Estimates of Time to Tumor Progression (TTP)|Kaplan-Meier Estimates of the Probability of Being Event Free at 6 Months|Duration of Response (CR+CRu+PR)|Area Under the Serum Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Inotuzumab Ozogamicin in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|AUClast of Inotuzumab Ozogamicin in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Time of the Last Quantifiable Serum Concentration in a Dosing Interval (Tlast) of Inotuzumab Ozogamicin in Participants Receving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Area Under the Steady-state Serum Concentration-time Curve (AUCtau) of Inotuzumab Ozogamicin in Participants Receving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Peak Serum Concentration (Cmax) of Inotuzumab Ozogamicin in Participants Receving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Time to Reach Maximum Concentration (Tmax) of Inotuzumab Ozogamicin in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Average Serum Concentration at Steady State (Cav) of Inotuzumab Ozogamicin in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Minimum Observed Serum Trough Concentration (Cmin) of Inotuzumab Ozogamicin in Participants Receiving Inotuzumab+Rituximab on Dosing Day 30 and Day 58|Clearance (CL) of Serum Inotuzumab Ozogamicin in Participants Receiving Inotuzumab+Rituximab on Dosing Day 30 and Day 58|Steady-state Volume of Distribution (Vss) of Inotuzumab Ozogamicin in Serum in Participants Receiving Inotuzumab MTD+Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|MRT of Inotuzumab Ozogamicin in Serum in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Serum Decay Half-Life (t1/2) of Inotuzumab Ozogamicin in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|AUCinf of Total Calicheamicin (Conjugated + Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|AUClast of Total Calicheamicin (Conjugated Plus Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Time of the Last Quantifiable Concentration in a Dosing Interval (Tlast) of Total Calicheamicin (Conjugated Plus Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Area Under the Steady-state Serum Concentration-time Curve (AUCtau) for Total Calicheamicin (Conjugated Plus Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30, and Day 58|Peak Serum Concentration (Cmax) of Total Calicheamicin (Conjugated Plus Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Time of Observed Maximum Concentration (Tmax) of Total Calicheamicin (Conjugated+Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Average Serum Concentration (Cav) of Total Calicheamicin (Conjugated Plus Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Minimum Observed Serum Trough Concentration (Cmin) of Total Calicheamicin (Conjugated Plus Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Clearance (CL) of Total Calicheamicin (Conjugated Plus Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Steady-state Volume (Vss) of Total Calicheamicin (Conjugated Plus Unconjugated) Distribution in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Mean Residence Time (MRT) of Total Calicheamicin (Conjugated Plus Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Serum Decay Half-Life (t1/2) of Total Calicheamicin (Conjugated Plus Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Area Under the Steady-state Serum Concentration-time Curve (AUClast) of Unconjugated Calicheamicin in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Time of the Last Quantifiable Concentration in a Dosing Interval (Tlast) of Unconjugated Calicheamicin in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Peak Serum Concentration (Cmax) of Unconjugated Calicheamicin in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Time of Observed Maximum Concentration (Tmax) of Unconjugated Calicheamicin in Participants Receiving Inotuzumab Ozogamicin + Rituximab on Dosing Day 1, Day 30 and Day 58|Minimum Observed Serum Trough Concentration (Cmin) of Unconjugated Calicheamicin in Participants Receiving Inotuzumab Ozogamicin+Rituximab on Dosing Day 30 and Day 58|Area Under the Serum Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Inotuzumab Ozogamicin Antibody in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m2 on Dosing Day 30 and Day 58|Area Under the Steady-state Concentration-time Curve (AUClast) of Serum Inotuzumab Ozogamicin Antibody in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Time of the Last Quantifiable Concentration in a Dosing Interval (Tlast) of Serum Inotuzumab Ozogamicin Antibody in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Serum Decay Half-Life (t1/2) of Inotuzumab Ozogamicin Antibody in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab on Dosing Day 30 and Day 58|Area Under the Steady-state Serum Concentration-time Curve (AUCtau) of Inotuzumab Ozogamicin Antibody in Participants Receiving Inotuzumab Ozogamicin MTD+ Rituximab 375 mg/m^2 on Dosing Day 1, Day 30, and Day 58|Peak Concentration (Cmax) of Serum Inotuzumab Ozogamicin Antibody in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Time to Reach Maximum Concentration (Tmax) of Serum Inotuzumab Ozogamicin Antibody in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Average Serum Concentration (Cav) of Inotuzumab Ozogamicin Antibody in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Minimum Observed Serum Trough Concentration (Cmin) of Inotuzumab Ozogamicin Antibody in Participants Receiving Inotuzumab MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Clearance (CL) of Serum Inotuzumab Ozogamicin Antibody in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Steady-state Volume (Vss) of Inotuzumab Ozogamicin Antibody Distribution in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58",Pfizer|UCB Pharma,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,119.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3129K3-101|B1931004|2005-005436-27,2006-05-04,"May 19, 2014",2014-06-02,"March 6, 2006","March 8, 2018","March 8, 2018","University of Alabama at Birmingham-, Birmingham, Alabama, United States|IDS Pharmacy, Birmingham, Alabama, United States|University of Alabama at Birmingham-, Birmingham, Alabama, United States|California Cancer Care, Inc., Greenbrae, California, United States|University of California Medical Center, San Francisco, California, United States|California Cancer Care, San Mateo, California, United States|Emory Clinic, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Emory University Investigational Drug Service, Atlanta, Georgia, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Nevada Cancer Institute-, Las Vegas, Nevada, United States|Rosewell Park Cancer Institute, Buffalo, New York, United States|Gabrail Cancer Center, Canton, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Gabrail Cancer Center, Dover, Ohio, United States|UHHS - Westlake, Westlake, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|Royal Brisbane and Women's Hospital, Herston, Brisbane, QLD, Australia|Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven, Vlaams-brabant, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|University Hospital Gent - Department of Hematology, Gent, Belgium|Hôpital André MIGNOT, Le Chesnay, France|Hôpital Saint-Louis, Paris, France|CH Lyon Sud, Pierre Benite, France|Universitaetsklinik Bonn, Medizinische Klinik und Poliklinik III, Bonn, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet, III. medizinische klinik und Poliklinik, Mainz, Germany|Prince Of Wales Hospital, Shatin N.T., Hong Kong|Universita La Sapienza Cattedra di Ematologia, Roma, Italy|Asan Medical Center, Seoul, Korea, Republic of|Erasmus Medisch Centrum--, Rotterdam, Zuid-holland, Netherlands|Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warszawa, Poland|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|University Hospital Zurich, Zurich, Switzerland|Derriford Hospital - Plymouth, Plymouth, Devon, United Kingdom|Somers Cancer Science Building MP824, Southampton, Hampshire, United Kingdom|Bart's Cancer Institute; Queen Mary University of London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00299494,2951.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
367,368,NCT03877055,A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma,,Completed,Has Results,Mantle Cell Lymphoma (MCL),Drug: Copanlisib|Drug: Ibrutinib,Complete Response,Memorial Sloan Kettering Cancer Center|Bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,8.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-450,2019-03-13,"October 7, 2022",2022-10-07,"March 15, 2019","December 14, 2022","December 14, 2022","Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT03877055/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03877055,1304.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
368,369,NCT02631577,A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma,,Completed,Has Results,"Lymphoma, Follicular",Drug: Atezolizumab (MPDL3280A) [TECENTRIQ]|Drug: Lenalidomide|Drug: Obinutuzumab,"Percentage of Participants Achieving Complete Response (CR) at End of Induction (EOI), as Determined by the Independent Review Committee (IRC) Using Modified Lugano 2014 Criteria|Percentage of Participants Achieving CR at EOI, as Determined by the Investigator Using Modified Lugano 2014 Criteria|Percentage of Participants Achieving CR at EOI, as Determined by the IRC and Investigator Using Lugano 2014 Criteria|Percentage of Participants With Objective Response (CR or PR) at EOI as Determined by the IRC and Investigator on the Basis of PET-CT Scans|Percentage of Participants With Objective Response (CR or PR) at EOI as Determined by the IRC and Investigator on the Basis of CT Scans Alone|Percentage of Participants With Best Response (CR or PR) During the Study as Determined by the Investigator on the Basis of CT Scans Alone|Percentage of Participants With Adverse Events and Serious Adverse Events|Number of Participants With Dose-limiting Toxicities (DLTs) During Cycle 2 of Study Treatment|Serum Concentration of Obinutuzumab (mcg/mL)|Serum Concentration of Atezolizumab (mcg/mL)|Serum Concentration of Lenalidomide (ng/mL)|Number of Participants Positive for Human Anti-human Antibodies (HAHA) to Obinutuzumab|Number of Participants Positive for Anti-therapeutic Antibodies (ATAs) to Atezolizumab",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,38.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BO29562|2015-002467-42,2015-12-31,"October 23, 2018",2020-10-07,"December 16, 2015","December 30, 2019","April 13, 2022","University of Alabama at Birmingham, Birmingham, Alabama, United States|University Miami, Miami, Florida, United States|Norton Medical Plaza II, Louisville, Kentucky, United States|Memorial Sloan-Kettering Cancer Center; Hematology/Oncology, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Chu Toulouse, Bron, France|Hopital Henri Mondor; 51 Av Mal Lattre De Tassigny, Creteil, France|Hopital du Bocage, Dijon, France|Centre Jean Bernard, Le Mans, France|Centre Hospitalier Le Mans, Le Mans, France|CHRU de Lille - Hopital Claude Huriez, Lille, France|CHU Montpellier - Saint ELOI, Montpellier, France|CHU - Hôtel Dieu hematolgie clinique, Nantes, France|Centre Hospitalier Lyon Sud; Hematolgie, Pierre Benite, France|CHU de Rennes - Hopital de Pontchaillo, Rennes, France|Centre Henri Becquerel, Rouen, France","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02631577/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02631577,1742.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
369,370,NCT02729896,"A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",,Completed,Has Results,Lymphoma,Drug: Atezolizumab [TECENTRIQ]|Drug: Obinutuzumab|Drug: Polatuzumab Vedotin|Drug: Rituximab,"Percentage of Participants With CR at EOI, as Determined by the Investigator on the Basis of Positron Emission Tomography and Computed Tomography (PET-CT) Scan|Percentage of Participants With CR at EOI, as Determined by Investigator on the Basis of CT Scans Alone|Percentage of Participants With Objective Response (CR + PR) at EOI, as Determined by the Investigator on the Basis of PET-CT Scans|Percentage of Participants With Objective Response (CR + PR) at EOI, as Determined by the Investigator on the Basis of CT Scans Alone|Percentage of Participants With Best Response of CR or PR During the Study, as Determined by the Investigator on the Basis of CT Scans Alone|Percentage of Participants With Adverse Events and Serious Adverse Events|Serum Obinutuzumab Concentration|Serum Rituximab Concentration|Serum Atezo Concentration|Serum Pola Concentration|Percentage of Participants With Human Anti-Human Antibodies (HAHAs) to Obinutuzumab|Percentage of Participants With Human Anti-Chimeric Antibodies (HACAs) to Rituximab|Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezo|Percentage of Participants With ATAs to Pola",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,36.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BO29561|2015-004845-25,2016-11-09,"September 3, 2018",2019-10-07,"April 6, 2016","November 5, 2019","December 23, 2020","UCLA, Los Angeles, California, United States|University Miami, Miami, Florida, United States|Stony Brook University Hospital, Stony Brook, New York, United States|Columbia Basin Hem-Onc; Department Hematology Oncology, Kennewick, Washington, United States|Robert Byrd Health Science; Dept of Medicine, Section of Hematology/Oncology, Morgantown, West Virginia, United States|Städtisches Klinikum Dessau Klinik für Innere Medizin Abt. Intensivmedizin, Dessau-Roßlau, Germany|Uniklinik Essen, Essen, Germany|Universitatsklinikum Frankfurt, Frankfurt, Germany|Universitätsklinikum Greifswald Klinik für Innere Medizin C und Poliklinik, Greifswald, Germany|Medizinische Hochschule; Zentrum Innere Medizin; Abt. Hämatologie u. Onkologie, Hannover, Germany|Universitätsklinikum Jena Klinik f.Chirurgie Abt. Allgemein- und Viszeralchirurgie, Jena, Germany|Klinikum rechts der Isar der Technischen Universität München, Munchen, Germany|Universitätsklinikum Würzburg, Wuerzburg, Germany|Szpitale Wojewodzkie w Gdyni Sp. z o.o., Gdynia, Poland|Wojewódzki Szpital Specjalistyczny im.MikołajaKopernika;KlinikaHematologiiUniwersytetuMedycznego, Lodz, Poland|Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych, Warsaw, Poland|MTZ Clinical Research Sp. z o.o., Warszawa, Poland|Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland|Medical Uni of Wroclaw; Hematology, Wroclaw, Poland","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02729896/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02729896,1062.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
371,372,NCT00004916,"Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma",,Completed,No Results Available,Lymphoma,Drug: ifosfamide|Drug: paclitaxel|Drug: teniposide|Procedure: peripheral blood stem cell transplantation,,Northwestern University|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,,Other|NIH,Interventional,Primary Purpose: Treatment,NU 98H2|NU-98H2|NCI-G00-1711,1999-02-01,October 2002,2002-10-01,"May 14, 2003",,"June 6, 2012","Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00004916,1338.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
372,373,NCT00633594,"Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma",,Completed,Has Results,Mantle Cell Lymphoma,Drug: Rituximab|Drug: Bortezomib|Drug: Lenalidomide,"Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants|Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II|Overall Response Rate (ORR) of Phase I and Phase II Participants|Overall Response Rate (ORR) of Previously Treated and Previously Untreated Participants|Time to Best Response of Phase I and Phase II Participants|Time to Best Response of Previously Treated and Previously Untreated Participants|Duration of Response (DoR) of Phase I and Phase II Participants|Duration of Response (DoR) of Previously Treated and Previously Untreated Participants|Progression Free Survival (PFS) of Phase I and Phase II Participants|Progression Free Survival (PFS) of Previously Treated and Previously Untreated Participants|Overall Survival of Phase I and Phase II Participants|Overall Survival of Previously Treated and Previously Untreated Participants","SCRI Development Innovations, LLC|Millennium Pharmaceuticals, Inc.|Celgene",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,39.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCRI LYM 58,2008-06-01,April 2015,2016-11-01,"March 12, 2008","January 31, 2017","January 31, 2017","Providence Medical Group, Terre Haute, Indiana, United States|RHHP/ Hope Cancer Center, Terre Haute, Indiana, United States|St. Louis Cancer Care, Chesterfield, Missouri, United States|Hematology-Oncology Associates of Northern NJ, Morristown, New Jersey, United States|Oncology Hematology Care Inc., Cincinnati, Ohio, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00633594,3075.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
373,374,NCT00550615,Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma,,Completed,Has Results,Non-Hodgkin's Lymphoma,Drug: Dasatinib|Drug: Dasatinib Maximum Tolerated Dose,Maximum Tolerated Dose|Number of Participants With Clinical Response Rates,University of Nebraska|Bristol-Myers Squibb,All,"19 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,38.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,244-07-FB|BMS Protocol 180129,2007-09-01,August 2016,2017-12-01,"October 30, 2007","February 1, 2019","February 1, 2019","University of Nebraska Medical Center - Internal Medicine Section of Oncology/Hematology, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT00550615,3744.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
374,375,NCT00963534,"Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.",LENA-BERIT,Completed,No Results Available,Mantle Cell Lymphoma,"Drug: lenalidomide, bendamustine, rituximab",MTD of lenalidomide (phase I) Progression free survival (phase II),Lund University Hospital|Mundipharma Pte Ltd.|Celgene|Roche Pharma AG,All,65 Years and older   (Older Adult),Phase 1|Phase 2,51.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NLG-MCL4,2009-09-01,August 2017,2017-08-01,"August 21, 2009",,"March 12, 2018","Herlev Hospital, Copenhagen, Denmark|Rigshospitalet, Department of Hematology, Copenhagen, Denmark|Århus University Hospital, Århus, Denmark|Helsinki University Central Hospital, Helsinki, Finland|Haukeland University Hospital, Department of Oncology, Bergen, Norway|Norwegian Radium Hospital, Oslo, Norway|Ulleval University Hospital, Department of Oncology, Oslo, Norway|University Hospital of Stavanger, Department of Haematology and Oncology, Stavanger, Norway|University Hospital of Tromso, Department of Oncology, Tromso, Norway|Sahlgrenska University Hospital, Department of Hematology, Göteborg, Sweden|University Hospital Linköping, Department of Hematology, Linköping, Sweden|Sunderbyn Hospital, Department of Medicine, Luleå, Sweden|University Hospital Lund, Department of Oncology, Lund, Sweden|Karolinska University Hospital, Department of Hematology, Stockholm, Sweden|Sundsvall Hospital, Department of Medicine, Sundsvall, Sweden|University Hospital of Norrland, Department of Oncology, Umeå, Sweden|Uppsala University Hospital, Department of Oncology, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT00963534,2891.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
375,376,NCT00562978,"Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients",,Completed,Has Results,Lymphoma,Biological: filgrastim|Drug: cyclophosphamide|Drug: etoposide|Procedure: AHSCT|Radiation: yttrium Y 90 ibritumomab tiuxetan,Number of Patients Achieving Complete Response (CR)|Number of Patients With Grade 3 or Greater Toxicity|5-Year Overall Survival (Phase II)|5-Year Disease-free Survival (Phase II),City of Hope Medical Center|National Cancer Institute (NCI),All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,54.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,98153|P30CA033572|P01CA030206|CHNMC-98153|CDR0000574716,2000-05-16,"May 21, 2018",2018-05-21,"November 26, 2007","June 18, 2021","June 18, 2021",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT00562978/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT00562978,6579.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
376,377,NCT01458366,"Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-Cell Lymphomas",,Completed,Has Results,Non-Hodgkin's Lymphoma,Drug: Bendamustine|Drug: Ofatumumab|Drug: Carboplatin|Drug: Etoposide|Procedure: CT Scan|Procedure: PET Scan|Genetic: Stem Cell Transplant (STC),"Phase I: Maximum-Tolerated Dose of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide (BOCE)|Overall Frequency of Response With Combination of Bendamustine, Ofatumumab, Carboplatin, and Etoposide at Maximum Tolerated Dose (MTD)|Phase I: Overall Frequency of Response|Overall Complete Response (CR) and Partial Response (PR) Rate|Overall Progression-Free Survival|Total Overall Survival for Transplant vs Non-transplant|Overall Proportion of Patients Who Are Able to Undergo Stem Cell Transplant (SCT)|Overall Safety and Tolerability of the Combination of Bendamustine, Ofatumumab, Carboplatin, and Etoposide",Sidney Kimmel Cancer Center at Thomas Jefferson University|GlaxoSmithKline|Novartis|Thomas Jefferson University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,38.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11D.404|2011-61,2011-11-09,"August 27, 2018",2020-07-23,"October 24, 2011","March 24, 2020","September 26, 2022","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT01458366/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01458366,3179.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
377,378,NCT00722488,"Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma",,Completed,No Results Available,Hematologic Malignancies|Multiple Myeloma|Lymphoma|Hodgkin Lymphoma,Drug: MLN4924,Evaluation of safety and tolerability|Disease response,"Millennium Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,56.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C15002,2008-06-01,July 2013,2013-09-01,"July 25, 2008",,"November 18, 2013","Winship Cancer Institute, Atlanta, Georgia, United States|Roswell Park Cancer Institute, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT00722488,1918.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
378,379,NCT02271945,Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas,,Completed,Has Results,Relapsed/Refractory Aggressive B-cell Lymphomas,Drug: MEDI-551 12 mg/kg|Drug: MEDI0680 2.5 mg/kg|Drug: MEDI0680 10 mg/kg,"Maximum Tolerated Dose (MTD) of MEDI-551|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Treatment-Emergent Serious Adverse Events (TESAEs)|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Related to Clinical Laboratory Abnormalities|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Related to Vital Signs, Physical Findings Abnormalities|Number of Participants With Best Overall Response|Mean Peak and Trough Concentrations of MEDI551|Mean Peak and Trough Concentrations of MEDI0680|Terminal Half-Life (t1/2) of MEDI551|Terminal Half-Life (t1/2) of MEDI0680|Number of Participants With Positive Anti-Drug Antibodies (ADA) for MEDI-551 and MEDI0680|Duration of Complete Response|Number of Participants With Disease Control|Duration of Disease Control|Progression-free Survival (PFS)|Overall Survival (OS)|Time to Response (TTR)",MedImmune LLC,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1|Phase 2,10.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D2852C00004,2014-12-01,"May 24, 2016",2016-05-24,"October 22, 2014","March 12, 2018","March 12, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Baltimore, Maryland, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Bronx, New York, United States|Research Site, Cleveland, Ohio, United States|Research Site, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02271945,540.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
379,380,NCT00002510,Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma,,Completed,No Results Available,Lymphoma,Biological: filgrastim|Drug: cyclophosphamide|Drug: etoposide|Drug: mesna|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,,Temple University|Fox Chase Cancer Center,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000078066|TUHSC-2049|NCI-V92-0206,1992-04-01,June 2001,2001-06-01,"August 23, 2004",,"October 1, 2010","Temple University Cancer Center, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00002510,3348.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
380,381,NCT03192202,AFM13 in Relapsed/Refractory Cutaneous Lymphomas,,Completed,No Results Available,"Lymphoma, T-Cell, Cutaneous",Drug: AFM13,"Percentage of Intratumoral NK-cells and T-cells infiltration into tumors|Number of immune cells (NK cells, T cells, and others) in tumor and peripheral blood|Level of plasma cytokine production plus release in tumor and peripheral blood as a function of treatment|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Overall Response Rate (ORR)|Duration of Response (DOR) after treatment with AFM 13|Progression Free Survival (PFS) after treatment with AFM 13",Ahmed Sawas|Columbia University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,18.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AAAP4461,2017-07-17,"April 1, 2020",2020-04-01,"June 20, 2017",,"July 16, 2020","Center for Lymphoid Malignancies, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03192202,989.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
381,382,NCT02059239,Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma,,Completed,Has Results,Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma,Drug: Bendamustine|Drug: Carmustine|Drug: Etoposide|Drug: Melphalan|Drug: Cytarabine|Drug: Alemtuzumab|Biological: Autologous Stem Cell Transplantation|Biological: Allogeneic Stem Cell Transplantation|Drug: Rituximab,Number of Patients Able to Proceed to Transplant|Number of Patients Achieving Neutrophil Engraftment|Number of Patients Achieving Platelet Engraftment|Overall Survival at Day 100 Post-Transplant|Overall Survival at Day 365 Post-Transplant|Transplant-Related Mortality|Disease Response Following Salvage Chemotherapy|Disease Response 30 Days Post-Transplant|Disease Response at 1 Year Post-Transplant|Progression-Free Survival After Stem Cell Transplant,Weill Medical College of Cornell University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,34.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1208012875,2014-06-04,"December 16, 2019",2020-06-15,"February 11, 2014","February 21, 2021","February 21, 2021","Weill Cornell Medical College, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT02059239/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02059239,2203.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
382,383,NCT00003356,Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma,,Completed,No Results Available,Lymphoma,Biological: aldesleukin|Biological: rituximab,,University of Rochester|National Cancer Institute (NCI),All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,58.0,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000066338|P30CA011198|URCC-U4497|NCI-G98-1442,1997-11-01,May 2002,2002-05-01,"March 22, 2004",,"October 16, 2013","University of Rochester Cancer Center, Rochester, New York, United States",,https://ClinicalTrials.gov/show/NCT00003356,1642.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
383,384,NCT00299182,Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma,,Completed,Has Results,Lymphoma,Drug: AMG 531|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Doxorubicin|Drug: Dexamethasone|Drug: Methotrexate|Drug: Cytarabine|Drug: Placebo,Platelet (PLT) Nadir|Days Platelets Count of < 100K/μL,M.D. Anderson Cancer Center|Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,50.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2005-0146,2006-03-01,April 2012,2012-04-01,"March 6, 2006","September 21, 2021","September 21, 2021","UT MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00299182,2223.0,Not Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,Not Open Label,Treatment/Diagnostic
384,385,NCT01078142,"Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma",BERT,Completed,No Results Available,Follicular Lymphoma|Mantle Cell Lymphoma,"Drug: Temsirolimus, Rituximab, Bendamustin",Phase I: MTD / Phase II: ORR|Progression free survival,"Georg Hess, MD|Wyeth is now a wholly owned subsidiary of Pfizer|Mundipharma Pte Ltd.|Johannes Gutenberg University Mainz",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,39.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,341,2010-02-02,"September 8, 2017",2017-09-08,"March 2, 2010",,"September 11, 2017","Universitätsmedizin Mainz, Mainz, Rheinland-Pfalz, Germany",,https://ClinicalTrials.gov/show/NCT01078142,2775.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
385,386,NCT00043420,CPG 7909 in Patients With Cutaneous T-Cell Lymphoma,,Completed,No Results Available,"Lymphoma, T-Cell, Cutaneous",Drug: PF-3512676,"Safety: Adverse events, vital signs, clinical and laboratory parameters, physical exams, and ECGs|Efficacy: Evaluate tumor response as measured by the Composite Assessment of Index Lesion Disease Severity (CA). The primary endpoint will be the overall tumor response rate as assessed by the CA.|Secondary efficacy endpoints include disease response assessed by the PGA, duration of overall response, duration of CCR, duration of PR, time to response and time to progression of disease.",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,42.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"C014|CO14, A8501014",2003-01-01,March 2007,2007-03-01,"August 12, 2002",,"February 12, 2009",,,https://ClinicalTrials.gov/show/NCT00043420,1520.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
387,388,NCT00688415,Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer,,Completed,No Results Available,Advanced Solid Tumors|Lymphoma,Drug: VTX-2337,Safety and identification of dose-limiting toxicities|Pharmacokinetics|Pharmacodynamics|Identification of the MTD,Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 1,33.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,VRXP-A101,2008-11-07,August 2010,2010-11-01,"June 3, 2008",,"September 25, 2019","Mayo Clinic, Scottsdale, Arizona, United States|Scottsdale Healthcare, Scottsdale, Arizona, United States",,https://ClinicalTrials.gov/show/NCT00688415,724.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
388,389,NCT00059995,MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma,,Completed,No Results Available,Lymphoma,Biological: iratumumab,,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),All,"12 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,,Other|NIH,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,MDX-060-01|MSKCC-02121|CDR0000298995,2003-01-01,October 2007,2009-11-01,"May 7, 2003",,"May 30, 2013","Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00059995,2496.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
389,390,NCT00244985,Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma,,Completed,Has Results,Lymphoma,Biological: rituximab|Drug: pegylated liposomal doxorubicin hydrochloride,Complete Response Rate at 20 Weeks|Partial Response Rate at 20 Weeks|Overall Response Rate (Complete and Partial Responses) at 20 Weeks|Progression Free Survival (PFS) Rate at 2 Years|Overall Survival (OS) Rate at 2 Years,"Roswell Park Cancer Institute|Ortho Biotech, Inc.",All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1|Phase 2,42.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000447130|RPC 02-04,2005-09-01,August 2008,2012-12-01,"October 27, 2005","July 14, 2017","August 17, 2017","Roswell Park Cancer Institute, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT00244985,2648.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
390,391,NCT00761384,"High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma",HITT,Completed,No Results Available,B-cell Lymphoma,Drug: 90Y-ibritumomab,"Maximal tolerable dose (MTD) absorbed dose to the liver, safety and time to treatment failure (TTF)|Overall response (OR), complete response (CR), their duration, absorbed dose to normal organ and tumours, relapse pattern, the effect of radioimmunotherapy (RIT) in its own right as assessed by positron emission tomography (PET)",Lund University Hospital|Bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,7.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6th radioimmunotherapy prot.|EudraCT number: 2007-002762-35,2008-04-01,January 2016,2016-01-01,"September 29, 2008",,"February 19, 2016","Lund University Hospital, Lund, Sweden",,https://ClinicalTrials.gov/show/NCT00761384,2831.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
391,392,NCT00787527,SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma,,Completed,Has Results,Lymphoma,Drug: Zolinza (vorinostat)|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone,Phase I Maximum Tolerated Dose (MTD) of Vorinostat|Number of Participants With Dose Limiting Toxicity for Determination Phase I (Schedule A) MTD of Vorinostat|Phase II MTD of Vorinostat,M.D. Anderson Cancer Center|Merck Sharp & Dohme LLC,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,14.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2008-0484,2008-11-01,December 2012,2012-12-01,"November 7, 2008","September 9, 2014","September 9, 2014","UT MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00787527,1491.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
392,393,NCT03974243,Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma,,Completed,No Results Available,Non-hodgkin's Lymphoma,Drug: Chiauranib|Drug: Chidamide,dose-limiting toxicity (DLT)|Area under the concentration versus time curve (AUC)|Peak plasma concentration (Cmax)|Time of Cmax (Tmax)|Objective response rate|complete response rate|disease control rate|time to progression|Progression free survival|Duration of response|Adverse events|Any single mutation of oncogene and copy number variation in ctDNA(single gene analysis)|Mutation of polygene and copy number variation in signal pathway(multi-gene analysis),"Chipscreen Biosciences, Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,9.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CAR106,2019-07-11,"December 31, 2021",2021-12-31,"June 4, 2019",,"March 9, 2022","Beijing Cancer Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT03974243,904.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
393,394,NCT00355472,Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL,,Completed,Has Results,Adult T-Cell Leukemia and Lymphoma (ATL)|Adult Peripheral T-Cell Lymphoma (PTCL),Drug: KW-0761,Incidence of Dose-Limiting Toxicities (DLTs)|Maximum Tolerated Dose (MTD)|Pharmacokinetics-Plasma KW-0761 Concentrations|Pharmacokinetics-Pharmacokinetic Parameters of KW-0761 (AUC0-7 Days)|Pharmacokinetics-Pharmacokinetic Parameters of KW-0761 (t1/2)|Antitumor Effect|Time to Progression (TTP),"Kyowa Kirin Co., Ltd.",All,"20 Years to 69 Years   (Adult, Older Adult)",Phase 1,16.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0761-0501,2007-02-01,October 2008,2008-10-01,"July 24, 2006","September 7, 2012","October 18, 2012","Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00355472,608.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
394,395,NCT01976585,In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy,,Completed,No Results Available,Low-Grade B-cell Lymphoma,Drug: rhuFlt3L/CDX-301|Drug: Poly-ICLC,response rate|safety profile|tumor-specific immune response,Joshua Brody|Celldex Therapeutics|Icahn School of Medicine at Mount Sinai,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,21.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GCO 13-1347,2014-01-03,"November 20, 2020",2020-11-20,"November 6, 2013",,"September 22, 2022","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01976585,2513.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
395,396,NCT00078637,Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma,,Completed,No Results Available,"Neoplasms|Lymphoma, Malignant",Drug: E7820,,Eisai Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,37.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E7820-A001-102,2004-01-01,August 2006,2007-02-01,"March 5, 2004",,"December 23, 2014","San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00078637,1127.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
396,397,NCT01134341,Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma,,Completed,No Results Available,Cutaneous T-cell Lymphoma|Mycosis Fungoides|Sezary Syndrome|Primary Cutaneous Anaplastic Large Cell Lymphoma,Drug: Pralatrexate Injection|Drug: Bexarotene Capsules|Dietary Supplement: Vitamin B12|Dietary Supplement: Folic Acid,Dose Limiting Toxicity (DLT) Rate|Overall Response Rate (ORR)|Number of Patients with Treatment-related Adverse Events (AEs) and Serious AEs (SAEs)|Pharmacokinetic Parameters,Acrotech Biopharma Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,34.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PDX-018,2010-03-01,August 2015,2015-08-01,"June 2, 2010",,"December 18, 2019","Stanford University School of Medicine, Stanford, California, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Ospedale Sant'Orsola - Policlinico Sant'Orsola, Bologna, Italy",,https://ClinicalTrials.gov/show/NCT01134341,1979.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
397,398,NCT00302757,Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma,,Completed,No Results Available,Non-Hodgkin Lymphoma,Drug: Radioimmunotherapy|Procedure: allogeneic hematopoietic cell transplantation,treatment related toxicity|engraftment|disease response|relapse rate|disease free survival|overall survival|graft versus host disease (GVHD)|immunoreconstitution,University Hospital Tuebingen,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,60.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2005-002206-37,2006-03-01,,2011-07-01,"March 14, 2006",,"May 29, 2014","Medical Center Charite Benjamin Franklin, Berlin, Germany|University of Dresden Medical Center, Dresden, Germany|Center for Marrow Transplantation, University of Essen, Essen, Germany|Medical Center University of Goettingen, Goettingen, Germany|Medical Center University of Hannover, Hannover, Germany|Medical Center University of Leipzig, Leipzig, Germany|Medical Center University of Muenster, Muenster, Germany|South West German Cancer Center, University of Tuebingen Medical Center, Tuebingen, Germany|Medical Center University of Ulm, Ulm, Germany|Stiftung Deutsche Klinik für Diagnostik GmbH, Wiesbaden, Germany|University of Wuerzburg Medical Center, Wuerzburg, Germany",,https://ClinicalTrials.gov/show/NCT00302757,1948.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
398,399,NCT00061880,BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma,,Completed,No Results Available,Lymphoma,Drug: forodesine hydrochloride,,BioCryst Pharmaceuticals|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,,Industry,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,BIOCRYST-1777BC-103|CDR0000301763,2003-02-01,January 2005,2008-01-01,"June 6, 2003",,"May 30, 2013","University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00061880,1795.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
399,400,NCT00412321,"A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease",,Completed,No Results Available,"Lymphoma, Non-Hodgkin|Multiple Myeloma|Giant Lymph Node Hyperplasia",Drug: CNTO 328,Number of Patients With Adverse Events as a Measure of Safety and Tolerability|Serum Concentration of CNTO 328|Pharmacodynamics of CNTO 328|Plasma antibodies to CNTO 328|Number of participants with Castleman's disease who achieved tumor response|Number of participants with multiple myeloma who achieved disease response|Number of participants with B-cell non-Hodgkin's lymphoma and multiple myeloma who achieved clinical benefit (CB)|Number of participants with Castleman's disease who achieved clinical benefit|Number of participants with B-cell non-Hodgkin's lymphoma who achieved disease response,"Centocor, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,67.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR008566|C0328T03,2005-05-01,April 2011,2011-04-01,"December 18, 2006",,"July 1, 2014","Little Rock, Arkansas, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Box 302, New York, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00412321,2161.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
400,401,NCT00572013,Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma,,Completed,No Results Available,Lymphoma,Drug: Rituxan|Drug: BEAM|Procedure: Autologous stem cell transplant,response rate|overall survival,University of Nebraska,All,"19 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,32.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,138-98|IRB#138-98,1998-05-01,January 2001,2009-09-01,"December 12, 2007",,"January 17, 2018","University of Nebraska Medical Center, Section of Oncology/Hematology, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT00572013,4141.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
401,402,NCT00031642,Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma That Has Relapsed After High-Dose Chemotherapy and Autologous Stem Cell Transplantation,,Completed,No Results Available,Lymphoma,Biological: rituximab|Radiation: yttrium Y 90 ibritumomab tiuxetan,Maximum tolerated dose|Safety and efficacy,University of Nebraska|Biogen,All,"19 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,26.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,535-00|CDR0000069211|NCI-V02-1691,2002-01-01,November 2005,2008-03-01,"January 27, 2003",,"December 17, 2013","UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT00031642,2251.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
402,403,NCT00052442,10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma,,Completed,Has Results,Lymphoma,Drug: pralatrexate,Response Rate|Toxicities of Pralatrexate,"Spectrum Pharmaceuticals, Inc|National Cancer Institute (NCI)|Memorial Sloan Kettering Cancer Center",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,72.0,Industry|NIH|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000258425|MSKCC-02078|NCI-H02-0100,2002-08-01,March 2009,2009-03-01,"January 27, 2003","August 25, 2021","August 25, 2021","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00052442,2404.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
403,404,NCT03010982,"Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors",,Completed,No Results Available,Diffuse Large B Cell Lymphoma|Primary Mediastinal Lymphoma|Mantle-Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Advanced Solid Tumors,Drug: Tazemetostat and [14C] Tazemetostat,"Plasma PK of [14C] tazemetostat, tazemetostat, and its metabolite EPZ-6930 after IV administration of approximately 12 µg of [14C] tazemetostat containing approximately 500 nCi of radioactivity and oral BID administration of 800 mg tazemetostat (AUC 0-7)|Total recovery and relative excretion of radioactivity in urine and feces after an oral 800 mg dose of [14C] tazemetostat containing approximately 400 µCi (14.8 MBq) of radioactivity|Estimate tazemetostat absolute bioavailability (F) after repeated oral administration of 800 mg BID (AUC 0-12 and AUC 0-~)|Compare the total radioactivity concentration-time profiles in blood and plasma after oral administration of [14C] tazemetostat (AUC 0-t, AUC 0-12, AUC 0-~)|Determine peak plasma concentration (Cmax) after oral administration of [14C] tazemetostat|Determine the plasma terminal half-life (t1/2) after oral administration of [14C] tazemetostat|Plasma PK of tazemetostat and EPZ6930 after administration of an oral 800 mg dose of [14C] tazemetostat containing approximately 400 µCi (14.8 MBq) of radioactivity (Plasma AUC 0-t, AUC 0-12)|Determine the peak plasma concentration (Cmax) of tazemetostat and EPZ6930 after administration of an oral 800 mg dose of [14C] tazemetostat containing approximately 400 µCi (14.8 MBq) of radioactivity|Determine the time to peak plasma concentration (Tmax) tazemetostat and EPZ6930 after administration of an oral 800 mg dose of [14C] tazemetostat containing approximately 400 µCi (14.8 MBq) of radioactivity","Epizyme, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,3.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EZH-103,2018-06-20,"January 8, 2019",2019-01-08,"January 5, 2017",,"January 13, 2020","The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom|Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, United Kingdom",,https://ClinicalTrials.gov/show/NCT03010982,202.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
404,405,NCT02243436,Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma,,Completed,No Results Available,CLASSICAL HODGKIN LYMPHOMA,Drug: Brentuximab Vedotin|Drug: Etoposide|Drug: Soludomerin|Drug: Cisplatin|Drug: Ara C,Recommended dose|Global response rate prior to ASCT|Complete response|Toxicity according to the CTC criteria|Stem cell mobilization capacity|Transplant-related mortality (TRM)|Overall Survival (OS)|Progression free survival (PFS)|Event-Free Survival|Time to HL Progression|Disease-Free Survival|Response Duration|Lymphoma-Specific Survival|Time to Next Treatment,"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Millennium Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,67.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BRESHAP-GELTAMO.LH-2013|2014-000835-17,2014-11-11,January 2019,2019-01-14,"September 18, 2014",,"April 24, 2019","Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Son Espases, Palma, Islas Baleares, Spain|Hospital del Mar, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Clínico de Valencia, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT02243436,1525.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
406,407,NCT00888927,Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma,,Completed,Has Results,Peripheral T-Cell Lymphoma,Biological: KW-0761,Maximum Tolerated Dose|Overall Response Rate (ORR),"Kyowa Hakko Kirin Pharma, Inc.|Kyowa Kirin, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,42.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KW-0761-001,2009-05-01,September 2012,2012-09-01,"April 28, 2009","December 29, 2020","December 29, 2020","Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|Stanford Medical Center, Stanford, California, United States|Yale Comprehensive Cancer Center, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|M.D.Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00888927,1219.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
407,408,NCT00989586,Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma,,Completed,Has Results,Lymphoma,"Biological: milatuzumab|Biological: veltuzumab|Procedure: Correlative/Special Studies|Procedure: Quantitative T-, B-, and NK cell subsets|Procedure: Pharmacokinetics|Procedure: Human Anti-Human Antibodies|Biological: veltuzumab and milatuzumab","Dose Limiting Toxicity (DLT) for Phase I Patients|Maximum Tolerated Dose (MTD)for Phase I Patients|Overall Objective Response Rate|Progression-free Survival (PFS)|Fcγ-receptor Polymorphism Response to Treatment|Quantitative T-, B-, and NK-cell Subsets Using Flow Cytometry|Access Pharmacokinetics Through AUC0-∞ (Area Under Curve)|Access Pharmacokinetics Through Cmax|Monitor Human Anti-veltuzumab Antibodies and Human Anti-milatuzumab (HAHA)",Beth Christian|Gilead Sciences|Ohio State University Comprehensive Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,35.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSU-09024|NCI-2011-03150,2009-09-01,April 2015,2015-09-01,"October 5, 2009","February 6, 2017","February 6, 2017","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00989586,2191.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
408,409,NCT00322608,Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma,,Completed,No Results Available,Cancer,Drug: NPI-2358,Safety|Tolerability|Maximum tolerated dose (MTD)|Pharmacokinetics|Pharmacodynamics|Response Evaluation Criteria in Solid Tumors (RECIST),"Nereus Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,35.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NPI-2358-100,2006-04-01,September 2009,2009-12-01,"May 8, 2006",,"January 10, 2011","Barbara Ann Karmanos Cancer Institute/Wayne State University, Detroit, Michigan, United States|Institute for Drug Development, San Antonio, Texas, United States|Northwest Medical Specialties, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT00322608,1340.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
409,410,NCT01622439,Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma,VALFRID,Completed,No Results Available,Diffuse Large B-cell Lymphoma,Drug: Valproate|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone,Establishment of maximum tolerable dose of valproate.,Lund University Hospital|Valcuria,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,50.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Version1.1,2012-06-01,March 2018,2018-03-01,"June 19, 2012",,"March 12, 2018","Skåne University Hospital, Dept. of Oncology, Lund, Sweden",,https://ClinicalTrials.gov/show/NCT01622439,2099.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
410,411,NCT00285428,Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma,,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: hA20-humanized anti-CD20 antibody,Safety and tolerance of different dose levels|Lack of immunogenicity|Pharmacodynamics|Pharmacokinetics|Efficacy,Gilead Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,82.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IM-T-hA20-01,2004-09-01,October 2007,2007-10-01,"February 2, 2006",,"August 17, 2021","New York Presbyterian Hospital/Cornell Medical Center, New York, New York, United States|University Hospital of Pennsylvania, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00285428,1125.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
411,412,NCT03892421,Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma,,Completed,No Results Available,Relapsed Non Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma,Drug: Rituximab|Drug: Carboplatin|Drug: Cytarabine Injection|Drug: Dexamethasone|Drug: Filgrastim 0.3 MG/ML,Overall Response Rate|Incidence of hematological toxicities > grade 2 by Common Terminology Criteria V4.0|Overall Survival|Progression Free Survival,La Raza Medical Center,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,22.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R-2018-3501-014,2018-04-05,"January 30, 2021",2021-04-30,"March 27, 2019",,"May 18, 2021","Hospital Especialidades Centro Medico La Raza, Mexico City, Azcapotzalco, Mexico",,https://ClinicalTrials.gov/show/NCT03892421,1121.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
413,414,NCT03107663,⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma,,Completed,No Results Available,Positron-Emission Tomography|Immunomodulation|Metastatic Solid Malignancies|Hodgkin Lymphoma,Drug: ⁸⁹Zr-Df-IAB22M2C Infusion,"Safety and tolerability of ⁸⁹Zr-Df-IAB22M2C assessed by local and systemic signs and symptoms of infusion reactions,incidence of adverse events,changes in laboratory test results,dose limiting toxicities,vital signs and 12-lead electrocardiogram findings|Evaluate imaging time window with ⁸⁹Zr-Df-IAB22M2C|Evaluate protein dose for imaging with ⁸⁹Zr-Df-IAB22M2C|Evaluate the radioactive pharmacokinetics of ⁸⁹Zr-Df-IAB22M2C by determining the time-activity curves for serum (% injected dose/liter), AUC, clearance, volume of distribution, Tmax and Cmax.|Evaluate the dosimetry of a single dose of ⁸⁹Zr-Df-IAB22M2C","ImaginAb, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,15.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2015-22M2C-01.02,2017-06-19,"August 16, 2018",2018-08-16,"April 11, 2017",,"September 18, 2018","Honor Health and Imaging Endpoints, Scottsdale, Arizona, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03107663,423.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
414,415,NCT01351935,"Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia",,Completed,No Results Available,B Cell Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia|Waldenstrom Macroglobulinemia,Drug: AVL-292,"Safety, tolerability,and dose limiting toxicities will be determined using AEs,PE,ophthalmologic examinations,clinical laboratory tests,vital signs, ECGs and echocardiograms/MUGA scans.|Establish recommended Phase 2 dose, after completing dose escalation in Part 1 and evaluating accumulated safety,PK,and PD data from the dose escalation phase (Part1)|Evaluate the Pharmacokinetic parameters of AVL-292|Evaluate the Pharmacodynamics of AVL-292 by measurement of free Btk|Characterize preliminary anti-tumor efficacy of AVL-292 in relapsed and/or refractory B-NHL, CLL and WM",Celgene|The Leukemia and Lymphoma Society,All,"18 Years and older   (Adult, Older Adult)",Phase 1,113.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVL-292-003,2011-07-18,"June 26, 2015",2015-06-26,"May 11, 2011",,"November 8, 2019","Clearview Cancer Institute Oncology Specialties, P.C, Huntsville, Alabama, United States|University of Arizona SPORE, Tucson, Arizona, United States|University of California San Diego, La Jolla, California, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Northwestern University, Chicago, Illinois, United States|Horizon Oncology Center, Lafayette, Indiana, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mount Sinai School of Medicine and Mount Sinai Graduate School of Biological Sciences, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Texas Health Sciences Center, San Antonio, Texas, United States|US Oncology, The Woodlands, Texas, United States",,https://ClinicalTrials.gov/show/NCT01351935,1439.0,Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
415,416,NCT00445341,Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma,,Completed,Has Results,Lymphoma,Drug: Flavopiridol,Number of Participants With Adverse Events (e.g. Toxicity)|Response Rate (Complete Response (CR) and Partial Response (PR)),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,28.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,070081|07-C-0081,2006-11-27,"April 30, 2012",2012-10-18,"March 9, 2007","October 5, 2012","January 30, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT00445341/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT00445341/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT00445341,2152.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
416,417,NCT00374699,Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas,,Completed,No Results Available,Peripheral T-Cell Lymphomas|Non-Hodgkin Lymphoma,Drug: Velcade,To define the dose-limiting toxicity and maximum tolerable dose|To evaluate the overall response rate|To evaluate the safety and tolerability of the treatment combination|To estimate the time to progression and the duration of overall response,Samsung Medical Center|Janssen Medical Affairs,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,55.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2005-07-021,2006-04-01,September 2009,2009-10-01,"September 11, 2006",,"October 14, 2009","Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00374699,1279.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
417,418,NCT01582776,Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma,,Completed,No Results Available,Follicular Lymphoma Patients (Phase IB)|Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II),Drug: Lenalidomide and GA101,Phase I part: Determination of the recommended dose of lenalidomide in combination with fixed doses of GA101|Phase II part: Overall Response Rate (CR+CRu+PR) after 6 cycles|Overall survival (OS)|Event Free survival|Progression free survival|Response duration|Response rate at the end of maintenance treatment|Complete response rate after induction|Complete response rate after 3 cycles,The Lymphoma Academic Research Organisation,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,317.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GALEN,2012-10-03,"July 11, 2018",2022-05-20,"April 23, 2012",,"March 17, 2023","ZNA Stuivenberg, Antwerpen, Belgium|A.Z. Sint Jan AV, Bruges, Belgium|institut Jules Bordet, Bruxelles, Belgium|Université Catholique de Louvain Saint Luc, Bruxelles, Belgium|AZ Groeninge - Campus Maria's Voorzienigheid, Kortrijk, Belgium|CHU de Liège, Liège, Belgium|Université Catholique de Louvain Mont Godinne, Yvoir, Belgium|CHU d'Amiens, Amiens, France|Institut Bergonié, Bordeaux, France|Institut d'Hématologie de Basse Normandie, Caen, France|CHU d'Estaing, Clermont-Ferrand, France|Hôpital Henri Mondor, Créteil, France|CHU de Dijon, Dijon, France|CHU de Grenoble, Grenoble, France|CHRU de Lille, Lille, France|Centre Léon Bérard, Lyon, France|Institut Paoli Calmette, Marseille, France|CHU St Eloi, Montpellier, France|CHU Brabois, Nancy, France|CHU Hôtel Dieu, Nantes, France|Hôpital St Louis, Paris, France|Centre François Magendie, Pessac, France|CH Lyon Sud, Pierre Bénite, France|CHU Pontchaillou, Rennes, France|Centre henri Becquerel, Rouen, France",,https://ClinicalTrials.gov/show/NCT01582776,3516.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
418,419,NCT01309789,A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms,,Completed,No Results Available,"Lymphoma, Large-Cell, Anaplastic|Lymphoma, NK-cell|Lymphoma, T-cell",Drug: brentuximab vedotin|Drug: cyclophosphamide|Drug: prednisone|Drug: doxorubicin|Drug: vincristine,Incidence of adverse events and laboratory abnormalities|Brentuximab vedotin concentration in blood|Antitherapeutic antibodies in blood|Best clinical response|Progression-free survival|Overall survival,"Seagen Inc.|Millennium Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,39.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SGN35-011|2010-022839-11,2011-02-01,April 2013,2017-02-28,"March 7, 2011",,"June 28, 2017","UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|City of Hope National Medical Center, Duarte, California, United States|Stanford Cancer Center, Stanford, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|St. Francis Hospital, Greenville, South Carolina, United States|MD Anderson Cancer Center / University of Texas, Houston, Texas, United States|Seattle Cancer Care Alliance / University of Washington Medical Center, Seattle, Washington, United States|Christie Hospital NHS Foundation Trust, Manchester, United Kingdom|Southampton General Hospital, Southampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT01309789,2219.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
419,420,NCT00477412,"Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma",,Completed,Has Results,Mantle Cell Lymphoma,Drug: Bortezomib|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dexamethasone|Drug: Doxorubicin|Drug: Methotrexate|Biological: Rituximab|Drug: Vincristine,Maximum Tolerated Dose of Bortezomib (Phase I)|Time to Failure (Phase II)|Number of Participants With Overall Response Rate|Overall Survival,M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 1|Phase 2,107.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2006-0697|NCI-2018-01851,2007-04-03,"October 28, 2020",2020-10-28,"May 23, 2007","January 28, 2022","January 28, 2022","M D Anderson Cancer Center, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT00477412/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT00477412,4957.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
420,421,NCT01555242,A Study of Aneustat (OMN54) in Patients With Advanced Cancer and Lymphomas,,Completed,No Results Available,Neoplasms,Drug: Aneustat (OMN54),Maximum Tolerated Dose (MTD) of two dosing regimens (once daily and twice daily)|Dose Limiting Toxicity (DLT) of two dosing regimens (once daily and twice daily)|Plasma blood concentrations of chemical markers|Tumor Response|Measurement of pathway biomarkers in plasma,"Omnitura Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,22.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OMN54-101,2012-08-01,January 2014,2014-01-01,"March 15, 2012",,"April 8, 2015","BC Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT01555242,518.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
421,422,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,,Completed,Has Results,Diffuse Large B Cell Lymphoma Relapsed|Diffuse Large B Cell Lymphoma Refractory,Drug: Ibrutinib|Drug: DA-EPOCH-R|Drug: Lenalidomide,Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability|Number of Participants With Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy-ORR|Number of Participants With Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy|Number of Subjects With Adverse Events as a Measure of Safety and Tolerability|Progression Free Survival (PFS) and Overall Survival (OS) as a Measure of Efficacy|Duration of Response (DOR),Pharmacyclics LLC.|Celgene Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,35.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PCYC-1124-CA,2014-05-01,August 2017,2017-08-01,"May 20, 2014","February 5, 2019","February 5, 2019","SITE-1, Duarte, California, United States|SITE-2, Los Angeles, California, United States|SITE-10, Orange, California, United States|SITE-3, Chicago, Illinois, United States|SITE-5, Baltimore, Maryland, United States|SITE-6, Bethesda, Maryland, United States|SITE-4, Ann Arbor, Michigan, United States|SITE-8, Albuquerque, New Mexico, United States|SITE-9, Stony Brook, New York, United States|SITE-7, Charleston, South Carolina, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02142049/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02142049/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02142049,1188.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
422,423,NCT00571493,"VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma",,Completed,Has Results,Non-hodgkin's Lymphoma|Mantle Cell Lymphoma,"Drug: Bortezomib|Drug: BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)","Maximum Tolerated Dose (MTD) of Bortezomib|Preliminary Estimate of Overall Response Rate (ORR)|Progression-free Survival (PFS), and Overall Survival (OS)","University of Nebraska|Millennium Pharmaceuticals, Inc.",All,"19 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,42.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,438-05|IRB 438-05|Protocol# X05184,2006-04-01,November 2014,2014-11-01,"December 12, 2007","July 26, 2018","August 22, 2018","University of Nebraska Medical Center, Section of Oncology/Hematology, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT00571493,3136.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
423,424,NCT00407303,Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL),,Completed,No Results Available,Mantle-Cell Lymphoma,Drug: Obatoclax mesylate|Drug: Bortezomib,Determine the response rate to obatoclax in combination with Bortezomib and characterize the safety profile|Peripheral blood counts; Bone marrow aspirates and biopsies; Transfusion and growth factor requirements,"Gemin X|Teva Branded Pharmaceutical Products R&D, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,24.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GEM012,2006-10-01,March 2009,2009-11-01,"December 5, 2006",,"July 21, 2016","NW Georgia Oncology Centers, Marietta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Medical Center, Buffalo, New York, United States|University of Wisconsin, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00407303,1127.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
424,425,NCT03343665,Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma,Nivo40,Completed,No Results Available,Hodgkin Lymphoma,Drug: Nivolumab 40 mg in 4 ml Injection,Overall Response Rate (ORR)|Frequency of grade 3 or higher treatment-related adverse events by CTCAE 4.03|Duration of Response (DOR)|Progression-Free Survival (PFS)|Overall Survival (OS),St. Petersburg State Pavlov Medical University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,30.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,№30/17-н,2017-08-01,"December 20, 2019",2019-12-20,"November 17, 2017",,"January 23, 2020","First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation",,https://ClinicalTrials.gov/show/NCT03343665,871.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
425,426,NCT01389427,"Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).",T³,Completed,No Results Available,Mantle Cell Lymphoma Refractory,Drug: Torisel dose 15 mg and R-CHOP|Drug: Torisel dose 15 mg and R-FC|Drug: Torisel dose 15 mg and R-DHA|Drug: Torisel dose 25 mg and R-CHOP|Drug: Torisel dose 50 mg and R-CHOP|Drug: Torisel dose 75 mg and R-CHOP|Drug: Torisel dose 25 mg and R-FC|Drug: Torisel dose 50 mg and R-FC|Drug: Torisel dose 75 mg and R-FC|Drug: Torisel dose 25 mg and R-DHA|Drug: Torisel dose 50 mg and R-DHA|Drug: Torisel 75 mg and R-DHA,Incidence of Dose Limiting Toxicities (DLT)|Complete Response Rate(CR) after 4 cycles and at the end of treatment|Progression-free survival (PFS)|Duration of Response|Overall Response at the end of treatment|Overall Survival (OS)|Safety of association Temsirolimus with the three chemotherapy regimens,The Lymphoma Academic Research Organisation|French Innovative Leukemia Organisation,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,41.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,T³,2011-11-01,May 2015,2015-09-01,"July 8, 2011",,"March 9, 2017","CHU de Grenoble MICHALLON, Grenoble Cedex 9, Hôpital Nord 217, France|Hôtel Dieu - Université de Nantes, Nantes cedex, Place Alexis Ricordeau, France|Hôpital Henri Mondor, Creteil, France|CHU de Dijon, Dijon, France|Hôpital Saint-Eloi, Montpellier, France|Hôpital Saint Louis, Paris, France|Hôpital Necker, Paris, France|Groupe hospitalier Sud Hôpital Haut-Lévêque, Pessac, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|CHU Pontchaillou, Rennes, France|CHU de Tours - Hôpital Bretonneau, Tours, France",,https://ClinicalTrials.gov/show/NCT01389427,1400.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
426,427,NCT04171791,A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL),,Completed,No Results Available,CTCL,Drug: ABT-199 (venetoclax),Body Temperature|Blood Pressure- Diastolic|Blood Pressure- Systolic|Pulse Rate|Respiratory Rate|Adverse Events|Skin Clinical Response|Duration of Response|Relapse Free and Progression Free Survival,Yale University,All,"18 Years and older   (Adult, Older Adult)",Phase 1,4.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2000022803,2020-01-15,"February 10, 2021",2021-06-22,"November 21, 2019",,"June 25, 2021","Yale New Haven Hospital / Smilow Cancer Center, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT04171791,524.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
427,428,NCT03141203,Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients,RomiCar,Completed,No Results Available,Peripheral T Cell Lymphoma,Drug: Romidepsin|Drug: Carfilzomib,"Maximum Tolerated Dose of the combination of romidepsin and carfilzomib|Best overall response rate (PR + CR) at the MTD|Toxicity of the combination of romidepsin and carfilzomib|Best overall response at the MTD|Maximum percentage change in the radiological sum of the product of the diameters from baseline, assessed using the Revised Response Criteria for Malignant Lymphoma|Duration of response from time of first documented response until relapse or progression|Progression free survival|Overall survival",University of Birmingham|Bloodwise|Celgene|Amgen,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,50.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RG_13-107|2013-001879-20,2015-07-13,August 2020,2021-09-23,"May 5, 2017",,"May 18, 2022","Queen Elizabeth Hospital, Birmingham, United Kingdom|St James's University Hospital, Leeds, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Clatterbridge Cancer Centre, Liverpool, United Kingdom|Guy's Hospital, London, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Nottingham University Hospitals, Nottingham, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom",,https://ClinicalTrials.gov/show/NCT03141203,2264.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
428,429,NCT01336920,Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma,,Completed,No Results Available,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma,Drug: carfilzomib,"MTD of carfilzomib, determined by incidence of dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0",University of Nebraska|National Cancer Institute (NCI)|Amgen,All,"19 Years and older   (Adult, Older Adult)",Phase 1,15.0,Other|NIH|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,518-10|NCI-2010-02257|P50CA136411|P30CA036727,2011-06-01,April 2015,2018-03-01,"April 18, 2011",,"July 27, 2018","Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01336920,2465.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
429,430,NCT01657331,Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL),SGN+Benda,Completed,No Results Available,Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma,Drug: Brentuximab Vedotin|Drug: Bendamustine|Drug: Neulasta,Maximum tolerated dose (MTD) of brentuximab vedotin and bendamustine (phase 1)|Dose limiting toxicities (DLT) of brentuximab vedotin and bendamustine (phase 1)|Overall Response Rate for the combination of brentuximab vedotin and bendamustine (phase 2)|Duration of Response (DoR) (phase 1)|Progression free survival (PFS) (phase 1)|Overall Survival (OS) (phase 2),Columbia University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,71.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AAAJ5050,2012-07-01,April 2020,2020-04-01,"August 6, 2012",,"July 17, 2020","Center for Lymphoid Malignancies at CUMC, New York, New York, United States|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01657331,2831.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
430,431,NCT00062868,LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma,ALCI,Completed,Has Results,Hodgkin Disease|Non Hodgkin Lymphoma|Lymphoepithelioma|Leiomyosarcoma,Biological: LMP1/2 CTLs (ALCI - Group A)|Biological: LMP1/2 CTLs (ALCI - Group B)|Biological: LMP1/2 CTLs (ALCI - Group C)|Biological: LMP2 CTLs (ALSCER - Group A)|Biological: LMP2 CTLs (ALSCER - Group B)|Biological: LMP2 CTLs (ALSCER - Group C)|Biological: LMP1/2 CTLs (ALCI - Expansion - Group A)|Biological: LMP1/2 CTLs (ALCI - Expansion Group B)|Biological: LMP1/2 CTLs (ALCI - Expansion Group C),Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I)|Response Rate According to the Harmonization Project (Protocol 8.5.1) or RECIST Criteria.|Grade III-IV Toxicity Rate in Participants Receiving an Extended Dosage Regimen According to the NCI Common Toxicity Criteria (CTCAE) Version 2.0 and the Method of Przepiorka et. al. (Protocol Appendix I).,"Baylor College of Medicine|The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",All,"Child, Adult, Older Adult",Phase 1,74.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9936-ALCI-ALASCAR|ALCI|ALASCAR,2003-09-01,April 2014,2020-04-01,"June 18, 2003","February 7, 2020","June 9, 2020","Texas Children's Hospital, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00062868,6057.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
431,432,NCT02572167,A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma,,Completed,Has Results,Hodgkin Lymphoma,Drug: brentuximab vedotin|Drug: nivolumab,Number of Participants With Adverse Events (AEs)|Complete Remission Rate|Objective Response Rate|Duration of Complete Response|Duration of Objective Response|Progression-free Survival Post-autologous Stem Cell Transplant,Seagen Inc.|Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,93.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SGN35-025,2015-10-31,"March 1, 2018",2021-10-21,"October 8, 2015","March 7, 2019","November 8, 2022","City of Hope National Medical Center, Duarte, California, United States|Stanford Cancer Center, Stanford, California, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States|Mayo Clinic Minnesota, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center - Commack, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|James Cancer Hospital / Ohio State University, Columbus, Ohio, United States|Charles A. Sammons Cancer Center / Baylor University Medical Center, Dallas, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT02572167/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT02572167/SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02572167,2182.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
432,433,NCT00457782,"A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma",,Completed,No Results Available,Multiple Myeloma|Chronic Lymphocytic Leukaemia|B-cell Non-Hodgkin's Lymphoma,Drug: KW-2478,To determine Safety & Tolerability by adverse event rates in order to determine recommended Phase II dose|Pharmacokinetics and Pharmacodynamics,"Kyowa Hakko Kirin UK, Ltd.|Kyowa Kirin, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,27.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2478-EU-001,2007-04-01,August 2010,2011-01-01,"April 6, 2007",,"February 1, 2011","St Bartholomew's Hospital, London, United Kingdom|UCLH, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Nottingham University NHS Trust, Nottingham, United Kingdom|Cancer Research UK Clinical Centre, Southampton, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom",,https://ClinicalTrials.gov/show/NCT00457782,1371.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
433,434,NCT01060384,Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma,,Completed,Has Results,Non-Hodgkin's Lymphoma,Drug: Lenalidomide|Drug: ofatumumab,Phase I: Maximum Tolerated Dose (MTD) of Lenalidomide|Phase I and Phase II: Event Free Survival and Overall Survival,University of Nebraska|Celgene Corporation|GlaxoSmithKline,All,"19 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,46.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,514-09-FB,2010-03-01,"October 25, 2016",2018-01-01,"February 2, 2010","August 8, 2018","March 5, 2019","Saint Francis Medical Center, Grand Island, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT01060384,2863.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
434,435,NCT02429375,Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma,,Completed,Has Results,Hodgkin Lymphoma,Drug: Mocetinostat Plus Brentuximab Vedotin,Maximum Tolerated Dose (MTD)|Overall Response Rate (ORR),Memorial Sloan Kettering Cancer Center|MethylGene Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,7.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-232,2015-04-22,"February 17, 2021",2021-02-17,"April 29, 2015","May 12, 2022","May 12, 2022","Memorial Sloan Kettering Cancer Center, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT02429375/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02429375,2128.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
435,436,NCT02049541,Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma,,Completed,No Results Available,Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia,Drug: PI3K inhibitor BKM120|Biological: rituximab|Other: Pharmacodynamics|Other: Correlative studies,"MTD defined as the dose level at which no more than one of 6 patients experiences a DLT summarized using the National Cancer Institute (NCI) CTCAE version 4.0|Incidence of grade 3 or greater adverse events summarized using the NCI CTCAE version 4.0|Overall response rate (ORR) evaluated by computed tomography (CT) or positron emission tomography (PET)/CT|Change in correlative markers in blood, bone marrow and tumor tissue","Kami Maddocks, MD|Novartis|Ohio State University Comprehensive Cancer Center",All,"18 Years and older   (Adult, Older Adult)",Phase 1,18.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSU-13027|NCI-2014-00110,2014-07-21,"September 12, 2018",2019-04-09,"January 30, 2014",,"June 30, 2022","Emory University, Atlanta, Georgia, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02049541,1723.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
436,437,NCT02013362,Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma,,Completed,No Results Available,Peripheral T-cell Lymphoma,Drug: Pralatrexate injection|Dietary Supplement: Vitamin B12|Dietary Supplement: Folic Acid,Objective response rate (ORR) per independent central review committee,Mundipharma K.K.,All,"20 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,25.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PDX-JP1,2014-03-01,December 2015,2017-09-01,"December 17, 2013",,"November 9, 2017","National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan|National Cancer Center Hospital, Chuo, Tokyo, Japan|Okayama University Hospital, Okayama,, Japan",,https://ClinicalTrials.gov/show/NCT02013362,1280.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
437,438,NCT00575068,Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma,,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: IDEC-114,To characterize the safety profile of IDEC-114 and to define their duration and reversibility|To evaluate PK|To monitor presence of human anti galiximab antibody|To evaluate efficacy|To identify Nk functional assays that may predict galiximab efficacy,Biogen,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,42.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,114-20,2002-01-01,September 2002,2010-11-01,"December 17, 2007",,"June 8, 2012","Research Site, Tucson, Arizona, United States|Research Site, Rochester, Minnesota, United States|Research Site, Buffalo, New York, United States|Research Site, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00575068,3226.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
438,439,NCT02723071,A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL),,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: Ocrelizumab,Number of Participants With Dose-limiting Toxicity (DLT)|Progression-free Survival According to the International Workshop to Standardize Response Criteria for NHL|Event-free Survival According to the International Workshop to Standardize Response Criteria for NHL|Area Under the Plasma Concentration-Time Curve From Time 0 to Day 28 (AUC0-28) of Ocrelizumab|Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity AUC(0-inf) of Ocrelizumab|Percentage of Participants With Overall Response According to the International Workshop to Standardize Response Criteria for NHL|Maximum Plasma Concentration (Cmax) of Ocrelizumab|Systemic Clearance (CL) of Ocrelizumab|Steady State Volume of Distribution (Vss) of Ocrelizumab|Terminal Elimination Half-Life (t1/2) of Ocrelizumab|Number of Participants With Peripheral Blood B-cell Depletion|Number of Participants With Peripheral Blood B-cell Recovery,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BO18414|2004-004110-17,2005-05-01,January 2008,2008-01-01,"March 30, 2016",,"March 30, 2016","Melbourne, Australia|Perth, Australia|Woolloongabba, Australia|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Halifax, Nova Scotia, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Creteil, France|Lille, France|Nantes, France|Pierre Benite, France|Rennes, France|Bergamo, Italy|Roma, Italy|Torino, Italy|Huddinge, Sweden|Lund, Sweden|Malmoe, Sweden|Umea, Sweden|Bern, Switzerland|Geneve, Switzerland|Lugano, Switzerland",,https://ClinicalTrials.gov/show/NCT02723071,975.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
439,440,NCT01983969,Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma,,Completed,Has Results,Advanced Cancers|Lymphoma,Drug: Azacitidine|Drug: Vorinostat|Drug: Gemcitabine|Drug: Busulfan|Drug: Melphalan|Drug: Dexamethasone|Other: Caphosol|Drug: Glutamine|Drug: Pyridoxine|Drug: Rituximab,Frequency of DLT|Participants With Event-free Survival (EFS),M.D. Anderson Cancer Center,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,61.0,Other,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013-0186|NCI-2014-01025,2013-11-07,"November 22, 2017",2017-11-22,"November 14, 2013","January 27, 2020","January 27, 2020","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT01983969/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01983969,1476.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
440,441,NCT02920697,Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma,,Completed,No Results Available,Chronic Lymphocytic Leukaemia (CLL)|B-Cell Non-Hodgkin Lymphoma (NHL)|Multiple Myeloma (MM),Drug: S 55746,Maximum Tolerated Dose (MTD)|Incidence of Adverse Events (AEs)|Plasma concentration of S 55746|The pharmacokinetic (PK) profile of S 55746: Area Under the Curve [AUC]|The PK profile of S 55746: Maximal Concentration [Cmax]|Apoptotic activity from blood samples|Objective Response Rate (ORR)|Clinical Benefit Rate (CBR)|Duration of response|Progression Free Survival (PFS),"Institut de Recherches Internationales Servier|ADIR, a Servier Group company|Servier",All,"18 Years and older   (Adult, Older Adult)",Phase 1,65.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CL1-55746-001|2013-003779-36|ISRCTN04804337,2014-03-01,"October 22, 2018",2018-10-22,"September 30, 2016",,"November 25, 2019","The Alfred Hospital Malignant Haematology & Stem Cell Transplantation Services, Melbourne, Australia|Hopital Claude Huriez, Lille, France|CHU de Nantes, Nantes, France|Centre hospitalier Lyon Sud, Pierre-Bénite, France|Gustave Roussy, Villejuif, France|Universitätsklinikum Carl Gustav Carus, Dresden, Germany|Städtisches Klinikum Schwabing, Munich, Germany|Universitätsklinikum Ulm, Ulm, Germany|National Oncology Institute, Budapest, Hungary|CRU Hungary Kft, Miskolc, Hungary|Severance Hospital, Seoul, Korea, Republic of|St. Mary's Hospital, Seoul, Korea, Republic of|Warsaw Institute of Oncology, Warsaw, Poland|Warsaw Medical University, Warsaw, Poland|National Cancer Center (NCC), Singapore, Singapore|National University Cancer Institute Singapore, Singapore, Singapore|University College London Hospitals, London, United Kingdom|Freeman Hospital, Newcastle, United Kingdom",,https://ClinicalTrials.gov/show/NCT02920697,1696.0,Not Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
441,442,NCT00186589,90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL,,Completed,No Results Available,"Lymphoma, Non-Hodgkin|Blood and Marrow Transplant (BMT)",Drug: 90Y Ibritumomab tiuxetan,Complete Response,Stanford University|Biogen|National Institutes of Health (NIH),All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,30.0,Other|Industry|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BMT134|80109,2004-05-01,July 2007,2007-07-01,"September 16, 2005",,"June 6, 2012","Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT00186589,1156.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
442,443,NCT02926833,Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL),ZUMA-6,Completed,Has Results,Refractory Diffuse Large B Cell Lymphoma,Biological: KTE-C19|Biological: Atezolizumab|Drug: Cyclophosphamide|Drug: Fludarabine,"Phase 1: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)|Phase 1 and 2: Complete Response Rate (CRR)|Phase 1 and 2: Objective Response Rate (ORR)|Phase 1 and 2: Duration of Response (DOR)|Phase 1 and 2: Progression-Free Survival (PFS)|Phase 1 and 2: Overall Survival (OS)|Phase 1 and 2: Percentage of Participants Experiencing Adverse Events (AEs)|Phase 1 and 2: Percentage of Participants With Serum Chemistry Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Values|Phase 1 and 2: Percentage of Participants With Serum Chemistry Toxicity Grade Shifts to Grade 3 or Higher Resulting From Decreased Parameter Values|Phase 1 and 2: Percentage of Participants With Hematology Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Values|Phase 1 and 2: Percentage of Participants With Hematology Toxicity Grade Shifts to Grade 3 or Higher Resulting From Decreased Parameter Values|Phase 1 and 2: Peak Anti-CD19 CAR T-Cell (KTE-C19) Level (Maximum Observed Plasma Concentration) in Blood|Phase 1 and 2: Percentage of Participants With Anti-KTE-C19 Antibodies|Phase 1 and 2: Atezolizumab Levels in Blood|Phase 1 and 2: Percentage of Participants With Anti-Atezolizumab Antibodies|Phase 1 and 2: Peak Serum Levels of C-Reactive Protein (CRP) in Blood|Phase 1 and 2: Peak Serum Levels of C-X-C Motif Chemokine 10 (CXCL10), Interferon-Gamma (IFN-γ), Interleukin-1 Receptor Antagonist (IL-1RA), Interleukin (IL)-2, IL-6, IL-8, IL-15, and Tumor Necrosis Factor-Alpha (TNF-α) in Blood|Phase 1 and 2: Peak Serum Levels of Ferritin in Blood|Phase 1 and 2: Peak Serum Levels of Interleukin-2 Receptor Alpha (IL-2Rα) in Blood","Kite, A Gilead Company|Genentech, Inc.|Gilead Sciences",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,37.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KTE-C19-106,2016-09-29,"February 21, 2019",2023-01-12,"October 6, 2016","June 26, 2020","February 2, 2023","City of Hope, Duarte, California, United States|Stanford Cancer Center, Palo Alto, California, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02926833/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02926833/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02926833,2296.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
443,444,NCT02340936,"Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma",,Completed,No Results Available,Diffuse Large B-cell Lymphoma,Drug: LR-ESHAP (lenalidomide 5 mg)|Drug: LR-ESHAP (lenalidomide 10 mg)|Drug: LR-ESHAP (lenalidomide 15 mg)|Drug: LR-ESHAP (lenalidomide 20 mg),"Phase I of the study: to evaluate the safety and the maximum-tolerated dose (MTD) of the combination R-ESHAP with lenalidomide as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma (determine maximum tolerated dose)|Phase II of the study: Phase II: to evaluate ORR of LR-ESHAP in patients with relapsed or refractory DLBCL candidates to HDT and ASCT (determine the overall response rate)|Phase I of the study: to analyze the adverse events of LR-ESHAP (frequency and severity of the adverse events)|Phase I of the study: preliminarily analyze effectiveness (response rates (CR and PR), duration of response and survival (DFS and OS)|Phase I of the study: evaluate haematopoietic progenitor cells mobilization after treatment with LR-ESHAP (Evaluate CD34+ cell count)|Phase I of the study: evaluate hematologic recovery after HSCT (recovery of blood parameters)|Phase II of the study: analyze effectiveness (Complete remission (CR) rate (determined by positron emission tomography [PET]/CT), event-free survival (EFS) and overall survival (OS)|Phase II of the study: rate of transplanted patients (number of patients that undergo HSCT)|Phase II of the study: to analyze the adverse events of LR-ESHAP and ASCT. (frequency and severity of the adverse events)|Phase II of the study: evaluate mobilization after treatment with LR-ESHAP (number of stem cells (2 x 106/Kg Hematopoietic progenitor cell antigen (CD34)+ cells) collected after the salvage therapy.)|Phase II of the study: influence of clinical and biological prognostic factors on response rates and survival (influence of clinical and biological (such as cell of origin) prognostic factors on response rates and survival.)","Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Celgene Corporation|Dynamic Science S.L.|Thermo Fisher Scientific, Inc",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,53.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LR-ESHAP,2011-01-01,September 2016,2019-02-20,"January 19, 2015",,"January 10, 2020","ICO- Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|ICO- Hospital Duran i Reynals, L´Hospitalet de Llobregat, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Alejandro Martín, Salamanca, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitario La Fe, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT02340936,2972.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
444,445,NCT01280526,A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas,Ro-CHOP,Completed,No Results Available,Peripheral T Cell Lymphoma,Drug: Romidepsin and CHOP,Incidence of Dose Limiting Toxicities|Complete Response Rate(CR) at the end of treatment|Progression-free survival (PFS)|Duration of Response|Safety of association Romidepsin-CHOP|Overall Response at the end of treatment|Overall Survival (OS),The Lymphoma Academic Research Organisation,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,37.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Ro-CHOP,2011-01-01,November 2012,2014-03-01,"January 20, 2011",,"May 22, 2014","Hôpital Henri Mondor, Créteil, France|CHU de Dijon, Dijon, France|Hôpital Claude Huriez, Lille, France|Centre Léon Bérard, Lyon cedex 8, France|Hôpital St Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, France|Centre Henri Becquerel, Rouen, France|Institut Gustave Roussy, Villejuif, France",,https://ClinicalTrials.gov/show/NCT01280526,1155.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
445,446,NCT01456039,"A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)",,Completed,Has Results,"Lymphoma, T-cell, Peripheral",Drug: Romidepsin,"Number of Participants With Dose-limiting Toxicity (DLT) in Accordance With National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 as Determined by the Efficacy and Safety Evaluation Committee (ESEC)|Percentage of PTCL Participants With an Overall Best Response in Accordance With a Modified International Workshop Response Criteria (IWC) 1999 in Phase 2|Participants With Treatment-Emergent Adverse Events (TEAEs) Associated With Romidepsin|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Romidepsin in Phase 1|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Romidepsin in Phase 1|Maximum Plasma Concentration (Cmax) of Romidepsin in Phase 1|Time to Maximum Plasma Concentration of Romidepsin (Tmax) in Phase 1|Terminal Phase Half-life of Romidepsin (t½) in Phase 1|Apparent Total Clearance of Romidepsin (CL/F) of Romidepsin in Phase 1|Apparent Volume of Distribution (Vz/F) of Romidepsin in Phase 1|AUC0-t, at Steady State (ss) of Romidepsin in Phase 1 at Cycle 1, Day 15|Cmax, ss of Romidepsin in Phase 1 at Cycle 1, Day 15|Tmax,ss of Romidepsin in Phase 1 at Cycle 1, Day 15|Terminal Phase Half-life of Romidepsin (t½) in Phase 1 at Cycle 1, Day 15|AUC0-t, Accumulation Ratio of Romidepsin in Phase 1, Cycle 1|Cmax Accumulation Ratio of Romidepsin in Phase 1, Cycle 1|The Percentage of Participants With Abnormal Q-wave and T Wave Intervals|Percentage of PTCL Participants With the Best Response in Accordance With the Modified 2007 International Workshop Response Criteria as Assessed by IER|Time to Response (TTR) for PTCL Participants With at Least a PR Based on the Modified 1999 IWC as Assessed by IER|Time to Response (TTR) for PTCL Participants With at Least a PR Based on the Modified 2007 IWC as Assessed by IER|Kaplan Meier Estimate of Duration of Response (DOR) for PTCL Responders Based on the Modified 1999 IWC as Assessed by the IER.|Kaplan Meier Estimate of Duration of Response (DOR) for PTCL Responders Based on the Modified 2007 IWC as Assessed by the IER.|Kaplan Meier Estimate of Time to Progression (TTP) in PTCL Participants Based on the 1999 IWC as Assessed by IER|Kaplan Meier (K-M) Estimate of Time to Progression (TTP) in PTCL Participants Based on the Modified 2007 IWC as Assessed by IER",Celgene,All,"20 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,51.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ROMI-TCL-001,2011-12-01,"July 28, 2015",2018-12-14,"October 20, 2011","August 19, 2016","February 11, 2019","Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan|Nagoya City University Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Ehime University Hospital, To-on, Ehime, Japan|Chugoku Central Hospital, Fukuyamashi, Hiroshima, Japan|Sapporo Hokuyu Hospital, Sapporo, Hokkaido, Japan|Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan|Tokai University School of Medicine, Isehara, Kanagawa, Japan|Kochi Medical School Hospital, Nankoku, Kochi, Japan|Kinki University Hospital, Sayama, Osaka, Japan|National Cancer Center Hospital, Chuo, Tokyo, Japan|Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan|Kyushu University Hospital, Fukuoka, Japan|Kumamoto University Hospital, Kumamoto, Japan|University hospital, Kyoto prefectural University of Medicine, Kyoto, Japan|Tohoku University Hospital, Miyagi, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01456039,2570.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
446,447,NCT01453504,Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma,HD-R3i,Completed,No Results Available,Hodgkin Lymphoma,Drug: DHAP|Drug: Everolimus,Dose Limiting Toxicity Rate (DLT)|Complete Remission Rate (CR)|Adverse event rate|Tumor status (assessed by CT) after chemotherapy|Tumor status (assessed by PET) after chemotherapy,University of Cologne,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,73.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HD-R3i,2012-08-01,March 2019,2019-03-01,"October 18, 2011",,"November 8, 2019","1st Dept. of Medicine, Cologne University Hospital, Cologne, Germany",,https://ClinicalTrials.gov/show/NCT01453504,2403.0,Not Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,Not Open Label,Treatment/Diagnostic
447,448,NCT01722305,Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma,,Completed,No Results Available,"B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma|Central Nervous System Lymphoma|Intraocular Lymphoma|Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System|Recurrent Adult Diffuse Large Cell Lymphoma|Retinal Lymphoma",Drug: Dexamethasone|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Pomalidomide,"MTD of pomalidomide when given in combination with dexamethasone determined by dose-limiting toxicities graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0|Incidence of adverse events, graded according to CTCAE 4.0|Overall response rate defined as number of patients with an objective status of complete response (CR), complete response/unconfirmed (Cru), or partial response (PR) divided by total number of evaluable patients|Overall survival time|Progression-free survival",Mayo Clinic|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,29.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MC1281|NCI-2012-01948|P30CA015083,2013-04-08,"June 3, 2016",2019-07-15,"November 6, 2012",,"July 22, 2019","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Dana-Farber Harvard Cancer Center, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01722305,2289.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
448,449,NCT00062894,Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab,,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: Iodine I 131 Tositumomab,To assess the blood pharmacokinetics in patients with previously untreated or relapsed follicular or transformed follicular non-Hodgkin's lymphoma|12 patients with previously untreated or relapsed follicular or transformed follicular non-Hodgkin's lymphoma will receive a dosimetric dose of fission-derived Iodine I 131 Tositumomab,GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,12.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CCBX001-048,2003-04-01,,2007-04-01,"June 19, 2003",,"September 17, 2007","Bay Pines VA Medical Center, Bay Pines, Florida, United States|Rush Medical Center, Chicago, Illinois, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Duke University Medical Center, Durham, North Carolina, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00062894,1461.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
449,450,NCT02077166,Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,,Completed,Has Results,Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma,Drug: Ibrutinib|Drug: Lenalidomide|Drug: Rituximab,"Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)|Phase 1b: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and Discontinuations Due to TEAEs|Phase 2: Overall Response Rate (ORR)|Phase 1b: ORR|Phase 1b: Complete Response (CR) Rate|Phase 2: CR Rate|Phase 2: Duration of Response (DOR)|Phase 2: Progression Free Survival (PFS)|Phase 2: Overall Survival (OS)|Phase 2: Number of Participants With TEAEs, Serious TEAEs, and Discontinuations Due to TEAEs","Pharmacyclics LLC.|Janssen Research & Development, LLC|Celgene Corporation",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,138.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PCYC-1123-CA|2013-004341-17,2014-03-13,"December 17, 2020",2020-12-17,"March 4, 2014","February 4, 2022","February 4, 2022","University of Alabama, Birmingham, Alabama, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Cedar Sinai Medical Center, Los Angeles, California, United States|UCLA Medical Center, Los Angeles, California, United States|University of Florida, Gainesville, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Comprehensive Cancer Center of Nevada, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Summit Medical Group, Morristown, New Jersey, United States|Weill Cornell Medical Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|University of Cincinnati Health Barrett Center, Cincinnati, Ohio, United States|Mid-Ohio Oncology/ Hematology, Columbus, Ohio, United States|University of TN Medical Center, Knoxville, Tennessee, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States|Baylor Charles Sammons Cancer Center, Dallas, Texas, United States|The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States|Medical Oncology Associates, PS, Spokane, Washington, United States|Northwest Medical Specialities, PLLC, Tacoma, Washington, United States|Ziekenhuis Netwerk Antwerpen - Campus Stuivenberg, Antwerpen, Belgium|CHU Brugmann, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|Universiaetsklinikum Ulm, Ulm, Baden-Wuerttemberg, Germany|Klinikum der Universitaet Muenchen - Campus Grosshadern, Muenchen, Bayern, Germany|Klinikum rechts der Isar - Technische Universitaet Muenchen, III. Medizinische Klinik und Polyklinik, Muenchen, Bayern, Germany|Universitaetsklinikum Wuerzburg, Medizinische Klinik und Poliklinik II, Wuerzburg, Bayern, Germany|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Northwick Park Hospital, Harrow, United Kingdom|The Leeds Teaching Hospitals, Leeds, United Kingdom|Kings College Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02077166/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02077166/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02077166,2471.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
450,451,NCT02264613,ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas,,Completed,No Results Available,Solid Tumor|Lymphoma|Peripheral T-Cell Lymphoma,Drug: ALRN-6924,"Evaluate the safety and tolerability of ALRN-6924 in adult patients with advanced solid tumors or lymphomas with wild-type (WT) TP53 who are refractory to or intolerant of standard therapy, or for whom no standard therapy exists - Phase 1|Evaluate the safety and tolerability of ALRN-6924 in adult patients with advanced solid tumors or lymphomas with wild-type (WT) TP53 who are refractory to or intolerant of standard therapy, or for whom no standard therapy exists - Phase 2|Determine the maximum tolerated dose (MTD) - Phase 1|Determine Overall Response Rate - Phase 2|Determine Pharmacokinetic parameters of ALRN-6924 when administered to patients with advanced solid tumors or lymphomas|Assess additional measures of anti-tumor activity, including duration of response, progression free survival, overall survival and time to response|Assess additional pharmacologic properties, including biomarkers and immunogenicity","Aileron Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,149.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALRN-6924-1-01,2014-10-01,March 2020,2020-04-01,"October 15, 2014",,"July 14, 2020","Birmingham, Alabama, United States|Duarte, California, United States|Denver, Colorado, United States|Sarasota, Florida, United States|Tampa, Florida, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Bronx, New York, United States|New York, New York, United States|Greenville, South Carolina, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02264613,2009.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
451,452,NCT02171260,"This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas",BOLD 113,Completed,Has Results,Pediatrics|Solid Tumors,Drug: Eribulin Mesylate,Maximum Tolerated Dose (MTD) of Eribulin Mesylate|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Values|Number of Participants With Clinically Significant Vital Sign Values|Number of Participants With Clinically Significant Electrocardiogram (EKG)|T1/2: Terminal Half-life for Eribulin Mesylate|Cmax: Maximum Observed Plasma Concentration for Eribulin Mesylate|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Eribulin Mesylate|AUC 0-t: Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration for Eribulin Mesylate|AUC 0-inf: Area Under the Concentration-time Curve From Zero (Pre-dose) Extrapolated to Infinite Time for Eribulin Mesylate|CL: Clearance for Eribulin Mesylate|Vd: Volume of Distribution for Eribulin Mesylate|Number of Participants With Best Overall Response,Eisai Inc.|Children's Oncology Group,All,6 Months to 17 Years   (Child),Phase 1,23.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E7389-A001-113 (ADVL1314),2014-07-31,"January 28, 2016",2016-01-28,"June 24, 2014","December 24, 2018","January 15, 2019","Children's Hospital of Alabama, Birmingham, Alabama, United States|Childrens Hospital of Orange County, Orange, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota Cancer Center-Fairview, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02171260,546.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
452,453,NCT01004991,Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma,,Completed,Has Results,Diffuse Large B Cell Lymphoma,Biological: rituximab|Drug: cyclophosphamide|Drug: vincristine|Drug: doxorubicin|Drug: prednisone|Drug: azacytidine,Complete Response,Weill Medical College of Cornell University|Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,14.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0907010513,2010-01-01,September 2013,2016-02-01,"October 30, 2009","April 10, 2017","April 10, 2017","Weill Cornell Medical College, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01004991,2222.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
453,454,NCT01169636,"Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma",,Completed,Has Results,Hodgkin's Lymphoma,Drug: Panobinostat|Drug: Ifosfamide|Drug: Mesna|Drug: Carboplatin|Drug: Etoposide|Drug: Pegfilgrastim,Maximum Tolerated Dose (MTD) of Panobinostat + ICE|Number of Participants With Complete Remission (CR)|Percentage of Participants With Failure Free Survival (FFS),M.D. Anderson Cancer Center|Novartis,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,62.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010-0065|NCI-2012-01779,2011-01-31,"May 17, 2017",2017-05-17,"July 26, 2010","January 6, 2021","January 6, 2021","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT01169636/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01169636,2298.0,Not Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
454,455,NCT00792467,Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma,,Completed,Has Results,Hodgkin's Lymphoma,Drug: ITF2357,Objective Response Rate (ORR)|Proportion of Responders (Complete -CR- or Partial PR-)|Progression-Free Survival (PFS)|Time To Response (TTR)|Response Duration (RD):,Italfarmaco,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,24.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DSC/07/2357/31|2007-007091-41,2008-02-01,July 2010,2010-09-01,"November 18, 2008","April 19, 2021","May 11, 2021","Istituto Nazionale per la Cura e lo Studio dei Tumori, Milano, Italy",,https://ClinicalTrials.gov/show/NCT00792467,943.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
455,456,NCT01992653,"A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma",,Completed,Has Results,"Lymphoma, Non Hodgkin",Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Obinutuzumab|Drug: Polatuzumab Vedotin|Drug: Prednisolone|Drug: Prednisone|Drug: Rituximab,"Number of Participants With Adverse Events in Diffuse Large B-Cell Lymphoma (DLBCL) Population|Number of Participants With Adverse Events in Non-DLBCL Population|Number of Participants With Dose Limiting Toxicities (DLTs) in DLBCL Population|Number of Participants With DLTs in Non-DLBCL Population|Percentage of Participants With Objective Response (CR or Partial Response [PR]), as Assessed by Investigator Using Cheson Criteria for DLBCL Population|Percentage of Participants With Objective Response (CR or Partial Response [PR]), as Assessed by Investigator Using Cheson Criteria for Non-DLBCL Population|Number of Participants With Anti-Polatuzumab Vedotin Antibodies|Number of Participants With Anti-Obinutuzumab Antibodies|Area Under the Concentration-Time Curve (AUC) of Polatuzumab Vedotin|Maximum Concentration (Cmax) of Polatuzumab Vedotin|Clearance (CL) of Polatuzumab Vedotin|Terminal Half-Life (t1/2) of Polatuzumab Vedotin|Steady-State Volume of Distribution (Vss) of Polatuzumab Vedotin|Plasma Levels of Cyclophosphamide|Plasma Levels of Doxorubicin|Peripheral Neuropathy Symptom Severity: Therapy-Induced Neuropathy Assessment Scale (TINAS) Overall Neuropathy Severity Score|Peripheral Neuropathy Symptom Interference: TINAS Numbness/Tingling Item Score|Duration of Response, as Assessed by Investigator Using Cheson Criteria for DLBCL Population|Duration of Response, as Assessed by Investigator Using Cheson Criteria for Non-DLBCL Population|Progression Free Survival, as Assessed by Investigator Using Cheson Criteria for DLBCL Population|Progression Free Survival, as Assessed by Investigator Using Cheson Criteria for Non-DLBCL Population|Event Free Survival, as Assessed by Investigator Using Cheson Criteria for DLBCL Population|Event Free Survival, as Assessed by Investigator Using Cheson Criteria for Non-DLBCL Population|Relative Dose Intensity of Polatuzumab Vedotin (Ratio of the Amount of Drug Actually Administered to the Amount Planned) for DLBCL Population|Relative Dose Intensity of Polatuzumab Vedotin (Ratio of the Amount of Drug Actually Administered to the Amount Planned) for Non-DLBCL Population|Overall Survival for DLBCL Population|Overall Survival for Non-DLBCL Population","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,85.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GO29044|2013-003541-42,2013-11-29,"December 19, 2018",2018-12-19,"November 25, 2013","March 3, 2020","March 14, 2023","The University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner MD Anderson Cancer Center, Greeley, Colorado, United States|Washington University; Pediatrics, Saint Louis, Missouri, United States|Northwest Cancer Specialists, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Willamette Valley Clinical Studies; Cancer Institute, Springfield, Oregon, United States|Blue Ridge Cancer Care, Roanoke, Virginia, United States|Hopital Henri Mondor, Unite Hemopathies lymphoides, Creteil, France|Hopital Claude Huriez - CHU Lille; Service des maladies du sang, Lille, France|Centre Hospitalier Lyon Sud; Hematolgie, Pierre Benite, France|Centre Henri Becquerel; Hematologie, Rouen, France","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT01992653/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01992653,1846.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
456,457,NCT00453427,Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas,ACCAPELA,Completed,No Results Available,Peripheral T-cell Lymphomas,Drug: Alemtuzumab (Campath-1H),toxicity|efficacy|tumour response|pharmacokinetic analysis|immunological monitoring,"Ontario Clinical Oncology Group (OCOG)|Sunnybrook Health Sciences Centre|Genzyme, a Sanofi Company",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CTA-Control-103662,2006-09-01,June 2013,2015-05-01,"March 29, 2007",,"June 3, 2015","St. Paul's Hospital, Vancouver, British Columbia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Sunnybrook Health Sciences Centre, Odette Cancer Centre, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00453427,3164.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
457,458,NCT02055820,"A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL",,Completed,Has Results,"Lymphoma, Non-Hodgkin",Drug: Venetoclax|Drug: Cyclophosphamide|Drug: Obinutuzumab|Drug: Rituximab|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone,Safety: Number of Participants With Dose-Limiting Toxicities (DLTs)|Percentage of Previously Untreated DLBCL Participants With Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Scan Using the Modified Lugano Classification Assessed by Independent Review Committee (IRC)|Percentage of Participants With CR Defined by PET/CT Scan in Previously Untreated DLBCL Co-Expressing Both Bcl-2 and c-Myc Proteins (DE-DLBCL) Participants Assessed by IRC|Venetoclax Plasma PK: Area Under the Plasma Concentration-Time Curve (AUC)|Venetoclax Plasma PK: Time to Maximum Observed Plasma Concentration (Tmax)|Venetoclax Plasma PK: Maximum Observed Plasma Concentration (Cmax)|Venetoclax Plasma PK: Minimum Plasma Concentration (Cmin) Within the Dosing Interval|Prednisone Plasma PK: AUC|Prednisone Plasma PK: Tmax|Prednisone Plasma PK: Cmax|Rituximab PK: Cmax|Rituximab PK: Cmin Within the Dosing Interval|Obinutuzumab PK: Cmax|Cyclophosphamide PK: Cmax|Doxorubicin PK: Cmax|Vincristine PK: Cmax|Percentage of Participants With Objective Response Defined as Partial Response (PR) or Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Using the Modified Lugano Classification Assessed by IRC|Percentage of Participants Who Are Alive and Without Disease Progression at Month 12|Percentage of Participants With CR Defined by Computed Tomography (CT) Scan Using the Modified Lugano Classification|Safety: Percentage of Participants With Adverse Events|Safety: Percentage of Participants Maintaining Relative Dose Intensity of CHOP Chemotherapy|Relative Dose Intensity of Venetoclax,Hoffmann-La Roche|AbbVie,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,267.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GO27878|2013-003749-40,2013-11-17,"June 28, 2017",2019-06-28,"February 5, 2014","December 20, 2018","June 11, 2020","St. Jude Heritage Healthcare, Fullerton, California, United States|UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|Central Coast Medical Oncology, Santa Maria, California, United States|The West Clinici, Saint Louis, Missouri, United States|Hackensack University Medical Center; WFAN - Imus Pediatric Center, Hackensack, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Uni of Rochester Medical Center; Wilmot Cancer Center, Pharmacy Department, Rochester, New York, United States|Tennessee Oncology, Nashville, Tennessee, United States|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Peter MacCallum Cancer Centre-East Melbourne, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|LKH - Universitätsklinikum der PMU Salzburg, Salzburg, Austria|Medizinische Universität Wien, Wien, Austria|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer Agency, CSI, Kelowna, British Columbia, Canada|BC Cancer Agency Vancouver Centre - PARENT; BC Cancer Agency, Vancouver, British Columbia, Canada|Jewish General Hospital; Research Unit, Montréal, Quebec, Canada|CHU de Quebec - Hôpital de l' Enfant Jésus, Quebec, Canada|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultni nemocnice Ostrava, Ostrava - Poruba, Czechia|Vseobecna Fakultni Nemocnice v Praze, I. Interni Klinika - Klinika Hematoonkologie VFN a 1. LF UK, Praha 2, Czechia|Hopital Henri Mondor, Unite Hemopathies lymphoides, Creteil, France|Centre Hospitalier Départemental Les Oudairies, La Roche sur Yon, France|Clinique Victor Hugo; Pharmacie, Le Mans, France|Hopital Claude Huriez - CHU Lille, Lille, France|Hopital Saint Eloi, Montpellier, France|CHU Nantes - Hôtel Dieu; Service Assistance Medicale à la Procreation, Nantes, France|Hôpital Saint-Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre-Benite, France|CHU Rennes - Hopital Pontchaillou, Rennes cedex 09, France|Centre Henri Becquerel; Hematologie, Rouen, France|Hôpital de Brabois Adultes, Vandoeuvre-les-nancy, France|Semmelweis Egyetem, Budapest, Hungary|Orszagos Onkologiai Intezet, Budapest, Hungary|Debreceni Egyetem; Belgyogyaszati Klinika Hematologiai Tanszek, Debrecen, Hungary|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, Italy|Azienda Ospedaliero Universitaria San Martino, Genova, Liguria, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Piemonte, Italy|Azienda Ospedaliera Vincenzo Cervello, Palermo, Sicilia, Italy|Azienda Ospedaliero Universitaria Pisana; U.O. Farmaceutica, Pisa, Toscana, Italy|Amsterdam UMC Location VUMC, Amsterdam, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|UMC Utrecht, Utrecht, Netherlands|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|ICO l´Hospitalet - Hospital Duran i Reynals; Hematology, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02055820/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02055820/SAP_003.pdf",https://ClinicalTrials.gov/show/NCT02055820,2049.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
458,459,NCT02048488,"A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas",,Completed,No Results Available,Solid Tumors|Lymphomas,Drug: TSR-011,Incidence of Adverse Events (AEs)|Area Under the Concentration-Time Curve (AUC)|Maximum Tolerated Dose (MTD)|Response Rate (RR)|Dose limiting toxicity (DLT)|Progression Free Survival (PFS)|Recommended Phase 2 Dose (RP2D),"Tesaro, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,72.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PR-20-5006-C,2012-10-01,September 2016,2018-06-01,"January 29, 2014",,"March 26, 2019","Goodyear, Arizona, United States|Scottsdale, Arizona, United States|Los Angeles, California, United States|Nashville, Tennessee, United States|Norfolk, Virginia, United States|Spokane, Washington, United States|Warsaw, Mazowieckie, Poland|Gdansk, Pomorskie, Poland|Olsztyn, Warminsko-Mazurskie, Poland|Poznan, Wielkopolskie, Poland|Madrid, Spain|Santiago de Compostela, Spain|Tainan City, Taiwan|Taipei, Taiwan|London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02048488,2069.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
459,460,NCT02661542,Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas,,Completed,No Results Available,Solid Tumors|Lymphomas,Drug: FF-10502-01,Incidence of Treatment Emergent Adverse Events (Safety and Tolerability)|Determination of overall response rates|Determination of duration of response.|Determination of duration of stable disease (SD) as measured from time of 1st evidence of response to time of 1st evidence of progressive disease as measured by CT or MRI.|Evaluate progression-free survival (PFS)|Evaluate overall survival (OS)|Evaluate the mean plasma concentrations of FF-10502-01|Evaluate FF-10502-01 incorporation into whole blood cellular DNA by LC-MS/MS as a pharmacodynamic marker,"Fujifilm Pharmaceuticals U.S.A., Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,99.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FF1050201US101,2016-01-01,"November 5, 2020",2020-11-05,"January 22, 2016",,"April 13, 2022","Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02661542,1770.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
460,461,NCT00048555,Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma,,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: IDEC-114,To characterize the safety profile and to define the dose of galiximab to be used for the Phase II portion of the study|To evaluate PK|To evaluate efficacy|To monitor for the presence of human anti galiximab antibody and human antichimeric antibody formation,Biogen,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,90.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,114-21,2002-11-01,March 2004,2010-11-01,"November 5, 2002",,"September 16, 2013","Research site, Birmingham, Alabama, United States|Research site, Tucson, Arizona, United States|Research site, Los Angeles, California, United States|Research site, Newport Beach, California, United States|Research site, San Diego, California, United States|Research site, Aurora, Colorado, United States|Research site, Washington, District of Columbia, United States|Research site, Tampa Bay, Florida, United States|Research site, Chicago, Illinois, United States|Research site, Maywood, Illinois, United States|Research site, Boston, Massachusetts, United States|Research site, Detroit,, Michigan, United States|Research site, Rochester, Minnesota, United States|Research site, Omaha, Nebraska, United States|Research site, Buffalo, New York, United States|Research site, New York, New York, United States|Research site, Rochester, New York, United States|Research site, Durham, North Carolina, United States|Research site, Philadelphia, Pennsylvania, United States|Research site, Columbia, South Carolina, United States|Research site, Houston, Texas, United States|Research site, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00048555,2922.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
461,462,NCT01562990,Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse,,Completed,No Results Available,Diffuse Large B-Cell Lymphoma,"Drug: Rituximab, CMC544, Gemcitabine and Oxaliplatine",Determination of the Recommended Dose of R-CMC544|OVERALL RESPONSE RATE|PROGRESSION-FREE SURVIVAL|EVENT FREE SURVIVAL|OVERALL SURVIVAL|COMPLETE RESPONSE RATE,The Lymphoma Academic Research Organisation|Pfizer,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,11.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CMC-R-GEMOX|2011-003849-18,2012-12-01,August 2014,2016-03-01,"March 26, 2012",,"May 23, 2016","AZ Sint Jan, Bruges, Belgium|University Hospital Gent, Gent, Belgium|CHU Mont-Godinne, Yvoir, Belgium|Hôpital Henri Mondor, Créteil, France|CHU de Dijon, Dijon, France|CHRU de Lille, Lille, France|CHU Lyon - Sud, Lyon, France|CHU Hôtel Dieu, Nantes, France|CHU Pontchaillou, Rennes, France|Centre Henri Becquerel, Rouen, France|CHU Brabois, Vandoeuvre les nancy, France",,https://ClinicalTrials.gov/show/NCT01562990,1186.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
462,463,NCT02973113,"Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)",PREVALE,Completed,No Results Available,NonHodgkin Lymphoma|Lymphoproliferative Disorders|EBV Related Lymphoma|EBV-Related PTLD|Hodgkin Lymphoma|EBV Related Non-Hodgkin's Lymphoma|EBV Related Hodgkin's Lymphoma,Biological: EBVST Cells|Biological: Nivolumab,Number of Dose-Limiting Toxicities|Duration of Overall Response,"Baylor College of Medicine|The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",All,"Child, Adult, Older Adult",Phase 1,8.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-39090 PREVALE|PREVALE,2016-02-16,"September 5, 2019",2020-07-11,"November 25, 2016",,"July 21, 2021","Houston Methodist Hospital, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT02973113/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT02973113,1607.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
463,464,NCT02541565,Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma,,Completed,Has Results,Composite Lymphoma|Grade 3b Follicular Lymphoma|Stage I Diffuse Large B-Cell Lymphoma|Stage I Follicular Lymphoma|Stage II Diffuse Large B-Cell Lymphoma|Stage II Follicular Lymphoma|Stage III Diffuse Large B-Cell Lymphoma|Stage III Follicular Lymphoma|Stage IV Diffuse Large B-Cell Lymphoma|Stage IV Follicular Lymphoma,Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Drug: Prednisone|Biological: Rituximab|Drug: Vincristine Sulfate,Number of Participants With a Grade 3 or Higher Toxicity Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0|Treatment-related Mortality|Event-free Survival|Overall Survival|Response Rate Measured by Tumor Imaging,University of Washington|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9291|NCI-2015-01309|MK-3475|P30CA015704,2015-11-24,"December 18, 2018",2018-12-18,"September 4, 2015","September 23, 2020","October 14, 2020","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02541565/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02541565,1120.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
464,465,NCT03013491,PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas,,Completed,No Results Available,Solid Tumor|Lymphoma,Drug: CX-072|Drug: ipilimumab|Drug: vemurafenib,The number of subjects experiencing a dose limiting toxicity at various dose levels when given multiple doses of CX-072 as a monotherapy or in combination with ipilimumab or vemurafenib|The percentage of subjects experiencing anti-cancer activity (ORR) at various dose levels when given multiple doses of CX-072 as a monotherapy or in combination with ipilimumab or vemurafenib,CytomX Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,300.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CTMX-M-072-001,2017-01-01,"October 6, 2021",2021-10-06,"January 6, 2017",,"February 9, 2022","PROCLAIM Investigative Site, Los Angeles, California, United States|PROCLAIM Investigative Site, Los Angeles, California, United States|PROCLAIM Investigative Site, New Haven, Connecticut, United States|PROCLAIM Investigative Site, Chicago, Illinois, United States|PROCLAIM Investigative Site, Indianapolis, Indiana, United States|PROCLAIM Investigative Site, Boston, Massachusetts, United States|PROCLAIM Investigative Site, Detroit, Michigan, United States|PROCLAIM Investigative Site, New York, New York, United States|PROCLAIM Investigative Site, New York, New York, United States|PROCLAIM Investigative Site, New York, New York, United States|PROCLAIM Investigative Site, Portland, Oregon, United States|PROCLAIM Investigative Site, Nashville, Tennessee, United States|PROCLAIM Investigative Site, Dallas, Texas, United States|PROCLAIM Investigative Site, Houston, Texas, United States|PROCLAIM Investigative Site, Fairfax, Virginia, United States|PROCLAIM Investigative Site, Madison, Wisconsin, United States|PROCLAIM Investigative Site, Amsterdam, Netherlands|PROCLAIM Investigative Site, Groningen, Netherlands|PROCLAIM Investigative Site, Rotterdam, Netherlands|PROCLAIM Investigative Site, Katowice, Poland|PROCLAIM Investigative Site, Pamplona, Navarre, Spain|PROCLAIM Investigative Site, Barcelona, Spain|PROCLAIM Investigative Site, Barcelona, Spain|PROCLAIM Investigative Site, Madrid, Spain|PROCLAIM Investigative Site, Madrid, Spain|PROCLAIM Investigative Ssite, Valencia, Spain|PROCLAIM Investigative Site, Dnepropetrovsk, Ukraine|PROCLAIM Invetigative Site, Glasgow, United Kingdom|PROCLAIM Investigative Site, London, United Kingdom|PROCLAIM Investigative Site, Manchester, United Kingdom|PROCLAIM Investigative Site, Newcastle upon Tyne, United Kingdom",,https://ClinicalTrials.gov/show/NCT03013491,1739.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
465,466,NCT00670592,Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies,,Completed,No Results Available,Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma,Drug: HCD122,"Primary endpoints (phase I) - Incidence rate of DLT and AE|Primary endpoint (phase II) - Response rate|Adverse events by frequency, severity, and duration; pharmacokinetics; immunogenicity; response duration; time to progression",Novartis Pharmaceuticals|XOMA (US) LLC|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,111.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHCD122A2103|2007-004888-22,2008-03-01,February 2013,2013-02-01,"May 2, 2008",,"December 17, 2020","Northwestern University, Chicago, Illinois, United States|St. Francis Cancer Research Foundation Dept.ofSt.FrancisCancerRes.(2), Beech Grove, Indiana, United States|Dana Farber Cancer Institute SC-5, Boston, Massachusetts, United States|Wake Forest University Baptist Medical Center Dept. of Industry Research (2), Winston-Salem, North Carolina, United States|University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(3), Houston, Texas, United States|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Prahran, Victoria, Australia|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Godinne, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, Le Mans Cedex, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Montpellier cedex 5, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pierre-Benite Cédex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Köln, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00670592,1798.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
466,467,NCT02650999,Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas,,Completed,Has Results,CD19+ Diffuse Large B-cell Lymphomas|Follicular Lymphomas|Mantle Cell Lymphomas,Drug: Pembrolizumab,Dose-limiting Toxicity|Overall Response Rates,Abramson Cancer Center of the University of Pennsylvania,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,12.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UPCC 46415,2016-01-01,"February 25, 2019",2020-06-12,"January 8, 2016","May 12, 2020","July 22, 2021","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02650999/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02650999/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02650999,1624.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
467,468,NCT01676831,Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL),,Completed,Has Results,Cutaneous T Cell Lymphoma,Drug: Topical resiquimod 0.06%|Drug: topical resiquimod 0.03%,The Number of Participants That Tolerated the Maximum Drug Dose|Secondary End Points: Efficacy- CAILDS SCORE|Secondary End Points: Efficacy- SWAT SCORE,Abramson Cancer Center of the University of Pennsylvania,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,13.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,813320(UPCC03411)|1R01FD004092-01A1,2012-02-01,January 2015,2015-09-28,"August 31, 2012","August 13, 2019","August 13, 2019","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01676831,1335.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
468,469,NCT02341014,"Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas",,Completed,No Results Available,T-cell Lymphomas|Relapsed or Refractory,Drug: Carfilzomib|Drug: Romidepsin|Drug: Lenalidomide,MTD (phase Ib)|overall response rate (orr),Memorial Sloan Kettering Cancer Center|University of Nebraska,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,31.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-179,2015-01-02,"January 11, 2023",2023-01-11,"January 19, 2015",,"January 13, 2023","University of Nebraska Medical Center, Omaha, Nebraska, United States|Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States",,https://ClinicalTrials.gov/show/NCT02341014,2931.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
469,470,NCT00596804,Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma,,Completed,No Results Available,"Non-Hodgkin's Lymphoma|Lymphoma, Diffuse|Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic",Drug: veltuzumab,Safety of hA20 with this administration schedule and dosing|tolerance of hA20 with this administration schedule and dosing|immunogenicity of hA20 with this administration schedule and dosing|Pharmacodynamics of hA20|pharmacokinetics hA20|assess efficacy,Gilead Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,39.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IM-T-hA20-01EU,2004-03-01,November 2007,2007-11-01,"January 17, 2008",,"August 18, 2021","Service Des Maladies Du Sang, Lille, Cedex, France|Centre hospitalier Lyon, Lyon, Pierre Benite Cedex, France|University of Leicester, Leicester, United Kingdom",,https://ClinicalTrials.gov/show/NCT00596804,1340.0,Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
470,471,NCT01492088,Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma,,Completed,Has Results,Relapsed or Refractory Hodgkin Lymphoma|Relapsed or Refractory Anaplastic Large-cell Lymphoma,Drug: Brentuximab vedotin,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (Phase 1)|Number of Participants With Abnormal Clinical Laboratory Values Reported as AEs (Phase 1)|Number of Participants With Clinically Significant Vital Signs Values Reported as AEs (Phase 1)|Antibody-drug Conjugate (ADC) Serum Concentrations (Phase 1)|Serum Concentration of Total Antibodies (Conjugated and Unconjugated) (Phase 1)|Monomethyl Auristatin E (MMAE) Plasma Concentrations (Phase 1)|Overall Response Rate (ORR) (Phase 1 and 2)|Number of Participants With Antitherapeutic Antibodies (ATA) and Neutralizing ATA (nATA) (Phase 1 and 2)|Overall Response Rate (ORR) (Phase 1)|Time to Progression (TTP) (Phase 1 and 2)|Time to Response (Phase 1 and 2)|Duration of Response (DOR) (Phase 1 and 2)|Event Free Survival (EFS) (Phase 1 and 2)|Progression Free Survival (PFS) (Phase 1 and 2)|Overall Survival (OS) (Phase 1 and 2)|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (Phase 1 and 2)|Number of Participants With Abnormal Clinical Laboratory Values Reported as AEs (Phase 1 and 2)|Number of Participants With Clinically Significant Vital Signs Reported as AEs (Phase 1 and 2)|Antibody-drug Conjugate (ADC) Serum Concentrations (Phase 1 and 2)|Serum Concentration of Total Antibodies (Conjugated and Unconjugated)|Monomethyl Auristatin E (MMAE) Plasma Concentrations (Phase 1 and 2),"Millennium Pharmaceuticals, Inc.|Takeda",All,"2 Years to 18 Years   (Child, Adult)",Phase 1|Phase 2,36.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C25002|2011-001240-29|U1111-1158-2613|133300410A0384|NL38209.078.11,2012-04-16,"October 12, 2016",2018-04-12,"December 14, 2011","May 15, 2017","November 20, 2018","Aurora, Colorado, United States|Kansas City, Missouri, United States|New York, New York, United States|Houston, Texas, United States|Bordeaux Cedex, France|Lyon, France|Paris Cedex 12, France|Berlin, Germany|Frankfurt, Germany|Giessen, Germany|Halle, Germany|Munster, Germany|Padova, Italy|Roma, Italy|Mexico Df, Mexico|Rotterdam, Netherlands|Barcelona, Spain|London, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT01492088/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT01492088/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT01492088,2187.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
471,472,NCT02253420,COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients,,Completed,No Results Available,Medical Oncology,Drug: Copanlisib (BAY80-6946)|Drug: Itraconazole|Drug: Rifampin,"AUC (0-168)|AUC|Cmax|QTcF|AUC(0-tlast)|tmax|tlast|t1/2|Urine [AE,ur(0-24)]|Number of participants with adverse events as a measure of safety and tolerability|PR intervals|QRS intervals|ECG waveform morphology|Left ventricular ejection fraction (LVEF)|QTcB",Bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,51.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,16270,2014-10-08,"March 12, 2018",2019-08-13,"October 1, 2014",,"December 14, 2020","Dallas, Texas, United States|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Hamilton, Ontario, Canada|Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02253420,1770.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
472,473,NCT01120834,Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL),,Completed,Has Results,Lymphoma,Drug: azacytidine|Drug: vorinostat,Overall Response Rate (ORR),Weill Medical College of Cornell University|Celgene|Merck Sharp & Dohme LLC,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,17.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0912010795,2010-09-01,April 2013,2016-10-20,"May 11, 2010","April 10, 2017","April 10, 2017","Weill Cornell Medical College, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01120834,2241.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
473,474,NCT00864942,"Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)",Phase I BLR,Completed,No Results Available,Chronic Lymphocytic Leukemia|Non-Hodgkin's Lymphoma,Drug: bendamustine and lenalidomide|Drug: BL-NHL|Drug: BLR-CLL|Drug: BLR-NHL,Maximum tolerated dose|Dose limiting toxicity|Recommended Phase II dose|overall safety profile|Plasma pharmacokinetics|Preliminary antitumor activity,Georgetown University|Celgene Corporation|Cephalon,All,"18 Years and older   (Adult, Older Adult)",Phase 1,28.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RV-CLL-NHL-PI-356|2008-186,2009-02-01,October 2014,2014-10-01,"March 19, 2009",,"March 13, 2015","Georgetown University Hospital/Lombardi Cancer Center, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT00864942,2068.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
474,475,NCT03322384,"UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma",,Completed,Has Results,Advanced Solid Tumors|Lymphoma,Drug: epacadostat|Drug: SD-101|Radiation: Radiotherapy,Maximum Tolerated Dose (MTD)|Incidence of Related Adverse Events [Safety and Tolerability]|Abscopal Response Rate,"University of California, Davis",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1057229|UCDCC#271,2018-01-17,"February 24, 2020",2020-04-08,"October 26, 2017","December 21, 2021","February 1, 2022","University of California Davis Comprehensive Cancer Center, Sacramento, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03322384/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03322384,812.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
475,476,NCT00450502,Safety of Batracylin in Patients With Solid Tumors and Lymphomas,,Completed,No Results Available,Neoplasms,Drug: Batracylin,"Define the maximum tolerated dose of batracylin administered daily x7 consecutive days, repeated every 28 days in slow acetylator NAT2 genotype (NAT2 5, NAT2 6, NAT2 7, or NAT2 14) patients with solid tumors and lymphomas.|Obtain preliminary evidence of anti-tumor activity of batracylin in patients with solid tumors or lymphoma.",National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",Phase 1,33.0,NIH,Interventional,Primary Purpose: Treatment,070097|07-C-0097,2007-02-24,"April 24, 2011",2011-04-24,"March 22, 2007",,"December 5, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00450502,1520.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
476,477,NCT00734890,Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma,,Completed,No Results Available,"Lung Cancer|Lymphoma|Lymphoproliferative Disorder|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Biological: bevacizumab|Drug: vandetanib|Other: laboratory biomarker analysis|Other: pharmacological study,Maximum tolerated dose|Safety|Toxicity,National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,18.0,NIH,Interventional,Primary Purpose: Treatment,080087|08-C-0087|NCI-P7189|CDR0000590152,2008-03-01,June 2010,2011-02-01,"August 14, 2008",,"March 16, 2012","Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00734890,1067.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
477,478,NCT01165112,"Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma",TREC,Completed,Has Results,Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma,Drug: Bendamustine Hydrochloride|Drug: Carboplatin|Biological: Rituximab|Drug: Etoposide|Other: Laboratory Biomarker Analysis,"Maximally Tolerated Dose of Bendamustine Hydrochloride That Can be Combined With Rituximab, Carboplatin, and Etoposide Chemotherapy in Patients With Relapsed or Refractory Lymphoid Malignancies|Safety and Toxicity of This Regimen|Preliminary Assessment of the Efficacy of This Regimen|Ability to Proceed to Peripheral Blood Stem Cell (PBSC) Collection Following Treatment (Impact of This Regimen on Stem Cell Reserve)",University of Washington|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,48.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PSOC 2502|NCI-2010-00907|P30CA015704,2010-09-01,June 2015,2015-06-01,"July 19, 2010","May 25, 2017","December 5, 2018","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01165112,1734.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
479,480,NCT01691898,A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL),ROMULUS,Completed,Has Results,Follicular Lymphoma|Diffuse Large B-Cell Lymphoma,Drug: Obinutuzumab|Drug: Pinatuzumab Vedotin|Drug: Polatuzumab Vedotin|Drug: Rituximab,"Percentage of Participants With a Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C)|Duration of Objective Response (DOR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C)|Percentage of Participants With CR at End of Treatment (EOT) Based on Positron Emission Tomographic/Computed Tomography (PET/CT) Assessment Determined by Independent Review Committee (IRC) Per Lugano 2014 Response Criteria: Cohorts E, G, and H|Number of Participants With Anti-Drug Antibodies (ADA) to Pinatuzumab Vedotin|Number of Participants With ADA to Polatuzumab Vedotin|Number of Participants With ADA to Obinutuzumab|Percentage of Participants With PD as Determined by Modified Response and Progression Criteria for NHL or Death Due to Any Cause: Rituximab Containing Regimens (Arms A and B, Cohort C)|Progression-free Survival (PFS) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C)|Percentage of Participants Who Died Due to Any Cause: Rituximab Containing Regimens (Arms A and B, Cohort C)|Overall Survival (OS): Rituximab Containing Regimens (Arms A and B, Cohort C)|Percentage of Participants With CR at EOT Based on PET/CT Assessment as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H)|Percentage of Participants With OR at EOT Based on PET/CT Assessment as Determined by IRC Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H)|Percentage of Participants With OR at EOT Based on PET/CT Assessment as Determined by the Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H)|Percentage of Participants With CR at EOT Based on CT Assessment Alone as Determined by IRC Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)|Percentage of Participants With CR at EOT Based on CT Assessment Alone as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)|Percentage of Participants With OR at EOT Based on CT Assessment Alone as Determined by IRC Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)|Percentage of Participants With OR at EOT Based on CT Assessment Alone as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)|Percentage of Participants With Best OR Based on PET/CT or CT Assessment as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H)|Area Under the Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C)|Maximum Observed Concentration (Cmax) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C)|Systemic Clearance (CL) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C)|Half-Life (t1/2) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C)|Volume of Distribution at Steady State (Vss) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C)|AUCinf of Total Antibody for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|AUCinf of Antibody Conjugated Monomethyl Auristatin E (acMMAE) for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|Area Under the Concentration-Time Curve From Time Zero To Last Measurable Concentration (AUClast) of Unconjugated MMAE for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|Cmax of Total Antibody for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|Cmax of acMMAE for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|Cmax of Unconjugated MMAE for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|AUCinf of Total Antibody for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|AUCinf of acMMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|AUClast of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|Cmax of Total Antibody for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|Cmax of acMMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|Cmax of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|AUCinf of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab|AUCinf of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab|AUClast of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab|Cmax of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab|Cmax of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab|Cmax of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab|AUCinf of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab|AUCinf of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab|AUClast of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab|Cmax of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab|Cmax of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab|Cmax of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab|Cmax of Obinutuzumab: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)|Overall Survival (OS): Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)|Percentage of Participants Who Died Due to Any Cause: Obinutuzumab Containing Cohorts (Cohorts E + H and E + G)|Progression-free Survival (PFS) as Determined by Modified Response and Progression Criteria for NHL: Obinutuzumab Containing Cohorts (Cohorts E + H and E + G)|Percentage of Participants With PD as Determined by Modified Response and Progression Criteria for NHL or Death Due to Any Cause: Obinutuzumab Containing Cohorts (Cohorts E + H and E + G)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,231.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GO27834|2011-004377-84,2012-09-27,"March 8, 2017",2019-02-07,"September 25, 2012","April 19, 2018","February 21, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States|Stanford Cancer Center, Stanford, California, United States|Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver, Colorado, United States|Georgetown University Medical Center Lombardi Cancer Center, Washington, District of Columbia, United States|Florida Cancer Specialists - Fort Myers (Colonial Center Dr), Fort Myers, Florida, United States|Florida Cancer Specialists; Sarasota, Sarasota, Florida, United States|Univ of Michigan Med School; Hematology Oncology, Ann Arbor, Michigan, United States|Comprehensive Cancer Centers of Nevada - Eastern Avenue, Las Vegas, Nevada, United States|Hematology Oncology Associates; Carol G. Simon Ctr, Morristown, New Jersey, United States|Regional Cancer Care Associates LLC - Morristown, Morristown, New Jersey, United States|Roswell Park Cancer Inst., Buffalo, New York, United States|New York University Cancer Cen, New York, New York, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Oregon Health Sciences Uni, Portland, Oregon, United States|Sarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville, Tennessee, United States|Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Texas Transplant Inst., San Antonio, Texas, United States|Texas Oncology, P.A. - Tyler; Tyler Cancer Center, Tyler, Texas, United States|Fairfax N Virginia Hem/Onc PC, Fairfax, Virginia, United States|Oncology & Hematolgy Associates of SW Va Inc. - Roanoke, Roanoke, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Northwest Cancer Specialists - Vancouver, Vancouver, Washington, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|Univ of Wisconsin-Madison, Madison, Wisconsin, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|Hopital Claude Huriez - CHU Lille, Lille, France|CHU Montpellier - Saint ELOI, Montpellier, France|Hopital Saint Louis ; Service d Oncologie Medicale Fougere 6 (Pr Misset), Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Centre Henri Becquerel; Hematologie, Rouen, France|Uniklinik Heidelberg, Medizinische Klinik & Poliklinik V, Heidelberg, Germany|Universitätsmedizin Johannes Gutenberg Universität; Klinik u. Poliklinik f. Neurologie, Mainz, Germany|Klinikum d.Universität München Campus Großhadern, München, Germany|A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna, Bologna, Emilia-Romagna, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, Italy|Azienda Ospedale San Giovanni, Torino, Piemonte, Italy|Academisch Medisch Centrum; Hematologie, Amsterdam, Netherlands","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT01691898/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01691898,2324.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
480,481,NCT00020579,MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma,,Completed,No Results Available,Cancer,Drug: entinostat,Dose-limiting toxicities and maximum tolerated dose|Pharmacology and pharmacokinetics|Acetylation of histones in peripheral blood|Tumor response by CT scan every 12 weeks,National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,75.0,NIH,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,010124|01-C-0124|NCI-2792|CDR0000068615,2001-03-01,April 2008,2008-10-01,"January 27, 2003",,"March 15, 2012","National Naval Medical Center, Bethesda, Maryland, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States|NCI - Center for Cancer Research, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00020579,2771.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
481,482,NCT00901615,Lenalidomide and R-CHOP in B-cell Lymphoma,R2CHOP-1,Completed,No Results Available,"Lymphoma, Large B-Cell, Diffuse|Follicular Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma",Drug: Lenalidomide and R-CHOP,Incidence of Dose Limiting Toxicities|Complete response rate and Overall response rate at the end of treatment|Complete and Overall response rates after induction|Progression-Free Survival and Overall survival|Duration of response|Collection of adverse events,Lymphoma Study Association,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,108.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R2CHOP-1,2009-01-06,"November 19, 2010",2015-11-23,"May 14, 2009",,"August 23, 2018","CHU de Dijon, Dijon, France|CHRU Lille, Lille, France|CHU Lyon Sud, Pierre Benite, France|Centre Henri Becquerel, Rouen, France|CHU Brabois, Vandoeuvre les Nancy, France",,https://ClinicalTrials.gov/show/NCT00901615,2512.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
482,483,NCT00306969,Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma,,Completed,No Results Available,Cutaneous T-Cell Lymphoma,Drug: bexarotene|Device: photopheresis,"Safety and tolerability of bexarotene in combination with ECP, assessed with NCI toxicity assessment, at each treatment visit, every 3 weeks and at final one month foll|Time to response of bexarotene with ECP in patients with CTCL, at month 4 (follow-up visit) patient's response by organ system involvement, with an overall assessment: complete response, partial response, no change, or progressive disease, flare.|Another secondary outcome is whether combination of instruments provides relevant information on CTCL patients' health related quality of life during therapy",Boston University|Ligand Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,18.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2001-391G,2001-12-01,,2004-04-01,"March 27, 2006",,"March 27, 2006","Boston University Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00306969,852.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
483,484,NCT00400556,ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells,,Completed,No Results Available,Multiple Myeloma|Cutaneous Lymphoma,"Drug: ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination",Toxicity data (NCI-CTC version 2.0 criteria)|skin toxicity|hepatotoxicity|mucosal toxicity|hematologic toxicity|neurologic toxicity|treatment response|CD34+ cell count peak level|time to CD34+ count peak level|time to reach level >5 x 10^6.L|area under curve for duration of time spent with CD34+ count >5 x 10^6/L|peripheral blood colony forming unit assays|peak CFU-GEMM level|time to peak CFU-GEMM level,"Peter MacCallum Cancer Centre, Australia|The Leukemia and Lymphoma Society",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,6.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,04/24,2005-03-01,,2005-05-01,"November 17, 2006",,"November 17, 2006","Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT00400556,61.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
484,485,NCT02596971,"A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)",,Completed,Has Results,"Diffuse Large B-Cell Lymphoma, Lymphoma Follicular",Drug: Atezolizumab|Drug: Bendamustine|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Obinutuzumab|Drug: Prednisone|Drug: Vincristine|Drug: Rituximab,"Percentage of Participants With Complete Response (CR) at End of Induction (EOI), as Determined by the Independent Review Committee (IRC) Using Modified Lugano 2014 Criteria|Percentage of Participants With Adverse Events|Percentage of Participants With CR at EOI, as Determined by the Investigator Using Lugano 2014 Criteria|Percentage of Participants With CR at EOI, as Determined by the IRC Using Modified Cheson 2007 Criteria|Percentage of Participants With CR at EOI, as Determined by the Investigator Using Modified Cheson 2007 Criteria|Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the IRC Using Modified Cheson 2007 Criteria|Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the Investigator Using Modified Cheson 2007 Criteria|Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the IRC Using Lugano 2014 Criteria|Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the Investigator Using Lugano 2014 Criteria|Percentage of Participants With Best Response of CR or PR During Study, as Determined by Investigator Using Modified Cheson 2007 Criteria|Observed Serum Obinutuzumab Concentration|Observed Serum Atezolizumab Concentration|Observed Serum Rituximab Concentration|Percentage of Participants With Human Anti-Human Antibodies (HAHAs) to Obinutuzumab|Percentage of Participants With Human Anti-Chimeric Antibodies (HACAs) to Rituximab|Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,91.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BO29563|2015-001364-19,2015-12-22,"April 11, 2018",2020-05-08,"November 4, 2015","June 13, 2019","May 24, 2021","Rocky Mountain Cancer Center - Aurora, Aurora, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University Miami, Miami, Florida, United States|New York Uni Medical Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Oncology Associates of Oregon, P.C.; Willamette Valley Cancer Institute, Springfield, Oregon, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Texas Oncology, Austin, Texas, United States|Texas Oncology-Tyler, Irving, Texas, United States|Concord Repatriation General Hospital; Haematology, Sydney, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|The Queen Elizabeth Hospital; Haematology/Oncology, Woodville South, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Azienda Ospedaliera S. Orsola-Malpighi, Bologna, Emilia-Romagna, Italy|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Emilia-Romagna, Italy|Az. Osp. S. Maria Delle Croci; U.O. Di Ematologia, Ravenna, Emilia-Romagna, Italy|Ospedale Infermi di Rimini, Rimini, Emilia-Romagna, Italy|AOU Città della Salute e della Scienza di Torino - Presidio Le Molinette, Torino, Lazio, Italy|Asst Papa Giovanni XXIII, Bergamo, Lombardia, Italy|Azienda Ospedaliera Univ, Firenze, Toscana, Italy","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02596971/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02596971,1599.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
485,486,NCT01580371,Safety and Pharmacokinetic Profile of CKD-581,CKD-581,Completed,No Results Available,Lymphoma|Multiple Myeloma,Drug: CKD-581,Maximum Tolerated Dose|Dose Limiting Toxicity|Pharmacokinetics|Objective response rate|Progression Free survival,Chong Kun Dang Pharmaceutical,All,"20 Years and older   (Adult, Older Adult)",Phase 1,39.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,133HL/NHL11L,2012-05-01,March 2016,2016-06-01,"April 19, 2012",,"October 6, 2016","ASAN Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01580371,1492.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
486,487,NCT00006029,Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma,,Completed,No Results Available,Lymphoma,Drug: gemcitabine hydrochloride|Drug: pegylated liposomal doxorubicin hydrochloride|Drug: vinorelbine tartrate,Overall response rate|Overall survival,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),All,"Child, Adult, Older Adult",Phase 1|Phase 2,91.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CALGB-59804|CLB-59804|CDR0000068042,2000-07-01,February 2007,2007-02-01,"January 27, 2003",,"July 14, 2016","Northeast Alabama Regional Medical Center, Anniston, Alabama, United States|Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|Veterans Affairs Medical Center - San Diego, San Diego, California, United States|UCSF Comprehensive Cancer Center, San Francisco, California, United States|Veterans Affairs Medical Center - San Francisco, San Francisco, California, United States|CCOP - Christiana Care Health Services, Newark, Delaware, United States|Lombardi Cancer Center, Washington, District of Columbia, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|Veterans Affairs Medical Center - Washington, DC, Washington, District of Columbia, United States|Broward General Medical Center, Fort Lauderdale, Florida, United States|Memorial Regional Hospital Comprehensive Cancer Center, Hollywood, Florida, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Helen and Harry Gray Cancer Institute at Good Samaritan Medical Center, West Palm Beach, Florida, United States|Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States|West Suburban Center for Cancer Care, River Forest, Illinois, United States|Saint Anthony Medical Center, Rockford, Illinois, United States|Fort Wayne Medical Oncology and Hematology, Incorporated, Fort Wayne, Indiana, United States|Hematology Oncology Associates of the Quad Cities, Bettendorf, Iowa, United States|Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Baptist Hospital East - Louisville, Louisville, Kentucky, United States|Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States|Veterans Affairs Medical Center - Baltimore, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center - University Campus, Worcester, Massachusetts, United States|Lakeland Medical Center - St. Joseph, Saint Joseph, Michigan, United States|Veterans Affairs Medical Center - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|Veterans Affairs Medical Center - Columbia (Truman Memorial), Columbia, Missouri, United States|Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Veterans Affairs Medical Center - Las Vegas, Las Vegas, Nevada, United States|Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|Cooper University Hospital, Camden, New Jersey, United States|Veterans Affairs Medical Center - Buffalo, Buffalo, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Elmhurst Hospital Center, Elmhurst, New York, United States|Queens Cancer Center of Queens Hospital, Jamaica, New York, United States|CCOP - North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|Mount Sinai Medical Center, NY, New York, New York, United States|State University of New York - Upstate Medical University, Syracuse, New York, United States|Veterans Affairs Medical Center - Syracuse, Syracuse, New York, United States|CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States|Veterans Affairs Medical Center - Asheville, Asheville, North Carolina, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|NorthEast Oncology Associates, Concord, North Carolina, United States|Veterans Affairs Medical Center - Durham, Durham, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Cape Fear Valley Health System, Fayetteville, North Carolina, United States|Lenoir Memorial Hospital Cancer Center, Kinston, North Carolina, United States|FirstHealth Moore Regional Hospital, Pinehurst, North Carolina, United States|New Hanover Regional Medical Center, Wilmington, North Carolina, United States|CCOP - Southeast Cancer Control Consortium, Winston-Salem, North Carolina, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|Veterans Affairs Medical Center - Fargo, Fargo, North Dakota, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States|Lifespan: The Miriam Hospital, Providence, Rhode Island, United States|Veterans Affairs Medical Center - Dallas, Dallas, Texas, United States|Green Mountain Oncology Group, Bennington, Vermont, United States|Vermont Cancer Center, Burlington, Vermont, United States|Veterans Affairs Medical Center - White River Junction, White River Junction, Vermont, United States|Martha Jefferson Hospital, Charlottesville, Virginia, United States|Virginia Oncology Associates - Norfolk, Norfolk, Virginia, United States|MBCCOP - Massey Cancer Center, Richmond, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., Roanoke, Virginia, United States|St. Mary's Medical Center, Huntington, West Virginia, United States|Ministry Medical Group - Northern Region, Rhinelander, Wisconsin, United States|University of Puerto Rico School of Medicine Medical Sciences Campus, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00006029,2406.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
488,489,NCT00374179,CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma,,Completed,No Results Available,Cancer,Drug: CT-322,Safety and tolerability of CT-322|To evaluate the pharmacokinetics of CT-322 in these patients;|to assess whether antibodies to this drug develop in these patients; and|to make a preliminary assessment of the biological activity of CT-322 to alter tumor growth.,"Adnexus, A Bristol-Myers Squibb R&D Company",All,"18 Years and older   (Adult, Older Adult)",Phase 1,40.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT-322.001,2006-08-01,November 2008,2009-02-01,"September 11, 2006",,"February 24, 2009","Indiana University Cancer Center, Indianapolis, Indiana, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States|Institute for Drug Development, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00374179,915.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
489,490,NCT01212380,"Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)",,Completed,No Results Available,B-cell Chronic Lymphocytic Leukemia|Hematopoietic/Lymphoid Cancer|Prolymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia,Drug: carfilzomib|Other: Cytokine Assessment|Other: Pharmacodynamic Studies|Other: Proteosome Inhibition Assessment|Other: Pharmacogenomic Studies,Determine safety of carfilzomib by evaluating the toxicity profile.|To evaluate the efficacy of Carfilzomib therapy in relapsed or refractory chromic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL)/prolymphocytic leukemia (PLL),Ohio State University Comprehensive Cancer Center|Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 1,21.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSU-09108|NCI-2010-01884,2010-10-01,July 2014,2015-09-01,"September 30, 2010",,"May 9, 2016","Ohio State University Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01212380,1796.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
492,493,NCT01527422,"Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL",CHOP-R,Completed,No Results Available,Lymphoma|Non Hodgkin's Lymphoma,"Drug: Cyclophosphamide, Doxorubicin, Vincristine and Prednisone",Phase I-II Study of Dose Dense of PEG-Filgrastim and GM-CSF combined with CHOP-R,"Fernando Cabanillas|Genzyme, a Sanofi Company|Auxilio Mutuo Cancer Center",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,60.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,2006-01-01,November 2010,2011-03-01,"February 7, 2012",,"February 7, 2012","Hospital Auxilio Mutuo Cancer Center, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT01527422,1885.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
493,494,NCT00068250,"Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma",,Completed,Has Results,Brain and Central Nervous System Tumors|Lymphoma,Drug: rituximab|Drug: methotrexate|Drug: temozolomide 100 mg/m^2|Drug: temozolomide 150 mg/m^2|Drug: temozolomide 200 mg/m^2|Radiation: radiation therapy|Drug: post-radiation therapy temozolomide,Number of Phase I Participants Experiencing Toxicity|Phase II: Overall Survival Rate at 2 Years (Including Phase I Patients at Same Dose)|Phase II: Pre-irradiation Chemotherapy Tumor Response Rate (Including Phase I Patients at Same Dose)|Phase II: Progression-free Survival (Including Phase I Patients at Same Dose),Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,60.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RTOG-0227|CDR0000301563,2003-07-01,December 2016,2016-12-01,"September 11, 2003","February 7, 2018","February 7, 2018","Integrated Community Oncology Network, Jacksonville Beach, Florida, United States|Baptist Cancer Institute - Jacksonville, Jacksonville, Florida, United States|Integrated Community Oncology Network at Southside Cancer Center, Jacksonville, Florida, United States|Baptist Medical Center South, Jacksonville, Florida, United States|Integrated Community Oncology Network - Orange Park, Orange Park, Florida, United States|Florida Cancer Center - Palatka, Palatka, Florida, United States|Flagler Cancer Center, Saint Augustine, Florida, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|CCOP - Kansas City, Kansas City, Missouri, United States|Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States|CCOP - Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|John F. Kennedy Medical Center, Edison, New Jersey, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Providence Cancer Center at Providence Portland Medical Center, Portland, Oregon, United States|CCOP - Columbia River Oncology Program, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States|Jon and Karen Huntsman Cancer Center at Intermountain Medical Center, Murray, Utah, United States|Utah Valley Regional Medical Center - Provo, Provo, Utah, United States|Southwest Washington Medical Center Cancer Center, Vancouver, Washington, United States|Community Memorial Hospital Cancer Care Center, Menomonee Falls, Wisconsin, United States|Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00068250,4902.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
494,495,NCT00667615,"Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)",,Completed,Has Results,Hodgkin's Disease|Lymphoma,"Drug: rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim","Maximum Tolerated Dose (MTD) of Vorinostat Given Orally for 10 Days in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma|Complete Response Rate to Rituximab and a Combination of Vorinostat With Cyclophosphamide, Etoposide, and Prednisone in Elderly Pts With Relapsed Diffuse Large B-cell Lymphoma Who Aren't Candidates for Autologous Stem Cell Transplantation.",Memorial Sloan Kettering Cancer Center|Merck Sharp & Dohme LLC|Northwestern University|NorthShore University HealthSystem|Weill Medical College of Cornell University,All,"60 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,08-045,2008-04-01,February 2017,2017-02-01,"April 28, 2008","November 7, 2017","January 5, 2018","Memorial Sloan Kettering Cancer Center @ BaskingRidge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center @ Phelps, Sleepy Hollow, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT00667615/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT00667615,3228.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
495,496,NCT02017613,Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies,PI3K,Completed,No Results Available,"Lymphoma, B-Cell|T-Cell Lymphoma",Drug: RP6530,Maximum tolerated dose (MTD) and pharmacokinetics (PK) of RP6530|Clinical response following administration of RP6530,Rhizen Pharmaceuticals SA,All,"18 Years and older   (Adult, Older Adult)",Phase 1,35.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RP6530-1301|2013-003769-32,2013-11-01,May 2016,2016-05-01,"December 23, 2013",,"June 24, 2016","Rhizen Trial Site, Paris, France|Rhizen Trial Site 1, Milano, Italy|Rhizen Trial Site 2, Milano, Italy",,https://ClinicalTrials.gov/show/NCT02017613,912.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
497,498,NCT00705874,Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma,,Completed,Has Results,Cancer,Drug: CGC-11047 and gemcitabine|Drug: CGC-11047 and docetaxel|Drug: CGC-11047 and bevacizumab|Drug: CGC-11047 and erlotinib|Drug: CGC-11047 and cisplatin|Drug: CGC-11047 and 5-flurouracil / leucovorin|Drug: CGC-11047 and sunitinib,Maximum Tolerated Dose (MTD)|Drug Safety|Pharmacokinetics,Progen Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 1,172.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,47-01-002,2006-05-01,August 2011,2011-09-01,"June 26, 2008","February 27, 2012","July 21, 2016","Rocky Mountain Cancer Centre, Denver, Colorado, United States|Cancer Centres of Florida, Ocoee, Florida, United States|Central Indiana Cancer Centres, Indianapolis, Indiana, United States|Comprehensive Cancer Centres of Nevada, Las Vegas, Nevada, United States|New York Oncology Hematology PC, Albany, New York, United States|Dayton Oncology and Hematology, PA, Kettering, Ohio, United States|Cancer Centres of the Carolinas, Greenville, South Carolina, United States|Texas Oncology, PA, Dallas, Texas, United States|Tyler Cancer Centre, Tyler, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Northwest Cancer Specialists - Vancouver Cancer Centre, Vancouver, Washington, United States|North Star Lodge Cancer Centre, Yakima, Washington, United States",,https://ClinicalTrials.gov/show/NCT00705874,1949.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
498,499,NCT02293109,Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma,,Completed,No Results Available,Contiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia,Drug: carfilzomib|Drug: cyclophosphamide|Drug: vincristine sulfate|Drug: doxorubicin hydrochloride|Drug: dexamethasone|Drug: methotrexate|Drug: cytarabine|Drug: leucovorin calcium|Drug: methylprednisolone|Biological: rituximab|Other: laboratory biomarker analysis,"Maximum tolerated dose of carfilzomib with hyper-CVAD, defined as the dose that produces dose limiting toxicity in 17% or fewer (1/6) of patients, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4|Rate of remission|Rate of minimal residual disease (MRD) in bone marrow aspirate samples|Rate of MRD in bone marrow aspirate samples","Mehrdad Abedi, MD|Amgen|University of California, Davis",All,18 Years to 64 Years   (Adult),Phase 1,10.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,660258|UCDCC#246|NCI-2014-02245,2015-12-17,"December 13, 2017",2018-01-11,"November 18, 2014",,"March 10, 2022","University of California Davis, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT02293109,756.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
500,501,NCT01691807,Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma,,Completed,No Results Available,Cancer,Drug: ofatumumab|Drug: bendamustine,Pharmacokinetic measures of Cmax and Area Under the Curve by analysis of blood samples for the amount of each drug present at different timepoints.|Changes in vital signs and the number adverse events|Measure the extent of the disease by CT scan or flow cytometry analysis,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,113603,2013-01-01,December 2015,2015-12-01,"September 25, 2012",,"February 28, 2018","Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Southaven, Mississippi, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Morgantown, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT01691807,1064.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
501,502,NCT02669017,Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL),,Completed,Has Results,"Non-Hodgkin Lymphoma|Burkitt's Lymphoma|Chronic Lymphocytic Leukemia|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular|Lymphoma, Mantle-Cell|Lymphoma, Marginal Zone|Waldenstrom Macroglobulinemia|Primary Mediastinal B-cell Lymphoma",Drug: ADCT-402,Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)|Recommended Dose of ADCT-402 for Part 2|Number of Participants Reporting at Least One Treatment Emergent Adverse Event (TEAE)|Number of Participants Reporting at Least One Treatment Emergent Serious Adverse Event (SAE)|Overall Response Rate (ORR)|Duration of Response (DoR)|Overall Survival (OS)|Progression-free Survival (PFS)|Maximum Observed Serum Concentration (Cmax) for ADCT-402|Time to Reach the Maximum Serum Concentration (Tmax) for ADCT-402|Area Under the Serum Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for ADCT-402|Area Under the Serum Concentration-Time Curve From Time 0 to the End of the Dosing Interval (AUCtau) for ADCT-402|Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf) for ADCT-402|Terminal Half-life (Thalf) of ADCT-402|Apparent Clearance (CL) at Steady State for ADCT-402|Volume of Distribution at Steady State (Vss) for ADCT-402|Accumulation Index (AI) for ADCT-402|Number of Participants With Anti-drug Antibody Response (ADA) Against ADCT-402,ADC Therapeutics S.A.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,183.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ADCT-402-101|2016-000952-92,2016-03-01,"February 21, 2019",2019-02-21,"January 29, 2016","April 13, 2020","May 19, 2021","UC San Diego Moores Cancer Center, La Jolla, California, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center Herbert Irving Pavilion, New York, New York, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Greenville Health System, Institute for Translational Oncology Research, Clinical Research Unit, Greenville, South Carolina, United States|Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|U.O Oncologia e Ematologia - Istituto Clinico Humanitas, Milano, Italy|University College London Hospitals, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02669017/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02669017/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02669017,1087.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
502,503,NCT01994850,"Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients",,Completed,Has Results,CD30 Positive Primary Mediastinal Large B-cell Lymphoma|CD30-Positive Diffuse Large B-Cell Lymphoma|CD30-Positive Gray Zone Lymphoma,Drug: brentuximab vedotin,Number of Subjects With Dose-limiting Toxicities|Overall Response Rate (ORR),Abramson Cancer Center of the University of Pennsylvania,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,32.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UPCC 17413,2013-11-01,August 2017,2019-01-01,"November 26, 2013","September 17, 2019","January 5, 2021","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT01994850/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01994850,1887.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
503,504,NCT00025129,VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas,,Completed,No Results Available,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: laromustine,,Vion Pharmaceuticals|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,,Industry,Interventional,Primary Purpose: Treatment,VION-CLI-011|CDR0000068919|NCI-V01-1669,2001-03-01,,2004-05-01,"January 27, 2003",,"July 18, 2013","Arizona Clinical Research Center, Tucson, Arizona, United States|Yale Comprehensive Cancer Center, New Haven, Connecticut, United States|Veterans Affairs Medical Center - West Haven, West Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00025129,1157.0,Industry Lead,Three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
504,505,NCT00016172,ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma,,Completed,No Results Available,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: pegylated liposomal doxorubicin hydrochloride|Drug: picoplatin,,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,,Other|NIH,Interventional,Primary Purpose: Treatment,00-044|CDR0000068603|NCI-G01-1942,2000-11-01,April 2002,2002-04-01,"February 16, 2004",,"June 18, 2013","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00016172,516.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
505,506,NCT02342665,"Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL",,Completed,No Results Available,Lymphoma Non-Hodgkin,Drug: Copanlisib (BAY80-6946),Number of participants with Adverse Events|Intensity of AE|Objective Tumor Response (OR)|Recommended dose determined in the dose escalation/safety evaluation,Bayer,All,"20 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,25.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17792,2015-04-21,"September 14, 2018",2022-02-10,"January 21, 2015",,"January 20, 2023","Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Maebashi, Gunma, Japan|Kobe, Hyogo, Japan|Sendai, Miyagi, Japan|Chuo-ku, Tokyo, Japan|Koto-ku, Tokyo, Japan|Fukuoka, Japan|Fukuoka, Japan|Kyoto, Japan",,https://ClinicalTrials.gov/show/NCT02342665,2487.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
507,508,NCT05176873,"A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants",,Completed,No Results Available,"Lymphoma, Non-Hodgkin",Drug: DZD8586|Drug: Placebo,"Number and percentage of participants with adverse event, serious adverse event, clinically defined abnormal vital signs, laboratory values, ECG abnormalities|Plasma and urine concentrations of DZD8586","Dizal (Jiangsu) Pharmaceutical Co., Ltd.|Dizal Pharmaceuticals",All,18 Years to 55 Years   (Adult),Phase 1,64.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DZ2021B0002,2021-12-09,"May 11, 2022",2022-05-22,"January 4, 2022",,"July 11, 2022","Frontage Clinical Service 200 Meadowlands Parkway, Secaucus, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT05176873,164.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,Not Open Label,Treatment/Diagnostic
508,509,NCT01969669,A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199,,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: ABT-199|Drug: Ketoconazole,"Determination of maximum observed plasma concentration (Cmax), time to Cmax (peak time, Tmax), terminal phase elimination rate constant (beta), terminal phase elimination half-life (t1/2), & area under the plasma concentration-time curve (AUC) of ABT-199|Number of subjects with adverse events|Percentage of subjects with adverse events|Change in physical exam finding, including vital signs|Change in clinical laboratory test results|Change in cardiac assessment findings","AbbVie|Genentech, Inc.",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1,12.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,M13-364,2013-12-01,September 2014,2014-09-01,"October 25, 2013",,"November 20, 2017","Site Reference ID/Investigator# 97498, Tucson, Arizona, United States|Site Reference ID/Investigator# 92593, Lebanon, New Hampshire, United States|Site Reference ID/Investigator# 101415, Hackensack, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT01969669,274.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
510,511,NCT00802113,Autologous and Allogeneic Transplant for Relapsed Lymphoma,,Completed,Has Results,Non-Hodgkin's Lymphoma|Hodgkins Disease,Drug: Fludarabine|Drug: Busulfan|Drug: Anti-Thymocyte Globulin,Total Number of Subjects With a Complete Response (CR) Following Myeloablative Conditioning (MAC) and Autologous Stem Cell Transplantation (AutoSCT)|Total Number of Subjects With a Disease Relapse or Progression Following MAC AutoSCT|Total Number of Subjects With Partial Response or Stable Disease Following MAC AutoSCT|Time to Neutrophil Engraftment|Time to Platelet Engraftment|Total Number of Subjects With Grade II-IV Acute Graft-versus-Host-Disease (GVHD)|Total Number of Subjects That Experienced Transplant-related Mortality (TRM),Columbia University,All,"up to 55 Years   (Child, Adult)",Phase 1|Phase 2,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AAAA5185|CHNY-01-501,2003-06-01,October 2014,2014-10-22,"December 4, 2008","March 27, 2019","March 27, 2019","Children's Memorial Hospital in Chicago, Chicago, Illinois, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University Medical Center, New York, New York, United States|New York Medical College, Valhalla, New York, United States|Duke University, Durham, North Carolina, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00802113,4161.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
511,512,NCT00295932,"Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma",,Completed,Has Results,Leukemia|Lymphoma,Biological: rituximab|Drug: bortezomib|Drug: cyclophosphamide|Drug: prednisone,"Maximum Tolerated Dose|Progression-free Survival|Duration of Response (Mean and Median)|Event-free Survival|Overall Survival|Toxicity of Participants Receiving Bortezomib, Rituximab, Cyclophosphamide, and Prednisone for Treatment of Non-Hodgkin's Lymphoma",Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey|Columbia University|Emory University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,79.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,05-103|MSKCC-05103,2005-12-13,"March 11, 2018",2018-03-11,"February 24, 2006","November 20, 2018","November 20, 2018","Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States|Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States|Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Memorial Sloan-Kettering at Mercy Medical Center, Rockville Centre, New York, United States|Memoral Sloan Kettering Cancer Center@Phelps, Sleepy Hollow, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT00295932/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT00295932,4471.0,Not Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
513,514,NCT00049712,Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma,,Completed,No Results Available,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Biological: etaracizumab,,"University of Wisconsin, Madison|National Cancer Institute (NCI)",All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1,,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000257810|P30CA014520|WCCC-CO-01905|NCI-5497,2002-10-01,February 2006,2006-02-01,"January 27, 2003",,"December 13, 2019","University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00049712,1219.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
514,515,NCT00861510,"A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies",,Completed,No Results Available,"Lymphoma, Mantle-cell|Leukemia, Lymphocytic, Chronic, B-Cell|Leukemia, Hairy Cell|Waldenstrom Macroglobulinemia|Multiple Myeloma",Drug: ON01910 Na,"Safety of escalating doses ON01910.Na at day 28.|The reduction in lymph nodes, quantification of circulating lymphoma cells, assessment of extranodal disease sites, and/or measurement of the malignant monoclonal proteins in the serum or urine after 4 cycles of therapy (day 56).","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1,16.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,090094|09-H-0094,2009-03-05,"October 19, 2012",2012-10-19,"March 13, 2009",,"December 3, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00861510,1324.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
515,516,NCT00005021,Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma,,Completed,No Results Available,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Biological: filgrastim|Drug: carboplatin|Drug: paclitaxel|Drug: topotecan hydrochloride,,Fox Chase Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,17.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FCCC-96004|CDR0000064913|NCI-T95-0075H,1996-07-01,May 2003,2003-05-01,"May 3, 2004",,"July 11, 2013","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00005021,2495.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
516,517,NCT03682796,Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma,,Completed,No Results Available,"Lymphoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Lymphoma, Mantle-Cell|Lymphoma, Marginal Zone|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular",Drug: TRPH-222,"Maximum Tolerated Dose (MTD)|Evaluate incidence and severity of AEs, serious AEs, TRPH-222-related AEs, AEs leading to death or discontinuation from treatment|Tumor Activity|TRPH-222 Pharmacokinetics (PK)|TRPH-222 anti-drug antibodies (ADA)",Triphase Research and Development III Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,32.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TRPH-222-100,2018-10-15,"November 17, 2021",2021-11-17,"September 25, 2018",,"May 19, 2022","Banner MD Anderson, Gilbert, Arizona, United States|Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Jewish General Hospital, Montréal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT03682796,1129.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
517,518,NCT01000285,EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma,ATLL,Completed,Has Results,"Leukemia-Lymphoma, Adult T-Cell",Drug: Bortezomib|Drug: Etoposide|Drug: Vincristine|Drug: Doxorubicin|Drug: Prednisone|Drug: Cyclophosphamide|Drug: Raltegravir,Tolerability of Treatment as Measured by Number of Participants With Grade 3 or Higher Adverse Events|Efficacy of Treatment as Measured by Best Overall Response|Time to Progression|Effects of on HTLV-1 DNA After Treatment as Measured by Proviral Loads|Relation of NFκB Gene Expression Profile on Response|Effects of HTLV-1 RNA Load After Treatment as Measured by Hbz Messenger RNA|Effects of HTLV-1 Integrase Gene Sequence After Treatment as Measured by Nucleotide Divergence|Effects of HTLV-1 Integration Sites After Treatment,Washington University School of Medicine,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,18.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,09-1758 / 201108212,2010-09-01,May 2014,2016-04-01,"October 23, 2009","December 13, 2016","March 28, 2017","University of Miami Hospital/Sylvester, Miami, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Montefiore Medical Center, Bronx, New York, United States|Columbia University, College of Physicians and Surgeons, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01000285,2039.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
519,520,NCT00001270,"Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma",,Completed,No Results Available,Breast Neoplasms|Lymphoma|Neoplasm Metastasis|Testicular Neoplasms,Drug: interleukin-1,,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",Phase 1,85.0,NIH,Interventional,Primary Purpose: Treatment,910156|91-C-0156,1991-06-01,,2000-03-01,"December 10, 2002",,"March 4, 2008","National Cancer Institute (NCI), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00001270,3196.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
520,521,NCT00003368,Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis,,Completed,No Results Available,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: irinotecan hydrochloride,,National Cancer Institute (NCI)|Alliance for Clinical Trials in Oncology,All,"18 Years and older   (Adult, Older Adult)",Phase 1,,NIH|Other,Interventional,Primary Purpose: Treatment,CDR0000066357|U10CA031946|CLB-9863,1998-06-01,,2006-07-01,"March 12, 2004",,"March 21, 2013","Veterans Affairs Medical Center - Birmingham, Birmingham, Alabama, United States|University of California San Diego Cancer Center, La Jolla, California, United States|Veterans Affairs Medical Center - San Francisco, San Francisco, California, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|CCOP - Christiana Care Health Services, Wilmington, Delaware, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States|University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States|Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Holden Comprehensive Cancer Center at The University of Iowa, Iowa City, Iowa, United States|Veterans Affairs Medical Center - Togus, Togus, Maine, United States|Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|Veterans Affairs Medical Center - Minneapolis, Minneapolis, Minnesota, United States|Veterans Affairs Medical Center - Columbia (Truman Memorial), Columbia, Missouri, United States|Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|Veterans Affairs Medical Center - Buffalo, Buffalo, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|CCOP - North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|New York Presbyterian Hospital - Cornell Campus, New York, New York, United States|Mount Sinai Medical Center, NY, New York, New York, United States|State University of New York - Upstate Medical University, Syracuse, New York, United States|Veterans Affairs Medical Center - Syracuse, Syracuse, New York, United States|CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Veterans Affairs Medical Center - Durham, Durham, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|CCOP - Southeast Cancer Control Consortium, Winston-Salem, North Carolina, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Tennessee, Memphis Cancer Center, Memphis, Tennessee, United States|Veterans Affairs Medical Center - Memphis, Memphis, Tennessee, United States|Veterans Affairs Medical Center - White River Junction, White River Junction, Vermont, United States|Veterans Affairs Medical Center - Richmond, Richmond, Virginia, United States|MBCCOP - Massey Cancer Center, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00003368,2952.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
521,522,NCT00993239,Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma,,Completed,No Results Available,Cancer,Drug: Birinapant (TL32711),Define the MTD|Tumor burden according to Response Evaluation Criteria in Solid Tumors (RECIST)/Revised Response Criteria Malignant Lymphoma|Translational biomarkers and pharmacokinetics,TetraLogic Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 1,50.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TL32711-FIH-007-PTL-F,2009-11-01,August 2012,2013-03-01,"October 12, 2009",,"March 3, 2016","Roswell Park Cancer Institute, Buffalo, New York, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00993239,1216.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
522,523,NCT01226277,"A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma",,Completed,No Results Available,Solid Cancers,Drug: GDC-0917,"Changes in vital signs, ECGs, and clinical laboratory results|Incidence and nature of dose-limiting toxicities and adverse events of special interest|Incidence, nature, and severity of all adverse events and serious adverse events|Pharmacokinetic parameters of GDC-0917 (including total exposure, maximum and minimum serum concentration, time to maximum observed plasma concentration, elimination of half-life, accumulation at steady-state)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,42.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4914g|GO01306,2010-10-01,September 2012,2012-09-01,"October 22, 2010",,"November 2, 2016","Nashville, Tennessee, United States|San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01226277,701.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
523,524,NCT02843061,Combination of Rituximab and NK Immunotherapy for B Lymphoma,,Completed,No Results Available,B-cell Lymphoma Recurrent,Drug: Rituximab|Biological: NK immunotherapy,Relief degree evaluated by the RECIST|Progress free survival (PFS)|Overall survival (OS),"Fuda Cancer Hospital, Guangzhou|Shenzhen Hank Bioengineering Institute",All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,30.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NK-Rituximab,2016-07-01,"July 1, 2017",2019-07-01,"July 25, 2016",,"September 12, 2019","Cancer Institute in Fuda cancer hospital, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT02843061,1095.0,Not Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
524,525,NCT00733824,Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma,,Completed,Has Results,"Lymphoma, Non-Hodgkin|Hodgkin Disease",Drug: AMD3100|Drug: G-CSF|Procedure: Apheresis,Maximum Tolerated Dose (MTD) of IV AMD3100 + G-CSF in Mobilization of Peripheral Blood Stem Cell in Patients With Lymphoma (Phase I Only)|Number of Participants Who Experienced Dose Limiting Toxicities in Phase I Portion of Study|Kinetics of Stem Cell Mobilization Using IV AMD3100 as Measured by Median Fold Change in the Number of CD34+ Cells After AMD3100 IV Administration|Pharmacodynamic Response to a Dose of SC AMD3100 as Measured by Mean Percentage of the Circulating CD34+ Count With the 34+RA-123+/- Phenotype|Toxicity of the Combination IV AMD3100 and G-CSF to Mobilize ≥ 2 x 106 CD34+ Cells/kg as Measured by Number of Participants Who Experience Grade 3 or Higher Adverse Event Broken Down by Adverse Event,Washington University School of Medicine,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,61.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,08-0897 / 201105349,2008-11-01,September 2012,2013-09-01,"August 13, 2008","October 28, 2016","March 9, 2017","Washington University School of Medicine, St. Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00733824,1765.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
525,526,NCT00185965,CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas,,Completed,Has Results,Non-Hodgkin Lymphoma|Mycosis Fungoides,Drug: CPG 7909,Objective Response Rate (ORR),Ronald Levy|Lymphoma Research Foundation|American Society of Clinical Oncology|Stanford University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB-13063|80057|LYMNHL0014,2004-07-01,March 2010,2010-03-01,"September 16, 2005","August 1, 2014","August 1, 2014","Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT00185965,2069.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
526,527,NCT01421173,"Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies",,Completed,No Results Available,Lymphoma,Drug: Vorinostat|Drug: Gemcitabine|Drug: Busulfan|Drug: Melphalan|Procedure: Stem Cell Infusion|Drug: Rituximab|Drug: G-CSF|Drug: Palifermin|Drug: Dexamethasone acetate,Recommended Dose of Vorinostat for combination with Gemcitabine/Busulfan/Melphalan (GemBuMel) based on Dose Limiting Toxicity (DLT),M.D. Anderson Cancer Center,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Phase 1,78.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2011-0407|NCI-2011-02891,2011-08-01,September 2015,2015-09-01,"August 22, 2011",,"November 18, 2015","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01421173,1492.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
527,528,NCT00720135,Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma,,Completed,No Results Available,Anaplastic Large Cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenstrom Macroglobulinemia,Biological: DI-Leu16-IL2 immunocytokine|Biological: rituximab|Other: flow cytometry|Other: immunohistochemistry staining method|Other: pharmacological study|Other: laboratory biomarker analysis|Other: enzyme-linked immunosorbent assay|Genetic: reverse transcriptase-polymerase chain reaction,Maximum tolerated dose of DI-Leu16-IL2|Optimal biologic dose of DI-Leu16-IL2|Toxicities associated with the DI-Leu16-IL2 regimen|Immunogenicity as a result of DI-Leu16-IL2 administration|Pharmacokinetics of DI-Leu16-IL2 administration|Clinical responses and survival,City of Hope Medical Center|National Cancer Institute (NCI),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,9.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,03131|NCI-2010-01228|CDR0000598679|P50CA107399,2008-01-01,July 2014,2014-07-01,"July 22, 2008",,"June 8, 2015","City of Hope, Duarte, California, United States",,https://ClinicalTrials.gov/show/NCT00720135,2373.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
529,530,NCT01273090,Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma,,Completed,No Results Available,"Brain and Central Nervous System Tumors|Lymphoma|Lymphoproliferative Disorder|Small Intestine Cancer|Unspecified Childhood Solid Tumor, Protocol Specific",Drug: imetelstat sodium|Other: laboratory biomarker analysis|Other: pharmacological study,Maximum-tolerated dose and/or recommended phase II dose of imetelstat sodium in children with refractory or recurrent solid tumors or lymphoma|Toxicities of imetelstat sodium,Children's Oncology Group|National Cancer Institute (NCI),All,"1 Year to 21 Years   (Child, Adult)",Phase 1,34.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ADVL1112|COG-ADVL1112,2011-05-01,September 2013,2013-10-01,"January 10, 2011",,"January 30, 2014","UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|Children's Hospital of Orange County, Orange, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Riley's Children Cancer Center at Riley Hospital for Children, Indianapolis, Indiana, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C.S. Mott Children's Hospital at University of Michigan Medical Center, Ann Arbor, Michigan, United States|Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, St. Louis, Missouri, United States|Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States|Baylor University Medical Center - Houston, Houston, Texas, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States|Midwest Children's Cancer Center at Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Hospital for Sick Children, Toronto, Ontario, Canada|Hopital Sainte Justine, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01273090,884.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
531,532,NCT01590732,"Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma",,Completed,No Results Available,"Mycosis Fungoides|Recurrent Anaplastic Large Cell Lymphoma|Recurrent Angioimmunoblastic T-Cell Lymphoma|Recurrent Enteropathy-Associated T-Cell Lymphoma|Recurrent Hepatosplenic T-Cell Lymphoma|Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified|Refractory Anaplastic Large Cell Lymphoma|Refractory Angioimmunoblastic T-Cell Lymphoma|Refractory Enteropathy-Associated T-Cell Lymphoma|Refractory Hepatosplenic T-Cell Lymphoma|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified",Drug: Carboplatin|Drug: Etoposide|Drug: Ifosfamide|Drug: Romidepsin,Maximum tolerated dose|Incidence of adverse events|Overall response rate|Complete response,M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,22.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012-0183|NCI-2018-01827|P30CA016672,2012-10-29,"May 2, 2018",2018-05-02,"May 3, 2012",,"September 19, 2018","M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01590732,2011.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
532,533,NCT02733042,"A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia",FUSION NHL 001,Completed,Has Results,"Lymphoma|Leukemia, Lymphocytic, Chronic, B-Cell",Drug: Durvalumab|Drug: Lenalidomide|Drug: Rituximab|Drug: Ibrutinib|Drug: Bendamustine,Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)|Number of Participants With Treatment-emergent Adverse Events|Overall Response Rate (ORR) During Durvalumab Treatment|Overall Response Rate During the Entire Study|Time to First Response|Kaplan-Meier Estimate of Duration of Response|Kaplan-Meier Estimate of Progression-free Survival (PFS)|Maximum Observed Plasma Concentration (Cmax) of Durvalumab|Time to Maximum Plasma Concentration (Tmax) of Durvalumab|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Durvalumab|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Durvalumab|Terminal Elimination Phase Half-Life (t½) of Durvalumab|Clearance (CL) of Durvalumab|Volume of Distribution (Vz) of Durvalumab|Maximum Observed Plasma Concentration (Cmax) of Lenalidomide|Time to Maximum Observed Plasma Concentration (Tmax) of Lenalidomide|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Lenalidomide|Maximum Observed Plasma Concentration (Cmax) of Ibrutinib|Time to Maximum Observed Plasma Concentration (Tmax) of Ibrutinib|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Ibrutinib|Change From Baseline in Soluble Programmed Cell Death Ligand-1 (sPD-L1) Concentration,Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,106.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MEDI4736-NHL-001|2015-003516-21,2016-05-11,"March 6, 2019",2022-08-21,"April 11, 2016","March 18, 2020","January 10, 2023","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Shands Cancer Center University of Florida, Gainesville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Medical College, New York, New York, United States|Local Institution - 005, Rochester, New York, United States|University of Rochester, Rochester, New York, United States|The Ohio State University, Columbus, Ohio, United States|University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Jefferson Medical Oncology Associates, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Houston Methodist Cancer Center, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Centre Hospitalier Universitaire d'Avicennes, Bobigny Cedex, France|Hopital Henri Mondor, Creteil, France|Centre Hospitalier, Dijon Cedex, France|Institut Paoli Calmettes, Marseille Cedex 9, France|CHU Montpellier, Montpellier Cedex 5, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Local Institution - 105, Nantes, France|Hopital Haut Leveque, Pessac Cedex, France|Centre Hospitalier Lyon-Sud, Pierre-Benite CEDEX, France|Local Institution - 103, Pierre-Benite CEDEX, France|CHRU Rennes, Rennes, France|Centre Henri Becquerel, Rouen Cedex, France|Universitatsklinikum Essen, Essen, Germany|UKG Universitatsklinikum Gottingen, GÃ¶ttingen, Germany|Universitatsklinikum des Saarlandes, Homburg-Saar, Germany|Universitatsklinik Koln, KÃ¶ln, Germany|Medizinische Klinik III Klinikum der UniversitÃ¤t MÃ¼nchen-GroÃŸhadern, MÃ¼nchen, Germany|University of Bologna, Bologna, Italy|Local Institution - 306, Brescia, Italy|Spedali Civili Di Brescia, Brescia, Italy|IEO- Istituto Europeo di Oncologia, Milano, Italy|A.O. Ospedale Ca Granda - Niguarda, Milano, Italy|Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Napoli, Campania, Italy|Local Institution - 304, Napoli, Campania, Italy|I.R.C.C.S. Policlinico San Matteo, Pavia, Italy|IRCCS Humanitas Clinical Institute, Rozzano (milano), Italy|Local Institution - 602, Chuo-ku, Tokyo, Japan|National Cancer Center Hospital, Chuo-ku, Japan|Tokai University Hospital, Isehara City, Kanagawa, Japan|Aichi Cancer Center, Nagoya, Japan|VU Academic Medical Center, Amsterdam, Amsterdam, Netherlands|UMC Groningen, Groningen, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Local Institution - 501, Rotterdam, Netherlands|Local Institution - 402, Plymouth, Devon, United Kingdom|Local Institution - 407, Nottingham, Nottinghamshire, United Kingdom|St James University Hospital, Leeds, United Kingdom|UCL Cancer Institute, London, United Kingdom|Christie Hospital NHS Trust, Manchester, United Kingdom|Local Institution - 404, Manchester, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Local Institution - 406, Oxford, United Kingdom|Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Southampton University Hospitals NHS Trust, Southampton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02733042/Prot_000.pdf|""Statistical Analysis Plan: MEDI4736-NHL-001_SAP_Redacted.14Dec2017"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02733042/SAP_001.pdf|""Statistical Analysis Plan: MEDI4736-NHL-001_SAP_Amendment_1_Redacted.14Dec2017"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02733042/SAP_002.pdf",https://ClinicalTrials.gov/show/NCT02733042,2293.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
533,534,NCT00667082,"NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma",,Completed,No Results Available,Non-Small Cell Lung Cancer|Pancreatic Cancer|Melanoma|Lymphoma|Multiple Myeloma,Drug: NPI-0052 (marizomib) + vorinostat,To determine the Maximum tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the combination NPI-0052 and Vorinostat|To evaluate the pharmacokinetics and pharmacodynamics of NPI-0052 and vorinostat|To evaluate the safety and toxicity profile of the combination of NPI-0052 and vorinostat|To evaluate the anti-tumor activity of NPI-0052 and vorinostat,Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 1,22.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,NPI-0052-103,2008-03-01,January 2010,2010-01-01,"April 25, 2008",,"November 22, 2017","Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Sir Charles Gairdner Hospital and University of Western Australia, Nedlands, Western Australia, Australia",,https://ClinicalTrials.gov/show/NCT00667082,671.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
535,536,NCT00968760,CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies,,Completed,No Results Available,Lymphoma|B-cell Lymphoma,Procedure: Leukapheresis|Procedure: Stem Cell Transplant|Procedure: CD19-specific T Cell Infusion|Drug: IL-2|Drug: Carmustine|Drug: Etoposide|Drug: Cytarabine|Drug: Melphalan,Maximum Tolerated Dose (MTD) of T-cells ± IL-2,M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Alaunos Therapeutics|Intrexon Corporation,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,34.0,Other|NIH|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2007-0635|5R01CA141303-03|NCI-2011-01129|RP120241,2011-06-20,"April 23, 2020",2020-04-23,"August 31, 2009",,"June 30, 2020","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00968760,3230.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
536,537,NCT01742286,"Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)",,Completed,Has Results,ALK-activated Tumors,Drug: Ceritinib,Incidence Rate of Dose Limiting Toxicities (DLTs) Occurring During First Cycle of Treatment|Summary of Best Overall Response by Overall Response Rate (ORR) Per Investigator Assessment|Duration of Response (DoR) Per Investigator Assessment|Progression Free Survival (PFS) Based on Investigator Assessment|Plasma Concentration Time Profiles by Treatment Group in Escalation Phase|Plasma Concentration Time Profiles by Treatment Group in Expansion Phase|Pharmacokinetics (PK) Parameters: AUC0 - 24h & AUClast in Cycle 1 Day 1 - Dose Escalation Phase (Single Dose)|Pharmacokinetics (PK) Parameters: AUC0 - 24h & AUClast in Cycle 2 Day 1 - Dose Escalation Phase (Single Dose)|Pharmacokinetics (PK) Parameters: AUC0 - 24h & AUClast in Cycle 2 Day 1 - Dose Expansion Phase (Multiple Dose)|PK Parameter: Cmax in Cycle 1 Day 1 - Dose Escalation Phase (Single Dose)|PK Parameter: Cmax in Cycle 2 Day 1 - Dose Escalation Phase (Single Dose)|PK Parameter: Cmax in Cycle 2 Day 1 - Dose Expansion Phase (Multiple Dose)|PK Parameter: Tmax in Cycle 1 Day 1 - Dose Escalation Phase (Single Dose)|PK Parameter: Tmax in Cycle 2 Day 1 - Dose Escalation Phase (Single Dose)|PK Parameter: Tmax in Cycle 2 Day 1 - Dose Expansion Phase (Multiple Dose)|PK Parameter: Racc in Dose Escalation Phase Cycle 2 Day 1,Novartis Pharmaceuticals|Novartis,All,12 Months to 17 Years   (Child),Phase 1,83.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLDK378X2103|2012-002074-31,2013-08-28,"April 26, 2019",2019-04-26,"December 5, 2012","June 9, 2020","June 9, 2020","Dana Farber Cancer Institute Dept of Onc, Boston, Massachusetts, United States|Memorial Sloan Kettering SC - 7, New York, New York, United States|Cincinnati Children s Hospital Medical Center Dept of Oncology, Cincinnati, Ohio, United States|St Jude s Childrens Research Hospital Dept of Oncology, Memphis, Tennessee, United States|Texas Children's Hospital Dept of Oncology, Houston, Texas, United States|Novartis Investigative Site, Randwick, New South Wales, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Utrecht, CS, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, West Midlands, Birmingham, United Kingdom|Novartis Investigative Site, Sutton, Surrey, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT01742286/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT01742286/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01742286,2067.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
538,539,NCT01029366,CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy,,Completed,Has Results,Hematopoietic/Lymphoid Cancer|Adult Acute Lymphoblastic Leukemia in Remission|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma,Biological: CART-19,Number of Participants With Adverse Events|Overall Response Summary,University of Pennsylvania,All,"18 Years and older   (Adult, Older Adult)",Phase 1,26.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UPCC04409, 809517|NCI-2009-01357",2010-03-17,July 2015,2016-05-01,"December 10, 2009","February 28, 2017","June 26, 2019","Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01029366,2237.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
539,540,NCT01292135,Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL),,Completed,Has Results,B-cell Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: PCI-32765,"Incidence of Prolonged Hematologic Toxicity Started in Cycle 1|Incidence of Adverse Events Requiring Dose Delay or Discontinuation of Ibrutinib|Overall Incidence of Grade ≥3 Adverse Events (AEs) Per NCI CTCAE V4.0|Overall Incidence of Serious Adverse Events (SAEs)|Overall Response Rate (Complete Response [CR] + Complete Response With Incomplete Marrow Recovery [CRi] + Nodular Partial Response [nPR] + Partial Response [PR])|Sustained Hematologic Improvement in Subjects With Neutropenia, Anemia, or Thrombocytopenia at Baseline|Progression Free Survival Rate at 12 Months",Pharmacyclics LLC.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,33.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PCYC-1108-CA|PCI-32765,2011-02-01,November 2012,2013-05-01,"February 9, 2011","July 24, 2014","July 24, 2014","Dana Farber Cancer Center, Boston, Massachusetts, United States|CLL Research and Treatment Program, New Hyde Park, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|University of Rochester, Rochester, New York, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01292135,820.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
541,542,NCT00002687,Interleukin-2 in Treating Patients With Mycosis Fungoides,,Completed,No Results Available,Lymphoma,Biological: aldesleukin,,University of Washington,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Primary Purpose: Treatment,CDR0000064412|UW-24218-A/E|NCI-V95-0758,1995-02-01,July 2003,2003-07-01,"January 27, 2003",,"December 4, 2012","University of Washington Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00002687,3072.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
542,543,NCT00121719,An Open Label Dose Escalation Study Of E7080,,Completed,Has Results,Solid Tumor or Lymphoma,Drug: Lenvatinib,Maximum Tolerated Dose (MTD)|Summary of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Dose-limiting Toxicities (DLTs)|Treatment-Related Adverse Events (All Grades) With an Overall Incidence Greater Than or Equal to 10%|Best Overall Response (BOR)|Maximum Plasma Concentration (Cmax) of Lenvatinib|Time to Maximum Plasma Concentration (Tmax) of Lenvatinib|Apparent Plasma Half-life (t1/2) of Lenvatinib|Area Under the Plasma Concentration Curve From Time 0 to Infinity (AUC(0-inf))|Area Under the Plasma Concentration Curve From Time 0 to 24 Hours (AUC(0-24))|Clearance Corrected for the Fraction of Lenvatinib Absorbed (CL/F)|Apparent Volume of Distribution (Vz/F)|Fraction of Unchanged Lenvatinib Excreted in the Urine (fe)|Renal Clearance (CLr) of Lenvatinib|Effect of Food on the Area Under the Curve From Zero to 24 Hours (AUC(0-24))|Effect of Food on the Maximum Plasma Concentration (Cmax) of Lenvatinib|Effect of Food on Time to Maximum Concentration (Tmax) of Lenvatinib,Eisai Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,82.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E7080-E044-101|2004-002265-21,2005-07-01,"June 19, 2009",2019-03-01,"July 21, 2005","May 27, 2016","April 6, 2020","Netherlands Cancer Institute- Antoni Van Leeuwenhoek Hospital, Amsterdam, Netherlands|Gartnavel General Hospital, Glasgow, United Kingdom",,https://ClinicalTrials.gov/show/NCT00121719,4991.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
543,544,NCT00201682,Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma,,Completed,No Results Available,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: Etanercept|Drug: Rituximab,To determine the feasibility and toxicity of the combination of etanercept and rituximab in patients with CLL/SLL.|Determine if etanercept increases the complete response rate while decreasing the frequency of infusion-related toxicity in patients with CLL/SLL receiving rituximab therapy.,John Byrd|Ohio State University Comprehensive Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,36.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSU-0113,2002-10-01,August 2006,2009-08-01,"September 20, 2005",,"February 8, 2017","Ohio State University Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00201682,2496.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
545,546,NCT05526313,Study of Prilinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant,,Completed,No Results Available,Diffuse Large B Cell Lymphoma，DLBCL,Drug: Prilinostat Mesylate 1.2mg/m2|Drug: Prilinostat Mesylate 2.4mg/m2|Drug: Prilinostat Mesylate 4.0mg/m2|Drug: Prilinostat Mesylate 6.0mg/m2|Drug: Prilinostat Mesylate 8.4mg/m2|Drug: Prilinostat Mesylate 11.2mg/m2|Drug: Prilinostat Mesylate 15mg/m2,Prilinostat Mesylate Pharmacokinetics (PK)：Cmax|Prilinostat Mesylate Pharmacokinetics (PK)：Tmax|Prilinostat Mesylate Pharmacokinetics (PK)：AUC0-72h|Prilinostat Mesylate Pharmacokinetics (PK)：AUC0-∞|Prilinostat Mesylate Pharmacokinetics (PK)：MRT|Prilinostat Mesylate Pharmacokinetics (PK)：Vd|Prilinostat Mesylate Pharmacokinetics (PK)：t1/2|Prilinostat Mesylate Pharmacokinetics (PK)：CLz/F|Prilinostat Mesylate Pharmacokinetics (PK)：Vz/F|Prilinostat Mesylate Pharmacokinetics (PK)：Ke,"Chengdu Zenitar Biomedical Technology Co., Ltd",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,29.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",GZ2018-001-1.0,2020-08-19,"October 30, 2022",2022-11-30,"September 2, 2022",,"January 18, 2023","West China Hospital Sichuan University, Chengdu, Sichuan, China",,https://ClinicalTrials.gov/show/NCT05526313,833.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,Not Open Label,Other/Basic/Prevention
546,547,NCT03205176,"AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas",,Completed,No Results Available,Malignant Solid Tumors|Lymphoma|Ovarian Cancer|Breast Cancer|Pancreatic Cancer|Prostate Cancer,Drug: AZD5153|Drug: Olaparib,Incidence of dose-limiting toxicity (DLT).|Peak plasma concentration (Cmax)|The urine concentration of AZD5153 and its co-former (if appropriate).|The effect of AZD 5153 on QTc interval.|Antitumor activity of AZD5153 in patients by assessing the disease control rate (DCR).|Antitumor activity of AZD5153 in patients by assessing progression free survival (PFS).|Antitumor activity of AZD5153 in patients by assessing overall response rate (ORR).|Antitumor activity of AZD5153 in patients by assessing duration of response (DoR).|Area under the plasma concentration versus time curve (AUC).|Time to reach peak plasma concentration (tmax).|Elimination half-lfe (t1/2).|Volume of distribution (Vd).|Clearance (CL).,AstraZeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 1,49.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D6520C00001|REFMAL 495,2017-06-30,"March 1, 2021",2021-04-08,"July 2, 2017",,"May 6, 2021","Research Site, Sarasota, Florida, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Nashville, Tennessee, United States|Research Site, Toronto, CA, Canada",,https://ClinicalTrials.gov/show/NCT03205176,1378.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
547,548,NCT01593696,Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma,,Completed,Has Results,ALL|B Cell Lymphoma|Leukemia|Large Cell Lymphoma|Non-Hodgkin Lymphoma,Biological: Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR),"Number of Participants Who Received Preparative Chemotherapy Followed by Cluster of Differentiation (CD)19-Chimeric Antigen Receptor (CAR): CD19 CAR T-cells With < Grade 4 Cytokine Release Syndrome|Number of Participants in Which the Prescribed Dose of Cluster of Differentiation (CD)19-Chimeric Antigen Receptor (CAR): CD19 CAR T-cells Were Successfully Manufactured|Number of Participants Who Were Administered Intensive Chemotherapy Prior to Cluster of Differentiation (CD)19-Chimeric Antigen Receptor (CAR): CD19 CAR Infusion|Mean Percentage Cluster of Differentiation 19 (CD19) - Chimeric Antigen-Receptor (CAR) T-Cells in Blood, Bone Marrow (BM) and Cerebrospinal Fluid (CSF)|Number of Patients With a Complete Response (CR)|Number of Participants With Grade 4 Cytokine Release Syndrome (CRS)|Number of Participants With Serious and Non-Serious Adverse Events",National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"1 Year to 30 Years   (Child, Adult)",Phase 1,53.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120112|12-C-0112,2012-06-29,"November 11, 2016",2017-10-02,"May 8, 2012","August 31, 2020","August 31, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT01593696/Prot_SAP_000.pdf|""Informed Consent Form: Standard Consent"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT01593696/ICF_001.pdf|""Informed Consent Form: Screening Consent"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT01593696/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT01593696,1921.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
548,549,NCT02242045,"Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)",,Completed,Has Results,Chronic Lymphocytic Leukemia|Indolent Non-Hodgkin Lymphoma|Follicular Lymphoma|Small Lymphocytic Lymphoma|Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia)|Marginal Zone Lymphoma,Drug: Idelalisib,Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Within 28 Days of Idelalisib Exposure|Percentage of Participants Experiencing TEAEs Related to Idelalisib Within 28 Days of Idelalisib Exposure|Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Within 28 Days of Idelalisib Exposure by Worst Grade at Postbaseline|Percentage of Participants Who Permanently Discontinued Idelalisib Due to a TEAE Within 28 Days of Idelalisib Exposure|Plasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 1|Plasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 8|Plasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 15|Plasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 22|Plasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 29|Percentage of Participants Experiencing TEAEs and SAEs Beyond 28 Days of Idelalisib Exposure|Percentage of Participants Experiencing TEAEs Related to Idelalisib Beyond 28 Days of Idelalisib Exposure|Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Beyond 28 Days of Idelalisib Exposure by Worst Grade at Postbaseline|Percentage of Participants Who Permanently Discontinued Idelalisib Due to a TEAE Beyond 28 Days of Idelalisib Exposure,Gilead Sciences,All,"20 Years and older   (Adult, Older Adult)",Phase 1,6.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-313-1380,2014-10-01,"December 25, 2014",2017-10-17,"September 16, 2014","March 19, 2021","March 19, 2021","Aichi, Japan|Miyagi, Japan|Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT02242045,1112.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
549,550,NCT02257242,"Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma",BRiM,Completed,Has Results,"Lymphoma, Non-Hodgkin|Lymphoma, Follicular|Lymphoma, Mantle-Cell|Lymphoma, Small-Cell|Waldenstrom Macroglobulinemia|Lymphoma, B-Cell, Marginal Zone",Drug: Rituximab|Drug: Bendamustine|Drug: Vincristine sulfate liposome injection,Maximum Tolerated Dose|Number of Participants Who Completed Six Cycles of Study Treatment|Response Rate|Complete Response Rate,"Brown University|Spectrum Pharmaceuticals, Inc|Rhode Island Hospital|The Miriam Hospital",All,"18 Years and older   (Adult, Older Adult)",Phase 1,11.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BrUOG 326,2017-05-10,"August 22, 2020",2020-11-18,"October 6, 2014","February 9, 2023","February 9, 2023","Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02257242/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT02257242,1288.0,Not Industry Lead,More than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
550,551,NCT01060904,A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma,,Completed,No Results Available,"Disease, Hodgkin",Drug: brentuximab vedotin|Drug: doxorubicin|Drug: vinblastine|Drug: dacarbazine|Drug: bleomycin,Incidence of adverse events and laboratory abnormalities|Brentuximab vedotin concentration in blood|Antitherapeutic antibodies in blood|Best clinical response,"Seagen Inc.|Millennium Pharmaceuticals, Inc.",All,18 Years to 60 Years   (Adult),Phase 1,51.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SGN35-009,2010-01-01,September 2012,2012-09-01,"February 2, 2010",,"December 18, 2014","Mayo Clinic, Rochester, Minnesota, United States|UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill, North Carolina, United States|MD Anderson Cancer Center / University of Texas, Houston, Texas, United States|British Columbia Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT01060904,974.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
551,552,NCT00500058,"A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18",,Completed,No Results Available,"Lymphoma, Non-Hodgkin",Drug: SB-485232|Drug: Rituximab,"safety/tolerability of combination treatment for 4 weeks safety/tolerability of SB-485232 for additional 8 weeks|assess blood values of combination treatment for 4 weeks assess blood values of SB-485232 for additional 8 weeks|Pharmacokinetic parameters for SB-485232 and Rituxan: AUCtau, Cmax, and Cmin.|Pharmacodynamic biomarker responses:|Plasma IFN-γ, GMCSF, IP-10, MIG, and MCP-1 changes|Plasma IL-18BP change|PBMC phenotype changes|Activated NK cells (CD16+/CD56+/CD3-/CD69+/FasL+ or IL-18Ra+)|Activated cytolytic T cells (CD8+/CD4-/CD3+/CD69+ FasL+ or IL- 18Ra+)|Activated B cells (CD19+/CD25-/CD3-/CD69+)|Activated Neutrophils/Monocytes (CD11b+/CD16+/CD64+/CD14+/CD45+/CD69+)|Regulatory T-cells (FoxP3+/CD25+/CD4+/CD127+)|Immunogenicity (anti-SB-485232 and anti-Rituximab antibodies)|Anti-tumor activity (Radiographic tumor assessments)|CD16 (FcγRIIIA) 158V/F genotyping",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ILI105618,2007-07-31,"March 4, 2010",2010-03-04,"July 12, 2007",,"July 26, 2017","GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00500058,947.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
552,553,NCT02950220,Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,,Completed,No Results Available,"B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3a Follicular Lymphoma|Mediastinal Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Waldenstrom Macroglobulinemia|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma",Drug: Ibrutinib|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab,Incidence of adverse events assessed using NCI CTCAE version 4|MTD defined as the dose level at which no more than one of 6 patients experiences a dose-limiting toxicity assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4|Complete response rates|ORR|Overall survival|Progressive-free survival,Kami Maddocks|National Cancer Institute (NCI)|Ohio State University Comprehensive Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1,2.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSU-16070|NCI-2016-01560|P30CA016058,2017-01-12,"November 19, 2018",2019-01-03,"November 1, 2016",,"July 30, 2019","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02950220,721.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
553,554,NCT03272256,Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma,,Completed,No Results Available,Advanced Solid Tumor,Drug: IM156,Dose Limiting Toxicity (DLT)|Maximum plasma concentration (Cmax)|Time to Cmax (Tmax)|Area under the curve (AUC)|Plasma half life (T1/2)|Volume of distribution (V/F)|Plasma Clearance (CL/F)|Exploratory Surrogate Biomarker|Preliminary tumor response,"ImmunoMet Therapeutics, Inc.",All,"19 Years and older   (Adult, Older Adult)",Phase 1,22.0,Industry,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IM_IM156-01,2017-10-09,"December 2, 2019",2020-07-28,"September 5, 2017",,"October 19, 2020","CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Yonsei University Severance Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03272256,1023.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
554,555,NCT02431988,Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation,COBALT,Completed,No Results Available,Diffuse Large B-Cell Lymphoma,Procedure: Leukapheresis|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: CAR19 T-Cells,Feasibility of adequate leucapheresis collection and generation of CAR19 T cells.|Toxicity evaluation following CAR19 T-cell administration.|Efficacy of CAR19 T-cells.|CAR19 T-cell engraftment|B cell compartment|Cytokine profile|Clinical complete response|Eligibility to allogeneic transplantation,"University College, London",All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Phase 1,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UCL/14/0385|2015-000348-40,2016-06-01,"February 2, 2020",2022-03-21,"May 1, 2015",,"May 26, 2022","University College London Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02431988,2119.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
555,556,NCT00004907,"Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma",,Completed,No Results Available,Lymphoma,Drug: busulfan|Drug: cyclophosphamide|Drug: etoposide|Procedure: allogeneic bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,,Northwestern University|National Cancer Institute (NCI),All,"15 Years to 60 Years   (Child, Adult)",Phase 1|Phase 2,,Other|NIH,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,NU 95H4T|NU-95H4T|NCI-G00-1692,1999-10-01,August 2004,2004-08-01,"January 27, 2003",,"June 12, 2012","Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00004907,1766.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
556,557,NCT00343564,A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma,,Completed,Has Results,Non-Hodgkin's Lymphoma|Hodgkin's Disease,Drug: SB-743921,Phase 1: Determination of Maximum Tolerated Dose (MTD) First Without and Then With Administration of Prophylactic G-CSF.|Characterization of PK (Cmax) of SB-743921 Administered as a 1-hour Intravenous Infusion on Day 1|Characterization of PK (Tmax) of SB-743921 Administered as a 1-hour Intravenous Infusion on Day1|Characterization of PK (Clast) of SB-743921 Administered as a 1-hour Intravenous Infusion on Day 1|Characterization of PK (AUClast) of SB-743921 Administered as a 1-hour Intravenous Infusion on Day 1|Characterization of PK (Cmax) of SB-743921 Administered as a 1-hour Intravenous Infusion on Day 15|Characterization of PK (Tmax) of SB-743921 Administered as a 1-hour Intravenous Infusion on Day 15|Characterization of PK (Clast) of SB-743921 Administered as a 1-hour Intravenous Infusion on Day 15|Characterization of PK (AUClast) of SB-743921 Administered as a 1-hour Intravenous Infusion on Day 15,Cytokinetics,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,68.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 2121,2006-04-01,July 2010,2010-07-01,"June 23, 2006","October 4, 2016","January 13, 2020","Hackensack University Medical Center, Hackensack, New Jersey, United States|Cornell University Medical Center, New York, New York, United States|Memorial Sloan-Kettering Caner Center, New York, New York, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Sarah Cannon Cancer Research Institute, Nashville, Tennessee, United States|Russian Medical Academy of Postgraduate Education, Moscow, Russian Federation|St. Petersburg State PAVLOV Medical University, Saint Petersburg, Russian Federation",,https://ClinicalTrials.gov/show/NCT00343564,1552.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
558,559,NCT00217412,"Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia",,Completed,No Results Available,"Childhood Acute Promyelocytic Leukemia (M3)|Childhood Atypical Teratoid/Rhabdoid Tumor|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Juvenile Myelomonocytic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Neuroblastoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Relapsing Chronic Myelogenous Leukemia|Unspecified Childhood Solid Tumor, Protocol Specific",Drug: vorinostat|Drug: isotretinoin,Maximum tolerated dose (MTD) defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicities DLT graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0|The proportion of patients who demonstrate each polymorphism,National Cancer Institute (NCI),All,"1 Year to 21 Years   (Child, Adult)",Phase 1,60.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2012-01821|CDR0000440999|COG-ADVL0416|NCI-06-C-0254|ADVL0416,2005-08-01,September 2009,2009-09-01,"September 22, 2005",,"June 17, 2014","Children's Oncology Group, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00217412,1492.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
560,561,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,,Completed,Has Results,Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm,Drug: RAD001|Drug: Sorafenib,Number of Participants Reporting a Dose Limiting Toxicity (DLT)|Proportion of Confirmed Tumor Responses|Survival Time|Progression Free Survival,Mayo Clinic|University of Iowa,All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1|Phase 2,103.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LS0689|07-000710,2007-08-29,"November 5, 2011",2019-08-08,"May 17, 2007","July 7, 2016","August 20, 2019","Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00474929,4362.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
561,562,NCT00761722,"Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma",RACE,Completed,No Results Available,"Acute Myeloid Leukemia|Myelodysplastic Syndromes|Lymphoma|Multiple Myeloma|Leukemia, Myelomonocytic, Chronic",Drug: azacitidine,To estimate the dose for a given oral formulation that would yield similar exposure [area under the curve (AUC)] to 75 mg/m2 of the subcutaneous formulation.|To determine the oral bioavailability of up to 6 different oral formulations in comparison to the subcutaneous formulation|To assess the safety and tolerability of subcutaneous and oral formulations of azacitidine|To assess response rates|To assess RBC transfusion independence|To investigate the pharmacokinetics of oral azacitidine|To assess the pharmacodynamic effects of oral azacitidine,Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 1,31.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AZA PH US 2008 CL008,2008-08-12,"April 6, 2016",2016-04-07,"September 29, 2008",,"November 8, 2019","California Cancer Care Inc, Greenbrae, California, United States|Main Cancer Centers of Florida, P.A., Ocoee, Florida, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Northwest Cancer Specialists, P.C., Albuquerque, New Mexico, United States|Willamette Valley Cancer Institute, Springfield, Oregon, United States|University of Texas- MD Anderson, Houston, Texas, United States|Hematology and Oncology Assoc. of South Texas, San Antonio, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Yakima Valley Memorial Hospital/ North Star Lodge, Yakima, Washington, United States",,https://ClinicalTrials.gov/show/NCT00761722,2795.0,Industry Lead,More than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
562,563,NCT00924326,CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma,,Completed,Has Results,"Primary Mediastinal B-cell Lymphoma|Diffuse, Large B-cell Lymphoma|Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma|Mantle Cell",Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL|Drug: Aldesleukin,Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma|Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0).,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,43.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,090082|09-C-0082,2009-02-17,"September 30, 2015",2021-11-17,"June 18, 2009","March 21, 2019","January 12, 2022","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT00924326/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT00924326/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT00924326,4656.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
563,564,NCT00232440,Reproducibility of an Immobilization Device (BodyFIX) - Hodgkins/Lymphoma,,Completed,No Results Available,"Hodgkin's Disease|Lymphoma, Non-Hodgkin",Device: BodyFIX,The primary outcome for the study is the average deviation in set-up.,"University Health Network, Toronto|Princess Margaret Hospital, Canada",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UHN REB 02-0526-C,2003-01-01,June 2009,2009-06-01,"October 4, 2005",,"August 11, 2010","University Health Network, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00232440,2343.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
564,565,NCT01897012,Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas,,Completed,No Results Available,MYC Positive|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Recurrent Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Refractory Hodgkin Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma,Drug: Alisertib|Other: Laboratory Biomarker Analysis|Drug: Romidepsin,"Incidence of adverse events as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (utilized for adverse event reporting beginning April 1, 2018)|Maximum tolerated dose graded according to NCI CTCAE version 5.0|Overall response rate|Complete response",National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,26.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2013-01272|TX035|2012-0602|9342|P30CA016672|U01CA062461|UM1CA186688,2013-07-17,"October 31, 2018",2018-11-30,"July 11, 2013",,"January 28, 2019","M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01897012,1962.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
565,566,NCT01284192,"Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)",,Completed,No Results Available,Advanced Malignancies|Positive for Anaplastic Lymphoma Kinase|Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS|Solid Tumor|B-Cell Lymphoma,Drug: ASP3026,"Safety and tolerability of ASP3026 assessed by recording of adverse events, laboratory assessments, vital signs, electrocardiograms (ECGs) and clinical observations|Pharmacokinetic assessment through analysis of blood and urine samples|Objective response rate (ORR)",Astellas Pharma Inc,All,"18 Years and older   (Adult, Older Adult)",Phase 1,46.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A3026-CL-0101,2010-12-01,February 2014,2016-03-01,"January 26, 2011",,"June 28, 2016","Site US160, Orange, California, United States|Site US184, Sacramento, California, United States|Site US11, Chicago, Illinois, United States|Site US2688, Detroit, Michigan, United States|Site US2492, Houston, Texas, United States|Site US1905, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01284192,1917.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
566,567,NCT01780662,Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma,,Completed,Has Results,Recurrent Adult Hodgkin Lymphoma|Recurrent Childhood Hodgkin Lymphoma|Refractory Childhood Hodgkin Lymphoma,Drug: Brentuximab Vedotin|Drug: Gemcitabine Hydrochloride,Maximum Tolerated Dose (MTD) for Brentuximab Vedotin|Adverse Events Graded According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0|The Number of Patients With Relapsed or Refractory HL Who Achieved Complete Response (CR)|The Number of Patients Who Had Disease Response Assessed by Deauville Scales Among Those in Phase I With Dose Level 2.|Percentage of Patients Who Achieved Overall Response (OR) as Measured by Complete Response (CR) and Partial Response (PR)|The Number of Patients Who Had Successful Peripheral Blood Stem Cell (PBSC) Collection|Plasma Level of Thymus and Activation-Regulated Chemokine (TARC)|Correlation Between Micro Ribonucleic Acid (miRNA) and Disease Response to Protocol Treatment|Number of Patients With FcyRIIIa-158 V/F (Valine/Phenylalanine) Polymorphism,National Cancer Institute (NCI),All,"13 Months to 30 Years   (Child, Adult)",Phase 1|Phase 2,46.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2013-00107|AHOD1221|COG-AHOD1221|U10CA180886|UM1CA097452,2013-01-31,"September 30, 2017",2021-09-30,"January 31, 2013","October 1, 2019","October 28, 2021","Children's Hospital of Alabama, Birmingham, Alabama, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|Kaiser Permanente Downey Medical Center, Downey, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|Children's Hospital of Orange County, Orange, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Children's National Medical Center, Washington, District of Columbia, United States|Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, United States|Nicklaus Children's Hospital, Miami, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Hospital, Orlando, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Saint Mary's Hospital, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Blank Children's Hospital, Des Moines, Iowa, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Saint Joseph's Regional Medical Center, Paterson, New Jersey, United States|Albany Medical Center, Albany, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|NYP/Weill Cornell Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Children's Hospital, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Saint Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Children's Hospital of San Antonio, San Antonio, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|Children's Hospital, London, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|The Montreal Children's Hospital of the MUHC, Montreal, Quebec, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Quebec, Quebec, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT01780662/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01780662,3164.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
567,568,NCT00151320,Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL,,Completed,Has Results,Non-Hodgkin's Lymphoma,"Drug: Bortezomib, CHOP, Rituximab",ORR,"Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,76.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0309006313,2004-01-01,April 2010,2013-04-24,"September 8, 2005","April 7, 2017","June 19, 2018","Dana Farber Cancer Institute, Boston, Massachusetts, United States|Nebraska Medical Center, Omaha, Nebraska, United States|Weill Medical College of Cornell University, New York, New York, United States|Columbia University College of Physicians and Surgeons, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00151320,3401.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
569,570,NCT01129193,"AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma",,Completed,No Results Available,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Prolymphocytic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Testicular Lymphoma|Waldenstrom Macroglobulinemia,Other: Pharmacodynamic Studies|Other: Fatigue Inventory|Other: Pharmacogenomic studies|Drug: AR-42,Adverse events described using the NCI CTCAE criteria|Clinical benefit|Duration of response|Time to progression,Amir Mortazavi|National Cancer Institute (NCI)|Arno Therapeutics|Ohio State University Comprehensive Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1,44.0,Other|NIH|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSU-09102|NCI-2010-01082|P30CA016058,2010-05-04,"January 7, 2017",2017-01-07,"May 24, 2010",,"June 4, 2018","The Ohio State University James Cancer Hospital, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01129193,2440.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
570,571,NCT03109353,Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease,,Completed,No Results Available,"Cutaneous T-Cell Lymphoma, Unspecified|Chronic Graft Versus Host Disease in Skin",Drug: ECP with 5-aminolevulinic acid,"Treatment safety: Monitored through recordings of ECG, vital signs and safety laboratory measurements including haematology, clinical chemistry and urinalysis.|Main efficacy for CTCL|Main efficacy for cGvHD",St. Olavs Hospital|Norwegian University of Science and Technology|Oslo University Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,7.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016-000872-78,2017-09-20,"December 31, 2022",2022-12-31,"April 12, 2017",,"January 13, 2023","St Olavs Hospital, Trondheim, Norway",,https://ClinicalTrials.gov/show/NCT03109353,1928.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
571,572,NCT00049400,S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction,,Completed,No Results Available,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: BMS-247550,dose defining|Progression|Symptomatic deterioration,Southwest Oncology Group|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,78.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,S0355|U01CA076642|P30CA016087|U10CA032102,2003-10-01,September 2006,2007-12-01,"January 27, 2003",,"April 3, 2015","City of Hope Comprehensive Cancer Center, Duarte, California, United States|USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|University of California Davis Cancer Center, Sacramento, California, United States|Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States|Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States|Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Community Oncology Group at Cleveland Clinic Cancer Center, Independence, Ohio, United States|Cleveland Clinic - Wooster, Wooster, Ohio, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Wilford Hall Medical Center, Lackland AFB, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|St. Joseph Hospital Community Cancer Center, Bellingham, Washington, United States|Olympic Hematology and Oncology, Bremerton, Washington, United States|Skagit Valley Hospital Cancer Care Center, Mt. Vernon, Washington, United States|Group Health Central Hospital, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Cancer Institute at Swedish Medical Center - First Hill Campus, Seattle, Washington, United States|University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States|North Puget Oncology at United General Hospital, Sedro-Wooley, Washington, United States|Cancer Care Northwest - Spokane South, Spokane, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States",,https://ClinicalTrials.gov/show/NCT00049400,1522.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
572,573,NCT01744626,Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,,Completed,No Results Available,Leukemia Lymphocytic Chronic B-Cell,Drug: CC-292|Drug: Rituximab,Adverse Events|PK-Cmax|PK-Tmax|PK-λz|PK-t1/2|PK-AUC (0-t)|PK-AUC0-∞|Efficacy,Celgene Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 1,40.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CC-292-CLL-002|2012-003767-21,2012-12-01,December 2015,2015-12-01,"December 7, 2012",,"April 19, 2016","Clearview Cancer Institute, Huntsville, Alabama, United States|Horizon Oncology Research, Inc, Lafayette, Indiana, United States|Hackensack UMC, Hackensack, New Jersey, United States|The West Clinic, Memphis, Tennessee, United States|Universitätsklinik Ulm, Ulm, Bayern, Germany|Städt. Klinikum München-Schwabing, Bayern, Germany|Universitatsklinikum Wurzburg, Bayern, Germany|Universitätsklinik Köln, Köln, Germany",,https://ClinicalTrials.gov/show/NCT01744626,1095.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
573,574,NCT02584920,"A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma",,Completed,No Results Available,B-cell Non Hodgkin's Lymphoma,Drug: HLX01|Drug: Rituximab,Area under the curve (AUC) for HLX01 and rituximab concentrations|The Maximum Concentration (Cmax) of the HLX01 and rituximab|Presence of Anti-Drug Antibodies against HLX01|Change from baseline of CD19+ B-cells,Shanghai Henlius Biotech,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,87.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HLX01-NHL02,2014-10-01,August 2015,2015-08-01,"October 23, 2015",,"May 9, 2022",,,https://ClinicalTrials.gov/show/NCT02584920,304.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,Not Open Label,Treatment/Diagnostic
574,575,NCT00004898,Radiation Therapy and Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With High-Grade Lymphoma or Acute Lymphoblastic Leukemia,,Completed,No Results Available,Leukemia|Lymphoma,Biological: filgrastim|Drug: cyclophosphamide|Drug: etoposide|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,,Northwestern University|National Cancer Institute (NCI),All,"up to 65 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,6.0,Other|NIH,Interventional,Primary Purpose: Treatment,NU 91H5T|NU-91H5I|NCI-G00-1687,1999-10-01,July 2003,2003-07-01,"March 3, 2004",,"June 12, 2012","Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00004898,1369.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
575,576,NCT00002625,Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma,,Completed,No Results Available,Esophageal Cancer|Lung Cancer|Lymphoma,Drug: topotecan hydrochloride|Radiation: low-LET electron therapy|Radiation: low-LET photon therapy,,National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,5.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000063990|WCCC-CO-9492|NCI-T94-0099C,1995-03-01,April 2000,2000-09-01,"June 10, 2004",,"February 11, 2013","University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00002625,2011.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
578,579,NCT01279603,Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas,,Completed,No Results Available,Solid Tumors,Drug: GO-203-2c,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,"Genus Oncology, LLC",All,"18 Years and older   (Adult, Older Adult)",Phase 1,23.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GO-2C-001,2011-01-01,May 2013,2013-05-01,"January 19, 2011",,"September 19, 2014","TGen Clinical Research Service, Scottsdale, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Texas Health Science Center San Antonio, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01279603,851.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
581,582,NCT01800838,Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma,,Completed,Has Results,Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IA Mycosis Fungoides/Sezary Syndrome|Stage IB Mycosis Fungoides/Sezary Syndrome|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IIA Mycosis Fungoides/Sezary Syndrome,Drug: silicon phthalocyanine 4|Drug: photodynamic therapy|Other: pharmacological study|Other: laboratory biomarker analysis,MTD of Photodynamic Therapy|MTD of Silicon Phthalocyanine 4 Defined as the Dose Immediately Below the Dose in Which 2 or More of 6 Patients Experience a Grade 4 Toxicity Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0,Kevin Cooper MD|National Cancer Institute (NCI)|Case Comprehensive Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1,11.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CASE2411|NCI-2013-00089|4130,2013-04-01,September 2014,2015-05-01,"February 28, 2013","May 16, 2019","May 16, 2019","University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01800838,760.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
582,583,NCT02018874,"A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With Gemcitabine",INPAKT,Completed,No Results Available,Solid Tumors and Non-Hodgkin's Lymphoma,Drug: LY2780301|Drug: Gemcitabine,Safety|Efficacy,"Gustave Roussy, Cancer Campus, Grand Paris",All,"18 Years and older   (Adult, Older Adult)",Phase 1,52.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013-000671-33|2013/1975,2013-09-01,April 2016,2016-04-01,"December 23, 2013",,"July 12, 2016","Gustave Roussy, Villejuif, Val de Marne, France",,https://ClinicalTrials.gov/show/NCT02018874,943.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
583,584,NCT01359696,"A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma",,Completed,No Results Available,Solid Tumor,Drug: GDC-0425|Drug: gemcitabine,"Incidence of all adverse events graded according to NCI CTCAE, v4.0|Incidence of dose limiting toxicities (DLTs)|Pharmacokinetic property of GDC-0425: determination of plasma drug concentration|Pharmacokinetic property of GDC-0425: exposure|Pharmacokinetic property of GDC-0425: half-life|Severity of all adverse events graded according to NCI CTCAE, v4.0|Antitumor activity of GDC-0425 in combination with gemcitabine: determination of tumor response using RECIST v1.1 for patients with measurable disease","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,40.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DPM4957g|GO00767,2011-07-11,"May 29, 2014",2014-05-29,"May 25, 2011",,"April 12, 2017","Karmanos Cancer Institute.., Detroit, Michigan, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Institut Gustave Roussy; Ser. de Med. Nucleaire; Cancerologie Endo, Villejuif, France",,https://ClinicalTrials.gov/show/NCT01359696,1053.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
584,585,NCT00379574,Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL,,Completed,Has Results,"Lymphoma, Large-Cell, Diffuse|Lymphoma, B-Cell",Drug: Bortezomib|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisolone|Drug: Lenograstim,Number of Patients Who Achieved Complete Response|Number of Patients Who Experienced Adverse Events,"Asan Medical Center|Janssen Korea, Ltd., Korea",All,"15 Years to 70 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,49.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AMC 2006-276,2006-09-01,January 2011,2011-01-01,"September 22, 2006","March 14, 2013","March 15, 2013","Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of|Asan Medical Cener, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00379574,1583.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
585,586,NCT01198665,RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas,RADCHOP,Completed,No Results Available,"Peripheral T Cell Lymphoma Unspecified|Anaplastic Large Cell Lymphoma, ALK-negative|Angioimmunoblastic T Cell Lymphoma|Cutaneous T Cell Lymphoma",Drug: RAD001 (Everolimus),determination of the maximum tolerable dose and evaluation of response rate|doe-limiting toxicity and pharmacogenomics,"Samsung Medical Center|Asan Medical Center|Yonsei University|National Cancer Center, Korea|Korea Cancer Center Hospital",All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,46.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010-01-001,2010-07-01,December 2014,2014-12-01,"September 10, 2010",,"March 3, 2015","National Cancer Center, Goyang-si, Kyoungki-do, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea Cancer Center Hospital, Seoul, Korea, Republic of|Yonsei Medical Center, Severance Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01198665,1614.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
586,587,NCT01306643,"Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma",,Completed,Has Results,Indolent Non-Hodgkin's Lymphoma|Follicular Lymphoma|Small Lymphocytic Lymphoma|Marginal Zone Lymphoma,Drug: Idelalisib,Overall Safety of Idelalisib|Clinical Response: Overall Response Rate|Flow Cytometric Measurement of Constitutive or Inducible Phosphorylation of Akt (at S473) and S6 Within Tumor B Cells|Flow Cytometric Measurement of Tumoral and Peripheral Blood T and NK Cells|Changes in Concentration of Peripheral Blood Chemokines and Cytokines|Changes in Liver Imaging as Assessed by Magnetic Resonance Imaging (MRI) and Gadoxetic Acid (GD-EOB-DTPA) Contrast,Gilead Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,18.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,101-10,2011-02-01,August 2015,2015-08-01,"March 2, 2011","December 21, 2016","November 19, 2018","Stanford Cancer Center, Palo Alto, California, United States|Mount Sinai School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01306643,1642.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
587,588,NCT01659255,Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL,,Completed,Has Results,Non Hodgkins Lymphoma|Chronic Lymphocytic Leukaemia,Drug: Tirabrutinib,Percentage of Participants Experiencing Dose-Limiting Toxicities|Overall Response Rate|Pharmacokinetic (PK) Parameter: Cmax of Tirabrutinib|PK Parameter: AUCtau of Tirabrutinib,Gilead Sciences|Ono Pharmaceutical Co. Ltd,All,"18 Years and older   (Adult, Older Adult)",Phase 1,90.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-4059POE001|2011-005033-39,2012-08-17,"February 23, 2015",2016-01-11,"August 7, 2012","January 28, 2021","March 16, 2021","CHRU - Hopital Claude HURIEZ, Lille, France|Centre hospitalier Lyon Sud, Lyon, France|CHU St Eloi, Montpellier, France|University Hospital of Wales, Cardiff, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom",,https://ClinicalTrials.gov/show/NCT01659255,1242.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
588,589,NCT01626495,Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma,Pedi CART19,Completed,Has Results,B Cell Leukemia|B Cell Lymphoma,Biological: CART-19,Number of Subjects With Study Related Adverse Events.|The Number of Subjects With a Successful Product Manufactured|Number of Subjects With Complete Remission (CR).|Number of Subjects With Complete Remission With Incomplete Blood Count Recovery (CRi).,University of Pennsylvania,All,"1 Year to 24 Years   (Child, Adult)",Phase 1|Phase 2,73.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"10-007706, 815870|CHP959",2011-08-17,"May 7, 2018",2019-07-11,"June 22, 2012","March 23, 2020","March 23, 2020","CHOP - http://www.chop.edu/service/oncology/pediatric-cancer-research/cart-19-trial.html, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT01626495/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01626495,2885.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
589,590,NCT03259529,"Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL",BeGeRN,Completed,No Results Available,Diffuse Large B Cell Lymphoma,Drug: Bendamustine hydrochloride|Drug: Gemcitabine 500 mg|Drug: Gemcitabine 700 mg|Drug: Gemcitabine 1000 mg|Drug: Nivolumab|Drug: Rituximab,The recommended phase 2 dose (RP2D)|Overall Response Rate (ORR)|Frequency of grade 3 or higher treatment-related adverse events by CTCAE 4.03|Duration of Response (DOR)|Progression-Free Survival (PFS)|Overall Survival (OS),St. Petersburg State Pavlov Medical University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DLBCL BeGeRN 1/2,2017-03-27,"January 27, 2020",2020-01-27,"August 23, 2017",,"June 7, 2021","First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation",,https://ClinicalTrials.gov/show/NCT03259529,1036.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
590,591,NCT01886859,Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,,Completed,No Results Available,Recurrent B-Cell Prolymphocytic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory B-Cell Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma,Drug: Ibrutinib|Drug: Lenalidomide,Maximum tolerated dose of lenalidomide when combined with ibrutinib|Response rates|Remission/response duration,National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,27.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2013-00888|13-0110|12-164|9254|P30CA046934|P50CA140158|U01CA076576|UM1CA186688|UM1CA186712,2013-04-26,"November 15, 2020",2022-09-21,"June 26, 2013",,"September 26, 2022","Stanford Cancer Institute Palo Alto, Palo Alto, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01886859,3435.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
591,592,NCT02252146,Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation,,Completed,Has Results,Diffuse Large B Cell Lymphoma,Drug: IMO-8400,"Number of Participants With Adverse Events, Injection Site Reactions, and Concomitant Medications","Idera Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,6.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8400-402,2014-06-01,December 2016,2016-12-01,"September 30, 2014","November 14, 2017","December 12, 2017","UCLA Medical Center, Los Angeles, California, United States|Emory University, Atlanta, Georgia, United States|Cancer Care Specialists of Illinois, Decatur, Illinois, United States|Horizon Bio Advance, Lafayette, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University Medical Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02252146/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02252146/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02252146,914.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
593,594,NCT02370160,HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma,,Completed,Has Results,Refractory B-Lineage Leukemia|Relapsed B-Lineage Leukemia|Refractory B-Lineage Lymphoma|Relapsed B-Lineage Lymphoma,Biological: DT2219ARL,Phase I: Incidence of Any DLT Attributed to DT2219 in the First Cycle|Phase ll: Overall Disease Response|Incidence of Serious Adverse Events|Phase II : Duration of Response|Disease-free Survival|Overall Survival|Time to Relapse/Progression,"Masonic Cancer Center, University of Minnesota",All,"12 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,18.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014LS093,2015-12-21,"April 8, 2018",2018-04-08,"February 24, 2015","January 13, 2020","January 13, 2020","Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT02370160/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02370160,839.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
596,597,NCT00416351,Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment,,Completed,Has Results,Leukemia|Lymphoma|Small Intestine Cancer,Drug: clofarabine,Maximum Tolerated Dose|Response Rate for Participants With Non-Hodgkin's Lymphoma|Participants Evaluated for Toxicity,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|University of Rochester|The Cleveland Clinic,All,"2 Years to 120 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,29.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,06-065|P30CA008748|MSKCC-06065,2006-06-27,"March 1, 2021",2021-03-01,"December 28, 2006","May 17, 2022","May 17, 2022","Memorial Sloan Kettering Cancer Center, New York, New York, United States|James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT00416351/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT00416351,5361.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
597,598,NCT01958996,"Phase I/II Study of Escalating Doses of Idarubicin Orally Given With Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patient With Disseminated High Grade Non Hodgkin Lymphoma",,Completed,No Results Available,High Grade Lymphomas CD20 Positive,Drug: idarubicin,Maximum tolerated dose of idarubicin|Remission rate after 4 cycles and 8 cycles,Poitiers University Hospital,All,65 Years to 80 Years   (Older Adult),Phase 1|Phase 2,27.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Primary Purpose: Treatment,OROCIEP,2009-01-01,"December 31, 2016",2016-12-31,"October 9, 2013",,"October 11, 2017","CHU de Poitiers, Poitiers, France",,https://ClinicalTrials.gov/show/NCT01958996,2921.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
598,599,NCT00275080,"Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia",,Completed,No Results Available,"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Blastic Phase Chronic Myelogenous Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Secondary Acute Myeloid Leukemia|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia",Drug: vorinostat|Drug: decitabine,Maximum tolerated dose and recommended phase II dose of vorinostat and decitabine|Minimal effective dose of vorinostat in combination with decitabine by bone marrow and/or peripheral blood (for leukemia)|Pharmacokinetics of vorinostat in conjunction with decitabine|Antitumor activity|Methylation status of gene promoter regions and gene expression|Altered response of leukemic cells to PPAr and RAR ligands,National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,80.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2009-00092|PMH-PHL-046|CDR0000456473|NCI-6869|PHL-046|6869|U01CA132123,2006-02-01,November 2009,2014-08-01,"January 11, 2006",,"August 27, 2014","Chedoke-McMaster Hospitals, Hamilton, Ontario, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada|University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00275080,3103.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
599,600,NCT01030536,Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL),,Completed,Has Results,Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia,Drug: CAT-8015 20 mcg/kg|Drug: CAT-8015 30 mcg/kg|Drug: CAT-8015 40 mcg/kg|Drug: CAT-8015 50 mcg/kg|Drug: CAT-8015 60 mcg/kg,"Maximum Tolerated Dose (MTD)|Number of Participants With Dose Limiting Toxicities (DLTs)|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)|Number of Participants With Clinically Significant Laboratory Abnormalities Recorded as Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Vital Signs Abnormalities Recorded as Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Electrocardiogram (ECG) Abnormalities Recorded as Treatment-Emergent Adverse Events (TEAEs)|Percentage of Participants With Complete Response (CR)|Duration of Complete Response|Percentage of Participants With Partial Response (PR)|Percentage of Participants With Objective Response (OR)|Time to Response (TTR)|Duration of Objective Response (DOR)|Duration of Stable Disease (SD)|Maximum Plasma Concentration (Cmax) of Moxetumomab Pasudotox|Area Under Concentration-Time Curve From Dosing Extrapolated to Infinity (AUCinf) of Moxetumomab Pasudotox|Clearance (CL) of Moxetumomab Pasudotox|Elimination Half Life (t1/2) of Moxetumomab Pasudotox|Number of Participants With Positive Anti-Drug Antibody|Number of Participants With CD22 Expression Levels|Number of Capillary Leak Syndrome (CLS) Participants With Weight Changes, Albumin, Hypotension, Edema, Hypoxia, and Pulmonary Adverse Events (AEs)|Percentage of Participants With Stable Disease (SD)",MedImmune LLC,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1|Phase 2,23.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MI-CP218,2010-02-15,"March 4, 2013",2013-03-04,"December 11, 2009","April 9, 2018","April 9, 2018","Research Site, Los Angeles, California, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Bethesda, Maryland, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Charleston, South Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, Temple, Texas, United States|Research Site, Łódź, Poland",,https://ClinicalTrials.gov/show/NCT01030536,1113.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
600,601,NCT01397825,MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine,,Completed,Has Results,Diffuse Large B-Cell Lymphoma|Transformed Follicular Lymphoma|Mantle Cell Lymphoma|Burkitt's Lymphoma,Drug: Alisertib (MLN8237)|Drug: Rituximab|Drug: Vincristine,Number of Participants With Clinically Significant Vital Signs Findings (Treatment Related and Unrelated) [Phase 1]|Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs) [Phase 1]|Number of Participants With Clinically Significant Changes in Multigated Acquisition (MUGA)/ Echocardiogram (ECHO) [Phase 1]|Number of Participants With Clinically Significant Changes in Physical Examination Findings [Phase 1]|Number of Participants With Clinically Significant Laboratory Tests Reported as Adverse Events [Phase 1]|Number of Participants With Treatment-Emergent Adverse Events [Phase 1]|Overall Response Rate [Phase 2]|Overall Response Rate as Assessed by the Investigator [Phase 1]|Complete Response Rate [Phase 2]|Duration of Response (DOR) [Phase 2]|Progression Free Survival (PFS) [Phase 2]|Number of Participants With Treatment-Emergent Adverse Events [Phase 2]|Number of Participants With Clinically Significant Vital Signs Findings [Phase 2]|Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs) [Phase 2]|Number of Participants With Clinically Significant Changes in Multigated Acquisition (MUGA)/ Echocardiogram (ECHO) [Phase 2]|Number of Participants With Clinically Significant Laboratory Tests Reported as Adverse Events [Phase 2]|Cmax: Maximum Plasma Concentration for Alisertib|Tmax: Time to First Occurrence of Cmax fo Alisertib|AUCt: Area Under the Concentration Time Curve Over the Dosing Interval From Time 0 to Time t for Alisertib|Cmax: Maximum Plasma Concentration for Vincristine|AUCt: Area Under the Concentration-time Time Curve Over the Dosing Interval From Time 0 to Time t for Vincristine|AUC∞: Area Under the Concentration-time Curve From Time 0 to Infinity for Vincristine|T1/2: Terminal Disposition Phase Half-life for Vincristine,"Millennium Pharmaceuticals, Inc.|Takeda",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,45.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C14011|2011-000609-32|U1111-1181-0333|12/NE/0268,2011-08-09,"February 5, 2015",2016-10-05,"July 20, 2011","March 27, 2018","March 27, 2018","Tucson, Arizona, United States|Beverly Hills, California, United States|Burbank, California, United States|Miami, Florida, United States|Lexington, Kentucky, United States|Worcester, Massachusetts, United States|New York, New York, United States|Rochester, New York, United States|Chapel Hill, North Carolina, United States|Philadelphia, Pennsylvania, United States|Germantown, Tennessee, United States|Memphis, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States|Burlington, Vermont, United States|Orbassano, Torino, Italy|Genova, Italy|Palermo, Italy|Roma, Italy|Madrid, Spain|Sevilla, Spain|Aberdeen, Grampian Region, United Kingdom|London, Greater London, United Kingdom|Southampton, Hampshire, United Kingdom|Birmingham, West Midlands, United Kingdom",,https://ClinicalTrials.gov/show/NCT01397825,1884.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
601,602,NCT00276536,"Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma",IFNa,Completed,No Results Available,"Breast Cancer|Kidney Cancer|Lymphoma|Melanoma|Multiple Myeloma|Sarcoma|Unspecified Adult Solid Tumor, Protocol Specific",Biological: recombinant interferon alpha-1b|Drug: IFN,Tolerance and safety as measured by any ≥ Grade IV granulocyte toxicity or any Grade III toxicity thought to be drug related at 1 week after each course,The Cleveland Clinic|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1,35.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CASE-CCF-3575|P30CA043703,2001-01-01,January 2004,2004-01-01,"January 13, 2006",,"October 14, 2015","Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00276536,1095.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
602,603,NCT00156013,Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL),,Completed,Has Results,"Lymphoma, B-Cell|Lymphoma, Non-Hodgkin",Drug: CLOFARABINE,Phase I Maximum Tolerated Dose|Phase II Overall Response|Toxicity,"Oncology Specialists, S.C.|Genzyme, a Sanofi Company",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,33.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1066306 (0408),2005-09-01,April 2010,2010-04-01,"September 12, 2005","July 9, 2012","November 29, 2017","Oncology Specialists, SC, Park Ridge, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00156013,1673.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
603,604,NCT00019019,Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas,,Completed,No Results Available,"Brain and Central Nervous System Tumors|Breast Cancer|Kidney Cancer|Lung Cancer|Lymphoma|Melanoma (Skin)|Ovarian Cancer|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: carboxyamidotriazole|Drug: paclitaxel,,National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,70.0,NIH,Interventional,Primary Purpose: Treatment,950015|95-C-0015|NCI-CPB-334|NCI-T94-0006N|CDR0000063881,1994-10-01,July 2006,2006-07-01,"January 27, 2003",,"March 15, 2012","Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States|NCI - Medical Oncology Clinical Research Unit, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00019019,4291.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
604,605,NCT01535924,Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma,,Completed,Has Results,Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma,Drug: gemcitabine hydrochloride|Drug: bendamustine hydrochloride,Adverse Events in Terms of Dose-limiting Toxicity (DLT) and MTD of Bendamustine Hydrochloride (Phase I)|Overall Response Rate (ORR) of Bendamustine Hydrochloride and Gemcitabine Hydrochloride in Patients With Relapsed or Refractory Hodgkin Lymphoma (Phase II),Beth Christian|Ohio State University Comprehensive Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,26.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSU-11015|NCI-2012-00022,2012-02-09,"February 20, 2019",2019-02-20,"February 20, 2012","November 19, 2021","November 19, 2021","Emory University, Atlanta, Georgia, United States|Ohio State University Medical Center, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT01535924/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01535924,2568.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
605,606,NCT02142530,Carfilzomib Plus Belinostat in Relapsed/Refractory NHL,,Completed,No Results Available,Non-Hodgkin Lymphoma|Diffuse Large B-cell Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Peripheral T-cell Lymphoma,Drug: Carfilzomib|Drug: Belinostat,Maximum tolerated doses of carfilzomib and belinostat in combination|Number of Participants with Serious Adverse Events|Plasma Concentration Time Profiles|Objective response rate,Massachusetts General Hospital|National Comprehensive Cancer Network,All,"18 Years and older   (Adult, Older Adult)",Phase 1,19.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-096,2014-10-01,March 2017,2018-01-01,"May 20, 2014",,"January 25, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|Beth-Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02142530,1188.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
606,607,NCT01065025,"Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies",AEGIS,Completed,No Results Available,Advanced and Incurable Solid Tumors|Malignant Lymphomas,Drug: 4SC-205,Safety and tolerability of repeated ascending oral doses of 4SC-205. Determination of the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT).|Pharmacokinetics|Anti-cancer activity of 4SC-205 after 6 weeks of treatment.|Effects of EG5 inhibition on biomarker modulation.,4SC AG,All,"18 Years and older   (Adult, Older Adult)",Phase 1,60.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4SC-205-1-2009,2010-01-01,April 2015,2015-04-01,"February 9, 2010",,"April 13, 2015","Universitätsklinikum Essen, Essen, Germany|Klinik für Tumorbiologie an der Albert-Ludwigs-Universität Freiburg (KTB), Freiburg, Germany",,https://ClinicalTrials.gov/show/NCT01065025,1916.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
607,608,NCT00741871,A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies,,Completed,No Results Available,"Lymphoma, Malignant|Hodgkin's Lymphoma|B Cell Lymphoma",Drug: SB1518,"To establish the maximum tolerated dose of SB1518 as a single agent when administered orally daily in subjects with advanced lymphoid malignancies.|To assess the safety and tolerability of SB1518, administered orally once daily in subjects with advanced lymphoid malignancies.|To assess the pharmacokinetic and pharmacodynamic profile of SB1518.",S*BIO,All,"18 Years and older   (Adult, Older Adult)",Phase 1,35.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SB1518-2007-002,2008-07-01,October 2011,2011-10-01,"August 26, 2008",,"April 20, 2012","MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00741871,1187.0,Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
608,609,NCT00003956,Combination Chemotherapy in Treating Patients With Advanced Cancer,,Completed,No Results Available,"Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",Drug: fluorouracil|Drug: leucovorin calcium|Drug: lonafarnib,,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,25.0,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000067155|MSKCC-99020|SPRI-C98-564-01|NCI-G99-1540,1999-04-01,January 2001,2009-12-01,"September 14, 2004",,"April 4, 2013","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00003956,3897.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
610,611,NCT00691210,Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies,SAHA,Completed,Has Results,Hodgkin's Disease|Non-Hodgkin's Lymphoma,Drug: Vorinostat|Drug: Niacinamide|Drug: Etoposide,The Maximum Tolerated Dose (MTD) of Niacinamide in the Combination of Vorinostat and Niacinamide|The Greatest Number of Cycles Received in Each Treatment Group|The Number of Dose Delays and Reductions at the MTD|The Prevalence of Anti-tumor Activity|Pharmacodynamic Markers of Target Effect in Paired Tissue Biopsies,Columbia University|Merck Sharp & Dohme LLC,All,"18 Years and older   (Adult, Older Adult)",Phase 1,40.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AAAJ3001,2008-06-01,February 2014,2015-03-01,"June 5, 2008","March 10, 2015","November 20, 2020","Center for Lymphoid Malignancies at CUMC, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00691210,2464.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
611,612,NCT04564040,A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole,,Completed,No Results Available,Mantle Cell Lymphoma|COVID-19,Drug: Acalabrutinib Treatment A|Drug: Acalabrutinib Treatment B|Drug: Acalabrutinib Treatment C|Drug: Acalabrutinib Treatment D,Part 1 and 2: Area under plasma concentration-time curve from time zero to infinity (AUCinf)|Part 1 and 2: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUClast)|Part 1 and Part 2: Maximum observed plasma concentration (Cmax)|Part 1 and Part 2: Area under the plasma concentration-time curve from time zero to 24 hours post dose (AUC0-24)|Part 1 and 2: Time to reach maximum observed plasma concentration (tmax)|Part 1 and 2: Half-life associated with terminal slope (λz) of a semi-logarithmic concentrationtime curve (t1/2)|Part 1 and 2: Mean residence time of the drug in the systemic circulation from zero to infinity (MRT)|Part 1 and 2: Terminal elimination rate constant (λz)|Part 1 and 2: Apparent total body clearance of drug from plasms after extravascular administration (acalabrutinib only (CL/F)|Part 1 and 2: Apparent volume of distribution during the terminal phase after extravascular administration (acalabrutinib only) (Vz/F)|Part 1 and 2: Metabolite to parent ratio based on AUCinf and/or AUClast (M:P[AUC])|Part 1 and 2: Metabolite to parent ratio based on Cmax (M:P[Cmax])|Number of subjects with serious and non-serious adverse events,AstraZeneca|Parexel,All,18 Years to 55 Years   (Adult),Phase 1,20.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D8223C00005,2020-10-12,"December 11, 2020",2020-12-11,"September 25, 2020",,"December 29, 2020","Research Site, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT04564040,60.0,Industry Lead,Less than three Conditions,Randomized,Crossover Assignment,None (Open Label),Treatment/Diagnostic
612,613,NCT00674024,Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function,,Completed,No Results Available,Neoplasms|Lymphoma,Drug: Pazopanib|Drug: Pazopanib (GW786034)(GW786034),"To establish the MTD and DLT of pazopanib in groups of patients with varying degrees of hepatic dysfunction (mild, moderate, and severe) to provide appropriate dosing recommendations for panzopanib in such patients.|To characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of pazopanib and metabolites (GSK1071306, GSK1268992, GSK1268997, and GW700201) in patients with varying degrees of hepatic dysfunction.",National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years to 110 Years   (Adult, Older Adult)",Phase 1,8.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,090003|09-C-0003,2008-10-07,"January 22, 2013",2013-01-22,"May 7, 2008",,"November 20, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00674024,1568.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
613,614,NCT00360438,Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS,,Completed,No Results Available,Leukemia|Lymphoma|Tumor Lysis Syndrome,Drug: Rasburicase,Effectiveness of rasburicase in treatment of patients with leukemia and/or lymphoma who are at high or potential risk for TLS.,M.D. Anderson Cancer Center|Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,18.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2006-0298,2006-07-01,April 2007,2007-04-01,"August 4, 2006",,"August 1, 2012","The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00360438,274.0,Not Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
614,615,NCT01680991,A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease,,Completed,Has Results,"Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma",Drug: Obinutuzumab,"Area Under the Serum Concentration Time Curve From Zero to Day 7 (AUC0-7) of Obinutuzumab on Day 1, Cycle 1|Maximum Observed Serum Concentration (Cmax) of Obinutuzumab on Day 1, Cycle 1|Area Under the Serum Concentration Versus Time Curve From 0 to Day 21 (AUC0-21) of Obinutuzumab at Cycle 8|Cmax of Obinutuzumab at Cycle 8|Time to Maximum Observed Serum Concentration (Tmax) of Obinutuzumab at Cycle 8|Apparent Terminal Half-life (t1/2)|Volume of Distribution at Steady State (Vss) of Obinutuzumab at Cycle 8|Total Systemic Clearance at Steady State (CLss) of Obinutuzumab at Cycle 8|Minimum Observed Serum Concentration of Obinutuzumab|Percentage of Participants With Complete Response (CR), CR Unconfirmed (CRu) at End of Treatment (1 Month After Cycle 8) in NHL Participants (DLBCL and FL Participants) Per Cheson 1999 Criteria|Percentage of Participants With Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD) at End of Treatment (1 Month After Cycle 8) in NHL Participants (DLBCL and FL Participants) Per Cheson 1999 Criteria|Percentage of Participants With Best Overall Response (BOR) of CR, CRu at Anytime During Study in NHL Participants (DLBCL and FL Participants) Per Cheson 1999 Criteria|Percentage of Participants With BOR of PR, SD, and PD at Anytime During Study in NHL Participants (DLBCL and FL Participants) Per Cheson 1999 Criteria|Percentage of Participants With Complete Remission (CRe), CRe With Incomplete BM Recovery (CRi) at End of Treatment (1 Month After Cycle 8) in CLL Participants According to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Guidelines|Percentage of Participants With PR, SD, and PD at End of Treatment (1 Month After Cycle 8) in CLL Participants According to IWCLL 2008 Guidelines|Percentage of Participants With BOR of CRe, CRi at Anytime During the Study in CLL Participants According to IWCLL 2008 Guidelines|Percentage of Participants With BOR of PR, SD, and PD at Anytime During Study in CLL Participants According to IWCLL 2008 Guidelines|Number of Participants With Positive Human Anti-Human Antibodies (HAHA)|Number of Participants With Positive Human Anti-Chimeric Antibodies (HACA)|Number of Participants With B-cell Depletion or Recovery|Duration of Depletion of CD19+ B-cell|Time to Recovery of CD19+ B-cell",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,YP25623,2012-09-01,December 2014,2014-12-01,"September 7, 2012","April 25, 2016","April 25, 2016","Beijing, China|Beijing, China|Guangzhou, China|Shanghai, China",,https://ClinicalTrials.gov/show/NCT01680991,821.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
615,616,NCT01625351,A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,,Completed,No Results Available,Ewing Sarcoma|Gastrointestinal Tumor|Germ Cell Tumor|Hepatic Tumor|Lymphoma|Wilms Tumor|Rhabdoid Tumor|Clear Cell Carcinoma|Renal Cell Carcinoma|Melanoma|Neuroblastoma|Rhabdomyosarcoma|Non-rhabdomyosarcoma,Drug: alemtuzumab|Drug: fludarabine|Drug: sirolimus|Drug: Busulfan|Drug: melphalan|Biological: stem cells|Device: CliniMACS,Feasibility of haploidentical HSCT|hematopoietic cell recovery and engraftment rates|infection rates and complications|overall survival (OS)|event-free survival,"St. Jude Children's Research Hospital|CURE Childhood Cancer, Inc.",All,"2 Years to 21 Years   (Child, Adult)",Phase 1,23.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RADIANT|NCI-2012-00588,2012-08-20,"February 10, 2020",2020-02-10,"June 21, 2012",,"October 19, 2020","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT01625351,2730.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
616,617,NCT02128945,Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies,FLUDATEP,Completed,No Results Available,Untreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma Patients,Other: [18F] - Fludarabine PET/CT,Standardized measure of [18F]-Fludarabine uptake in tumor tissue.|Calculation of the equivalent dose to all organs and evaluation of effective dose to the whole body,"University Hospital, Caen|CNRS, UMR ISTCT 6301, LDM-TEP Groupe, GIP Cyceron, Caen, France",All,"18 Years and older   (Adult, Older Adult)",Phase 1,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2013-002796-18|13-090,2014-04-01,April 2016,2016-05-01,"May 1, 2014",,"September 14, 2016","University Hospital, Caen, France",,https://ClinicalTrials.gov/show/NCT02128945,761.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
617,618,NCT00646139,KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment,,Completed,No Results Available,"Lymphoma|Lymphoproliferative Disorder|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: Src kinase inhibitor KX2-391|Other: immunoenzyme technique|Other: pharmacological study,Maximum tolerated dose|Safety|Pharmacokinetics|Biological effects,Roswell Park Cancer Institute,All,"18 Years and older   (Adult, Older Adult)",Phase 1,7.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000589972|RPCI-I-112607|KINEX-KX01-01-07,2007-10-01,August 2008,2009-03-01,"March 28, 2008",,"March 2, 2011","Roswell Park Cancer Institute, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT00646139,517.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
618,619,NCT01871675,Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies,,Completed,No Results Available,Lymphoma|Chronic Lymphocytic Leukemia|Non-Hodgkin Lymphoma|T-cell Lymphoma,Drug: IPI-145|Drug: Rituximab|Drug: Bendamustine,"The number of adverse events, serious adverse events, and dose limiting toxicities as a measure of safety and tolerability|Antitumor activity","SCRI Development Innovations, LLC|Infinity Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,48.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCRI HEMREF 34,2013-05-01,June 2016,2016-06-01,"June 7, 2013",,"July 11, 2016","The Colorado Blood Cancer Institute, Denver, Colorado, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Oklahoma University, Oklahoma City, Oklahoma, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT01871675,1127.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
619,620,NCT00290004,Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,,Completed,No Results Available,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Leukemia|Lymphoma,Drug: motexafin gadolinium,Phase I|To determine the maximum tolerated dose (MTD) of MGd when administered once weekly to patients with relapsed or refractory CLL/SLL|To determine the dose-limiting toxicities (DLTs) of MGd when administered once weekly to patients with relapsed or refractory CLL/SLL|Phase II|To assess the complete and partial response rate in patients with relapsed or refractory CLL/SLL when administered MGd once weekly at the MTD,Pharmacyclics LLC.,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,35.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PCYC-0223,2005-11-01,February 2007,2007-02-01,"February 10, 2006",,"September 11, 2008","USC Norris Cancer Hospital, Los Angeles, California, United States|Scripps Cancer Center, San Diego, California, United States|Northwestern University, Chicago, Illinois, United States|The Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00290004,457.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
620,621,NCT00035022,Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas,,Completed,No Results Available,"Leukemia, Lymphocytic|Lymphoma",Drug: BCX-1777,,BioCryst Pharmaceuticals,All,"0 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,71.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BC-01-02,2001-08-01,,2004-03-01,"May 3, 2002",,"January 13, 2006","M.D. Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00035022,943.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
621,622,NCT01422499,Vorinostat in Children,,Completed,No Results Available,"Children With Relapsed Solid Tumor, Lymphoma or Leukemia",Drug: zolinza/vorinostat,"To determine a safe dose recommended (SDR) for the routine application of oral vorinostat (involving dose escalation) in children and adolescents (3-18 years) with relapsed/refractory solid tumor, lymphoma or leukemia.|pharmacokinetics|antitumor effectiveness|association of the histone deacetylase (HDAC)-inhibiting activity with the dose administered, toxicity, and treatment response|safety|duration of response in responding patients","National Center for Tumor Diseases, Heidelberg|University Hospital Heidelberg|Merck Sharp & Dohme LLC",All,"3 Years to 18 Years   (Child, Adult)",Phase 1|Phase 2,50.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCT-2007-11-02-1004,2012-03-01,"March 24, 2017",2017-03-24,"August 24, 2011",,"April 11, 2018","Clinic for Pediatric Oncology, Hematology, Immunology and Clinical Cooperation Unit Pediatric Oncology, Heidelberg, BW, Germany|Childrens's Hospital, Pediatric Oncology and Hematology, Augsburg, Germany|Prof. Hess Childrens's Hospital, Pediatric Oncology and Hematology, Bremen, Germany|University Childrens's Hospital, Pediatric Oncology and Hematology, Essen, Germany|University Children's Hospital, Clinic IV, Freiburg, Germany|Department of Pediatric Oncology and Hematology University Hospital Eppendorf (UKE), Hamburg, Germany|University Children's Hospital, Pediatric Oncology and Hematology, MHH, Hannover, Germany|University Childrens's Hospital, Pediatric Oncology and Hematology, Jena, Germany|University Children's Hospital, Pediatric Oncology and Hematology, Köln, Germany|Department of Pediatric Oncology and Hematology University Children's Hospital, Münster, Germany",,https://ClinicalTrials.gov/show/NCT01422499,1849.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
622,623,NCT00727831,"Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma",,Completed,No Results Available,Chemotherapeutic Agent Toxicity|Lymphoma|Mucositis|Neurotoxicity,Drug: glucarpidase|Drug: leucovorin calcium|Drug: methotrexate|Other: laboratory biomarker analysis|Procedure: quality-of-life assessment|Radiation: radiation therapy,"Immediate toxicity (incidence of reactions to glucarpidase) as determined by the NCI CTC|Incidence and severity of renal dysfunction as determined by the NCI CTC|Incidence and severity of mucositis as determined by the NCI CTC and WHO mucositis grading scale|Incidence and severity of CNS toxicity and neurocognitive changes taken from patients' medical records and measured using the Mini-Mental State questionnaire and MRI data|Hematological toxicity (i.e., number of courses of therapy associated with neutrophils < 0.5 x 10e9/L or platelets < 50 x 10e9/L as measured by routine blood counts)|Incidence of infection (i.e., number of days with fever ≥ 38 C° measured by clinical examination and days of intravenous antibiotics taken from patients' medical records)|Number of inpatient days taken from patients' medical records|Disease response and remission rates measured by serial MRI scanning (and eye examination and lumbar puncture if necessary)|Disease outcome, time to progression, and overall survival at 2 years from start of therapy measured by clinical examination and serial MRI scanning|Relative dose intensity|Methotrexate levels post-glucarpidase (expressed as a clinically important reduction, which is defined as a methotrexate level of < 1 μmol/L in all post-glucarpidase samples)|Incidence of antibodies to glucarpidase measured serologically at the start of each methotrexate course and at follow-up visits if present during therapy","University College, London|Cancer Research UK",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,4.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000599206|CRUK-BRD/07/004|2007-002570-58|EU-20861,2008-07-01,July 2011,2011-07-01,"August 4, 2008",,"January 27, 2014","Leeds General Infirmary, Leeds, England, United Kingdom|Torbay Hospital, Torquay, England, United Kingdom",,https://ClinicalTrials.gov/show/NCT00727831,1095.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
623,624,NCT00003874,Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia,,Completed,No Results Available,Leukemia|Lymphoma,Biological: monoclonal antibody CD19|Biological: monoclonal antibody CD20|Procedure: in vitro-treated peripheral blood stem cell transplantation,,Fred Hutchinson Cancer Center|National Cancer Institute (NCI),All,"up to 70 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,,Other|NIH,Interventional,Primary Purpose: Treatment,1345.00|FHCRC-1345.00|NCI-G99-1514|CDR0000067039,1999-02-01,,2001-09-01,"July 16, 2004",,"November 29, 2011","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00003874,943.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
624,625,NCT01900509,"Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies",,Completed,No Results Available,Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Acute Leukemia,Drug: Bendamustine|Drug: Clofarabine|Drug: Etoposide|Drug: Etoposide phosphate|Drug: Dexamethasone,Maximum tolerated dose|Dose limiting toxicities|Event free survival|Proportion of leukemia participants with positive minimal residual disease|Plasma concentration of bendamustine,St. Jude Children's Research Hospital|Teva Pharmaceuticals USA,All,"up to 21 Years   (Child, Adult)",Phase 1,16.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BECHEM|TEVA ISS|NCI-2013-01148,2013-08-01,May 2016,2016-05-01,"July 16, 2013",,"March 22, 2017","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT01900509,1004.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
625,626,NCT00002681,Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma,,Completed,No Results Available,Leukemia|Lymphoma,Biological: aldesleukin|Biological: daclizumab,,Roger Williams Medical Center|National Cancer Institute (NCI)|Beth Israel Deaconess Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,25.0,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000064351|BIDMC-92020534|NEDH-92020534|BIDMC-FDR001054|NCI-H95-0732,1995-07-01,September 2003,2003-12-01,"January 27, 2003",,"June 10, 2011","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00002681,3075.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
626,627,NCT02141451,ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL,,Completed,Has Results,Diffuse Large B Cell Non-Hodgkin Lymphoma,Drug: Rituximab|Drug: INCB7839,Number of Participants With Dose Limiting Toxicity Events|Number of Participants With Progression Free Survival at 6 Months|Incidence of Serious Adverse Events|Overall Survival|Time to Progression,"Masonic Cancer Center, University of Minnesota",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013LS081|HM2013-24,2014-05-01,"January 23, 2019",2019-06-01,"May 19, 2014","February 19, 2020","February 19, 2020","University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02141451/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02141451,1857.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
628,629,NCT01497184,Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood,,Completed,No Results Available,Leukemia|Lymphoma,Procedure: HSCT|Genetic: DLI,Maximum Tolerated dose (MTD) of Donor Lymphocyte Infusion (DLI),M.D. Anderson Cancer Center|Ziopharm Oncology,All,"1 Year to 65 Years   (Child, Adult, Older Adult)",Phase 1,95.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2009-0525|NCI-2012-00015,2011-12-01,"March 8, 2021",2021-03-08,"December 22, 2011",,"March 11, 2021","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01497184,3385.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
629,630,NCT00081874,"RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma",,Completed,No Results Available,Leukemia|Mantle Cell Lymphoma|Myelofibrosis,Drug: RAD001,Maximum Tolerated Dose (MTD)|Objective Response Rate (ORR),M.D. Anderson Cancer Center|Novartis,All,"Child, Adult, Older Adult",Phase 1|Phase 2,29.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2003-0948,2004-04-01,September 2006,2006-09-01,"April 27, 2004",,"March 21, 2012","M.D. Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00081874,883.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
630,631,NCT00234169,A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone,,Completed,No Results Available,Multiple Myeloma|Lymphoma,Drug: VTP195183,PB CD34+ kinetics using VTP195183 plus G-CSF|The toxicity of VTP195183 pretreatment when used with G-CSF,"Peter MacCallum Cancer Centre, Australia|The Leukemia and Lymphoma Society",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,30.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,05/09,2005-10-01,January 2008,2008-01-01,"October 6, 2005",,"May 10, 2012","Peter MacCallum Cancer centre, Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT00234169,822.0,Not Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
631,632,NCT03593187,A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma,GENHIV,Completed,No Results Available,HIV-1 Infection,Drug: Cal-1 (LVsh5/C46) drug product,Incidence of adverse event post transplant|Success of hematopoietic stem cell engraftment|Overall survival|Absence of detection of vector-derived Replication competent lentivirus (RCL)|Frequency and severity of clinical adverse events|Absence of tropism shift from R5 to dual/mixed or X4 at any point after Day 0|Quantify gene transfer efficiency and expression|Time to restart antiretroviral therapy,Assistance Publique - Hôpitaux de Paris|CSL Behring,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,2.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P 141004|2015-004453-41,2019-01-15,"July 28, 2020",2020-07-28,"July 20, 2018",,"November 7, 2022","Hôpital Saint Louis, Paris, France",,https://ClinicalTrials.gov/show/NCT03593187,560.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
632,633,NCT01362452,Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells,,Completed,No Results Available,Leukemia|Lymphoma,Genetic: T-Cell Infusion|Procedure: Cord Blood Infusion,Maximum Tolerated Dose (MTD) of T-Cell Infusions|Secondary Graft Failure of T-Cell Infusions,M.D. Anderson Cancer Center,All,"1 Year to 75 Years   (Child, Adult, Older Adult)",Phase 1,5.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010-0835|FD-R-04369-01|NCI-2011-01046|RP130516,2012-12-07,"July 25, 2017",2017-07-25,"May 30, 2011",,"August 3, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01362452,1691.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
633,634,NCT01369849,"Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",,Completed,Has Results,Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia,Drug: Akt Inhibitor MK2206|Drug: Bendamustine Hydrochloride|Other: Laboratory Biomarker Analysis|Biological: Rituximab,"Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I)|Proportion of Complete Response Defined to be a CR or CRi Noted as the Objective Status (Phase II)|Biomarker Analysis (IgVH Gene Mutation)|Biomarker Analysis (CD38, CD49d, and ZAP-70)|Fluorescent in Situ Hybridization (FISH) Biomarker Analysis|Duration of Response|Minimal-residual Disease|Overall Response Rate|Treatment-free Survival",National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,15.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2011-02675|CDR0000701372|NCCTG-N1087|N1087|U10CA180821|U10CA025224,2011-09-01,February 2014,2014-02-01,"June 9, 2011","June 28, 2016","September 15, 2017","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Mercy Medical Center-Sioux City, Sioux City, Iowa, United States|Saint Luke's Regional Medical Center, Sioux City, Iowa, United States|Essentia Health Saint Joseph's Medical Center, Brainerd, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Metro-Minnesota NCI Community Oncology Research Program, Saint Louis Park, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology and Hematology PA-Woodbury, Woodbury, Minnesota, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Columbus CCOP, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Genesis HealthCare System, Zanesville, Ohio, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States",,https://ClinicalTrials.gov/show/NCT01369849,884.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
634,635,NCT01287104,A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias,,Completed,Has Results,Leukemia|Lymphoma,Biological: Natural Killer (NK) Cell Infusion|Biological: Stem Cell Infusion,"Number of Patients Who Received 2 Doses of Natural Killer (NK) Cell Infusions|Number of Patients Who Received the Highest Dose Level of NK Cells (1x10^6 NK Cells/kg for Patients With Related Donors and 1 x10^5 NK Cells/kg for Patients With Unrelated Donors) With Sustained Donor Lymphoid Engraftment|Number of Participants With Mild, Moderate and/or Severe Chronic Graft Versus Host Disease (cGVHD)|Disease-free Survival|Overall Survival Since Date of Transplant|Number of Occurrences of Viral Infection and/or Reactivation in Allogeneic Peripheral Blood Stem Cell Transplant (PBSCT) Followed by Natural Killer-donor Lymphocyte Infusion (NK-DLI)|Number of Participants With a Decline in Interleukin 7 (IL-7) and Interleukin 15 (IL-15) Cell Numbers Post-Transplant|Number of Participants With Presence of Killer-cell Immunoglobulin-like Receptors (KIR) Gene Mismatch|Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)",National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"4 Years to 35 Years   (Child, Adult)",Phase 1,34.0,NIH,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,110073|11-C-0073,2011-01-29,"June 28, 2018",2018-06-28,"February 1, 2011","August 22, 2019","August 22, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT01287104/Prot_SAP_000.pdf|""Informed Consent Form: Standard-Addendum"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT01287104/ICF_001.pdf|""Informed Consent Form: Donor"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT01287104/ICF_002.pdf|""Informed Consent Form: Recipient"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT01287104/ICF_003.pdf",https://ClinicalTrials.gov/show/NCT01287104,2707.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
635,636,NCT00588328,The Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment Planning,,Completed,No Results Available,Lung Cancer|Non-Hodgkin's Lymphoma,Device: PET/CT scan,"To measure the amount of tumor motion in breathing synchronized CT scans and determine the fraction of patients whose radiation treatment planning margins would be modified based on this information.|To measure changes in tumor definition with breathing synchronized PET compared to standard free breathing PET, and determine the fraction of patients whose radiation treatment plans would be modified based on this information.",Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,35.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,00-008,2000-03-01,July 2008,2010-05-01,"January 8, 2008",,"December 24, 2015","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00588328,3713.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
636,637,NCT00961220,O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma,,Completed,Has Results,Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7|Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7,Drug: Carmustine|Other: Laboratory Biomarker Analysis|Drug: O6-Benzylguanine,Overall Response Rate|Changes in AGT (O6-alkylguanine DNA Alkyltransferase) Activity|Changes in the Apoptosis|Changes in the Cell Cycle/Proliferation|Changes in DNA Damage- Cytotoxicity|Changes in AGT Inactivation in Non-responding Patients,National Cancer Institute (NCI),All,"19 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,17.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2012-02927|3405|CASE 3405-CC304|7080|P30CA043703|R21CA115057|U01CA062502,2010-02-01,"April 8, 2012",2014-04-08,"August 18, 2009","March 23, 2015","May 22, 2018","Henry Ford Hospital, Detroit, Michigan, United States|Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00961220,1527.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
637,638,NCT01449461,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)",,Completed,Has Results,"Lymphoma, Large-Cell, Anaplastic|Carcinoma, Non-Small-Cell Lung",Drug: Brigatinib,Recommended Phase 2 Dose (RP2D) of Brigatinib|Objective Response Rate (ORR)|Number of Participants Who Had at Least One Treatment-Emergent Adverse Event (TEAE)|Maximum Tolerated Dose (MTD) Assessed in Dose Escalation Phase of the Study|Number of Participants With Dose Limiting Toxicities (DLTs) Assessed in Dose Escalation Phase of the Study|Cmax: Maximum Observed Plasma Concentration for Brigatinib at Cycle 1 Day 1|Cmax: Maximum Observed Plasma Concentration for Brigatinib at Cycle 2 Day 1|Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Brigatinib at Cycle 1 Day 1|Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Brigatinib at Cycle 2 Day 1|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Brigatinib at Cycle 1 Day 1|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Brigatinib at Cycle 2 Day 1|T1/2: Terminal Phase Elimination Half-life for Brigatinib at Cycle 2 Day 1|Best Overall Response|Duration of Response|Progression Free Survival (PFS)|Overall Survival (OS)|Intracranial Objective Response Rate|Duration of Intracranial Response|Intracranial Progression Free Survival (PFS),Ariad Pharmaceuticals|Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,137.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AP26113-11-101|2011-005718-12|U1111-1196-8197,2011-09-20,"November 16, 2015",2020-02-18,"October 10, 2011","June 21, 2017","August 17, 2021",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT01449461/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT01449461/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01449461,3073.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
638,639,NCT00141297,"A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer",,Completed,Has Results,"Neoplasms|Lymphoma, Non-Hodgkin",Drug: PD-0332991,Number of Participants With Dose-Limiting Toxicities (DLT)|Maximum Administered Dose (MAD)|Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose Level (RP2D)|Number of Dose-Limiting Toxicities (DLTs) Categorized as Per the Nature|Number of Participants With Treatment Emergent Adverse Events Categorized by Severity|Number of Participants With Treatment-Related Treatment Emergent Adverse Events|Number of Participants Who Died Due to Adverse Event on the Basis of Relatedness to Study Drug|Maximum Observed Plasma Concentration (Cmax) on Day 1: Single Dose|Maximum Observed Plasma Concentration (Cmax) on Day 8: Multiple Dose|Maximum Observed Plasma Concentration (Cmax) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose|Maximum Observed Plasma Concentration (Cmax) on Day 1: Food Effect|Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1: Single Dose|Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 8: Multiple Dose|Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose|Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1: Food Effect|Terminal Half-life (t½ ) on Day 1: Single Dose|Terminal Half-life (t½ ) on Day 8: Multiple Dose|Terminal Half-life (t½) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose|Terminal Half-life (t½ ) on Day 1: Food Effect|Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 1: Single Dose|Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 8: Multiple Dose|Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose|Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 1: Food Effect|Area Under the Curve From Time Zero to End of the Dosing Interval [AUC(0 to Tau)] on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] on Day 1: Single Dose|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] on Day 8: Multiple Dose|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] on Day 1: Food Effect|Apparent Oral Clearance (CL/F) on Day 1: Single Dose|Apparent Oral Clearance (CL/F) on Day 8: Multiple Dose|Apparent Oral Clearance (CL/F) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose|Apparent Oral Clearance (CL/F) on Day 1: Food Effect|Apparent Volume of Distribution (Vz/F) on Day 1: Single Dose|Apparent Volume of Distribution (Vz/F) on Day 8: Multiple Dose|Apparent Volume of Distribution (Vz/F) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose|Apparent Volume of Distribution (Vz/F) on Day 1: Food Effect|Accumulation Ratio (Rac) on Day 8: Multiple Dose|Accumulation Ratio (Rac) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose|Terminal Phase Rate Constant [Lambda (z)] on Day 1: Single Dose|Terminal Phase Rate Constant [Lambda (z)] on Day 8: Multiple Dose|Terminal Phase Rate Constant [Lambda (z)] on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose|Terminal Phase Rate Constant [Lambda (z)] on Day 1: Food Effect|Cumulative Amount of Drug Recovered Unchanged in the Urine (Ae): Single Dose|Cumulative Amount of Drug Recovered Unchanged in the Urine (Ae): Food Effect|Percent Dose Recovered Unchanged in Urine (Percent Ae): Single Dose|Percent Dose Recovered Unchanged (Percent Ae) in Urine: Food Effect|Number of Participants With Best Response|Inhibition of Cyclin-dependent Kinases 4 and 6 (Cdk4/6) Based on Phosphorylated Retinoblastoma (p-Rb) in Tumor Tissue|Correlation of Cyclin-dependent Kinases 4 and 6 (Cdk4/6) With PD 0322991 Dose|Correlation of Cyclin-dependent Kinases 4 and 6 (Cdk4/6) With Exposure|Correlation of Cyclin-dependent Kinases 4 and 6 (Cdk4/6) With Tumor Response,Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,74.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A5481001,2004-09-01,July 2008,2014-12-01,"September 1, 2005","October 28, 2015","January 5, 2016","Karmanos Cancer Institute, Detroit, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Abramson Cancer Center Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Pharmacy/PCAM/West Pavillion, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00141297,3743.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
639,640,NCT01388335,A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin,,Completed,Has Results,"Solid Tumor|Lymphoma, Malignant",Drug: warfarin|Drug: enzastaurin,"Pharmacokinetics: Maximum Plasma Concentration (Cmax) of S-Warfarin and R-Warfarin|Pharmacokinetics: Time of Maximal Plasma Concentration (Tmax) of S-Warfarin and R-Warfarin|Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)] of S-Warfarin and R-Warfarin|Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) at Steady State of Enzastaurin, Its Principle Metabolites and Total Analyte|Pharmacokinetics: Time of Maximal Plasma Concentration (Tmax) of Enzastaurin, Its Principle Metabolites and Total Analyte|Pharmacokinetics: Area Under Concentration-Time Curve Over a Dosing Interval at Steady State (AUCss) of Enzastaurin, Its Principle Metabolites and Total Analyte|Pharmacokinetics: Average Concentration During a Dosing Interval Steady State (Cav,ss) of Enzastaurin, Its Principle Metabolites and Total Analyte|Pharmacodynamics: Maximum International Normalised Ratio (INRmax) Following Warfarin Alone|Pharmacodynamics: Area Under International Normalised Ratio-time Curve AUC(INR) Following Warfarin Alone|Pharmacodynamics: Maximum International Normalised Ratio (INRmax) Following Concomitant Administration of Warfarin and Enzastaurin|Pharmacodynamics: Area Under International Normalised Ratio-Time Curve AUC(INR) Following Concomitant Administration of Warfarin and Enzastaurin|Pharmacodynamics: International Normalised Ratio (INR) Following Enzastaurin Alone",Eli Lilly and Company,All,18 Years to 60 Years   (Adult),Phase 1,13.0,Industry,Interventional,Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,9763|H6Q-MC-JCAX,2011-08-01,October 2012,2012-12-01,"July 6, 2011","July 1, 2020","July 1, 2020","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bordeaux, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dijon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Herblain, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France",,https://ClinicalTrials.gov/show/NCT01388335,488.0,Industry Lead,Less than three Conditions,N/A,Crossover Assignment,None (Open Label),Other/Basic/Prevention
640,641,NCT02979522,"A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma",,Completed,Has Results,Hodgkin Disease,Drug: Brentuximab vedotin|Drug: Doxorubicin|Drug: Vinblastine|Drug: Dacarbazine,"Phase 1: Recommended Dose of Brentuximab Vedotin in Combination With Doxorubicin, Vinblastine, and Dacarbazine in a Pediatric Population|Phase 1: Percentage of Participants Who Experienced Adverse Events (AEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy|Phase 1: Percentage of Participants Who Experienced Serious Adverse Events (SAEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy|Phase 2: Percentage of Participants Who Achieved a Complete Remission (CR) Per Independent Review Facility (IRF) Assessment Per International Working Group (IWG) Criteria at End of Treatment (EOT) Visit|Phase 2: Percentage of Participants Whose Disease Was Positron Emission Tomography (PET) Negative After 2 Cycles of Protocol Therapy Per IRF Assessment|Phase 2: Percentage of Participants Who Achieved a Partial Remission (PR) Per IRF Assessment Per IWG Criteria at EOT Visit|Phase 2: Percentage of Participants Who Achieved an Overall Response Rate (ORR) Per IRF Assessment Per IWG Criteria at EOT Visit|Phase 2: Percentage of Participants Who Were Able to Complete 6 Cycles of Protocol Therapy at the Recommended Dose|Phase 1: Mean Maximum Observed Serum Concentration (Cmax) of Brentuximab Vedotin Total Conjugated and Therapeutic Antibody (TAb)|Phase 1: Mean Maximum Observed Plasma Concentration (Cmax) of Monomethyl Auristatin E (MMAE)|Phase 1: Mean Area Under the Serum Concentration-Time Curve From Day 0 to Day 15 (AUC0-15) of Brentuximab Vedotin and TAb|Phase 1: Mean Area Under the Plasma Concentration-Time Curve From Day 0 to Day 15 (AUC0-15) of MMAE|Phase 1: Median Time to Reach Cmax (Tmax) of Brentuximab Vedotin and TAb in Serum|Phase 1: Median Time to Reach Cmax (Tmax) of MMAE in Plasma|Phase 1: Percentage of Participants Who Achieved a CR Per IRF Assessment Per IWG Criteria at EOT Visit|Phase 1: Percentage of Participants Who Achieved a PR Per IRF Assessment Per IWG Criteria at EOT Visit|Phase 1: Percentage of Participants Who Achieved an ORR Per IRF Assessment Per IWG Criteria at EOT Visit|Phase 1: Percentage of Participants Whose Disease Was PET Negative After 2 Cycles of Protocol Therapy Per IRF Assessment|Phase 1: Percentage of Participants Whose Disease Was PET Positive After 6 Cycles of Protocol Therapy Per IRF Assessment|Phase 1: Percentage of Participants Who Were Antitherapeutic Antibody (ATA) Positive, Persistently Positive or Transiently Positive, and Neutralizing Antitherapeutic Antibody (nATA) Positive|Phase 2: Progression-free Survival (PFS)|Phase 2: Event-free Survival (EFS)|Phase 2: Overall Survival (OS)|Phase 2: Duration of Response (DOR)|Phase 2: Percentage of Participants Receiving Irradiation for HL Following Study Treatment|Phase 2: Percentage of Participants Who Experienced AEs From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy|Phase 2: Percentage of Participants Who Experienced SAEs From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy|Phase 2: Percentage of Participants Who Were ATA Positive, Persistently Positive, or Transiently Positive, and nATA Positive|Phase 2: Mean Serum Cmax of Brentuximab Vedotin and TAb|Phase 2: Mean Plasma Cmax of MMAE|Phase 2: Mean Serum AUC0-15d of Brentuximab Vedotin and TAb|Phase 2: Mean Plasma AUC0-15 of MMAE|Phase 2: Median Tmax of Brentuximab Vedotin and TAb in Serum|Phase 2: Median Tmax of MMAE in Plasma|Phase 2: Percentage of Participants Who Experienced Peripheral Neuropathy, Regardless of Seriousness, From the First Dose of Protocol Therapy|Phase 2: Time to Onset and Resolution for All Peripheral Neuropathy Events|Phase 2: Immune Reconstitution-Change From Baseline Immunoglobulin G Levels at End of Treatment (EOT)|Phase 1: Percentage of Participants With Low and High ATA Titer Values|Phase 2: Percentage of Participants With Low and High ATA Titer Values|Phase 1: Mean Cmax of Brentuximab Vedotin in ATA Positive and ATA Negative Participants|Phase 1: Mean AUC 0-15d of Brentuximab Vedotin in ATA Positive and ATA Negative Participants|Phase 1: Percentage of Participants Achieving CR Per IRF Assessment Per IWG Criteria in ATA Positive and ATA Negative Participants|Phase 1: Number of ATA Positive and ATA Negative Participants With AEs and SAEs|Phase 2: Mean Cmax of Brentuximab Vedotin in ATA Positive and ATA Negative Participants|Phase 2: Mean AUC 0-15 of Brentuximab Vedotin in ATA Positive and ATA Negative Participants|Phase 2: Percentage of Participants Achieving CR Per IRF Assessment Per IWG Criteria in ATA Positive and ATA Negative Participants|Phase 2: Number of ATA Positive and ATA Negative Participants With AEs and SAEs|Phase 2: Immune Reconstitution-Change From Baseline in Immunoglobulin M at the End of Treatment (EOT)|Phase 2: Immune Reconstitution-Change From Baseline in Immunoglobulin A at EOT|Phase 2: Immune Reconstitution-Change From Baseline in Tetanus at EOT|Phase 2: Immune Reconstitution-Change From Baseline in Haemophilus Influenzae B Antibody, IgG at EOT|Phase 2: Immune Reconstitution-Change From Baseline Poliovirus Antibodies Ratio at EOT|Phase 2: Immune Reconstitution-Change From Baseline Total Immunoglobulin at EOT|Phase 2: Immune Reconstitution-Change From Baseline in Peripheral Blood CD34+A at EOT|Phase 2: Immune Reconstitution-Change From Baseline in Total Lymphocyte Count at EOT|Phase 2: Immune Reconstitution-Change From Baseline in the Percentage of CD4+ (CD4+CD45RA-CD197- and CD4+CD45RA+CD197+) Subset of Cells at EOT|Phase 2: Immune Reconstitution-Change From Baseline in the Percentage of CD8+ (CD8+CD45RA-CD197- and CD8+CD45RA-CD197+) Subset of Cells at EOT",Takeda,All,5 Years to 17 Years   (Child),Phase 1|Phase 2,59.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C25004|2015-004112-38|U1111-1171-0984,2017-09-06,"May 5, 2020",2021-09-24,"December 1, 2016","June 1, 2021","June 24, 2022","Children's Hospital Colorado, Aurora, Colorado, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Hospital Sao Rafael S/A, Salvador, Bahia, Brazil|Jardim das Americas, Parana, Brazil|INCA - Instituto Nacional de Cancer, Rio de Janeiro, Brazil|GRAACC - Grupo de Apoio ao Adolescente e a Crianca com Cancer, Sao Paulo, Brazil|ICr - Instituto da Crianca - HCFMUSP, Sao Paulo, Brazil|Hospital Santa Marcelina, Sao Paulo, Brazil|Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer, Firenze, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Pediatrico Bambino Gesu,UOC Onco-ematologia, Roma, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|NHO Nagoya Medical Center, Nagoya-shi, Aichi-Ken, Japan|St. Marianna University School of Medicine Hospital, Kawasaki-shi, Kanagawa-Ken, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT02979522/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT02979522/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02979522,1479.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
641,642,NCT01897571,"Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL",,Completed,No Results Available,B-cell Lymphomas (Phase 1)|Advanced Solid Tumors (Phase 1)|Diffuse Large B-cell Lymphoma (Phase 2)|Follicular Lymphoma (Phase 2)|Transformed Follicular Lymphoma|Primary Mediastinal Large B-Cell Lymphoma,Drug: Tazemetostat,"Maximum tolerated dose (MTD) (Phase 1 only)|Objective response rate (ORR; complete response + partial response [CR + PR]) (Phase 2)|The effect of a high fat meal on the bioavailability of tazemetostat (Phase 1)|The effect of tazemetostat on exposure of midazolam, a CYP3A4 substrate|To assess the preliminary activity of tazemetostat (Phase 1)|The effect of tazemetostat monotherapy and tazemetostat in combination with prednisolone on progression-free survival (PFS) (Phase 2)|The effect of tazemetostat monotherapy and tazemetostat in combination with prednisolone on duration of response (DOR) (Phase 2)|The effect of tazemetostat monotherapy on overall survival (Cohorts 4 and 5 only)|The safety and tolerability of tazemetostat monotherapy and tazemetostat in combination with prenisolone (Phase 1 and Phase 2)|The pharmacokinetic (PK) profile of tazemetostat monotherapy and tazemetostat in combination with prednisolone (Phase 1 and Phase 2)","Epizyme, Inc.",All,"16 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,420.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E7438-G000-101,2013-06-01,"November 12, 2021",2021-11-15,"July 12, 2013",,"December 10, 2021","Birmingham, Alabama, United States|Duarte, California, United States|Santa Barbara, California, United States|Aurora, Colorado, United States|Washington, District of Columbia, United States|Ocala, Florida, United States|Ann Arbor, Michigan, United States|New York, New York, United States|Houston, Texas, United States|San Antonio, Texas, United States|Arlington, Virginia, United States|Seattle, Washington, United States|Clayton, Australia|Geelong, Australia|Melbourne, Australia|Montreal, Canada|Toronto, Canada|Bordeaux, France|Caen, France|Creteil, France|Lille, France|Lyon, France|Marseille, France|Montpellier, France|Nantes, France|Paris, France|Pierre Benite, France|Rennes, France|Rouen, France|Villejuif Cedex, France|Gottingen, Germany|Muenster, Germany|Bologna, Italy|Napoli, Italy|Krakow, Poland|Lublin, Poland|Poznan, Poland|Warsaw, Poland|Taipei City, Taiwan|Chernivtsi, Ukraine|Dnipro, Ukraine|Ivano-Frankivs'k, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|Mykolayiv, Ukraine|Uzhgorod, Ukraine|Zaporizhzhya, Ukraine|Zhytomyr, Ukraine|Glasgow, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Southampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT01897571,3089.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
642,643,NCT01400685,Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL,,Completed,No Results Available,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|B Chronic Lymphocytic Leukemia,Drug: Lenalidomide|Drug: Bendamustine|Drug: Rituximab,"Identify the maximum tolerated dose of lenalidomide when combined with bendamustine and rituximab in CLL/SLL|Define dose limiting toxicities of bendamustine, rituximab and lenalidomide in CLL|Clinical efficacy",Massachusetts General Hospital|Dana-Farber Cancer Institute,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,34.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11-016,2012-12-01,December 2017,2018-01-01,"July 22, 2011",,"January 25, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01400685,1857.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
643,644,NCT01851551,Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL,,Completed,No Results Available,Non-Hodgkin's Lymphoma|Diffuse Large B-cell Lymphoma|Mantle Cell Lymphoma,Drug: Vincristine Sulfate Liposome Injection plus rituximab,Objective response rate|Assessment of the number of events and number and percentage of patients with treatment-emergent AEs|Time to Progression|Overall survival,Acrotech Biopharma Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,22.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA00005,2001-09-01,April 2004,2005-04-01,"May 10, 2013",,"January 3, 2020","University of California, San Francisco, California, United States|Leeds General Infirmary, Leeds, West Yorkshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT01851551,1308.0,Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
644,645,NCT01647971,Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,,Completed,No Results Available,Non-Hodgkins Lymphoma|B-cell Lymphoma|Waldenstrom's Macroglobulinemia|Marginal Zone Lymphoma|Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)|Primary Central Nervous System Lymphoma,Drug: Ublituximab,Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Maximum Tolerated Dose acceptable for participants|Efficacy,"TG Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,39.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TGTX 1101-101,2012-07-19,May 2015,2015-05-01,"July 24, 2012",,"November 21, 2022","TG Therapeutics Investigational Trial Site, Huntsville, Alabama, United States|TG Therapeutics Investigational Trial Site, Jonesboro, Arkansas, United States|TG Therapeutics Investigational Trial Site, Athens, Georgia, United States|TG Therapeutics Investigational Trial Site, Macon, Georgia, United States|TG Therapeutics Investigational Trial Site, Bethesda, Maryland, United States|TG Therapeutics Investigational Trial Site, Morristown, New Jersey, United States|TG Therapeutics Investigational Trial Site, New York, New York, United States|TG Therapeutics Investigational Trial Site, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT01647971,1016.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
645,646,NCT01035463,Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy,,Completed,Has Results,"Anaplastic Large Cell Lymphoma, ALK-Negative|Recurrent Anaplastic Large Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma",Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Drug: Cytarabine|Drug: Etoposide|Drug: Lenalidomide|Drug: Melphalan|Biological: Rituximab,Maximum Tolerated Dose of Lenalidomide (Phase I)|Event-free Survival|Overall Survival,University of Nebraska|National Cancer Institute (NCI),All,"19 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,74.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,446-08|NCI-2009-01436|RV-LYM-PI-0328|P30CA036727,2009-11-12,"July 27, 2017",2018-07-27,"December 18, 2009","November 8, 2019","November 8, 2019","University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT01035463/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01035463,3179.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
646,647,NCT00283439,A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma,,Completed,Has Results,Chemotherapy-Induced Thrombocytopenia|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Cancer|Oncology|Thrombocytopenia,Biological: AMG 531,Change in Platelet Nadir|Percentage of Subjects Experiencing Grade 3 or 4 Thrombocytopenia|Duration of Grade 3 or 4 Thrombocytopenia|Percentage of Subjects That Received Platelet Transfusions,Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,39.0,Industry,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,20050144,2005-10-01,May 2008,2008-09-01,"January 30, 2006","September 13, 2010","June 20, 2011",,,https://ClinicalTrials.gov/show/NCT00283439,1066.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Supportive Care
647,648,NCT00421395,Safety Study of NHL With 90Y-hLL2 IgG,,Completed,No Results Available,NHL|B-cell NHL|Non-Hodgkins Lymphoma,Biological: 90Y-hLL2,"Safety will be evaluated from physical examinations, hematology and chemistry testing and toxicity evaluation|Determine maximum tolerated dose (MTD)|Evaluate the immunogenicity and safety of repeated infusions of 90Y-hLL2 in NHL patients.|Determine the therapeutic effects, in terms of objective response rate and duration, of the therapeutic agent in NHL patients.",Gilead Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,59.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IM-T-hLL2-06EU,2002-08-01,October 2007,2007-10-01,"January 12, 2007",,"August 16, 2021","Research Unit 463 INSERM, Nantes, Cedex, France|Service des Maladies du Sang, Lille, France|University Hospital Dresden, Dresden, Germany|Klinikum der Georg-August-Universitat Gottingen, Gottingen, Germany|Universitatsklinikum University of Saarland, Homburg/Saar, Germany",,https://ClinicalTrials.gov/show/NCT00421395,1887.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
649,650,NCT02581631,An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas,CheckMate 436,Completed,Has Results,Non-Hodgkin's Disease,Biological: Nivolumab|Drug: Brentuximab Vedotin,Safety Analysis - Number of Participants With Dose Limiting Toxicities (DLT) in the DLT Evaluation Phase|Safety Analysis - Number of Participant Deaths|Safety Analysis - Number of Participants With Adverse Advents|Safety Analysis - Number of Participants With Serious Adverse Events|Safety Analysis - Number of Participants With Adverse Events Leading to Discontinuation|Safety Analysis - Number of Participants With Adverse Events Leading to Dose Delay or Reduction|Safety Analysis - Number of Participants With Drug Related Adverse Events|Safety Analysis - Percentage of Participants With Thyroid Test Abnormalities|Safety Analysis - Percentage of Participants With Liver Test Abnormalities|Objective Response Rate (ORR)|Duration of Response (DOR)|Complete Response Rate (CRR)|Duration of Complete Response|Progression Free Survival (PFS)|Overall Survival (OS),Bristol-Myers Squibb|Seagen Inc.,All,"15 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,145.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA209-436|2015-003286-28,2016-02-11,"January 16, 2020",2022-02-07,"October 21, 2015","March 7, 2023","March 7, 2023","Local Institution - 0017, Birmingham, Alabama, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Local Institution - 0012, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|University Of Chicago, Chicago, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Local Institution - 0003, New York, New York, United States|Local Institution - 0010, New York, New York, United States|University Of Rochester, Rochester, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|Bon Secours-St Francis Hosp, Greenville, South Carolina, United States|University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Local Institution - 0011, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Hopital Saint Louis, Paris, France|Local Institution - 0020, Pierre Benite Cedex, France|Local Institution - 0018, Bergamo, Italy|Local Institution - 0024, Bologna, Italy|Istituto Clinico Humanitas, Rozzano (milano), Italy|Local Institution - 0027, Hospitalet de Llobregat - Barcelona, Spain|Churchill Hospital, Oxford, Oxfordshire, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02581631/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02581631/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02581631,2188.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
650,651,NCT00001575,"Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia",,Completed,Has Results,"Hodgkin's Disease|Lymphoma, Non-Hodgkin",Biological: Y-90 Humanized Anti-Tac|Drug: Calcium-DTPA,Maximum Tolerated Dose (MTD) of 90Y-HAT|Clinical Response|Number of Participants With Adverse Events,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,87.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,970110|97-C-0110,1997-04-01,November 2013,2013-11-01,"November 4, 1999","December 7, 2015","December 7, 2015","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00001575,6058.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
651,652,NCT01207921,Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma,,Completed,No Results Available,Hodgkin Disease,Drug: Lenalidomide,"To evaluate the feasibility of lenalidomide maintenance therapy in patients with relapsed Hodgkin lymphoma after ASCT, as measured by dropout rate.|Overall survival (OS)|Adverse event profile|Conversion of partial response/stable disease post-ASCT to complete response.|Evaluate immune response|Event-free survival (EFS)|Progression-free survival (PFS)",Washington University School of Medicine|Celgene Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 1,28.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201010719,2011-04-28,"September 19, 2016",2021-03-05,"September 23, 2010",,"March 10, 2021","Washington University School of Medicine, Saint Louis, Missouri, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Ohio State University, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01207921,3599.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
652,653,NCT01791595,A Phase I Trial of AZD3965 in Patients With Advanced Cancer,,Completed,Has Results,Adult Solid Tumor|Diffuse Large B Cell Lymphoma|Burkitt Lymphoma,Drug: AZD3965,"MTD of AZD3965|Number of Patients Who Experienced DLTs|Number of Patients Who Experienced Serious AEs|Number of Patients Who Experienced Non-Serious AEs|Area Under the Concentration-Time Curve (AUC) From 0 to 24 Hours Post AZD3965 Dosing|AUC From 0 to 12 Hours Post AZD3965 Dosing|Maximum Observed Plasma Concentration of AZD3965|Time to Maximum Observed Concentration of AZD3965|Elimination Half Life for AZD3965|Plasma Level of Cell Death Marker M30 (Caspase-Cleaved CK18; Part 1 Only)|Plasma Level of Cell Death Marker M65 (Total Plus Caspase-Cleaved CK18; Part 1 Only)|Plasma Level of Nucleosomal DNA (nDNA) as a Measure of Apoptosis (Part 1 Only)|Number of Patients Who Experienced a Complete Response, Partial Response or Stable Disease According to RECIST 1.1 or a Complete Remission, Partial Remission or Stable Disease According to the IWG Criteria for Lymphoma (Part 2 Only)",Cancer Research UK|AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 1,53.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CRUKD/12/004|2010-024463-41,2013-04-23,"November 17, 2020",2020-11-17,"February 15, 2013","April 11, 2022","April 11, 2022","Royal Marsden Hospital, Sutton, London, United Kingdom|The Beatson West of Scotland, Glasgow, Glasgow, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|University College London Hospitals, London, United Kingdom|The Christie, Manchester, United Kingdom|Freeman Hospital, Newcastle upon Tyne, United Kingdom|Derriford Hospital, Plymouth, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT01791595/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT01791595,2765.0,Not Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
653,654,NCT01943682,Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma,,Completed,No Results Available,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Burkitt Lymphoma|Diffuse Large Cell Lymphoma|Gray Zone Lymphoma|Lymphoblastic Lymphoma|Anaplastic Large Cell Lymphoma|Hodgkin Lymphoma,Drug: CPX-351,"Determine rate of dose limiting toxicities|Number of participants with dose limiting toxicities to determine maximum tolerated dose.|Pharmacokinetics: Serum concentration of CPX-351 components (cytarabine and daunorubicin) and metabolites.|Tumor measurement by bone marrow biopsy, blood counts, and/or PET/CT scan|Serum levels of biomarkers (troponin-1, troponin-T, and B-type natriuretic) of cardiac injury.","Children's Hospital Medical Center, Cincinnati|Jazz Pharmaceuticals",All,"12 Months to 30 Years   (Child, Adult)",Phase 1,27.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CPX-MA-1201|2013-4305,2013-09-01,March 2019,2019-04-01,"September 17, 2013",,"November 9, 2020","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01943682,2038.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
654,655,NCT02580552,"Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL",,Completed,No Results Available,"Cutaneous T-cell Lymphoma (CTCL)|Mycosis Fungoides (MF)|Chronic Lymphocytic Leukemia (CLL)|Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype|Adult T-Cell Leukemia/Lymphoma (ATLL)",Drug: Cobomarsen,"Safety and tolerability of cobomarsen based on vital signs, physical examination, clinical laboratory tests, ECG, and incidence and severity of adverse events|Area under the plasma concentration vs. time curve (AUC) of cobomarsen following single and repeat doses administered intratumorally, subcutaneously or intravenously|Peak plasma concentration (Cmax) of cobomarsen following single and repeat doses administered intratumorally, subcutaneously or intravenously|Trough plasma concentration (Ctrough) of cobomarsen following each 4-week cycle of dosing|Skin disease severity (index lesions) - MF only|Skin disease severity (whole body) - MF only|Overall Response Rate in the skin - MF|Overall Response Rate - CLL|Minimal Residual Disease (MRD) - CLL only|Overall Response Rate - DLBCL|Overall Response Rate - ATLL|Duration of Response|Time to Progression|Progression Free Survival (PFS)|Overall Survival (OS)","miRagen Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,66.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MRG106-11-101,2016-02-09,"October 6, 2020",2020-10-06,"October 20, 2015",,"November 23, 2020","City of Hope, Duarte, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|UCLA Department of Medicine, Los Angeles, California, United States|Chao Family Comprehensive Cancer Center at University of California, Irvine, Orange, California, United States|Stanford University Hospital and Clinics, Stanford, California, United States|University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States|Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States|University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Northwestern University; Department of Dermatology, Chicago, Illinois, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Inova Melanoma and Skin Cancer Center / Inova Schar Cancer Institute, Fairfax, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02580552,1701.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
655,656,NCT01995669,Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma,,Completed,No Results Available,Grade 3a Follicular Lymphoma|Recurrent Follicular Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Follicular Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Small Lymphocytic Lymphoma,Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Biological: Obinutuzumab,Maximum tolerated dose of lenalidomide when given with obinutuzumab defined as the highest dose level in which 6 patients have been treated with less than 2 instances of dose limiting toxicity (DLT) (Phase I)|Incidence of DLTs after course 1 assessed using NCI CTCAE version 4 (Phase II)|Overall response rate (complete response + partial response) (Phase II)|Overall survival|Progression-free survival,M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,70.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013-0261|NCI-2014-00943|ML28301,2014-05-21,"January 23, 2023",2023-01-23,"November 26, 2013",,"February 2, 2023","M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01995669,3169.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
656,657,NCT01177397,"Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",,Completed,Has Results,Multiple Myeloma|Diffuse Large B-Cell Lymphoma|Glioblastoma Multiforme|Hepatocellular Carcinoma|Non-Small Cell Lung Cancer|Neuroendocrine Tumors of Non-Pancreatic Origin|Hormone Receptor-Positive Breast Cancer,Drug: CC-223,Part A: Number of Participants With Dose-limiting Toxicities|Maximum Observed Plasma Concentration (Cmax) of CC-223|Time to Maximum Concentration (Tmax) of CC-223|Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUCt) for CC-223|Area Under the Concentration Time-Curve From 0-24 Hours After a Dose (AUC0-24) for CC-223|Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf) For CC-223|Part A: Terminal Elimination Phase Half-Life (T1/2) of CC-223|Apparent Total Body Clearance (CL/F) of CC-223|Apparent Volume of Distribution (Vz/F) of CC-223|Part B: Progression Free Survival (PFS) Rate at 6 Months for GBM Participants|Part A: Percent Change From Baseline in Levels of Phosphorylated Ribosomal Protein S6 (pS6RP) in Stimulated B Cells|Part A: Percent Change From Baseline in Levels of Phosphorylated Elongation I Initiation Binding Protein (p4E-BP1) in Stimulated T Cells|Part A: Percent Change From Baseline in Levels of Phosphorylated Protein Kinase B (pAKT) in Stimulated Monocytes|Part B: Percent Change From Baseline in p4E-BP1 in Monocytes by Tumor Cohort|Part B: Percent Change From Baseline in p4E-BP1 in Monocytes in the HCC and NET Cohorts by Dose|Part B: Percent Change From Baseline in Levels of pAKT in Monocytes by Tumor Cohort|Part B: Percent Change From Baseline in Levels of pAKT in Monocytes in the HCC and NET Cohorts by Dose|Part B: Percent Change From Baseline in pS6RP Levels in Tumor Tissue by Tumor Type|Part A: Overall Response Rate|Part B: Overall Response Rate|Maximum Observed Concentration (Cmax) of Metabolite M1|Time to Maximum Concentration (Tmax) of Metabolite M1|Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUCt) for Metabolite M1|Area Under the Concentration Time-Curve From 0-24 Hours After a Dose (AUC0-24) for Metabolite M1,Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,226.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CC-223-ST-001,2010-07-20,"November 15, 2016",2016-12-09,"August 9, 2010","November 15, 2022","December 13, 2022","Cedars-Sinai Medical Center, Los Angeles, California, United States|UCLA Neuro-Oncology Program, Los Angeles, California, United States|University of California, San Francisco Hellen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Mayo Clinic Cancer Clinical Studies Unit, Rochester, Minnesota, United States|Billings Clinic, Billings, Montana, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|NYU Cancer Institute - Bellevue Hospital, New York, New York, United States|Sarah Cannon Research Institute Drug Development Unit, Nashville, Tennessee, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|Institut Claudius Regaud, Toulouse Cedex, France|Institut Gustave Roussy Faculte de Medecine Paris Sud Service de pneumologie, Villejuif, France|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Sarah Cannon Research Institute UK, London, United Kingdom|UCL Cancer Institute, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01177397,2334.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
658,659,NCT02912676,Thiopurine EnhAnced Maintenance Therapy,TEAM,Completed,No Results Available,Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma,Drug: Thioguanine (oral),Obtaining a stable mean DNA-TGN level > 500 fmol/microgram DNA after addition of 6TG. DNA-TGN calculated as a 4 weeks mean (maximum 6TG dose 12.5 mg/m.xq.).|Erythrocyte 6MP cytosol metabolite levels|Myelotoxicity|Severe hepatotoxicity including sinusoidal obstruction syndrome,"Kjeld Schmiegelow|Danish Child Cancer Foundation|Nordic Society for Pediatric Hematology and Oncology|Rigshospitalet, Denmark",All,"6 Months to 45 Years   (Child, Adult)",Phase 1|Phase 2,30.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Rigshospitalet - TEAM,2016-10-01,March 2020,2020-04-01,"September 23, 2016",,"April 15, 2020","Aarhus University Hospital Skejby, Skejby, Aarhus, Denmark|Odense University Hospital, Dept. Pediatric Oncology, Odense, Odense C, Denmark|Department of Pediatrics, Rigshospitalet, Copenhagen, Denmark|Rigshospitalet, Department of Hematology, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT02912676,1278.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
659,660,NCT02273739,"Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation",,Completed,Has Results,Solid Tumor|Glioma|Angioimmunoblastic T-cell Lymphoma|Intrahepatic Cholangiocarcinoma|Chondrosarcoma,Drug: Enasidenib,Number of Participants With Treatment-emergent Adverse Events (TEAEs)|Number of Participants With Dose-limiting Toxicities|Eastern Cooperative Oncology Group (ECOG) Performance Status at Each Visit|Maximum Observed Plasma Concentration (Cmax) After a Single Dose of Enasidenib on Day -3|Time of Maximum Plasma Concentration (Tmax) of Enasidenib After a Single Dose on Day -3|Area Under the Plasma Concentration Time Curve From Time Zero to 10 Hours Postdose (AUC0-10) of Enasidenib After a Single Oral Dose on Day -3|Area Under the Plasma Concentration Time Curve From Time Zero to 72 Hours Postdose (AUC0-72) of Enasidenib After a Single Dose on Day -3|Maximum Observed Plasma Concentration (Cmax) of Metabolite AGI-16903 After a Single Dose of Enasidenib on Day -3|Time of Maximum Plasma Concentration (Tmax) of Metabolite AGI-16903 After a Single Dose of Enasidenib on Day -3|Area Under the Plasma Concentration-time Curve From Time 0 to 10 Hours Postdose (AUC0-10) for Metabolite AGI-16903 After a Single Dose of Enasidenib on Day -3|Area Under the Plasma Concentration-time Curve From Time 0 to 72 Hours Postdose (AUC0-72) for AGI-16903 After a Single Dose of Enasidenib on Day -3|Area Under the Plasma Concentration-time Curve From Time 0 to 10 Hours Postdose (AUC0-10) for Enasidenib After Multiple Doses|Maximum Observed Plasma Concentration (Cmax) of Enasidenib After Multiple Doses|Time of Maximum Plasma Concentration (Tmax) of Enasidenib After Multiple Doses|Area Under the Plasma Concentration-time Curve From Time 0 to 10 Hours Postdose (AUC0-10) for Metabolite AGI-16903 After Multiple Doses of Enasidenib|Maximum Observed Plasma Concentration (Cmax) of Metabolite AGI-16903 After Multiple Doses of Enasidenib|Time of Maximum Plasma Concentration (Tmax) of Metabolite AGI-16903 After Multiple Doses of Enasidenib|Percentage of Participants With Solid Tumors (Excluding Glioma) Who Achieved an Objective Response|Percentage of Participants With Glioma Who Achieved an Objective Response|Percentage of Participants With AITL Who Achieved an Objective Response,Celgene|Celgene Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,21.0,Industry,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AG221-C-003|2014-003424-47,2014-12-08,"June 3, 2016",2016-06-03,"October 24, 2014","February 23, 2021","February 23, 2021","Los Angeles, California, United States|Los Angeles, California, United States|Miami, Florida, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Omaha, Nebraska, United States|New York, New York, United States|Cleveland, Ohio, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Bordeaux, France|Villejuif Cedex, France",,https://ClinicalTrials.gov/show/NCT02273739,543.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
660,661,NCT04323657,TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia,,Completed,No Results Available,Non Hodgkin Lymphoma|Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma|Primary Mediastinal Large B Cell Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma,Drug: TC-110 T Cells|Drug: Fludarabine|Drug: Cyclophosphamide,"Establish the recommended phase 2 dose (RP2D) for the NHL and ALL indications according to the observed adverse events, including potential dose-limiting toxicities (DLT).|To evaluate the efficacy of autologous genetically modified TC-110 T cells in adult patients with R/R NHL as determined by overall response rate (ORR)|To evaluate the efficacy of autologous genetically modified TC-110 T cells in adult patients with R/R ALL as determined by overall response rate and Minimum Residual Disease (MRD) negativity rates",TCR2 Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,6.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TCR2-19-01,2020-03-27,"February 24, 2023",2023-02-24,"March 26, 2020",,"March 16, 2023","Colorado Blood Cancer Institute, Denver, Colorado, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04323657,1064.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
661,662,NCT00644189,Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma,,Completed,Has Results,"Follicular Lymphoma|Marginal Zone Lymphoma|Mantle Cell Lymphoma|Small Lymphocytic Lymphoma|Lymphoplasmacytic Lymphoma|Low Grade B-cell Lymphoma, Not Otherwise Specified|Diffuse Large B-cell Lymphoma|Peripheral T-cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Anaplastic Large-cell Lymphoma",Drug: Clofarabine,All Phase I-II Participants: Overall Response Rate (ORR)|Phase I Participants Only: Overall Response Rate (ORR)|Phase I-II Participants Treated at the RP2D (3mg): Overall Response Rate (ORR)|All Phase I-II Participants: Progression-free Survival (PFS)|All Phase I-II Participants: Overall Survival (OS)|All Phase I-II Participants: Safety|Phase I Participants Treated at the RP2D (3mg): Overall Response Rate (ORR)|Phase I Participants: Progression-free Survival (PFS)|All Phase I Participants: Overall Survival (OS)|Phase I Participants: Safety,"Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Genzyme, a Sanofi Company",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,50.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,07-401,2008-06-01,December 2013,2021-07-01,"March 26, 2008","May 8, 2017","March 15, 2023","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00644189,4778.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
662,663,NCT01776411,Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients,,Completed,No Results Available,Recurrent or Refractory PTCL,Drug: forodesine hydrochloride,Objective response rate (ORR) based on evaluation by image assessment committee,Mundipharma K.K.,All,"20 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,49.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FDS-J02,2013-01-01,March 2016,2017-04-26,"January 28, 2013",,"May 11, 2017","National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan|Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime,, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan|Hyogo Cancer Center, Akashi, Hyogo, Japan|Tokai University Hospital, Isehara, Kanagawa, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|Osaka University Hospital, Suita, Osaka, Japan|Shimane University Hospital, Izumo, Shimane, Japan|Tochigi Cancer Center, Utsunomiya, Tochigi, Japan|National Cancer Center Hospital, Chuo, Tokyo, Japan|The Cancer Institute Hospital Japanese Foundation for Cancer Research, Koto, Tokyo, Japan|University of Fukui Hospital, Fukui, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Fukuoka University Hospital, Fukuoka, Japan|Imamura Bun-in Hospital, Kagoshima, Japan|National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan|University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan|Okayama University Hospital, Okayama,, Japan",,https://ClinicalTrials.gov/show/NCT01776411,1576.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
663,664,NCT03010358,"Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma",,Completed,No Results Available,Anemia|B-Cell Prolymphocytic Leukemia|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3a Follicular Lymphoma|Hairy Cell Leukemia|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma|Richter Syndrome,Drug: Entospletinib|Other: Laboratory Biomarker Analysis|Biological: Obinutuzumab|Other: Pharmacological Study,Maximum tolerated dose (MTD) and/or a recommended phase II dose (Phase I)|Complete response (CR) defined as the proportion of subjects who achieve CR (Phase II)|Objective response rate (ORR) (Phase II)|Event free survival (EFS) (Phase II)|Incidence of adverse events,"Alexey Danilov, MD|Gilead Sciences|Oregon Health and Science University|OHSU Knight Cancer Institute",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,24.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00016140|NCI-2016-02029,2017-07-17,"April 29, 2021",2021-04-29,"January 5, 2017",,"May 4, 2021","OHSU Knight Cancer Institute, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT03010358,1382.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
664,665,NCT00562380,AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma,,Completed,No Results Available,"Lymphoma|Prostate Cancer|Sarcoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Biological: ganitumab|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: biopsy,Safety|Pharmacokinetic profile|Level of insulin-like growth factor receptor-1 (IGF-1R) on peripheral blood cells|Tumor response measured by modified RECIST|Tumor glucose metabolism as measured by fludeoxyglucose F 18-PET/CT scan|Anti-AMG-479 antibody formation|The incidence of dose-limiting toxicities and the severity of adverse events|Levels of cross-linked c-telopeptides of type 1 collagen and bone-specific alkaline phosphatase (may also include tartrate-resistant acid phosphatase 5b) in blood|Circulating levels of IGF-1R and IGF-BP3,Amgen|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,64.0,Industry|NIH,Interventional,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,AMGEN-479|CDR0000577404|AMGEN-20050118|VU-VICC-050630|VU-VICC-PHI-0542,2005-10-01,April 2010,2010-06-01,"November 22, 2007",,"July 18, 2013","Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00562380,1704.0,Industry Lead,More than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
665,666,NCT01026233,Cardiac Safety Study of Brentuximab Vedotin (SGN-35),,Completed,No Results Available,"Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin",Drug: brentuximab vedotin,QTc interval|ECG parameters|Blood MMAE levels|Incidence of proarrhythmic adverse events|Incidence of adverse events and laboratory abnormalities,"Seagen Inc.|Millennium Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,52.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SGN35-007,2010-01-01,August 2010,2011-08-01,"December 4, 2009",,"December 12, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States|City of Hope National Medical Center, Duarte, California, United States|Stanford Cancer Center, Stanford, California, United States|University of Miami Hospital and Clinics, Miller School of Medicine, Miami, Florida, United States|Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States|New York University Cancer Institute, New York, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Baylor University Medical Center, Dallas, Texas, United States|University Hospital of Cologne, Koln, Germany",,https://ClinicalTrials.gov/show/NCT01026233,577.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
666,667,NCT00939770,Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,,Completed,Has Results,Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Neuroblastoma|Refractory Anaplastic Large Cell Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Neuroblastoma,Drug: Crizotinib|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Questionnaire Administration,Maximum-tolerated Dose and Recommended Phase 2 Dose of Crizotinib|Number of Participants With Toxicities of Crizotinib|Steady State C Max of Crizotinib|Steady State C Average of Crizotinib|Steady State AUC of Crizotinib|Steady State Clearance of Crizotinib|Number of Participants (Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (ALCL))With Response to Crizotinib|Number of Participants (Relapsed or Refractory Neuroblastoma or Anaplastic Large Cell Lymphoma (ALCL)) With Response to Crizotinib|Number of Participants With Minimum Residual Disease (MRD),Children's Oncology Group|National Cancer Institute (NCI)|Pfizer,All,"1 Year to 21 Years   (Child, Adult)",Phase 1|Phase 2,122.0,Other|NIH|Industry,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ADVL0912|NCI-2011-01937|P10666|COG-ADVL0912|CDR0000647587|UM1CA097452,2009-09-21,"December 31, 2018",2018-12-31,"July 15, 2009","May 5, 2020","June 9, 2020","Children's Hospital of Alabama, Birmingham, Alabama, United States|University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Children's Hospital of Orange County, Orange, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Hospital for Sick Children, Toronto, Ontario, Canada","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT00939770/Prot_SAP_ICF_001.pdf",https://ClinicalTrials.gov/show/NCT00939770,3388.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
667,668,NCT01874054,Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma,,Completed,Has Results,Hodgkin Disease,Drug: brentuximab vedotin|Drug: bendamustine,Complete Remission Rate|Incidence of Adverse Events (AEs)|Incidence of Dose-limiting Toxicities|Overall Best Response Rate|Duration of Response|Progression-free Survival,Seagen Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,55.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SGN35-016,2013-06-01,December 2015,2018-02-20,"June 10, 2013","April 6, 2017","February 12, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|Stanford Cancer Center, Stanford, California, United States|Oncology Institute of Hope & Innovation, The, Whittier, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic Minnesota, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Columbia University Medical Center, New York, New York, United States|Jewish Hospital, The, Cincinnati, Ohio, United States|Case Western Reserve University / University Hospitals Case Medical Center, Cleveland, Ohio, United States|Saint Francis Hospital / Bon Secours, Greenville, South Carolina, United States|Charles A. Sammons Cancer Center / Baylor University Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01874054,1725.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
668,669,NCT01307267,A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab,,Completed,Has Results,"Lymphoma, Non-Hodgkin|Lymphoma, Follicular|Lymphoma, Large B-Cell, Diffuse|Carcinoma, Non-Small-Cell Lung|Carcinoma, Renal Cell|Carcinoma, Squamous Cell of Head and Neck|Malignant Melanoma",Drug: PF-05082566|Drug: rituximab,Number of Participants With Dose-Limiting Toxicities (DLTs) in First 2 Cycles of Portion A|Number of Participants With DLTs in First 2 Cycles of Portion B|Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) in Portion A|Number of Participants With Treatment-Emergent AEs by Maximum National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Grade in Portion A|Number of Participants With Hematology Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion A|Number of Participants With Chemistries Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion A|Number of Participants With Clinically Significant Vital Sign Abnormalities in Portion A|PF-05082566 Maximum Observed Serum Concentration (Cmax) in Portion A|PF-05082566 Pre-dose Trough Concentration During Multiple Dosing (Ctrough) in Portion A|PF-05082566 Time for Maximum Observed Serum Concentration (Tmax) in Portion A|PF-05082566 Area Under the Serum Concentration-Time Profile (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUClast) in Portion A|PF-05082566 AUC From Time 0 to Infinity (AUCinf) in Portion A|PF-05082566 AUC From Time 0 to Time of Dosing Interval (AUCtau) in Portion A|PF-05082566 Clearance (CL) in Portion A|PF-05082566 Volume of Distribution at Steady State (Vss) in Portion A|Number of Participants With Positive Anti-Drug Antibody (ADA) for PF-05082566 in Portion A|Number of Participants With QTc Interval Meeting Categorical Summarization Criteria in Portion A|Percentage of Participants Achieving Objective Response Per Response Evaluation Criteria in Solid Tumor (RECIST) Version 1.1 in Portion A|Duration of Response in Portion A|Time to Response in Portion A|Progression-Free Survival in Portion A|Overall Survival in Portion A|Number of Participants With Treatment-Emergent AEs and SAEs in Portion B|Number of Participants With Treatment-Emergent AEs by Maximum NCI CTCAE Grade in Portion B|Number of Participants With Hematology Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion B|Number of Participants With Chemistries Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion B|Number of Participants With Clinically Significant Vital Sign Abnormalities in Portion B|PF-05082566 Cmax in Portion B|PF-05082566 Ctrough in Portion B|PF-05082566 Tmax in Portion B|PF-05082566 AUClast in Portion B|PF-05082566 AUCinf in Portion B|PF-05082566 AUCtau in Portion B|PF-05082566 CL in Portion B|PF-05082566 Vss in Portion B|Rituximab Cmax and Ctrough in Portion B|Number of Participants With Positive ADA for PF-05082566 and Rituximab in Portion B|Number of Participants With QTc Interval Meeting Categorical Summarization Criteria in Portion B|Percentage of Participants Achieving Objective Response Per Cheson 2007 Criteria in Portion B|Duration of Response in Portion B|Time to Response in Portion B|Progression-Free Survival in Portion B|Overall Survival in Portion B,Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,190.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B1641001|2011-002799-17,2011-06-21,"February 20, 2019",2019-02-20,"March 2, 2011","March 17, 2020","March 17, 2020","City of Hope, Duarte, California, United States|UC San Diego Moores Cancer Center-Investigational Drug Services, La Jolla, California, United States|UC San Diego Medical Center-La Jolla (Jacobs Medical Center/Thornton Hospital), La Jolla, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Research Administration Office: Clinical Research Unit, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Drug Information Center, Los Angeles, California, United States|UCLA Bowyer Clinic, Los Angeles, California, United States|UCLA Hematology-Oncology Clinic, Los Angeles, California, United States|Stanford University Medical Center, Palo Alto, California, United States|Stanford University Medical Center, Palo Alto, California, United States|UC San Diego Medical Center - Hillcrest, San Diego, California, United States|Santa Monica UCLA Hematology & Oncology Clinic, Santa Monica, California, United States|Stanford University Medical Center, Stanford, California, United States|Georgetown University Medical Center Department of Pharmacy, Research, Washington, District of Columbia, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|The Emory Clinic, Building A, Atlanta, Georgia, United States|The Emory Clinic, Atlanta, Georgia, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Brigham and Woman's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Siteman Cancer Center-West County, Creve Coeur, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University Infusion Center Pharmacy, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center- South County, Saint Louis, Missouri, United States|Siteman Cancer Center - St. Peters, Saint Peters, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|The University of Texas - M.D. Anderson Cancer Center, Houston, Texas, United States|South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Centre d'investigation clinique, RENNES cedex 9, France|Az. Ospedaliera-Univer. di Bologna Policlinico S. Orsola Malpighi, Bologna, BO, Italy|Ospedale San Raffaele di Milano, Milano, MI, Italy|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Akita University Hospital, Akita, Japan|The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT01307267/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT01307267/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01307267,2801.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
670,671,NCT00438880,"Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma",,Completed,Has Results,Adult Non-Hodgkin Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Nodal Marginal Zone Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia,Drug: Agatolimod Sodium|Radiation: Indium In-111 Ibritumomab Tiuxetan|Other: Laboratory Biomarker Analysis|Procedure: Radionuclide Imaging|Biological: Rituximab|Procedure: Single Photon Emission Computed Tomography|Radiation: Yttrium Y-90 Ibritumomab Tiuxetan,Maximum Tolerated Dose of CpG 7909 as Determined Using the Number of Participants With a DLT at Each Dose Level|Tumor Response|Progression-free Survival|Duration of Response,Mayo Clinic|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,38.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LS0382|NCI-2009-01275|P30CA015083,2004-10-01,October 2010,2014-11-01,"February 22, 2007","September 1, 2014","February 4, 2016","University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00438880,3683.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
671,672,NCT01381692,"Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma",,Completed,Has Results,Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Recurrent Waldenstrom Macroglobulinemia|Refractory Follicular Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Small Lymphocytic Lymphoma,Drug: Bortezomib|Drug: Dexamethasone|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment|Biological: Rituximab|Drug: Temsirolimus,"Phase I: The Maximum Tolerated Dose (MTD) of Temsirolimus in Combination With Bortezomib, Rituximab and Dexamethasone|Phase II: Progression-free Survival|Phase II: Time to Progression|Phase II: Major Response Rate|Phase II: Minor Response Rate|Phase II: Time to Response|Phase II: Duration of Response|Phase II: Time to Next Therapy|Phase II: Overall Survival",National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,9.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2011-02650|CDR0000701362|ECOG-E1A10|E1A10|U10CA180820|U10CA021115,2011-07-20,"December 8, 2014",2021-09-01,"June 27, 2011","May 5, 2021","October 4, 2021","Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01381692,3696.0,Not Industry Lead,More than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
672,673,NCT00058240,Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma,,Completed,Has Results,B-cell Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Waldenström Macroglobulinemia,Drug: alvocidib,Number of Patients With Dose Limiting Toxicities (DLTs)|Recommended Dose Level of Flavopiridol|Overall Response Rate (CR + PR) of Flavopiridol in Patients Evaluated Utilizing the Revised National Cancer Institute-sponsored Working Group Guidelines,National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,52.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2012-01435|CDR0000287197|NCI-5746|OSU-0055|OSU 0055|5746|R21CA112947|P30CA016058|U01CA076576,2003-04-01,February 2009,2009-02-01,"April 9, 2003","June 2, 2017","July 2, 2017","Ohio State University Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00058240,2133.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
673,674,NCT00484874,Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma,,Completed,Has Results,Hodgkin's Disease,Drug: I-131 Tositumomab therapeutic regimen,Non-myeloablative Maximum Tolerated Dose of I-131 Tositumomab That Can be Given to Patients With Relapsed/Refractory Hodgkin's Lymphoma.|Overall and Complete Response Rates|Median Time to Progression Following I-131 Tositumomab Therapy.|Frequency of Visualization of Hodgkin's Lymphoma With I-131 Tositumomab Imaging and Tumor Radiation Absorbed Dose,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,12.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,J0703|NA_00005743,2007-06-01,January 2014,2015-11-01,"June 11, 2007","August 1, 2018","August 1, 2018","Johns Hopkins Medical Institutions, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00484874,3075.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
674,675,NCT00002663,"Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies",,Completed,Has Results,EBV-induced Lymphomas|EBV-associated Malignancies|Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma,Biological: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs),Objective Response Rate (ORR)|Overall Survival (OS)|OS Rate at 12 Months|OS Follow-up Time|Time to Response (TTR)|Clinical Benefit Rate (CBR),Atara Biotherapeutics|Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),All,"Child, Adult, Older Adult",Phase 1|Phase 2,58.0,Industry|Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,95-024|P30CA008748|MSKCC-95024|NCI-V95-0685,1995-03-01,July 2019,2019-07-01,"January 27, 2003","February 13, 2023","February 13, 2023","Memorial Sloan Kettering Cancer Center, New York, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT00002663/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT00002663/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT00002663,8888.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
675,676,NCT01076543,Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma,,Completed,Has Results,AIDS-Related Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Waldenstrom Macroglobulinemia,Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Drug: Temsirolimus,"Incidence of Dose-limiting Toxicity (DLT), Phase I Patients Only|Complete Response (Phase II)|Overall Response Rate (Phase II)|Progression-free Survival (PFS) (Phase II)|Overall Survival (OS) (Phase II)",National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,110.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2011-01456|09-443-A|CDR0000666432|8309|N01CM00071|N01CM62201|P30CA014599,2010-04-15,"December 31, 2017",2018-09-30,"February 26, 2010","October 16, 2019","October 16, 2019","Northwestern University, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT01076543/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01076543,3090.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
676,677,NCT00918723,"Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",,Completed,Has Results,Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage I Small Lymphocytic Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Small Lymphocytic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Small Lymphocytic Lymphoma,Drug: Fludarabine Phosphate|Drug: Cyclophosphamide|Biological: Rituximab|Drug: Vorinostat,"Maximum Tolerated Dose (MTD) of Vorinostat That Can be Combined With Fludarabine Phosphate, Cyclophosphamide and Rituximab (FCR) (Phase I)|Percentage of Patients With Progression-free Survival at 2 Years|Overall Survival|To Eliminate Residual Disease (Documented by Flow Cytometry and/or Polymerase Chain Reaction [PCR]) in Patients Who Have Achieved Complete Response (CR) After Fludarabine, Cyclophosphamide, and Rituximab (FCR) Plus Vorinostat|To Estimate the Rate of Conversion of Partial Response (PR) to Complete Response (CR) After Fludarabine, Cyclophosphamide and Rituximab (FCR) Plus Vorinostat",Fred Hutchinson Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,40.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PSOC 2401|NCI-2010-00324|P30CA015704,2009-06-01,October 2016,2016-10-01,"June 11, 2009","February 8, 2018","February 25, 2020","Swedish Cancer Institute-Breast Center at First Hill Campus, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00918723,2679.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
677,678,NCT02561273,Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma,,Completed,Has Results,"Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Hepatosplenic T-Cell Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Stage II Angioimmunoblastic T-cell Lymphoma|Stage II Enteropathy-Associated T-Cell Lymphoma|Stage III Angioimmunoblastic T-cell Lymphoma|Stage III Enteropathy-Associated T-Cell Lymphoma|Stage IV Angioimmunoblastic T-cell Lymphoma|Stage IV Enteropathy-Associated T-Cell Lymphoma",Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Prednisone|Drug: Vincristine Sulfate,Maximum Tolerated Dose (MTD) of Lenalidomide and CHOEP|Number of Participants With Adverse Events Graded According to Common Toxicity Criteria (CTC) (Phase I)|Complete Response Rate (Phase II)|Overall Response Rate|Number of Participants With Adverse Events Graded According to CTC (Phase II)|Overall Survival|Progression-free Survival,University of Nebraska|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,54.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,511-14|NCI-2015-00088|RV-CL-PTCL-PI-003858|P30CA036727,2015-10-01,November 2019,2020-11-01,"September 28, 2015","June 18, 2021","November 8, 2022","City of Hope Comprehensive Cancer Center, Duarte, California, United States|Stanford Cancer Institute, Palo Alto, California, United States|University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT02561273/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02561273,1858.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
678,679,NCT01326702,"Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors",,Completed,Has Results,Adult B Acute Lymphoblastic Leukemia|Adult Nasal Type Extranodal NK/T-Cell Lymphoma|Adult Solid Neoplasm|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Chronic Lymphocytic Leukemia|Cutaneous B-Cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Hepatosplenic T-Cell Lymphoma|Intraocular Lymphoma|Lymphomatous Involvement of Non-Cutaneous Extranodal Site|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Nodal Marginal Zone Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-Cell Leukemia/Lymphoma|Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides and Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Plasma Cell Myeloma|Small Intestinal Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenstrom Macroglobulinemia,Drug: Bendamustine Hydrochloride|Other: Pharmacological Study|Biological: Rituximab|Drug: Veliparib,Maximum Tolerated Dose of Veliparib When Combined With Bendamustine Hydrochloride|Response Rate|Number of Participants With Adverse Events|Complete Response (CR) to Study Treatment (Phase IIa)|Duration of Remission (Phase IIa)|Overall Survival (Phase IIa)|Pharmacokinetic Parameters of Veliparib (Phase Ib)|Progression-free Survival Using RECIST Version 1.1 (Phase IIa)|Participants With Dose Limiting Toxicities,National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,43.0,NIH,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2011-02583|CDR0000697580|10-174|8818|P30CA008748|U01CA069856,2011-07-01,April 2015,2015-04-01,"March 31, 2011","December 16, 2019","December 16, 2019","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01326702,1370.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
679,680,NCT01943838,A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma,,Completed,No Results Available,Neoplasm Malignant,Drug: SAR245408,Dose Limiting Toxicities|Number of patients with treatment-emergent adverse events|Maximum SAR245408 plasma concentration|Area under the SAR245408 plasma concentration versus time curve,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 1,18.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TED12863|2012-003368-39|U1111-1132-9056,2013-10-01,February 2015,2015-02-01,"September 17, 2013",,"April 22, 2016","Investigational Site Number 056001, Leuven, Belgium",,https://ClinicalTrials.gov/show/NCT01943838,488.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
680,681,NCT00586703,Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT,,Completed,Has Results,Lymphoma,Device: NK-CD56,Toxicity|Efficacy - Overall Survival,"David Rizzieri, MD|Duke University",All,"18 Years and older   (Adult, Older Adult)",Phase 1,21.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00005123,2005-04-01,April 2013,2013-11-01,"January 4, 2008","March 27, 2014","June 12, 2014","Duke University Health Systems, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00586703,3136.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
681,682,NCT00586690,Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT,,Completed,Has Results,Lymphoma,Device: NK Cell infusion using CD56 monoclonal antibody|Procedure: Donor Apheresis,Toxicity|Efficacy - Progression Free Survival|Efficacy - Overall Survival|Efficacy - Disease Progression,"David Rizzieri, MD|Duke University",All,"18 Years and older   (Adult, Older Adult)",Phase 1,47.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00005124,2005-05-01,May 2013,2013-11-01,"January 4, 2008","June 2, 2014","February 8, 2017","Duke University Health System, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00586690,3106.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
682,683,NCT02556892,A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,,Completed,No Results Available,Lymphocytic Leukemia,Drug: Ibrutinib,Intensity of Adverse Events (AEs)|Incidence of Adverse Events|Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval|Overall Response Rate (Complete Response [CR] and Partial Response [PR])|Time to Response,Janssen Pharmaceutical K.K.,All,"20 Years and older   (Adult, Older Adult)",Phase 1,8.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR107620|54179060LEU1001,2015-07-03,"August 20, 2018",2018-08-20,"September 22, 2015",,"August 14, 2019","Fukuoka-city, Japan|Hiroshima, Japan|Isehara, Japan|Kobe-city,, Japan|Koto-ku, Japan|Osaka, Japan|Sapporo, Japan|Tachikawa, Japan",,https://ClinicalTrials.gov/show/NCT02556892,1144.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
683,684,NCT01596270,A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma,,Completed,No Results Available,Neoplasm Malignant,Drug: SAR245409,Dose Limiting Toxicities|Number of patients with treatment-emergent adverse events|Maximum SAR245409 plasma concentration|Area under the SAR245409 plasma concentration versus time curve|Ratio of maximum SAR245409 plasma concentration between fed and fasted dosing|Ratio of area under the SAR245409 plasma concentration versus time curve between fed and fasted dosing,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 1,49.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,TED12471|U1111-1123-1488,2012-06-01,October 2014,2014-10-01,"May 10, 2012",,"October 28, 2020","Investigational Site Number 840001, Detroit, Michigan, United States|Investigational Site Number 840002, New Brunswick, New Jersey, United States|Investigational Site Number 840003, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01596270,852.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
684,685,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,,Completed,Has Results,AIDS-Related Plasmablastic Lymphoma|AIDS-Related Primary Effusion Lymphoma|Ann Arbor Stage I Diffuse Large B-Cell Lymphoma|Ann Arbor Stage I Grade 3 Follicular Lymphoma|Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Grade 3 Follicular Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Grade 3 Follicular Lymphoma|HIV Infection|Plasmablastic Lymphoma|Primary Effusion Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 3 Follicular Lymphoma,Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Prednisone|Biological: Rituximab|Drug: Vincristine Sulfate|Drug: Vorinostat,Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II)|Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II)|Recommended Phase II Dose of Vorinostat Determined According to Dose-limiting Toxicities Graded Using Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase I)|Change in CD8 Cell Counts (Phase I)|Changes in Absolute CD4 Cell Counts (Phase I)|Changes in Epstein-Barr Virus (EBV) Viral Load|Changes in Human Herpes Virus (HHV)-8 Viral Load|Changes in Human Immunodeficiency Virus (HIV) Viral Load|Event-free Survival (EFS) (Phase II)|Overall Survival (OS) (Phase II)|Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I)|Pharmacokinetic Clearance (Phase I)|Tumor Response (Phase I),National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,107.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2011-02508|CDR0000683379|AMC #75|AMC-075|UM1CA121947,2010-10-06,"November 12, 2016",2022-05-19,"September 2, 2010","June 12, 2018","December 20, 2022","Jackson Hospital and Clinic, Montgomery, Alabama, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States|UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|San Diego VA Medical Center, San Diego, California, United States|Zuckerberg San Francisco General Hospital, San Francisco, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|Jackson Memorial Hospital-Holtz Children's Hospital, Miami, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida, United States|Northwestern University, Chicago, Illinois, United States|John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States|Stroger Hospital of Cook County MBCCOP, Chicago, Illinois, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States|Washington University - Jewish, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|Montefiore Medical Center-Weiler Hospital, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Miriam Hospital, Providence, Rhode Island, United States|Thomas Street Clinic, Houston, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01193842,4243.0,Not Industry Lead,More than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
685,686,NCT00188461,Dose Reduction in Thoracic CT,,Completed,No Results Available,Lymphoma,Device: CT Thorax,Evaluating the diagnostic quality of thoracic CT exams performed at 50% of standard dose parameters,"University Health Network, Toronto",All,"16 Years and older   (Child, Adult, Older Adult)",Phase 1,100.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,03-0875,2004-01-01,,2005-08-01,"September 16, 2005",,"April 23, 2007","Toronto General Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00188461,578.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
686,687,NCT01732861,Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma,,Completed,No Results Available,Leukemia Lymphocytic Chronic B-Cell,Drug: CC-292|Drug: Lenalidomide,Adverse Events|Percentage of Participants Who Have Received Some Form of Response|PK-Cmax|PK-Tmax|PK-λz|PK-t1/2|PK-AUC (0-t)|PK-AUC0-∞,Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CC-292-CLL-001|2012-003766-41,2012-12-28,"January 23, 2019",2019-01-23,"November 26, 2012",,"December 20, 2019","Clearview Cancer Institute Oncology Specialties, P.C, Huntsville, Alabama, United States|Horizon Oncology Center, Lafayette, Indiana, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|The West Clinic, Memphis, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Universitatsklinik fur Innere Medizin, Innsbruck, Austria|AKh Linz, Linz, Austria|Universitatsklinik der PMU, Salzburg, Austria|Allgemeines Krankenhaus Wien, Wien, Austria|Medizinische Abteilung-Zentrum fur Onkologie und Hamatologie, Wien, Austria",,https://ClinicalTrials.gov/show/NCT01732861,2217.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
687,688,NCT00430846,Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies,,Completed,No Results Available,"Lymphoma, Non-Hodgkin|Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic",Drug: SGN-35,Incidence of adverse events and laboratory abnormalities|PK profile|Immunogenicity (anti-SGN-35 antibodies)|Anti-tumor activity,Seagen Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,45.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SG035-0001,2006-11-01,July 2009,2009-07-01,"February 2, 2007",,"December 18, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States|Washington University, St. Louis, Missouri, United States|Weill Cornell Medical College, New York, New York, United States|University of Texas/MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00430846,973.0,Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
688,689,NCT03763149,"A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas",,Completed,No Results Available,Advanced Malignancies,Biological: IBI188,Number of patients with AEs and SAEs|Pharmacokinetics: AUC|Pharmacokinetics: Cmax|Immunogenicity: Percentage of ADA positive patients|Preliminary anti-tumor activity of IBI188 (Objective Response Rate),Innovent Biologics (Suzhou) Co. Ltd.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CIBI188A102,2019-02-19,"March 29, 2021",2021-03-29,"December 4, 2018",,"December 6, 2021","START Midwest, Grand Rapids, Michigan, United States|Thomas Jefferson Univerity, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|START (South Texas Accelerated Research Therapeutics, LLC), San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT03763149,769.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
689,690,NCT00918333,"Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma",,Completed,Has Results,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|B-cell Adult Acute Lymphoblastic Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Primary Central Nervous System Non-Hodgkin Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Splenic Marginal Zone Lymphoma|T-cell Adult Acute Lymphoblastic Leukemia|Waldenström Macroglobulinemia,Drug: panobinostat|Drug: everolimus|Other: laboratory biomarker analysis|Other: pharmacological study,Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I)|Overall Response Rate (Phase II)|Overall Survival Time (Phase II)|Progression-free Survival (Phase II)|Duration of Response (Phase II),Mayo Clinic|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,124.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MC0886|NCI-2009-00934|08-004746|CLBH589BUS17T|P30CA015083,2009-06-01,"December 1, 2015",2019-07-16,"June 11, 2009","May 18, 2018","March 10, 2020","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mark O Hatfield-Warren Grant Magnuson Clinical Center, Bethesda, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00918333,3697.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
690,691,NCT01865617,"Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia",,Completed,Has Results,CD19-Positive Neoplastic Cells Present|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Small Lymphocytic Lymphoma,Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes,Death Within 8 Weeks of the Study Cell Infusion Thought to be Definitely or Probably Related to Chimeric Antigen Receptor (CAR) T Cell Therapy|Dose Limiting Toxicities|Objective Response Rate of Complete Response and Partial Response|Overall Survival|Progression Free Survival|Duration of Persistence of Adoptively Transferred CD19 Chimeric Antigen Receptor (CAR)-T Cells|Migration of Adoptively Transferred CD19 Chimeric Antigen Receptor (CAR)-T Cells,Fred Hutchinson Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,204.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2639.00|NCI-2013-00073|2639|RG9213011|P50CA107399|R01CA136551,2013-05-22,"March 26, 2021",2021-03-26,"May 31, 2013","May 25, 2022","May 25, 2022","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT01865617/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT01865617,2865.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
691,692,NCT02933320,BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia,,Completed,Has Results,B-cell Lymphoma|Chronic Lymphocytic Leukaemia|Waldenström Macroglobulinemia,Biological: BI-1206 single agent dose escalation phase|Biological: Combination of BI-1206 with rituximab escalation phase|Biological: BI-1206 single agent expansion phase|Biological: Combination of BI-1206 with rituximab expansion phase,"Documenting Adverse Events (AEs), Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs) (Graded According to NCI-CTCAE Version 4.02) and Laboratory Parameters and Determining Their Causality in Relation to BI-1206.|Documenting AEs, SAEs (Graded According to NCI-CTCAE Version 4.02) and Laboratory Parameters and Determining Their Causality in Relation to BI-1206 and, Where Appropriate, Anti-CD20 Antibody.|Measurement of PK Parameter Maximum Observed Serum Concentration (Cmax) for BI-1206|Measurement of PK Parameter Area Under the Serum Concentration-time Curve From Time 0 to the Last Time Point (AUClast) for BI-1206|Measurement of PK Parameter Half-life (T1/2) for BI-1206|Measurement of PK Parameter Total Body Clearance (CL) for BI-1206|Measurement of PK Parameter Volume of Distribution (Vss) for BI-1206|Measurement of Anti-drug Antibody (ADA) Response to BI-1206 During the BI-1206 Treatment Period Using ELISA|Measurement of Peripheral Blood B-lymphocyte Depletion During the BI-1206 Treatment Period Using Flow Cytometry.|Assessment of Best Disease Response According to Criteria for Malignant Lymphoma (Cheson, 2014) Waldenström Macroglobulinaemia Assessment Criteria (Owen 2013, Kimby 2006) or NCI Chronic Lymphocytic Leukaemia (CLL) Criteria (Hallek, 2008).|Measure Progression Free Survival at 1 Year After the First BI-1206 Administration on the Study for All Patients|Measure Overall Survival at 1 Year After the First BI-1206 Administration on the Study for All Patients",Cancer Research UK|BioInvent International AB|Bloodwise,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,14.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CRUKD16001|2015-004999-29,2016-10-27,"March 19, 2020",2020-03-19,"October 14, 2016","July 8, 2021","July 8, 2021","Leicester Royal Infirmary, Leicester, England, United Kingdom|Christie Hospital, Manchester, England, United Kingdom|Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, England, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02933320/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02933320,1239.0,Not Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
692,693,NCT01283516,A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase,,Completed,Has Results,Tumors Characterized by Genetic Abnormalities of ALK,Drug: LDK378,Number of Participants With Dose Limiting Toxicities (DLTs)|Overall Response Rate (ORR) Based on Investigator Assessment|Overall Response Rate Based on Blinded Independent Review Committee (BIRC) Assessment|Duration of Response (DOR) Based on Investigator Assessment|Duration of Response (DOR) Based on BIRC|Progression-free Survival Based on Investigator Assessment|Progression-free Survival Based on BIRC Assessment|Primary Pharmacokinetics (PK) Parameter: AUC0-last|Primary Pharmacokinetics (PK) Parameter: AUC0-24h|Primary Pharmacokinetics (PK) Parameter: Tmax|Primary Pharmacokinetics (PK) Parameter: Cmax|Secondary Pharmacokinetics (PK) Parameter: T1/2|Secondary Pharmacokinetics (PK) Parameter: CL/F|Secondary Pharmacokinetics (PK) Parameter: Vz/F|Secondary Pharmacokinetics (PK) Parameter: CLss/F|Secondary Pharmacokinetics (PK) Parameter: Racc,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,304.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLDK378X2101|2010-019827-70,2011-01-24,"May 3, 2016",2016-05-03,"January 26, 2011","August 11, 2014","March 15, 2019","University of Colorado School of Medicine Colorado Univ, Aurora, Colorado, United States|Massachusetts General Hospital Mass General, Boston, Massachusetts, United States|Memorial Sloan Kettering MSK, New York, New York, United States|Fox Chase Cancer Center Fox Chase Cancer (2), Philadelphia, Pennsylvania, United States|University of Utah / Huntsman Cancer Institute Huntsman, Salt Lake City, Utah, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Glasgow, Scotland, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom",,https://ClinicalTrials.gov/show/NCT01283516,1926.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
693,694,NCT02797964,A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer,,Completed,Has Results,Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL),Drug: SRA737,Number of Subjects With Adverse Events as Assessed by CTCAE 4.03|Maximum Tolerated Dose of SRA737|Recommended Phase 2 Dose of SRA737|Disease Control Rate (DCR) of SRA737|Time to Progression (TTP)|Progression Free Survival (PFS)|Overall Survival (OS),"Sierra Oncology, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,107.0,Industry,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SRA737-01,2016-07-01,"October 28, 2019",2019-10-28,"June 14, 2016","March 10, 2022","March 10, 2022","Royal Marsden Hospital, Sutton, London, United Kingdom|Belfast City Hospital, Belfast, Northern Ireland, United Kingdom|Oxford University Hospitals, Headington, Oxford, United Kingdom|Velindre Cancer Centre - Cardiff, Cardiff, Whitchurch, United Kingdom|The Clatterbridge Cancer Centre, Bebington, Wirral, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|The Leeds Teaching Hospitals of St James University Hospital, Leeds, United Kingdom|University Hospitals of Leicester, Leicester, United Kingdom|Guy's and St. Thomas, London, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|University College London Hospitals, London, United Kingdom|The Christie, Manchester, United Kingdom|Freeman Hospital, Newcastle upon Tyne, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02797964/Prot_000.pdf|""Statistical Analysis Plan: Revised (final) statistical analyses"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02797964/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02797964,1214.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
694,695,NCT00687622,"Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma",,Completed,No Results Available,Solid Tumours,Drug: GSK1120212,"- To determine the maximum tolerated dose of GSK1120212|- To characterize the PK of GSK1120212 after single and repeat-dose administration|- To evaluate the pharmacodynamic response in tumors after treatment with GSK1120212|- To explore relationships between GSK1120212 PK, MAPK signalling inhibition and clinical endpoints|- To explore the clinical tumor response after treatment with GSK1120212|- To determine the association of clinical and PK endpoints with genetic and protein profiles from tumor tissue",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,206.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MEK111054,2008-07-28,"June 7, 2011",2011-11-08,"June 2, 2008",,"November 13, 2017","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Aurora, Colorado, United States|GSK Investigational Site, Fort Myers, Florida, United States|GSK Investigational Site, Ocoee, Florida, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Albany, New York, United States|GSK Investigational Site, Kettering, Ohio, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00687622,1198.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
696,697,NCT00058604,Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).,EUCLID,Completed,No Results Available,Epstein-Barr Virus Infections|Lymphoproliferative Disorders,Biological: Intravenous injection of EBV specific CTLs,"Generate autologous, EBV-specific, cytotoxic T cell lines (CTLs) from individuals receiving or having received a solid organ transplant (SOT).|Administer autologous, EBV-specific CTLs to patients, to determine the safety of intravenous injections in these individuals|Evaluate the antiviral and immunological efficacy of the infused CTLs","Baylor College of Medicine|The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",All,"up to 70 Years   (Child, Adult, Older Adult)",Phase 1,12.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H9454|Euclid,2001-01-01,December 2008,2008-12-01,"April 9, 2003",,"January 18, 2020","Texas Children's Hospital, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00058604,2891.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
697,698,NCT00256191,Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies,,Completed,No Results Available,Neoplasms|Hodgkin's Disease|Non-Hodgkin's Lymphoma,Drug: TPI 287 Injection,To determine the maximum tolerated dose of TPI 287 administered every 21 days|To determine the safety of TPI 287|To determine the antitumor activity of TPI 287|To determine the pharmacokinetic profile of TPI 287,"Cortice Biosciences, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,45.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TPI 287-02,2005-11-01,,2007-02-01,"November 21, 2005",,"October 15, 2007","Rocky Mountain Cancer Center, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT00256191,457.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
698,699,NCT01567709,"Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma",,Completed,No Results Available,Adult B Acute Lymphoblastic Leukemia|Adult T Acute Lymphoblastic Leukemia|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Chronic Lymphocytic Leukemia|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Hepatosplenic T-Cell Lymphoma|Intraocular Lymphoma|Lymphomatous Involvement of Non-Cutaneous Extranodal Site|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Nodal Marginal Zone Lymphoma|Primary Cutaneous B-Cell Non-Hodgkin Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-Cell Leukemia/Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides and Sezary Syndrome|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Small Intestinal Lymphoma|Splenic Marginal Zone Lymphoma|T-Cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenstrom Macroglobulinemia,Drug: Alisertib|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Vorinostat,MTD of alisertib defined as the highest dose tested in which less than 33% of patients experienced dose-limiting toxicity (DLT) graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v.)4.0|Incidence of toxicities produced by alisertib in combination with vorinostat assessed by the NCI CTCAE version 4.0|Clinical response rate,National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,34.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2012-00715|NCI#9091|PHI-67|CDR0000729769|CHNMC-PHI-67|9091|P30CA033572|U01CA062505|UM1CA186717,2012-04-16,"March 29, 2018",2018-03-29,"March 30, 2012",,"April 11, 2018","City of Hope Comprehensive Cancer Center, Duarte, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01567709,2173.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
699,700,NCT01324323,Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer,,Completed,Has Results,Hematologic Malignancy|Malignant Lymphoma,Drug: Romidepsin|Drug: Rifampin,Area Under the Plasma Concentration Time-curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t)of Romidepsin|Area Under the Plasma Concentration Time-curve From Time 0 to 24-hour (AUC0-24) for Romidepsin|Area Under the Plasma Concentration Time-curve From Time Zero Extrapolated to Infinity (AUC0-∞).|Maximum Observed Plasma Concentration (Cmax)of Romidepsin|Time to Maximum Observed Plasma Concentration (Tmax)|Estimate of the Terminal Elimination Half-life in Plasma (t1/2)|Clearance (CL): Apparent Total Plasma Clearance.|Apparent Total Volume of Distribution (Vz).|Summary of Participants With Treatment Emergent Adverse Events (TEAEs),Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 1,14.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,ROMI-ADVM-002|2010-022149-75,2011-04-01,"February 1, 2012",2012-03-01,"March 29, 2011","May 13, 2013","November 25, 2019","Florida Cancer Specialists, Sarasota, Florida, United States|Sarah Canon Research Institute, Nashville, Tennessee, United States|Sarah Cannon Research UK, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01324323,335.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
700,701,NCT01324310,Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer,,Completed,Has Results,Hematologic Malignancy|Malignant Lymphoma,Drug: Romidepsin|Drug: Ketoconazole,Area Under the Plasma Concentration Time-curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t)of Romidepsin|Area Under the Plasma Concentration Time-curve From Time 0 to 24-hour (AUC 0-24)|Area Under the Plasma Concentration Time-curve From Time 0 Extrapolated to Infinity (AUC0-∞)|Maximum Observed Plasma Concentration (Cmax)|Time to Maximum Observed Plasma Concentration (Tmax)|Estimate of the Terminal Elimination Half-life in Plasma (t1/2)|Apparent Total Plasma Clearance (CL)|Apparent Total Volume of Distribution (Vz)|Summary of Participants With Treatment Emergent Adverse Events (TEAEs),Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 1,15.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,ROMI-ADVM-001|2010-022144-20,2011-04-01,"January 1, 2012",2012-01-01,"March 29, 2011","May 15, 2013","November 25, 2019","Florida Cancer Specialists, Sarasota, Florida, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Sarah Cannon Research UK, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01324310,275.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
702,703,NCT00005803,Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma,,Completed,Has Results,Prolymphocytic Leukemia|Recurrent Adult Hodgkin Lymphoma|Recurrent Childhood Hodgkin Lymphoma|Recurrent Childhood Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Small Lymphocytic Lymphoma|T-Cell Chronic Lymphocytic Leukemia|T-Cell Prolymphocytic Leukemia,Procedure: Autologous Hematopoietic Stem Cell Transplantation|Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Drug: Cyclophosphamide|Drug: Cyclosporine|Drug: Cytarabine|Drug: Etoposide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Melphalan|Drug: Mycophenolate Mofetil|Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Procedure: Peripheral Blood Stem Cell Transplantation|Biological: Therapeutic Autologous Lymphocytes|Radiation: Total-Body Irradiation,Engraftment of HLA Identical PBSC Allografts|Non-Relapse Mortality|Overall Survival (OS)|Progression Free-survival (PFS),Fred Hutchinson Cancer Center|National Cancer Institute (NCI),All,"up to 75 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,76.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1409.00|NCI-2010-00130|P30CA015704,1999-09-01,January 2016,2018-10-01,"January 27, 2003","December 7, 2017","January 29, 2020","Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|VA Puget Sound Health Care System, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States|Universitaet Leipzig, Leipzig, Germany",,https://ClinicalTrials.gov/show/NCT00005803,6970.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
705,706,NCT00005639,Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment,,Completed,No Results Available,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: Azacitidine Injection|Drug: sodium phenylbutyrate,Minimal Effective Dose (MED) of Azacitidine with Phenylbutyrate|Toxicity as assessed by number of participants experiencing adverse events Grade 3 or higher as defined by CTCAE v2.0|Pharmacokinetics of Azacitidine combined with Phenylbutyrate as measured by maximal plasma concentration (Cmax)|Gene-re-expression of epigenetic modulation in Peripheral Blood Mononuclear Cells (PBMC) as measured by change in Epstein-Barr Virus (EBV) viral load (number of copies per 1 million cells) after treatment with Azacitidine,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1,34.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,J9982|U01CA070095|R01CA075525|P50CA058236|P30CA006973|CDR0000067799|NCI-270|99-12-03-02,2000-03-01,July 2005,2005-07-01,"January 27, 2003",,"January 11, 2019","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00005639,1948.0,Not Industry Lead,Three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
706,707,NCT00031941,CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy,,Completed,No Results Available,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: lenalidomide,,National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,,NIH,Interventional,Primary Purpose: Treatment,020083|02-C-0083|CDR0000069241,2002-04-01,September 2007,2009-04-01,"January 27, 2003",,"March 15, 2012","Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States|NCI - Center for Cancer Research, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00031941,2557.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
708,709,NCT00387608,ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer,,Completed,No Results Available,"Leukemia|Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",Drug: veliparib|Other: pharmacological study|Procedure: biopsy,Change in tumor poly (ADP-ribose) (PAR) levels from baseline to 3-6 hours after ABT-888 administration|Pharmacokinetics|Safety of administering 1 dose of ABT-888|Changes in PAR levels in peripheral blood mononuclear cells from baseline to after ABT-888 administration,National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,23.0,NIH,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,060172|06-C-0172|NCI-P6890|CDR0000487701,2006-06-01,February 2008,2009-04-01,"October 13, 2006",,"March 15, 2012","Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00387608,1035.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
709,710,NCT00003294,Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer,,Completed,No Results Available,"Leukemia|Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",Biological: filgrastim|Drug: amifostine trihydrate|Drug: carboplatin|Drug: paclitaxel,,Roswell Park Cancer Institute|National Cancer Institute (NCI),All,"Child, Adult, Older Adult",Phase 1,24.0,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000066227|P30CA016056|RPCI-DS-97-14|NCI-G98-1410,1997-05-01,April 1999,2004-05-01,"August 13, 2004",,"March 7, 2011","Roswell Park Cancer Institute, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT00003294,2557.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
710,711,NCT00531284,"Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma",,Completed,Has Results,Ovarian Cancer|Renal Cancer|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Solid Tumors|Multiple Myeloma|Lymphoma,Drug: Carfilzomib|Drug: Dexamethasone,Phase 1b: Number of Participants With Dose-limiting Toxicities (DLT)|Phase 2: Percentage of Participants With an Overall Response After 4 Treatment Cycles|Percentage of Participants With an Overall Response Throughout the Study|Duration of Response|Progression-Free Survival|Time to Progression|Maximum Observed Plasma Concentration of Carfilzomib|Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Concentration Measured (AUC0-last) for Carfilzomib|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) for Carfilzomib|Elimination Half-life (t½) of Carfilzomib|Clearance (CL) of Carfilzomib|Volume of Distribution at Steady State (Vss) of Carfilzomib|Mean Residence Time (MRT) Extrapolated to Infinity for Carfilzomib,Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,184.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PX-171-007,2007-09-01,October 2014,2017-05-22,"September 18, 2007","December 9, 2015","August 15, 2017","Pinnacle Oncology, Scottsdale, Arizona, United States|Tower Cancer Research Foundation, Beverly Hills, California, United States|Northwestern University, Chicago, Illinois, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|The Sarah Cannon Research Institute, Nashville, Tennessee, United States|South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00531284,3551.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
712,713,NCT02745769,A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents,,Completed,No Results Available,Advanced Cancer|Colorectal Cancer|Mantle Cell Lymphoma,Drug: Ramucirumab|Drug: Merestinib|Drug: Abemaciclib,"Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)|Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab, Merestinib and Abemaciclib|Proportion of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]|Progression Free Survival (PFS)",Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 1,23.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16165|I4T-MC-JVDK|2015-004381-28,2016-10-21,"November 5, 2018",2019-01-22,"April 20, 2016",,"March 5, 2019","UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02745769,823.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
713,714,NCT01805375,A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies,,Completed,No Results Available,Indolent B-cell Lymphoma|Chronic Lymphocytic Leukaemia|Waldenström Macroglobulinaemia,Drug: DI-B4,"To recommend a dose for future trials with a new drug called DI-B4 by finding the highest safe dose which can be given to patients|Measuring of PK parameter values for DI-B4 including AUC, Cmax, Tmax, and half life T1/2.|To evaluate the effect of DI-B4 on the depletion of peripheral blood and bone marrow B-cells.|To look for signs of anti-tumour activity of DI-B4 in patients with relapsed or refractory indolent B-cell malignancies.|To assess immunogenicity of DI-B4 in patients with relapsed or refractory indolent B-cell malignancies|To measure the time to disease progression and eighteen month survival",Cancer Research UK,All,"18 Years and older   (Adult, Older Adult)",Phase 1,28.0,Other,Interventional,Primary Purpose: Treatment,CRUKD/12/003,2013-04-01,"December 14, 2017",2017-12-14,"March 6, 2013",,"February 5, 2018","Royal Liverpool and Broadgreen University Hospital NHS Trust, Liverpool, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|The Churchill Hospital, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT01805375,1718.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
714,715,NCT00002543,"Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors",,Completed,No Results Available,"Brain and Central Nervous System Tumors|Lymphoma|Neuroblastoma|Sarcoma|Unspecified Childhood Solid Tumor, Protocol Specific",Drug: gallium nitrate,,Medical College of Wisconsin|National Cancer Institute (NCI),All,"up to 21 Years   (Child, Adult)",Phase 1,3.0,Other|NIH,Interventional,Primary Purpose: Treatment,MCW-ARRC-22393|CDR0000063244|CHW-93/59|NCI-T93-0097D,1995-02-01,,2004-10-01,"October 5, 2004",,"July 18, 2013","Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States|Boston Floating Hospital Infants and Children, Boston, Massachusetts, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00002543,3530.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
715,716,NCT00659568,Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma,,Completed,No Results Available,"Breast Cancer|Endometrial Cancer|Kidney Cancer|Lung Cancer|Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",Drug: metformin hydrochloride|Drug: temsirolimus,"Maximum tolerated dose and recommended phase II dose of metformin hydrochloride when administered with temsirolimus|Toxicity and safety, with particular reference to glucose and lipid deregulation|Antitumor activity, including tumor response rate and time to progression|Objective response|Survival|Frequency and severity of adverse events",London Health Sciences Centre|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,28.0,Other,Interventional,Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,CAN-LRCC-UWOREB13877|CDR0000593360|WYETH-CAN-LRCC-UWOREB13877,2008-03-01,February 2010,2010-08-01,"April 16, 2008",,"May 30, 2013","London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00659568,883.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
716,717,NCT01748721,MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma,,Completed,No Results Available,"Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",Biological: anti-endosialin/TEM1 monoclonal antibody MORAb-004|Other: pharmacological study|Other: laboratory biomarker analysis,"MTD, defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicities (DLT) graded according to the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Incidence of toxicities, graded according to NCI CTCAE version 4.0",Morphotek|National Cancer Institute (NCI)|Children's Oncology Group,All,"13 Months to 21 Years   (Child, Adult)",Phase 1,27.0,Industry|NIH|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ADVL1213|NCI-2012-01702|U01CA097452,2013-11-01,May 2015,2015-05-01,"December 12, 2012",,"January 8, 2016","Children's Hospital of Alabama, Birmingham, Alabama, United States|Children's Hospital of Orange County, Orange, California, United States|University of California San Francisco Medical Center - Parnassus, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia, United States|Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota Cancer Center-Fairview, Minneapolis, Minnesota, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies & Children's Hospital, Cleveland, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01748721,546.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
717,718,NCT02406742,"A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",ENHANCE,Completed,Has Results,"Leukemia, Lymphocytic, Chronic, B-Cell",Drug: CC-122|Drug: Ibrutinib|Drug: Obinutuzumab,Number of Participants and Severity of AEs|Determination of Non Tolerated Dose (NTD) and Maximum Tolerated Dose (MTD)|CC-122 Plasma Concentrations When Administered Alone or in Combination With Ibrutinib or Obinutuzumab|Ibrutinib Plasma Concentrations When Administered in Combination With CC-122|Best Overall Response (BOR)|Minimal Residual Disease Response Rate|Duration of Response|Progression Free Survival (PFS)|Cmax When Administered Alone or in Combination With Ibrutinib|Tmax of CC-122 When Administered Alone or in Combination With Ibrutinib|AUC of CC-122 When Administered Alone or in Combination With Ibrutinib,Celgene,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 1|Phase 2,47.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CC-122-CLL-001,2015-07-27,"July 7, 2020",2020-07-07,"April 2, 2015","September 20, 2021","September 20, 2021","University of California San Diego, La Jolla, California, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Medical College Dr. Feldman's Office, New York, New York, United States|Ohio State University Medical CenterJames Cancer Hospital, Columbus, Ohio, United States|The West Clinic, Memphis, Tennessee, United States|MD Anderson Cancer Center The University of Texas, Houston, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|University Hospital Innsbruck, Innsbruck, Austria|University Hospital of Salzburg St Johanns Spital, Salzburg, Austria|Allgemeines Krankenhaus Wien, Wien, Austria|Universitaetsklinikum EssenInnere Klinik und Poliklinik, Essen, Germany|University of Schleswig-Holstein, Kiel, Germany|Universitat zu Koln, Köln, Germany|Universitatsklinikum Würzburg, Würzburg, Germany|Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy|Ospedale Niguarda Milano, Milano, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Hospital Universitario Vall D hebron, Barcelona, Spain|Fundacion Jimenez Daaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02406742/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02406742/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02406742,1807.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
719,720,NCT02216890,Safety Study of SGN-CD70A in Cancer Patients,,Completed,No Results Available,"Renal Cell Carcinoma|Mantle-Cell Lymphoma|Diffuse, Large B-Cell, Lymphoma|Follicular Lymphoma, Grade 3",Drug: SGN-CD70A,Incidence of adverse events|Incidence of laboratory abnormalities|Blood concentrations of SGN-CD70A and metabolites|Incidence of antitherapeutic antibodies|Objective response rate|Progression-free survival|Duration of response,Seagen Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,38.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SGN70A-001,2014-08-01,"February 15, 2017",2017-02-15,"August 15, 2014",,"April 19, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|City of Hope National Medical Center, Duarte, California, United States|Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|James P. Wilmot Cancer Center / University of Rochester Medical Center, Rochester, New York, United States|UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill, North Carolina, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States|Case Western Reserve University / University Hospitals Case Medical Center, Cleveland, Ohio, United States|University of Pennsylvania / Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Medical University of South Carolina/Hollings Cancer Center, Charleston, South Carolina, United States|Texas Oncology - Austin Midtown, Austin, Texas, United States|Methodist Cancer Center, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Seattle Cancer Care Alliance / University of Washington, Seattle, Washington, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States",,https://ClinicalTrials.gov/show/NCT02216890,929.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
721,722,NCT02091063,ACY-1215 for Relapsed/Refractory Lymphoid Malignancies,,Completed,No Results Available,Lymphoma|Lymphoid Malignancies,Drug: ACY-1215,Phase I: Number of patients who experience a dose-limiting toxicity (DLT)|Phase II: Objective response rate|Number of Adverse Events (AEs)|Progression free survival (PFS)|Duration of response (DoR),Jennifer Amengual|Acetylon Pharmaceuticals Incorporated|Columbia University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,24.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AAAM4054,2014-04-02,"February 25, 2019",2019-05-05,"March 19, 2014",,"February 10, 2020","Moffit Cancer Center, Tampa, Florida, United States|Columbia University Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02091063,1859.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
722,723,NCT05720767,HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study,,Completed,No Results Available,Relapsed or Refractory Lymphoma,Drug: HMPL-523|Drug: Itraconazole|Drug: Rifampin,PK parameter for HMPL-523: AUC0-t|PK parameter for HMPL-523: AUC0-inf|PK parameter for HMPL-523: Cmax|Incidence of Adverse Events/ Serious Adverse Events,Hutchmed,All,18 Years to 55 Years   (Adult),Phase 1,28.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,2022-523-00US2,2022-11-04,"February 5, 2023",2023-02-05,"February 9, 2023",,"March 1, 2023","PPD Austin, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT05720767,93.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
723,724,NCT05602597,HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI,,Completed,No Results Available,Relapsed or Refractory Lymphoma,Drug: Itraconazole 200 mg|Drug: Fluconazole 400 mg|Drug: Rifampin 600 mg|Drug: Rabeprazole 40 mg,AUC0-t|AUC0-inf|Cmax|Incidence of AEs/SAEs,Hutchmed,All,18 Years to 55 Years   (Adult),Phase 1,59.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,2021-689-00US1,2022-06-01,"August 6, 2022",2022-08-06,"November 2, 2022",,"January 17, 2023","QPS- Miami, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT05602597,66.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
724,725,NCT05571787,HMPL-523 Food Effect and Proton Pump Inhibitor Study,,Completed,No Results Available,Relapsed or Refractory Lymphoma,Drug: HMPL-523|Drug: Rabeprazole,PK parameter for HMPL-523: AUC0-t|PK parameter for HMPL-523: AUC0-inf|PK parameter for HMPL-523: Cmax|PK parameter for HMPL-523: tmax|Assessment of safety procedures findings|PK parameter for metabolite M1: AUC0-t|PK parameter for metabolite M1: AUC0-inf|PK parameter for metabolite M1: Cmax,Hutchmed,All,18 Years to 55 Years   (Adult),Phase 1,26.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,2022-523-00US1,2022-07-13,"September 22, 2022",2022-09-22,"October 7, 2022",,"February 23, 2023","PPD Austin, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT05571787,71.0,Industry Lead,Less than three Conditions,Randomized,Crossover Assignment,None (Open Label),Other/Basic/Prevention
725,726,NCT00871910,Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630),,Completed,No Results Available,"Solid Tumors|Lymphoma, Non-Hodgkin|Multiple Myeloma",Drug: SCH 727965|Drug: Aprepitant|Drug: Ondansetron|Drug: Dexamethasone,"Safety and tolerability of SCH 727965, including maximum administered dose and dose-limiting toxicity|In Part 1 and Part 2, pharmacodynamic effects of SCH 727965 with an ex vivo lymphocyte stimulation assay of participant's peripheral blood lymphocytes.|In Part 3, area under the plasma concentration versus time curve and maximum concentration of SCH 727965 administered as a 2 hour intravenous infusion with or without aprepitant in participants with advanced malignancies.",Merck Sharp & Dohme LLC,All,"18 Years and older   (Adult, Older Adult)",Phase 1,81.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P04630,2006-10-11,"February 22, 2010",2010-02-22,"March 30, 2009",,"October 23, 2017",,,https://ClinicalTrials.gov/show/NCT00871910,1230.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
726,727,NCT00608361,Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery,,Completed,No Results Available,Adult Acute Lymphoblastic Leukemia in Remission|Adult B Acute Lymphoblastic Leukemia|Adult Hepatocellular Carcinoma|Adult Nasal Type Extranodal NK/T-Cell Lymphoma|Adult Solid Neoplasm|Adult T Acute Lymphoblastic Leukemia|Advanced Adult Hepatocellular Carcinoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Chronic Lymphocytic Leukemia|Cutaneous B-Cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Hepatosplenic T-Cell Lymphoma|Intraocular Lymphoma|Localized Non-Resectable Adult Liver Carcinoma|Localized Resectable Adult Liver Carcinoma|Lymphomatous Involvement of Non-Cutaneous Extranodal Site|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Nodal Marginal Zone Lymphoma|Progressive Hairy Cell Leukemia Initial Treatment|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Lymphoma|Recurrent Adult Liver Carcinoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-Cell Leukemia/Lymphoma|Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides and Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Small Intestinal Lymphoma|Splenic Marginal Zone Lymphoma|Stage II Small Lymphocytic Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-Cell Leukemia/Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IIIA Mycosis Fungoides and Sezary Syndrome|Stage IIIB Mycosis Fungoides and Sezary Syndrome|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-Cell Leukemia/Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Stage IVA Mycosis Fungoides and Sezary Syndrome|Stage IVB Mycosis Fungoides and Sezary Syndrome|T-Cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Hairy Cell Leukemia|Waldenstrom Macroglobulinemia,Drug: Dasatinib|Other: Pharmacological Study,"Maximum tolerated dose of dasatinib, defined as the highest dose level at which less than 33% of 6-9 evaluable patients experience dose-limiting toxicity|Pharmacokinetic parameters of dasatinib",National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,80.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2009-00792|CDR0000583976|SWOG-S0711|S0711|U10CA180888|U10CA032102,2008-10-01,August 2014,2014-08-01,"February 6, 2008",,"July 2, 2015","City of Hope Comprehensive Cancer Center, Duarte, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Hays Medical Center, Hays, Kansas, United States|Hutchinson Regional Medical Center, Hutchinson, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Olathe Cancer Center, Olathe, Kansas, United States|Via Christi Hospital-Pittsburg, Pittsburg, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|Saint Francis Hospital and Medical Center - Topeka, Topeka, Kansas, United States|Henry Ford Hospital, Detroit, Michigan, United States|Truman Medical Center, Kansas City, Missouri, United States|Audie L Murphy Veterans Affairs Hospital, San Antonio, Texas, United States|Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas, United States|University Hospital, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Swedish Medical Center-Edmonds, Edmonds, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00608361,2130.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
729,730,NCT00968656,Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1,FISO PET/CT,Completed,No Results Available,Breast Cancer|Head and Neck Cancer|Diffuse Large B-cell Lymphoma,Radiation: PET/CT|Other: Laboratory Testing|Other: Safety Testing|Other: Immunohistochemistry staining|Drug: F-18-ISO,"The primary out come is to assess the diagnostic quality of [18F]ISO-1-PET/CT images at the proposed 8 mCi dose.|Secondary outcome is to quantitatively determine the relationship between tumor [18F]ISO-1 uptake and Ki-67, S-phase, mitotic index and sigma-2 receptors content of the tumor.",Washington University School of Medicine|Isotrace Technologies,All,"18 Years and older   (Adult, Older Adult)",Phase 1,31.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,FISO 08-1010,2009-01-01,November 2011,2011-11-01,"August 31, 2009",,"December 9, 2014","Washington University / Barnes Jewish Hospital, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00968656,1034.0,Not Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
731,732,NCT01767766,Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies,,Completed,No Results Available,Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia|Peripheral T-Cell Lymphoma|Hodgkin's Lymphoma,Drug: TGR-1202,Maximum Tolerated Dose acceptable for participants|Overall Response Rate,"TG Therapeutics, Inc.|SCRI Development Innovations, LLC",All,"18 Years and older   (Adult, Older Adult)",Phase 1,90.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TGR-1202-101 (HEMREF 31),2013-01-07,February 2018,2018-02-01,"January 14, 2013",,"August 23, 2021","TG Therapeutics Trial Site, Sarasota, Florida, United States|TG Therapeutics Trial Site, Hackensack, New Jersey, United States|TG Therapeutics Trial Site, New York, New York, United States|TG Therapeutics Trial Site, Durham, North Carolina, United States|TG Therapeutics Trial Site, Cincinnati, Ohio, United States|TG Therapeutics Trial Site, Nashville, Tennessee, United States|TG Therapeutics Investigational Trial Site, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01767766,1851.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
732,733,NCT03291938,IACS-010759 in Advanced Cancers,,Completed,No Results Available,Advanced Malignant Solid Neoplasm|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Negative|HER2/Neu Negative|Metastatic Malignant Solid Neoplasm|Pancreatic Ductal Adenocarcinoma|Progesterone Receptor Negative|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Lymphoma|Refractory Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage IIA Pancreatic Cancer AJCC v8|Stage IIB Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Triple-Negative Breast Carcinoma|Unresectable Solid Neoplasm,Drug: Oxidative Phosphorylation Inhibitor IACS-010759|Other: Pharmacodynamic Study|Other: Pharmacokinetic Study,Incidence of adverse events|Maximum tolerated dose|Maximum Plasma concentration of IACS-010759 [Cmax]|Overall response rate|Duration of response,M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,29.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2017-0023|NCI-2018-01042|P30CA016672,2017-11-13,"November 23, 2020",2020-11-23,"September 25, 2017",,"November 24, 2020","M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03291938,1106.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
733,734,NCT03229278,Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma,,Completed,No Results Available,Lymphoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Renal Cell Cancer|Recurrent Bladder Carcinoma|Recurrent Classical Hodgkin Lymphoma|Recurrent Head and Neck Squamous Cell Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Renal Cell Carcinoma|Stage III Bladder Cancer|Stage III Lymphoma|Stage III Non-Small Cell Lung Cancer AJCC v7|Stage III Renal Cell Cancer|Stage III Skin Melanoma|Stage IIIA Non-Small Cell Lung Cancer AJCC v7|Stage IIIA Skin Melanoma|Stage IIIB Non-Small Cell Lung Cancer AJCC v7|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Bladder Cancer|Stage IV Lymphoma|Stage IV Non-Small Cell Lung Cancer AJCC v7|Stage IV Renal Cell Cancer|Stage IV Skin Melanoma|Stage IVA Bladder Cancer|Stage IVB Bladder Cancer|Unresectable Head and Neck Squamous Cell Carcinoma|Unresectable Solid Neoplasm,Drug: Enzyme Inhibitor Therapy|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Biological: Pembrolizumab,"Maximum tolerated dose (MTD))/recommended phase 2 dose of trigriluzole|Adverse event (AE) type, severity and frequency|Objective response rate assessed according to Response Evaluation Criteria in Solid Tumors version 1.1|Overall survival|Landmark survival rates|Duration of response for responding patients|Progression-free survival|Time to treatment failure|Time to next therapy or death|Freedom from new metastases","Rutgers, The State University of New Jersey|National Cancer Institute (NCI)",All,"18 Years and older   (Adult, Older Adult)",Phase 1,14.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro20170000453|NCI-2017-01155|051707|P30CA072720,2017-08-17,"January 8, 2020",2020-01-30,"July 25, 2017",,"November 21, 2022","Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03229278/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT03229278,896.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
734,735,NCT00113724,Study of TPI 287 in Patients With Advanced Malignancies,,Completed,No Results Available,Neoplasms|Non-Hodgkin Lymphoma|Hodgkin Disease,Drug: TPI 287 Injection,To determine the maximum tolerated dose of TPI 287|To determine the safety of TPI 287|To determine the antitumor activity of TPI 287|To determine the pharmacokinetic profile of TPI 287|To determine the pharmacodynamic profile of TPI 287,"Cortice Biosciences, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TPI 287-01,2005-05-01,January 2008,2008-01-01,"June 10, 2005",,"June 4, 2009","Arizona Clinical Research Center, Tucson, Arizona, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Georgetown University Medical Center/Lombardi Cancer Center, Washington, DC, District of Columbia, United States|New York Medical College, Valhalla, New York, United States",,https://ClinicalTrials.gov/show/NCT00113724,975.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
735,736,NCT00432562,A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.,,Completed,Has Results,Breast Cancer|Non-small Cell Lung Cancer|Non-Hodgkins Lymphoma,Drug: Vinorelbine Tartrate,Time to Reach Maximum Observed Plasma Concentration (Tmax)|Maximum Observed Plasma Concentration (Cmax)|Area Under the Plasma Concentratio-Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUClast)|Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf)|Percentage of AUCinf Based on Extrapolation (AUCextrap)|Observed Elimination Rate Constant Associated With the Terminal Portion of the Curve (λ z)|Observed Terminal Elimination Half-Life (t1/2)|Time of Last Measurable Concentration (Tlast)|Last Quantifiable Drug Concentration (Clast)|Mean Residence Time (MRTinf),"Mast Therapeutics, Inc.|Synteract, Inc.|Thywill Latam Solutions SRL|OCASA Soluciones Logísticas S.A.|Worldwide Clinical Trials",All,"18 Years and older   (Adult, Older Adult)",Phase 1,31.0,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,530-01,2007-02-01,November 2007,2007-12-01,"February 8, 2007","February 23, 2012","February 23, 2012","Clinical Investigative Site, Buenos Aires, Argentina|Clinical Investigative Site, Mendoza, Argentina|Clinical Investigative Site, Rosario, Argentina|Clinical Investigative Site, Santa Fe, Argentina|Clinical Investigative Site, Tucuman, Argentina",,https://ClinicalTrials.gov/show/NCT00432562,303.0,Industry Lead,Three Conditions,Randomized,Crossover Assignment,None (Open Label),Treatment/Diagnostic
738,739,NCT01772797,Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer,,Completed,No Results Available,Anaplastic Lymphoma Kinase (ALK)|Non-small Cell Lung Cancer,Drug: LDK378|Drug: AUY922,"Incidence rate of Dose Limiting Toxicities (DLT)|Number of patients with adverse events|Changes in laboratory values|Assessments of electrocardiograms|Assessments of dose interruptions, reductions, and dose intensity|Plasma PK parameter of LDK378 and AUY922: Tmax|Overall response rate (ORR)|Duration of Response (DoR)|Time to Response (TTR)|Progression free survival (PFS)|Number of patients with serious adverse events|Plasma PK parameter of LDK378 and AUY922: Cmax|Plasma PK parameter of LDK378 and AUY922: AUClast|Plasma PK parameter of LDK378 and AUY922: AUCtau|Plasma PK parameter of LDK378 and AUY922: Cmin|Plasma PK parameter of LDK378 and AUY922: Racc",Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,22.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLDK378X2102|2012-004632-29,2013-06-01,January 2016,2016-01-01,"January 21, 2013",,"December 19, 2020","University of Colorado Dept. of Anschutz Cancer (3), Aurora, Colorado, United States|Massachusetts General Hospital Mass General, Boston, Massachusetts, United States|Fox Chase Cancer Center Fox Chase Cancer (2), Philadelphia, Pennsylvania, United States|University of Utah / Huntsman Cancer Institute Huntsman, Salt Lake City, Utah, United States|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Barcelona, Catalunya, Spain",,https://ClinicalTrials.gov/show/NCT01772797,944.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
739,740,NCT01842672,Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia,MITCL,Completed,No Results Available,Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Lymphoblastic Lymphoma|Diffuse Large B-cell Lymphoma|Burkitt Lymphoma/Leukemia,Drug: Clofarabine|Drug: Mitoxantrone,Determine MTD|Response Rate|Monitor for Minimal Residual Disease,New York Medical College,All,"up to 30 Years   (Child, Adult)",Phase 1|Phase 2,41.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"NYMC 542|L 10, 819",2013-03-01,August 2021,2022-09-01,"April 30, 2013",,"October 25, 2022","New York Medical College, Valhalla, New York, United States|Levine Children's Hospital, Charlotte, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01842672,3471.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
742,743,NCT01955668,AZD6738 First Time in Patient Multiple Ascending Dose Study,,Completed,No Results Available,"11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),|Prolymphocytic Leukaemia (PLL)|B Cell Lymphomas",Drug: Administration of AZD6738,"Parts A and B: Safety and tolerability in terms of AE and SAE (including death), as recorded in safety measures.|Part A only: Define either the Maximum tolerated dose (MTD), if possible, or maximum feasible dose (MFD)|Part B only: Preliminary assessment of the effect of food on the Pharmacokinetic (PK) parameters of AZD6738 via plasma analysis|Parts A&B: Establish pharmacokinetics characteristics of AZD6738 and its active metabolite from plasma analysis|Part A and B: Anti tumour activity by assessing tumour response via CT or MRI scans|Part A and B: Measuring 4 beta-hydroxy cholesterol concentration for assessment of CYP3A4 induction potential|Part B: Pharmacokinetic profile of AZD6738 and its active metabolite from urinalysis|Part B only: Preliminary assessment of the effect of food on the PK parameters of AZD6738 via urinalysis|Part A: Determine the extent of ATR target inhibition using pharmacodynamic biomarkers|Part A and B: Biomarker analysis using lymph node biopsies|Part A and B: Confirmation of tumour response assessment by analysing bone marrow / aspirate|Part A and B: Bone marrow biopsy or aspirate will be analysed for biomarkers|Part A and B: Determination of 11q del status to investigate any potential changes in FISH cytogenetic's post treatment|Parts A and B: Identify patients with ATM deficient status, determine ATM mutation load and correlate this with clinical efficacy in order to better understand patient population which will most likely benefit from AZD6738 treatment|Part B: The extent of ATR target inhibition identified using pharmacodynamic biomarkers",AstraZeneca|CLL Consortium,All,"18 Years and older   (Adult, Older Adult)",Phase 1,2.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D5330C00001,2013-11-01,December 2013,2013-12-01,"October 7, 2013",,"June 19, 2014","Research Site, La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT01955668,30.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
743,744,NCT03052933,Copanlisib and Gemcitabine in Relapsed/Refractory PTCL,,Completed,No Results Available,Mature T-Cell and NK-Cell Neoplasm,Drug: Copanlisib|Drug: Gemcitabine,"Dose limiting toxicity (DLT), Maximum tolerated dose (MTD) for phase I|Objective response rate for phase II|adverse events|Progression-free survival (PFS)|Overall survival (OS)",Chonnam National University Hospital|Bayer|Consortium for Improving Survival of Lymphoma,All,"19 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,28.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COPGEM,2018-02-01,"July 1, 2021",2021-07-01,"February 14, 2017",,"June 10, 2022","Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03052933,1246.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
744,745,NCT01155817,Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease,,Completed,No Results Available,"Bone Marrow Transplant Failure|Lymphoma, Non-Hodgkin|Lymphoma, T-Cell, Peripheral",Drug: Nilotinib,Frequency and severity of adverse events graded according to CTCAE v4.0|Chronic GVHD response measured as change in physical exam and laboratory testing|Chronic GVHD response measured as change in daily corticosteroid requirement|Chronic GVHD response measured as frequency of treatment failure defined as discontinuation of study drug due to severe adverse effects or initiation of a new treatment for cGVHD|Chronic GVHD response measured as change in cGVHD symptom burden,Stanford University|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,33.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB-18743|SU-06112010-6317|BMT222,2010-08-01,December 2013,2013-12-01,"July 2, 2010",,"April 15, 2020","Stanford University School of Medicine, Stanford, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Gordon and Leslie Diamond Health Care Centre Hematology Administration, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT01155817,1218.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
745,746,NCT00019227,Monoclonal Antibody Therapy in Treating Patients With Leukemia,,Completed,No Results Available,Lymphoma|Radiation Toxicity,Drug: pentetic acid calcium|Radiation: yttrium Y 90 daclizumab,,National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,,NIH,Interventional,Primary Purpose: Treatment,CDR0000065240|NCI-96-C-0147K,1996-10-01,,2006-07-01,"January 27, 2003",,"June 20, 2013","Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00019227,3560.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
746,747,NCT00049699,VNP40101M in Treating Patients With Advanced or Metastatic Cancer,,Completed,No Results Available,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: laromustine,,Vion Pharmaceuticals|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,,Industry,Interventional,Primary Purpose: Treatment,VION-CLI-028|CDR0000258355|YALE-HIC-16775,2002-10-01,,2008-01-01,"January 27, 2003",,"July 18, 2013","Yale Comprehensive Cancer Center, New Haven, Connecticut, United States|Veterans Affairs Medical Center - West Haven, West Haven, Connecticut, United States|Ireland Cancer Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00049699,1918.0,Industry Lead,Three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
747,748,NCT00410982,"Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies",,Completed,No Results Available,Leukemia|Lymphoma|Myeloma,Drug: Busulfan|Drug: Gemcitabine|Drug: Melphalan|Other: Hematopoietic Cell Transplantation|Drug: Rituximab for Patients with B-Cell Malignancies|Drug: Palifermin,Maximum Tolerated Dose (MTD) of Gemcitabine with Busulfan + Melphalan,M.D. Anderson Cancer Center,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 1,145.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2006-0803,2006-12-01,September 2012,2012-09-01,"December 13, 2006",,"June 3, 2016","UT MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00410982,2101.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
748,749,NCT00222443,"Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy",,Completed,No Results Available,Lymphomas|Tumors,Drug: Irinotecan,Determine toxicity and maximum tolerated dose of escalating daily protracted irinotecan.|Evaluate feasibility of repetitive cycles of this combination .|Estimate response rate in children and adolescents with recurrent solid tumors and lymphomas.,University of Oklahoma,All,"1 Year to 21 Years   (Child, Adult)",Phase 1,40.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,JEC Toca One,2004-09-01,December 2007,2007-12-01,"September 22, 2005",,"September 22, 2008","Oklahoma University Health Sciences Center-Jimmy Everest Center, Oklahoma City, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT00222443,1186.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
749,750,NCT02467946,Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old Patient,HALO,Completed,No Results Available,Clinical Efficacy|Safety,Drug: Adcetris-Levact,toxicity analysis|Efficacy analysis|Progression Free Survival|Complete Response Rate,Centre Antoine Lacassagne|Millennium: The Takeda Oncology Company,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,60.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013/24,2016-01-14,"April 6, 2022",2022-04-06,"June 10, 2015",,"January 4, 2023","Centre Antoine Lacassagne, Nice, France",,https://ClinicalTrials.gov/show/NCT02467946,2274.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
750,751,NCT03019666,Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL,,Completed,No Results Available,Multiple Myeloma|Non-Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma|Mantle-Cell Lymphoma|Follicular Lymphoma|Indolent B Cell Lymphoma|Primary Mediastinal Lymphoma|Lymphoplasmacytic Lymphoma,Biological: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells,Occurrence of any grade 4 or greater suspected adverse reaction|Occurrence of Grade III or IV acute graft-versus-host disease (aGVHD)|Occurrence of treatment related mortality (TRM)|Occurrence of disease response|Number of patients alive without progression,"Masonic Cancer Center, University of Minnesota",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,39.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015LS057|MT2015-46,2017-10-18,"August 15, 2022",2022-08-15,"January 12, 2017",,"November 4, 2022","Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03019666,1762.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
751,752,NCT02013128,Ublituximab + Ibrutinib in Select B-cell Malignancies,,Completed,No Results Available,Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma,Drug: Ublituximab|Drug: Ibrutinib,To evaluate the safety of ublituximab in combination with ibrutinib in patients with select B-cell malignancies|Overall Response Rate,"TG Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,66.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UTX-IB-104,2014-01-06,December 2015,2015-12-01,"December 17, 2013",,"October 24, 2022","TG Therapeutics Investigational Trial Site, Huntsville, Alabama, United States|TG Therapeutics Investigational Trial Site, Tucson, Arizona, United States|TG Therapeutics Investigational Trial Site, Santa Barbara, California, United States|TG Therapeutics Investigational Trial Site, Boulder, Colorado, United States|TG Therapeutics Investigational Trial Site, Niles, Illinois, United States|TG Therapeutics Investigational Trial Site, Urbana, Illinois, United States|TG Therapeutics Investigational Trial Site, Bethesda, Maryland, United States|TG Therapeutics Investigational Trial Site, Morristown, New Jersey, United States|TG Therapeutics Investigational Trial Site, Portland, Oregon, United States|TG Therapeutics Investigational Trial Site, Springfield, Oregon, United States|TG Therapeutics Investigational Trial Site, Greenville, South Carolina, United States|TG Therapeutics Investigational Trial Site, Memphis, Tennessee, United States|TG Therapeutics Investigational Trial Site, Austin, Texas, United States|TG Therapeutics Investigational Trial Site, Dallas, Texas, United States|TG Therapeutics Investigational Trial Site, Tyler, Texas, United States|TG Therapeutics Investigational Trial Site, Blacksburg, Virginia, United States|TG Therapeutics Investigational Trial Site, Fairfax, Virginia, United States|TG Therapeutics Investigational Trial Site, Vancouver, Washington, United States",,https://ClinicalTrials.gov/show/NCT02013128,694.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
752,753,NCT01947140,Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies,PDX+Romi,Completed,No Results Available,Lymphoid Malignancies|Multiple Myeloma|Lymphoma|Hodgkin Lymphoma|Non-hodgkin Lymphoma,Drug: Pralatrexate|Drug: Romidepsin,Maximum tolerated dose (MTD) of the combination of pralatrexate and romidepsin|Overall response rate (ORR) (complete + partial response) of the combination of pralatrexate and romidepsin in patients with relapsed/refractory T-Cell Lymphoma|Maximum number of cycles received|Number of dose delays at the MTD|Overall response rate (ORR) of the study population|Duration of response (DOR) of the combination in patients with T-Cell Lymphoma|Overall survival (OS) of patients with T-Cell Lymphoma on study|Progression free survival (PFS) of the combination in patients with T-Cell Lymphoma|Number of dose reductions at the MTD|Progression free survival (PFS) of the study population|Duration of response (DOR) of the study population.,Jennifer Amengual|Columbia University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,57.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AAAJ5656,2013-09-09,"September 1, 2022",2022-09-01,"September 20, 2013",,"November 23, 2022","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Columbia University Irving Medical Center, New York, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01947140,3279.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
753,754,NCT02686346,Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE,BV-ICE,Completed,No Results Available,Hodgkin Disease,Drug: Brentuximab Vedotin|Drug: Etoposide|Drug: Carboplatine|Drug: Ifosfamide,Phase I : Maximal Tolerated Dose (MTD) determination|Phase II = fraction of responding patients according to Lugano classification (metabolic Complete Response)|Phase I : Number of participants with treatment-related adverse events as assessed by CTCAE v4.03|Phase I = Preliminary Overall Response Rate (ORR)|Phase II = ORR|Phase II : Number of participants with treatment-related adverse events as assessed by CTCAE v4.03|Phase II = number of patients with hematological recovery after each cycle|Phase II = Feasibility of Autologous Stem Cell Transplant (ASCT) after BV-ICE = fraction of patients for whom harvest is possible|Phase II = Fraction of patients eligible for ASCT|Phase II = Number of patients Positron Emission Tomography (PET) 4- after PET 2+|Phase II = Progression Free Survival (PFS)|Phase II = Overall Survival (OS),"The Lymphoma Academic Research Organisation|Millennium Pharmaceuticals, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,53.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BV-ICE,2016-03-01,"October 31, 2018",2021-07-12,"February 19, 2016",,"December 7, 2021","Clinique Universitaire Saint-Luc, Bruxelles, Belgium|CHU Dinant Godinne, Yvoir, Belgium|Institut d'Hématologie de Basse Normandie - CHU Côte de Nacre, Caen, France|APHP-Hôpital Henri Mondor, Créteil, France|CHU de Dijon - Hôpital le Bocage, Dijon, France|CHRU Lille - Hôpital Claude Huriez, Lille, France|Centre Léon Bérard, Lyon, France|CHU Saint Eloi, Montpellier, France|CHU De Nantes, Nantes, France|APHP - Hôpital Saint Louis, PARIS Cedex 10, France|Hôpital Necker, Paris, France|CHU Lyon Sud, Pierre Bénite Cedex, France|CHU de Poitiers - Hôpital de La Milétrie, Poitiers, France|CHU De Rennes, Rennes, France|Centre Henri Becquerel, Rouen, France|CHU De Strasbourg, Strasbourg, France|IUCT Toulouse, Toulouse, France|CHU De Nancy - Hôpital Brabois, Vandœuvre-lès-Nancy, France|Institut Gustave Roussy, VILLEJUIF Cedex, France",,https://ClinicalTrials.gov/show/NCT02686346,1959.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
754,755,NCT03310619,A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies,PLATFORM,Completed,No Results Available,"Lymphoma, Non-Hodgkin|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular",Biological: JCAR017|Drug: Durvalumab|Drug: CC-122|Drug: Ibrutinib|Drug: CC-220|Drug: Relatlimab|Drug: Nivolumab|Drug: CC-99282,Dose-limiting toxicity (DLT) rates|Complete Response Rate|Adverse Events (AEs)|Progression-free survival (PFS)|Overall survival (OS)|Overall response rate (ORR)|Duration of response (DOR)|Event-free survival (EFS)|Pharmacokinetic (PK)- Cmax|Pharmacokinetic (PK)- Tmax|Pharmacokinetic (PK)- AUC|Health-related quality of life (HRQoL)|Quality of Life C30 questionnaire (EORTC-QLQ-C30)|European Quality of Life-5 Dimensions health state classifier to 5 Levels (EQ-5D-5L),Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,62.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JCAR017-BCM-002|U1111-1201-2046,2017-11-28,"February 15, 2023",2023-02-15,"October 16, 2017",,"March 24, 2023","Local Institution - 011, Duarte, California, United States|Local Institution - 022, Atlanta, Georgia, United States|Local Institution - 014, Chicago, Illinois, United States|Local Institution - 012, Boston, Massachusetts, United States|Local Institution - 021, Boston, Massachusetts, United States|Local Institution - 015, Omaha, Nebraska, United States|Local Institution - 016, Philadelphia, Pennsylvania, United States|Local Institution - 020, Pittsburgh, Pennsylvania, United States|Local Institution - 013, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03310619,1905.0,Industry Lead,Three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
755,756,NCT00304005,VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders,,Completed,No Results Available,Leukemia|Lymphoma,Drug: laromustine,Maximum tolerated dose|Toxicity|Efficacy,Vion Pharmaceuticals|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,35.0,Industry,Interventional,Primary Purpose: Treatment,VION-CLI-041|CDR0000465217|MDA-2005-0249,2005-07-01,October 2005,2008-08-01,"March 17, 2006",,"July 18, 2013","M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00304005,1127.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
756,757,NCT00019513,"Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas",,Completed,No Results Available,"Colorectal Cancer|Esophageal Cancer|Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Liver Cancer|Lung Cancer|Lymphoma|Pancreatic Cancer|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug: leucovorin calcium,,National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,108.0,NIH,Interventional,Primary Purpose: Treatment,980143|98-C-0143|CDR0000066587,1998-08-01,,2004-06-01,"January 27, 2003",,"March 23, 2012","Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00019513,2131.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
757,758,NCT03019055,Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell,,Completed,Has Results,"Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma",Biological: CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)|Biological: CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)|Biological: CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)|Biological: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg),Number of Adverse Events After CAR 20/19-T Cell Infusion,"Medical College of Wisconsin|Children's Hospital and Health System Foundation, Wisconsin",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,26.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO00028724,2017-10-16,"October 1, 2019",2021-08-24,"January 12, 2017","May 7, 2021","July 14, 2022","Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT03019055/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT03019055/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03019055,1408.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
758,759,NCT02423915,Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention,,Completed,No Results Available,Leukemia|Lymphoma,Drug: Rituximab|Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total Body Radiation|Procedure: Fucosylated Regulatory T Cells|Procedure: Cord Blood Infusions|Drug: Mycophenolate mofetil|Drug: Sirolimus|Procedure: Bone Marrow Aspiration|Drug: G-CSF|Procedure: Non-Fucosylated Regulatory T Cells,"Severe Infusional Toxicity|Safety of Administering Fucosylated Umbilical Cord Blood (CB) Regulatory T cells (Tregs) in a CBT, MRD, or MUD Transplant|Time to Severe Graft Versus Host Disease (GVHD) or Death",M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Cancer Prevention Research Institute of Texas,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,5.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014-0150|NCI-2015-00705|1R44CA192601-01A1|RP160121,2015-07-30,"October 6, 2020",2020-10-06,"April 22, 2015",,"January 8, 2021","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02423915,1895.0,Not Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
759,760,NCT00103246,"Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides",,Completed,No Results Available,Lymphoma|Non-melanomatous Skin Cancer|Precancerous Condition,Drug: silicon phthalocyanine 4,Maximum tolerated dose|Local toxicity as measured by physical exam and punch biopsy|Treatment efficacy as measured by physical exam and punch biopsy|Systemic photosensitivity as measured by minimum erythema dose (MED) testing,Case Comprehensive Cancer Center|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1,43.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CASE1Y04|P30CA043703|CASE-CWRU-1Y04|10-03-01,2004-09-01,December 2008,2010-08-01,"February 8, 2005",,"January 22, 2019","Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00103246,2160.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
760,761,NCT00048737,Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies,,Completed,Has Results,Lymphoma|Leukemia,Drug: Zevalin Radioimmunotherapy|Drug: Rituximab|Drug: Fludarabine|Drug: Cyclophosphamide|Procedure: Allogeneic Stem Cell Transplantation,Number of Participants With Graft Failure,M.D. Anderson Cancer Center|Biogen,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,70.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ID01-233,2002-10-01,December 2011,2011-12-01,"November 8, 2002","June 13, 2013","June 13, 2013","MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00048737,3348.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
761,762,NCT04626843,Intermittent Fasting and CLL/SLL,,Completed,No Results Available,"Neoplasms|Leukemia, Lymphocytic, Chronic|Lymphoma, Small Lymphocytic|Intermittent Fasting|Diet Habit|Inflammation",Other: Intermittent fast,Change in lymphocyte count|Change in quality of life|Change in inflammation|Change in metabolic profiles|Change in autophagy status|Immune cell gene expression profiles|Change in gut microbiome (optional),Eleah Stringer|BC Cancer Foundation|British Columbia Cancer Agency,All,"19 Years to 85 Years   (Adult, Older Adult)",Phase 1,15.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H19-03702,2021-02-03,"October 30, 2022",2022-12-31,"November 13, 2020",,"February 14, 2023","Eleah Stringer, Victoria, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT04626843,696.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
762,763,NCT02518113,A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL,,Completed,Has Results,T-cell Acute Lymphoblastic Leukemia|T-cell Lymphoblastic Lymphoma,Drug: LY3039478|Drug: Dexamethasone|Drug: Placebo,"Number of Participants With Dose Limiting Toxicities (DLTs)|Recommended Dose of LY3039478 in Combination With Dexamethasone|Number of Participants Who Achieve Complete Remission (CR) or CR With Incomplete Blood Count Recovery (CRi): Overall Remission Rate (ORR)|Pharmacokinetics (PK): Area Under the Concentration-Time Curve (AUC[0-∞]) of LY3039478 in Combination With Dexamethasone in Day 1|Pharmacokinetics (PK): Area Under the Concentration-Time Curve (AUC[0- 48]) of LY3039478 in Combination With Dexamethasone in Day 8|Number of Participants With CR or CRi and Notch-1 or FBXW7 Mutations|Phase 2: Number of Participants Who Achieve CR, CRi or Partial Remission (PR): Overall Remission Rate (ORR) Plus PR|Phase 2: Number of Participants Who Achieve PR|Phase 2: Duration of Remission (DoR)|Phase 2:Relapse Free Survival (RFS)|Phase 2: Event Free Survival (EFS)|Phase 2: Overall Survival (OS)|Phase 2: Change From Baseline in the Functional Assessment of Cancer Therapy-Leukemia-General (FACT-Leu-G) Score",Eli Lilly and Company,All,"2 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,36.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14548|I6F-MC-JJCB|2014-005024-10,2015-10-01,"January 15, 2018",2018-01-15,"August 7, 2015","February 6, 2019","September 11, 2019","City of Hope National Medical Center, Duarte, California, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Montefiore Medical Center, Bronx, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|University of Texas MD Anderson, Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., LIlle, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Nantes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Pierre Benite, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Toulouse, France|Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jerusalem, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ramat Gan, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Aviv, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Napoli, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Torino, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT02518113/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT02518113/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02518113,837.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
763,764,NCT00718757,"Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies",,Completed,No Results Available,Non-Hodgkins Lymphoma|Hodgkin's Disease|Acute Lymphoblastic Leukemia,Drug: Dexamethasone|Drug: Irinotecan|Drug: Vincristine,Estimate the maximum tolerated dose of dexamethasone given for 5 consecutive days when combined with fixed doses of irinotecan and vincristine in children with relapsed hematologic malignancies,St. Jude Children's Research Hospital,All,"up to 21 Years   (Child, Adult)",Phase 1,4.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VIDML,2005-01-01,January 2009,2009-01-01,"July 21, 2008",,"August 28, 2013","Rady's Children Hospital San Diego, San Diego, California, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00718757,1461.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
764,765,NCT03905135,Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies,,Completed,Has Results,Peripheral T-cell Lymphoma NOS|Mycosis Fungoides|Sezary Syndrome|Anaplastic Large Cell Lymphoma,Drug: rhIL-15|Biological: Avelumab,Maximum Tolerated Dose (MTD) of Interleukin 15|Mean Progression Free Survival (PFS)|Mean Event-free Survival (EFS)|Mean Overall Survival (OS)|Overall Response in Participants With Greater Than or Equal to 50% Programmed Death-ligand 1 (PD-L1) Expressing Tumor Cells|Number of Participants With Overall Best Response|Mean Duration of Response (DOR),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",Phase 1,8.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,190076|19-C-0076,2019-06-07,"March 25, 2021",2022-05-17,"April 5, 2019","September 13, 2022","September 13, 2022","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT03905135/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT03905135/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03905135,1075.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
765,766,NCT00735930,Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,,Completed,No Results Available,Anemia|Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Thrombocytopenia,Drug: Alvocidib Hydrochloride|Drug: Lenalidomide|Other: Pharmacological Study|Other: Laboratory Biomarker Analysis,"MTD of lenalidomide when combined with alvocidib, defined as the maximum dose level with fewer than 2 of 6 patients experiencing dose limiting toxicity (DLT)|Incidence of DLT in patients treated with alvocidib and lenalidomide graded according to NCI CTCAE version 4.0|Pharmacokinetic parameters of alvocidib and lenalidomide alone and in combination in plasma samples|Plasma IL-6 and selected cytokine levels|B-cell activation as assessed by surface antigen (CD40, CD80, CD86, HLA-DR, and CD95) expression|Intracellular pharmacodynamic targets including STAT3, Mcl-1, and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB)|Response assessed by National Cancer Institute-Sponsored Working Group guidelines|Progression-free survival (PFS)|Toxicity graded according to NCI CTCAE version 4.0|Presence of minimal residual disease",National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,39.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2009-00269|OSU-08056|2008C0033|CDR0000738866|OSU 08056|8046|P30CA016058|U01CA076576,2008-08-01,March 2013,2014-11-01,"August 15, 2008",,"April 2, 2015","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00735930,2283.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
766,767,NCT04955340,"A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat",,Completed,No Results Available,Cutaneous T Cell Lymphoma|Mycosis Fungoides|Sezary Syndrome,Drug: [14C]-resminostat,AUC0-tlast|AUC0-∞|Cmax|tmax|tlag|λz|t1/2|CL/F|Vz/F|AUC0-∞ Plasma resminostat/Total Radioactivity Ratio|AUC0-∞ Blood/Plasma Ratio|Aeu|cumulative Aeu|feu|cumulative feu|Aef|cumulative Aef|fef|cumulative fef.|Safety and Tolerability|Heart rhythm|Ventricular rate|PR-interval (synonymous: PQ interval)|QRS complex|QT interval|QTcF interval|Vital Signs (Body Temperature)|Vital Signs (Blood pressure)|Physical Examination|metabolic profiles of resminostat|identification and quantification of resminostat metabolites,4SC AG,Male,35 Years to 55 Years   (Adult),Phase 1,5.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4SC-201-7-2020|2021-000555-39|8448213,2021-10-12,"January 19, 2022",2022-01-19,"July 8, 2021",,"February 18, 2022","Covance Clinical research Unit Ltd., Leeds, United Kingdom",,https://ClinicalTrials.gov/show/NCT04955340,99.0,Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
767,768,NCT00412243,Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients,,Completed,Has Results,Burkitt's Lymphoma|Lymphoblastic Lymphoma|Acute Lymphoblastic Leukemia,Drug: Clofarabine|Drug: Cyclophosphamide,Maximum Tolerated Dose for Cyclophosphamide (MTD),"M.D. Anderson Cancer Center|Genzyme, a Sanofi Company",All,"21 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,51.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2005-0552,2006-03-01,April 2012,2012-04-01,"December 18, 2006","March 4, 2013","March 12, 2013","UT MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00412243,2223.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
768,769,NCT03383055,CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig,,Completed,No Results Available,Lymphoma|Multiple Myeloma,Biological: CMV-MVA Triplex Vaccine,Change in the absolute number of CMV-induced adaptive NK cells (CD56dimCD57+NKG2C+) between days 28 and 100 post-auto-HCT in patients with lymphoid malignancies.|Change in absolute Number of CMV-induced adaptive NK Cells|Response to CMV-MVA Triplex vaccine in CMV seropositive vs. seronegative patients|Progression Free Survival (PFS)|Response to CMV-MVA Triplex vaccine in lymphoma vs. myeloma patients,"Masonic Cancer Center, University of Minnesota",All,"18 Years and older   (Adult, Older Adult)",Phase 1,28.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2017LS091|MT2017-29,2018-11-16,"July 10, 2021",2021-07-10,"December 26, 2017",,"August 17, 2021","Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT03383055/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT03383055,967.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
769,770,NCT02795182,Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies,,Completed,Has Results,Lymphoma|Leukemia,Drug: Zanubrutinib|Drug: Tislelizumab,Dose Escalation: Maximum Tolerated Dose (MTD) of Tislelizumab|Dose Escalation: RP2D of Tislelizumab|Number of Participants With TEAEs and SAEs|Overall Response Rate|Duration of Response (DOR)|Progression Free Survival (PFS)|Number of Participants With Anti-Drug Antibodies (ADAs) to Tislelizumab,BeiGene,All,"18 Years and older   (Adult, Older Adult)",Phase 1,75.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BGB-3111_BGB-A317_Study_001,2016-06-29,"December 18, 2020",2020-12-18,"June 10, 2016","July 1, 2022","July 1, 2022","St Vincent's Hospital, Darlinghurst, New South Wales, Australia|Concord Hospital, Sydney, New South Wales, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Monash Hospital, Clayton, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Epworth Healthcare, Richmond, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Guangdong General Hospital, Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Shanghai jiaotong university school of medicine Ruijin Hospital, Shanghai, Shanghai, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02795182/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02795182/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02795182,1633.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
770,771,NCT00024180,FR901228 in Treating Patients With Hematologic Cancer,,Completed,No Results Available,Leukemia|Lymphoma,Drug: romidepsin,,Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000068898|OSU-00H0350|NCI-27,2002-01-01,,2006-08-01,"January 27, 2003",,"January 31, 2013","Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00024180,1673.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
771,772,NCT02780804,Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors,,Completed,Has Results,Brain Stem Neoplasm|Pineal Region Neoplasm|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Primary Central Nervous System Neoplasm|Recurrent Visual Pathway Glioma|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Primary Central Nervous System Neoplasm|Refractory Visual Pathway Glioma,Drug: Entinostat|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study,Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (R2PD) of Entinostat|Frequency of Adverse Events for Entinostat|Half-life of Entinostat|Peak Plasma Concentration of Entinostat: C-Max|Total Area Under the Plasma Concentration Curve of Entinostat: AUC|Time to Reach Maximum Plasma Concentration of Entinostat: T-Max|Antitumor Activity of Entinostat|Change in Histone H3 Acetylation of Entinostat|Change in Histone H4 Acetylation of Entinostat,National Cancer Institute (NCI),All,"12 Months to 21 Years   (Child, Adult)",Phase 1,21.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2016-00708|ADVL1513|UM1CA097452,2016-12-26,"June 30, 2021",2021-09-30,"May 24, 2016","January 31, 2023","January 31, 2023","Children's Hospital of Alabama, Birmingham, Alabama, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02780804/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02780804,1739.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
772,773,NCT01572493,Continuous Infusion of rhIL-15 for Adults With Advanced Cancer,,Completed,Has Results,Lymphoma|Carcinoma,Biological: rh IL-15 (10 DAYS)|Biological: rh IL-15 (5 DAYS),"Maximum Tolerated Dose (MTD) of Recombinant Human Interleukin-15 (rhIL-15) for 10 Day Dosing|Maximum Tolerated Dose (MTD) of Recombinant Human Interleukin-15 (rhIL-15) for 5 Day Dosing|Number of Participants With Grades 3, 4 or 5 Dose-Limiting Toxicity (DLT) Related to Study Drug|Clinical Response Rate|Time to Progression (TTP)|Maximum Observed Plasma Concentration (Cmax) of Recombinant Human Interleukin-15 (rhIL-15)|Concentration of Drug in Plasma at Steady State (Css)|Area Under the Curve (AUClast)|Inflammatory Cytokines",National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",Phase 1,38.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120113|12-C-0113,2012-04-04,"June 20, 2019",2019-07-02,"April 6, 2012","March 6, 2023","March 6, 2023","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT01572493/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT01572493/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01572493,2645.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
773,774,NCT02014129,A Study of LY2835219 in Japanese Participants With Advanced Cancer,,Completed,Has Results,Neoplasm Metastasis|Lymphoma,Drug: LY2835219,Number of Participants With Abemaciclib Dose-Limiting Toxicity (DLT)|Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of Abemaciclib|Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve (AUC) of Abemaciclib|Percentage of Participants With a Tumor Response: Objective Response Rate (ORR),Eli Lilly and Company,All,"20 Years and older   (Adult, Older Adult)",Phase 1,12.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15154|I3Y-JE-JPBC,2013-12-18,"April 1, 2015",2019-08-21,"December 18, 2013","August 24, 2020","August 24, 2020","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician., Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT02014129,2072.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
774,775,NCT00517530,A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN),,Completed,Has Results,Lymphoma,Drug: Obinutuzumab,Percentage of Participants Who Experienced a Dose-limiting Toxicity in Phase I of the Study|Percentage of Participants With Best Overall Response in Phase II of the Study|Percentage of Participants With Complete Response (CR/CRu/CRi) in Phase II of the Study|Percentage of Participants With Partial Response (PR) in Phase II of the Study|Progression-free Survival (PFS) in Phase II of the Study|Duration of Response by Disease Type in Phase II of the Study|Participants With Event-Free Survival (EFS) in Phase II of the Study|Pharmacodynamics: Participants With Peripheral B-cell Recovery After Having Had Depletion at End of Treatment During Phase II of the Study|Percentage of Retreated Participants With Response|Maximum Plasma Concentration (Cmax) of Obinutuzumab in NHL Participants|Area Under the Concentration-time Curve of Obinutuzumab Administered on Day 1 of Cycle 1 in Phase I of the Study,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,134.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BO20999|2007-001103-37,2007-09-01,November 2013,2013-11-01,"August 17, 2007","September 22, 2015","October 11, 2016","Creteil, France|Le Mans, France|Lille, France|Marseille, France|Montpellier, France|Nantes, France|Paris, France|Paris, France|Pessac, France|Pierre Benite, France|Rennes, France|Rouen, France|Toulouse, France|Tours, France|Vandoeuvre Les Nancy, France|Köln, Germany",,https://ClinicalTrials.gov/show/NCT00517530,2253.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
775,776,NCT00546377,"Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer",,Completed,Has Results,Leukemia|Lymphoma,Biological: filgrastim|Biological: pegfilgrastim|Biological: rituximab|Biological: sargramostim|Drug: cyclophosphamide|Drug: mitoxantrone hydrochloride|Drug: pentostatin|Genetic: fluorescence in situ hybridization|Genetic: gene rearrangement analysis|Genetic: polymerase chain reaction|Genetic: protein expression analysis|Other: flow cytometry|Procedure: biopsy,Overall Response|Maximum Tolerated Dose (MTD) of Mitoxantrone,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1|Phase 2,50.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,05-077|MSKCC-05077,2005-07-01,May 2014,2014-05-01,"October 18, 2007","May 12, 2016","May 12, 2016","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00546377,3226.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
776,777,NCT01066663,Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,,Completed,Has Results,Chronic Lymphocytic Leukemia|Small Lymphocytic Leukemia,Drug: pyrimethamine,Phase I: Maximum Tolerated Dose (MTD)|Phase II: Overall Response Rate (ORR)|Incidence of Grade 3 or Higher Treatment-Related Toxicity|Median Progression Free Survival (PFS),Dana-Farber Cancer Institute|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Lymphoma Research Foundation,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,09-421,2010-03-01,February 2022,2023-01-01,"February 10, 2010","December 1, 2022","February 22, 2023","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT01066663/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01066663,4689.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
777,778,NCT00935792,Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,,Completed,Has Results,Lymphocytic Leukemia,Drug: alemtuzumab|Drug: everolimus,Clinical Response (Complete or Partial Remission)|Number of Participants With Dose-Limiting Toxicities|Test the Safety and Tolerability of the Combination of Everolimus and Alemtuzumab.|Survival Time|Progression-free Survival|Duration of Response|Time to Subsequent Therapy,Mayo Clinic,All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1|Phase 2,28.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MC088C|NCI-2009-00935|08-008775,2009-07-01,December 2015,2015-12-01,"July 9, 2009","December 12, 2016","September 26, 2017","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00935792,2344.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
778,779,NCT00001579,A Phase I Trial of 5-Fluorouracil Given With 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients With Solid Tumors,,Completed,No Results Available,Lymphoma|Neoplasms,Drug: 5-Fluorouracil|Drug: Ethynyluracil|Drug: Leucovorin,,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",Phase 1,50.0,NIH,Interventional,Primary Purpose: Treatment,970136|97-C-0136,1997-06-01,,2001-03-01,"December 10, 2002",,"July 17, 2006","National Cancer Institute (NCI), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00001579,1369.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
779,780,NCT00658970,Evaluation of KX2-391 in Patients With Advanced Malignancies,,Completed,No Results Available,Solid Tumors|Lymphoma,Drug: KX2-391,"Determine maximum tolerated dose of the drug|Pharmacokinetics, Pharmacodynamics, Efficacy","Athenex, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,50.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KX01-01-07,2007-11-01,March 2010,2011-05-01,"April 16, 2008",,"June 8, 2011","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00658970,1277.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
780,781,NCT01217749,Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL,PCYC-1109-CA,Completed,Has Results,B-cell Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Prolymphocyctic Leukemia|Richter's Transformation,Drug: PCI-32765|Drug: ofatumumab,Percentage of Participants Achieving Response|Safety During Dose-Limiting Toxicity (DLT) Observation Period|Number of Participants With Treatment Emergent Adverse Events (AEs)|Progression Free Survival (PFS) at 12 Months,Pharmacyclics LLC.|Ohio State University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,71.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PCYC-1109-CA|PCI-32765,2010-12-01,June 2013,2014-05-01,"October 8, 2010","April 16, 2015","June 25, 2015","The Ohio State University, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01217749,1247.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
781,782,NCT01026415,Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35),,Completed,No Results Available,"Carcinomas|Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin|Neoplasms",Drug: brentuximab vedotin|Drug: rifampin|Drug: midazolam|Drug: ketoconazole,"Midazolam blood concentrations +/- brentuximab vedotin|Brentuximab vedotin blood concentrations +/- rifampin|Brentuximab vedotin in urine, feces, and blood|Brentuximab vedotin blood concentrations in special populations|Brentuximab vedotin blood concentrations +/- ketoconazole|Incidence of adverse events and laboratory abnormalities","Seagen Inc.|Millennium Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,73.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SGN35-008,2009-12-01,May 2012,2012-05-01,"December 4, 2009",,"December 18, 2014","City of Hope, Duarte, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|St. Francis Medical Group Oncology & Hematology Specialists, Indianapolis, Indiana, United States|Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Seattle Cancer Care Alliance / University of Washington Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01026415,882.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
782,783,NCT01515176,"Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia",,Completed,Has Results,Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia,Drug: Dinaciclib|Other: Laboratory Biomarker Analysis|Biological: Ofatumumab|Other: Pharmacological Study,"Maximum-tolerated Dose of Dinaciclib When Given in Combination With Ofatumumab, Defined as a Dose Level Where at Most One of 6 Evaluable Patients Has a Dose Limiting Toxicity (Phase Ia)|Number of Patients With Dose-limiting Toxicity Incidents Graded According to the NCI CTCAE v4.0 (Phase I)|Percentage of Patients Who Achieve an Overall Response, Defined as Achieving a Complete Response, an Unconfirmed Complete Response (SLL Only), or a Partial Response (Phase II)|Complete Response Rate|Overall Survival|Progression Free Survival|Time to Treatment Failure",National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,36.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2012-00101|OSU-11120|OSU11120|CDR0000721353|OSU 11120|9031|N01CM00070|N01CM62207|P30CA016058|P50CA140158|U01CA076576|UM1CA186712,2012-01-01,"March 4, 2015",2016-07-19,"January 23, 2012","March 15, 2018","March 15, 2018","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01515176,1661.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
783,784,NCT03106428,A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies,,Completed,No Results Available,Acute Myeloid Leukemia|Multiple Myeloma|Diffuse Large B-cell Lymphoma,Drug: MEDI7247,Occurrence of adverse events (AEs)|Occurrence of serious adverse events (SAEs)|Occurrence of dose-limiting toxicities (DLTs)|Number of patients with changes in laboratory parameters from baseline|Number of patients with changes in vital signs from baseline|Number of patients with changes in electrocardiogram (ECG) results from baseline|Percentage of patients with changes in laboratory parameters from baseline|MEDI7247 maximum observed concentration for PK|MEDI7247 area under the concentration-time curve for PK|MEDI7247 clearance for PK|MEDI7247 terminal half-life for PK|Number of subjects who develop anti-drug antibodies (ADAs)|Best overall response (BOR)|Objective response rate (ORR)|Time to response (TTR)|Duration of response (DoR)|Progression-free survival (PFS)|Overall survival (OS),MedImmune LLC,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 1,67.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D8540C00001,2017-03-29,"January 3, 2020",2020-01-03,"April 10, 2017",,"February 28, 2020","Research Site, Los Angeles, California, United States|Research Site, Denver, Colorado, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Boston, Massachusetts, United States|Research Site, Saint Louis, Missouri, United States|Research Site, New York, New York, United States|Research Site, Greer, South Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, San Antonio, Texas, United States|Research Site, Pierre Benite, France|Research Site, Villejuif, France|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03106428,1010.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
784,785,NCT00345189,Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors,,Completed,No Results Available,Tumors|Lymphoma,Drug: CNF2024,To determine the maximum tolerated dose (MTD)|To determine the safety profile|pharmacokinetic profile|effect on pharmacodynamic biomarkers|antitumor activity,Biogen,All,"18 Years and older   (Adult, Older Adult)",Phase 1,70.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CNF2024-ST-05003|120ST101,2006-02-01,July 2008,2009-04-01,"June 27, 2006",,"July 14, 2009","Research site, Scottsdale, Arizona, United States|Research site, New Haven, Connecticut, United States|Research site, San Antonio, Texas, United States|Research site, Sutton, Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT00345189,1155.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
785,786,NCT01994382,"Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL",,Completed,Has Results,Follicular Lymphoma (FL/Indolent NHL)|Aggressive NHL (a NHL)|Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)|T-cell Lymphoma (PTCL and CTCL)|B-cell Non Hodgkin Lymphoma (NHL),Drug: Cerdulatinib|Biological: Rituximab,Phase 1: Number of Participants With a Dose Limiting Toxicity (DLT)|Phase 2a: Number of Participants Achieving Overall Response Rate (Partial Response [PR] Plus Complete Response [CR]) as Assessed by the Investigator|Phase 1: Number of Participants Achieving Overall Response Rate (Partial Response [PR] Plus Complete Response [CR]) as Assessed by the Investigator|Phase 1: Number of Participants Achieving Clinical Benefit|Phase 1 and Phase 2: Number of Participants With an Adverse Event (AE) or a Serious Adverse Event (SAE)|Phase 1: Area Under the Plasma Concentration-Time Curve From 0 to 12 Hours (AUC0-12) of Cerdulatinib|Phase 2a: Median Time to Progression-Free Survival (PFS)|Phase 2a: Number of Participants Achieving Clinical Benefit|Phase 2a: Number of Participants Achieving Dominant Mass Response (DMR),Alexion|Portola Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,260.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-601,2013-08-30,"December 15, 2020",2020-12-15,"November 25, 2013","April 5, 2022","April 5, 2022","Huntsville, Alabama, United States|Gilbert, Arizona, United States|Los Angeles, California, United States|Palo Alto, California, United States|Washington, District of Columbia, United States|Gainesville, Florida, United States|Sarasota, Florida, United States|Lawrenceville, Georgia, United States|Chicago, Illinois, United States|Louisville, Kentucky, United States|Baltimore, Maryland, United States|Ann Arbor, Michigan, United States|Hattiesburg, Mississippi, United States|Hackensack, New Jersey, United States|Morristown, New Jersey, United States|New York, New York, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Arlington, Texas, United States|Lubbock, Texas, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Milwaukee, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT01994382/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT01994382/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01994382,2664.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
786,787,NCT01075321,Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma,,Completed,Has Results,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia,Drug: everolimus|Drug: lenalidomide|Other: laboratory biomarker analysis|Genetic: polymorphism analysis|Other: immunohistochemistry staining method|Genetic: microarray analysis|Genetic: fluorescence in situ hybridization,Number of Patients Reporting Dose-Limiting Toxicity (DLT) (Phase I)|Best Response to Dose Level 0|Overall Survival for All Eligible Patients|Progression-Free Survival For All Eligible Patients|Duration of Response for All Eligible Patients|Time to Treatment Failure for All Eligible Patients,Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,58.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MC0981|NCI-2010-00235|09-003801|RV-NHL-HL-PI-0466|CRAD001NUS113T,2011-01-10,"February 28, 2015",2020-02-13,"February 25, 2010","March 23, 2020","October 22, 2020","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01075321,3321.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
787,788,NCT00003962,Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer,,Completed,No Results Available,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm,Biological: aldesleukin,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI),All,"up to 65 Years   (Child, Adult, Older Adult)",Phase 1,,Other|NIH,Interventional,Primary Purpose: Treatment,J9825 CDR0000067162|P01CA015396|JHOC-98040902|JHOC-J9825|NCI-H99-0033,1998-04-01,June 2000,2000-06-01,"August 27, 2004",,"May 2, 2014","Johns Hopkins Oncology Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00003962,792.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
790,791,NCT02254772,A Phase I/II Study of Intratumoral Injection of SD-101,,Completed,Has Results,Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma,Biological: Ipilimumab|Drug: SD-101|Radiation: Radiation therapy,Number of Dose-limiting Toxicity (DLT) Events of Ipilimumab Plus a Fixed Dose of SD-101 (1 mg/Week)|Tumor Response|Median Time to Progression (TTP),Robert Lowsky|National Cancer Institute (NCI)|Stanford University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,9.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB-31133|NCI-2014-01978|LYMNHL0119|5R01CA188005-02,2014-09-01,"November 10, 2016",2017-01-26,"October 2, 2014","September 29, 2017","November 27, 2019","Stanford University Hospitals and Clinics, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT02254772,878.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
791,792,NCT03097770,Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20,,Completed,No Results Available,Hematopoietic/Lymphoid Cancer|Adult Acute Lymphoblastic Leukemia in Remission|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma,Biological: anti-CD19/20-CAR vector-transduced T cells,Occurrence of study related adverse events|Anti-tumor responses to tanCART19/20 cell infusions,Chinese PLA General Hospital,All,"16 Years to 70 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,100.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHN-PLAGH-BT-020,2017-04-01,"May 10, 2019",2020-01-31,"March 31, 2017",,"September 2, 2020","Biotherapeutic Department and Pediatrics Department of Chinese PLA General Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT03097770,1035.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
792,793,NCT01191775,A Study of PNT2258 in Patients With Advanced Solid Tumors,,Completed,No Results Available,Cancer|Lymphoma|Prostate Cancer|Melanoma,Drug: PNT2258,To determine the safety of PNT2258 in patients with advanced solid tumors|Pharmacokinetic profile of PNT2258,"Sierra Oncology, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,22.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P06-10091 (PNT2258-01),2010-08-01,April 2012,2012-04-01,"August 31, 2010",,"January 24, 2017","South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01191775,609.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
793,794,NCT03349281,Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL,,Completed,No Results Available,Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia,Drug: Pevonedistat|Drug: Vincristine|Drug: Dexamethasone|Drug: PEG-asparaginase|Drug: Doxorubicin|Drug: Cytarabine|Drug: Methotrexate|Drug: Hydrocortisone,Rate of Toxicity in Study Participants Receiving Protocol Therapy|Determination of the Maximum Tolerated Dose (MTD) in Study Participants Receiving Protocol Therapy|Rate of Clinical Response in Study Participants Receiving Protocol Therapy|Pharmacodynamics (PD): Expression Levels of Endoplasmic Reticulum (ER) Stress Response and Unfolded Protein Response (UPR) in Primary ALL Cells to Pevonedistat Therapy|Pharmacokinetics (PK): Maximum (Peak) Plasma Concentration (Cmax) of Pevonedistat|Pharmacokinetics (PK): Single-dose time to reach maximum (peak) concentration (Tmax) of Pevonedistat|Pharmacokinetics (PK): Area Under the Curve (AUC) of Plasma Concentration of Pevonedistat|Pharmacokinetics (PK): Terminal disposition phase half-life (t1/2) of Plasma Concentration of Pevonedistat,"Julio Barredo, MD|Takeda|University of Miami",All,"16 Years to 39 Years   (Child, Adult)",Phase 1,6.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20170602|X15015,2019-03-25,"August 11, 2021",2022-10-12,"November 21, 2017",,"October 20, 2022","University of Miami, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT03349281,1297.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
794,795,NCT00383994,"Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation",,Completed,No Results Available,"Lymphoma|Leukemia|Transplantation, Stem Cell|Lymphoid Malignancies|Disorder Related to Transplantation",Drug: GM-CSF|Drug: Rituximab|Biological: NK Cell Infusion,Dose-limiting toxicities (DLTs) for NK cells infusions after non-myeloablative transplantation for lymphoid malignancies,"M.D. Anderson Cancer Center|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",All,"Child, Adult, Older Adult",Phase 1,6.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2005-0234|NCI-2012-01375,2006-09-01,"July 22, 2019",2019-07-22,"October 4, 2006",,"July 31, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00383994,4707.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
795,796,NCT00003395,Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer,,Completed,No Results Available,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm,Drug: arsenic trioxide,,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),All,"17 Years and older   (Child, Adult, Older Adult)",Phase 1,,Other|NIH,Interventional,Primary Purpose: Treatment,98-023|CDR0000066395|NCI-G98-1449,1998-04-01,March 2000,2000-03-01,"August 16, 2004",,"June 25, 2013","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00003395,700.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
796,797,NCT02228772,Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults,,Completed,No Results Available,Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|B-cell Adult Acute Lymphoblastic Leukemia|T-cell Adult Acute Lymphoblastic Leukemia,Drug: MLN 9708|Drug: Vincristine|Drug: Cytarabine|Drug: Doxorubicin|Drug: Mercaptopurine|Drug: Cyclophosphamide|Drug: Methotrexate,Maximum Dose Tolerated of MLN 9708|Percentage of Patient with Complete Remission (CR) rate at the end of induction therapy|Percentage of Participants with Disease Free Survival|Rate of Overall survival (OS)|Complete Remission Rate|Rate of Toxicity,"Massachusetts General Hospital|Millennium Pharmaceuticals, Inc.",All,"51 Years to 75 Years   (Adult, Older Adult)",Phase 1,19.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-200,2014-12-01,October 2016,2019-11-01,"August 29, 2014",,"November 26, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02228772,1796.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
797,798,NCT02006485,Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies,,Completed,No Results Available,Chronic Lymphocytic Leukemia|Non-Hodgkin's Lymphoma,Drug: Ublituximab + TGR-1202|Drug: Ublituximab + TGR-1202 + ibrutinib|Drug: Ublituximab + TGR-1202 + bendamustine,Maximum Tolerated Dose acceptable for participants|Overall Response Rate,"TG Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,160.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UTX-TGR-103,2013-12-13,October 2019,2019-10-01,"December 10, 2013",,"November 5, 2019","TG Therapeutics Investigational Trial Site, Huntsville, Alabama, United States|TG Therapeutics Investigational Trial Site, Jonesboro, Arkansas, United States|TG Therapeutics Investigational Trial Site, Duarte, California, United States|TG Therapeutics Investigational Trial Site, Atlanta, Georgia, United States|TG Therapeutics Investigational Trial Site, Omaha, Nebraska, United States|MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02006485,2118.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
798,799,NCT00504972,Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies,,Completed,No Results Available,Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia,Drug: hLL1,To determine the toxicity profile and maximum tolerated dose (MTD) of hLL1 when administered to patients with recurrent non-Hodgkin's lymphoma and chronic lymphocytic leukemia,Weill Medical College of Cornell University|Gilead Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 1,23.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0608008669,2007-06-01,"April 1, 2011",2015-10-07,"July 20, 2007",,"May 29, 2018","Weill Cornell Medical College, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00504972,3050.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
799,800,NCT01832922,BR in Patients With CLL With Comorbidities and/or Renal Dysfunction,,Completed,No Results Available,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: Bendamustine|Drug: Rituximab,Number of participants with adverse events|tumor response to treatment,Dartmouth-Hitchcock Medical Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,8.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D13067|3P30CA023108-31S4,2013-04-01,"April 27, 2015",2016-11-28,"April 16, 2013",,"March 30, 2018","Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dartmouth-Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, New Hampshire, United States",,https://ClinicalTrials.gov/show/NCT01832922,1337.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
800,801,NCT04185220,Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome,,Completed,Has Results,Adult T-Cell Lymphoma/Leukemia|Sezary Syndrome|Mycosis Fungoides,Drug: Recombinant human Interleukin-15 (rhIL-15)|Biological: Mogamulizumab,Maximum Tolerated Dose (MTD) of Recombinant Human Interleukin 15 (IL-15) (rhIL-15)|Number of Grade 1-4 Treatment Related Adverse Events|Event Free Survival|Progression-free Survival|Number of Participants Overall Response,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",Phase 1,6.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,200011|20-C-0011,2020-02-26,"November 6, 2020",2022-05-18,"December 4, 2019","December 14, 2021","January 4, 2023","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT04185220/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT04185220/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04185220,812.0,Not Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
801,802,NCT00603668,Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL,,Completed,No Results Available,Chronic Lymphocytic Lymphoma,Biological: milatuzumab,"Safety of the anti-CD74 antibody will be evaluated based upon physical examinations, hematology and chemistry laboratory evaluations and toxicity events|Efficacy (to see if the study drug works) in patients with NHL and CLL|Pharmacokinetics (how the drug is processed by the body)|Pharmacodynamics (how the study drug is absorbed by the body)'|Immunogenicity|optimal dose",Gilead Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,19.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IM-T-hLL1-02,2008-08-01,January 2013,2013-02-01,"January 29, 2008",,"August 16, 2021","Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|Georgetown University Hospital Lombardi Cancer Center, Washington, District of Columbia, United States|M. D. Anderson Cancer Center, Orlando, Florida, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00603668,1645.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
802,803,NCT01161511,Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia,,Completed,No Results Available,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Biological: XmAb5574,To determine the dose limiting toxicities,"Xencor, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,27.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XmAb5574-01,2010-09-01,January 2013,2013-01-01,"July 13, 2010",,"April 21, 2014","Medical College of Georgia, Augusta, Georgia, United States|The Ohio State University, Columbus, Ohio, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT01161511,853.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
803,804,NCT00608907,An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib),,Completed,Has Results,Multiple Myeloma|Non-Hodgkin's Lymphoma,"Drug: bortezomib|Drug: bortezomib, rifampicin|Drug: bortezomib, dexamethasone",Area Under the Plasma Concentration-time Curve (AUC) 0-72 Hours,"Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,61.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,26866138-CAN-1006,2007-09-01,March 2010,2010-04-01,"February 6, 2008","July 13, 2011","January 30, 2012","Hematology Institute - Davidoff Center - Rabin Medical Center, Petach Tikva, Israel|Divisione di Ematologia - Ospedale S Eugenio - P. le dell'Umanesimo, Rome, Italy|Medical Academy - Dept of Hematology and Transplantology, Gdansk, Poland|Klinika Nowotworow Ukladu - Chlonnego - Centrum Onkologii - Instytut, Warszawa, Poland|Hematological Oncology, Parow, Cape Town, South Africa|Department of Hematology - University of the Free State, Bloemfontein, South Africa|Department of Medical Oncology - Ward 51 - Pretoria Academic Hospital, Pretoria, South Africa|Plymouth Hospitals NHS Trust - Derriford Hospital, Derriford, Plymouth, United Kingdom|Hematology Department Combined Laboratories - Derriford Hospital, Plymouth, United Kingdom",,https://ClinicalTrials.gov/show/NCT00608907,943.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
804,805,NCT01713582,A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001),,Completed,Has Results,Acute Myeloid Leukemia|Diffuse Large B-cell Lymphoma|Acute Lymphoblastic Leukemia|Multiple Myeloma,Drug: OTX015/Birabresib,Number of Participants With Dose Limiting Toxicities (DLTs)|Number of Participants Who Experienced at Least One Adverse Event (AE)|Number of Participants Who Discontinued Study Therapy Due to AEs|Number of Participants Whose Best Response Was Partial Response (PR) or Complete Response (CR)|Maximum Concentration (Cmax) of MK-8628/OTX015|Time to Maximum Concentration (Tmax) of MK-8628/OTX015|Apparent Terminal Half-Life (t1/2) of MK-8628/OTX015|Area Under the Concentration Time Curve of MK-8628/OTX015 From Time 0 to Infinity (AUC 0-inf)|Apparent Total Body Clearance (CL/F) of MK-8628/OTX015|Volume of Distribution at Steady State (Vz/F) of MK-8628/OTX015,Oncoethix GmbH,All,"18 Years and older   (Adult, Older Adult)",Phase 1,141.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8628-001|OTX015_104|2012-003380-22|MK-8628-001,2012-12-14,"January 20, 2017",2017-01-20,"October 24, 2012","October 1, 2018","January 26, 2021",,"""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT01713582/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT01713582/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT01713582,1498.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
805,806,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,,Completed,Has Results,Myelodysplastic Syndrome|Hodgkin's Lymphoma|Non-Hodgkin's Disease|Acute Leukemia|Multiple Myeloma,Biological: Rituximab|Drug: Cyclosporine|Drug: Allogenic stem cell transplant (ASCT)|Drug: Conditioning Chemotherapy|Drug: TMS|Drug: FLAG|Drug: EPOCH-F|Biological: Alemtuzumab,Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD)|Percentage of Participants With Chronic Graft Versus Host Disease (cGVHD)|Recovery of Naïve Cluster of Differentiation 4 (CD4) T Cells|Recovery of Naïve Cluster of Differentiation 8 (CD8) T Cells|Changes in Cluster of Differentiation 4 (CD4) T Cell Receptor Vbeta Repertoire|Changes in CD8 T Cell Receptor Vbeta Repertoire|Percentage of Participants With Grade III-IV Acute Graft Versus Host Disease (GVHD)|Toxicities|Days to Engraftment of Neutrophils|Days to Engraftment of Platelets|Days to Engraftment of Lymphocytes|Overall Survival|Early Treatment Related Mortality|Percentage of Participants With Late Treatment Related Mortality|Decline in Homeostatic Cytokine Interleukin 7 (IL-7) Post-Transplant|Immune Reconstitution of Normal Killer (NK) Cells|Immune Reconstitution of Cluster of Differentiation 4 (CD4) T Cell Populations|Immune Reconstitution of Cluster of Differentiation 8 (CD8) T Cell Populations,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years to 74 Years   (Adult, Older Adult)",Phase 1|Phase 2,92.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,070195|07-C-0195,2007-10-30,"October 14, 2015",2018-12-31,"August 23, 2007","August 24, 2017","March 5, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT00520130/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT00520130/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT00520130,4080.0,Not Industry Lead,More than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
806,807,NCT00446342,Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies,,Completed,No Results Available,B-lymphoid Malignancies|Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma|Multiple Myeloma,Drug: SNS-032 Injection,To assess the safety and tolerability of SNS-032|To characterize the pharmacokinetic profile of SNS-032|Identify a recommended Phase 2 dose and schedule of administration,Sunesis Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 1,21.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SPO-0009,2007-02-01,December 2008,2009-03-01,"March 12, 2007",,"April 11, 2017","City of Hope, Duarte, California, United States|Stanford Cancer Center, Stanford, California, United States|Winship Cancer Institute at Emory University, Atlanta, Georgia, United States|Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States|Hackensack University Medical Center at the Cancer Center, Hackensack, New Jersey, United States|MD Anderson Cancer Center, University of Texas, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00446342,759.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
807,808,NCT04030195,Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL,,Completed,Has Results,"Non-Hodgkin's Lymphoma, Relapsed|Chronic Lymphoid Leukemia in Relapse|Non-Hodgkin's Lymphoma Refractory|Chronic Lymphocytic Leukemia|Lymphoma, Non-Hodgkin|Leukemia, Lymphocytic, Chronic|B-cell Chronic Lymphocytic Leukemia|B-cell Non Hodgkin Lymphoma|Small Lymphocytic Lymphoma",Genetic: PBCAR20A|Drug: Fludarabine|Drug: Cyclophosphamide,Maximum Tolerated Dose (MTD)|Number of Participants With Dose-Limiting Toxicities|Objective Response Rate|Progression-free Survival (PFS),"Precision BioSciences, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,18.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PBCAR20A-01,2020-03-24,"June 24, 2021",2021-06-24,"July 23, 2019","January 31, 2023","January 31, 2023","City of Hope, Duarte, California, United States|Stanford University, Stanford, California, United States|Columbia University, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|MD Anderson Cancer Center, Houston, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT04030195/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT04030195/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04030195,457.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
808,809,NCT01121133,A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax,,Completed,No Results Available,"Lymphoma, Including Chronic Lymphocytic Leukemia|Solid Tumors",Drug: navitoclax|Drug: Rifampin,To determine the effect of rifampin on the pharmacokinetics of navitoclax.|To determine the safety of navitoclax when administered alone and in combination with rifampin in these patients.,AbbVie,All,"18 Years and older   (Adult, Older Adult)",Phase 1,12.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M10-955,2010-05-01,May 2011,2011-05-01,"May 12, 2010",,"November 21, 2017",,,https://ClinicalTrials.gov/show/NCT01121133,365.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
809,810,NCT02071888,Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors,,Completed,No Results Available,"Non-Hodgkin's Lymphoma (NHL)|Multiple Myeloma|Waldenstrom's Macroglobulinemia (WM)|Other B-cell NHL Subtypes, Including WM|T-cell NHL","Drug: CB-839|Drug: CB-839 and low dose dexamethasone|Drug: CB-839, pomalidomide, and low dose dexamethasone",Safety and tolerability of CB-839: Incidence of adverse events|Pharmacokinetics: Area under the Curve (AUC) of CB-839 concentration in blood|Pharmacodynamics: % inhibition of glutaminase in blood|Clinical activity: Change in tumor size from baseline,"Calithera Biosciences, Inc",All,"18 Years and older   (Adult, Older Adult)",Phase 1,25.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CX-839-002,2014-02-01,April 2016,2016-04-01,"February 26, 2014",,"July 18, 2018","Mayo Clinic, Scottsdale, Arizona, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Winship Cancer Institute of Emory School of Medicine, Atlanta, Georgia, United States|John Theruer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Medical College, New York, New York, United States|University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02071888,790.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
810,811,NCT00546793,Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL,,Completed,No Results Available,"NHL|Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Lymphoma, Follicular|Lymphoma, Intermediate-Grade|Lymphoma, Large-Cell|Lymphoma, Low-Grade|Lymphoma, Mixed-Cell|Lymphoma, Small-Cell|Leukemia, Lymphocytic, Chronic|Leukemia, B-Cell, Chronic|Leukemia, Prolymphocytic|Leukemia, Small Lymphocytic|Lymphoma, Small Lymphocytic|Lymphoma, Lymphoplasmacytoid, CLL|Lymphoplasmacytoid Lymphoma, CLL|CLL|SLL",Biological: veltuzumab,Safety/tolerability,Gilead Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,32.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IM-T-hA20-08,2008-01-01,March 2013,2013-03-01,"October 19, 2007",,"August 16, 2021","Lewis Cancer Center and Research Pavilion, Savannah, Georgia, United States|Cancer Care at Saint Clare's/Saint Clares Hospital Oncology & Hematology Specialists, P.A., Denville, New Jersey, United States|Morristown Memorial Hospital, Morristown, New Jersey, United States|New York Hospital Weill Cornell Medical Center, New York, New York, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00546793,1886.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
811,812,NCT00006340,Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus,,Completed,No Results Available,Leukemia|Lymphoma|Precancerous Condition|Small Intestine Cancer,Drug: arginine butyrate|Drug: ganciclovir,,Boston Medical Center,All,"3 Years and older   (Child, Adult, Older Adult)",Phase 1,,Other,Interventional,Primary Purpose: Treatment,CDR0000064947|BUMC-3756|BUSM-FDR001532|NCI-V00-1609,1994-12-01,July 2000,2000-07-01,"January 27, 2003",,"July 26, 2013","Methodist Cancer Center at Methodist Hospital, Indianapolis, Indiana, United States|Cancer Research Center at Boston Medical Center, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Hopital Necker, Paris, France|Medizinische Hochschule Hannover, Hannover, Germany|Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy",,https://ClinicalTrials.gov/show/NCT00006340,2039.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
812,813,NCT00972686,Dose-Escalation Study of GSK2126458,FTIH,Completed,No Results Available,Solid Tumours,Drug: GSK2126458,"Adverse events (AEs) and changes in laboratory values and vital signs. Pharmacokinetic parameter values for GSK2126458, Change from baseline in protein markers in tumor and/or blood. Blood glucose and insulin levels. Tumor response, RECIST defined|Metabolic profile in plasma at the maximum tolerated dose",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,79.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,112826,2009-08-31,"December 12, 2012",2015-03-31,"September 7, 2009",,"May 9, 2017","GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, New Brunswick, New Jersey, United States|GSK Investigational Site, Chapel Hill, North Carolina, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT00972686,2038.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
814,815,NCT00506922,Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT,,Completed,Has Results,Leukemia|Lymphoma,Drug: Pentostatin|Drug: Tacrolimus|Drug: Methotrexate,Number of Patients Without GVHD at 100 Days,"M.D. Anderson Cancer Center|Astex Pharmaceuticals, Inc.",All,"Child, Adult, Older Adult",Phase 1|Phase 2,150.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ID00-132,2000-09-01,November 2009,2009-11-01,"July 25, 2007","March 28, 2011","April 28, 2015","U.T.M.D. Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00506922,3348.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
815,816,NCT00070421,Study of @neWorld: A Virtual Community for Children With Cancer,,Completed,No Results Available,"Leukemia|Lymphoma|Psychosocial Effects of Cancer and Its Treatment|Unspecified Childhood Solid Tumor, Protocol Specific",Procedure: complementary or alternative medicine procedure|Procedure: management of therapy complications|Procedure: psychosocial assessment and care,,Leap of Faith Technologies|National Cancer Institute (NCI),All,10 Years to 15 Years   (Child),Phase 1|Phase 2,,Industry|NIH,Interventional,NaN,LFT-NEWORLD|CDR0000334398|WCCC-2000-194,2003-04-01,,2005-01-01,"October 7, 2003",,"May 15, 2013","Leap of Faith Technologies, Incorporated, Crystal Lake, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00070421,641.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,N/A
816,817,NCT00423410,"A Safety Study of EPC2407, A Anti-Cancer Drug With Vascular Disrupting Activity: In Patients With Advanced Cancer",,Completed,No Results Available,Advanced Cancer,Drug: EPC2407 (crinobulin),Safety,EpiCept Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EPC2006-04,2006-12-01,April 2009,2009-09-01,"January 18, 2007",,"September 10, 2009","Scottsdale Healthcare, Scottsdale, Arizona, United States|Tower Oncology Research, Beverly Hills, California, United States|Rebecca and John Moores UCSD Cancer Center, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00423410,1005.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
817,818,NCT00871663,Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6),,Completed,No Results Available,"Solid Tumors|Lymphoma, Non-Hodgkin|Multiple Myeloma|Leukemia, Lymphocytic, Chronic. B-Cell",Drug: SCH 727965,"Safety and tolerability of SCH 727965, including maximum administered dose and dose-limiting toxicity.|In participants with advanced solid tumors, non Hodgkin's lymphoma or multiple myeloma, pharmacodynamic effects of SCH 727965 with an ex vivo lymphocyte stimulation assay of participant's peripheral blood lymphocytes.",Merck Sharp & Dohme LLC,All,"18 Years and older   (Adult, Older Adult)",Phase 1,123.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P04629,2006-08-01,October 2012,2012-10-01,"March 30, 2009",,"April 20, 2015",,,https://ClinicalTrials.gov/show/NCT00871663,2253.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
818,819,NCT01149668,A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer,,Completed,No Results Available,Lymphoma|Non-Hodgkin's Lymphoma|Hodgkin Disease|Multiple Myeloma|Leukemia|Lymphocytic,Drug: PCI-24781,Safety|Tumor Response,Pharmacyclics LLC.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,7.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PCYC-0405-CA|PCI-24781,2010-06-01,December 2012,2013-04-01,"June 23, 2010",,"June 19, 2013","Northwestern Univ. Med School, Chicago, Illinois, United States|Horizon Oncology Center, Lafayette, Indiana, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Univ. of Nebraska Medical Center, Omaha, Nebraska, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT01149668,1035.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
819,820,NCT02689453,Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL),,Completed,Has Results,T-Cell Lymphoma Relapsed|Adult T-Cell Leukemia (ATL)|Peripheral T-Cell Lymphoma (PTCL)|Cutaneous T Cell Lymphoma (CTCL)|T-Cell Prolymphocytic Leukemia,Biological: IL-15 plus|Biological: alemtuzumab,"Maximum Tolerated Dose (MTD) of Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15)|Number of Dose-limiting Toxicities (DLTs) of Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) Administered With 3 Times Per Week Intravenous (IV) Alemtuzumab|Number of Participants With Serious Adverse Events Possibly, Probably, and/or Definitely Related to Subcutaneous (s.c. rhIL-15) by Grade Who Have Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)Cancer|Number of Participants With a Clinical Response|Progression Free Survival (PFS)|Percentages of Circulating Lymphocytes (T and NK Cells) and the T-cell Subsets|Plasma Levels of Pro-inflammatory Cytokines",National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",Phase 1,11.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,160062|16-C-0062,2017-01-19,"June 15, 2021",2021-06-15,"February 24, 2016","April 29, 2022","April 29, 2022","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT02689453/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT02689453/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02689453,1608.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
820,821,NCT01399840,"Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies",,Completed,No Results Available,Acute Myeloid Leukemia|Myelodysplastic Syndrome|Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma,Drug: BMN 673,The primary outcome of this study is to determine the MTD of daily oral BMN 673 in patients with AML and MDS (Arm 1) and patients with CLL and MCL (Arm 2).|Number of participants with adverse events|Determine the pharmacokinetic (PK) profile of BMN 673|Determine the Recommended Phase 2 Dose (RP2D) of oral daily BMN 673|Assess preliminary efficacy of BMN 673 by evaluating per response publications,"Pfizer|Medivation, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,33.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRP-002|2010-023964-42|C3441022,2011-06-30,"March 31, 2014",2014-05-31,"July 22, 2011",,"September 15, 2017","Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States|University College London, London, United Kingdom|King's College Hospital, London, United Kingdom|The Christie NHS Foundation, Manchester, United Kingdom|University of Newcastle Upon Tyne, NHS Foundation Trust, Newcastle upon Tyne, United Kingdom",,https://ClinicalTrials.gov/show/NCT01399840,1066.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
821,822,NCT01105247,Safety of PCI-32765 in Chronic Lymphocytic Leukemia,,Completed,Has Results,B-cell Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: PCI-32765,Number of Participants With Treatment Emergent Adverse Events (AEs)|Food Effect Cohort Assessments|Progression Free Survival Rate at 24 Months|Percentage of Participants Achieving Response,Pharmacyclics LLC.,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,133.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PCYC-1102-CA|PCI-32765,2010-05-01,December 2012,2013-02-01,"April 16, 2010","March 31, 2014","March 31, 2014","Stanford University School of Medicine, Stanford, California, United States|New York Presbyterian Hosptial Cornell Med Center, New York, New York, United States|The Ohio State University, Columbus, Ohio, United States|Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States|Sarah Cannon, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Texas Oncology - Tyler, Tyler, Texas, United States|University of Vermont and Fletcher Allen Health Care, Burlington, Vermont, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States|Yakima Valley Memorial, Yakima, Washington, United States",,https://ClinicalTrials.gov/show/NCT01105247,1007.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
822,823,NCT00585195,"A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer",PROFILE 1001,Completed,Has Results,Non-Small Cell Lung Cancer ALK-positive|Non-Small Cell Lung Cancer c-Met Dependent|Non-Small Cell Lung Cancer ROS Marker Positive|Systemic Anaplastic Large-Cell Lymphoma|Advanced Malignancies Except Leukemia,Drug: PF-02341066|Drug: Rifampin|Drug: Itraconazole,"Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib|Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib|Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7|Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7|Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 1|Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15|Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1|Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib Cycle 1 Day 15|Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib on Cycle 2 Day 1|Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7|Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 1|Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15|Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1|Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7|Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 1|Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15|Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1|Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7|Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)|Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT)|Midazolam Interaction Cohort: Maximum Observed Plasma Concentration (Cmax) of Midazolam When Taken Alone or Taken With Crizotinib|Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Midazolam When Taken Alone or Taken With Crizotinib|RP2D Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-24)] of Crizotinib When Taken With Food|RP2D Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib When Taken With Food|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib Alone and When Taken With Rifampin|Rifampin Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib Alone and When Taken With Rifampin|Rifampin Cohort: Ctrough of Crizotinib Alone and When Taken With Rifampin|Itraconazole Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib When Taken Alone and When Taken With Itraconazole|Itraconazole Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib When Taken Alone and When Taken With Itraconazole|Itraconazole Cohort: Trough Plasma Concentration (Ctrough) of Crizotinib When Taken Alone and When Taken With Itraconazole|Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Objective Response (OR)|Recommended Phase 2 Dose (RP2D) Cohort: Duration of Response (DOR)|Recommended Phase 2 Dose (RP2D) Cohort: Time to Response (TTR)|Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 8|Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 16|Recommended Phase 2 Dose (RP2D) Cohort: Progression Free Survival (PFS)|Recommended Phase 2 Dose (RP2D) Cohort: Probability of Being Event Free at Month 6|Recommended Phase 2 Dose (RP2D) Cohort: Overall Survival (OS)|Probability of Participant Survival at Month 6|Probability of Participant Survival at Month 12|Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 1 Day 15|Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 2 Day 1|Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 4 Day 1|Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 6 Day 1|Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 9 Day 1|Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 12 Day 1|Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 15 Day 1|Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 18 Day 1|Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 21 Day 1|Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 24 Day 1|Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 27 Day 1|Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 30 Day 1|Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at End of Treatment",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,596.0,Industry,Interventional,Allocation: N/A|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A8081001|PROFILE 1001,2006-04-19,"July 30, 2020",2022-01-19,"January 3, 2008","October 14, 2021","February 8, 2023","University of California, Irvine Medical Center, Orange, California, United States|University of Colorado Hospital/ Anschutz Cancer Pavilion, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|University of Colorado, Aurora, Colorado, United States|University of Chicago, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Ophthalmic Consultants of Boston Inc., Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Center, Boston, Massachusetts, United States|Joslin Beetham Eye Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Kresge Eye Institute, Detroit, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center: Breast and Imaging Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|UNC Hospitals, Chapel Hill, North Carolina, United States|The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States|Ohio State Eye and Ear Institute, Columbus, Ohio, United States|The Ohio State University Martha Morehouse Medical Plaza, Columbus, Ohio, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States|Vanderbilt Eye Institute, Nashville, Tennessee, United States|The University of Vermont Medical Center, Burlington, Vermont, United States|The University of Vermont Cancer Center, Burlington, Vermont, United States|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Aichi cancer center central hospital, Nagoya, Aichi, Japan|Hyogo Cancer Center, Akashi, Hyogo, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Seoul National University Hospital, Seoul, Korea, Republic of","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT00585195/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT00585195/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT00585195,5754.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
823,824,NCT00880815,"Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant",,Completed,No Results Available,CD20 Positive|Chronic Lymphocytic Leukemia|Follicular Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|T-Cell Non-Hodgkin Lymphoma,Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Biological: Anti-Thymocyte Globulin|Drug: Bendamustine|Biological: Filgrastim|Drug: Fludarabine|Drug: Methotrexate|Biological: Rituximab|Drug: Tacrolimus,Maximum tolerated dose of bendamustine,M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,60.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2008-0246|NCI-2018-01844|P30CA016672,2009-02-17,"May 28, 2019",2019-05-28,"April 14, 2009",,"June 3, 2019","M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00880815,3752.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
824,825,NCT00923520,"A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies",,Completed,No Results Available,Renal Cell Carcinoma|Breast Cancer|Colon Cancer|Lung Cancer|Non-Hodgkin Lymphoma,Drug: DMS 612,Determine the Maximum Tolerated Dose|Evaluate non-dose limiting toxicity|PK|Anti-tumor Effects,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1,60.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,090111|09-C-0111,2009-03-25,"May 12, 2016",2018-12-03,"June 18, 2009",,"December 5, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00923520,3540.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
825,826,NCT02543879,Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies,,Completed,No Results Available,Acute Myeloid Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Non-Hodgkin Lymphoma,Drug: FT-1101|Drug: Azacitidine,Maximum Tolerated Dose (MTD)|Dose Limiting Toxicities (DLT)|Recommended Phase 2 Dose (RP2D)|Area under the plasma concentration versus time curve (AUC)|Peak Plasma Concentration (Cmax)|Time of peak plasma concentration (TMax)|Time for half of the drug to be absent in blood stream following dose (T 1/2)|Rate at which drug is removed from blood stream (CL/F)|Rate of drug distribution within the blood stream (Vd/F)|Observe patients for any evidence of anti-leukemic or anti-myelodysplastic activity of FT-1101,"Forma Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,94.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1101-HEM-101,2015-09-01,March 2019,2019-03-01,"September 7, 2015",,"June 26, 2019","Cedars Sinai, Los Angeles, California, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02543879,1277.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
826,827,NCT01164709,Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer,,Completed,No Results Available,Leukemia|Lymphoma|Mature T-cell and Nk-cell Neoplasms|Multiple Myeloma and Plasma Cell Neoplasm,Drug: bortezomib|Drug: nelfinavir mesylate,Dose limiting toxicity|Objective response|Adverse events according to NCI CTCAE v.4.0,Swiss Group for Clinical Cancer Research,All,"18 Years and older   (Adult, Older Adult)",Phase 1,18.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SAKK 65/08|SWS-SAKK-65/08|EU-21051|SWS-SAKK-JC26866138LYM1005|CDR0000681442,2010-07-01,July 2012,2013-11-01,"July 19, 2010",,"May 15, 2019","Inselspital Bern, Bern, Switzerland|Kantonsspital Graubuenden, Chur, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kantonsspital - St. Gallen, St. Gallen, Switzerland",,https://ClinicalTrials.gov/show/NCT01164709,1219.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
828,829,NCT01775631,Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma,,Completed,No Results Available,B-Cell Malignancies,Biological: Urelumab|Biological: Rituximab,"Safety and tolerability of Urelumab in combination with Rituximab as measured by incidence of adverse events (AEs), serious AEs, death, vital sign changes, electrocardiograms (ECGs), physical examination results, and laboratory test abnormalities|Efficacy-Antitumor Activity of Urelumab in combination with Rituximab as measured by best overall response, progression-free survival, time to response, and duration of response|Maximum observed serum concentration (Cmax) of Urelumab and Rituximab|Time of maximum observed serum concentration (Tmax) of Urelumab|Area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of Urelumab|Trough observed serum concentration (Cmin) of Urelumab and Rituximab|Area under the concentration-time curve (AUC) in one dosing interval (AUC(TAU)) of Urelumab|Immunogenicity of Urelumab in combination with Rituximab as determined by blood sample measurements of anti-drug antibodies (ADA)",Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 1,47.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA186-017,2013-03-01,August 2016,2016-08-01,"January 25, 2013",,"March 31, 2017","Ucla Department Of Medicine, Los Angeles, California, United States|Stanford University Medical Center, Stanford, California, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Dana Faber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Providence Cancer Center Oncology And Hematology Care- Eastside, Portland, Oregon, United States|Hospital Of The University Of Pennsylvania, Philadelphia, Pennsylvania, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|University Of Virginia School Of Medicine, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01775631,1249.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
829,830,NCT02132624,CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.,,Completed,No Results Available,B Cell Lymphoma|B Cell Leukemia,Biological: Autologous 3rd generation CD19-targeting CAR T cells,CAR T cell persistence|Tumor load,Uppsala University|Uppsala University Hospital|Karolinska University Hospital|AFA Insurance|Swedish Cancer Society,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,15.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,003:TCELL|2013-001393-19,2014-04-01,"May 31, 2017",2017-05-31,"May 7, 2014",,"October 30, 2017","Uppsala University Hospital, Dept of Oncology, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT02132624,1156.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
830,831,NCT00660166,Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions,,Completed,No Results Available,Lymphoma|Myeloma|Leukemia,Biological: NK-Cell Infusion,"An evaluation of general safety will be undertaken: · Number of systemic clinical and biological adverse events occurring during the study. · Number of patients who prematurely discontinued study treatment for reasons linked to the general safety.|Duration of donor NK cells in the recipient's blood|Patient survival at 100 days and at one year post treatment (all cause mortality)|Occurrence of new cancer during the first year post infusion of allogeneic NK-cells|Documented systemic infections during the first 30 days post infusion of allogeneic NK-cells.|Occurrence of other possible NK-infusions related complications such as,fever, capillary leak syndrome and/or allergic reaction.",Tufts Medical Center|University of Minnesota,All,"13 Years to 70 Years   (Child, Adult, Older Adult)",Phase 1,13.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Allogeneic NKCell post ABMT,2006-04-01,June 2012,2012-06-01,"April 17, 2008",,"June 27, 2012","Tufts Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00660166,2253.0,Not Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
831,832,NCT01342289,"Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide",,Completed,No Results Available,Hodgkin's Lymphoma|Leukemia|Myelodysplastic Syndrome(MDS)|Multiple Myeloma|Non Hodgkin's Lymphoma,Drug: Cyclophosphamide|Drug: Fludarabine|Radiation: Total body irradiation|Drug: Mycophenolate Mofetil|Drug: Tacrolimus 60|Drug: Tacrolimus 90|Drug: Tacrolimus 120|Biological: Bone marrow transplant,Safety of reduced-dose tacrolimus as assessed by Percentage of Participants with severe graft versus host disease (GVHD)|Tolerability of tacrolimus as assessed by percentage of participants with treatment-emergent adverse events|Percentage of participants experiencing acute GVHD|Percentage of participants experiencing chronic GVHD|Disease relapse|Non-relapse mortality|Use of immunosuppression|Survival|Chimerism|Engraftment,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,All,"6 Months to 75 Years   (Child, Adult, Older Adult)",Phase 1,127.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,J1151|NA_00048378,2011-08-01,March 2018,2018-03-01,"April 27, 2011",,"October 17, 2018","Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT01342289/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01342289,2404.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
832,833,NCT01602289,A Study of LY2875358 in Japanese Participants With Advanced Cancer,,Completed,No Results Available,"Solid Tumors|Lymphoma|Carcinoma, Non-Small-Cell Lung",Biological: LY2875358|Drug: Erlotinib|Drug: Gefitinib,"Number of participants with one or more drug (or procedure)-related adverse events (AEs) or any serious AEs|Pharmacokinetics (PK): Maximum concentration (Cmax) of LY2875358, erlotinib and gefitinib|Pharmacokinetics (PK): Area under the concentration time curve (AUC) of LY2875358, erlotinib and gefitinib|Number of participants with a tumor response",Eli Lilly and Company,All,"20 Years and older   (Adult, Older Adult)",Phase 1,17.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14637|I4C-JE-JTBD,2012-06-01,August 2014,2014-08-01,"May 18, 2012",,"June 8, 2015","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan",,https://ClinicalTrials.gov/show/NCT01602289,791.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
833,834,NCT00299780,Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization.,,Completed,No Results Available,Lymphoma|Multiple Myeloma|Acute Myelogenous Leukemia,Drug: Stem cell mobilization,"To assess safety of parathyroid hormone in combination with G-CSF when used as a mobilization agent at four different dosing levels.|To evaluate the peripheral blood CD34+ count after second mobilization.|To evaluate CD34+ cells/kg from apheresis after second mobilization.|To evaluate the percent of patients for whom adequate numbers of CD34+ cells are obtained.|To evaluate transfusion support.|To evaluate the days to neutrophil engraftment (ANC >500) post autologous transplant.|To evaluate the days to platelet engraftment (platelet count > 20,000 unsupported).",Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,12.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,04-109,2004-07-01,,2007-04-01,"March 7, 2006",,"April 24, 2007","Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00299780,1004.0,Not Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
834,835,NCT00215605,Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies,,Completed,No Results Available,Lymphoma|Cancer|Thyroid Carcinoma,Drug: XL184,"Safety, tolerability, maximum tolerated dose (MTD), and dose-limiting toxicity of oral administration of XL184|Evaluate plasma pharmacokinetics and estimate renal elimination of oral administration of XL184|Long-term safety/tolerability of XL184 after oral administration for up to 1 year|Evaluate preliminary tumor response after repeated XL184 administration|In MTD expanded cohort: Progression-free survival and duration of response in subjects with advanced or recurrent medullary thyroid cancer",Exelixis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,85.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XL184-001,2005-09-01,April 2011,2012-07-01,"September 22, 2005",,"February 27, 2013","University of Chicago, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Univ. of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00215605,2495.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
835,836,NCT03076437,Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies,,Completed,No Results Available,Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Lymphoma,Combination Product: Drugs and Anti-CD19-CAR transduced T cells,Number of participants with Adverse Events|Number of participants with Clinical responses,Shenzhen Institute for Innovation and Translational Medicine|Dongguan People's Hospital,All,"1 Year to 80 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,28.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SIITM20160115,2016-01-15,"May 26, 2019",2019-12-31,"March 10, 2017",,"March 19, 2021","Department of Hematology, Dongguan People's Hospital, Dongguan, Guangdong, China",,https://ClinicalTrials.gov/show/NCT03076437,1446.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
836,837,NCT00104923,Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer,,Completed,No Results Available,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm,Drug: fenretinide,To determine the maximum tolerated dose of fenretinide|To describe the toxicities of fenretinide,California Cancer Consortium|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1,29.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000413887|P30CA033572|CCC-PHI-42|NCI-6528|LAC-USC-0C-04-3|NCI-06-C-0227|NCI-P6820,2005-02-01,April 2017,2017-04-01,"March 4, 2005",,"July 19, 2017","USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States",,https://ClinicalTrials.gov/show/NCT00104923,4442.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
837,838,NCT01205737,"A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects",,Completed,No Results Available,DLBCL,Biological: TL011|Biological: Rituximab,AUC during a dosing interval for Rituximab|PK and PD parameters,"Teva Branded Pharmaceutical Products R&D, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,186.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NHL-TL011-102,2010-09-01,July 2013,2013-09-01,"September 20, 2010",,"October 22, 2013","Teva Investigational Site 59005, Pleven, Bulgaria|Teva Investigational Site 59003, Plovdiv, Bulgaria|Teva Investigational Site 59001, Sofia, Bulgaria|Teva Investigational Site 59002, Sofia, Bulgaria|Teva Investigational Site 59004, Varna, Bulgaria|Teva Investigational Site 55001, Tallinn, Estonia|Teva Investigational Site 55002, Tartu, Estonia|Teva Investigational Site 35066, Paris Cedex 13, France|Teva Investigational Site 51026, Debrecen, Hungary|Teva Investigational Site 30001, Firenze, Italy|Teva Investigational Site 30002, Napoli, Italy|Teva Investigational Site 56002, Daugavpils, Latvia|Teva Investigational Site 56001, Riga, Latvia|Teva Investigational Site 56003, Riga, Latvia|Teva Investigational Site 53010, Warsaw, Poland|Teva Investigational Site 50011, Arkhangelsk, Russian Federation|Teva Investigational Site 50001, Chelyabinsk, Russian Federation|Teva Investigational Site 50004, Ekaterinburg, Russian Federation|Teva Investigational Site 50006, Kazan, Russian Federation|Teva Investigational Site 50014, Kursk, Russian Federation|Teva Investigational Site 50005, Moscow, Russian Federation|Teva Investigational Site 50009, Moscow, Russian Federation|Teva Investigational Site 50010, Moscow, Russian Federation|Teva Investigational Site 50003, Novosibirsk, Russian Federation|Teva Investigational Site 50017, Pyatigorsk, Russian Federation|Teva Investigational Site 50012, St. Petersburg, Russian Federation|Teva Investigational Site 50015, Tomsk, Russian Federation|Teva Investigational Site 31005, Elche-Alicante, Spain|Teva Investigational Site 31006, Las Palmas de Gran Canaria, Spain|Teva Investigational Site 31002, Madrid, Spain|Teva Investigational Site 31001, Majadahonda-Madrid, Spain|Teva Investigational Site 31003, Valencia, Spain|Teva Investigational Site 31004, Valencia, Spain|Teva Investigational Site 58011, Cherkasy, Ukraine|Teva Investigational Site 58013, Dnipropetrovsk, Ukraine|Teva Investigational Site 58014, Donetsk, Ukraine|Teva Investigational Site 58017, Khmelnytskyi, Ukraine|Teva Investigational Site 58010, Kyiv, Ukraine|Teva Investigational Site 58012, Kyiv, Ukraine|Teva Investigational Site 58015, Kyiv, Ukraine|Teva Investigational Site 58016, Simferopol, Ukraine",,https://ClinicalTrials.gov/show/NCT01205737,1096.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,Not Open Label,Treatment/Diagnostic
839,840,NCT01695005,A Study of LY3039478 in Participants With Advanced Cancer,,Completed,No Results Available,Neoplasms|Neoplasm Metastasis|Lymphoma,Drug: LY3039478|Drug: Prednisone,"Part A and F: Number of Participants with Dose Limiting Toxicities (DLTs)|Part B, C, D, E and F: Number of Participants with Tumor Response|Pharmacokinetics: Maximum Concentration (Cmax) of LY3039478|Pharmacokinetics: Time to Maximum Concentration (Tmax) of LY3039478|Part A: Number of Participants with Tumor Response|Part B, C, D, E and F: Duration of Response (DoR)|Part B, C, D, E and F: Progression Free Survival (PFS)|Part B, C, D, E and F: Overall Survival (OS)",Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 1,237.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14547|I6F-MC-JJCA,2012-10-01,"June 26, 2018",2018-06-26,"September 27, 2012",,"August 7, 2018","University of Miami School of Medicine, Miami, Florida, United States|Harvard Medical School, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Montefiore Medical Center, Bronx, New York, United States|Columbia University Medical Center, New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kobenhavn, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Villejuif, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tübingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01695005,2094.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
840,841,NCT00150462,Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies,,Completed,Has Results,Waldenstrom's Macroglobulinemia|Non-Hodgkin's Lymphoma|Hodgkin's Disease|Multiple Myeloma,Drug: Carfilzomib|Drug: Dexamethasone,Number of Participants With Dose-limiting Toxicities (DLTs)|Maximum Observed Plasma Concentration of Carfilzomib (Cmax)|Time to Maximum Observed Plasma Concentration of Carfilzomib (Tmax)|Area Under the Concentration-time Curve to Last Measureable Timepoint (AUClast) for Carfilzomib|Area Under the Concentration-time Curve Extrapolated to Infinity (AUCinf) for Carfilzomib|Best Clinical Response to Treatment|Duration of Response|Time to Progression|Progression-free Survival,Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 1,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PX-171-002,2005-09-01,October 2009,2009-10-01,"September 8, 2005","December 3, 2015","May 2, 2017","Tower Cancer Research Foundation, Beverly Hills, California, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weil Medical College of Cornell University, New York, New York, United States|Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00150462,1491.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
841,842,NCT00070616,Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support,,Completed,No Results Available,Leukemia|Lymphoma|Myeloma,Drug: Palifermin 6 x 60 μg/kg/day|Drug: Palifermin 2 x 180 μg/kg/day|Radiation: radiotherapy|Drug: Chemotherapy,To characterize the PK profile of 3 daily intravenous (IV) doses of rHuKGF before total body irradiation (TBI) / high-dose chemotherapy conditioning treatment and after PBPC transplantation|To assess the safety and tolerability of rHuKGF in subjects with hematologic malignancies undergoing TBI and high-dose chemotherapy followed by PBPC transplantation.|To assess oral mucositis in subjects receiving rHuKGF.,Swedish Orphan Biovitrum|Amgen,All,"18 Years to 76 Years   (Adult, Older Adult)",Phase 1,25.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20010182,2001-12-01,March 2005,2005-03-01,"October 8, 2003",,"October 24, 2014",,,https://ClinicalTrials.gov/show/NCT00070616,1186.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
842,843,NCT00060645,"Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)",,Completed,No Results Available,Tumors|Lymphoma|Multiple Myeloma,Drug: ridaforolimus,"To determine safety, tolerability, and maximum tolerated dose of AP23573 when administered once daily for 5 days on a every 2 week schedule",Merck Sharp & Dohme LLC|Ariad Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 1,33.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8669-013|AP23573-02-102,2003-05-01,May 2006,2009-02-01,"May 12, 2003",,"August 27, 2015","Cancer Therapy and Research Center, University of Texas Health Center at San Antonio, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00060645,2103.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
843,844,NCT00060632,"Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)",,Completed,No Results Available,Tumors|Lymphoma|Multiple Myeloma,Drug: ridaforolimus,Maximum Tolerated Dose (MTD)|Number of Participants Reporting Adverse Events (AE)|Number of Participants Discontinuing Due to AEs|Best Overall Tumor Response|Maximum Concentration (Cmax) of Ridaforolimus|Area Under the Curve (AUC[0 to Infinity]) of Ridaforolimus|Apparent Terminal Half-Life (t1/2) of Ridaforolimus|Clearance (CL) of Ridaforolimus|Volume of Distribution at Steady State (Vss) of Ridaforolimus|Phosphorylated 4E Binding Protein 1 (Phospho-4E-BP1) Blood Levels,Merck Sharp & Dohme LLC|Ariad Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 1,46.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8669-001|AP23573-02-101,2003-04-01,October 2005,2005-10-01,"May 12, 2003",,"August 27, 2015",,,https://ClinicalTrials.gov/show/NCT00060632,914.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
844,845,NCT01953692,A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013),,Completed,Has Results,Myelodysplastic Syndrome|Multiple Myeloma|Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Primary Mediastinal B-Cell Lymphoma,Biological: Pembrolizumab|Drug: Lenalidomide 20 mg|Drug: Lenalidomide 25 mg,"Number of Participants Who Experienced One or More Adverse Events (AEs):|Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)|Objective Response Rate (ORR) in Cohort 1: Myelodysplastic Syndrome (MDS)|Objective Response Rate (ORR) in Cohort 2: Relapsed Refractory/Refractory (rR/R) Multiple Myeloma (MM)|Complete Remission Rate (CRR) in Cohort 3: Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)|Objective Response Rate (ORR) in Participants Pooled From the Cohort 4 Non-Hodgkin Lymphoma (NHL) Sub-Cohorts (Cohorts 4A+4B+4C+4D)|Objective Response Rate (ORR) in the Cohort 4 Non-Hodgkin Lymphoma (NHL) Individual Sub-Cohorts (Cohorts 4A, 4B, 4C, and 4D)|Objective Response Rate (ORR) in Participants Pooled From Cohort 5 (Pembrolizumab + 20 or 25 mg Doses of Lenalidomide) Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)|Objective Response Rate (ORR) in Cohort 3: Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)|Overall Survival (OS)|Overall Survival (OS) in Participants Pooled From the Cohort 4 Non-Hodgkin Lymphoma (NHL) Sub-Cohorts (Cohorts 4A+4B+4C+4D)|Overall Survival (OS) in Participants Pooled From Cohort 5 (Pembrolizumab + 20 or 25 mg Doses of Lenalidomide) Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)|Duration of Response (DOR) in Cohort 1: Myelodysplastic Syndrome (MDS)|Duration of Response (DOR) in Cohort 2: Relapsed Refractory/Refractory (rR/R) Multiple Myeloma (MM)|Duration of Response (DOR) in Cohort 3: Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)|Duration of Response (DOR) in Participants Pooled From the Cohort 4 Non-Hodgkin Lymphoma (NHL) Sub-Cohorts (Cohorts 4A+4B+4C+4D)|Duration of Response (DOR) in the Cohort 4 Non-Hodgkin Lymphoma (NHL) Individual Sub-Cohorts (Cohorts 4A, 4B, 4C, and 4D)|Duration of Response (DOR) in Participants Pooled From Cohort 5 (Pembrolizumab + 20 or 25 mg Doses of Lenalidomide) Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)|Objective Response Rate (ORR) in Programmed Cell Death Ligand 1 (PD-L1) Positive Participants in Cohort 1: Myelodysplastic Syndrome (MDS)|Objective Response Rate (ORR) in Programmed Cell Death Ligand 1 (PD-L1) Negative Participants in Cohort 1: Myelodysplastic Syndrome (MDS)|Objective Response Rate (ORR) in Programmed Cell Death Ligand 1 (PD-L1) Indeterminate Participants in Cohort 1: Myelodysplastic Syndrome (MDS)|Objective Response Rate (ORR) in Programmed Cell Death Ligand 1 (PD-L1) Positive Participants in Cohort 2: Relapsed Refractory/Refractory (rR/R) Multiple Myeloma (MM)|Objective Response Rate (ORR) in Programmed Cell Death Ligand 1 (PD-L1) Negative Participants in Cohort 2: Relapsed Refractory/Refractory (rR/R) Multiple Myeloma (MM)|Objective Response Rate (ORR) in Programmed Cell Death Ligand 1 (PD-L1) Indeterminate Participants in Cohort 2: Relapsed Refractory/Refractory (rR/R) Multiple Myeloma (MM)|Objective Response Rate (ORR) in Programmed Cell Death Ligand 1 (PD-L1) Positive Participants in Cohort 3: Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)|Objective Response Rate (ORR) in Programmed Cell Death Ligand 1 (PD-L1) Negative Participants in Cohort 3: Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)|Objective Response Rate (ORR) in Programmed Cell Death Ligand 1 (PD-L1) Indeterminate Participants in Cohort 3: Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)|Objective Response Rate (ORR) in Programmed Cell Death Ligand 1 (PD-L1) Positive Participants Pooled From the Cohort 4 Non-Hodgkin Lymphoma (NHL) Sub-Cohorts (Cohorts 4A+4B+4C+4D)|Objective Response Rate (ORR) in Programmed Cell Death Ligand 1 (PD-L1) Negative Participants Pooled From the Cohort 4 Non-Hodgkin Lymphoma (NHL) Sub-Cohorts (Cohorts 4A+4B+4C+4D)|Objective Response Rate (ORR) in Programmed Cell Death Ligand 1 (PD-L1) Indeterminate Participants Pooled From the Cohort 4 Non-Hodgkin Lymphoma (NHL) Sub-Cohorts (Cohorts 4A+4B+4C+4D)|Objective Response Rate (ORR) in Programmed Cell Death Ligand 1 (PD-L1) Positive Participants in the Cohort 4 Non-Hodgkin Lymphoma (NHL) Individual Sub-Cohorts (Cohorts 4A, 4B, 4C, and 4D)|Objective Response Rate (ORR) in Programmed Cell Death Ligand 1 (PD-L1) Negative Participants in the Cohort 4 Non-Hodgkin Lymphoma (NHL) Individual Sub-Cohorts (Cohorts 4A, 4B, 4C, and 4D)|Objective Response Rate (ORR) in Programmed Cell Death Ligand 1 (PD-L1) Indeterminate Participants in the Cohort 4 Non-Hodgkin Lymphoma (NHL) Individual Sub-Cohorts (Cohorts 4A, 4B, 4C, and 4D)|Objective Response Rate (ORR) in Programmed Cell Death Ligand 1 (PD-L1) Positive Participants Pooled From Cohort 5 (Pembrolizumab + 20 or 25 mg Doses of Lenalidomide): Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)|Objective Response Rate (ORR) in Programmed Cell Death Ligand 1 (PD-L1) Negative Participants Pooled From Cohort 5 (Pembrolizumab + 20 or 25 mg Doses of Lenalidomide): Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)|Objective Response Rate (ORR) in Programmed Cell Death Ligand 1 (PD-L1) Indeterminate Participants Pooled From Cohort 5 (Pembrolizumab + 20 or 25 mg Doses of Lenalidomide): Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)|Progression-free Survival (PFS) in Cohort 2: Relapsed Refractory/Refractory (rR/R) Multiple Myeloma (MM)|Progression-free Survival (PFS) in Cohort 3: Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)|Progression-free Survival (PFS) in Participants Pooled From the Cohort 4 Non-Hodgkin Lymphoma (NHL) Sub-Cohorts (Cohorts 4A+4B+4C+4D)|Progression-free Survival (PFS) in the Cohort 4 Non-Hodgkin Lymphoma (NHL) Individual Sub-Cohorts (Cohorts 4A, 4B, 4C, and 4D)|Progression-free Survival (PFS) in Participants Pooled From the Cohort 5 (Pembrolizumab + 20 or 25 mg Doses of Lenalidomide) Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)|Marrow Complete Response (mCR) in Cohort 1: Myelodysplastic Syndrome (MDS)|Cytogenic Complete Response in Cohort 1: Myelodysplastic Syndrome (MDS)|Cytogenic Partial Response in Cohort 1: Myelodysplastic Syndrome (MDS)|Erythroid Response in Cohort 1: Myelodysplastic Syndrome (MDS)|Neutrophil Response in Cohort 1: Myelodysplastic Syndrome (MDS)|Platelet Response in Cohort 1: Myelodysplastic Syndrome (MDS)|Time to Progression (TTP) in Cohort 2: Relapsed Refractory/Refractory (rR/R) Multiple Myeloma (MM)|Stringent Complete Remission (sCR) in Cohort 2: Relapsed Refractory/Refractory (rR/R) Multiple Myeloma (MM)|Complete Response (CR) in Cohort 2: Relapsed Refractory/Refractory (rR/R) Multiple Myeloma (MM)",Merck Sharp & Dohme LLC,All,"18 Years and older   (Adult, Older Adult)",Phase 1,197.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3475-013|2013-001603-37|MK-3475-013,2013-11-22,"June 26, 2020",2020-06-26,"October 1, 2013","July 12, 2021","August 4, 2021",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT01953692/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01953692,2408.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
845,846,NCT00871702,Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease,,Completed,No Results Available,"Leukemia|Lymphoma, Non-Hodgkin|Hodgkin Disease|Myelodysplastic Syndromes|Multiple Myeloma",Genetic: CD34-TK75 transduced donor lymphocytes|Radiation: Sub Study - 18 FHBG PET/CT Scans,"To determine if there is significant toxicity associated with the administration of CD34-TK75 transduced donor lymphocytes after allogeneic BMT for relapsed hematologic malignancies|Perform PET imaging to allow us to locate the donor T cells within the recipient as they exert anti-leukemic effects, and the T cells can then be eliminated in response to administration of ganciclovir, before morbidity and mortality from GvHD occurs|To determine if the patient develops any evidence of anti-leukemic effect from the administration of CD34-TK75 transduced donor lymphocytes|To determine if GCV administration to patients who develop GvHD results in clinical improvement after infusions of CD34-TK75 transduced lymphocytes.",Washington University School of Medicine,All,"18 Years and older   (Adult, Older Adult)",Phase 1,12.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,09-0744 / 201103095,2010-10-01,November 2012,2012-11-01,"March 30, 2009",,"July 11, 2013","Washington University School of Medicine, St. Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00871702,762.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
846,847,NCT00001333,Phase I Study of Intrathecal Topotecan,,Completed,No Results Available,Leukemia|Lymphoma|Meningeal Neoplasms,Drug: topotecan,,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",Phase 1,30.0,NIH,Interventional,Primary Purpose: Treatment,930085|93-C-0085,1993-02-01,,2000-12-01,"December 10, 2002",,"March 4, 2008","National Cancer Institute (NCI), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00001333,2860.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
847,848,NCT00634504,Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze,LVPK,Completed,Has Results,Osteosarcoma|Leukemia|Lymphoma,"Drug: glucarpidase, high-dose methotrexate, leucovorin|Drug: high-dose methotrexate, leucovorin",Pharmacokinetics (PK) of Leucovorin,BTG International Inc.,All,"Child, Adult, Older Adult",Phase 1,20.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PR001-CLN-pro017,2008-05-01,August 2009,2009-08-01,"March 13, 2008","July 3, 2014","June 6, 2022","Phoenix Children's Hospital, Phoenix, Arizona, United States|Good Samaritan Hospital, Los Angeles, California, United States|Children's Hospital of Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Los Angeles, California, United States|Oakland's Children's Hospital, Oakland, California, United States|Stanford University Medical Center & Lucile Packard Children's Hospital, Palo Alto, California, United States|California Pacific Medical Center, San Francisco, California, United States|Children's Hospital for Cancer & Blood Disorders, Aurora, Colorado, United States|St. Joseph's Hospital, Tampa, Florida, United States|NorthShore University Health System, Evanston, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|University of Kentucky, Lexington, Kentucky, United States|University of Massachusetts - Umass Memorial Medical Center, Worcester, Massachusetts, United States|University of MS Medical Center, Jackson, Mississippi, United States|University of Missouri-Columbia, Columbia, Missouri, United States|Washington University Medical Center, Saint Louis, Missouri, United States|St. Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|ECU Brody School of Medicine, Greenville, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|Huntsman Cancer Center, Salt Lake City, Utah, United States|Children's Hospital and Regional Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00634504,457.0,Not Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
848,849,NCT00005092,"Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer",,Completed,No Results Available,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,Drug: Cyclophosphamide|Drug: Psoralen|Drug: Thiotepa|Procedure: Allogeneic bone marrow transplantation|Procedure: In vitro-treated peripheral blood stem cell transplantation (PBSCT)|Radiation: Radiation Therapy (RT),Maximum Tolerated Dose (MTD) of T-cells photochemically treated with psoralen and ultraviolet A,M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"up to 49 Years   (Child, Adult)",Phase 1,7.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DM98-283|P30CA016672|MDA-DM-98283|NCI-G00-1742|CDR0000067734,1999-05-28,"August 28, 2002",2002-08-28,"April 23, 2004",,"October 26, 2018","University of Illinois at Chicago, Chicago, Illinois, United States|Washington University Barnard Cancer Center, Saint Louis, Missouri, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00005092,1188.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
849,850,NCT00301951,"Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer",,Completed,No Results Available,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,Biological: anti-thymocyte globulin|Biological: sargramostim|Drug: busulfan|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: umbilical cord blood transplantation,Safety and Feasibility of donor cord blood transplant,"University of California, San Francisco|National Cancer Institute (NCI)",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,7.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000465362|UCSF-04253|UCSF-2407|UCSF-H24045-25271-02,2004-09-01,July 2009,2009-07-01,"March 13, 2006",,"October 12, 2017","UCSF Comprehensive Cancer Center, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00301951,1764.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
850,851,NCT00304018,Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer,,Completed,No Results Available,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,Biological: anti-thymocyte globulin|Biological: sargramostim|Drug: busulfan|Drug: etoposide|Drug: fludarabine phosphate|Drug: prednisone|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: umbilical cord blood transplantation,Determine the safety and feasibility of performing donor umbilical cord blood transplantation (UCBT) in patients with advanced hematologic malignancies,"University of California, San Francisco|National Cancer Institute (NCI)",All,18 Years to 55 Years   (Adult),Phase 1,5.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000463370|UCSF-02253|UCSF-H24045-21269-04|UCSF-2207,2002-10-01,March 2009,2009-03-01,"March 17, 2006",,"August 14, 2013","UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00304018,2343.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
851,852,NCT00990717,Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies,,Completed,No Results Available,Leukemia|Lymphoma|Myeloma|Hodgkin's Disease,Biological: NK-92 cells,"Determine if there are any dose limiting toxicities to this therapy, as well as the maximum tolerated dose.|Document any preliminary efficacy information from the NK-92 cell infusion.|Assess any immune response directed against the infused NK-92 cells.|Determine kinetics of infused NK92 cells.","University Health Network, Toronto",All,"18 Years and older   (Adult, Older Adult)",Phase 1,8.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CTP04.NK92.01,2005-03-01,July 2012,2012-07-01,"October 7, 2009",,"June 23, 2016","Princess Margaret Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00990717,2679.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
852,853,NCT00006098,PS-341 in Treating Patients With Hematologic Cancer,,Completed,No Results Available,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,Drug: bortezomib,,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,,Other|NIH,Interventional,Primary Purpose: Treatment,00-031|CDR0000068105|NCI-G00-1827,2000-04-01,October 2001,2001-10-01,"March 17, 2004",,"June 18, 2013","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00006098,548.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
854,855,NCT00005946,Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation,,Completed,No Results Available,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,Biological: filgrastim|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: etoposide,,"University of Maryland, Baltimore",All,"up to 120 Years   (Child, Adult, Older Adult)",Phase 1,,Other,Interventional,Primary Purpose: Treatment,MSGCC-9951|CDR0000067863|NCI-V00-1588,2000-10-01,June 2002,2002-06-01,"March 5, 2004",,"October 17, 2019","Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00005946,608.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
855,856,NCT00001251,Phase I Study of Intrathecal Mafosfamide,,Completed,No Results Available,Leukemia|Lymphoma|Meningeal Neoplasm,Drug: Mafosfamide,,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",Phase 1,65.0,NIH,Interventional,Primary Purpose: Treatment,900095|90-C-0095,1989-11-01,,2003-11-01,"November 4, 1999",,"August 19, 2013","National Cancer Institute (NCI), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00001251,5113.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
856,857,NCT01471067,Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies,,Completed,No Results Available,"Blood And Marrow Transplantation|Leukemia|Lymphoma|Transplantation Infection|Transplantation, Bone Marrow",Drug: Melphalan|Drug: Fludarabine|Drug: Mycophenolate mofetil|Drug: Tacrolimus|Procedure: Cord Blood Infusion|Drug: Rituximab|Drug: ATG|Drug: Busulfan|Drug: Clofarabine|Radiation: Total Body Irradiation (TBI),Number of Participants with engraftment within 42 days|Mean Time to Engraftment,"M.D. Anderson Cancer Center|American Stem Cell, Inc.|National Cancer Institute (NCI)",All,"1 Year to 80 Years   (Child, Adult, Older Adult)",Phase 1,33.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010-0658|NCI-2011-03742|2R01CA06158|5P01CA148600,2012-07-13,"April 25, 2017",2017-04-25,"November 11, 2011",,"April 28, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01471067,1747.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
857,858,NCT00062140,"Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer",,Completed,No Results Available,Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,Drug: cyclophosphamide|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,,Fred Hutchinson Cancer Center|National Cancer Institute (NCI),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,,Other|NIH,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,1797.00|FHCRC-1797.00|CDR0000304522,2003-04-01,,2004-07-01,"June 6, 2003",,"September 21, 2010","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00062140,457.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
858,859,NCT00481871,Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies,,Completed,Has Results,Relapsed or Refractory Lymphoproliferative Malignancies|Hodgkin's Lymphoma|Peripheral T-cell Lymphoma|B-cell Lymphoma|Waldenstrom's Macroglobulinemia,Drug: Pralatrexate Injection|Drug: Gemcitabine Hydrochloride|Dietary Supplement: Vitamin B12|Dietary Supplement: Folic Acid,Objective Responses Assessed by International Workshop Criteria (IWC)|Duration of Response|Progression-free Survival (PFS) Time,Acrotech Biopharma Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,119.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PDX-009,2007-05-01,May 2011,2011-08-01,"June 4, 2007","September 18, 2012","January 7, 2020","University of California at Los Angeles, Los Angeles, California, United States|Stanford University School of Medicine, Stanford, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|University of Chicago Hospital, Chicago, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|The Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|New York University Hospital, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|UT MD Anderson Cancer Center, Houston, Texas, United States|Cancer Therapy & Research Center, San Antonio, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00481871,1553.0,Industry Lead,More than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
860,861,NCT01147991,Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer,,Completed,No Results Available,Gastric Cancer|Head and Neck Cancer|Lymphoma|Lymphoproliferative Disorder|Nonneoplastic Condition,Biological: EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine|Other: laboratory biomarker analysis|Other: pharmacological study,"Occurrence of drug-related grade 3 or 4 systemic or local adverse events (defined using the NCI CTCAE version 3.0)|Occurrence of local skin reactions considered related to the vaccination|Occurrence of drug-related systemic reactions (e.g., transient fever)|Demonstration by ELIspot assays of the frequency of T-lymphocytes recognizing major histocompatibility complex (MHC) class I and II-restricted epitopes within EBNA1 and LMP2 in peripheral blood at sequential time-points before, during, and up to 9 mo ...|Measurement of EBV-genome levels in plasma",Cancer Research UK,All,"18 Years and older   (Adult, Older Adult)",Phase 1,16.0,Other,Interventional,Primary Purpose: Treatment,CDR0000675266|CRUK-PH1-101|EUDRACT-2004-001931-46,2005-03-01,April 2011,2011-04-01,"June 22, 2010",,"February 28, 2012","University of Birmingham, Birmingham, England, United Kingdom|Royal Marsden - London, London, England, United Kingdom|Christie Hospital, Manchester, England, United Kingdom",,https://ClinicalTrials.gov/show/NCT01147991,2222.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
861,862,NCT00002818,High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies,,Completed,No Results Available,Drug/Agent Toxicity by Tissue/Organ|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm,Drug: cytarabine|Drug: deoxycytidine,,Virginia Commonwealth University|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1,15.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000064976|P30CA016059|MCV-MCC-9409-2CC|VCU-FDR000637|NCI-V96-0966,1995-02-01,February 2001,2001-02-01,"April 22, 2004",,"December 14, 2015","Massey Cancer Center, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00002818,2192.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
862,863,NCT01563302,"Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers",,Completed,No Results Available,Advanced Cancers|DLBCL|Lymphoma,Drug: IONIS-STAT3Rx,Safety of IONIS-STAT3Rx in patients with Advanced Cancers|Maximum-tolerated dose (MTD) of IONIS-STAT3Rx in patients with Advanced Cancers.|Clinical activity of IONIS-STAT3Rx|Pharmacokinetics-Cmax|STAT3 and other biomarkers|Pharmacokinetics - Tmax,"Ionis Pharmaceuticals, Inc.|AstraZeneca",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,64.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 481464-CS1,2012-02-27,"March 23, 2016",2016-03-23,"March 26, 2012",,"June 25, 2018","Mayo Clinic Arizona, Scottsdale, Arizona, United States|Moores UC San Diego Cancer Center, La Jolla, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|Blood and Marrow Transplant Group of Georgia at Northside Hospital, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mary Crowley Cancer Research Centers, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01563302,1486.0,Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
863,864,NCT01300026,AMG 319 Lymphoid Malignancy FIH,,Completed,No Results Available,Cancer|Chronic Lymphocytic Leukemia|Diffuse Large Cell Lymphoma|Hematologic Malignancies|Hematology|Leukemia|Low Grade Lymphoma|Lymphoma|Mantle Cell Lymphoma|Non-Hodgkin's Lymphoma|Oncology|Oncology Patients|T Cell Lymphoma|Tumors,Drug: AMG 319,"Clinically significant or > or = to Grade 3 CTCAE changes in safety laboratory tests, physical exams, ECGs or vital signs|PK parameters|Clinical/radiological response rate for CLL subjects|Treatment-emergent adverse events|Phospho-AKT level in circulating CLL cells|Number of patients with clinical/radiological response",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 1,28.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20101262|AMG 319 FIH Lymphoid,2011-04-01,October 2013,2016-12-01,"February 21, 2011",,"February 9, 2017","Research Site, Hackensack, New Jersey, United States|Research Site, Durham, North Carolina, United States|Research Site, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01300026,2071.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
864,865,NCT01460134,A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers,,Completed,No Results Available,"CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma|Marginal Zone B Cell Lymphoma)|Any T-cell Malignancy|Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma|Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer|Colorectal Adenocarcinoma, Non-small Cell Lung Cancer)|Burkett's Lymphoma|Primary Lymphoma of the Central Nervous System",Drug: CDX-1127,Characterize the adverse events associated with CDX-1127 administration|Levels of anti-CD27 antibodies in circulating blood.|Levels of CDX-1127 in circulating blood.|Activity Evaluations|Immune system effects (eg: lymphoid cell populations and serum cytokine levels),Celldex Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1,90.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDX1127-01,2011-10-01,December 2015,2017-10-16,"October 26, 2011",,"January 31, 2018","Mayo Clinic Arizona - Cancer Clinical Research Unit, Scottsdale, Arizona, United States|Stanford Cancer Center - Stanford University, Stanford, California, United States|Mayo Clinic, Rochester, Minnesota, United States|Icahn School of Medicine at Mount Sinai Hess Center for Science and Medicine, New York, New York, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Mary Crowley Cancer Research Centers - Medical City, Dallas, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01460134,2207.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
865,866,NCT00920257,"A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795",,Completed,No Results Available,Cancer,Drug: GSK2141795,"To determine the recommended Phase II dose and schedule of GSK214179 using the following information: safety and tolerability, pharmacokinetic (single and repeat dose administration) and pharmacodynamic data|• To explore the clinical efficacy of GSK2141795 in subjects with solid tumor malignancies or lymphomas|To characterize the metabolite profile of oral GSK2141795 after repeat dose administration in subjects with solid tumor malignancies or lymphoma",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,77.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,112689,2009-06-16,"April 17, 2013",2013-04-17,"June 15, 2009",,"November 13, 2017","GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00920257,1401.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
866,867,NCT01344876,Phase I Study of OPB-51602 in Patients With Hematologic Malignancies,,Completed,Has Results,Multiple Myeloma|Non-Hodgkin Lymphoma|Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Chronic Myeloid Leukemia,Drug: OPB-51602,Subjects With Treatment Emergent Adverse Events|Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)|Treatment Response,"Otsuka Pharmaceutical Co., Ltd.",Male,"20 Years to 75 Years   (Adult, Older Adult)",Phase 1,20.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,266-10-001|JapicCTI-111478,2011-04-01,April 2014,2014-04-01,"April 29, 2011","June 8, 2015","June 8, 2015","Nagoya, Japan|Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01344876,1096.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
867,868,NCT02192346,α-TEA in Advanced Cancer,,Completed,No Results Available,Metastatic Carcinoma|Metastatic Sarcoma|Metastatic Lymphoma,Drug: 2.4 mg/kg α-TEA|Drug: 4.8 mg/kg α-TEA|Drug: 8.0 mg/kg α-TEA|Drug: 9.6 mg/kg α-TEA|Drug: 12 mg/kg α-TEA|Drug: 16.8 mg/kg α-TEA|Drug: 19.2 mg/kg α-TEA|Drug: 22.3 mg/kg α-TEA|Drug: 26.8 mg/kg α-TEA,Number of Participants with Adverse Events|Number of Adverse Events Possibly Caused by α-TEA|Blood serum levels of α-TEA,Providence Health & Services,All,"18 Years and older   (Adult, Older Adult)",Phase 1,17.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-043A,2014-08-04,"December 11, 2017",2018-05-08,"July 16, 2014",,"August 17, 2018","Providence Oncology & Hematology Care Clinic- Southeast, Clackamas, Oregon, United States|Providence Oncology & Hematoloty Care Clinic- Newberg, Newberg, Oregon, United States|Providence Oncology & Hematology Care Clinic- Willamette Falls, Oregon City, Oregon, United States|Providence Oncology & Hematology Care Clinic- Eastside, Portland, Oregon, United States|Providence Oncology & Hematology Care Clinic- Westside, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT02192346,1373.0,Not Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
868,869,NCT03458117,T-VEC in Non-melanoma Skin Cancer,20139157 T-VEC,Completed,No Results Available,Non-melanoma Skin Cancer|Basal Cell Carcinoma|Squamous Cell Carcinoma|Cutaneous Lymphoma|Merkel Cell Carcinoma,Genetic: Talimogene Laherparepvec (T-VEC),Change from Baseline local immune effects after repeated T-VEC injections|Detection of Tumor Regression using World Health Organization (WHO) response criteria|Systemic immune response|Analysis of Adverse events,University of Zurich,All,"18 Years and older   (Adult, Older Adult)",Phase 1,26.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20139157,2018-04-19,"February 4, 2022",2022-03-15,"March 8, 2018",,"March 18, 2022","Department of Dermatology, University Hospital Zurich, Zurich, Switzerland",,https://ClinicalTrials.gov/show/NCT03458117,1426.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
870,871,NCT00710528,Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies,,Completed,No Results Available,"Chronic Lymphocytic Leukemia (CLL)|Lymphoma, Non-Hodgkin (NHL)|Acute Myeloid Leukemia (AML)|Multiple Myeloma (MM)",Drug: CAL-101,"To evaluate the safety of CAL-101 and determine the dose limiting toxicity in patients with hematologic malignancies.|To evaluate the pharmacokinetic parameters, pharmacodynamic effects and clinical response rate following CAL-101 treatment in patients with hematologic malignancies.",Gilead Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 1,192.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,101-02,2008-06-01,December 2011,2012-08-01,"July 4, 2008",,"August 31, 2012","Stanford Cancer Center, Palo Alto, California, United States|The Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Weill Medical College of Cornell, New York, New York, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|University of Wisconsin, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00710528,1522.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
871,872,NCT00697346,Study of MLN8237 in Participants With Advanced Hematological Malignancies,,Completed,Has Results,B-cell Follicular Lymphoma|B-cell Marginal Zone Lymphoma|Diffuse Large B-cell Lymphoma|B-cell Mantle Cell Lymphoma|B-cell Small Lymphocytic Lymphoma|B-Cell Chronic Lymphocytic Leukemia|Multiple Myeloma|Waldenstrom's Macroglobulinemia|Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified|Angioimmunoblastic T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Enteropathy Associated T-cell Lymphoma|NK Lymphoma,Drug: Alisertib,Number of Participants With Dose-Limiting Toxicity (DLT)|Maximum Tolerated Dose (MTD) of Alisertib|Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 1|Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21|Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 1|Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21|AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21|Terminal Half-Life (t1/2) for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21|Accumulation Ratio (Rac) for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21|Peak/Trough Ratio for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21|CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21|Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 1|Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14|Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 1|Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14|AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14|Accumulation Ratio (Rac) for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14|Peak/Trough Ratio for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14|CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14|Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 1|Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14|Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 1|Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14|AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14|Terminal Half Life for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14|Peak/Trough Ratio for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14|CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14|Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 1|Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7|Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 1|Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7|AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 1|AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7|Terminal Half-Life (t1/2) for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7|Accumulation Ratio (Rac) for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7|Peak/Trough Ratio for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7|CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7|Best Overall Response Rate Based on Investigator's Assessment|Duration of Response (DOR)|Number of Participants With Polymorphisms in Gene Encoding Enzyme UGT1A1|Number of Participants With Polymorphisms in Aurora A Kinase,"Millennium Pharmaceuticals, Inc.|Takeda",All,"18 Years and older   (Adult, Older Adult)",Phase 1,58.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C14003|U1111-1187-1184,2008-07-11,"October 1, 2016",2016-10-19,"June 13, 2008","May 31, 2019","May 31, 2019","Scottsdale, Arizona, United States|Lexington, Kentucky, United States|Baltimore, Maryland, United States|Omaha, Nebraska, United States|Hackensack, New Jersey, United States|Buffalo, New York, United States|Chapel Hill, North Carolina, United States|Nashville, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00697346,3022.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,Not Open Label,Treatment/Diagnostic
872,873,NCT00652626,Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function,RENAL,Completed,Has Results,MDS|AML|Solid Tumors|Multiple Myeloma|Non-Hodgkin's Lymphoma|Hodgkin's Disease,Drug: azacitidine,Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity|Maximum Plasma Concentration of Azacitidine (Cmax)|Time to Maximum Plasma Concentration of Azacitidine (Tmax)|Terminal Phase Half-life of Azacitidine (t½)|Apparent Total Clearance of Azacitidine (CL/F)|Apparent Volume of Distribution of Azacitidine (Vz/F)|Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose After Single and Multiple Doses of Azacitidine|Area Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Time Point After Single and Multiple Doses of Azacitidine|Area Under the Plasma Concentration-time Curve From Time 0 to Infinity After Single and Multiple Doses of Azacitidine|Maximum Plasma Concentration of Azacitidine (Cmax) After Single and Multiple Doses of Azacitidine|Time to Maximum Plasma Concentration of Azacitidine (Tmax) After Single and Multiple Doses of Azacitidine|Terminal Phase Half-life of Azacitidine (t½) After Single and Multiple Doses of Azacitidine|Apparent Total Clearance of Azacitidine (CL/F) After Single and Multiple Doses of Azacitidine|Apparent Volume of Distribution of Azacitidine (Vz/F) After Single and Multiple Doses of Azacitidine|Number of Participants With Adverse Events (AEs),Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 1,31.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,AZA PH US 2007 PK006,2008-11-01,"July 1, 2012",2012-07-01,"April 4, 2008","October 17, 2013","November 19, 2019","Sutter East Bay Hospitals, Berkeley, California, United States|Palm Springs Research Institute, Hialeah, Florida, United States|MCG Cancer Center, Augusta, Georgia, United States|Joliet Oncology-Hematology Associates, Ltd., Joliet, Illinois, United States|University of Kentucky-Markey Cancer Center Clinical Research Organization, Lexington, Kentucky, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|Montefiore Medical Center, Bronx, New York, United States|Mid Dakota Clinical P.C. - Cancer Treatment and Research Center, Bismarck, North Dakota, United States|Gabrail Cancer Center, Canton, Ohio, United States|Pharma Resource, East Providence, Rhode Island, United States|Cancer Therapy and Research Center, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00652626,1338.0,Industry Lead,More than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
873,874,NCT00562224,Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients,,Completed,No Results Available,"Neoplasms by Site|Lymphoma, Non-hodgkin|Hodgkin Disease|Multiple Myeloma|Leukemia, Lymphocytic, Chronic",Drug: PCI-24781,Dose limiting toxicity assessment at the end of the first 28 day cycle.|Measure: Adverse event assessed through 30 days after last dose of study drug Measure: Tumor response Measure: Pharmacokinetic/Pharmacodynamic assessments,Pharmacyclics LLC.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,36.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PCYC-0402,2007-11-01,June 2010,2010-09-01,"November 21, 2007",,"September 28, 2011","California Cancer Care, Greenbrae, California, United States|University of Chicago, Chicago, Illinois, United States|Sarah Cannon Research Institue, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00562224,1035.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
874,875,NCT01447056,Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases,MALTED,Completed,No Results Available,Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Lymphoproliferative Disorder|Nasopharyngeal Carcinoma|Leiomyosarcoma|Severe Chronic Active EBV (SCAEBV),Biological: LMP specific T cells,Patients with dose limiting toxicities after T-cell infusions|Safety and response to a repeated dosage regimen|Analysis of immune function of CTLs|Number of patients with an EBV and/or disease response to the CTLs,"Baylor College of Medicine|The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",All,"Child, Adult, Older Adult",Phase 1,37.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-28361-MALTED|MALTED,2012-02-01,March 2015,2020-01-22,"October 5, 2011",,"February 7, 2020","Houston Methodist Hospital, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01447056,2912.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
875,876,NCT02240719,Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer,,Completed,No Results Available,Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Multiple Myeloma,Drug: everolimus|Drug: bendamustine hydrochloride,"MTD of everolimus, defined as the dose that produces dose-limiting toxicity (DLT) in =< 1/6 patients, determined by incidence of DLT graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Incidence and severity of adverse events as defined by the NCI CTCAE version 4.03|Response rates (complete response, partial response, stable disease)","University of California, Davis|Novartis",All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,637004|CRAD001NUS235T|UCDCC#245|NCI-2014-01934,2014-10-01,"April 9, 2018",2018-04-09,"September 16, 2014",,"January 4, 2019","University of California Davis, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT02240719,1286.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
877,878,NCT00714103,8-Chloro-Adenosine in Chronic Lymphocytic Leukemia,,Completed,No Results Available,Leukemia|Chronic Lymphocytic Leukemia,Drug: 8-Chloro-Adenosine,Dose-limiting Toxicity and Maximum Tolerated Dose,M.D. Anderson Cancer Center|National Cancer Institute (NCI)|FDA Office of Orphan Products Development,All,"18 Years and older   (Adult, Older Adult)",Phase 1,11.0,Other|NIH|U.S. Fed,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2004-0144|NCI-2012-01679,2008-06-01,October 2016,2016-10-01,"July 14, 2008",,"October 13, 2016","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00714103,3044.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
878,879,NCT00878189,A Trial In Patients With Advanced Cancer And Leukemia,,Completed,Has Results,Neoplasms by Histologic Type,Drug: PF-03084014,"Number of Solid Tumor Participants With First-Cycle Dose-Limiting Toxicity (DLT)|Number of T-ALL/LBL Participants With First-Cycle DLT|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (All Causality)|Number of Participants With TEAEs (Treatment-Related)|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (All Causality) by Severity (by Maximum Common Terminology Criteria for Adverse Events [CTCAE] Grade)|Number of Participants With TEAEs (Treatment-Related) by Severity (by Maximum CTCAE Grade)|Number of Participants With Potentially Clinical Significant Categorical Changes From Baseline in Electrocardiogram (ECG) Findings in QTc Interval|Number of Participants With Laboratory Tests Abnormalities Meeting the Criteria of Potential Clinical Concern (Hematology and Chemistries, All Cycles)|Maximum Observed Serum Concentration (Cmax) After a Single Dose on Cycle 1 Day 1|Dose-normalized Cmax [Cmax (dn)] After a Single Dose on Cycle 1 Day 1|Area Under the Time-Concentration Curve From Time 0 to the Dosing Interval (AUCtau) After a Single Dose on Cycle 1 Day 1|Dose-normalized AUCtau [AUCtau (dn) ] After a Single Dose on Cycle 1 Day 1|Time to Reach Cmax (Tmax) After a Single Dose on Cycle 1 Day 1|Cmax After Multiple Dose on Cycle 1 Day 21|Time to Reach Cmax (Tmax) After Multiple Dose on Cycle 1 Day 21|AUCtau After Multiple Dose on Cycle 1 Day 21|Apparent Volume of Distribution (Vz/F) on Cycle 1 Day 21|Serum Decay Half-Life (t1/2) After Multiple Dose on Cycle 1 Day 21|Apparent Oral Clearance (CL/F) on Cycle 1 Day 21|Minimum Observed Serum Concentration (Cmin) After Multiple Dose on Cycle 1 Day 21|Average Serum Concentration (Cavg) at Steady State on Cycle 1 Day 21|Accumulation Ratio (Rac) on Cycle 1 Day 21|Dose-normalized AUCtau [AUCtau (dn)] After Multiple Dose on Cycle 1 Day 21|Dose-normalized Cmax [Cmax (dn)] After Multiple Dose on Cycle 1 Day 21|AUCtau in the Fasted State for Solid Tumor Participants|AUCtau in the Fed State for Solid Tumor Participants|Cmax in the Fasted State for Solid Tumor Participants|Cmax in the Fed State for Solid Tumor Participants|Dose-normalized AUCtau [AUCtau(dn)] in the Fasted State for Solid Tumor Participants|Dose-normalized AUCtau [AUCtau(dn)] in the Fed State for Solid Tumor Participants|Dose-normalized Cmax [Cmax(dn)] in the Fasted State for Solid Tumor Participants|Dose-Normalized Cmax [Cmax(dn)] in the Fed State for Solid Tumor Participants|AUCtau on Cycle 2 Day 1|Dose-normalized AUCtau [AUCtau (dn)] on Cycle 2 Day 1|Cmax on Cycle 2 Day 1|Dose-normalized Cmax [Cmax (dn)] on Cycle 2 Day 1|Tmax on Cycle 2 Day 1|Percentage of Solid Tumor Participants With Objective Response (OR)|Time to Tumor Progression (TTP) for Solid Tumor Participants|Duration of Response (DR) for Solid Tumor Participants|Progression-Free Survival (PFS) for Solid Tumor Participants|Percentage of T-ALL/LBL Participants With OR|Relapse Free Survival (RFS) for T-ALL/LBL Participants|Peripheral Blast Count Reduction (PBR) for T-ALL/LBL Participants|Changes in Expression Levels of Notch 1 Target Genes in Tumor Biopsies for Solid Tumor Participants: Hairy and Enhancer of Split-4 (Hes4) Gene Expression Levels on Cycle 1 Day 21 Relative to That at Baseline|Changes From Baseline in Expression Levels of Notch 1 Target Genes in Peripheral Blood for T-ALL/LBL Participants: Hes4 Gene Expression Levels on Cycle 1 Day 8, Cycle 1 Day 15, Cycle 1 Day 21 Relative to That at Baseline|Changes in Expression Levels of Notch 1 Target Genes in Peripheral Blood for Solid Tumor Participants: Hes4 Gene Expression Level on Cycle 1 Day 8 and Cycle 1 Day 21 Relative to That at Baseline|Changes From Baseline in Notch Intracellular Domain (NICD) Levels in Peripheral Blood for T-ALL/LBL Participants|Changes From Baseline in Notch Intracellular Domain (NICD) Levels in Bone Marrow for T-ALL/LBL Participants",Pfizer,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 1,72.0,Industry,Interventional,Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,A8641014|2010-022036-36,2009-06-25,"January 10, 2013",2016-11-22,"April 8, 2009","November 12, 2019","November 12, 2019","Anschutz Cancer Pavilion, Aurora, Colorado, United States|University of Colorado Denver CTRC, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Massachusetts General Hospital Clinical Laboratory, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Ferber Cancer institute, Boston, Massachusetts, United States|Karmanos Cancer Center / Wayne State University, Detroit, Michigan, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|DIPRTMNT CLIN Scienze RADIOL e Istocitopatologiche, Bologna, Italy|Istituto di Ematologia Seragnoli, Bologna, Italy",,https://ClinicalTrials.gov/show/NCT00878189,2707.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
879,880,NCT03885947,VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies,,Completed,No Results Available,Hematological Malignancy|Acute Leukemia in Remission|Acute Lymphoblastic Leukemia in Remission|Myelodysplastic Syndromes|Non-Hodgkin Lymphoma|Hodgkin Lymphoma,Biological: Cord blood stem cells|Drug: Valproic Acid|Drug: Fludarabine|Drug: cytoxan|Drug: Thiotepa|Biological: TBI,Number of Infusion Reaction|Number of Graft Failure|Time to neutrophil engraftment|Time to platelets engraftment|Number of transplant-related mortality (TRM)|Number of disease free survivals|Number of overall survivals|Number of participants at risk of GVHD|Number of infectious complications|Time to myeloid engraftment|Time to lymphoid engraftment|Change in T cell count,Alla Keyzner|Icahn School of Medicine at Mount Sinai,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,7.0,Other,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GCO 14-0451,2019-02-21,"March 10, 2021",2021-03-10,"March 22, 2019",,"May 24, 2021","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03885947,748.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
880,881,NCT01611623,Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies,,Completed,No Results Available,Cancer,Drug: SNX-5422,Number of patients with dose limiting toxicities|Pharmacokinetic profiles of parent drug and metabolite|Number of patients with adverse events as a measure of tolerability,Esanex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,9.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SNX-5422-CLN1-004,2012-05-01,November 2012,2013-03-01,"June 5, 2012",,"April 2, 2013",,,https://ClinicalTrials.gov/show/NCT01611623,304.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
881,882,NCT01068301,A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation,,Completed,No Results Available,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma,Drug: Plerixafor,"To determine the dose-limiting toxicity and maximum tolerated dose of plerixafor in combination with fludarabine, thiotepa and melphalan as a conditioning regimen for patients undergoing a second allogeneic transplant procedure.","St. Jude Children's Research Hospital|Genzyme, a Sanofi Company",All,"up to 21 Years   (Child, Adult)",Phase 1,12.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MOZBMT,2010-05-01,October 2013,2013-10-01,"February 12, 2010",,"January 1, 2014","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT01068301,1249.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
882,883,NCT04349969,"A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104",,Completed,No Results Available,Neoplasms Malignant,Drug: AK117|Drug: AK117+AK104,Incidence and nature of adverse events (AEs)|Number of participants with a Dose Limiting Toxicity (DLT)|Objective response rate (ORR)|Disease control rate (DCR)|Maximum observed concentration (Cmax) of AK117 as monotherapy or in combination with AK104 and Minimum observed concentration (Cmin) of AK117 at steady stateconcentration (Cmin) of AK117 at steady state|Number of subjects who develop detectable anti-drug antibodies (ADAs) of AK117 as monotherapy or in combination with AK104|Area under the curve (AUC) of AK117 as monotherapy or in combination with AK104 for assessment of pharmacokinetics|Receptor occupancy (RO) of AK117 as monotherapy or in combination with AK104 to evaluate target engagement,Akesobio Australia Pty Ltd|Akeso,All,"18 Years and older   (Adult, Older Adult)",Phase 1,50.0,Industry,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AK117-101,2020-04-23,"November 8, 2022",2022-11-08,"April 16, 2020",,"January 9, 2023","Blacktown Hospital, Sydney, New South Wales, Australia|ICON Cancer Foundation, South Brisbane, Queensland, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|Austin Health, Heidelberg, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT04349969,929.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
883,884,NCT01474681,Safety and Tolerability of HSC835 in Patients With Hematological Malignancies,,Completed,Has Results,Acute Myelocytic Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Myelodysplastic Syndrome|Chronic Lymphocytic Leukemia|Marginal Zone Lymphoma|Follicular Lymphomas|Large-cell Lymphoma|Lymphoblastic Lymphoma|Burkitt's Lymphoma|High Grade Lymphomas|Mantle-cell Lymphoma|Lymphoplasmacytic Lymphoma,Biological: HSC835,Safety and Tolerability of HSC835 for Clinical Use Were Measured by Infusional Toxicity (Within First 48 Hours After Transplant) and Absence of Graft Failure After 32 Days in Excess of That Currently Observed With UCBT.|Incidence of Neutrophil Recovery Within 42 Days|Incidence of Platelet Recovery Within Six Months|Frequency of Expanded Unit Predominance at Day 100 (DUCBT Recipients Only)|Incidence of Transplant Related Mortality (TRM) Within 100 Days and One Year|Incidence of Acute Graft Versus Host Disease (aGVHD) Within 100 Days and Chronic Graft Versus Host Disease (cGVHD) Within 1 Year|Incidence of Relapse Within One Year|Overall Survival (OS) Within One Year|Disease Free Survival (DFS) Within One Year,Novartis Pharmaceuticals|Novartis,All,"10 Years to 55 Years   (Child, Adult)",Phase 1|Phase 2,27.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHSC835X2201,2012-01-09,"October 3, 2016",2016-10-03,"November 18, 2011","May 12, 2017","December 30, 2020","Novartis Investigative Site, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01474681,1729.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
884,885,NCT03056339,Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies,,Completed,No Results Available,B-Lymphoid Malignancies|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Non-hodgkin Lymphoma,Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Mesna|Biological: iC9/CAR.19/IL15-Transduced CB-NK Cells|Drug: AP1903,Optimal NK Cell Dose Level of Chimeric Antigen Receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood Natural Killer (CB-NK) Cells in Patients with Relapsed/Refractory CD19+ B Lymphoid Malignancies|Toxicity of Chimeric Antigen Receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood Natural Liller (CB-NK) Cells in Patients with Relapsed/Refractory CD19+ B Lymphoid Malignancies|Efficacy of Chimeric Antigen Receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood Natural Killer (CB-NK) Cells in Patients with Relapsed/Refractory CD19+ B Lymphoid Malignancies|Response of Chimeric Antigen Receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood Natural Killer (CB-NK) Cells in Patients with Relapsed/Refractory CD19+ B Lymphoid Malignancies,M.D. Anderson Cancer Center,All,"7 Years to 80 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,44.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016-0641|NCI-2018-01221,2017-06-21,"March 6, 2023",2023-03-06,"February 17, 2017",,"March 8, 2023","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03056339,2084.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
885,886,NCT00621244,A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies,,Completed,Has Results,Lymphoma|Leukemia|Multiple Myeloma,Drug: LBH589,"Number of Participants DLT in Arm 1 in Dose Escalation Phase|Number of Participants DLT in Arm 2 in Dose Escalation Phase|Response as Per Investigator Assessment for Patients With Acute Myelogenous Leukemia (AML)|Response as Per Investigator Assessment for Patients With Acute Myelogenous Leukemia (AML) in Expansion Phase|Response as Per Investigator Assessment for Patients With Hodgkin's Lymphoma (HD)|Response as Per Investigator Assessment for Patients With Myelodysplastic Syndromes (MDS)|Maximum Plasma Concentration of Panobinostat After the First Dose in Arms 1 and 2|Half Life of Panobinostat After the First Dose in Arms 1 and 2|Maximum Plasma Concentration of Panobinostat After Multiple Doses in Arm 1 on Day 15|Half Life of Panobinostat After Multiple Doses in Arm 1 on Day 15|Geometric Mean Ratio (GMR) Comparing Treatment Days in Arm 1|Percentages of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 1 (MWF Every Week), Group X|Percentages of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 1 (MWF Every Week), Group Y|Percentages of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 2 (MWF Every Other Week), Group X|Percentage of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 2 (MWF Every Other Week), Group Y|Highest Percent Change in Fetal Hemoglobin From Baseline in Arm 1 (MWF Every Week)|Highest Percent Change of Fetal Hemoglobin From Baseline in Arm 2 (MWF Every Other Week)",Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,175.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLBH589B2102|2005-003670-26,2003-03-01,"December 3, 2009",2009-12-03,"February 22, 2008","August 17, 2017","January 5, 2021","Georgia Health Sciences University Dept.ofMedicalCollegeOfGeorgia, Augusta, Georgia, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|MD Anderson Cancer Center/University of Texas, Houston, Texas, United States|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Prahran, Victoria, Australia|Novartis Investigative Site, Frankfurt/M, Germany|Novartis Investigative Site, Mainz, Germany",,https://ClinicalTrials.gov/show/NCT00621244,2469.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
886,887,NCT01925131,"S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia",,Completed,Has Results,Acute Leukemias of Ambiguous Lineage|B-cell Adult Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma,Drug: cyclophosphamide|Drug: vincristine sulfate|Drug: prednisone|Biological: inotuzumab ozogamicin|Other: laboratory biomarker analysis,MTD of Inotuzumab Ozogamicin With CVP for Patients With Relapsed or Refractory CD22+ Acute Leukemia|Response Rate (CR+CRi) Among Expansion Cohort|Frequency and Severity of Toxicities,Southwest Oncology Group|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,50.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,S1312|NCI-2013-01368|U10CA180888|U10CA032102,2014-04-01,"January 1, 2022",2023-01-01,"August 19, 2013","April 6, 2022","March 2, 2023","City of Hope Comprehensive Cancer Center, Duarte, California, United States|Stanford Cancer Institute Palo Alto, Palo Alto, California, United States|University of Rochester, Rochester, New York, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ben Taub General Hospital, Houston, Texas, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT01925131/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT01925131,3197.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
887,888,NCT00506805,Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies,,Completed,No Results Available,Cancer,Drug: SNX-5422,adverse events and other safety assessments|tumor response measured by X-rays or scans,"Esanex Inc.|Serenex, Inc.|Pfizer",All,"18 Years and older   (Adult, Older Adult)",Phase 1,44.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B1311001|SNX-5422-CLN1-001,2007-06-01,March 2010,2010-03-01,"July 25, 2007",,"May 28, 2012","Pfizer Investigational Site, Scottsdale, Arizona, United States|Pfizer Investigational Site, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00506805,1004.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
888,889,NCT01673737,A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer,,Completed,No Results Available,Neoplasm Malignant,Drug: SAR260301|Drug: Vemurafenib,"Maximal tolerated dose (MTD) of SAR260301 in monotherapy (Study Part A)|Maximal tolerated dose (MTD) of SAR260301 in combination with vemurafenib (Study Part B)|Number of patients with treatment emergent events|Assessment of PK parameters for SAR260301 and vemurafenib, including tmax, Cmax, AUC, Rac (Day 28/Day1), half-life, CL, Ctrough|Assessment of PK parameters for SAR260301 including tmax, Cmax, AUC fasting and fed (food effect)(Only part A)|Assessment of urine excretion of SAR2690301 (Part A)|Assessment of potential for CYP induction (4beta-hydroxycholesterol)(Part A)|Assessment of PK parameter Rac (Day 28/Day 1) on AUC and Cmax|Assessment of PD parameter Serine/threonine protein kinase Akt (AKT) phosphorylation in blood platelets|Assessment of PD parameter AKT phosphorylation in tumor (expansion phase only)|Assessment of preliminary antitumor activity as documented by tumor response (defined by RECIST1.1 criteria for solid tumors, international working group (IWG) and revised response for lymphomas, and tumor markers when relevant)",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 1,75.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TCD12739|U1111-1129-2696,2012-08-01,February 2015,2015-02-01,"August 28, 2012",,"April 10, 2015","Investigational Site Number 840001, Boston, Massachusetts, United States|Investigational Site Number 840101, Boston, Massachusetts, United States|Investigational Site Number 840002, Houston, Texas, United States|Investigational Site Number 124001, Toronto, Canada",,https://ClinicalTrials.gov/show/NCT01673737,914.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
889,890,NCT01164033,A Study of RO5045337 in Patients With Solid Tumors,,Completed,No Results Available,Neoplasms,Drug: RO5045337,Examination of potential food-effect on pharmacokinetics of RO5045337|Evaluation of relative bioavailability of RO5045337|Evaluation of safety and tolerability of RO5045337|Evaluation of pharmacodynamics and biomarkers,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1,76.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NP25299,2010-08-01,May 2013,2013-05-01,"July 16, 2010",,"November 2, 2016","Scottsdale, Arizona, United States|Kansas City, Kansas, United States|Kensignton, Maryland, United States|Dallas, Texas, United States|San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01164033,1004.0,Industry Lead,Less than three Conditions,Randomized,Crossover Assignment,None (Open Label),Treatment/Diagnostic
890,891,NCT00623870,A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.,,Completed,No Results Available,Hematologic Neoplasms,Drug: RO5045337,Maximum tolerated dose/Dose-limiting toxicities|Safety: Incidence of adverse events|Comparison of daily versus twice daily dosing: Incidence of adverse events|Pharmacokinetics: Blood/Urine concentrations|Pharmacodynamics: Blood leukemia cells/MIC-1 protein level/CD33+CD34 markers|Clinical response: Clinical/hematologic malignancy assessments,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1,116.0,Industry,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NO21279,2008-05-01,November 2012,2012-11-01,"February 26, 2008",,"November 2, 2016","Duarte, California, United States|New Brunswick, New Jersey, United States|New York, New York, United States|Houston, Texas, United States|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Bologna, Emilia-Romagna, Italy|Roma, Lazio, Italy|Glasgow, United Kingdom|Leeds, United Kingdom|Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT00623870,1645.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
891,892,NCT00809276,Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY,,Completed,Has Results,Lymphoma|Multiple Myeloma|Leukemia|Myelodysplastic Syndrome,"Drug: Busulfan, Fludarabine, Cytoxan","To Determine the Optimal Regimen of Post-graft Immunosuppression With High-dose Cy Following Fludarabine, Busulfan, and Transplantation of Fully HLA-matched Bone Marrow That Leads to an Acceptable Incidence of Grades III/IV Acute GVHD","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|M.D. Anderson Cancer Center|Fred Hutchinson Cancer Center|Otsuka Pharmaceutical Co., Ltd.",All,"up to 65 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,92.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,J0844|NA_00017193,2009-05-01,December 2011,2011-12-01,"December 17, 2008","January 19, 2015","February 16, 2015","The Sydney Kimmel Comprehensive Cancer center, Baltimore, Maryland, United States|Marcos deLima, MD, Houston, Texas, United States|Paul V. O'Donnell, M.D., Ph.D., Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00809276,944.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
892,893,NCT01254578,Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers,,Completed,No Results Available,Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A|Adult Acute Promyelocytic Leukemia With PML-RARA|Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-Cell Lymphoma|Alkylating Agent-Related Acute Myeloid Leukemia|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Hepatosplenic T-Cell Lymphoma|Intraocular Lymphoma|Lymphomatous Involvement of Non-Cutaneous Extranodal Site|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Nodal Marginal Zone Lymphoma|Post-Transplant Lymphoproliferative Disorder|Primary Cutaneous B-Cell Non-Hodgkin Lymphoma|Prolymphocytic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-Cell Leukemia/Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides and Sezary Syndrome|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Richter Syndrome|Small Intestinal Lymphoma|Splenic Marginal Zone Lymphoma|T-Cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenstrom Macroglobulinemia,Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Other: Pharmacological Study,MTD of lenalidomide after allogeneic hematopoietic stem cell transplantation graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0|Overall response in patients treated with lenalidomide according to the International Working Group (IWG) criteria,National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,17.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2011-02551|OSU 10079|OSU-10079|CDR0000688918|2010C0069|OSU-2010C0069|8305|P30CA016058|U01CA076576,2010-11-24,"November 9, 2012",2012-11-09,"December 6, 2010",,"September 25, 2017","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01254578,716.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
893,894,NCT01810120,Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT,,Completed,No Results Available,Acute Lymphoblastic Leukemia|Leukemia Acute Myeloid - AML|Non-Hodgkin Lymphoma|Myelodysplastic Syndromes,Biological: TCR alfa beta T cell depletion,CD34+ cells|Primary and secondary graft failure|Acute and chronic GvHD|Overall survival (OS) and disease-free survival|TCR alfa beta cells,Mariella Enoc|Bambino Gesù Hospital and Research Institute,All,"3 Months to 20 Years   (Child, Adult)",Phase 1|Phase 2,30.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OPBG_359.11,2012-01-01,September 2016,2016-12-01,"March 13, 2013",,"January 23, 2017","Department of Oncology/Hematology of the Hospital Bambino Gesù (Roma), Rome, Italy",,https://ClinicalTrials.gov/show/NCT01810120,1796.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
894,895,NCT00088101,STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors,,Completed,No Results Available,Hematological Malignancies|Leukemia|Lymphoma|Metastatic or Unresectable Solid Tumors,Drug: STA-5312,,Synta Pharmaceuticals Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,42.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,5312-01,2004-02-01,,2004-12-01,"July 21, 2004",,"December 4, 2008","Wilshire Oncology Medical Group, Pamona, California, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|University of Chicago, Chicago, Illinois, United States|Tufts New England Medical Center, Boston, Massachusetts, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Carolinas HealthCare System, Charlotte, North Carolina, United States|The West Clinic, Memphis, Tennessee, United States|The Sarah Cannon Cancer Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00088101,304.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
895,896,NCT03329950,A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies,,Completed,No Results Available,Melanoma|Non-small Cell Lung Cancer|Breast Cancer|Gastric Cancer|Renal Cell Carcinoma|Ovarian Cancer|Cholangiocarcinoma|Bladder Urothelial Carcinoma|Pancreatic Adenocarcinoma|Colorectal Cancer|Esophageal Cancer|Hepatic Cancer|Head and Neck Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Other Solid Tumors|Diffuse Large B-cell Lymphoma (DLBCL)|Mantle Cell Lymphoma|Indolent B-cell Lymphomas|Non-Hodgkin Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Waldenstrom's Disease|Marginal Zone Lymphoma|Mucosa Associated Lymphoid Tissue|Small Lymphocytic Leukemia,Drug: CDX-1140|Drug: CDX-301|Drug: Pembrolizumab|Drug: Chemotherapy,Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0|Objective Response Rate|Clinical benefit rate|Duration of Response|Progression-free survival|Overall survival|Immunogenicity evaluation|Pharmacokinetic evaluation,Celldex Therapeutics|Merck Sharp & Dohme LLC,All,"18 Years and older   (Adult, Older Adult)",Phase 1,132.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDX1140-01|Keynote-A23,2017-12-01,"September 13, 2022",2022-09-13,"November 6, 2017",,"September 29, 2022","HonorHealth Research Insititute, Scottsdale, Arizona, United States|Northside Hospital, Inc., Atlanta, Georgia, United States|Georgia Cancer Center at Augusta University, Augusta, Georgia, United States|Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Gabrail Cancer Center Research LLC, Canton, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Hospital (RIH) The Miriam Hospital (TMH), Providence, Rhode Island, United States|Houston Methodist, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03329950,1747.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
896,897,NCT00558675,A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy,,Completed,No Results Available,Hematological Malignancy|Leukemia|Lymphoma|Multiple Myeloma,Biological: AlloStim,Determination of toxicity related to AlloStim infusion in accordance with NCI Common Toxicity Criteria v.3|Evaluation and reporting of anti-tumor response will be conducted in accordance with internationally accepted criteria for the disease indication being evaluated|Immunological Response,"Immunovative Therapies, Ltd.|Hadassah Medical Organization",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,6.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ITL-001-HMC,2010-12-01,December 2012,2013-03-01,"November 15, 2007",,"January 22, 2020","Hadassah-Hebrew University Medical Center, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT00558675,821.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
897,898,NCT00602693,T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer,,Completed,No Results Available,Leukemia|Lymphoma|Multiple Myeloma|Plasma Cell Neoplasm|Myelodysplastic Syndromes,Biological: umbilical cord blood transplantation|Drug: Allopurinol|Drug: fludarabine phosphate|Drug: Cyclophosphamide|Radiation: Total body irradiation|Biological: Treg infusion|Drug: Sirolimus,Maximum tolerated dose|Number of patients with detectable Treg cells|Number of Patients with grade II-IV and grade III-IV acute graft versus host disease (GVHD)|Number of patients with sustained donor engraftment|Number of patients with double chimerism|Incidence of neutrophil recovery after umbilical cord blood (UCB) transplantation|Number of Patients with Chronic Graft Versus Host Disease (GVHD)|Number of Patients with disease-free survival|Number of Patients with Fungal and Viral Infections|Incidence of platelet recovery after umbilical cord blood (UCB)|Number of Patients with Disease Relapse|Percent of Patients with Immune Cell Recovery,"Masonic Cancer Center, University of Minnesota",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,41.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2007LS022|MT2006-01|0701M00303,2007-07-23,"September 25, 2014",2015-04-16,"January 28, 2008",,"December 2, 2017","Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00602693,2824.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
900,901,NCT00082784,Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms,,Completed,No Results Available,Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Nodal Marginal Zone Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory Plasma Cell Myeloma|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia,Drug: Bortezomib|Drug: Alvocidib Hydrochloride|Other: Pharmacological Study,"Recommended phase II dose|Maximum tolerated dose, assessed according to NCI CTCAE v4.0|Response|Response duration|Time to progression|Survival",National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,93.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2009-00058|CDR0000360816|MCC 6413|MCC-6413|6413|R21CA110953|P30CA076292|N01CM00100,2004-03-01,October 2012,2014-09-01,"May 19, 2004",,"December 23, 2014","Moffitt Cancer Center, Tampa, Florida, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00082784,3836.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
901,902,NCT03820596,Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL,,Completed,No Results Available,Safety and Efficacy,Drug: Sintilimab|Drug: Chidamide,Phase 1 Study: Percentage of Participants Experiencing Adverse Events defined as Dose Limiting Toxicities (DLTs) of Chidamide.|Phase 1 Study: Maximum tolerable dose of chidamide among participants|Phase 1 Study: Maximum tolerable dose(MTD) and recommended Phase 2 dose (RP2D) of chidamide among participants|Phase 2 Safety Management Study|Efficacy of sintilimab plus chidamide in refractory and relapsed ENKTCL|Progression-Free Survival (PFS)|Duration of Response (DOR)|Overall Survival (OS),Huiqiang Huang|Sun Yat-sen University,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,40.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCENT,2019-03-29,"May 20, 2020",2021-11-30,"January 29, 2019",,"April 14, 2022","Department of hematology department, Nanfang hospital, Guangzhou, Guangdong, China|Guangdong General Hospital; Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China|Sun Yat-sen University Cancer Center, Guangzhou, China",,https://ClinicalTrials.gov/show/NCT03820596,977.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
903,904,NCT03297424,A Study of PLX2853 in Advanced Malignancies.,,Completed,No Results Available,Small Cell Lung Cancer|Uveal Melanoma|Ovarian Clear Cell Carcinoma|Non-Hodgkin Lymphoma|Advanced Malignancies|Solid Tumor|Diffuse Large B Cell Lymphoma|Follicular Lymphoma,Drug: PLX2853,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.|Area under the concentration-time curve (AUC) of PLX2853.|Maximum observed concentration (Cmax) of PLX2853.|Time to peak concentration (Tmax) of PLX2853.|Half life (t1/2) of PLX2853.|Number of participants who experience dose limiting toxicity as defined in the protocol.|Change in disease burden using RECIST 1.1 (solid tumors) or Lugano criteria (NHL).|Overall response rate (ORR) defined according to standard criteria for the relevant malignancy [Phase1b]|Duration of response (DOR)|Progression-Free Survival (PFS)|Overall Survival (OS),Opna-IO LLC,All,"18 Years and older   (Adult, Older Adult)",Phase 1,49.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PLX124-01,2017-09-12,"June 7, 2021",2021-06-07,"September 29, 2017",,"July 25, 2022","Honor Health, Scottsdale, Arizona, United States|Sylvester Comprehensive Cancer Center / University of Miami Miller School of Medicine, Miami, Florida, United States|Columbia University Medical Center, New York, New York, United States|South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States",,https://ClinicalTrials.gov/show/NCT03297424,1364.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
905,906,NCT00006362,PS-341 in Treating Patients With Advanced Cancer,,Completed,No Results Available,"Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific",Drug: bortezomib,,Mayo Clinic|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000068233|U01CA069912|P30CA015083|980111|1443-99,1999-11-01,August 2003,2003-08-01,"January 27, 2003",,"August 3, 2011","Mayo Clinic, Rochester, Minnesota, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00006362,1369.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
906,907,NCT00005988,Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy,,Completed,No Results Available,Graft Versus Host Disease|Leukemia|Lymphoma|Myelodysplastic Syndromes|Myeloma,Drug: cyclophosphamide|Drug: cyclosporine|Drug: leucovorin calcium|Drug: methotrexate|Drug: methylprednisolone|Procedure: in vitro-treated bone marrow transplantation|Radiation: radiation therapy,Incidence of primary graft failure|Incidence of hyperacute GVHD|Incidence of Grade D acute GVHD|Incidence of adverse events,Dana-Farber Cancer Institute|National Cancer Institute (NCI),All,"up to 40 Years   (Child, Adult)",Phase 1,5.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,99-205|P30CA006516|GENE-C9909-38|NCI-G00-1801|CDR0000067977,2000-02-01,"June 16, 2001",2002-03-08,"May 3, 2004",,"April 4, 2017","Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00005988,766.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
907,908,NCT03886831,A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies,,Completed,No Results Available,Relapsed/Refractory Advanced Solid Tumors|Relapsed/Refractory Diffuse Large B-cell Lymphoma|Relapsed/Refractory Myelodysplasia|Relapsed/Refractory Myelofibrosis|Adenoid Cystic Carcinoma|Relapsed/Refractory Mantle Cell Lymphoma|Relapsed/Refractory Acute Myeloid Leukemia|Refractory Chronic Myelomonocytic Leukemia,Drug: PRT543,To describe dose limiting toxicities (DLT) of PRT543|To determine the maximally tolerated dose (MTD)|To determine the recommended phase 2 dose (RP2D) and schedule of PRT543|To describe the adverse event profile and tolerability of PRT543|To determine the maximum observed plasma concentration (Cmax) of PRT543|To determine the time to reach maximum observed plasma concentration (Tmax) of PRT543,Prelude Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1,232.0,Industry,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRT543-01,2019-02-11,"November 16, 2022",2022-11-16,"March 22, 2019",,"November 25, 2022","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|UCSF Precision Cancer Medicine Building, San Francisco, California, United States|Christiana Care Health Services, Christiana Hospital, Newark, Delaware, United States|Florida Cancer Specialists, Lake Mary, Florida, United States|Florida Cancer Specialist, Sarasota, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Georgia Cancer Center at Augusta University, Augusta, Georgia, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Atlantic Health System / Morristown Medical Center, Morristown, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|The Ohio State University and Wexner Medical Center, Columbus, Ohio, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|PLLC, Nashville, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03886831,1374.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
908,909,NCT01527838,Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit,,Completed,No Results Available,Non-Hodgkin's Lymphoma (NHL)|Hodgkin's Disease|Chronic Lymphocytic Leukemia (CLL)|Acute Myelogenous Leukemia (AML)|Acute Lymphoblastic Leukemia (ALL),Biological: Single FT1050 treated UCB unit,Neutrophil engraftment/chimerism|Safety|Immune reconstitution|Donor search,Fate Therapeutics,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,10.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FT1050-02,2012-01-01,October 2013,2013-11-01,"February 7, 2012",,"September 12, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute-Hematopoietic Stem Cell Transplant Program, Boston, Massachusetts, United States|Ohio State Univeristy Comprehensive Cancer Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01527838,670.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
909,910,NCT00428545,Bevacizumab and Bortezomib in Patients With Advanced Malignancy,,Completed,No Results Available,Advanced Malignancy|Lymphoma|Myeloma|Solid Tumors,Drug: Bevacizumab|Drug: Bortezomib,Maximum tolerated dose (MTD) and Dose-limiting toxicities (DLT) of Combination Treatment with Bevacizumab and Bortezomib,M.D. Anderson Cancer Center,All,"Child, Adult, Older Adult",Phase 1,104.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2006-0764,2007-01-01,November 2012,2012-11-01,"January 30, 2007",,"February 12, 2013","UT MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00428545,2131.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
910,911,NCT01445379,Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer,,Completed,No Results Available,Sarcoma|Wilm's Tumor|Lymphoma|Neuroblastoma,Drug: Ipilimumab,To determine the tolerance and toxicity profile|Pharmacokinetics|Evaluate immunomodulatory activity.|Quantify antitumor effects,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"3 Years to 21 Years   (Child, Adult)",Phase 1,33.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,080007|08-C-0007,2007-10-01,"April 18, 2014",2015-11-13,"October 3, 2011",,"December 17, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01445379,2965.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
911,912,NCT00891137,Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy,,Completed,No Results Available,Leukemia|Lymphoma|Multiple Myeloma|Plasma Cell Neoplasm|Myelodysplastic Syndromes,Biological: human myeloid progenitor cells,Safety and tolerability|Neutrophil and platelet recovery|Persistence of CLT-008 derived cells|Graft-versus-host disease (GVHD)|Non-relapse mortality|Infections,Cellerant Therapeutics|Department of Health and Human Services,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Phase 1,30.0,Industry|U.S. Fed,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,MT 2008-38,2009-04-01,June 2014,2014-06-01,"May 1, 2009",,"October 27, 2014","Children's Hospital of Orange County, Orange, California, United States|Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States|University of Minnesota: Masonic Cancer Center, BMT Clinic, and Fairview Medical Center, Minneapolis, Minnesota, United States|Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00891137,1887.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Supportive Care
913,914,NCT00248430,Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer,,Completed,No Results Available,Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm,Biological: aldesleukin|Biological: therapeutic allogeneic lymphocytes|Drug: melphalan|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation,"Feasibility|Toxicity|Extent, degree, and duration of donor chimerism|Complete response rate",Fred Hutchinson Cancer Center,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 1|Phase 2,20.0,Other,Interventional,Primary Purpose: Treatment,1838.00|FHCRC-1838.00|CDR0000430694,2003-08-01,,2007-07-01,"November 4, 2005",,"September 21, 2010","Seattle Cancer Care Alliance, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00248430,1430.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
914,915,NCT00943319,Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies,,Completed,Has Results,Leukemia|Lymphoma|Myeloma,Drug: Busulfan|Drug: Fludarabine|Drug: Campath|Procedure: Stem Cell Transplant,Maximum Tolerated Dose|Overall Survival|Disease Free Survival,University of Chicago,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,50.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12-0132,2012-03-01,December 2017,2018-12-01,"July 22, 2009","February 4, 2019","February 4, 2019","The University of Chicago, Chicago, Illinois, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT00943319/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT00943319,2466.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
915,916,NCT00544284,Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment,,Completed,No Results Available,"Brain and Central Nervous System Tumors|Lymphoma|Metastatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: bortezomib|Drug: temozolomide|Other: pharmacological study,Dose-limiting toxicity and maximum tolerated dose|Pharmacokinetics|Confirmed complete or partial response|Percentage of patients with 6-month progression-free survival,City of Hope Medical Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,25.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,04032|P30CA033572|CHNMC-04032|CDR0000570245,2005-01-01,January 2012,2012-01-01,"October 16, 2007",,"February 15, 2013","City of Hope Comprehensive Cancer Center, Duarte, California, United States|City of Hope Medical Group, Pasadena, California, United States",,https://ClinicalTrials.gov/show/NCT00544284,2556.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
916,917,NCT00556452,Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen,,Completed,Has Results,Leukemia|Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Multiple Myeloma|Myelodysplastic Syndrome,Drug: Clofarabine/Busulfan x 4|Procedure: Peripheral blood stem cell transplant|Radiation: Total Lymphoid Irradiation,Regimen Related Toxicities|One-year Overall Survival Rate for AML|Two-year Overall Survival for All Cases.|Five Year Overall Survival for All Cases,"University of Michigan Rogel Cancer Center|Genzyme, a Sanofi Company",All,"up to 70 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,46.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UMCC 2007.055,2007-10-01,June 2011,2012-09-01,"November 12, 2007","January 13, 2015","December 5, 2017","University of Michigan, Department of Internal Medicine, Blood and Marrow Transplant Program, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00556452,1797.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
917,918,NCT03263637,"Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies",,Completed,No Results Available,Relapsed or Refractory Haematological Malignancies Including|Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|High Risk Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Richter's Syndrome|B-cell Non-Hodgkin Lymphoma|T-cell Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma|Multiple Myeloma,Drug: AZD4573,Incidence of adverse events|Dose limiting toxicities|Maximum tolerated dose|Maximum observed plasma concentration of AZD4573|Area under the concentration-time curve for plasma concentrations of AZD4573|Volume of distribution (Vd).|Clearance (CL).|Antitumor activity of AZD4573 in patients by assessing overall response rate (ORR).|Duration of response (DOR)|Antitumor activity of AZD4573 in patients by assessing overall survival (OS).|Minimal Residual Disease (MRD)|Progression free survival (PFS),AstraZeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 1,44.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D8230C00001,2017-10-24,"September 30, 2021",2021-09-30,"August 28, 2017",,"October 22, 2021","Research Site, Aachen, Germany|Research Site, Bonn, Germany|Research Site, Göttingen, Germany|Research Site, Heidelberg, Germany|Research Site, Ulm, Germany|Research Site, Amsterdam, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Cardiff, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Southampton, United Kingdom|Research Site, Sutton, United Kingdom",,https://ClinicalTrials.gov/show/NCT03263637,1437.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
918,919,NCT01871805,A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC),,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Alectinib,Number of Participants With Dose Limiting Toxicities (DLTs): Phase I|Recommended Phase II Dose (RP2D): Phase I|Percentage of Participants With Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Independent Review Committee (IRC): Phase II|Percentage of Participants With Objective Response According to RECIST v1.1 by Investigator: Phase I|Duration of Response (DOR) According to RECIST v1.1 by Investigator: Phase I|Percentage of Participants With Objective Response According to RECIST v1.1 by Investigator: Phase II|Percentage of Participants With Disease Control According to RECIST v1.1 by Investigator: Phase II|Percentage of Participants With Disease Progression According to RECIST v1.1 by IRC or Death : Phase II|Progression-Free Survival (PFS) According to RECIST v1.1 by IRC: Phase II|Percentage of Participants With Disease Progression According to RECIST v1.1 by Investigator or Death : Phase II|PFS According to RECIST v1.1 by Investigator: Phase II|Percentage of Participants Who Died Due to Any Cause: Phase II|Overall Survival (OS) Time: Phase II|DOR According to RECIST v1.1 by IRC: Phase II|DOR According to RECIST v1.1 by Investigator: Phase II|Percentage of Participants With Central Nervous System Objective Response (COR) According to RECIST v1.1 by IRC: Phase II|Percentage of Participants With COR According to Response Assessment in Neuro-Oncology (RANO) Criteria by IRC: Phase II|CNS Duration of Response (CDOR) According to RECIST v1.1 by IRC: Phase II|CDOR According to RANO Criteria by IRC: Phase II|Percentage of Participants With CNS Progression According to RECIST v1.1 by IRC: Phase II|Percentage of Participants With CNS Progression According to RANO Criteria by IRC: Phase II|Maximum Observed Plasma Concentration (Cmax) After Single Dose of Alectinib: Phase I|Cmax After Multiple Dose of Alectinib: Phase I|Area Under the Plasma Concentration (AUC) Versus Time Curve Extrapolated to Infinity (AUCinf) After Single Dose of Alectinib: Phase I|AUC From Time Zero to Last Measurable Concentration (AUClast) After Multiple Dose of Alectinib: Phase I|Ctrough After Multiple Dose of Alectinib: Phase II|Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30): Phase II|Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13): Phase II,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,134.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NP28761,2013-09-30,"October 24, 2014",2017-08-31,"June 7, 2013","February 12, 2016","August 21, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California Irvine, Irvine, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|Loma Linda Cancer Center, Loma Linda, California, United States|UCLA, Los Angeles, California, United States|Univ of Colorado Canc Ctr, Aurora, Colorado, United States|National Jewish Health, Denver, Colorado, United States|Lynn Regional Cancer Center West, Boca Raton, Florida, United States|Florida Hospital Cancer Inst, Orlando, Florida, United States|UF Health Orlando, Orlando, Florida, United States|H. Lee Moffitt Cancer Center and Research Inst., Tampa, Florida, United States|University of Illinois Cancer Center, Chicago, Illinois, United States|Monroe Medical Associates; Ingalls Memorial Hosp, Harvey, Illinois, United States|Massachussets General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Can Ins, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|St. Joseph Mercy Hospital; Cancer Care Center., Ann Arbor, Michigan, United States|Wayne State Uni ; Karmanos Cancer Center, Detroit, Michigan, United States|Hackensack Univ Med Ctr, Hackensack, New Jersey, United States|Roswell Park Cancer Inst., Buffalo, New York, United States|Memorial Sloan-Kettering Cancer Center, Commack, New York, United States|Richmond University Medical Center; Pharmacy Department, Staten Island, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Oregon Health & Science Uni, Portland, Oregon, United States|St. Luke's Hospital; Pharmacy Department, Bethlehem, Pennsylvania, United States|Penn State Hershey Cancer Institute, Hershey, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Pavillion, Pittsburgh, Pennsylvania, United States|MUSC Hollings Cancer Center, Charleston, South Carolina, United States|Center for Biomedical Research LLC, Knoxville, Tennessee, United States|Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Swedish Cancer Inst., Seattle, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|Lakeridge Health Oshawa; Oncology, Oshawa, Ontario, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01871805,1431.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
919,920,NCT00104975,Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer,,Completed,No Results Available,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,Biological: alemtuzumab|Biological: therapeutic allogeneic lymphocytes|Drug: fludarabine phosphate|Drug: melphalan|Drug: tacrolimus|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation,,Yale University|National Cancer Institute (NCI),All,18 Years to 55 Years   (Adult),Phase 1,20.0,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000413698|YALE-25971|NCI-6765,2005-02-01,May 2008,2008-05-01,"March 4, 2005",,"December 15, 2016","Yale Cancer Center, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00104975,1185.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
922,923,NCT01801111,A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment,,Completed,Has Results,Non-Small-Cell Lung Carcinoma,Drug: Erlotinib|Drug: Alectinib,"Recommended Phase 2 Dose (RP2D) of Alectinib|Percentage of Participants With Dose Limiting Toxicities (DLTs)|Percentage of Participants Achieving Objective Response (Complete Response [CR] or Partial Response [PR]) as Assessed by Independent Radiological Review Committee (IRC) in Response Evaluable (RE) Population|Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by IRC in Chemotherapy-Pretreated Participants|Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by IRC in Chemotherapy-Naive Participants|Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by Investigator in RE Population|Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by Investigator in Chemotherapy-Pretreated Participants|Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by Investigator in Chemotherapy-Naive Participants|Duration of Response (DoR) as Assessed by IRC in RE Population|Percentage of Participants With PD as Assessed by IRC According to RECIST v1.1 or Death From Any Cause in Safety Population|Progression Free Survival (PFS) as Assessed by IRC in Safety Population|Percentage of Participants Who Died of Any Cause|Overall Survival (OS)|Percentage of Participants Achieving CR, PR or Stable Disease (SD) According to RECIST v1.1 in RE Population|Percentage of Participants Achieving Central Nervous System (CNS) Objective Response as Assessed by IRC According to RECIST v1.1|Percentage of Participants Achieving CNS Objective Response as Assessed by IRC According to Radiology Assessment in Neuro-Oncology (RANO) Criteria|CNS Duration of Response (CDoR) as Assessed by IRC According to RECIST v1.1|CDoR as Assessed by IRC According to RANO Criteria|Percentage of Participants With CNS Progression as Assessed by IRC According to RECIST v 1.1|Maximum Observed Plasma Concentration (Cmax) of Alectinib|Time to Cmax (Tmax) of Alectinib|Time to Last Measurable Plasma Concentration (Tlast) of Alectinib|Area Under the Plasma Concentration-Time Curve From Time 0 to 10 Hours Post-dose (AUC[0-10]) of Alectinib|Area Under the Plasma Concentration-Time Curve From Time 0 to Tlast (AUC[0-last]) of Alectinib|Cmax of Alectinib Metabolite|Tmax of Alectinib Metabolite|Tlast of Alectinib Metabolite|AUC(0-10) of Alectinib Metabolite|AUC(0-last) of Alectinib Metabolite|Metabolite to Parent Ratio Based on AUC(0-10)|Metabolite to Parent Ratio Based on AUC(0-last)|Trough Plasma Concentration (Ctrough) of Alectinib|Ctrough of Alectinib Metabolite|Peak to Trough Ratio of Alectinib|Accumulation Ratio of Alectinib|Accumulation Ratio of Alectinib Metabolite",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,138.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NP28673|2012-004455-36,2013-06-20,"October 24, 2014",2017-10-27,"February 28, 2013","May 26, 2016","November 2, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|St. Jude Heritage Healthcare, Fullerton, California, United States|UC Irvine Medical Center, Orange, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|UCLA Cancer Center; Premiere Oncology, A Medical Corporation, Santa Monica, California, United States|Advanced Medical Specialties, Miami, Florida, United States|Florida Hospital Cancer Inst, Orlando, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Midwestern Regional Medical Center; Office of Research, Zion, Illinois, United States|Washington University; Wash Uni. Sch. Of Med, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Columbia University Medical Center; Department of Hematology/Oncology, New York, New York, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Texas Oncology, P.A., Dallas, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Prince Charles Hospital, Chermside, Queensland, Australia|Townsville General Hospital, Douglas, Queensland, Australia|UZ Antwerpen, Edegem, Belgium|UZ Gent, Gent, Belgium|AZ Delta (Campus Wilgenstraat), Roeselare, Belgium|University Hospital Herlev, Herlev, Denmark|CHU Angers - Hôpital Hôtel Dieu, Angers, France|Hopital Morvan, Brest, France|Centre Francois Baclesse, Caen, France|Centre Georges François Leclerc; Service Pharmacie, Bp 77980, Dijon, France|CHU de Grenoble - Hôpital Nord; Service d'Oncologie Thoracique, Grenoble, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|Hôpital Nord - AP-HM Marseille#; Gastroenterology and Hepatology, Marseille cedex 20, France|Groupe Hospitalier Sud - Hôpital Haut Lévêque, Pessac, France|Hopital Pontchaillou - CHU de Rennes, Rennes, France|ICO Rene Gauducheau; CEC, St Herblain, France|Nouvel Hopital Civil - CHU Strasbourg, Strasbourg, France|CHU de Toulouse - Hôpital Larrey, Toulouse, France|Charité Campus Virchow-Klinikum; Department of Cardiology, Berlin, Germany|Diakonie Kaiserswerth; Florence-Nightingale-Krankenhaus, Düsseldorf, Germany|LungenClinic Großhansdorf, Großhansdorf, Germany|Lungenklinik Hemer, Hemer, Germany|Klinikum Koeln-Merheim, Koeln, Germany|Mathias-Spital Rheine, Rheine, Germany|A.O. Universitaria Di Parma, Parma, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO), Aviano, Friuli-Venezia Giulia, Italy|Istituto Nazionale Tumori Regina Elena IRCCS, Roma, Lazio, Italy|AO San Camillo Forlanini, Roma, Lazio, Italy|Ospedale San Raffaele, Milano, Lombardia, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, Italy|Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda), Milano, Lombardia, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Toscana, Italy|Ospedale Versilia, Lido Di Camaiore, Toscana, Italy|Presidio Ospedaliero Campo di Marte, Lucca, Toscana, Italy|Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia, Perugia, Umbria, Italy|National Cancer Center, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System; Pharmacy, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg|Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Maastricht University Medical Centre; Afdeling Klinische Farmacie en Toxicologie, Maastricht, Netherlands|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin""; Chemotherapy Departement, Moskva, Moskovskaja Oblast, Russian Federation|National University Hospital; Investigational Medicine Unit, Singapore, Singapore|Johns Hopkins Singapore, Singapore, Singapore|Hospital General Univ. de Alicante, Alicante, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitario Quiron Dexeus, Barcelona, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Regional Universitario de Malaga, Malaga, Spain|Hosp Clinico Univ Lozano Blesa, Zaragoza, Spain|Karolinska, Stockholm, Sweden|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung Univ Hosp, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Royal Marsden Hospital;Dept of Haematology Oncology Research, London, United Kingdom|Royal Marsden Hospital - London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01801111,1590.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
923,924,NCT00003077,Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss,,Completed,No Results Available,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm,Dietary Supplement: omega-3 fatty acid,survival,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1|Phase 2,63.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,CALGB-9473|U10CA031946|CLB-9473|NCI-P97-0097|CDR0000065766,1995-10-01,July 2004,2004-11-01,"October 22, 2003",,"July 13, 2016","CCOP - Christiana Care Health Services, Wilmington, Delaware, United States|Holden Comprehensive Cancer Center at The University of Iowa, Iowa City, Iowa, United States|North Shore University Hospital, Manhasset, New York, United States|New York Presbyterian Hospital - Cornell Campus, New York, New York, United States|CCOP - Southeast Cancer Control Consortium, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00003077,3319.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Supportive Care
924,925,NCT00053118,Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer,,Completed,No Results Available,Brain and Central Nervous System Tumors|Lymphoma|Neuroblastoma|Retinoblastoma,Biological: filgrastim|Drug: carboplatin|Drug: etoposide|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation,,Roswell Park Cancer Institute,All,"up to 18 Years   (Child, Adult)",Phase 1,1.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000269284|RPCI-DS-00-03,2002-03-01,July 2004,2004-07-01,"January 28, 2003",,"March 1, 2011","St. Louis Children's Hospital, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00053118,853.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
925,926,NCT00002750,Melphalan in Patients With Neoplastic Meningitis,,Completed,No Results Available,Brain and Central Nervous System Tumors|Extragonadal Germ Cell Tumor|Leukemia|Lymphoma|Ovarian Cancer,Drug: melphalan,,Duke University,All,"3 Years and older   (Child, Adult, Older Adult)",Phase 1,6.0,Other,Interventional,Primary Purpose: Treatment,2117|DUMC-2117-00-11R8|DUMC-1631-96-11R4|DUMC-1728-97-11R5|DUMC-1818-98-11R6|DUMC-1961-99-11R7|NCI-V96-0869|CDR0000064684,1992-12-01,May 2001,2001-05-01,"May 24, 2004",,"February 20, 2013","Duke Comprehensive Cancer Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00002750,3073.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
926,927,NCT02265731,Study Evaluating Venetoclax in Subjects With Hematological Malignancies,,Completed,No Results Available,Non-Hodgkin Lymphoma (NHL)|Multiple Myeloma (MM)|Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)|Acute Myeloid Leukemia (AML),Drug: azacitadine|Drug: venetoclax|Drug: rituximab / IDEC-C2B8,Number of participants having treatment-emergent adverse events|Time to maximum plasma concentration (Tmax) of venetoclax|Maximum plasma concentration (Cmax) of venetoclax|Area under the plasma concentration-time curve from 0 to 24 hours (AUC24) post-dose of venetoclax|Objective Response Rate (Phase 2)|Objective Response Rate (Phase 1)|Minimal Residual Disease (MRD)|Duration of Response|Time to disease progression|complete response or remission (CR) rate|Partial response or remission (PR) rate|Progression Free Survival (PFS),"AbbVie|Genentech, Inc.",All,"20 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,38.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M13-834,2014-09-22,"March 12, 2021",2021-03-12,"October 16, 2014",,"August 2, 2021","Nagoya City University Hospital /ID# 129278, Nagoya shi, Aichi, Japan|NHO Nagoya Medical Center /ID# 129222, Nagoya-shi, Aichi, Japan|Aichi Cancer Center Hospital /ID# 129061, Nagoya-shi, Aichi, Japan|University of Fukui Hospital /ID# 165801, Yoshida-gun, Fukui, Japan|National Hospital Organization Kyushu Cancer Center /ID# 149741, Fukuoka-shi, Fukuoka, Japan|Kyushu University Hospital /ID# 163202, Fukuoka-shi, Fukuoka, Japan|Kobe City Medical Center General Hospital /ID# 170919, Kobe-shi, Hyogo, Japan|Tohoku University Hospital /ID# 129275, Sendai-shi, Miyagi, Japan|Kindai University Hospital /ID# 169554, Osakasayama-shi, Osaka, Japan|Osaka University Hospital /ID# 169862, Suita-shi, Osaka, Japan|National Cancer Center Hospital /ID# 129044, Chuo-ku, Tokyo, Japan|The Cancer Institute Hospital Of JFCR /ID# 129277, Koto-ku, Tokyo, Japan|Toranomon Hospital /ID# 148229, Minato-ku, Tokyo, Japan|NTT Medical Center Tokyo /ID# 166281, Shinagawa-ku, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT02265731,2363.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
927,928,NCT01697020,Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions,,Completed,No Results Available,Acute Lymphoblastic Leukemia,Drug: Mercaptopurine 20mg/ml oral suspension|Drug: Mercaptopurine 50mg tablet,Bioequivalence,Nova Laboratories Limited,Male,18 Years to 50 Years   (Adult),Phase 1,70.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INV298,2012-09-01,November 2012,2012-11-01,"October 2, 2012",,"December 2, 2013","Parexel International, Bloemfontein Early Phase Clinical Unit, Bloemfontein, South Africa",,https://ClinicalTrials.gov/show/NCT01697020,61.0,Industry Lead,Less than three Conditions,Randomized,Crossover Assignment,None (Open Label),Treatment/Diagnostic
928,929,NCT01752426,"Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL",,Completed,Has Results,Leukemia,Other: Heavy Water (2H2O)|Drug: PCI-32765,Change in Leukemia Cell Death|Percentage of Recently Born Leukemia Cells Mobilized Into the Blood by PCI-32765 Treatment,M.D. Anderson Cancer Center|Pharmacyclics LLC.,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012-0086|NCI-2013-00029,2012-12-17,"August 9, 2018",2018-08-09,"December 19, 2012","February 24, 2020","February 24, 2020","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT01752426/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01752426,2061.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
930,931,NCT00406809,A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies,,Completed,No Results Available,Chronic Lymphoid Leukemia|Lymphoid Malignancies|Non-Hodgkin's Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma|Peripheral T-cell Lymphoma,Drug: ABT-263,"Phase 1a: Determine dose limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase 2 dose (RPTD) and schedule - intermittent dosing.|Phase 1b: Determine dose limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase 2 dose (RPTD) and schedule - continuous dosing.|Phase 2a: Continued assessment of safety profile at the recommended Phase 2 dose (RPTD) and schedule - continuous dosing.|Phase 2a: Assessment of preliminary efficacy signals including biomarker assessment - continuous dosing.|Extension Study: Continued assessment of the safety profile of ABT-263|Extension Study: Continued assessment of the preliminary efficacy signals of ABT-263.|Phase 1a or Phase 1b safety assessment|Phase 1a, Phase 1b, or Phase 2a pharmacokinetic profile evaluation|Phase 1a effect of food on bioavailability","AbbVie (prior sponsor, Abbott)|AbbVie",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1|Phase 2,81.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M06-814,2006-11-01,October 2016,2016-10-01,"December 4, 2006",,"August 2, 2021","Site Reference ID/Investigator# 4997, Los Angeles, California, United States|Site Reference ID/Investigator# 9104, Los Angeles, California, United States|Site Reference ID/Investigator# 2613, Bethesda, Maryland, United States|Site Reference ID/Investigator# 40243, Boston, Massachusetts, United States|Site Reference ID/Investigator# 4745, Boston, Massachusetts, United States|Site Reference ID/Investigator# 2628, Buffalo, New York, United States|Site Reference ID/Investigator# 23543, New York, New York, United States|Site Reference ID/Investigator# 2627, New York, New York, United States|Site Reference ID/Investigator# 2614, New York, New York, United States|Site Reference ID/Investigator# 5383, New York, New York, United States|Site Reference ID/Investigator# 12306, Rochester, New York, United States|Site Reference ID/Investigator# 8941, Edmonton, Canada",,https://ClinicalTrials.gov/show/NCT00406809,3622.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
931,932,NCT00299767,Phase I Study of Sequential Cord Blood Transplants,,Completed,No Results Available,Lymphoma|Leukemia|Multiple Myeloma|Myelodysplastic Syndrome,Procedure: sequential cord blood transplantation,"To evaluate the 100-day transplant-related (non-relapse) mortality, including relapse-related mortality associated with Grade 4 toxicity.|To evaluate the 6 month transplant related (non-relapse) mortality.|To evaluate the days to neutrophil engraftment (ANC > 500).|To evaluate the days of platelet engraftment (platelet count > 20K unsupported).|To evaluate the risk of acute and chronic graft versus host disease.|To evaluate percent donor chimerism - contribution of each cord unit.|To evaluate relapse rate.|To evaluate overall survival.|To evaluate transfusion support needed to cord blood transplant recipients.",Massachusetts General Hospital|Dana-Farber Cancer Institute,All,"up to 65 Years   (Child, Adult, Older Adult)",Phase 1,21.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,03-061,2003-05-01,May 2005,2009-05-01,"March 7, 2006",,"May 11, 2016","Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00299767,2192.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
932,933,NCT03018223,Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT,,Completed,Has Results,Non-Hodgkin's Lymphoma|Acute Leukemia in Remission|Chronic Myeloid Leukemia|Primary Myelofibrosis|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes|Hodgkin Lymphoma|Multiple Myeloma,Drug: Fludarabine|Drug: Busulfan|Drug: Cyclophosphamide|Radiation: Total body irradiation (TBI)|Procedure: Peripheral Blood Hematopoietic Cell Transplantation (HCT)|Drug: Sirolimus (SIR)|Drug: Mycophenolate mofetil (MMF)|Drug: Granulocyte-colony stimulating factor (G-CSF),Incidence of Grade II-IV Acute Graft vs. Host Disease (GVHD)|Incidence of Chronic GVHD|Overall Survival (OS)|Progression Free Survival (PFS),H. Lee Moffitt Cancer Center and Research Institute,All,"18 Years and older   (Adult, Older Adult)",Phase 1,32.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,MCC-18766,2017-01-31,"December 15, 2018",2021-03-18,"January 11, 2017","January 21, 2020","September 16, 2021","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT03018223/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03018223,1507.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
933,934,NCT02223052,Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies,,Completed,No Results Available,Hematological Neoplasms|Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma|Lymphoma|Multiple Myeloma|Acute Myeloid Leukemia|Leukemia|Myelodysplastic Syndromes|Neoplasms|Melanoma|Breast Cancer|Metastatic Breast Cancer|Non-Small Cell Lung Cancer|Small Cell Lung Cancer|Renal Cell Carcinoma|Glioblastoma Multiforme|Osteosarcoma|Sarcoma|Thyroid Cancer|Genitourinary,Drug: CC-486|Drug: Vidaza,Pharmacokinetics Cmax - Stage I (Bioequivalence)|Pharmacokinetics Tmax - Stage I (Bioequivalence)|Pharmacokinetics AUC-t - Stage I (Bioequivalence)|Pharmacokinetics AUC-infinity - Stage I (Bioequivalence)|Pharmacokinetics λz (Terminal Rate) - Stage I (Bioequivalence)|Pharmacokinetics Terminal Half-Life (t½) - Stage I (Bioequivalence)|Pharmacokinetics Apparent total clearance (CL/F) - Stage I (Bioequivalence)|Pharmacokinetics Apparent volume of distribution (Vd/F) - Stage I (Bioequivalence)|Pharmacokinetics Cmax - Stage II (Food Effect Bioavailability)|Pharmacokinetics Tmax - Stage II (Food Effect Bioavailability)|Pharmacokinetics AUC-t - Stage II (Food Effect Bioavailability)|Pharmacokinetics AUC-infinity - Stage II (Food Effect Bioavailability)|Pharmacokinetics λz (Terminal Rate) - Stage II (Food Effect Bioavailability)|Pharmacokinetics Terminal Half-Life (t½) - Stage II (Food Effect Bioavailability)|Pharmacokinetics Apparent total clearance (CL/F) - Stage II (Food Effect Bioavailability)|Pharmacokinetics Apparent volume of distribution (Vd/F) - Stage II (Food Effect Bioavailability)|Adverse Events (AEs),Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 1,89.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CC-486-CAGEN-001,2014-10-27,"June 11, 2018",2018-12-18,"August 22, 2014",,"May 12, 2020","Scottsdale Healthcare Research Institute, Scottsdale, Arizona, United States|Mayo Clinic - Arizona, Scottsdale, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|University of Iowa, Iowa City, Iowa, United States|Henry Ford Health System, Detroit, Michigan, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Greenville Hospital System, Greenville, South Carolina, United States|Vanderbilt- Ingram Cancer Center, Nashville, Tennessee, United States|The Methodist Hospital Research Institute l, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02223052,1513.0,Industry Lead,More than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
934,935,NCT01658319,Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies,,Completed,No Results Available,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Chronic Lymphocytic Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia,Drug: fludarabine phosphate|Drug: methoxyamine|Other: laboratory biomarker analysis|Other: pharmacological study|Genetic: western blotting|Other: mass spectrometry|Genetic: DNA analysis,"Maximum Tolerated Dose (MTD) of methoxyamine given in conjunction with fludarabine in subjects with relapsed or refractory hematologic malignancies|MTD of methoxyamine given in conjunction with fludarabine in subjects with relapsed or refractory hematologic malignancies|Number of Participants with Adverse Events as a Measure of Dose limiting toxicities of the combination of methoxyamine and fludarabine|Pharmacokinetics of methoxyamine when given in combination with fludarabine as determined by methoxyamine levels at different time points.|Number of apurinic/pyrimidinic (AP) sites.|Change in miRNA profiles in CLL cells in a cohort of CLL patients|Number of DNA strand breaks determination by comet assay to monitor drug effects on DNA damage in clinical studies.|Measure of Proteins (Bcl-2, Bax, cleaved PARP, Topoisomerase I and II, GammaH2AX)",Case Comprehensive Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CASE2Y10|NCI-2010-02141,2011-05-01,February 2015,2015-05-01,"August 7, 2012",,"August 13, 2015","Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01658319,1461.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
935,936,NCT00001683,"A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer",,Completed,No Results Available,Lymphoma|Melanoma|Neoplasm Metastasis|Renal Cell Carcinoma,Drug: COL-3,,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",Phase 1,35.0,NIH,Interventional,Primary Purpose: Treatment,980015|98-C-0015,1997-10-01,,2003-08-01,"November 4, 1999",,"March 4, 2008","National Cancer Institute (NCI), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00001683,2130.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
936,937,NCT03239392,A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL,,Completed,No Results Available,LGL Leukemia|CTCL,Drug: BNZ132-1-40,"Incidence, severity and relationship of treatment-emergent adverse events|Pharmacodynamics|Single-dose and steady-state Cmax|Single-dose and steady-state AUC|Steady-state Elimination half-life (t1/2)",Bioniz Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,50.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BNZ1-CT-201,2018-04-01,"June 30, 2020",2020-06-30,"August 4, 2017",,"May 25, 2021","City of Hope National Medical Center, Duarte, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|The James Cancer Center, Ohio State University, Columbus, Ohio, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT03239392,821.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
937,938,NCT02167958,"Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source",,Completed,No Results Available,Leukemia|MDS|Myelofibrosis|Lymphoma,Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Mesna|Radiation: Total Body Irradiation|Other: Hematopoietic stem cell infusion|Drug: Tacrolimus|Drug: Mycophenolate|Drug: G-CSF,Acute GvHD|Chronic Graft-versus-Host Disease|Nonrelapse Mortality (NRM)|Relapse of Malignancy|Neutrophil Recovery|Primary graft failure|Secondary graft failure|Platelet recovery|Donor Cell Engraftment|Progression-free Survival|Infections,"Rafic Farah, MD|University of Pittsburgh",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,28.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-131,2015-02-11,"September 21, 2019",2019-09-21,"June 19, 2014",,"October 15, 2019","UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02167958,1683.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
938,939,NCT01484015,Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia,,Completed,No Results Available,"Adult Acute Lymphoblastic Leukemia|Adult Acute Myeloid Leukemia|Adult Burkitt Lymphoma|Adult Diffuse Large Cell Lymphoma|Adult Diffuse Mixed Cell Lymphoma|Adult Diffuse Small Cleaved Cell Lymphoma|Adult Hodgkin Lymphoma|Adult Immunoblastic Large Cell Lymphoma|Adult Lymphoblastic Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Breast Cancer|Chronic Eosinophilic Leukemia|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Cutaneous T-cell Non-Hodgkin Lymphoma|Disseminated Neuroblastoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3 Follicular Lymphoma|Malignant Testicular Germ Cell Tumor|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Multiple Myeloma|Mycosis Fungoides/Sezary Syndrome|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Neutropenia|Nodal Marginal Zone B-cell Lymphoma|Ovarian Epithelial Cancer|Ovarian Germ Cell Tumor|Plasma Cell Neoplasm|Poor Prognosis Metastatic Gestational Trophoblastic Tumor|Primary Myelofibrosis|Prolymphocytic Leukemia|Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma",Drug: cefepime hydrochloride,Defervescence (without hypothermia)|Clinical success or failure|Need for additional antimicrobials|Mortality (in-house)|Time to defervescence|Hospital length of stay|Successful treatment of baseline infection,Wake Forest University Health Sciences|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,70.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00015247|NCI-2011-02422|CCCWFU 02110,2011-02-01,June 2012,2012-10-01,"December 2, 2011",,"July 18, 2018","Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01484015,608.0,Not Industry Lead,More than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
941,942,NCT01523223,Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies,,Completed,No Results Available,Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Relapsing Chronic Myelogenous Leukemia|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia,Biological: therapeutic allogeneic lymphocytes,"Occurrence (individual listings and summary) of dose-limiting toxicities|Incidence of GVHD|Disease response as assessed by complete remission, partial remission, stable disease, and progressive disease from radiographic and cellular or tissue samples|Incidence of donor-specific chimerism assessed by STR analysis",Robert Lowsky|National Cancer Institute (NCI)|Stanford University,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,16.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BMT243|NCI-2012-00044|SU-01272012-9028|22626,2012-01-01,September 2016,2016-10-01,"February 1, 2012",,"March 19, 2019","Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01523223,1735.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
942,943,NCT00001444,A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms,,Completed,No Results Available,Breast Cancer|Lymphoma|Neoplasm|Prostatic Neoplasm,Drug: 7-hydroxystaurosporine (UCN-01),,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",Phase 1,51.0,NIH,Interventional,Primary Purpose: Treatment,950171|95-C-0171,1995-08-01,,2002-05-01,"November 4, 1999",,"March 4, 2008","National Cancer Institute (NCI), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00001444,2465.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
944,945,NCT00001830,Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants,,Completed,No Results Available,Chronic Lymphocytic Leukemia|Graft vs Host Disease|Hodgkin's Disease|Multiple Myeloma|Non Hodgkin's Lymphoma,Drug: Th2 cells in allo HSCTT|Drug: Th2 Cells,,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"12 Years to 75 Years   (Child, Adult, Older Adult)",Phase 1,110.0,NIH,Interventional,Primary Purpose: Treatment,990143|99-C-0143,1999-07-20,,2015-05-19,"November 4, 1999",,"July 5, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00001830,5782.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
945,946,NCT00187109,"Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy",,Completed,No Results Available,Germ Cell Tumors|Hepatic Cancer|Neuroblastoma|Osteosarcoma|Rhabdomyosarcoma,Drug: Recombinant Human Thrombopoietin,"To evaluate the safety of recombinant human thrombopoietin following chemotherapy which includes ifosfamide, carboplatin and etoposide for solid tumors and lymphoma.|To evaluate whether recombinant human thrombopoietin will reduce the time necessary for platelet counts to recover following chemotherapy.",St. Jude Children's Research Hospital,All,"up to 21 Years   (Child, Adult)",Phase 1|Phase 2,40.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TPO,2000-06-01,February 2007,2007-02-01,"September 16, 2005",,"April 10, 2008","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00187109,2436.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
947,948,NCT01704963,A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms,,Completed,No Results Available,Recurrent Mature B-cell Neoplasms,Drug: PCI-32765,Number of patients with adverse events|Area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration (AUClast)|Area under the plasma concentration-time curve from time 0 to infinity time (AUC∞)|Maximum plasma concentration (Cmax)|Time to reach maximum plasma concentration (tmax)|Terminal elimination half-life (t1/2)|Pharmacodynamic evaluations|Tumor response,Janssen Pharmaceutical K.K.|Pharmacyclics LLC.,All,"20 Years and older   (Adult, Older Adult)",Phase 1,15.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR100896|PCI-32765-JPN-101,2012-09-12,"November 20, 2015",2017-02-01,"October 12, 2012",,"February 5, 2018","Kyoto, Japan|Nagoya, Japan|Sendai, Japan|Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01704963,1603.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
948,949,NCT00891072,"Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",,Completed,No Results Available,"Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",Drug: R-(-)-gossypol acetic acid|Drug: paclitaxel|Drug: carboplatin|Other: pharmacological study,"MTD, defined as the highest dose level below the maximally administered dose at which no more than 1 out of 6 patients experience DLT graded according to NCI CTCAE version 4.0|AT-101 level (bound and unbound)|Paclitaxel level (bound and unbound)|Pharmacokinetics of AT-101|Pharmacokinetics of paclitaxel",National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,36.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2012-03109|050905|U01CA132194|CDR0000640622,2009-07-01,April 2011,2011-04-01,"April 30, 2009",,"January 10, 2013","Cancer Institute of New Jersey, New Brunswick, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00891072,639.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
950,951,NCT04543305,A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies,,Completed,No Results Available,Multiple Myeloma|Acute Myeloid Leukemia|Non Hodgkin Lymphoma|Myelodysplastic Syndromes,Drug: PRT1419,To describe dose limiting toxicities (DLT) of PRT1419|To determine the maximally tolerated dose (MTD) and/or optimal biological dose (OBD)|To determine the recommended phase 2 dose (RP2D) and schedule of PRT1419|To describe the adverse event profile and tolerability of PRT1419|To describe the pharmacokinetic profile of PRT1419|To describe any anti-tumor activity of PRT1419,Prelude Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1,16.0,Industry,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRT1419-01,2020-09-28,"March 21, 2022",2022-03-21,"September 10, 2020",,"November 15, 2022","Colorado Blood Cancer Institute, Denver, Colorado, United States|Florida Cancer Specialists, Lake Mary, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04543305,539.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
951,952,NCT02960646,Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies,,Completed,No Results Available,"Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Aplastic Anemia|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Lymphoblastic Lymphoma|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Plasma Cell Myeloma|Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Therapy-Related Myelodysplastic Syndrome",Drug: Cyclophosphamide|Biological: Filgrastim|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Melphalan|Procedure: Peripheral Blood Stem Cell Transplantation|Biological: Rituximab|Drug: Tacrolimus|Radiation: Total-Body Irradiation,"Incidence of treatment failure defined as primary graft failure, grade 3-4 acute graft versus host disease (aGVHD), or non-relapse mortality|Immune reconstitution|Incidence of infectious episodes|Disease free survival (DFS) time|Overall survival (OS) time",M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,11.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014-0738|NCI-2016-01915,2017-01-18,"February 13, 2023",2023-02-13,"November 9, 2016",,"February 16, 2023","M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02960646,2217.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
952,953,NCT01120457,"First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers",,Completed,No Results Available,Acute Myelogenous Leukemia|Diffuse Large B-Cell Leukemia|Chronic Lymphocytic Leukemia|Follicular Lymphoma,Drug: BMS-936564 (Anti-CXCR4),"Safety and tolerability as monotherapy|Safety, as measured by vital signs, clinical laboratory tests,ECOG performance status, physical exams, 12 lead ECGs incidence and severity of adverse events|Efficacy- including best overall response (BOR) derived from changes in tumor burden and metabolic response based on FDG-PET (for DLBCL)|Immunogenicity measurement for human anti human antibodies (HAHA) -characterizing the immunogenicity of BMS-936564|Maximum observed serum concentration (Cmax) of BMS-936564 (MDX-1338) will be derived from serum concentration versus actual time|Trough observed serum concentration (Cmin) of BMS-936564 (MDX-1338) will be derived from serum concentration versus actual time|Time of maximum observed concentration (Tmax) of BMS-936564 (MDX-1338) will be derived from serum concentration versus actual time|Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-936564 (MDX-1338) will be derived from serum concentration versus actual time|Area under the concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)] of BMS-936564 (MDX-1338) will be derived from serum concentration versus actual time|Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-936564 (MDX-1338) will be derived from serum concentration versus actual time|Half life (T-HALF) of BMS-936564 (MDX-1338) will be derived from serum concentration versus actual time|Total body clearance(CLT) of BMS-936564 (MDX-1338) will be derived from serum concentration versus actual time|Volume of distribution at steady-state (Vss) of BMS-936564 (MDX-1338) will be derived from serum concentration versus actual time|Biomarker- characterizing the pharmacodynamic (PD) profiles of BMS-936564 (MDX-1338). The main PD biomarkers are cell trafficking|Exploratory Biomarkers- are detection of apoptosis, cytokine analyses, CXCR4 expression, ZAP-70 and CD38 expression",Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 1,96.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA212-001,2010-08-01,November 2014,2014-11-01,"May 11, 2010",,"March 6, 2015","Uab Comprehensive Cancer Center, Birmingham, Alabama, United States|Uc San Diego Moores Cancer Center, La Jolla, California, United States|Usc - Norris Comprehensive Cancer Center And Hospital, Los Angeles, California, United States|Ucla-Division Of Hematology/Oncology, Los Angeles, California, United States|Mayo Clinic, Jacksonville, Florida, United States|Northwestern University Feinberg School Of Medicine, Chicago, Illinois, United States|University Of Kansas Cancer Center And Medical Pavillion, Westwood, Kansas, United States|B. Douglas Smith, M.D., Baltimore, Maryland, United States|Dana-Farber Cancer Inst, Boston, Massachusetts, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|University Of Washington School Of Medicine, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01120457,1553.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
953,954,NCT00005634,Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy,,Completed,No Results Available,"Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Prostate Cancer|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: vorinostat,,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,,Other|NIH,Interventional,Primary Purpose: Treatment,99-059|CDR0000067789|NCI-H00-0051,2000-01-01,October 2002,2002-10-01,"December 17, 2003",,"June 19, 2013","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00005634,1004.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
954,955,NCT00054236,Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia,,Completed,No Results Available,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: umbilical cord blood transplantation|Drug: methylprednisolone,Event-free survival by disease assessment|Umbilical cord blood donor engraftment by chimerism and complete blood count (CBC),Case Comprehensive Cancer Center,All,"up to 120 Years   (Child, Adult, Older Adult)",Phase 1,55.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CWRU6Y01,2002-05-01,March 2011,2011-03-01,"February 6, 2003",,"July 27, 2020","Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00054236,3226.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
955,956,NCT00789776,"Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer",,Completed,Has Results,"Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Aggressive Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma|Previously Treated Myelodysplastic Syndrome|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Indolent Adult Non-Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Small Lymphocytic Lymphoma|Waldenstrom Macroglobulinemia",Procedure: Allogeneic Bone Marrow Transplantation|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Biological: Natural Killer Cell Therapy|Drug: Tacrolimus|Radiation: Total-Body Irradiation,Number of Participants With Dose Limiting Toxicities|Number of Participants With Relapsed Disease|Number of Participants With Grades III-IV Acute GVHD|Number of Non-relapse Participant Mortalities|Number of Participants Who Experienced Graft Failure|Number of Subjects Surviving Post-transplant.|Number of Participants Who Experienced Chronic Extensive GVHD,Fred Hutchinson Cancer Center|National Cancer Institute (NCI)|The Wayne D. Kuni and Joan E. Kuni Foundation,All,"Child, Adult, Older Adult",Phase 1|Phase 2,41.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2230.00|NCI-2010-00106|P01CA078902|P30CA015704,2008-10-13,May 2017,2017-05-01,"November 13, 2008","July 12, 2018","January 31, 2020","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT00789776/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT00789776/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT00789776,3122.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
956,957,NCT00080925,T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies,,Completed,No Results Available,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,Biological: filgrastim|Biological: graft-versus-tumor induction therapy|Biological: rituximab|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: cyclosporine|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: fludarabine phosphate|Drug: prednisone|Drug: vincristine sulfate|Procedure: peripheral blood stem cell transplantation,,National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI),All,18 Years to 55 Years   (Adult),Phase 1,20.0,NIH,Interventional,Primary Purpose: Treatment,040116|04-C-0116|CDR0000357432,2004-02-01,,2010-12-01,"April 8, 2004",,"March 8, 2012","Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00080925,2495.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
957,958,NCT03538028,A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies,,Completed,No Results Available,Cervical Cancer|Microsatellite Instability (MSI)-High Endometrial Cancer|Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])|Esophageal Cancer|Hepatocellular Carcinoma|Melanoma (Uveal Melanoma Excluded)|Merkel Cell Carcinoma|Mesothelioma|MSI-high Colorectal Cancer|Non-small Cell Lung Cancer (NSCLC)|Ovarian Cancer|Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Small Cell Lung Cancer (SCLC)|Renal Cell Carcinoma (RCC)|Triple-negative Breast Cancer|Urothelial Carcinoma|Diffuse Large B-cell Lymphoma,Biological: INCAGN02385,Number of treatment-emergent adverse events (TEAEs)|Cmax of INCAGN02385|Tmax of INCAGN02385|Cmin of INCAGN02385|AUC0-t of INCAGN02385|Objective response rate (ORR) in participants with advanced or metastatic solid tumors|Disease control rate (DCR) in participants with advanced or metastatic solid tumors|Duration of response (DOR) in participants with advanced or metastatic solid tumors|Progression-free survival (PFS) in participants with advanced or metastatic solid tumors|ORR in participants with diffuse large B-cell lymphoma (DLBCL)|DOR in participants with DLBCL|PFS in participants with DLBCL,Incyte Biosciences International Sàrl|Incyte Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 1,22.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INCAGN 2385-101,2018-06-18,"October 7, 2020",2020-10-07,"May 25, 2018",,"October 30, 2020","The Angeles Clinic and Research Center, Los Angeles, California, United States|Hackensack Medical Center, Hackensack, New Jersey, United States|Carolina BioOncology Institute, Huntersville, North Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03538028,842.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
959,960,NCT01866839,Preventing Stem Cell Transplant Complications With a Blood Separator Machine,,Completed,Has Results,"MDS (Myelodysplastic Syndrome)|Myeloproliferative Disorder|Lymphoma, Non-Hodgkin|ALL (Acute B-Lymphoblastic Leukemia)|AML (Acute Myelogenous Leukemia",Device: Graft Manipulation (CD34+ Selection),Overall Survival|Disease Free Survival at 2 Years|Disease Progression|Incidence of Acute GVHD|Incidence of Chronic GVHD|Median Time to ANC>500/mm3|Median Time to Platelets>20K/mm3|Severity of Acute GVHD|Severity of Chronic GVHD,"National Heart, Lung, and Blood Institute (NHLBI)|Children's National Research Institute|National Institutes of Health Clinical Center (CC)",All,"2 Years to 80 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,41.0,NIH|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,130144|13-H-0144,2013-05-29,"May 23, 2018",2018-06-28,"June 3, 2013","May 26, 2020","July 21, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT01866839/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01866839,1856.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
960,961,NCT00952237,Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF,,Completed,No Results Available,"Non-Hodgkin's Lymphoma|Hodgkin's Disease|Multiple Myeloma|Other Plasma Cell Dyscrasia (Waldenstrom, Amyloidosis)|Leukemia",Drug: GM-CSF|Drug: IL-2,Can IL-2 be administered with GM-CSF to efficiently mobilize autologous peripheral blood stem cells. This study will determine the maximum tolerated dose of IL-2 and the optimal biological dose with GM-CSF for stem cell mobilization.|Will immune-mobilized stem cell products be well tolerated once infused into patients and will engraft normally following high-dose chemotherapy and APBSCT.,Dartmouth-Hitchcock Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1,13.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D0227,2003-01-01,April 2011,2011-04-01,"August 6, 2009",,"April 25, 2018","Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",,https://ClinicalTrials.gov/show/NCT00952237,3012.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
961,962,NCT01475058,CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant,,Completed,No Results Available,Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia,Biological: allogeneic cytomegalovirus-specific cytotoxic T lymphocytes,"Safety and toxicity assessment of study treatment|Feasibility assessment of study treatment|Anti-tumor efficacy and duration of persistence, migration, and function of adoptively transferred bi-specific effector cells",Fred Hutchinson Cancer Center|National Cancer Institute (NCI),All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,1.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2494.00|NCI-2011-01819|P30CA015704|R01CA136551,2012-04-01,April 2014,2014-07-01,"November 21, 2011",,"February 15, 2017","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01475058,821.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
962,963,NCT00640796,"Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors",,Completed,No Results Available,"Leukemia, Myeloid, Acute|Leukemia, Lymphocytic, Acute, T-Cell|Juvenile Myelomonocytic Leukemia Lymphoblastic|T-cell Lymphoblastic Lymphoma|Myelodysplastic Syndrome",Procedure: Haploidentical donor derived natural killer cell infusion|Drug: Chemotherapy|Device: CliniMACS,To determine the maximum tolerated dose of expanded NK cells in research participants with relapsed or refractory hematologic malignancies and sarcomas.,St. Jude Children's Research Hospital|National Cancer Institute (NCI)|Assisi Foundation,All,"up to 18 Years   (Child, Adult)",Phase 1,22.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NKEXP|R01CA113482,2008-09-01,April 2014,2014-04-01,"March 21, 2008",,"April 24, 2014","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00640796,2038.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
963,964,NCT00448357,Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen,LCCC0510,Completed,Has Results,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,Biological: rabbit anti-thymocyte globulin (ATG)|Biological: therapeutic allogeneic lymphocytes|Drug: busulfan|Drug: fludarabine phosphate|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Drug: methotrexate,Three-year Relapse-free Survival (RFS) Rate at the Maximum Tolerated Dose Identified During Phase I of the Trial (Target AUC 6912)|Number of Participants With Dose Limiting Toxicities (DLTs)|Capacity of Test Dosing of Busulfan That Would Result in the Desired Area Under the Curve Concentration Exposure of Patients Receiving a Full-dose Busulfan Regimen|Incidence of Graft vs Host Disease in Patients Between One Month and Two Years Post Transplant|Incidence of DNA Chimerism in Patients Between One Month Post Transplant|Overall Survival,UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)|Otsuka America Pharmaceutical,All,18 Years to 55 Years   (Adult),Phase 1|Phase 2,54.0,Other|NIH|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LCCC 0510|P30CA016086,2005-10-01,November 2015,2015-11-01,"March 16, 2007","July 17, 2017","July 17, 2017","Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00448357,3683.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
964,965,NCT00006225,Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer,,Completed,No Results Available,Breast Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic/Myeloproliferative Diseases,Biological: filgrastim|Biological: recombinant flt3 ligand|Biological: recombinant human thrombopoietin|Biological: recombinant interleukin-3|Procedure: in vitro-treated peripheral blood stem cell transplantation,,Northwestern University,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,,Other,Interventional,Allocation: Randomized|Primary Purpose: Treatment,NU 97B2|NU-97B2|NCI-V00-1611,1999-11-01,January 2004,2004-01-01,"May 7, 2003",,"June 6, 2012","Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00006225,1522.0,Not Industry Lead,More than three Conditions,Randomized,None-Crossover Assignment,N/A,Treatment/Diagnostic
965,966,NCT02890758,Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803,,Completed,No Results Available,Acute Myeloid Leukemia|Myelodysplastic Syndrome|Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia|Chronic Lymphocytic Leukemia|Non Hodgkin Lymphoma|Hodgkin Lymphoma|Myeloproliferative Syndromes|Plasma Cell Myeloma|Colon Carcinoma|Adenocarcinoma of Rectum|Soft Tissue Sarcoma|Ewing's Sarcoma|Rhabdomyosarcoma,Biological: Natural Killer (NK) Cells|Biological: ALT803,MTD of ex vivo expanded non-HLA matched donor NK cells in combination with ALT-803|Number of participants without Graft Versus Host Disease (GVHD)|Number of patients with hematological response|Patients response for radiographically measurable lesions|Patients with malignant lymphoma response|Patients response for Waldenstrom's macroglobulinemia (WM)|Patients response for cutaneous lymphomas|Patients response for multiple myeloma|Patients response for chronic myeloid leukemia (CML)|Patients response for metastatic colon/rectal carcinoma and soft tissue sarcomas|Average duration of response|Average duration of Overall Survival|Average duration of relapse free survival|in vivo Natural Killer (NK) levels,"Brenda Cooper, MD|Case Comprehensive Cancer Center",All,"18 Years and older   (Adult, Older Adult)",Phase 1,14.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CASE2Z16,2018-05-22,"June 1, 2021",2023-02-17,"September 7, 2016",,"February 21, 2023","University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02890758,1732.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
966,967,NCT02129582,"Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies",,Completed,No Results Available,Acute Myeloid Leukemia|Hematologic Malignancies|Acute Lymphocytic Leukemia|Non Hodgkin Lymphoma|Hodgkin Lymphoma|Multiple Myeloma|Myelodysplastic Syndrome|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia|Myelofibrosis|Myeloproliferative Syndrome,Radiation: total marrow irradiation|Drug: fludarabine phosphate|Drug: busulfan|Procedure: myeloid progenitor cell transplantation|Biological: anti-thymocyte globulin|Drug: tacrolimus|Drug: methotrexate|Other: laboratory biomarker analysis,"Maximum tolerated dose of targeted marrow irradiation defined as the dose level immediately below that in which greater than or equal to 2/6 subjects experience a dose limiting toxicity assessed using NCI CTCAE version 4.0|Incidence of toxicities assessed using NCI CTCAE version 4.0|Patient mortality|Organ avoidance|Target coverage|Planning time|Treatment delivery time|Disease response status, assessed by standard criteria for the presence of relapse|Rates of acute GVHD, graded and staged according to the Blood and Marrow Transplant Clinical Trials Network Manual of Operations",Case Comprehensive Cancer Center,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,14.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CASE9Z13,2014-11-05,"March 15, 2019",2020-03-05,"May 2, 2014",,"May 7, 2021","University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02129582,1947.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
967,968,NCT01634217,Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation,,Completed,No Results Available,Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Non-Hodgkin Lymphoma|Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Multiple Myeloma|Myelodysplastic Syndrome,Biological: iTreg,Incidence of grade 3-5 infusional toxicity|Cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD)|Incidence of chronic graft-versus-host disease (GVHD)|Relapse of Disease|Survival,"Masonic Cancer Center, University of Minnesota",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,16.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012LS019|MT2012-06R,2013-11-08,"December 1, 2017",2018-12-01,"July 6, 2012",,"January 18, 2019","Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01634217,1849.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
968,969,NCT00923910,Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood,,Completed,Has Results,"Leukemia, Acute Myelogenous (AML)|Leukemia, Acute Lymphocytic (ALL)|Leukemia, Chronic Myelogenous (CML)|Myelodysplastic Syndrome (MDS)|Non-Hodgkin's Lymphoma (NHL)",Drug: WT1 Peptide-Pulsed Dendritic Cells|Drug: Donor Lymphocytes|Drug: IL-4|Drug: KLH|Drug: WT1 Peptides|Drug: Endotoxin|Drug: Diphenhydramine|Drug: Acetaminophen,Toxicity|Number of Participants With Graft Versus Host Disease (GVHD) Greater Than or Equal to Grade 3|Time to Immune Response|Wilm's Tumor 1 (WT1) Enzyme-Linked Immunospot (ELISpot)|Wilm's Tumor (WT1) Delayed-type Hypersensitivity (DTH)|Keyhole Limpet Hemocyanin (KLH) Delayed-type Hypersensitivity (DTH)|Number of Participants With Progressive Disease,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"1 Year to 74 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,10.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,080051|08-C-0051,2008-02-22,"October 18, 2013",2016-11-15,"June 18, 2009","May 8, 2014","April 12, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00923910,3189.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
969,970,NCT02529813,CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies,,Completed,No Results Available,Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia|Blasts 5 Percent or More of Bone Marrow Nucleated Cells|CD19 Positive|Minimal Residual Disease|Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia,Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Biological: Tisagenlecleucel,"Maximum tolerated dose of genetically modified, CD19-specified T cells|The proportion of patients for which a T cell product could not be prepared|Proportion of patients experiencing response (complete response and partial response)",M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Ziopharm Oncology,All,"1 Year to 80 Years   (Child, Adult, Older Adult)",Phase 1,26.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013-1018|NCI-2015-01492|20152145|1159157,2015-12-16,"November 8, 2021",2021-11-08,"August 20, 2015",,"June 30, 2022","M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02529813,2154.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
970,971,NCT01169584,Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients,,Completed,No Results Available,Neuroblastoma|Rhabdomyosarcoma|Lymphoma|Wilm's Tumor|Ewing's Sarcoma,Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594),Determine the maximally-tolerated dose (MTD) and/or maximum-feasible dose (MFD) of JX-594|Determine the safety/toxicity of JX-594 administered by IT injection in this patient population|Determine the JX-594 pharmacokinetics and pharmacodynamics over time following IT injection in this patient population|Determine the immune response to JX-594 following IT injection in this patient population,"Jennerex Biotherapeutics|Solving Kids' Cancer|SillaJen, Inc.",All,"2 Years to 21 Years   (Child, Adult)",Phase 1,6.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JX594-IT-P009,2010-08-01,March 2012,2014-11-01,"July 26, 2010",,"January 21, 2016","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Texas Children's Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01169584,1553.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
971,972,NCT00042900,Pyroxamide in Treating Patients With Advanced Cancer,,Completed,No Results Available,"Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous Condition|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: pyroxamide,,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,,Other|NIH,Interventional,Primary Purpose: Treatment,99-090|CDR0000069483|NCI-2110,2002-04-01,September 2002,2002-09-01,"July 8, 2003",,"June 5, 2013","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00042900,153.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
972,973,NCT00513474,Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,,Completed,Has Results,Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporin-A|Drug: etoposide|Drug: methotrexate|Drug: rasburicase|Drug: sirolimus|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation|Drug: fludarabine|Drug: allopurinol,Percentage of Participants With Grades II to IV Acute Graft-Versus-Host Disease (aGVHD)|Uric Acid Levels|Number of Participant With Adverse Events (AE)|Graft-versus-host and Host-versus-graft Immune Responses,Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,46.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,CDR0000558480|MGH-07-071|DFCI-07-071,2008-01-01,"February 12, 2013",2013-02-12,"August 8, 2007","April 11, 2017","May 25, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00513474,1869.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Supportive Care
973,974,NCT00004258,EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer,,Completed,No Results Available,"Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: cilengitide,To evaluate the safety and tolerability of escalating doses of twice weekly EMD 121974 in patients with cancer.,Indiana University School of Medicine|National Cancer Institute (NCI)|Indiana University,All,"18 Years and older   (Adult, Older Adult)",Phase 1,40.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9909-40; T99-0076|IUMC-9909-40|NCI-T99-0076,1999-12-01,August 2001,2001-09-01,"July 26, 2004",,"September 17, 2014","Indiana University Cancer Center, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00004258,640.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
977,978,NCT00003082,Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer,,Completed,No Results Available,"Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition|Unspecified Adult Solid Tumor, Protocol Specific",Biological: monoclonal antibody A27.15|Biological: monoclonal antibody E2.3,,University of Arizona|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,27.0,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000065781|P30CA023074|UARIZ-HSC-95178|NCI-T96-0025,1997-12-01,February 2001,2001-02-01,"July 19, 2004",,"March 16, 2010","Arizona Cancer Center, Tucson, Arizona, United States",,https://ClinicalTrials.gov/show/NCT00003082,1158.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
978,979,NCT00004904,Stem Cell Transplantation in Treating Patients With Hematologic Cancer,,Completed,No Results Available,Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition|Small Intestine Cancer,Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: cladribine|Drug: cyclophosphamide|Drug: etoposide|Drug: methylprednisolone|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Procedure: in vitro-treated peripheral blood stem cell transplantation,,Northwestern University|National Cancer Institute (NCI),All,"up to 45 Years   (Child, Adult)",Phase 1,,Other|NIH,Interventional,Primary Purpose: Treatment,NU FDA97H1|NU-97H1|NCI-G00-1691,1999-10-01,July 2000,2000-07-01,"March 3, 2004",,"June 4, 2012","Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00004904,274.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
979,980,NCT00004232,Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer,,Completed,No Results Available,Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition,Biological: filgrastim|Drug: cyclosporine|Drug: methylprednisolone|Drug: prednisone|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation,,Northwestern University|National Cancer Institute (NCI),All,"10 Years to 65 Years   (Child, Adult, Older Adult)",Phase 1,,Other|NIH,Interventional,Primary Purpose: Supportive Care,NU FDA96H4|NU-96H4|NCI-G99-1660,1999-10-01,October 2002,2002-10-01,"May 9, 2003",,"June 1, 2012","Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00004232,1096.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Supportive Care
980,981,NCT01822509,Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant,,Completed,No Results Available,"Allogeneic Hematopoietic Stem Cell Transplant Recipient|Myeloproliferative Neoplasm|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma",Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab,Maximum tolerated dose (MTD) of ipilimumab according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (Phase I)|Maximum tolerated dose (MTD) of nivolumab according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (Phase I)|Incidence of adverse events as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (Phase Ib)|Clinical response|Progression-free survival (PFS)|Overall survival (OS),National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,71.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2013-00739|12-537|9204|P30CA006516|R01CA183559|U01CA062490|UM1CA186709,2013-05-16,"December 31, 2018",2021-06-10,"April 2, 2013",,"June 24, 2021","City of Hope Comprehensive Cancer Center, Duarte, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|City of Hope South Pasadena, South Pasadena, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Moffitt Cancer Center-International Plaza, Tampa, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Charlestown, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01822509,2947.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
981,982,NCT02914977,Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia,,Completed,No Results Available,Acute Lymphocytic Leukemia|Acute Myeloid Leukemia,Drug: Daunorubicin,Molecular pharmacodynamic effect of low dose daunorubicin on beta-catenin phosphorylation as assessed by quantitative immunohistochemistry assay performed on serial bone marrow samples of patients with relapsed leukemia.|Number of participants with treatment-related adverse events and/or toxicity as assessed by CTCAE 4.03.|Maximum Plasma Concentration [Cmax]|Area Under the Curve [AUC],Tara Lin|University of Kansas Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1,18.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IIT-2016-RP-HEM-LD-DNR,2016-11-01,"April 3, 2019",2021-07-15,"September 26, 2016",,"January 14, 2022","University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States",,https://ClinicalTrials.gov/show/NCT02914977,1717.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
982,983,NCT01221857,Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies,,Completed,Has Results,Acute Lymphoblastic Leukemia (ALL)|Acute Myelogenous Leukemia (AML)|Myelodysplastic Syndrome (MDS)|Non-Hodgkin's Lymphoma|Hodgkin's Disease,Drug: NiCord®,Acute Toxicity Associated With the Infusion of NiCord|Proportion of Patients With Neutrophil Engraftment|Proportion of Patients Who Developed Acute GvHD Grade II-IV and III-IV|Non-relapse Mortality,Gamida Cell ltd,All,"8 Years to 65 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,12.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GC P#01.01.020,2010-11-01,September 2012,2013-05-01,"October 15, 2010","February 26, 2019","August 3, 2021","Loyola University, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States|Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01221857,912.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
984,985,NCT02141828,A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene,,Completed,No Results Available,Leukemia|Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Acute Leukemias,Drug: EPZ-5676,Determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of EPZ-5676.|To assess the safety and tolerability of EPZ-5676 administered as a continuous intravenous (CIV) infusion|Determine the pharmacokinetic (PK) and pharmacodynamic (PD) profile of EPZ-5676|Evaluate early evidence of anti-tumor activity,"Epizyme, Inc.|Celgene Corporation",All,"3 Months to 18 Years   (Child, Adult)",Phase 1,18.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EPZ-5676-12-002,2014-05-01,May 2016,2016-06-01,"May 20, 2014",,"May 8, 2020","Childrens Hospital Los Angeles, Los Angeles, California, United States|University of California San Francisco Medical Center-Parnassus, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Emory Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|The Hospital for Sick Kids, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02141828,762.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
985,986,NCT00006368,Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer,,Completed,No Results Available,Brain and Central Nervous System Tumors|Breast Cancer|Gastrointestinal Carcinoid Tumor|Islet Cell Tumor|Lung Cancer|Lymphoma|Melanoma (Skin)|Neoplastic Syndrome,Radiation: yttrium Y 90-edotreotide,,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,60.0,Industry,Interventional,Primary Purpose: Treatment,NOVARTIS-SMT-B151|MCC-12275|MCC-IRB-5473|CDR0000068241|NCI-G00-1857,1998-01-01,November 2003,2003-11-01,"April 2, 2004",,"May 1, 2013","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,https://ClinicalTrials.gov/show/NCT00006368,2130.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
986,987,NCT00697671,Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies,,Completed,No Results Available,Acute Lymphoblastic Leukemia|Chronic Myelogenous Leukemia|Juvenile Myelomonocytic Leukemia|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma,Other: NK Cell Infusion|Biological: Immunotherapy|Device: Miltenyi Biotec CliniMACS device|Drug: Interleukin-2 (IL-2)|Drug: Clofarabine|Drug: Cyclophosphamide|Drug: Etoposide,"To assess the safety of chemotherapy and IL-2 administration to facilitate transient NK-cell engraftment in research participants with chemotherapy refractory non-acute myelogenous leukemia (non-AML) hematologic malignancies|To study the persistence, phenotype and function of donor natural killer (NK) cells after infusion in research participants with chemotherapy refractory hematologic malignancies.|To explore the efficacy of NK cell infusion in research participants with chemotherapy refractory hematologic malignancies",St. Jude Children's Research Hospital|Assisi Foundation,All,"up to 18 Years   (Child, Adult)",Phase 1,48.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NKHEM,2007-03-01,February 2013,2013-05-01,"June 16, 2008",,"July 16, 2013","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00697671,2253.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
990,991,NCT00001689,A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia,,Completed,No Results Available,Acute Lymphocytic Leukemia|Leukemia,Drug: Vincristine,,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",Phase 1,90.0,NIH,Interventional,Primary Purpose: Treatment,980053|98-C-0053,1998-01-01,,2003-11-01,"November 4, 1999",,"March 4, 2008","National Cancer Institute (NCI), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00001689,2130.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
991,992,NCT01921387,Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies,,Completed,Has Results,Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Refractory Mantle Cell Lymphoma|Refractory T-Cell Non-Hodgkin Lymphoma,Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Drug: Cytarabine|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Drug: Melphalan|Procedure: Peripheral Blood Stem Cell Transplantation|Radiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8,Maximum-tolerated Dose (MTD) of Yttrium-90-BC8-DOTA|Progression-free Survival Following Autologous Stem Cell Transplant (ASCT)|Estimated Dose to Tumor Sites Based on the Tumor to Normal Organ Ratios Derived From Dosimetry Estimates Coupled With the Absorbed Dose to Normal Organs Based on the Administered Activity of Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|The Lowest Antibody (Yttrium 90-BC8-DOTA) Dose (mg/kg) That is Consistent With a Favorable Biodistribution Rate >= 80% in Lymphoma Patients,Fred Hutchinson Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2728.00|NCI-2013-01378|P01CA044991|P30CA015704,2013-10-09,"July 26, 2017",2020-07-26,"August 13, 2013","September 4, 2018","August 4, 2020","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT01921387/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT01921387/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01921387,2482.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
992,993,NCT01521611,Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy,,Completed,No Results Available,Acute Leukaemia|Chronic Leukaemia|Myeloma|Lymphoma,Radiation: Targeted radiotherapy,Toxicities related to radiolabelled antibody.|Dosimetry model,University Hospital Southampton NHS Foundation Trust|Royal Free and University College Medical School,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,62.0,Other,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RHMCAN0227,2002-01-01,"July 1, 2017",2018-07-01,"January 30, 2012",,"April 8, 2019","Southampton University Hospitals NHS Trust, Southampton, Hampshire, United Kingdom|Royal Free Hospital and University College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01521611,6025.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
993,994,NCT01386619,NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT),,Completed,No Results Available,"Leukemia, Myeloid, Acute|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Myelodysplastic Syndromes|Lymphoma|Neuroblastoma|Rhabdomyosarcoma",Biological: CD3-depleted/CD56+ selected natural killer cells collected from apheresis products,Feasibility of NK-DLI production|Safety of NK DLI Infusion|Efficacy of NK DLI Infusions,"University Hospital, Basel, Switzerland",All,"Child, Adult, Older Adult",Phase 1|Phase 2,15.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NK-DLI Allo-Tx,2004-01-01,March 2011,2011-03-01,"July 1, 2011",,"September 15, 2015","Universitätsklinikum, Frankfurt, Germany|University Hospital, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT01386619,2616.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
995,996,NCT01655225,A Study of LY3023414 in Participants With Advanced Cancer,,Completed,No Results Available,Advanced Cancer|Metastatic Cancer|Non-Hodgkin's Lymphoma|Metastatic Breast Cancer|Malignant Mesothelioma|Non-small Cell Lung Cancer,Drug: LY3023414|Drug: Midazolam|Drug: Fulvestrant|Drug: Pemetrexed|Drug: Cisplatin|Drug: Abemaciclib|Drug: Letrozole,Recommended Phase 2 dose|Pharmacokinetics: Maximum concentration (Cmax)|Pharmacokinetics: Time of maximal concentration|Number of participants with tumor response|Potential of LY3023414 to inhibit CYP3A4-mediated metabolism,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 1,156.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13517|I6A-MC-CBBA,2012-07-31,"April 4, 2019",2022-02-02,"August 1, 2012",,"April 8, 2022","UCLA Medical Center, Los Angeles, California, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Peggy and Charles Stephenson Oklahoma Cancer Center, Oklahoma City, Oklahoma, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Azienda Ospedaliero - Universitaria S. Luigi Gonzaga, Orbassano, Torino, Italy|Fundacion de Investigacion de Diego, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT01655225,3473.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
997,998,NCT00237627,Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer,,Completed,No Results Available,"Breast Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Ovarian Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: PS-341|Drug: Doxil|Drug: Velcade,Maximum tolerated dose (MTD) of PS-341 in combination with Doxil (Phase I)|Response rate of the combination of Velcade and Doxil in patients with metastatic breast cancer,UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,107.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LCCC 2020|UNC-LCCC-2020|CDR0000368767,2001-05-01,December 2006,2010-01-01,"October 12, 2005",,"May 18, 2012","Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00237627,3167.0,Not Industry Lead,More than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
999,1000,NCT00723346,Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia,GRASPALL,Completed,No Results Available,Acute Lymphoblastic Leukemia,Biological: GRASPA|Drug: native L asparaginase,Duration of plasmatic asparagin depletion (< 2µmol/l),ERYtech Pharma|Centre Leon Berard,All,"1 Year to 55 Years   (Child, Adult)",Phase 1|Phase 2,25.0,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GRASPALL 2005-01,2006-01-01,August 2008,2009-03-01,"July 28, 2008",,"January 11, 2012","Hopital Debrousse, Lyon, France",,https://ClinicalTrials.gov/show/NCT00723346,1155.0,Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1000,1001,NCT00089596,Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers,,Completed,No Results Available,Acute Lymphocytic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Non-Hodgkin Lymphoma|Chronic Myelogenous Leukemia,Procedure: Expansion of umbilical cord stem cells,,ViaCell,All,"12 Years to 60 Years   (Child, Adult)",Phase 1|Phase 2,10.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CB001,2004-03-01,,2006-10-01,"August 10, 2004",,"April 12, 2007","Loyola University Medical Center, Maywood, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT00089596,944.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1001,1002,NCT00068718,"Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant",,Completed,Has Results,"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma",Biological: Therapeutic Allogeneic Lymphocytes,"Safety of DLI Following a Non-myeloablative Transplant, Defined as Incidence of Grade IV Acute GVHD|Incidence of Graft Rejection|Incidence of Relapse/Progression|Incidence of Grade II-IV GVHD in Patients Undergoing DLI Following a Non-myeloablative Transplant|Incidence of Infections in Patients Undergoing DLI Following a Non-myeloablative Transplant|Overall Survival|Progression-free Survival",Fred Hutchinson Cancer Center|National Cancer Institute (NCI),All,"Child, Adult, Older Adult",Phase 1|Phase 2,35.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1803.00|NCI-2010-00163|P01CA078902|P30CA015704,2003-05-01,April 2013,2013-04-01,"September 11, 2003","March 10, 2017","January 31, 2020","VA Puget Sound Health Care System, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States|Universitaet Leipzig, Leipzig, Germany|University of Torino, Torino, Italy",,https://ClinicalTrials.gov/show/NCT00068718,3623.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1002,1003,NCT00027820,Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer,,Completed,No Results Available,Adult Acute Myeloid Leukemia in Remission|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Myelodysplastic Syndrome|Childhood Renal Cell Carcinoma|Chronic Myelomonocytic Leukemia|Clear Cell Renal Cell Carcinoma|de Novo Myelodysplastic Syndrome|Metastatic Renal Cell Cancer|Previously Treated Myelodysplastic Syndrome|Progression of Multiple Myeloma or Plasma Cell Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult Non-Hodgkin Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Non-Hodgkin Lymphoma|Refractory Anemia|Refractory Anemia With Ringed Sideroblasts|Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Renal Medullary Carcinoma|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia,Drug: Fludarabine Phosphate|Radiation: Total-Body Irradiation|Procedure: Peripheral Blood Stem Cell Transplantation|Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclosporine|Drug: Mycophenolate Mofetil,Risk of true graft rejection in patients with and without preceding chemotherapy|Risk of grades II-IV acute GVHD in those patients with sustained engraftment|Incidence of reversing impending graft rejection (less than 40% donor cluster of differentiation [CD]3+ T cell chimerism)|Overall survival|Progression-free survival,"Fred Hutchinson Cancer Center|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)",All,"Child, Adult, Older Adult",Phase 1|Phase 2,106.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1641.00|NCI-2012-00591|P30CA015704|P01CA018029,2001-08-01,September 2004,2004-09-05,"January 27, 2003",,"December 20, 2019","University of Arizona Health Sciences Center, Tucson, Arizona, United States|Stanford University Hospitals and Clinics, Stanford, California, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States|Baylor Medical Center at Garland, Garland, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Universitaet Leipzig, Leipzig, Germany|University of Torino, Torino, Italy",,https://ClinicalTrials.gov/show/NCT00027820,1131.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1003,1004,NCT00365287,"Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer",,Completed,No Results Available,Breast Cancer|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,Drug: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: radiation therapy|Procedure: umbilical cord blood transplantation,"Safety as assessed by a non-relapse mortality < 30% within day 100|Hematopoietic recovery and the degree of chimerism at days 21, 60, 100, 180, and 360 after study completion","Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI)",All,"up to 69 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,148.0,Other|NIH,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,2000LS039|MT2000-15,2000-06-01,December 2005,2005-12-01,"August 17, 2006",,"November 29, 2017",,,https://ClinicalTrials.gov/show/NCT00365287,2009.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1004,1005,NCT02643303,A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers,,Completed,Has Results,Head and Neck Squamous Cell Carcinoma|Breast Cancer|Sarcoma|Merkel Cell Carcinoma|Cutaneous T-Cell Lymphoma|Melanoma|Renal Cancer|Bladder Cancer|Prostate Cancer|Testicular Cancer|Solid Tumor,Drug: Durvalumab|Drug: Tremelimumab|Drug: Poly-ICLC,Number of Subjects With Treatment-emergent Adverse Events (TEAEs)|Number of Subjects With Best Overall Tumor Response by Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST)|Median Progression-free Survival (PFS) by Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) as Estimated Using the Kaplan-Meier Method|Overall Disease Control Rate as Measured by Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST)|Number of Subjects With Best Overall Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Median PFS by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as Estimated Using the Kaplan-Meier Method|Overall Disease Control Rate as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Median Overall Survival (OS) as Estimated Using the Kaplan-Meier Method,"Ludwig Institute for Cancer Research|MedImmune LLC|Cancer Research Institute, New York City",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,58.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LUD2014-011,2016-12-28,"February 23, 2022",2022-02-23,"December 31, 2015","December 2, 2022","December 2, 2022","Research Facility, Atlanta, Georgia, United States|Research Facility, Lebanon, New Hampshire, United States|Research Facility, Buffalo, New York, United States|Research Facility, New York, New York, United States|Research Facility, Cleveland, Ohio, United States|Research Facility, Toledo, Ohio, United States|Research Facility, Charlottesville, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02643303/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02643303/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02643303,1883.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1005,1006,NCT00118326,Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease,,Completed,No Results Available,Kidney Cancer|Leukemia|Lymphoma|Myelodysplastic Syndromes|Neuroblastoma|Sarcoma,Biological: filgrastim|Procedure: allogeneic bone marrow transplantation,Safety and feasibility,Fred Hutchinson Cancer Center,All,"up to 18 Years   (Child, Adult)",Phase 1|Phase 2,,Other,Interventional,Primary Purpose: Treatment,1802.00|FHCRC-1802.00|PBMTC-STC0233|CDR0000430709,2003-08-01,,2007-05-01,"July 11, 2005",,"May 14, 2010","Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00118326,1369.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
1006,1007,NCT01561911,A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment,,Completed,No Results Available,Cancer|Neoplasms|Lymphoma|Non-Hodgkin|B-Cell,Drug: Chi Lob 7/4 (A chimeric monoclonal antibody),"1. To establish the Maximum tolerated dose (MTD)of ChiLob 7/4 ;|2. To determine the Biologically Active Dose of Chi Lob 7/4, which is defined as the dose level at which peripheral blood B-cells are reduced by the end of therapy to 10% or less of the starting number.|3. To determine the toxicity profile of Chi Lob 7/4 (CTCAE version 3.0) and to identify the dose limiting toxicity|4. To propose a safe dose for Phase II evaluation|1. To examine the Biological effects of ChiLob 7/4 Treatment|2. To examine the Pharmacokinetics of ChiLob 7/4 treatment: (Measurement of Serum Chi Lob 7/4)|3. To examine the Possible Anti-Tumour activity of Chi Lob 7/4 (RECIST 1.0 criteria)",Cancer Research UK,All,"18 Years and older   (Adult, Older Adult)",Phase 1,29.0,Other,Interventional,Masking: None (Open Label),PH1/103,2007-07-01,October 2014,2014-10-01,"March 23, 2012",,"December 2, 2014","Cancer Research UK Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, United Kingdom|Cancer Research UK Medical Oncology Unit, Southampton General Hospital, Tremona Road,, Southampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT01561911,2649.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),N/A
1007,1008,NCT02145559,A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors,,Completed,No Results Available,Breast Neoplasms|Lung Neoplasms|Cancer of Liver|Lymphoma|Cancer of Kidney,Drug: Metformin XR|Drug: Delayed Metformin|Drug: Sirolimus,Pharmacodynamic Biomarker p70S6K|Pharmacodynamic Biomarkers p4EBP1 and pAKT|Tolerability - Full physical Exam|Fasting Serum Glucose and Triglycerides,University of Chicago,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB13-0614,2014-04-01,"November 15, 2016",2018-07-01,"May 23, 2014",,"April 22, 2019","University of Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02145559,1552.0,Not Industry Lead,More than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1008,1009,NCT01916135,"PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative",,Completed,No Results Available,Carcinoma|Sarcoma|Myeloma|Lymphoma|Melanoma,Radiation: [18F]-SKI-249380|Procedure: PET/CT scan|Other: Blood draws,pharmacokinetics|metabolism|biodistribution|radiation dosimetry,Memorial Sloan Kettering Cancer Center,All,"21 Years to 90 Years   (Adult, Older Adult)",Phase 1,11.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,12-182,2013-07-01,"April 23, 2020",2020-04-23,"August 5, 2013",,"April 27, 2020","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01916135,2488.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1009,1010,NCT00741403,A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies,,Completed,No Results Available,Advanced Cancer|Metastatic Cancer|Lymphoma|Solid Tumors|Advanced Malignancies,Drug: CPI-613,"To evaluate the safety, tolerability, maximum tolerated dose (MTD), and efficacy pharmacokinetics of CPI-613 given twice weekly for three consecutive weeks in cancer patients|To evaluate pharmacokinetics, toxicity profile, biological activity, and anti-tumor activity of CPI-613 given twice weekly for three consecutive weeks in cancer patients",Cornerstone Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 1,39.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CL-CPI-613-002,2008-08-01,December 2016,2016-12-01,"August 26, 2008",,"December 29, 2016","Pivotal Research Centers, Peoria, Arizona, United States|Eastchester Center for Cancer Care, Bronx, New York, United States|Mary Crowley Cancer Research Centers, Dallas, Texas, United States|British Columbia Cancer Agency, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT00741403,3044.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1010,1011,NCT00001748,HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies,,Completed,No Results Available,Graft vs Host Disease|Hematologic Neoplasms|Lymphoma|Myelodysplastic Syndromes|Myeloid Leukemia,Procedure: Peripheral blood progenitor cell transplant,,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"Child, Adult, Older Adult",Phase 1,35.0,NIH,Interventional,Primary Purpose: Treatment,980122|98-H-0122,1998-06-01,,2000-05-01,"December 10, 2002",,"March 4, 2008","National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00001748,700.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
1011,1012,NCT00001302,A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833,,Completed,No Results Available,Breast Cancer|Kidney Neoplasm|Lymphoma|Neoplasm Metastasis|Ovarian Cancer,Drug: PSC 833,,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",Phase 1,80.0,NIH,Interventional,Primary Purpose: Treatment,920268|92-C-0268,1992-09-01,,2002-06-01,"November 4, 1999",,"March 4, 2008","National Cancer Institute (NCI), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00001302,3560.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
1012,1013,NCT00613665,Safety and Immunogenicity of Chiron's Investigational H. Pylori Vaccine in Healthy Adults,,Completed,No Results Available,Helicobacter Pylori|Gastritis|Gastric Cancer|Gastroduodenal Ulcers|Lymphoma,Biological: helicobacter pylori vaccine|Biological: Placebo,Safety measures: injection site and systemic reactions|Immunogencity measures: antigen-specific antibodies and cellular immune response,Novartis Vaccines|Novartis,All,18 Years to 40 Years   (Adult),Phase 1,113.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,HPP002,2001-02-01,December 2001,2002-04-01,"February 13, 2008",,"June 11, 2013","Universitaetsklinikum Charité, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT00613665,424.0,Industry Lead,More than three Conditions,Randomized,None-Crossover Assignment,Not Open Label,Other/Basic/Prevention
1013,1014,NCT00001383,A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833,,Completed,No Results Available,"Breast Cancer|Cancer|Carcinoma, Renal Cell|Lymphoma|Ovarian Cancer",Drug: PSC 833|Drug: paclitaxel,,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",Phase 1,52.0,NIH,Interventional,Primary Purpose: Treatment,940119|94-C-0119,1994-03-01,,2001-01-01,"December 10, 2002",,"March 4, 2008","National Cancer Institute (NCI), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00001383,2498.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
1014,1015,NCT00241358,Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies,,Completed,Has Results,"Leukemia, Myeloid, Acute|Leukemia, Myelogenous, Chronic|Leukemia, Lymphoblastic, Acute|Lymphocytic Leukemia, Chronic|Myelodysplastic Syndromes|Multiple Myeloma|Lymphoma, Non-Hodgkin|Hodgkin Disease",Drug: AMD3100|Procedure: Stem Cell Transplant,Proportion of Donors From Whom a Sufficient Number of Cells for Transplantation Are Collected in no More Than 2 LP Procedures Following Mobilization With AMD3100 (Donor Only)|Proportion of Recipients Who Experience Grade 2-4 Acute GVHD (Recipient Only)|Proportion of Recipients Who Successfully Engraft by Day +21 After Transplant (Recipient Only)|Proportion of Recipients Who Experience Chronic GVHD (Recipient Only)|Proportion of Recipients Who Experience Mortality Before Day 100 After Transplant (Recipient Only)|Quality of Life During Stem Cell Mobilization (Recipients Only)|Proportion of Donors Who Experience Infusional Toxicity (Donor Only)|To Determine the Pharmacokinetics of IV AMD3100 (IV Donor Arm Only) as Measured by Cmax|To Determine the Pharmacokinetics of IV AMD3100 (IV Donor Arm Only) as Measured by Mean AUC From Time 0 to Infinity,Washington University School of Medicine,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,92.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,03-0349,2004-05-01,December 2009,2010-02-01,"October 18, 2005","June 6, 2017","June 6, 2017","Washington University School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00241358,2102.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1015,1016,NCT00606437,Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants,,Completed,No Results Available,Lymphoma|Myeloma|Leukemia|Myelodysplasia|Solid Tumors|Hodgkin's Disease|Myelofibrosis,Procedure: Total Body Irradiation with Fludarabine in UCB Transplants,"The primary objective will be to measure the time to and rate of hematologic engraftment following transplant and the frequency of treatment-related mortality.|The secondary objective will be to estimate the proportion of patients developing acute and chronic graft-versus-host disease, 100 day treatment-related mortality, and to measure disease-free survival.|The tertiary objective will be to measure the time to immunologic reconstitution as defined by normal numbers of T and B cells, normal T-cell proliferative responses, normal natural killer (NK) cell function, and normal immunoglobulin synthesis.",Duke University,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Phase 1,40.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00009529,2005-09-01,February 2014,2014-02-01,"February 4, 2008",,"May 16, 2014","Duke University Health System, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00606437,3075.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1016,1017,NCT01413568,Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies,,Completed,No Results Available,"Acute Myeloid Leukemia in Remission|Adult Acute Lymphoblastic Leukemia in Remission|Chronic Myelogenous Leukemia (CML)|Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease (HD) in 2nd or Greater Complete Remission, Partial Remission|Chronic Lymphocytic Leukemia (CLL)|Multiple Myeloma (MM)|Myelodysplastic Syndrome (MDS)|Myeloproliferative Disorders",Drug: POL6326|Procedure: Leukapheresis|Procedure: PBSC Transplant,Phase I Study - safety and tolerability of POL6326 as a mobilization agent.|Phase II Study - determine the number of allogeneic donors who require a second leukapheresis|Phase I Study - define maximum tolerated dose of POL6326|Phase II Study - the proportion of HLA-identical sibling donors who experience grade 3-4 infusional toxicity and the proportion who are safely mobilized|Phase II Study - pharmacokinetics and pharmacodynamics of IV POL6326|Phase II Study - rate of acute GVHD and chronic GVHD in patients who receive IV POL6326 mobilized peripheral blood stem cells.|Phase II Study - kinetics of neutrophil and platelet engraftment in recipients of POL6326 mobilized peripheral blood stem cells.,Polyphor Ltd.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,38.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201112026|POL-4,2012-04-01,November 2015,2015-12-01,"August 10, 2011",,"February 26, 2016","University of Kansas Cancer Center, Kansas City, Kansas, United States|Washington University School of Medicine, St. Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT01413568,1339.0,Industry Lead,More than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1017,1018,NCT02337595,Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation,45RA_NEG_DLI,Completed,No Results Available,"Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Myeloid, Acute|Immune Deficiency Disease|Bone Marrow Failure Syndromes|Opportunistic Infections|Graft vs Host Disease",Biological: CD45RA-depleted peripheral blood mononuclear cells,"Cumulative incidence of grade 2-4 acute graft-versus-host disease|Immune reconstitution (Quantitative evaluation of lymphocyte subsets in the peripheral blood, quantitative evaluation of pathogen-specific immune response by ELISPOT assay)|1-year survival|Transplant-related mortality|Incidence of chronic graft-versus-host disease","Federal Research Institute of Pediatric Hematology, Oncology and Immunology",All,"up to 25 Years   (Child, Adult)",Phase 1|Phase 2,30.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CD45RA_NEG_DLI_2014FRCPHOI,2014-08-01,March 2015,2016-01-01,"January 13, 2015",,"April 22, 2016","Federal Research Center for pediatric hematology, oncology and immunology, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT02337595,518.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
1018,1019,NCT00823524,Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer,,Completed,No Results Available,"Brain and Central Nervous System Tumors|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Unspecified Adult Solid Tumor, Protocol Specific",Biological: donor natural killer cell infusion,"Safety|Clinical efficacy of donor NK cell infusion, in terms of tumor response, response duration, and survival",Asan Medical Center|Korea Research Institute of Bioscience & Biotechnology,All,"15 Years to 75 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,47.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000632275|AMC-UUCM-2008-0383,2009-01-01,February 2013,2013-02-01,"January 15, 2009",,"February 20, 2013","University of Ulsan, Asan Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00823524,1492.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1019,1020,NCT00003406,Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer,,Completed,No Results Available,"Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition|Unspecified Adult Solid Tumor, Protocol Specific",Drug: carboplatin|Drug: docetaxel|Drug: ifosfamide|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation,,Cancer Treatment Centers of America|National Cancer Institute (NCI),All,"up to 65 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,30.0,Other,Interventional,Primary Purpose: Treatment,CDR0000066415|MRMC-CTCA-9711|NCI-V98-1446,1997-10-01,,2000-03-01,"August 26, 2004",,"March 26, 2013","Midwestern Regional Medical Center, Zion, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00003406,882.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
1020,1021,NCT00245037,"Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer",Bu Flu TBI,Completed,Has Results,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Precancerous Condition,Biological: therapeutic allogeneic lymphocytes|Drug: busulfan|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: peripheral blood stem cell transplantation|Radiation: Total Body Irradiation (TBI)|Drug: Granulocyte colony-stimulating factor (G-CSF)|Drug: Phenytoin|Drug: Methotrexate,Regimen-Related Toxicities|Non-relapse Mortality|Overall Survival|Progression-Free Survival|Relapse Mortality|Acute Graft-Versus-Host Disease (aGVHD) Outcome|Chronic Graft-Versus-Host Disease (cGVHD) Outcome,OHSU Knight Cancer Institute|National Cancer Institute (NCI),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,147.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00000210|P30CA016058|OHSU-HEM-05011-L|OHSU-210,2005-06-01,August 2015,2015-08-01,"October 27, 2005","July 2, 2017","September 27, 2017","Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT00245037,3713.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1021,1022,NCT00010283,"Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon",,Completed,No Results Available,Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Graft Versus Host Disease|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor,Drug: beclomethasone dipropionate,,Fred Hutchinson Cancer Center|National Cancer Institute (NCI),All,"5 Years to 75 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,,Other|NIH,Interventional,Primary Purpose: Supportive Care,1500.00|FHCRC-1500.00|RPCI-DS-99-27|NCI-H01-0067|CDR0000068475,2000-07-01,July 2002,2002-07-01,"April 13, 2004",,"April 2, 2010","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00010283,730.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Supportive Care
1022,1023,NCT00089037,"Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation",,Completed,No Results Available,Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,Drug: methotrexate|Drug: sirolimus|Drug: tacrolimus,,Fred Hutchinson Cancer Center|National Cancer Institute (NCI),All,"Child, Adult, Older Adult",Phase 1|Phase 2,,Other|NIH,Interventional,Masking: None (Open Label)|Primary Purpose: Supportive Care,1811.00|FHCRC-1811.00|CDR0000378004,2003-06-01,April 2005,2005-04-01,"August 5, 2004",,"July 15, 2011","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00089037,670.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Supportive Care
1023,1024,NCT01702155,Phase I/II Study of DFP-10917 in Patients With Acute Leukemia,,Completed,No Results Available,Acute Myeloid Leukemia|Acute Lymphocytic Leukemia,Drug: DFP-10917,Number of patients with adverse events,"Delta-Fly Pharma, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,69.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D11-11002,2012-10-10,"January 18, 2017",2017-10-11,"October 5, 2012",,"October 25, 2019","MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01702155,1827.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1024,1025,NCT01222780,"To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer",,Completed,No Results Available,Sarcoma|Neuroblastoma|Wilms Tumor|Leukemia|Lymphoma|Brain Tumors,Drug: Marqibo,"Define the toxicity spectrum of Marqibo in children with cancer|Determine of Marqibo® administered as a 60 minute intravenous infusion weekly (every 28 days constitute 1 cycle), in children and adolescents with refractory solid tumors and hematologic malignancies.|Determine dose limiting toxicities (DLT) of Marqibo® administered as a 60 minute intravenous infusion weekly (every 28 days constitute 1 cycle), in children and adolescents with refractory solid tumors and hematologic malignancies.|Evaluate the plasma pharmacokinetics of Marqibo in children with cancer.",Acrotech Biopharma Inc.|National Cancer Institute (NCI),All,"2 Years to 20 Years   (Child, Adult)",Phase 1,22.0,Industry|NIH,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"100220|IND 59,056",2010-09-01,December 2014,2014-12-01,"October 18, 2010",,"January 18, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01222780,1552.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1025,1026,NCT00064311,Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation,,Completed,No Results Available,Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Infection|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor,Drug: ravuconazole,,National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,,NIH,Interventional,Masking: None (Open Label)|Primary Purpose: Supportive Care,030205|03-C-0205|CDR0000315356,2003-06-01,,2004-09-01,"July 9, 2003",,"March 8, 2012","Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00064311,458.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Supportive Care
1026,1027,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,,Completed,Has Results,Leukemia,Drug: clofarabine|Drug: cytarabine|Drug: methotrexate|Other: laboratory biomarker analysis,"Overall Response (CR for ALL Patients), (CR + CRp for AML Patients)|Safety and Tolerability as Measured by CTCAE v3.0|Correlate the Expression of Apoptosis Specific Genes",Children's Oncology Group|National Cancer Institute (NCI),All,"1 Year to 30 Years   (Child, Adult)",Phase 1|Phase 2,74.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AAML0523|CDR0000494654|NCI-2009-00319|COG-AAML0523,2007-03-01,August 2012,2012-08-01,"September 7, 2006","February 3, 2014","June 5, 2017","UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|Southern California Permanente Medical Group, Downey, California, United States|Jonathan Jaques Children's Cancer Center at Miller Children's Hospital, Long Beach, California, United States|Children's Hospital Central California, Madera, California, United States|Children's Hospital of Orange County, Orange, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Children's Hospital Colorado Center for Cancer and Blood Disorders, Aurora, Colorado, United States|Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, D.C., District of Columbia, United States|Children's National Medical Center, Washington, D.C., District of Columbia, United States|Lee Cancer Care of Lee Memorial Health System, Fort Myers, Florida, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Nemours Children's Clinic - Orlando, Orlando, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|St. Joseph's Cancer Institute at St. Joseph's Hospital, Tampa, Florida, United States|AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States|Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, Georgia, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|University of Illinois Cancer Center, Chicago, Illinois, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Simmons Cooper Cancer Institute, Springfield, Illinois, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|St. Vincent Indianapolis Hospital, Indianapolis, Indiana, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Tulane Cancer Center Office of Clinical Research, Alexandria, Louisiana, United States|CancerCare of Maine at Eastern Maine Medical Center, Bangor, Maine, United States|Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|UMASS Memorial Cancer Center - University Campus, Worcester, Massachusetts, United States|C.S. Mott Children's Hospital at University of Michigan Medical Center, Ann Arbor, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|University of Mississippi Cancer Clinic, Jackson, Mississippi, United States|Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States|CCOP - Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Hackensack University Medical Center Cancer Center, Hackensack, New Jersey, United States|Overlook Hospital, Morristown, New Jersey, United States|Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States|Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States|James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States|SUNY Upstate Medical University Hospital, Syracuse, New York, United States|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina, United States|Presbyterian Cancer Center at Presbyterian Hospital, Charlotte, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's - Dayton, Dayton, Ohio, United States|Legacy Emanuel Hospital and Health Center and Children's Hospital, Portland, Oregon, United States|Penn State Children's Hospital, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Palmetto Health South Carolina Cancer Center, Columbia, South Carolina, United States|Greenville Hospital Cancer Center, Greenville, South Carolina, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States|Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States|Baylor University Medical Center - Houston, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States|Carilion Medical Center for Children at Roanoke Community Hospital, Roanoke, Virginia, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States|Providence Cancer Center at Sacred Heart Medical Center, Spokane, Washington, United States|Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States|Midwest Children's Cancer Center at Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|CancerCare Manitoba, Winnipeg, Manitoba, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|Hopital Sainte Justine, Montreal, Quebec, Canada|Allan Blair Cancer Centre at Pasqua Hospital, Regina, Saskatchewan, Canada",,https://ClinicalTrials.gov/show/NCT00372619,1980.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1027,1028,NCT00027547,Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia,,Completed,No Results Available,Leukemia,Biological: therapeutic allogeneic lymphocytes|Drug: cyclosporine|Drug: cytarabine|Drug: fludarabine phosphate|Drug: methotrexate|Drug: mycophenolate mofetil|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,,Fred Hutchinson Cancer Center|National Cancer Institute (NCI),All,"up to 75 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,,Other|NIH,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,1586.00|FHCRC-1586.00|NCI-H01-0080|CDR0000069042,2001-07-01,,2004-07-01,"January 27, 2003",,"November 30, 2011","Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Universitaet Leipzig, Leipzig, Germany",,https://ClinicalTrials.gov/show/NCT00027547,1096.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1028,1029,NCT00289562,Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia,,Completed,No Results Available,B-cell Acute Lymphoblastic Leukemia,Drug: forodesine hydrochloride (BCX-1777),,BioCryst Pharmaceuticals,All,"Child, Adult, Older Adult",Phase 1|Phase 2,20.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BCX1777-Bi-04-106,2004-09-01,December 2007,2007-12-01,"February 10, 2006",,"January 20, 2012","Denver, Colorado, United States|Chicago, Illinois, United States|Kansas City, Kansas, United States|New York, New York, United States|New York, New York, United States|Houston, Texas, United States|Abingdon, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00289562,1186.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1029,1030,NCT00460694,Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies,alloCIK,Completed,No Results Available,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia|Non Hodgkin's Lymphoma|Hodgkin's Disease|Myelodysplastic Syndrome|Multiple Myeloma,Biological: infusion of allogeneic CIK cells,Feasibility of expansion of frozen donor mononuclear cells into CIK|Toxicity including GVHD and marrow aplasia|Efficacy in terms of disease response as compared to previous treatment modality ie unmanipulated DLI,"Singapore General Hospital|National Medical Research Council (NMRC), Singapore",All,"12 Years to 60 Years   (Child, Adult)",Phase 1|Phase 2,24.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CIK#2/2007|NMRC/1097/2006,2006-08-01,December 2012,2012-12-01,"April 16, 2007",,"February 10, 2017","Singapore General Hospital, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT00460694,2314.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1030,1031,NCT05563545,Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia,,Completed,No Results Available,Acute Lymphoblastic Leukemia,Biological: CAR-NK-CD19 Cells,Safety of CAR NK-CD19 Cell|Cell count of CAR NK-CD19|Cmax of CAR NK-CD19|Tmax of CAR NK-CD19|AUC of CAR NK-CD19|Other pharmacokinetic of CAR NK-CD19 Cell|The overall response rate (ORR)|Concentration of anti-drug antibody (ADA)|The changes of cytokines,"Shanghai Simnova Biotechnology Co.,Ltd.|Hebei Yanda Ludaopei Hospital",All,"3 Years and older   (Child, Adult, Older Adult)",Phase 1,2.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XB-NK-1003,2022-07-21,"November 25, 2022",2022-11-25,"October 3, 2022",,"November 28, 2022","Hebei Yanda Ludaopei Hospital, Sanhe, Hebei, China",,https://ClinicalTrials.gov/show/NCT05563545,127.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1031,1032,NCT00592046,A Phase I Trial of ZIO-101 in Hematologic Cancers,,Completed,No Results Available,Acute Leukemia|Chronic Myeloproliferative Disease|Chronic Lymphoproliferative Disease|Multiple Myeloma|Lymphoma|Poor-risk Myelodysplasia (MDS),Drug: ZIO-101 (Darinaparsin),"Response Rate|The RECIST criteria will be used for patients with all leukemias and myelodysplastic syndromes.|Patients with lymphoma or myeloma will be assessed by the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas.|EBMT, IBMTR and ABMTR criteria for definition of response, relapse and progression in patients with multiple myeloma .",Alaunos Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1,12.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SGL1001,2005-05-01,June 2008,2008-06-01,"January 11, 2008",,"July 19, 2012","Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00592046,1127.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1032,1033,NCT04888468,Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents,,Completed,No Results Available,Acute Lymphoblastic Leukemia|Relapsed Pediatric ALL|Refractory Acute Lymphoblastic Leukemia,Biological: pCAR-19B cells,Incidence of Adverse events after pCAR-19B infusion [Safety and Tolerability]|Obtain the maximum tolerated dose of pCAR-19B cells[Safety and Tolerability]|Objective response rate after pCAR-19B infusion [Effectiveness]|AUCS of pCAR-19B cells [Cell dynamics]|CMAX of pCAR-19B cells [Cell dynamics]|TMAX of pCAR-19B cells [Cell dynamics]|Pharmacodynamics of pCAR-19B cells[Cell dynamics]|Immunogenicity of pCAR-19B cells,"Chongqing Precision Biotech Co., Ltd",All,"3 Years to 21 Years   (Child, Adult)",Phase 1,9.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PB01,2019-11-05,"June 29, 2021",2021-09-01,"May 17, 2021",,"March 18, 2022","Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China",,https://ClinicalTrials.gov/show/NCT04888468,666.0,Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1033,1034,NCT04524455,Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL,,Completed,No Results Available,Acute Lymphoblastic Leukemia,Drug: Blinatumomab|Drug: AMG 404|Drug: Dexamethasone Premedication,Number of Participants who Experience Dose-Limiting Toxicities (DLTs)|Number of Participants who Experience Treatment-Emergent Adverse Events (TEAEs)|Number of Participants who Experience Serious Treatment-Emergent Adverse Events|Number of Participants who Experience Treatment-Related Treatment-Emergent Adverse Events|Number of Participants who Experience Adverse Events of Interest (EOI)|Rate of Complete Remission (CR) Including Complete Remission with Partial Hematological Recovery (CRh*)|Complete Remission (CR) Rate|Duration of Complete Remission (CR)|Duration of Complete Remission (CR) or Complete Remission with Partial Hematological Recovery (CRh*)|Steady State Concentrations (Css) of Blinatumomab|Maximum Observed Concentration (Cmax) of AMG 404|Time to Maximum Observed Concentration (Tmax) of AMG 404|Area Under the Plasma Concentration-Time Curve (AUC) of AMG 404|Number of Participants with Incidences of Anti-Blinatumomab Antibodies|Number of Participants with Incidences of Anti-AMG 404 Antibodies,Amgen,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1,17.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20190177,2020-10-02,"January 24, 2023",2023-01-24,"August 24, 2020",,"January 26, 2023","City of Hope National Medical Center, Duarte, California, United States|University of Chicago, Chicago, Illinois, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Royal Melbourne Hospital, Parkville, Victoria, Australia|Ordensklinikum Linz Elisabethinen, Linz, Austria|Hôpital Saint Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Klinikum und Fachbereich Medizin Johann Wolfgang Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Germany|Universitaetsklinikum Regensburg, Regensburg, Germany|Azienda Ospedaliera Universitaria di Bologna Policlinico S Orsola Malpighi, Bologna, Italy|Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, Italy|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Hospital Universitari Germans Trias i Pujol, Badalona, Cataluña, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Cataluña, Spain|University College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT04524455,844.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1034,1035,NCT03472573,Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia,,Completed,No Results Available,Recurrent B Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia,Drug: Palbociclib|Drug: Dexamethasone,Incidence of dose limiting toxicities (DLT) of the combination of palbociclib and dexamethasone|Maximum tolerated dose (MTD) of the combination of palbociclib and dexamethasone defined as the highest dose level where a DLT occurs in at most one out of six patients treated|Clinically relevant responses to therapy determined by bone marrow biopsy,Sidney Kimmel Cancer Center at Thomas Jefferson University|Pfizer|Thomas Jefferson University,All,"18 Years and older   (Adult, Older Adult)",Phase 1,7.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17P.676,2018-05-09,"August 4, 2021",2021-08-04,"March 21, 2018",,"June 3, 2022","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03472573,1183.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1035,1036,NCT02975687,CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia,,Completed,No Results Available,"Acute Lymphoblastic Leukemia, Adult B-Cell|Acute Lymphoblastic Leukaemia Recurrent",Biological: CD19 CAR T cells,The complete remission (CR) rate|Disease-free survival (DFS)|Number of adverse event of CD19 CAR T cells treatment|Grade of adverse event of CD19 CAR T cells treatment|Duration of in vivo survival of CD19 CAR T cells.,Institute of Hematology & Blood Diseases Hospital|Union Stem cell & gene engineering Co.LTD|Juventas Cell Therapy Ltd.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,20.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XH-CD19CART-001|HY001001,2016-11-01,December 2018,2018-12-31,"November 29, 2016",,"July 9, 2019","Institute of Hematology & Blood Diseases Hospital, Tianjin, China",,https://ClinicalTrials.gov/show/NCT02975687,790.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1036,1037,NCT02808442,Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia,PALL,Completed,No Results Available,Refractory B-cell Acute Lymphoblastic Leukemia|Relapsed B-cell Acute Lymphoblastic Leukemia,Biological: UCART19,Incidence and Severity of Adverse Events|Molecular Remission Rate,"Institut de Recherches Internationales Servier|ADIR, a Servier Group company|Servier",All,up to 17 Years   (Child),Phase 1,13.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UCART19_02 (CL1-68587-001)|2015-004293-15,2016-06-03,"September 17, 2020",2020-11-04,"June 21, 2016",,"October 8, 2021","Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Hôpital Robert-Debré, Paris, France|Hospital San Juan De Dios, Barcelona, Spain|UCL Great Ormond Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02808442,1615.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1037,1038,NCT02746952,Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia,CALM,Completed,No Results Available,B-cell Acute Lymphoblastic Leukemia,Biological: UCART19,Dose escalation part: Dose Limiting Toxicities (DLTs) occurence. Dose expansion part: AE throughout the study.|Incidence and Severity of Adverse Events as a Measure of Safety and Tolerability|Objective Remission Rate|Duration of remission|Time to remission|Progression Free Survival (PFS)|Overall Survival (OS),"Institut de Recherches Internationales Servier|ADIR, a Servier Group company|Servier",All,"16 Years to 69 Years   (Child, Adult, Older Adult)",Phase 1,25.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CL1-68587-002|2016-000296-24,2016-08-01,"July 28, 2020",2020-07-28,"April 21, 2016",,"October 1, 2021","Massachusetts General Hospital, Boston, Massachusetts, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Hôpital Saint-Antoine, PARIS Cedex 12, France|Hôpital Saint-Louis, Paris, France|Kyushyu University Hospital, Fukuoka, Japan|Hokkaido University Hospital, Sapporo, Japan|King's College Hospital NHS Foundation Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT02746952,1457.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1038,1039,NCT00581815,Spectroscopy With Surface Coils and Decoupling,,Completed,No Results Available,Adrenal Cortical Cancer|Brain Cancer|Breast Cancer|CNS Cancer|Colon Cancer|HEENT Cancer|Hodgkin's Disease|Kaposi's Sarcoma|Liver Cancer|Lung Cancer|Non-Hodgkin's Lymphoma|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Rectal Cancer|Renal Cancer|Sarcoma|Squamous Cell Carcinoma|Thyroid Cancer,Device: Proton-decoupled 31P MRS at 1.5T|Device: 1H Spectroscopy at 1.5T and 3T,"To obtain high resolution spectra from tumors using surface coils to improve sensitivity.|In some of these studies, to enhance our spectral resolution and obtain additional metabolic information, we propose to use decoupling, which will increase both signal quality (the signal to noise ratio) and spectral resolution.","Memorial Sloan Kettering Cancer Center|Columbia University|University of Pennsylvania|St. George's Hospital, London|Royal Marsden NHS Foundation Trust|University Medical Center Nijmegen|Weill Medical College of Cornell University",All,"18 Years and older   (Adult, Older Adult)",Phase 1,582.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,97-014,1997-02-01,February 2014,2014-02-01,"December 28, 2007",,"December 28, 2015","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00581815,6209.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1039,1040,NCT01523977,Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL,CRAD001NUS175T,Completed,No Results Available,Acute Lymphoblastic Leukemia,Drug: Everolimus|Drug: Prednisone|Drug: Vincristine|Drug: PEG-Asparaginase|Drug: Doxorubicin|Drug: Dexrazoxane,Safety and Feasibility|Clinical Activity|Impact on biologic markers|Determinants of Response,Dana-Farber Cancer Institute|Novartis,All,"18 Months to 21 Years   (Child, Adult)",Phase 1,22.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11-237,2011-11-01,January 2017,2018-11-01,"February 1, 2012",,"March 22, 2023","UCSF, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Columbia University Medical Center, New York, New York, United States|Seattle Children's Hospital, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01523977,2557.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1040,1041,NCT01324180,"Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)",,Completed,No Results Available,Acute Lymphoblastic Leukemia,Drug: Metformin|Drug: Vincristine|Drug: Dexamethasone|Drug: PEG-asparaginase|Drug: Doxorubicin|Drug: Intrathecal chemotherapy,Maximum Tolerated Dose (MTD)|The Number of Participants with Complete Remission|The Number of Participants with Biological Response to Treatment|The Number of Participants with Adverse Events as a Measure of Safety and Feasibility,H. Lee Moffitt Cancer Center and Research Institute|Pediatric Cancer Foundation,All,"1 Year to 30 Years   (Child, Adult)",Phase 1,14.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MCC-16601|Sunshine Project 001,2011-07-18,"November 16, 2016",2017-07-27,"March 28, 2011",,"August 7, 2017","Holtz Children's Hospital University of Miami Miller School of Medicine, Miami, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|Montefiore Medical Center, The Children's Hospital at Montefiore, The Bronx, New York, United States|Nationwide Children's Hospital, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01324180,2201.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1041,1042,NCT01216332,Standard Versus High-Dose Trivalent Inactivated Flu Vaccine in Pediatric Acute Lymphoblastic Leukemia Patients,,Completed,Has Results,Pediatric Patients With Acute Lymphoblastic Leukemia,Drug: High-dose trivalent inactivated influenza vaccine|Drug: Standard dose trivalent inactivated influenza vaccine,Local Reactions After Each Vaccination|Systemic Reaction|Immunogenicity: Number of Participants With a Post-titer Greater Than or Equal to a Fourfold Titer Rise|Immunogenicity:Number of Participants With a Pre-titer ≥1:40|Immunogenicity: Number of Participants With a Post-titer ≥1:40|Immunogenicity: The Geometric Mean Titers Pre-vaccine in Study Participants|Immunogenicity: Geometric Mean Titers Post-vaccine in Study Participants,Vanderbilt University|Vanderbilt University Medical Center,All,3 Years to 17 Years   (Child),Phase 1,50.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",VICC PED 1067,2010-10-01,May 2013,2013-05-01,"October 7, 2010","May 3, 2019","May 3, 2019","Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT01216332,943.0,Not Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,Not Open Label,Other/Basic/Prevention
1042,1043,NCT01196013,A Study of Clofarabine in Japanese Paediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukaemia,,Completed,No Results Available,Acute Lymphoblastic Leukemia,Drug: Clofarabine,"Maximum Tolerated Dose (MTD)|Safety as evaluated by adverse events (incidence, severity, duration, causality, seriousness, type)|Pharmacokinetics as measured by maximum drug serum concentration (Cmax)|Pharmacokinetics as measured by Time to maximum serum concentration (Tmax)|Pharmacokinetics as measured by Area Under the drug-concentration curve (AUC)|Pharmacokinetics as measured by half life (t1/2)|Pharmacokinetics as measured by renal clearance (CLr)","Genzyme, a Sanofi Company|Sanofi",All,"1 Year to 21 Years   (Child, Adult)",Phase 1,7.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLO05908,2010-08-01,May 2011,2011-05-01,"September 8, 2010",,"March 19, 2014","National Kyusyu Cancer Center, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Kagoshima University Medical and Dental Hospital, Kagoshima, Japan|Tokai University Hospital, Kanagawa, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Osaka City General Hospital, Osaka, Japan|Saitama Chilidren's Medical Center, Saitama, Japan|Shizuoka Children's Hospital, Shizuoka, Japan|St. Luke's International Hospital, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT01196013,273.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1043,1044,NCT01137747,Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia,AML ALL,Completed,No Results Available,Leukemia,Drug: Carfilzomib,"To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT)|To determine the rate of morphologic complete remission (CR)|To determine the rates of cytogenetic complete remission (CRc) morphologic complete remission with incomplete count recovery (CRi), overall response rate (CR+ CRi), partial remission (PR), stable disease and hematologic improvement.|To determine the time to response, remission duration, progression-free survival, event-free survival and overall survival of patients treated with carfilzomib.|To determine the safety and tolerability of carfilzomib by evaluating the number of participants with adverse events as a measure of safety and tolerability.|To prospectively collect serum and bone marrow specimens to determine biomarkers of response and correlative ex vivo studies of the anti-leukemic activity of carfilzomib.",Washington University School of Medicine,All,"18 Years and older   (Adult, Older Adult)",Phase 1,18.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10-0913 / 201107117,2010-10-01,August 2014,2015-07-01,"June 4, 2010",,"June 14, 2016","Washington University School of Medicine, St. Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT01137747,1734.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1044,1045,NCT00995137,Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia,,Completed,No Results Available,"Lymphoblastic Leukemia, Acute",Biological: NK Cell Infusion,This study will determine the maximum tolerated dose of genetically modified NK cells in research participants with relapsed or refractory B-lineage ALL|This study will determine the persistence and phenotype of genetically modified NK cells in research participants with relapsed or refractory B-lineage ALL.|This study will explore the efficacy of genetically modified NK cells in research participants with relapsed or refractory B-lineage ALL.,St. Jude Children's Research Hospital|National Cancer Institute (NCI)|Assisi Foundation,All,"up to 18 Years   (Child, Adult)",Phase 1,14.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NKCD19|R01CA113482|NCI-2011-01226,2009-10-01,May 2013,2014-05-01,"October 15, 2009",,"April 26, 2017","St Jude Children's Research Hospital, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00995137,1673.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1045,1046,NCT00991133,"A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)",,Completed,No Results Available,"Lymphoblastic Leukemia, Acute, Childhood",Drug: Clofarabine incorporated into a 5-drug regimen,"The incidence of DLTs (Dose Limiting Toxicities) experienced with 1 cycle of this 5-drug regimen in this patient population (in all patients who receive any doses of study drugs)|Overall toxicity profile documented by incidence of AEs, SAEs, and/or DLTs|Efficacy as documented by complete remission (CR), time and duration of remission, event-free survival (EFS), 4-month EFS, disease-free survival (DFS), and overall survival","Genzyme, a Sanofi Company|Sanofi",All,"1 Year to 30 Years   (Child, Adult)",Phase 1,8.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLO08808,2009-10-01,April 2011,2011-04-01,"October 7, 2009",,"April 30, 2015","Children's Hospital Los Angeles, Los Angeles, California, United States|The Children's Hospital, Aurora, Colorado, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Children's Memorial Hospital, Chicago, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Seattle Children's Hospital, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00991133,547.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1046,1047,NCT00874562,Rapamycin in Relapsed Acute Lymphoblastic Leukemia,,Completed,No Results Available,Acute Lymphoblastic Leukemia,Drug: Corticosteroid|Drug: Rapamycin,"Compare changes in gene expression signatures in steroid alone versus steroid plus rapamycin treated patients.|Compare biologic measures of ""pro-apoptotic state"" in steroid alone versus steroid plus rapamycin treated patients|Assess clinical response by percent reduction of peripheral leukemia blasts at day 2 of therapy and at completion of the 5-day investigational window",Dana-Farber Cancer Institute|Brigham and Women's Hospital|Boston Children's Hospital|National Cancer Institute (NCI),All,"365 Days and older   (Child, Adult, Older Adult)",Phase 1,6.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),06-429,2007-07-01,November 2009,2016-04-01,"April 2, 2009",,"November 23, 2016","Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00874562,3197.0,Not Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),N/A
1047,1048,NCT00866307,Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011),,Completed,Has Results,Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia,Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Daunorubicin Hydrochloride|Drug: Dexamethasone|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Mercaptopurine|Drug: Methotrexate|Drug: Pegaspargase|Drug: Prednisone|Radiation: Prophylactic Cranial Irradiation|Drug: Thioguanine|Drug: Vincristine Sulfate,AALL08P1 Safety Outcome|AALL08P1 Feasibility Outcome,Children's Oncology Group|National Cancer Institute (NCI),All,"1 Year to 30 Years   (Child, Adult)",Phase 1,104.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AALL08P1|NCI-2009-01169|CDR0000636174|COG-AALL08P1|U10CA098413|U10CA180886|U10CA180899|U10CA098543,2009-02-23,"June 30, 2014",2021-03-31,"March 20, 2009","December 7, 2016","April 27, 2021","Phoenix Childrens Hospital, Phoenix, Arizona, United States|Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|UCSF Medical Center-Mount Zion, San Francisco, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|Harbor-University of California at Los Angeles Medical Center, Torrance, California, United States|Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Advocate Children's Hospital-Oak Lawn, Oak Lawn, Illinois, United States|Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Norton Children's Hospital, Louisville, Kentucky, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Legacy Emanuel Hospital and Health Center, Portland, Oregon, United States|Children's Oncology Group, Philadelphia, Pennsylvania, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|Royal Children's Hospital, Parkville, Victoria, Australia|Princess Margaret Hospital for Children, Perth, Western Australia, Australia|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00866307,4419.0,Not Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1048,1049,NCT02071927,Study of the Glutaminase Inhibitor CB-839 in Leukemia,,Completed,No Results Available,Acute Myeloid Leukemia (AML)|Acute Lymphocytic Leukemia (ALL),Drug: CB-839|Drug: CB-Aza,Safety and tolerability of CB-839: Incidence of adverse events|Pharmacokinetics: Area under the Curve (AUC) of CB-839 concentration in blood|Pharmacodynamics: % inhibition of glutaminase in blood|Clinical Activity: % of Tumor Cells in Bone Marrow,"Calithera Biosciences, Inc",All,"18 Years and older   (Adult, Older Adult)",Phase 1,43.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CX-839-003,2014-03-01,October 2016,2016-12-01,"February 26, 2014",,"February 9, 2017","Colorado Blood Cancer Institute, Denver, Colorado, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02071927,1006.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1049,1050,NCT00450944,Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia,,Completed,No Results Available,Leukemia,Biological: deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins,Optimum dose of deglycosylated ricin A chain-conjugated anti-CD19 and anti-CD22 immunotoxins (Combotox)|Efficacy of treatment,Albert Einstein College of Medicine|National Cancer Institute (NCI),All,"17 Years to 120 Years   (Child, Adult, Older Adult)",Phase 1,10.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2005-536|P30CA013330|AECM-CCI-2005-536|AECM-CCI-05-428|AECM-MMC-05-10-265C,2006-02-22,"October 27, 2008",2010-04-01,"March 22, 2007",,"April 14, 2021","Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT00450944,1499.0,Not Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1050,1051,NCT00313079,Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia,,Completed,No Results Available,"Leukemia, Lymphocytic|Leukemia|Acute Lymphocytic Leukemia",Drug: MAb 216|Drug: Vincristine,In this phase I study the endpoint is the determination of the maximum tolerable dose without toxicity.|A decrease in leukemic blasts. The study will be terminated if unacceptable doseSecondary endpoints are a decrease in leukemic blasts. The study will be terminated if unacceptable dose limiting toxicity is found. This is a phase I trial to study safety.,Steven E. Coutre|Stanford University,All,"18 Years and older   (Adult, Older Adult)",Phase 1,9.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HEMALL0003|96613,2006-05-01,February 2009,2009-07-01,"April 11, 2006",,"July 3, 2012","Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT00313079,1157.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1051,1052,NCT00295841,Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,,Completed,No Results Available,Leukemia,Drug: clofarabine|Drug: cytarabine,Response rate|Safety profile and tolerability,Wake Forest University Health Sciences|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1,53.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000466307|CCCWFU-21204|ILEX-CCCWFU-21204|CCCWFU-BG04-519,2005-02-01,"January 7, 2015",2015-01-07,"February 24, 2006",,"August 10, 2018","Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00295841,3627.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1052,1053,NCT01885897,IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT,,Completed,Has Results,Acute Myelogenous Leukemia (AML)|Acute Lymphoblastic Leukemia (ALL)|Myelodysplastic Syndromes (MDS)|Lymphoma|Myeloma|Chronic Lymphocytic Leukemia (CLL)|Chronic Myelogenous Leukemia (CML),Biological: ALT-803,Number of Participants With Dose Limiting Toxicity (DLT) Events|Number of Participants Experiencing Potential Efficacy of ALT 803|Number of Participants With Excessive Toxicity|Number of Participants With Incidence of Acute Graft Versus Host Disease|Number of Participants With Incidence of Chronic Graft Versus Host Disease,"Masonic Cancer Center, University of Minnesota",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,33.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012LS023|HM2013-12,2013-11-11,July 2019,2020-07-01,"June 25, 2013","August 12, 2020","August 12, 2020","Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT01885897/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01885897,2424.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1054,1055,NCT00349596,A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL),,Completed,No Results Available,Acute Lymphocytic Leukemia,Drug: Decitabine,To determine the safety and tolerability of 5-aza-2'-deoxycytidine (decitabine) administered daily for 5 days every other week in patients with relapsed or refractory acute lymphocytic leukemia (ALL).|To determine the clinical activity of this schedule of decitabine in this patient population.|To determine the safety and tolerability of decitabine in combination with hyperCVAD based chemotherapy in patients with relapsed or refractory ALL.|To determine the clinical activity of this schedule of decitabine in combination with hyperCVAD in this patient population.|To determine the effects of decitabine administration on DNA methylation and gene expression in this patient population.,M.D. Anderson Cancer Center|Eisai Inc.,All,"Child, Adult, Older Adult",Phase 1,40.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2005-0895|NCI-2012-01369,2006-07-01,October 2014,2014-10-01,"July 7, 2006",,"October 15, 2014","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00349596,3014.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1055,1056,NCT03841110,FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors,,Completed,No Results Available,Advanced Solid Tumors|Lymphoma|Gastric Cancer|Colorectal Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|EGFR Positive Solid Tumor|HER2-positive Breast Cancer|Hepatocellular Carcinoma|Small Cell Lung Cancer|Renal Cell Carcinoma|Pancreas Cancer|Melanoma|NSCLC|Urothelial Carcinoma|Cervical Cancer|Microsatellite Instability|Merkel Cell Carcinoma,Drug: FT500|Drug: Nivolumab|Drug: Pembrolizumab|Drug: Atezolizumab|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: IL-2,The incidence of subjects with Dose Limiting Toxicities within each dose level cohort.|Objective-response rate (ORR)|Duration of FT500 persistence,Fate Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1,37.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FT500-101,2019-02-15,"November 15, 2022",2022-11-15,"February 15, 2019",,"January 30, 2023","UCSD Moores Cancer Center, San Diego, California, United States|University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States|Hackensack University Medical Center/John Theurer Cancer Center, Hackensack, New Jersey, United States|MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03841110,1369.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1056,1057,NCT00807677,A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies,,Completed,No Results Available,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Chronic Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Multiple Myeloma|Waldenstrom's Macroglobulinemia|Myelodysplastic Syndrome|Philadelphia Chromosome-negative CML|Myeloid Metaplasia|Myelofibrosis|Advanced Polycythemia|Non-Hodgkins Lymphoma,Drug: TAK-901,To determine the maximum tolerated dose(MTD)of TAK-901 in subjects with advanced hematologic malignancies.|To further assess the safety and tolerability of TAK-901 at or below the MTD in an expanded cohort of subjects in order to select a dose for future studies.|To evaluate the pharmacokinetic profile of TAK-901 and its primary metabolite (M-I).|To make a preliminary assessment of the clinical activity of TAK-901.|To make a preliminary assessment of the effects of TAK-901 on pharmacodynamic biomarkers.|To make a preliminary assessment of the association between selected genetic markers and TAK-901 response and/or pharmacokinetic parameters.,"Millennium Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,31.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TAK-901_101,2009-03-01,September 2012,2013-03-01,"December 12, 2008",,"July 2, 2013","University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00807677,1461.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1057,1058,NCT01986426,LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab,,Completed,No Results Available,Cancer|Melanoma|Breast Cancer|Head and Neck Cancer|Lymphoma|Triple-Negative Breast Cancer,Drug: LTX-315 consecutive lesions|Drug: LTX-315|Drug: LTX-315 + ipilimumab|Drug: LTX-315 + pembrolizumab,Dose limiting toxicity|Anti tumour activity in injected tumour|Complete response (irCR) and partial response (irPR)|Overall response rate (OR)|Disease control rate (CR + PR + SD)|Progression free survival (PFS),Lytix Biopharma AS|Theradex|ICON plc,All,"18 Years and older   (Adult, Older Adult)",Phase 1,80.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C12-315-03,2013-11-01,April 2018,2018-08-31,"November 18, 2013",,"October 3, 2018","Jules Bordet Institute, Bruxelles, Belgium|Cliniques Universitaires St-Luc, Service d'oncologie médicale, Bruxelles, Belgium|Institut Curie, Paris, France|Institute Gustave Roussy, Paris, France|Intotuto Europeo di Oncologia (IEO), Milano, Italy|San Raffaele Hospital, Milano, Italy|Intituto Nazionale dei Tumori, Napoli, Italy|Instituto Oncologico Venneto (IOV), Padova, Italy|Haukeland University Hospital, Bergen, Norway|Oslo University Hospital Radiumhospitalet, Oslo, Norway|Guy's Hospital, London, United Kingdom|Royal Marsden Hospital, London, United Kingdom|University College of London Hospital, London, United Kingdom|Christie Hospital NHS Foundatin Trust, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT01986426,1764.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1058,1059,NCT02660281,URMC Related Haplo-identical Donor BMT,HaploOnly,Completed,No Results Available,Hematological Disease|Immune Deficiencies|Solid Tumors|Myelofibrosis|Multiple Myeloma|Lymphoma,Radiation: Total Body Irradiation 1200 cGy|Drug: Fludarabine|Drug: Pre-Stem Cell Infusion Cyclophosphamide|Drug: Pre-Stem Cell Infusion Mesna|Drug: Busulfan|Drug: Melphalan|Procedure: Stem Cell Infusion|Drug: Post-Stem Cell Infusion Cyclophosphamide|Drug: Post-Stem Cell Infusion Mesna|Drug: Thiotepa,"The number of days from the date of the stem cell infusion to engraftment of absolute neutrophils (ANC) and platelets (PLT) will be determined based on daily CBC and differential counts.|Rate of non-engraftment and secondary graft failure|Percentage of subjects who develop acute graft-versus-host disease.|Assess the Maximum Overall Grades 0- IV of acute GvHD and Maximum Severity (0-4) by involved organ system in patients who develop acute graft-versus-host disease.|Percentage of subjects who develop chronic graft-versus-host disease.|Assess the Maximum Grade: Limited versus Extensive; Maximum Severity: Mild, Moderate or Severe) of chronic GvHD in patients who develop chronic graft-versus-|Disease-free survival|Time to relapsed disease|Immune reconstitution",University of Rochester,All,"6 Months to 75 Years   (Child, Adult, Older Adult)",Phase 1,74.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UBMT 15056,2015-10-01,"October 28, 2019",2021-01-07,"January 21, 2016",,"November 3, 2021","Wilmot Cancer Institute, Rochester, New York, United States",,https://ClinicalTrials.gov/show/NCT02660281,1925.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1059,1060,NCT02064387,"Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916",,Completed,Has Results,Multiple Myeloma,Drug: GSK2857916,Number of Participants With Serious Adverse Events (SAEs) and Common (>=5%) Non-serious Adverse Events- Part 1|Number of Participants With SAEs and Common (>=5%) Non-serious Adverse Events- Part 2 (MM)|Number of Participants With SAEs and Common (>=5%) Non-serious Adverse Events- Part 2 (NHL)|Number of Participants With Dose-limiting Toxicities (DLTs) During the Determinative Period- Part 1|Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 1|Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 2 (MM)|Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 2 (NHL)|Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 1|Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (MM)|Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (NHL)|Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1|Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)|Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)|Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1|Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)|Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)|Number of Participants With Grade Change From Baseline in Hematology Data-Part 1|Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)|Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)|Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1|Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)|Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)|Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 1|Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (MM)|Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (NHL)|Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.06 mg/kg|Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.03 mg/kg and 0.12 mg/kg|Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.24 mg/kg|Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.48 mg/kg|Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.96 mg/kg|Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 1.92 mg/kg|Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 2.50 mg/kg|Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg|Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)|Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (NHL)|Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1|AUC[0-infinity] of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg|Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1|AUC[0-tau] of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg|Area Under the Concentration-time Curve From Zero to Time of Last Quantifiable Concentration (AUC[0-tlast]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1|AUC[0-tlast]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg|Clearance (CL) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1|CL of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg|Maximum Observed Concentration (Cmax) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1|Cmax of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg|Trough Plasma Concentration (Ctrough) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1|Ctrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg|Terminal Half-life (t1/2) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1|t1/2 of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg|Volume of Distribution at Steady State (Vss) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1|Vss of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg|Time to Reach Maximum Observed Concentration (Tmax) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1|Tmax of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg|Ctrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM-Part 2|Ctrough of GSK2857916 Following IV Dose in Participants With NHL-Part 2|AUC(0-tlast) of Cys Monomethyl Auristatin F (Cys-mcMMAF) Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1|AUC(0-tlast) of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg|Cmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1|Cmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg|Ctrough of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1|Ctrough of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg|Tmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1|Tmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM-Part 1: GSK2857916 2.50 mg/kg|Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 1|Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 2 (MM)|Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 2 (NHL)|Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1|Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)|Number of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL)|Overall Response Rate (ORR)- Part 1|ORR-Part 2 (MM)|ORR-Part 2 (NHL)|Clinical Benefit Rate (CBR)- Part 1|CBR- Part 2,GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,79.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,117159|2013-004549-18,2014-07-29,"August 31, 2018",2019-08-01,"February 17, 2014","September 26, 2019","August 11, 2020","GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Chapel Hill, North Carolina, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Vancouver, British Columbia, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02064387/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02064387/SAP_002.pdf",https://ClinicalTrials.gov/show/NCT02064387,1829.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1060,1061,NCT03289455,CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL),AMELIA,Completed,Has Results,B Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Refractory Childhood Acute Lymphoblastic Leukemia|B-cell Acute Lymphoblastic Leukemia,Biological: AUTO3 (CD19/22 CAR T cells,Number of Patients With Grade 3-5 Toxicities Occurring Within the Dose Limiting Toxicity (DLT) Period of AUTO3 Infusion|Number of Patients With Dose Limiting Toxicity (DLT) of AUTO3|Number of Patients Achieving Morphological Remission (Complete Response(CR) or Complete Response With Incomplete Count Recovery (CRi) and Minimal Residual Disease (MRD)-Negative Response in the Bone Marrow (PCR)).|Feasibility of Generating AUTO3: Number of Patients' Cells Successfully Manufactured as a Proportion of the Number of Patients Undergoing Leukapheresis|Event-Free Survival (EFS) by Morphological Analysis|Number of Patients With CD19- and/or CD22-negative Relapse|Relapse-Free Survival (RFS) by Morphological Analysis|Overall Survival (OS)|Expansion of AUTO3 Following Adoptive Transfer|Persistence of AUTO3 Following Adoptive Transfer|Duration of B Cell Aplasia,Autolus Limited,All,"1 Year to 24 Years   (Child, Adult)",Phase 1|Phase 2,23.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AUTO3-PA1|2016-004680-39,2017-06-26,"May 18, 2020",2020-05-18,"September 21, 2017","February 1, 2021","February 1, 2021","Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom|Royal Manchester Children's Hospital, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT03289455/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT03289455/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03289455,1057.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1061,1062,NCT03005392,Home-exercise Program for Children and Adolescent Survivors of Acute Lymphoblastic Leukemia,,Completed,No Results Available,Acute Lymphoblastic Leukemia,Other: exercise,Cardiorespiratory exercise test|Echocardiography|Functional mobility|Strength|Flexibility|Level of physical activity,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,All,"7 Years to 18 Years   (Child, Adult)",Phase 1|Phase 2,24.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IIBSP-EJE-2013-150,2015-06-01,September 2015,2016-03-01,"December 29, 2016",,"December 29, 2016","Claudia Delgado, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT03005392,274.0,Not Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1062,1063,NCT02412306,Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia,,Completed,Has Results,Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia,Drug: Blinatumomab,Phase 1b: Number of Participants With Dose-limiting Toxicities|Phase 2: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment|Expansion Cohort: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs|Phase 1b Adults: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment|Phase 1b Pediatric: Percentage of Participants With M1 Remission Within 2 Cycles of Treatment|Phase 1b and Phase 2: Duration of Response|Phase 1b and Phase 2: Relapse-free Survival|Phase 1b and Phase 2: Overall Survival|Phase 2: Best Overall Response Within 2 Cycles of Treatment|Phase 2: Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission|Phase 2: 100-Day Mortality After Allogeneic HSCT|Phase 1b and Phase 2: Number of Participants With TEAEs|Phase 1b and Phase 2: Serum Blinatumomab Concentration at Steady State|Phase 1b and Phase 2: Systemic Clearance of Blinatumomab|Phase 1b and Phase 2: Terminal Half-life of Blinatumomab|Phase 1b and Phase 2: Volume of Distribution of Blinatumomab|Phase 1b and Phase 2: Number of Participants Who Developed Anti-Blinatumomab Antibodies|Phase 1b and Phase 2: Interleukin-2 Concentration|Phase 1b and Phase 2: Interleukin-6 Concentration|Phase 1b and Phase 2: Interleukin-10 Concentration|Phase 1b and Phase 2: Tumor Necrosis Factor-Alpha (TNFα) Concentration|Phase 1b and Phase 2: Interferon Gamma (IFN-γ) Concentration|Expansion Cohort Adult: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment|Expansion Cohort Pediatric: Percentage of Participants With M1 Remission Within 2 Cycles of Treatment,Amgen|Amgen Astellas Biopharma K.K.,All,"0 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,66.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20130265,2015-06-04,"February 6, 2019",2019-07-04,"April 9, 2015","January 10, 2020","December 12, 2022","National Hospital Organization Nagoya Medical Center, Nagoya-shi, Aichi, Japan|Nagoya University Hospital, Nagoya-shi, Aichi, Japan|Kyushu University Hospital, Fukuoka-shi, Fukuoka, Japan|Gunmaken Saiseikai Maebashi Hospital, Maebashi-shi, Gunma, Japan|Sapporo Hokuyu Hospital, Sapporo-shi, Hokkaido, Japan|Kobe University Hospital, Kobe-shi, Hyogo, Japan|Kanagawa Childrens Medical Center, Yokohama-shi, Kanagawa, Japan|Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan|Niigata Cancer Center Hospital, Niigata-shi, Niigata, Japan|Okayama University Hospital, Okayama-shi, Okayama, Japan|Osaka City General Hospital, Osaka-shi, Osaka, Japan|Osaka Metropolitan University Hospital, Osaka-shi, Osaka, Japan|Saitama Childrens Medical Center, Saitama-shi, Saitama, Japan|Jichi Medical University Hospital, Shimotsuke-shi, Tochigi, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02412306/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02412306/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02412306,1491.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1063,1064,NCT01471782,Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia,,Completed,Has Results,Acute Lymphoblastic Leukemia,Biological: Blinatumomab,Phase I: Number of Participants With Dose-limiting Toxicities (DLTs)|Percentage of Participants With Complete Remission in the First Two Cycles|Number of Participants With Adverse Events|Steady State Concentration of Blinatumomab|Time to Hematological Relapse (Duration of Response)|Overall Survival|Relapse-free Survival|Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant During Blinatumomab Induced Remission|Number of Participants Who Developed Anti-blinatumomab Antibodies|Serum Cytokine Peak Levels,Amgen Research (Munich) GmbH,All,up to 17 Years   (Child),Phase 1|Phase 2,93.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MT103-205|2010-024264-18,2012-01-01,August 2014,2016-05-01,"November 16, 2011","February 8, 2017","February 8, 2017","Children's Hospital Denver, Aurora, Colorado, United States|Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States|Washington University, ST. Louis, Missouri, United States|Memorial Sloan Kettering, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St Jude Children's Research Hospital, Memphis, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Texas Children's Cancer Center/ Baylor, Houston, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|St. Anna Kinderspital, Vienna, Austria|Hospital for Sick Children, Toronto, Ontario, Canada|(CHU Besancon) Hopital Saint-Jaques, Besancon, France|Hôpital de la Timone (Enfants), Marseille, France|Hopital Robert Debré (AP-HP), Paris Cedex 19, France|Charité Campus Virchow Klinikum, Otto-Heubner-Centrum (OHC) für Kinder- und Jugendmedizin, Berlin, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Universitätsklinikum Essen, Essen, Germany|Klinikum der Johann Wolfgang Goethe-Universität Frankfurt/Main, Frankfurt am Main, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum der Universität München, Dr. von Haunersches Kinderspital, München, Germany|Universitätsklinik für Kinder- und Jugendmedizin Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|University of Milano-Bicocca, Hospital San Gerardo, Monza, Italy|Dipartimento della Donna e del Bambino, Padova, Italy|The Bambino Gesù Children's Hospital, Rome, Italy|Erasmus MC, Sophia Children's Hospital, Rotterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT01471782,1582.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1064,1065,NCT00440726,Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL),,Completed,Has Results,Acute Lymphoblastic Leukemia,Drug: Bortezomib|Drug: Dexamethasone|Drug: PEG-asparaginase|Drug: Doxorubicin|Drug: Cytarabine|Drug: Methotrexate|Drug: Vincristine|Drug: Triple IT Therapy,Occurrence of a Dose-Limiting Toxicity (Phase 1)|Achievement of Complete Remission (CR),Therapeutic Advances in Childhood Leukemia Consortium,All,"1 Year to 21 Years   (Child, Adult)",Phase 1|Phase 2,31.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,T2005-003,2006-08-04,"February 26, 2011",2011-02-26,"February 27, 2007","February 19, 2020","February 19, 2020","City of Hope, Duarte, California, United States|Miller Children's Hospital, Long Beach, California, United States|Childrens Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital & Research Center Oakland, Oakland, California, United States|Stanford University Medical Center, Palo Alto, California, United States|UCSF School of Medicine, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Miami Cancer Center, Miami, Florida, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Johns Hopkins / Sydney Kimmel Cancer Center, Baltimore, Maryland, United States|Dana Farber Cancer Center, Boston, Massachusetts, United States|C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States|Childrens Hospital & Clinics of Minnesota, Minneapolis, Minnesota, United States|New York University Medical Center, New York, New York, United States|Children's Hospital New York-Presbyterian, New York, New York, United States|Levine Children's Hospital, Charlotte, North Carolina, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|Sydney Children's Hospital, Randwick, New South Wales, Australia|The Children's Hospital at Westmead, Westmead, New South Wales, Australia|Universidade Federale de Sao Paulo/Hospital Sao Paulo, São Paulo, Brazil|Sick Kids, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00440726,1667.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1065,1066,NCT00144963,Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,,Completed,Has Results,Acute Lymphoblastic Leukemia,Drug: Vincristine Sulfate Liposomes Injection|Drug: Dexamethasone,MTD of VSLI,Acrotech Biopharma Inc.,All,"Child, Adult, Older Adult",Phase 1|Phase 2,36.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VSLI-06-ALL,2002-07-01,August 2006,2006-08-01,"September 5, 2005","January 18, 2012","December 12, 2019","Emory University, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00144963,1492.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1066,1067,NCT00098839,Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL),,Completed,Has Results,Recurrent Childhood Acute Lymphoblastic Leukemia,Drug: L-asparaginase|Drug: doxorubicin hydrochloride|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate|Biological: epratuzumab|Drug: cytarabine|Drug: prednisone|Drug: pegaspargase|Drug: dexrazoxane hydrochloride|Drug: methotrexate|Drug: etoposide|Drug: cyclophosphamide|Drug: leucovorin calcium|Biological: filgrastim,Remission Re-induction (CR2) Rate|Event-free Survival Rate|Rate of Minimal Residual Disease (MRD) < 0.01%|Pharmacokinetics,Children's Oncology Group|National Cancer Institute (NCI),All,"2 Years to 31 Years   (Child, Adult)",Phase 1|Phase 2,134.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ADVL04P2|NCI-2011-01624|COG-ADVL04P2|CDR0000396777|U10CA098543,2005-02-01,April 2011,2011-04-01,"December 9, 2004","March 26, 2015","December 12, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California San Francisco Medical Center-Parnassus, Frisco, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Miller Children's Hospital, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Children's Hospital Central California, Madera, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Childrens Hospital of Orange County, Orange, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Saint Joseph Children's Hospital of Tampa, Tampa, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|University of Kentucky, Lexington, Kentucky, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Johns Hopkins University, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|Wayne State University, Detroit, Michigan, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|The Childrens Mercy Hospital, Kansas City, Missouri, United States|UMDNJ - Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|New York University Langone Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States|The Children's Hospital at Westmead, Sydney, New South Wales, Australia|Princess Margaret Hospital for Children, Perth, Western Australia, Australia|Hospital Sainte-Justine, Montreal, Quebec, Canada|San Jorge Children's Hospital, Santurce, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00098839,2250.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1067,1068,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,,Completed,Has Results,Leukemia|Acute Lymphocytic Leukemia,Drug: Everolimus (RAD001)|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Doxorubicin|Drug: Dexamethasone|Drug: Mesna|Drug: Methotrexate|Drug: Ara-C (Cytarabine)|Drug: Methylprednisone|Drug: G-CSF,"Maximum Tolerated Dose [MTD] Determination by Number of Participants With Dose Limiting Toxicity (DLT)|Overall Response Rate (OR) Where OR = CR + CRp + CRi|Participant Responses by Daily Dose Level Assignment (RAD001 5 mg, 10 mg and MTD 5 mg)",M.D. Anderson Cancer Center|Novartis,All,"10 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,24.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2009-0100|NCI-2011-01814,2009-11-01,December 2015,2015-12-01,"August 28, 2009","May 31, 2018","February 27, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00968253,2221.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1068,1069,NCT00773149,Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia,Campath,Completed,No Results Available,Acute Lymphocytic Leukemia,Drug: Alemtuzumab (CAMPATH 1H) associated to G-CSF,"Partial and complete remission, overall response rates|Valuation of tolerance, more particularly targeted at the immunodeficiency shortage, contagious complications and neurotoxicity assessed according to the NCI (National Cancer Institute) classification.|Valuation of the response waiting time, from the first day of the induction treatment to the REEVOLUTING.",Assistance Publique - Hôpitaux de Paris,All,"15 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,12.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P051003,2006-10-01,January 2011,2011-07-01,"October 16, 2008",,"July 26, 2012","Saint Antoine Hospital, Hematology Unit, Paris, France",,https://ClinicalTrials.gov/show/NCT00773149,1734.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1069,1070,NCT01670175,Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors,,Completed,No Results Available,Malignant Solid Tumor|Childhood Solid Tumor,"Drug: Sirolimus, Cyclophosphamide, Topotecan",Dose Limiting Toxicity|Antitumor Activity|Biologic efects of drug combination|Antiangiogenic properties of drug combination,"University of California, San Francisco|Hyundai Hope On Wheels",All,"up to 25 Years   (Child, Adult)",Phase 1,21.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UCSF CC# 12083|IRB # 12-09399,2012-08-01,September 2016,2016-09-01,"August 22, 2012",,"June 21, 2017","UCSF Benioff Children's Hospital, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT01670175,1492.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1070,1071,NCT04327037,Safety of Expanded Haploidentical Natural Killer Cells for Leukemia,,Completed,No Results Available,"Leukemia, Acute Myeloid|Leukemia, Acute Lymphoblastic",Biological: Expanded Haploidentical Natural Killer cells|Drug: IL-2,"Incidence of Treatment-Emergent Adverse Events|Days of persistence of adoptively-transferred haploidentical NK cells|Occurrence of disease response|Median time to leukocytes and platelets recovery|Number of T, B, NK, activated T and NK cells after immunotherapy","Belarusian Research Center for Pediatric Oncology, Hematology and Immunology",All,"1 Year to 30 Years   (Child, Adult)",Phase 1,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BelarusianPediatric_NK_Pilot,2019-01-02,"June 6, 2021",2021-06-30,"March 30, 2020",,"March 2, 2022","Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Minsk Region, Belarus",,https://ClinicalTrials.gov/show/NCT04327037,910.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1071,1072,NCT04082286,Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia,,Completed,No Results Available,Acute Myeloblastic Leukemia|Acute Lymphoblastic Leukemia|Juvenile Myelomonocytic Leukemia,Other: Yttrium-90 labelled monoclonal antibody against CD66,maximum tolerated dose (MTD)|dose limited toxicity (DLT),Great Ormond Street Hospital for Children NHS Foundation Trust,All,"1 Year to 18 Years   (Child, Adult)",Phase 1,9.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,07MI05,2016-05-01,"May 14, 2020",2020-05-14,"September 9, 2019",,"June 25, 2021","Great Ormond Street Hospital for Children, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT04082286,1474.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1072,1073,NCT03483324,Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation,,Completed,No Results Available,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia in Remission|Myelodysplastic Syndromes|Other Acute Leukemias,Biological: Unmanipulated Umbilical Cord Blood (UCB)|Biological: AB-110,Occurrence of adverse events grade 4 or grade 5 as assessed by CTCAEv4|Graft failure defined as survival to day 42 without absolute neutrophil count greater than or equal to 500/mm3|Time to neutrophil engraftment|Cumulative incidence of sustained donor-derived neutrophil engraftment|Incidence of engraftment syndrome|Cumulative incidence of graft failure|Presence of post-transplant phenotype in hematopoietic cells of donor origin|Cumulative incidence of grade II - IV acute graft versus host disease (aGVHD)|Cumulative incidence of grade II - IV acute graft versus host disease (GVHD)|Cumulative incidence of chronic GVHD|Time to lymphoid recovery|Cumulative incidence of transplant related mortality (TRM)|Overall survival (OS)|Disease Free Survival (DFS),Angiocrine Bioscience|California Institute for Regenerative Medicine (CIRM),All,18 Years to 60 Years   (Adult),Phase 1,10.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AB-110-001,2018-04-24,"December 21, 2020",2022-01-31,"March 30, 2018",,"May 31, 2022","City of Hope Comprehensive Cancer Center, Duarte, California, United States|University of Colorado Cancer Center University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03483324,1378.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1073,1074,NCT02906371,Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome,,Completed,No Results Available,"Lymphoblastic Leukemia, Acute, Childhood",Drug: Tocilizumab|Biological: CART 19,the frequency of grade 4 CRS|tumor response,University of Pennsylvania|Children's Hospital of Philadelphia,All,"1 Year to 24 Years   (Child, Adult)",Phase 1,80.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"16CT022, 825445",2016-08-01,"March 11, 2020",2021-06-30,"September 20, 2016",,"July 2, 2021","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02906371,1794.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1074,1075,NCT01700751,Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation,,Completed,No Results Available,"Leukemia, Acute Myeloid|Leukemia, Lymphoblastic,Acute|Myelodysplastic Syndromes",Drug: brentuximab vedotin,MTD of brentuximab vedotin when administered with a GVHD prophylaxis regimen|Safety and tolerability of brentuximab vedotin when administered with a GVHD prophylaxis regimen|Rate of acute GVHD|Rate of chronic GVHD|Progression-free survival|Overall survival.|1-year non-relapse mortality rate|2-year non-relapse mortality rate|1-year disease relapse rate|2-year disease relapse rate,Washington University School of Medicine|Seagen Inc.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,17.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201211047,2013-02-25,"November 11, 2015",2016-11-21,"October 4, 2012",,"April 16, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT01700751,1365.0,Not Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1075,1076,NCT01684150,"A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving",,Completed,No Results Available,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome|Myeloproliferative Disorders,Drug: EPZ-5676,The maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of EPZ-5676 as determined by incidence of protocol-specified dose-limiting adverse events.|Pharmacokinetic profile of EPZ-5676|The incidence of adverse events in patients treated with EPZ-5676|Anti-leukemic activity of EPZ-5676 in patients with acute leukemia harboring a MLL-rearrangement|Effects of EPZ-5676 on histone H3K79 methylation in peripheral blood mononuclear cells (PBMC).|Effects of EPZ-5676 on histone H3K79 methylation in leukemia cells,"Epizyme, Inc.|Celgene",All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 1,51.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EPZ-5676-12-001,2012-09-01,November 2015,2016-02-01,"September 12, 2012",,"August 4, 2016","Mayo Clinic Scottsdale-Phoenix, Scottsdale, Arizona, United States|Northwestern University, Chicago, Illinois, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Health System, Durham, North Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|UT MD Anderson Cancer, Houston, Texas, United States|Universitätsklinikum Ulm, Ulm, Germany|Erasmus University Medical Center, Rotterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT01684150,1248.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1076,1077,NCT01279096,Safety of Clofarabine With Multiagent Chemotherapy in Childhood Acute Lymphoblastic Leukemia,Vandevol,Completed,No Results Available,Acute Lymphoid Leukemia Relapse|Acute Lymphoid Leukemia Relapse After Bone Marrow Transplant,Drug: Clofarabine,"maximum tolerated dose of clofarabine in combination with etoposide, asparaginase, mitoxantrone and dexamethasone|efficacy of clofarabine used in combination with etoposide, asparaginase, mitoxantrone and dexamethasone|Event free survival","University Hospital, Lille|Centre Hospitalier Universitaire de Besancon|Saint-Louis Hospital, Paris, France|Assistance Publique - Hôpitaux de Paris|Hospices Civils de Lyon|University Hospital, Toulouse|Central Hospital, Nancy, France|University Hospital, Marseille|University Hospital, Bordeaux|Nantes University Hospital|Rennes University Hospital",All,"1 Year to 23 Years   (Child, Adult)",Phase 1,20.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2009-010826-20|2008_40/0905,2010-01-01,June 2012,2013-06-01,"January 19, 2011",,"December 9, 2014","Besançon University Hospital, Besançon, France|Lille University Hospital, Lille, France",,https://ClinicalTrials.gov/show/NCT01279096,1247.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1078,1079,NCT00940524,"Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia",,Completed,No Results Available,Leukemia|Acute Lymphoblastic Leukemia,"Drug: Dasatinib, Mitoxantrone, Cytarabine","To determine the dose of dasatinib that can be safely administered with cytarabine, and high-dose mitoxantrone in patients with Ph+ ALL / lymphoid blast crisis of known chronic myelogenous leukemia.|To determine the toxicity of this combination in these patients.|To determine Abl-mutational status at baseline and at the time of disease progression as a possible mechanism of resistance.",Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 1,7.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,09-046,2009-07-01,April 2014,2014-04-01,"July 16, 2009",,"April 10, 2014","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00940524,1735.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1079,1080,NCT00466895,Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.,,Completed,No Results Available,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Chronic Lymphocytic Leukemia,Drug: lenalidomide,Maximum tolerable dose|Toxicities of lenalidomide|preliminary clinical activity|plasma and cellular pharmacokinetics|pharmacodynamics,Leslie Andritsos|Celgene Corporation|Ohio State University Comprehensive Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1,37.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSU-06003|NCI-2011-03218,2007-04-01,December 2014,2016-07-01,"April 27, 2007",,"November 14, 2017","Ohio State University Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00466895,3379.0,Not Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1080,1081,NCT00251368,Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia,,Completed,No Results Available,"Leukemia, Myelocytic, Acute|Acute Lymphocytic Leukemia",Drug: 9-Aminocamptothecin (9-AC),To evaluate the toxicity and maximum tolerated dose of 9-AC administered as a 72 hour infusion in patients with relapsed/refractory leukemia.|To analyze the pharmacokinetics in these patients.,Dana-Farber Cancer Institute|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 1,52.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,94-115,1995-01-01,September 2007,2007-09-01,"November 10, 2005",,"March 10, 2011","Massachusetts General Hosptial, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00251368,4626.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1081,1082,NCT00458250,Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H,,Completed,No Results Available,"Leukemia, Myeloid, Acute|Leukemia, Lymphoblastic, Acute",Procedure: Haploidentical hematopoietic stem cell transplantation|Drug: Busulfan|Drug: Cyclophosphamide|Drug: CAMPATH-1H|Drug: Cyclosporin A|Drug: Methotrexate,Engraftment one month after transplantation|six months survival,Tehran University of Medical Sciences,All,"2 Years to 50 Years   (Child, Adult)",Phase 1,10.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,418-A-1954,2006-09-01,,2008-02-01,"April 10, 2007",,"November 18, 2008","Hematology-Oncology & BMT Research Center, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT00458250,518.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1083,1084,NCT01977638,Phase 1 Trial of CXD101 in Patients With Advanced Cancer,,Completed,No Results Available,Advanced Cancer,Drug: CXD101,To determine the maximum tolerated dose of CXD101 administered twice daily for 5 consecutive days every 21 days|To determine the pharmacokinetic (PK) profile of CXD101 following single and multiple dosing|To enable a preliminary assessment of the anti-tumour activity of CXD101|To evaluate the tissue expression of the biomarker HR23B|To assess the pharmacodynamic effect of CXD101,"Oxford University Hospitals NHS Trust|University of Oxford|National Institute for Health Research, United Kingdom|Cancer Research UK",All,"18 Years and older   (Adult, Older Adult)",Phase 1,51.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CXD101-0901|2009-012743-42,2014-02-14,"October 8, 2019",2022-10-14,"November 7, 2013",,"October 18, 2022","Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT01977638,3164.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1084,1085,NCT00768391,Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available,,Completed,No Results Available,Solid Tumors,Biological: IMC-3G3,Summary of Participants Reporting Adverse Events|Maximum Tolerated Dose (MTD)|Pharmacokinetics|Anti-IMC-3G3 Antibody Assessment|Antitumor Activity of IMC-3G3 as Monotherapy|Pharmacodynamics,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),13937|CP15-0601|I5B-IE-JGDC,2006-12-01,March 2009,2010-01-01,"October 8, 2008",,"June 28, 2011","ImClone Investigational Site, Indianapolis, Indiana, United States|ImClone Investigational Site, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00768391,1127.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),N/A
1085,1086,NCT03027284,A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer,,Completed,No Results Available,Advanced Cancer|Metastatic Cancer|Biliary Tract Carcinoma|Cholangiocarcinoma|Gall Bladder Carcinoma|Solid Tumor|Non-Hodgkin's Lymphoma,Drug: Merestinib|Drug: Cisplatin|Drug: Gemcitabine,"Number of Participants with Merestinib Dose-Limiting Toxicities (DLTs)|Pharmacokinetics (PK): Maximum Concentration (Cmax) of Merestinib and its Metabolites|PK: Area Under the Concentration Time Curve (AUC) of Merestinib and its Metabolites|Objective Response Rate (ORR): Percentage of Participants With a Complete or Partial Response|Disease Control Rate (DCR): Percentage of Participants with a Best Overall Response of Complete Response, Partial Response, and Stable Disease",Eli Lilly and Company,All,"20 Years and older   (Adult, Older Adult)",Phase 1,19.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16330|I3O-JE-JSBG,2017-02-03,"June 20, 2019",2020-03-17,"January 23, 2017",,"May 19, 2020","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Chiba, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT03027284,1138.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1086,1087,NCT02391480,A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer,,Completed,No Results Available,Cancer|Breast Cancer|Non-Small Cell Lung Cancer|Acute Myeloid Leukemia (AML)|Multiple Myeloma|Prostate Cancer|Small Cell Lung Cancer|Non-Hodgkins Lymphoma,Drug: ABBV-075|Drug: Venetoclax,"Maximum Tolerated Dose of ABBV-075|Time to Cmax (peak time, Tmax) for ABBV-075|Number of participants with adverse events|Maximum observed plasma concentration (Cmax) of ABBV-075|Area under the curve (AUC)|Duration of overall response (DOR)|Objective Response Rate (ORR)|Progression Free Survival (PFS)",AbbVie,All,"18 Years and older   (Adult, Older Adult)",Phase 1,128.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M14-546,2015-04-14,"July 5, 2019",2019-07-05,"March 18, 2015",,"November 29, 2019","Scottsdale Healthcare /ID# 132963, Scottsdale, Arizona, United States|City of Hope /ID# 154053, Duarte, California, United States|UC Davis Comp Cancer Ctr /ID# 154644, Sacramento, California, United States|Yale University /ID# 136982, New Haven, Connecticut, United States|University of Chicago /ID# 155453, Chicago, Illinois, United States|Indiana Univ School Medicine /ID# 132946, Indianapolis, Indiana, United States|Duke Univ Med Ctr /ID# 154647, Durham, North Carolina, United States|Mary Crowley Cancer Research /ID# 154059, Dallas, Texas, United States|Univ TX, MD Anderson /ID# 132276, Houston, Texas, United States|UT MD Anderson Cancer Center /ID# 164122, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02391480,1543.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1087,1088,NCT00397384,"Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer",,Completed,No Results Available,Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Advanced Adult Primary Liver Cancer|Carcinoma of the Appendix|Gastrointestinal Stromal Tumor|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Colon Cancer|Recurrent Esophageal Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Pancreatic Cancer|Recurrent Rectal Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Small Intestine Adenocarcinoma|Small Intestine Leiomyosarcoma|Small Intestine Lymphoma|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Anal Cancer|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Colon Cancer|Stage IV Esophageal Cancer|Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IV Gastric Cancer|Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Pancreatic Cancer|Stage IV Rectal Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Tongue Cancer|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer,Drug: cetuximab|Drug: erlotinib hydrochloride|Other: laboratory biomarker analysis,"Incidence of DLT, defined as recurring grade 2 or greater non-hematological or grade 3 or greater hematological toxicities or skin rash graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE-v3)|MTD defined as the dose level at which fewer than 2 out of 6 patients experience DLT graded using CTCAE-v3|Change in molecular inhibition of the EGFR signaling pathway|OBD defined as the dose at which either a >= 75% inhibition of phosphorylation of the EGF receptor or of its downstream effectors p44/42 MAPK or Akt is observed, or Ki67 is decreased by >= 25%|Antitumor effect observed",National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,43.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2009-00107|CDR0000511880|GI 0622|6980|P30CA068485,2007-01-01,June 2013,2013-06-01,"November 9, 2006",,"September 30, 2015","Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00397384,2343.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1088,1089,NCT00047060,Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome,,Completed,Has Results,Mycosis Fungoides|Sezary Syndrome,Other: A matched peripheral donor stem cells|Drug: cyclosporine|Drug: fludarabine|Drug: Campath,Efficacy of Nonmyeloablative Preparative Regimen,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,5.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,020250|02-H-0250,2002-07-30,"January 24, 2019",2019-01-24,"January 27, 2003","February 24, 2020","March 10, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT00047060/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT00047060,6022.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1090,1091,NCT01401504,"Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors",,Completed,No Results Available,Solid Tumor,Drug: ASP3026,"Safety and tolerability of ASP3026 assessed by recording of adverse events, laboratory assessments, vital signs, electrocardiograms (ECGs) and clinical observations|Pharmacokinetics of ASP3026 by assessment of area under the curve over the time (AUC) and maximum concentration (Cmax) in plasma and urine|Objective response rate (ORR)",Astellas Pharma Inc,All,"20 Years and older   (Adult, Older Adult)",Phase 1,29.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3026-CL-0102,2011-05-01,January 2014,2014-01-01,"July 25, 2011",,"June 11, 2014","Kansai, Japan",,https://ClinicalTrials.gov/show/NCT01401504,976.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1091,1092,NCT02822586,TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome,,Completed,No Results Available,Mycosis Fungoides|Sézary Syndrome,Radiation: TSEB Therapy|Drug: Brentuximab vedotin,Cutaneous toxicity of combining TSEB and brentuximab vedotin in patients with MF or SS (Cohorts A and B).|Number of patients who achieved Complete Response (CR) and Partial Response(PR)|Duration of complete skin response (Cohorts A and B)|Tumor response in lymph nodes (Cohort B)|Tumor response in blood (Cohort B)|Overall Toxicity (Cohorts A and B)|Skin-related Quality of Life (QOL) (Cohorts A and B)|Patient-reported chemotherapy-induced peripheral neuropathy (CIPN) (Cohort A)|Duration of clinical benefit (DOCB),Virginia Commonwealth University|Seagen Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,5.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MCC-15-10917|IST2015100830|NCI-2016-01509,2016-12-19,"April 29, 2019",2019-04-29,"July 4, 2016",,"August 30, 2019","Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02822586,861.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1092,1093,NCT03058289,A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6,IT-01,Completed,No Results Available,Breast Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|Lymphoma|Pancreatic Cancer|Liver Cancer|Colon Cancer|Lung Cancer|Bile Duct Cancer|Chordoma of Sacrum|Sarcoma,Drug: INT230-6|Biological: anti-PD-1 antibody|Biological: anti-CTLA-4 antibody,"Rate and severity of treatment-emergent adverse events ≥ grade 3 attributed to study drug using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5)|Preliminary Efficacy: Control or Regression of Injected Tumors by Measurement of Length, Width and Height (in centimeters) Radio-graphically Using Computer Tomography or Magnetic Resonance Imaging to Calculate Tumor Volumes (cubic centimeters) Over Time.|Determine pharmacokinetic parameter Peak Plasma (Cmax in ng/mL) of each of the 3 main components of INT230-6.|Determine key pharmacokinetic parameter, Area Under the Curve (AUC) (ng*hr/mL) of each of the 3 main components of INT230-6.|Key pharmacokinetic parameters, half live (hours) of each of the 3 main components of INT230-6.","Intensity Therapeutics, Inc.|Merck Sharp & Dohme LLC|Bristol-Myers Squibb",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,110.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IT-01|KEYNOTE KN-A10|CA184-592,2017-02-09,"February 22, 2023",2023-02-22,"February 20, 2017",,"March 2, 2023","USC Norris, Los Angeles, California, United States|USC HOAG, Newport Beach, California, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|UMASS Memorial Medical Center, Worcester, Massachusetts, United States|Columbia University Medical Center, New York, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Center for Oncology and Blood Disorders, Houston, Texas, United States|Princess Margaret Cancer Center - University Health Network, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03058289,2204.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1093,1094,NCT02327078,"A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)",,Completed,No Results Available,B-cell Malignancies|Colorectal Cancer (CRC)|Head and Neck Cancer|Lung Cancer|Lymphoma|Melanoma|Ovarian Cancer|Glioblastoma,Drug: Nivolumab (Phase 1)|Drug: Epacadostat (Phase 1)|Drug: Chemotherapy (Phase 1)|Drug: Nivolumab (Phase 2)|Drug: Epacadostat (Phase 2),"Phase 1, Part 1: Safety and tolerability of epacadostat and nivolumab assessed by number of subjects with dose limiting toxicities (DLTs)|Phase 1, Part 2: Safety and tolerability of epacadostat administered in combination with nivolumab and chemotherapy regimen assessed by number of subjects with DLTs|Phase 1, Part 1 and 2: Safety assessed by the frequency of adverse events, serious adverse events, and deaths|Phase 2: Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for subjects with solid tumors and per Cheson criteria for subjects with DLBCL|Phase 2: Progression free survival (PFS)|Phase 2: Overall survival (OS) for subjects with Glioblatoma|Phase 1, Part 1: ORR per RECIST v1.1 and mRECIST for subjects with solid tumors; per Cheson and mCheson criteria for subjects with B-cell NHL; and per RANO and mRANO criteria for subjects with GBM|Phase 1, Part 2: ORR per RECIST v1.1 and modified RECIST for subjects with advanced or metastatic SCCHN and advanced or metastatic NSCLC|Phase 1, Part 2: Duration of response (DOR) for subjects with advanced or metastatic SCCHN and advanced or metastatic NSCLC|Phase 1, Part 2: PFS for subjects with advanced or metastatic SCCHN and advanced or metastatic NSCLC|Phase 2: Duration of response (DOR)|Phase 2: Duration of disease control, defined as CR, PR, and stable disease (SD)|Phase 2: Safety and tolerability measured by the frequency of adverse events (AEs), serious adverse events (SAEs), and deaths",Incyte Corporation|Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,307.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INCB 24360-204 / ECHO-204,2014-11-26,"July 10, 2020",2020-07-10,"December 30, 2014",,"August 28, 2020","UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|The Angeles Clinic and Research Institute, Los Angeles, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|UCSF - University of California San Francisco, San Francisco, California, United States|University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|The University of Kansas Clinical Research Center, Fairway, Kansas, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|NYU Cancer Center, New York, New York, United States|Columbia University, Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Medical Center Boulevard, Winston-Salem, North Carolina, United States|Sanford Research, Fargo, North Dakota, United States|University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States|Sanford Research, North Sioux City, South Dakota, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology Research, Austin, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|The Christie NHS Foundation Trust, Manchester, United Kingdom|Oxford University Hospitals NHS Trust, Oxford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02327078/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02327078/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02327078,2053.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1094,1095,NCT00315705,A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.,,Completed,Has Results,Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Relapsed Leukemia,Drug: clofarabine|Drug: Etoposide|Drug: Cyclophosphamide,Maximum Tolerated Dose (MTD) in Phase 1|Participants With Dose Limiting Toxicity in Phase 1|Percentage of Participants Achieving A Response Over the First Two Treatment Cycles in Phase 2|Summary of Participants With Adverse Events (AEs) in Phase 1|Percentage of Participants Achieving A Response Over the First Two Treatment Cycles in Phase 1|Time to Remission for Participants Who Had a Response in Phase 1|Kaplan Meier Estimate of Duration of Remission (DOR) for Participants Who Achieved Overall Remission (OR) in Phase 1|Kaplan Meier Estimates of Event-free Survival (EFS) for Participants in Phase 1|Number of Participants With 4-month Event Free Survival in Phase 1|Kaplan Meier Estimates of Overall Survival (OS) for Participants in Phase 1|Summary of Participants With Adverse Events (AEs) in Phase 2|Time to Remission for Participants Who Had a Response in Phase 2|Kaplan Meier Estimate of Duration of Remission (DOR) for Participants Who Achieved Overall Remission (OR) in Phase 2|Kaplan Meier Estimates of Event-free Survival (EFS) for Participants in Phase 2|Number of Participants With 4-month Event Free Survival in Phase 2|Kaplan Meier Estimates of Overall Survival (OS) for Participants in Phase 2,"Genzyme, a Sanofi Company|Sanofi",All,"1 Year to 21 Years   (Child, Adult)",Phase 1|Phase 2,50.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLO21800205,2006-03-01,May 2010,2010-05-01,"April 19, 2006","June 30, 2011","April 14, 2014","Children's Hospital of Alabama, Birmingham, Alabama, United States|Children's Hospital of Los Angeles, Los Angeles, California, United States|Rady Children's Hospital, San Diego, California, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Children's Memorial Hospital, Chicago, Illinois, United States|St. Vincent Children's Hospital, Indianapolis, Indiana, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|New York School of Medicine, New York, New York, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00315705,1522.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1095,1096,NCT00061945,Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia,,Completed,Has Results,Acute Undifferentiated Leukemia|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|L1 Adult Acute Lymphoblastic Leukemia|L1 Childhood Acute Lymphoblastic Leukemia|L2 Adult Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia,Drug: allopurinol|Drug: cyclophosphamide|Drug: daunorubicin hydrochloride|Drug: vincristine sulfate|Drug: dexamethasone|Drug: asparaginase|Biological: filgrastim|Drug: imatinib mesylate|Drug: methotrexate|Drug: cytarabine|Drug: trimethoprim-sulfamethoxazole|Drug: mercaptopurine|Drug: leucovorin calcium|Biological: alemtuzumab|Drug: acyclovir|Other: laboratory biomarker analysis|Other: pharmacological study,"Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I)|Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)|Minimal Residual Disease (MRD) During Treatment With Alemtuzumab (Phase II)|Disease-free Survival, for Only Complete Response Patients|Overall Survival",National Cancer Institute (NCI),All,"15 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,302.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2012-02807|CDR302482|CALGB 10102|CALGB-10102|U10CA031946,2003-06-01,December 2007,2012-10-01,"June 6, 2003","April 16, 2014","May 3, 2022","Cancer and Leukemia Group B, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00061945,3410.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1096,1097,NCT02178722,"Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers",,Completed,Has Results,Microsatellite-instability (MSI) High Colorectal Cancer (CRC)|Endometrial Cancer|Head and Neck Cancer|Hepatocellular Carcinoma (HCC)|Gastric Cancer|Lung Cancer|Lymphoma|Renal Cell Carcinoma (RCC)|Ovarian Cancer|Solid Tumors|UC (Urothelial Cancer)|Melanoma|Bladder Cancer|Triple Negative Breast Cancer (TNBC),Drug: MK-3475|Drug: INCB024360,Phase 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAE) and Serious Treatment-Emergent Adverse Events|Phase 2: Objective Response Rate (ORR)|Phase 2: Duration of Response (DOR)|Phase 2: Progression Free Survival (PFS)|Phase 2: Duration of Disease Control|Phase 2: Overall Survival (OS)|Phase 2: Ordinal Categorical Response Score|Phase 2: Percentage of Participants With Treatment-Emergent Adverse Events (TEAE) and Serious Treatment-Emergent Adverse Events,Incyte Corporation|Merck Sharp & Dohme LLC,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,444.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INCB 24360-202/ ECHO-202,2014-07-17,"November 26, 2018",2020-11-06,"July 1, 2014","December 19, 2019","February 14, 2022","UC San Diego Moores Cancer Center, La Jolla, California, United States|The Angeles Clinic and Research Institute, Los Angeles, California, United States|US Davis Cancer Center, Sacramento, California, United States|University Of Colorado Cancer Center, Aurora, Colorado, United States|University of Connecticut Health Center Carole And Ray Neag Comprehensive Cancer Center, Farmington, Connecticut, United States|Miami Cancer Institute at Baptist Health, Inc, Miami, Florida, United States|Georgia Cancer Specialists affiliated with Northside Hospital Cancer Institute, Atlanta, Georgia, United States|The University of Chicago Medicine, Chicago, Illinois, United States|St. Francis Cancer Center, Topeka, Kansas, United States|Greater Baltimore Cancer Center, Baltimore, Maryland, United States|St. Agnes Hospital Cancer Institute, Baltimore, Maryland, United States|The Center for Cancer and Blood Disorders (RCCA MD LLC- Maryland Division), Bethesda, Maryland, United States|University of Michigan Hospital and Health Systems, Ann Arbor, Michigan, United States|Health Partners Institute, Saint Louis Park, Minnesota, United States|Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey, United States|The Christ Hospital Hematology Oncology, Lindner Research Center, Cincinnati, Ohio, United States|University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Greenville Health System Cancer Institute, Greenville, South Carolina, United States|West Cancer Center, Germantown, Tennessee, United States|Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center At Dallas, Dallas, Texas, United States|Virginia Cancer Specialists, Arlington, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT02178722/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT02178722/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02178722,2304.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1097,1098,NCT00878423,Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors,,Completed,No Results Available,Metastatic Solid Tumors,Drug: AT13387,"The identification of the maximum tolerated dose for twice or once weekly dosing, on three weeks out of four|Pharmacokinetic profile, Safety and tolerability of maximum tolerated dose, pharmacodynamic effect, identify dose limiting toxicities","Astex Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,62.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,AT13387/0001,2008-05-01,May 2013,2014-03-01,"April 9, 2009",,"January 18, 2020","The University of Arizona Cancer Center, Tucson, Arizona, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00878423,2130.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
1098,1099,NCT02925000,Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy,,Completed,No Results Available,Cancer,Drug: TLC178,"Maximum tolerated dose (MTD) determination|Pharmacokinetics (PK) parameters of AUC (0-inf) calculated by plasma concentration of vinorelbine[|Pharmacokinetics (PK) parameters of AUC (0-inf) calculated by plasma concentration of majormetabolite, 4-O-deacetylvinorelbine|Pharmacokinetics (PK) parameters of AUC(0 - last) calculated by plasma concentration ofvinorelbine|Pharmacokinetics (PK) parameters of AUC(0 - last) calculated by plasma concentration of majormetabolite, 4-O-deacetylvinorelbine|Pharmacokinetics (PK) parameters of Cmax calculated by plasma concentration of vinorelbine|Pharmacokinetics (PK) parameters of tmax calculated by plasma concentration of vinorelbine|Pharmacokinetics (PK) parameters of tmax calculated by plasma concentration of major metabolite,4-O-deacetylvinorelbine|Pharmacokinetics (PK) parameters of t1/2 calculated by plasma concentration of vinorelbine|Pharmacokinetics (PK) parameters of t1/2 calculated by plasma concentration of 4-O-deacetylvinorelbine|Pharmacokinetics (PK) parameters of MRT(0-inf) calculated by plasma concentration of vinorelbine|Pharmacokinetics (PK) parameters of MRT(0-inf) calculated by plasma concentration of 4-O-deacetylvinorelbine|Dose exposure relationship in patients with advanced malignancies treated with single and multipledoses of LipoVNB|Number of participants with treatment-related adverse events as assessed by CTCAE v4.03|Incidence of Treatment-Emergent Adverse Events|LipoVNB antitumor activity assessed by response rate|LipoVNB antitumor activity assessed by duration of response|Progression free survival (PFS) of patients with advanced malignancies treated with LipoVNB",Taiwan Liposome Company,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,46.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TLC178A1001,2017-06-19,"October 6, 2020",2020-10-06,"October 5, 2016",,"July 23, 2021","Karmanos Cancer Center, Detroit, Michigan, United States|Montefiore Medical Center, Bronx, New York, United States|Taipei Veterans General Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT02925000,1205.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1099,1100,NCT02086773,Red Cell Transfusion Goals in Patients With Acute Leukemias,,Completed,No Results Available,Acute Lymphoblastic Leukemia|Acute Lymphocytic Leukemia (ALL)|Acute Myelogenous Leukemia (AML)|Acute Promyelocytic Leukemia (APL),Biological: Red blood cell transfusion,Tolerance of low transfusion threshold as assessed by the percentage of participants who crossed over from the low arm to the high arm.|Safety of low vs. high transfusion threshold as assessed by total difference in number of transfusions given per participant|Safety of low vs. high transfusion threshold as assessed by number of participants experiencing neutropenic infections|Safety of low vs. high transfusion threshold as assessed by number of grade 3-4 bleeding events as defined by CTCAE 4.0|Safety of low vs. high transfusion threshold as assessed by number of deaths attributed to induction chemotherapy|Safety of low vs. high transfusion threshold as assessed by number of participants with at least one grade 3-5 non-hematological toxicity by CTCAE 4.0.|Feasibility as determined by percentage of participants consented|Feasibility as determined by percentage of participants who tolerate 7g/dL transfusion|Feasibility as determined by percentage of participants who crossed over from the low arm to the high arm|Number of transfusions|Neutropenic infections|Bleeding|Length of stay|Treatment-related mortality|End organ dysfunction|Performance status scores|Incidence of crossover|Cost savings|Fatigue scores,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,All,"18 Years and older   (Adult, Older Adult)",Phase 1,90.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,J13126|NA_00089706,2014-04-01,September 2015,2015-09-01,"March 13, 2014",,"January 24, 2019","The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02086773,518.0,Not Industry Lead,More than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Supportive Care
1100,1101,NCT01861002,A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML,,Completed,Has Results,"Lymphoblastic Leukemia, Acute, Childhood|Myelogenous Leukemia, Acute, Childhood",Drug: Azacytidine|Drug: Fludarabine|Drug: Cytarabine|Drug: Intrathecal (IT) Cytarabine|Drug: Intrathecal Methotrexate (IT MTX),Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)|Disease Response Rate After Treatment,Therapeutic Advances in Childhood Leukemia Consortium|Gateway for Cancer Research,All,"1 Year to 21 Years   (Child, Adult)",Phase 1,15.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,T2011-002,2013-05-22,"July 28, 2014",2014-07-28,"May 23, 2013","April 30, 2021","June 9, 2021","Childrens Hospital Los Angeles, Los Angeles, California, United States|UCSF School of Medicine, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, United States|Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber, Boston, Massachusetts, United States|C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States|Childrens Hospital & Clinics of Minnesota, Minneapolis, Minnesota, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|Children's Hospital New York-Presbyterian, New York, New York, United States|Levine Children's Hospital at Carolinas Medical Center, Charlotte, North Carolina, United States|Rainbow Babies & Children's Hospital, Cleveland, Ohio, United States|Nationwide Childrens Hospital, Columbus, Ohio, United States|Vanderbilt Children's Hospital, Nashville, Tennessee, United States|University of Texas at Southwestern, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Sydney Children's Hospital, Randwick, New South Wales, Australia|Children's Hospital at Westmead, Westmead, New South Wales, Australia|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|Sainte-Justine University Hospital Center, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01861002,432.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1101,1102,NCT01756118,"A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia",,Completed,No Results Available,"Acute Lymphoblastic Leukemia|Leukemia, Myelocytic, Acute|Chronic Myelogenous Leukemia With Crisis of Blast Cells",Drug: BEZ235,"Recommended Phase 2 dose (RP2D) of BEZ235 in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and chronic myeloid leukemia in blastic phase (CML-BP)|Incidence of dose-limiting toxicity (DLT)|Adverse events as graded by NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.|Investigator-reported best overall response (BOR) as determined from the response categories during treatment period.|Time to progression|Remission duration|Biomarker evaluation|BEZ235 and metabolite levels in plasma|Clinical laboratory tests as graded by NCI CTCAE v4.",Goethe University,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CBEZ235ZDE01T|2011-005050-61,2012-06-01,December 2017,2020-02-07,"December 24, 2012",,"February 16, 2023","Johann Wolfgang Goethe University Hospitals, Frankfurt, Hessen, Germany",,https://ClinicalTrials.gov/show/NCT01756118,2807.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1102,1103,NCT03555955,A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351,,Completed,No Results Available,Hematologic Malignancy|Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndromes,Drug: CPX-351,"Pharmacokinetics (PK) of CPX-351|PK parameter of the individual components of CPX-351, and their respective metabolites|Incidence of Treatment Emergent Adverse Events (TEAEs)",Jazz Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 1,21.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CPX351-102,2018-11-20,"May 26, 2021",2021-05-26,"June 14, 2018",,"July 22, 2021","Georgetown University Medical Center, Washington, District of Columbia, United States|Northside Hospital - Blood and Bone Marrow Transplant Group of Georgia, Atlanta, Georgia, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Medical College, New York, New York, United States|New York Medical/Westchester, Valhalla, New York, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Baylor University Medical Center, Dallas, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Vancouver General Hospital, Vancouver, British Columbia, Canada|University Health Network/Princess Margaret Cancer Center, Toronto, Ontaro, Canada",,https://ClinicalTrials.gov/show/NCT03555955,918.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1103,1104,NCT01411267,AC220 for Children With Relapsed/Refractory ALL or AML,,Completed,Has Results,"Lymphoblastic Leukemia, Acute, Childhood|Myelogenous Leukemia, Acute, Childhood",Drug: AC220|Drug: Cytarabine|Drug: Etoposide|Drug: Methotrexate,The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide|Disease Response|Count of Participants According to Inhibition of FLT3 Phosphorylation,Therapeutic Advances in Childhood Leukemia Consortium|Ambit Biosciences Corporation,All,"1 Month to 21 Years   (Child, Adult)",Phase 1,24.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,T2009-004,2011-09-01,"September 12, 2013",2013-09-12,"August 8, 2011","February 20, 2020","April 4, 2022","Childrens Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital Central California, Madera, California, United States|UCSF School of Medicine, San Francisco, California, United States|The Children's Hospital, University of Colorado, Aurora, Colorado, United States|Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, United States|Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber, Boston, Massachusetts, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|Levine Children's Hospital at Carolinas Medical Center, Charlotte, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Seattle Children's Hospital, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01411267,742.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1104,1105,NCT03190174,Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers,,Completed,No Results Available,Ewing Sarcoma|PEComa|Epithelioid Sarcoma|Desmoid Tumor|Chordoma|Non Small Cell Lung Cancer|Urothelial Carcinoma|Melanoma|Renal Cell Carcinoma|Squamous Cell Carcinoma|Hepatocellular Carcinoma|Classical Hodgkin Lymphoma|Colorectal Cancer|MTOR Activating Mutation,Drug: Nab-Rapamycin|Biological: Nivolumab,Maximum tolerated dose|Disease control rate|Progression free survival|Overall survival,"Sarcoma Oncology Research Center, LLC|Aadi Bioscience, Inc.",All,"12 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,34.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SOC-1701,2017-08-24,"December 1, 2021",2021-12-02,"June 16, 2017",,"December 6, 2021","Sarcoma Oncology Research Center, Santa Monica, California, United States",,https://ClinicalTrials.gov/show/NCT03190174,1561.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1105,1106,NCT02779283,Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia,,Completed,No Results Available,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia,Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dasatinib|Drug: Dexamethasone|Drug: Doxorubicin Hydrochloride|Drug: Idarubicin|Drug: Idelalisib|Device: In Vitro Kinase Inhibitor Assay|Drug: Leucovorin Calcium|Drug: Methotrexate|Drug: Methylprednisolone Sodium Succinate|Drug: Ponatinib Hydrochloride|Biological: Rituximab|Drug: Ruxolitinib Phosphate|Drug: Sorafenib Tosylate|Drug: Sunitinib Malate|Drug: Vincristine Sulfate,"Proportion of subjects who start a targeted drug|Incidence of any grade 3 or higher dose limiting toxicity graded (DLT) according to Common Terminology Criteria for Adverse Events version 4.0|Overall objective response rates defined as morphologic, cytogenetic and molecular complete response (CR) rates at the end of induction period|Proportion of patients who show sensitivity to each of the study kinase inhibitors|Overall survival",OHSU Knight Cancer Institute|National Cancer Institute (NCI),All,18 Years to 64 Years   (Adult),Phase 1,7.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00011766|NCI-2016-00083|P30CA069533,2016-01-13,"April 19, 2018",2018-09-20,"May 20, 2016",,"May 26, 2020","OHSU Knight Cancer Institute, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT02779283,981.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1106,1107,NCT02264873,"Phase I, Dose Escalation Study of Decitabine",,Completed,No Results Available,"Leukemia, Lymphoblastic, Acute|Leukemia, Myeloid Acute|Hematopoetic Myelodysplasia",Drug: Decitabine,Maximum Tolerated Dose as a Measure of Safety and Tolerability|Adverse Event Profile After Single Cycle Decitabine Post Transplant|Grade 3 Adverse Events after Decitabine,University of Florida|Hyundai Hope On Wheels,All,"1 Year to 30 Years   (Child, Adult)",Phase 1,3.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB201400612|PEDS004,2014-10-01,October 2016,2018-09-18,"October 15, 2014",,"October 15, 2018","UF Health Shands Hospital, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT02264873,1448.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1107,1108,NCT01077544,A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL),,Completed,Has Results,Chronic Myeloid Leukemia|Acute Lymphoblastic Leukemia,Drug: Nilotinib,Summary of Nilotinib Non-compartmental PK Parameters: Cmax|Summary of Nilotinib Non-compartmental PK Parameters: Tmax|Summary of Nilotinib Non-compartmental PK Parameters: AUClast (Last = 24h)|Summary of Nilotinib Non-compartmental PK Parameters: AUC0-12h|Summary of Nilotinib Steady-state PK Parameters: AUCss|Summary of Nilotinib Steady-state PK Parameters: CLF (Body Surface Area (BSA) Adjusted)|Summary of Nilotinib Steady-state PK Parameters: Cmin|Number of Ph+ CML Participants With Confirmed Complete Hematologic Response (CHR)|Number of Ph+ CML Participants With Cytogenic Response|Number of Ph+ CML Participants With Major Molecular Response (MMR)|Efficacy Endpoints for Ph+ ALL Patients,Novartis Pharmaceuticals|Novartis,All,1 Year to 17 Years   (Child),Phase 1,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CAMN107A2120|2010-018419-14,2011-04-14,"July 1, 2015",2015-07-01,"March 1, 2010","January 27, 2016","December 29, 2020","Novartis Investigative Site, Bordeaux, Aquitaine, France|Novartis Investigative Site, Lille cedex, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Poitiers, France|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, West Midlands, Birmingham, United Kingdom|Novartis Investigative Site, Sutton, Surrey, United Kingdom|Novartis Investigative Site, Bristol, United Kingdom",,https://ClinicalTrials.gov/show/NCT01077544,1539.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1108,1109,NCT00686556,Total Marrow Irradiation for Refractory Acute Leukemia,,Completed,No Results Available,Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome|Multiple Myeloma,Drug: cyclophosphamide|Drug: cyclosporine|Drug: Fludarabine|Drug: mycophenolate mofetil|Radiation: total marrow irradiation|Procedure: umbilical cord blood transplantation|Biological: Granulocyte colony-stimulating factor|Biological: HLA-matched related donor bone marrow,Maximum tolerated dose (MTD) of total marrow irradiation (TMI)|Incidence of neutrophil engraftment|Incidence of platelet engraftment|Incidence of complete donor chimerism|Incidence of transplantation-related mortality|Incidence of grade II-IV and grade III-IV acute graft-versus-host disease (GVHD) after transplantation|Incidence of chronic GVHD after transplantation|Incidence of relapse after transplantation|Disease-free survival after transplantation|Durability of remission based on presence of rapid early response after transplantation|Overall survival after transplantation,"Masonic Cancer Center, University of Minnesota",All,"up to 55 Years   (Child, Adult)",Phase 1,12.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2007LS024|MT2006-24|0708M14041,2012-08-01,November 2016,2016-12-01,"May 30, 2008",,"December 5, 2017","Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00686556,1583.0,Not Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1112,1113,NCT00352677,Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia,,Completed,No Results Available,Chronic Myeloid Leukemia|Acute Lymphocytic Leukemia,Drug: INNO-406,To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of INNO-406 when administered as a single agent to adult patients with imatinib-resistant or intolerant Ph+ leukemias.|To determine the safety profile (including acute and chronic toxicities) and tolerability of INNO-406 in this patient population.|To determine the pharmacokinetic (PK) profile of INNO-406.|To assess BCR-ABL transcript levels and to analyze BCR-ABL mutations.|To assess leukemia response rates in this patient population.,CytRx,All,"18 Years and older   (Adult, Older Adult)",Phase 1,100.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INNO-406,2006-07-01,May 2008,2008-05-01,"July 17, 2006",,"June 1, 2009","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Charite University of Medicine, Berlin, Germany|Johann Wolfgang Goethe Universität, Frankfurt am Main, Germany|University of Heidelberg Medical Clinic, Mannheim, Germany|Chaim Sheba Medical Center, Tel Hashomer, Israel",,https://ClinicalTrials.gov/show/NCT00352677,670.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1113,1114,NCT01644968,Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer,,Completed,No Results Available,Advanced Cancer,Drug: Cohort 1 anti-OX40|Drug: Cohort 2 anti-OX40|Drug: Cohort 3 anti-OX40|Biological: Tetanus Day 29|Biological: Tetanus Day 1|Biological: KLH Day 1|Biological: KLH Day 29,Dose limiting toxicity|Immune Response,Providence Health & Services,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,03-066A,2003-11-01,May 2009,2017-04-01,"July 19, 2012",,"May 17, 2022","Providence Cancer Center, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01644968,4900.0,Not Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1114,1115,NCT01551524,Phase I Study of mPEG-R-Crisantaspase Given IV,,Completed,No Results Available,Hematologic Malignancies,Biological: mPEG-r-crisantaspase,Maximum Tolerated Dose|Asparaginase Activity in serum,Jazz Pharmaceuticals|EUSA SAS|The Lymphoma Academic Research Organisation,All,18 Years to 50 Years   (Adult),Phase 1,36.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AZPO2-CLT-001|2011-000295-34,2012-03-01,February 2015,2015-02-01,"March 12, 2012",,"May 7, 2015","Centre Henri Becquerel, Rouen, Cedex, France|Hôpital Henri Mondor, Créteil, France|Hôpitaux du CHU de Nantes, Nantes, France|Hospices Civils de Lyon, Pierre-Bénite, France|Institut Claudius Regaud, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01551524,1067.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1115,1116,NCT00704054,"A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)",,Completed,No Results Available,Solid Tumors,Drug: ridaforolimus,"To establish the DLT and the MTD of ridaforolimus administered daily x 5 every 14 days in pediatric patients with recurrent/refractory solid tumors, including lymphoma and tumors of the central nervous system.|To determine the pharmacokinetic and pharmacodynamic properties of ridaforolimus in pediatric patients with recurrent/refractory solid tumors, including tumors of the central nervous system. Screening at Day 1-18, Cycle 2 Day 1, Cycle 2 Day 15.|To evaluate the safety and efficacy data of ridaforolimus when administered at the MTD or recommended phase II dose and schedule in an expanded cohort of patients when administered daily x 5 every 14 days|To assess pharmacogenomic parameters from archival tumor specimens that may correlate with response to ridaforolimus.","Merck Sharp & Dohme LLC|H. Lee Moffitt Cancer Center and Research Institute|Pediatric Cancer Foundation|University of Colorado, Denver|Johns Hopkins All Children's Hospital|Memorial Sloan Kettering Cancer Center",All,1 Year to 17 Years   (Child),Phase 1,15.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8669-028|SUN08-01|AP23573-07-110,2008-01-01,June 2010,2010-06-01,"June 24, 2008",,"February 13, 2015",,,https://ClinicalTrials.gov/show/NCT00704054,882.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1116,1117,NCT00062881,Intrathecal Mafosfamide,,Completed,No Results Available,Malignant Meningeal Neoplasms,Drug: Intrathecal Mafosfamide,,Baylor College of Medicine,All,"3 Years and older   (Child, Adult, Older Adult)",Phase 1,65.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H3241|I.T. Mafosfamide,1990-06-01,,2005-09-01,"June 18, 2003",,"March 4, 2020","Children'sHospital Los Angeles, Los Angeles, California, United States|Children's Hospital National Medical Center, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Florida, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Pediatric Branch, National Cancer Institute, Bethesda, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|M.D. Anderson Cancer Center, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|Neurological Research Center, Bennington, Vermont, United States|Children's Hospital and Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00062881,5571.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1117,1118,NCT01795378,Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation,DNKI-II,Completed,No Results Available,Acute Myelogenous Leukemia|Acute Lymphoblastic Leukemia,Biological: donor natural killer cell infusion,occurrence and severity of side effects of donor natural killer cell infusion|anti-leukemia effect of donor natural killer cell infusion,Asan Medical Center|Korea Research Institute of Bioscience & Biotechnology,All,"17 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,56.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AMC 2012-0478,2013-02-01,May 2015,2015-05-01,"February 20, 2013",,"December 31, 2015","Asan Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01795378,819.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1119,1120,NCT00529360,"Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL",,Completed,No Results Available,Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia,Drug: Clofarabine,"To determine the maximum tolerated dose (MTD) and/or the safe, tolerated dose of clofarabine in combination with ARA-C and TBI followed by AlloSCT in children with ALL and ANLL.|To define the toxicity and safety of the conditioning regimen of clofarabine, ARA-C, TBI followed by AlloSCT in children with ALL and ANLL.|To define the pharmacokinetics of clofarabine given in combination with ARA-C and TBI followed by AlloSCT in children with ALL and ANLL.|To determine the event-free, disease-free and overall survival of the conditioning regimen of clofarabine, ARA-C and TBI followed by AlloSCT in children with ALL and AML.|To estimate the time to hematopoietic reconstitution, stratified by cell source, following clofarabine, ARA-C and TBI followed by AlloSCT in children with ALL and AML.|To measure the changes in minimal residual disease with ALL and AML following clofarabine, ARA-C and TBI followed by AlloSCT","New York Medical College|Genzyme, a Sanofi Company",All,"up to 30 Years   (Child, Adult)",Phase 1|Phase 2,32.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,L 9471,2007-06-01,January 2016,2016-03-01,"September 14, 2007",,"March 24, 2016","New York Medical College, Vallhala, New York, United States",,https://ClinicalTrials.gov/show/NCT00529360,3196.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1120,1121,NCT02799147,GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia,,Completed,No Results Available,"Leukemia, Acute Lymphoblastic|Acute Myeloid Leukemia|Mixed-Lineage Acute Leukemias",Procedure: Allogeneic stem cell transplantation|Drug: Fludarabine monophosphate|Drug: Busulfan|Drug: Bendamustine,"Engraftment rate|Relapse rate analysis|Non-relapse mortality analysis|Incidence of acute GVHD, grades II-IV|Incidence of chronic GVHD, moderate and severe (NIH criteria)|Overall survival analysis|Event-free survival analysis|Toxicity (NCI CTCAE 4.03)|Infectious complications, including analysis of severe bacterial, fungal and viral infections incidence",St. Petersburg State Pavlov Medical University,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,27.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,05/16-n,2016-06-01,November 2020,2020-11-01,"June 14, 2016",,"November 23, 2020","First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation",,https://ClinicalTrials.gov/show/NCT02799147,1614.0,Not Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1121,1122,NCT02544438,Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,BSTPHASE1-01,Completed,No Results Available,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia,Drug: Astarabine (BST-236),Maximal tolerated dose (MTD)|Dose limiting Toxicity (DLTs)|safety and tolerability expressed by any grade adverse events (AEs)|PharmacoKintetics (PK): maximum plasma concentration (Cmax)|response rate: complete remission + partial remission (CR + PR)|Phrmacokinetics (PK): area under the curve (AUC) versus time curve,BioSight Ltd.,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BST-PHASE1-01,2015-09-01,"September 20, 2017",2017-09-20,"September 9, 2015",,"September 27, 2017","Rambam medical center hematology department, Haifa, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel",,https://ClinicalTrials.gov/show/NCT02544438,750.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1122,1123,NCT00253513,"Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome",,Completed,Has Results,Leukemia|Myelodysplastic Syndromes,Drug: fludarabine|Drug: treosulfan|Procedure: allogeneic blood or bone marrow transplantation,Number of Patients Experiencing Regimen-related Toxicity Events in Study Population|Number of Patients Experiencing Graft Failure|Incidence (Percent of Participants) With Nonrelapse Mortality (NRM) by Day 200 (Secondary Phase Only)|Number of Subjects Who Are Without Disease at One Year as Indicator of Disease Free Survival.,OHSU Knight Cancer Institute|medac GmbH|National Cancer Institute (NCI),All,"up to 60 Years   (Child, Adult)",Phase 1|Phase 2,60.0,Other|Industry|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000445306|FHCRC-1931.00|MEDAC-FHCRC-1931.00|OHSU-HEM-05107-LM|1765,2005-06-01,October 2009,2009-10-01,"November 15, 2005","February 11, 2011","June 1, 2012","OHSU Knight Cancer Institute, Portland, Oregon, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00253513,1583.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1123,1124,NCT02081378,A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL,,Completed,No Results Available,Chronic Myelogenous Leukemia|Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia,Drug: ABL001|Drug: ABL001 + Nilotinib|Drug: ABL001+imatinib|Drug: ABL001+dasatinib,Incidence of dose limiting toxicities (DLTs) during the first cycle of study treatment|Hematologic Response|Cytogenetic response|BCR-ABL transcript level|Cmax of ABL001 as measured in plasma|Cmin of ABL001 as measured in plasma|AUCinf of ABL001 as measured in plasma|AUClast of ABL001 as measured in plasma|AUCtau of ABL001 as measured in plasma|T1/2 of ABL001 as measured in plasma|Adverse events,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,326.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CABL001X2101,2014-04-24,"June 3, 2021",2023-03-13,"March 7, 2014",,"March 22, 2023","Dana Farber Cancer Institute Hematology / Oncology, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center SC, Ann Arbor, Michigan, United States|Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering, New York, New York, United States|Oregon Health and Science Univ SC-6, Portland, Oregon, United States|University of Texas/MD Anderson Cancer Center UT MD Anderson, Houston, Texas, United States|Huntsman Cancer Institute SC, Salt Lake City, Utah, United States|Novartis Investigative Site, Adelaide, South Australia, Australia|Novartis Investigative Site, Paris Cedex 10, Cedex 10, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Kobe-shi, Hyogo, Japan|Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT02081378,3245.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1124,1125,NCT00103701,"BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia",,Completed,No Results Available,"Leukemia, Myeloid, Chronic-phase|Leukemia, Lymphoblastic, Acute, Philadelphia-positive",Drug: Dasatinib,Establishment of MTD and recommended Phase II dose.|1) Hematologic Response 2) Cytogenetic Response.,Bristol-Myers Squibb,All,"14 Years and older   (Child, Adult, Older Adult)",Phase 1,,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA180-002,2003-11-01,March 2006,2006-03-01,"February 15, 2005",,"April 14, 2011","Local Institution, Los Angeles, California, United States|Local Institution, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00103701,851.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1125,1126,NCT02212561,Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome,,Completed,No Results Available,Acute Myeloid Leukemia (AML)|Acute Lymphoblastic Leukemia (ALL)|Myelodysplastic Syndrome (MDS)|Mixed Phenotype Acute Leukemia (MPAL),Drug: Selinexor|Drug: Fludarabine|Drug: Cytarabine|Drug: methotrexate/hydrocortisone/cytarabine,"Maximum tolerated dose (MTD) of combination selinexor, fludarabine and cytarabine|Dose limiting toxicity of combination selinexor, fludarabine and cytarabine|Maximum plasma concentration (Cmax) of selinexor|complete response rate|Overall response rate|Area under the curve (AUC) of selinexor",St. Jude Children's Research Hospital|Karyopharm Therapeutics Inc,All,"up to 24 Years   (Child, Adult)",Phase 1,19.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SELHEM|NCI-2014-01704,2014-08-01,December 2015,2015-12-01,"August 8, 2014",,"March 26, 2020","Phoenix Children's Hospital, Phoenix, Arizona, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|University of Chicago, Chicago, Illinois, United States|Duke University Medical Center, Durham, North Carolina, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Cook Children's Medical Center, Fort Worth, Texas, United States",,https://ClinicalTrials.gov/show/NCT02212561,487.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1126,1127,NCT00629473,Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies,,Completed,No Results Available,Advanced Cancer,"Drug: NPI-0052 on Days 1, 8, 15 every 28 days|Drug: NPI-0052 on Days 1, 4, 8, 11 every 21 days|Drug: Dexamethasone",Determine Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of NPI-0052|To evaluate the pharmacokinetics activity of NPI-0052|To evaluate the safety and tolerability of NPI-0052|To evaluate the pharmacodynamics of NPI-0052,Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 1,86.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NPI-0052-102,2007-07-01,April 2013,2013-04-01,"March 6, 2008",,"November 22, 2017","Mater Adult Hospital, South Brisbane, Queensland, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Peter MacCallum Cancen Center, Melbourne, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Border Medical Oncology, Wodonga, Victoria, Australia|Sir Charles Gairdner Hospital and University of Western Australia, Nedlands, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia",,https://ClinicalTrials.gov/show/NCT00629473,2101.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1127,1128,NCT00125840,Clofarabine in Adult Patients With Advanced Solid Tumors,,Completed,No Results Available,"Solid Tumors|Leukemia, Lymphocytic, Acute, Pediatric|Leukemia, Lymphocytic, Acute, Adult|Leukemia, Myelocytic, Acute, Pediatric|Leukemia, Myelocytic, Acute, Adult|Myelodysplastic Syndromes, Adult",Drug: clofarabine (IV formulation),The maximum tolerated dose (MTD)/recommended phase II dose (RP2D) is the dose at which less than or equal to 1 of 6 patients experience a dose limiting toxicity (DLT) with the next higher dose having at least 2 of 3 or 2 of 6 patients experiencing a DLT.,"Genzyme, a Sanofi Company|Sanofi",All,"18 Years and older   (Adult, Older Adult)",Phase 1,,Industry,Interventional,NaN,CLO151,2002-08-01,,2007-08-01,"August 2, 2005",,"February 5, 2014","Mary Crowley Medical Research Center, Dallas, Texas, United States|US Oncology Tyler Cancer Center, Tyler, Texas, United States",,https://ClinicalTrials.gov/show/NCT00125840,1826.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,N/A
1128,1129,NCT00891592,Umbilical Cord Blood Transplant for Hematological Malignancies,UCB,Completed,No Results Available,CML|AML|MDS|ALL|NHL|Multiple Myeloma|Hodgkin's Disease,Biological: Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells|Other: Observation Arm,Dose limiting toxicity (DLT) is defined as grade 4 acute GVHD within the first 90 days following infusion.,University of Pennsylvania,All,21 Years to 50 Years   (Adult),Phase 1,5.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UPCC 02707,2009-01-01,November 2011,2016-05-01,"May 1, 2009",,"August 19, 2016","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00891592,2677.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1129,1130,NCT01957735,"BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors",,Completed,No Results Available,Metastatic Cancer|Cancer|Solid Tumor,Drug: BP31510 monotherapy|Drug: BP31510 in combination with chemotherapy,Determine Maximum Tolerated Dose (MTD) of BP31510|To evaluate plasma pharmacokinetics (PK) of BPM31510|To estimate renal clearance of BPM31510,"Berg, LLC",All,"18 Years and older   (Adult, Older Adult)",Phase 1,97.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,BP-31510IV-04,2013-10-01,"February 1, 2017",2017-02-01,"October 8, 2013",,"November 8, 2019","Palo Alto Medical Foundation, Sunnyvale, California, United States|Weill Cornell Solid Tumor Oncology Practice, New York, New York, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01957735,1219.0,Industry Lead,Three Conditions,Non-Randomized,Crossover Assignment,None (Open Label),Other/Basic/Prevention
1130,1131,NCT02730312,PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies,,Completed,No Results Available,"Acute Myelogenous Leukemia|B-cell Acute Lymphoblastic Leukemia|Blastic Plasmacytoid Dendritic Cell Neoplasm|Chronic Myeloid Leukemia, Blast Crisis",Biological: XmAb14045,Safety as determined by the number of participants with treatment-related adverse events|Identify maximum tolerated (MTD) and/or recommended dose (RD) and schedule for XmAb14045 dosing,"Xencor, Inc.|ICON Clinical Research",All,"18 Years and older   (Adult, Older Adult)",Phase 1,120.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XmAb14045-01,2016-08-01,September 2021,2021-09-01,"April 6, 2016",,"March 8, 2022","Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|Wexner Medical Center at The Ohio State University, Columbus, Ohio, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02730312,1857.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1131,1132,NCT02226861,Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation,,Completed,No Results Available,Acute Lymphoblastic Leukemia (ALL)|Acute Myelogenous Leukemia (AML)|Chronic Lymphocytic Leukemia (CLL)|Chronic Myelogenous Leukemia (CML)|MDS,Device: CliniMACS CD34 selection system|Biological: ULD IL-2,Safety of ULD IL-2 as GVHD proph,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,24.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,140180|14-H-0180,2014-08-26,"May 23, 2018",2018-06-27,"August 27, 2014",,"July 5, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02226861,1401.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
1132,1133,NCT01149915,Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias,,Completed,No Results Available,Acute Myelogenous Leukemia|Acute Lymphoblastic Leukemia|Chronic Myelogenous Leukemia|High-risk Myelodysplastic Syndrome|Chronic Lymphocytic Leukemia|Advanced Myelofibrosis,Drug: TH-302,To determine the maximum tolerated dose of TH-302|To determine the dose-limiting toxicity of TH-302|TO determine the number of participants with Adverse Events as a measure of safety and tolerability|To determine the efficacy of TH-302 via specific response criteria,Threshold Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 1,40.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TH-CR-407,2010-06-01,August 2013,2013-08-01,"June 24, 2010",,"May 7, 2015","University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01149915,1157.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1133,1134,NCT01110473,ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies,,Completed,No Results Available,Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|B-cell Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Myelodysplasia,Drug: ABT-348|Drug: ABT-348 and azacitidine,"Determine the safety profile (adverse events by toxicity grade and relationship to study drug, serious adverse events, adverse events leading to discontinuation and relevant clinical laboratory abnormalities) of ABT-348 as monotherapy or in combination|Study the pharmacokinetic interaction (plasma concentrations and pharmacokinetic parameter values) of ABT-348 as monotherapy and in combination|Determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RPTD) of ABT-348 when administered as a monotherapy and in combination in subjects with advanced hematologic malignancies","AbbVie (prior sponsor, Abbott)|AbbVie",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1,52.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M10-943,2010-04-01,June 2013,2013-06-01,"April 26, 2010",,"November 20, 2017","Site Reference ID/Investigator# 59324, Scottsdale, Arizona, United States|Site Reference ID/Investigator# 26523, Atlanta, Georgia, United States|Site Reference ID/Investigator# 26522, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01110473,1157.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1134,1135,NCT00816283,Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia,,Completed,No Results Available,Leukemia,Drug: dasatinib|Drug: vorinostat|Genetic: cytogenetic analysis|Genetic: gene expression analysis|Genetic: mutation analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: flow cytometry|Other: laboratory biomarker analysis,Maximum tolerated dose|Toxicity as assessed by NCI CTCAE v3.0|Response rate|Objective tumor response|Survival|Time to treatment failure|Duration of response,City of Hope Medical Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,5.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,08047|P30CA033572|CHNMC-08047|CDR0000631569,2008-09-01,June 2011,2011-06-01,"January 1, 2009",,"July 17, 2012","City of Hope Comprehensive Cancer Center, Duarte, California, United States|City of Hope Medical Group, Pasadena, California, United States",,https://ClinicalTrials.gov/show/NCT00816283,1003.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1135,1136,NCT01094860,Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies,,Completed,No Results Available,Leukemia,Drug: Nelarabine,Maximum Tolerated Dose (MTD) of a 5-day Continuous Infusion Schedule of Nelarabine,M.D. Anderson Cancer Center|GlaxoSmithKline,All,"Child, Adult, Older Adult",Phase 1,29.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2009-0717|NCI-2010-01659,2010-06-08,"August 9, 2018",2018-08-09,"March 29, 2010",,"February 11, 2020","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01094860,2984.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1137,1138,NCT02381080,Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy,,Completed,No Results Available,B-Cell Chronic Lymphocytic Leukemia,Drug: Ibrutinib|Drug: Erythromycin|Drug: Voriconazole,Maximum Observed Plasma Concentration (Cmax) of Ibrutinib|Minimum Observed Plasma Concentration (Cmin) of Ibrutinib|Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ibrutinib|Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC[0-24]) of Ibrutinib|Metabolite to Parent (M/P) Ratio of Ibrutinib|Partial Area Under the Plasma Concentration-Time Curve Between 2 Defined Timepoints (AUC [t1 and t2]) of Voriconazole|Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs),"Janssen Research & Development, LLC",All,"18 Years and older   (Adult, Older Adult)",Phase 1,26.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR106609|PCI-32765LYM1003|2015-000325-36,2015-05-19,"June 24, 2016",2016-06-24,"March 6, 2015",,"June 26, 2017","N/a N/a, Canada|Moscow, Russian Federation|Petrozavodsk, Russian Federation|St. Petersburg, Russian Federation|Madrid, Spain|Pamplona, Spain",,https://ClinicalTrials.gov/show/NCT02381080,402.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1139,1140,NCT00911066,"MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia",,Completed,No Results Available,Acute Myelogenous Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome,Drug: MLN4924|Drug: Azacitidine,"Adverse events, serious adverse events, assessments of clinical laboratory values, and vital sign measurements|Pharmacokinetic parameters|Pharmacodynamic effects|Assess disease response|Heart corrected QT intervals","Millennium Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,72.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C15003,2009-06-01,August 2013,2013-10-01,"June 1, 2009",,"December 5, 2013","Stanford University Medical Center, Stanford, California, United States|Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago, Illinois, United States|Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Institute for Drug Development, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00911066,1583.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1140,1141,NCT01586455,Human Placental-Derived Stem Cell Transplantation,HPDSC,Completed,No Results Available,Mucopolysaccharidosis I|Mucopolysaccharidosis VI|Adrenoleukodystrophy|Niemann-Pick Disease|Metachromatic Leukodystrophy|Wolman Disease|Krabbe's Disease|Gaucher's Disease|Fucosidosis|Batten Disease|Severe Aplastic Anemia|Diamond-Blackfan Anemia|Amegakaryocytic Thrombocytopenia|Myelodysplastic Syndrome|Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia,Drug: Human Placental Derived Stem Cell,Safety|donor chimerism|engraftment|Survival|Relapse|Mortality,New York Medical College,All,"0 Years to 55 Years   (Child, Adult)",Phase 1,43.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"NYMC 550|NYMC IRB L-10,733",2013-04-01,June 2020,2022-09-01,"April 26, 2012",,"October 25, 2022","Children's Hospital Colorado, Denver, Colorado, United States|New York Medical College, Valhalla, New York, United States|University of Utah, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01586455,3440.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1141,1142,NCT00374933,Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation,,Completed,No Results Available,Acute Myelogenous Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome,"Drug: Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI|Drug: ""Prophylactic"" delayed ADLI|Drug: ""Prophylactic"" delayed activated donor lymphocyte infusion",Evaluate the safety and feasibility of administering prophylactic donor lymphocyte infusion (DLI) after non-myeloablative transplant (NMT).,Abramson Cancer Center of the University of Pennsylvania,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,18.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UPCC 08405,2007-04-01,December 2009,2009-12-01,"September 12, 2006",,"July 12, 2019","Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00374933,975.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1142,1143,NCT02083250,"Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant",,Completed,No Results Available,Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia in Remission|Allogeneic Hematopoietic Stem Cell Transplantation Recipient|Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia,Procedure: Allogeneic Bone Marrow Transplantation|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Biological: Anti-Thymocyte Globulin|Drug: Busulfan|Drug: Clofarabine|Drug: Fludarabine Phosphate|Procedure: Peripheral Blood Stem Cell Transplantation|Other: Pharmacological Study|Drug: Vorinostat,"Maximum tolerated dose of vorinostat when given in combination with fludarabine phosphate, clofarabine, and busulfan before stem cell transplant assessed using Common Terminology Criteria for Adverse Events version 4|Recurrence-free survival|Overall survival",M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"up to 60 Years   (Child, Adult)",Phase 1,70.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012-0999|NCI-2014-01982|P30CA016672,2014-03-06,"November 12, 2021",2021-11-12,"March 11, 2014",,"January 6, 2022","M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02083250,2808.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1144,1145,NCT00964873,"A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia",,Completed,No Results Available,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Blast-phase Chronic Myelogenous Leukemia|AML|ALL|CML,Drug: STA-9090 (ganetespib),"To assess efficacy in subjects with AML, ALL and blast-phase CML based on standard response criteria|To characterize the safety and tolerability of once-weekly STA-9090 (ganetespib) in subjects with AML, ALL and blast-phase CML",Synta Pharmaceuticals Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,29.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9090-04,2009-08-01,December 2010,2011-08-01,"August 25, 2009",,"September 18, 2014","Tampa, Florida, United States|Baltimore, Maryland, United States|Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00964873,730.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1145,1146,NCT01300572,"Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS",,Completed,Has Results,Chronic Myelomonocytic Leukemia|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts|Secondary Acute Myeloid Leukemia,Procedure: Allogeneic Bone Marrow Transplantation|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclosporine|Drug: Fludarabine Phosphate|Biological: Indium In 111 Anti-CD45 Monoclonal Antibody BC8|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Procedure: Peripheral Blood Stem Cell Transplantation|Other: Pharmacological Study|Radiation: Total-Body Irradiation|Radiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8,"The MTD of Radiation Delivered Via 90Y-DOTA-BC8 When Combined With FLU and 2 Gy TBI as a Preparative Regimen for Patients Aged ≥ 18 With Advanced AML, ALL, and High-risk MDS.|Achievement of Remission|Disease-free Survival|Duration of Remission|Estimation of Absorbed Radiation Doses to Normal Organs, Marrow and Tumor|Overall Survival|Rates of Acute GvHD|Rates of Donor Chimerism|Rates of Engraftment|Rates of Non-relapse Mortality",Fred Hutchinson Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,16.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2468.00|NCI-2011-00150|2468.00A|2468|P01CA044991|P30CA015704,2012-01-01,"October 29, 2017",2019-11-22,"February 21, 2011","January 25, 2019","December 10, 2019","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/72/NCT01300572/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01300572,2882.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1147,1148,NCT01169012,PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias,,Completed,No Results Available,Myelodysplastic Syndrome|Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Chronic Myelomonocytic Leukemia,Drug: Clofarabine,"Define human intra-patient bioavailability of clofarabine; Compare the pharmacokinetics of intravenously-administered clofarabine when administered alone, with the pharmacokinetics of clofarabine when co-administered with cimetidine, an OCT2 inhibitor.|Examine safety of orally-administered clofarabine; Examine the safety of a combined intravenous and oral clofarabine regimen|Examine efficacy of orally-administered clofarabine|Explore the influence of OCT2-encoding single nucleotide polymorphisms on clofarabine pharmacokinetics and pharmacodynamics","UNC Lineberger Comprehensive Cancer Center|Genzyme, a Sanofi Company",All,"18 Years and older   (Adult, Older Adult)",Phase 1,13.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,LCCC 0909|10-0256,2010-09-01,April 2012,2013-01-01,"July 23, 2010",,"August 22, 2017","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01169012,853.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
1148,1149,NCT01159028,"Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS",,Completed,No Results Available,Recurrent Adult Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome|Ph1 Positive CML,Drug: BP1001|Drug: BP1001 in combination with LDAC,Safety of BP1001|Safety of BP1001 in combination with LDAC|Optimal biologically active dose|In vivo pharmacokinetics|Correlate PK data with historical experience,"Bio-Path Holdings, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,60.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2003-0578 (v) 08-8,2010-06-01,"March 30, 2017",2017-03-30,"July 9, 2010",,"May 28, 2020","M. D. Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01159028,2494.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1149,1150,NCT01075425,Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome,,Completed,No Results Available,Acute Lymphocytic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Chronic Myelogenous Leukemia,Drug: bortezomib|Drug: belinostat|Other: laboratory biomarker analysis|Genetic: western blotting|Other: pharmacological study|Other: flow cytometry,Recommended phase II doses for the combination of bortezomib and belinostat|Toxicity|Pharmacodynamic response|Activity of belinostat and bortezomib,Virginia Commonwealth University|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,41.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MCC-12517|NCI-2010-00127|RC2CA148431,2010-05-01,February 2015,2015-02-01,"February 25, 2010",,"April 15, 2016","M D Anderson Cancer Center, Houston, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01075425,1737.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1150,1151,NCT00383474,Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase,,Completed,No Results Available,Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With Maturation|Adult Acute Myeloid Leukemia With Minimal Differentiation|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Myeloid Leukemia Without Maturation|Adult Acute Myelomonocytic Leukemia|Adult Erythroleukemia|Adult Pure Erythroid Leukemia|Blastic Phase|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Disease|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia,Drug: Bortezomib|Other: Laboratory Biomarker Analysis|Drug: Tipifarnib,"Dose-limiting toxicity and maximum tolerated dose of tipifarnib and bortezomib|Changes in apoptotic protein expression (Bim, Bax, AKT)|Clinical efficacy (response rate) evaluated using the revised International Working Group Criteria (IWG) for AML|Farnesytransferase and proteasome inhibition in peripheral blood mononuclear cells",National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,35.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2009-00147|CDR0000502258|MCC-14796|7306|N01CM62208|P30CA076292,2006-08-01,June 2012,2012-06-01,"October 3, 2006",,"April 15, 2015","Moffitt Cancer Center, Tampa, Florida, United States",,https://ClinicalTrials.gov/show/NCT00383474,2131.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1154,1155,NCT01705847,A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies,,Completed,No Results Available,Lymphoid Malignancies,Drug: GS-9820,"Maximum tolerated dose (MTD)|Overall safety|Pharmacokinetic parameters of GS-9820 as measured by Cmax, Tmax, Ctrough, and AUC|Pharmacodynamics to measure changes in the phosphatidylinositol 3-kinase (P13K) delta pathway activation and changes in plasma concentration of disease-associated chemokines and cytokines|Tumor control|Patient well-being assessed using changes in baseline in HRQL (health related quality of life questionnaire) domain and symptom scores based on the Functional Assessment of Cancer Therapy: Lymphoma (FACT-Lym)|Drug exposure",Gilead Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 1,39.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-315-0102|2012-000360-19,2012-11-01,May 2016,2016-05-01,"October 12, 2012",,"May 17, 2016","VU Medical Center (VUmc), Amsterdam, Netherlands|Academic Medical Center, Amsterdam, Netherlands|St. Antonius Hospital, Nieuwegein, Netherlands|Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT01705847,1277.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1155,1156,NCT00854646,Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS),,Completed,No Results Available,Acute Myelocytic Leukemia|Acute Lymphocytic Leukemia|Chronic Myelocytic Leukemia|Chronic Lymphocytic Leukemia|Myelodysplastic Syndromes,Drug: ON 01910.Na,"Safety data, including laboratory parameters and adverse events, will be collected for all patients in order to determine the qualitative and quantitative toxicity, and reversibility of toxicity, of ON 01910.Na.|To investigate the clinical pharmacology of ON 01910.Na including plasma pharmacokinetics, pharmacodynamics and biological effects on cell-cycle pathways.","Onconova Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,22.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Onconova 04-05,2008-10-01,November 2014,2015-12-01,"March 3, 2009",,"January 10, 2018","Mount Sinai Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00854646,2617.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1161,1162,NCT01030718,Rollover Study of BMS-354825 in Patients With CML and Ph+ALL,,Completed,Has Results,Chronic Myelogenous Leukemia|Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,Drug: dasatinib,"Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuation|Participants With Chronic Phase CML (CML-CP): Percentage of Participants With Cytogenetic Response|Participants With CML-Accelerated or Blast Phase (AP/BP): Percentage of Participants With Cytogenetic Response|Participants With Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL): Percentage of Participants With Cytogenetic Response|Participants With CML-CP: Time to Complete Cytogenetic Response (CCyR)|Participants With CML-AP/BP and Ph+ ALL: Time to Complete Cytogenetic Response (CCyR)|Participants With CML-CP: Duration of Complete Cytogenetic Response (CCyR)|Participants With CML-AP/BP and Ph+ALL: Duration of Complete Cytogenetic Response (CCyR)|Participants With CML-CP: Time to Major Cytogenetic Response (MCyR)|Participants With CML-AP/BP and Ph+ALL: Time to Major Cytogenetic Response (MCyR)|Participants With CML-CP: Duration of Major Cytogenetic Response (MCyR)|Participants With CML-AP/BP and Ph+ ALL: Duration of Major Cytogenetic Response (MCyR)|Participants With CML-CP: Percentage of Participants With Complete Hematologic Response (CHR)|Participants With CML-AP/BP: Percentage of Participants With Hematologic Response|Participants With Ph+ ALL: Percentage of Participants With Hematologic Response|Time to Complete Hematologic Response (CHR) in Chronic Phase CML, Accelerated or Blast Phase CML, and Ph+ALL|Duration of Complete Hematologic Response (CHR) in Chronic Phase CML, Accelerated or Blast Phase CML, and Ph+ALL|Time to Major Hematologic Response (MaHR) in Accelerated or Blast Phase CML, and Ph+ALL|Duration of Major Hematologic Response (MaHR) in Accelerated or Blast Phase CML, and Ph+ALL|Time to Overall Hematologic Response (OHR) in Accelerated or Blast Phase CML, and Ph+ALL|Duration of Overall Hematologic Response (OHR) in Accelerated or Blast Phase CML, and Ph+ALL|Participants With Detectable Mutations of RNA (mRNA) of BCR-ABL at Baseline and at Best Achievement|Status of Point Mutations of BCR-ABL at Baseline (BL) and End of Study (EOS)|Collection of Blood Samples for Pharmacokinetic Analysis of Dasatinib Twice Daily (BID) That Will Contribute to Population Pharmacokinetic Modeling",Bristol-Myers Squibb,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,54.0,Industry,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA180-036,2006-01-01,June 2009,2009-06-01,"December 11, 2009","December 14, 2010","December 14, 2010",,,https://ClinicalTrials.gov/show/NCT01030718,1247.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1165,1166,NCT00351975,Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases,,Completed,No Results Available,"Accelerated Phase of Disease|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phase|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndrome|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia|Previously Treated Myelodysplastic Syndrome|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Disease|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndrome",Drug: Belinostat|Drug: Azacitidine|Other: Laboratory Biomarker Analysis,"Maximum tolerated dose of belinostat in combination with azacitidine|Changes in pharmacodynamic variables (target gene expression, apoptosis)|Association of methylation status, categorized as positive or negative, with changes in target gene expression|Clinical activity (complete remission, partial remission, stable disease, hematologic improvement)",National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,56.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2009-00146|UCCRC-14510A|NCI-7285|CDR0000486418|14510A|7285|U01CA069852|U01CA132123|P30CA014599|U01CA062491,2006-06-01,March 2013,2013-03-01,"July 14, 2006",,"December 23, 2014","University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada|Princess Margaret Hospital, Cashmere, Canterbury, New Zealand",,https://ClinicalTrials.gov/show/NCT00351975,2465.0,Not Industry Lead,More than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1170,1171,NCT01667133,A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL),,Completed,Has Results,Chronic Myeloid Leukemia (CML)|Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL),Drug: ponatinib - Phase 1|Drug: ponatinib - Phase 2,"Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) as a Measure of Safety Profile to Determine Recommended Dose of Ponatinib|Phase 2, CP-CML Participants: Percentage of Participants With Major Cytogenetic Response (MCyR)|Phase 2, BP-CML and Ph+ALL: Percentage of Participants With Major Hematologic Response (MaHR)|CP-CML Participants: Percentage of Participants With CHR|CP-CML, AP-CML, BP-CML, and Ph+ALL Participants: Percentage of Participants With Confirmed MCyR|CP-CML, AP-CML, BP-CML, and Ph+ALL Participants: Percentage of Participants With Major Molecular Response (MMR)|CP-CML, AP-CML, BP-CML, and Ph+ALL Participants: Median Time to Response (TTR)|CP-CML and Advanced Phase Participants: Median Duration of Response (DOR)|CP-CML and Advanced Phase Participants: Median Progression-free Survival (PFS)|CP-CML and Advanced Phase Participants: Overall Survival (OS)|Cmax: Maximum Observed Plasma Concentration for Ponatinib|Tmax: Time to Reach the Cmax for Ponatinib|AUC(0-24): Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for Ponatinib|T1/2: Terminal Phase Elimination Half-life for Ponatinib",Ariad Pharmaceuticals|Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,35.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AP24534-11-106,2012-08-31,"August 2, 2018",2018-08-02,"August 17, 2012","June 13, 2022","June 13, 2022","Aichi Cancer Center Hospital, Nagoya-shi, Aichi, Japan|Akita University Hospital, Akita-shi, Akita, Japan|Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima-shi, Hiroshima, Japan|Kyushu University Hospital, Hukuoka-shi, Hukuoka, Japan|Kinki University Hospital, Faculty of Medicine, Osakasayama-shi, Osaka, Japan|The Cancer Institute Hospital Japanese Foundation for Cancer Research, Koto, Tokyo, Japan|The University of Tokyo, The Institute of Medical Science, Minato-ku, Tokyo, Japan|Keio University Hospital, Shinjuku-ku, Tokyo, Japan|Osaka City University Hospital, Shinjuku-ku, Tokyo, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Tokyo Medical University Hospital, Shinjuku-ku, Tokyo, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT01667133/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT01667133/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01667133,2162.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1174,1175,NCT00246662,Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies,,Completed,No Results Available,"Leukemia, Lymphocytic, Acute|Leukemia, Nonlymphocytic, Acute|Leukemia, Myeloid, Chronic|Myelodysplastic Syndromes",Drug: Vosaroxin,Safety and tolerability|Pharmacokinetic profile|Duration of leukemia-free survival|Anti-tumor activity,Sunesis Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 1,75.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SPO-0004,2005-11-14,"December 23, 2008",2009-04-01,"October 30, 2005",,"March 30, 2017","H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States|University of Texas, MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00246662,1234.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1176,1177,NCT01297543,Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia,,Completed,No Results Available,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia|Myelodysplasia,Biological: human myeloid progenitor cells|Drug: G-CSF,Incidence of serious adverse reactions|Duration of neutropenia|Duration of thrombocytopenia|Duration of presence of CLT-008 derived cells in blood|Duration of presence of CLT-008 derived cells in bone marrow|Incidence of mucositis|Incidence of infections|Duration of fever|Duration of antibiotic use|Incidence of hospitalization|Duration of hospitalization,Cellerant Therapeutics|Department of Health and Human Services,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,45.0,Industry|U.S. Fed,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,CLT008-02,2011-03-01,November 2014,2015-01-01,"February 16, 2011",,"July 1, 2016","Moores UCSD Cancer Center, La Jolla, California, United States|University of California San Francisco Medical Center, San Francisco, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States|Indiana Blood and Marrow Transplantation, LLC, Beech Grove, Indiana, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01297543,1402.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Supportive Care
1177,1178,NCT00161187,Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor,,Completed,No Results Available,Cancer,Biological: therapeutic allogeneic lymphocytes,Toxicity|Response|Presence of disease or antigen-specific lymphocytes,"University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey",All,"Child, Adult, Older Adult",Phase 1,37.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,010101|P30CA072720|0220003330|CDR0000540298,2001-05-01,October 2010,2011-10-01,"September 12, 2005",,"November 6, 2015","Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00161187,3805.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1178,1179,NCT00081133,Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia,,Completed,No Results Available,Leukemia,Drug: arsenic trioxide|Drug: imatinib mesylate,,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,,Other|NIH,Interventional,Primary Purpose: Treatment,03-126|CDR0000358923,2003-12-01,February 2005,2005-02-01,"April 8, 2004",,"June 5, 2013","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00081133,428.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
1179,1180,NCT00049296,Thalidomide and Docetaxel in Treating Patients With Advanced Cancer,,Completed,No Results Available,Cancer,Drug: docetaxel|Drug: thalidomide,"Determine the maximum tolerated dose of docetaxel when administered with thalidomide in patients with advanced solid tumors, multiple myeloma, and non-Hodgkin's lymphoma.",Case Comprehensive Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,26.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CWRU4Y01|P30CA043703|CWRU-4Y01|NCI-G02-2123,2002-07-01,December 2004,2006-01-01,"January 27, 2003",,"June 11, 2010","Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00049296,1280.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1180,1181,NCT00720785,Natural Killer Cells and Bortezomib to Treat Cancer,,Completed,No Results Available,"Chronic Myeloid Leukemia (CML)|Pancreatic Ca|Colon/Rectal Ca|Multiple Myeloma|Carcinoma, Non-Small -Cell Lung",Drug: Bortezomib|Biological: NK cells,safety of escalating NK cell doses of adoptively infused ex vivo expanded autologous NK cells in subjects with treatment refractory metastatic tumors or hematological malignancies that are sensitized to NK cell toxicity with bortezomib.,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,35.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,080186|08-H-0186,2008-08-01,"April 6, 2021",2021-04-06,"July 23, 2008",,"February 21, 2023","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00720785,4631.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1181,1182,NCT00569283,Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant,,Completed,No Results Available,Cancer,Biological: therapeutic allogeneic lymphocytes,Maximum tolerated dose of donor natural killer (NK) cells|Safety|Effectiveness of donor NK cell infusion in preventing tumor relapse and graft failure after HLA-haploidentical familial donor bone marrow transplantation,Asan Medical Center|National Cancer Institute (NCI),All,"up to 65 Years   (Child, Adult, Older Adult)",Phase 1,18.0,Other,Interventional,Primary Purpose: Treatment,CDR0000577508|AMC-UUCM-2006-0383,2007-05-01,December 2008,2008-12-01,"December 7, 2007",,"March 26, 2013","Korea Research Institute of Bioscience and Biotechnology, Dajeon, Korea, Republic of|Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00569283,580.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
1182,1183,NCT00509691,Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy,,Completed,No Results Available,Cancer,Biological: cytomegalovirus pp65-specific cytotoxic T lymphocytes|Genetic: polymerase chain reaction|Other: diagnostic laboratory biomarker analysis|Other: flow cytometry|Other: immunologic technique,Toxicity|Treatment failure|Safety|Time to development of cytomegalovirus (CMV) specific immune reconstitution|CMV DNA levels|Time during post-infusion follow up at which the dominant CMV pp65 epitope for the donor is recognized by the cytotoxic t-cell lymphocyte recipient,University of Louisville|Penn State University,All,"2 Years to 120 Years   (Child, Adult, Older Adult)",Phase 1,20.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,CDR0000557037|PSCI-25114,2007-06-01,December 2011,2011-12-01,"July 31, 2007",,"May 9, 2017","Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00509691,1644.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Supportive Care
1183,1184,NCT00361049,Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant,,Completed,No Results Available,Cancer,Biological: graft versus host disease prophylaxis/therapy|Genetic: fluorescence in situ hybridization|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Procedure: in vitro-treated bone marrow transplantation|Procedure: management of therapy complications,"Safety|Complete and partial resolution of graft-vs-host disease (GVHD)|Cytokine levels, lymphocyte subsets, and donor-reactive lymphocyte numbers in patients with acute GVHD",Case Comprehensive Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,49.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CWRU3Y03|P30CA043703|CASE-CWRU-3Y03,2004-09-01,June 2009,2010-11-01,"August 7, 2006",,"November 5, 2010","Geauga Regional Hospital, Cleveland, Ohio, United States|Lake/University Ireland Cancer Center, Cleveland, Ohio, United States|Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|University Suburban Health Center, Cleveland, Ohio, United States|UHHS Chagrin Highlands Medical Center, Cleveland, Ohio, United States|Southwest General Health Center, Cleveland, Ohio, United States|UHHS Westlake Medical Center, Cleveland, Ohio, United States|Mercy Cancer Center at Mercy Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00361049,2252.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1184,1185,NCT01607892,Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer,,Completed,Has Results,Hematological Malignancies,Drug: KPT-330,"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)|Recommended Phase 2 Dose (RP2D) of Selinexor|Maximum Observed Plasma Concentration (Cmax) of Selinexor|Time to Maximum Observed Concentration (Tmax) of Selinexor|Average Concentration From Time 0 to 24 Hours (Cavg0-24h) of Selinexor|Area Under the Concentration-Time Curve From Time 0 to t (AUC0-t) of Selinexor|Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Selinexor|Apparent Volume of Distribution Uncorrected for Fraction Absorbed (Vd/F) of Selinexor|Apparent Total Body Clearance, Uncorrected for Fraction Absorbed (Cl/F) of Selinexor|Terminal Half-Life (t½) of Selinexor|Number of Participants With Overall Response of Selinexor|Duration of Response|Progression-free Survival|Duration of at Least Stable Disease|Overall Survival",Karyopharm Therapeutics Inc,All,"18 Years and older   (Adult, Older Adult)",Phase 1,286.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KCP-330-001,2012-07-23,"October 13, 2015",2015-10-13,"May 30, 2012","April 1, 2021","January 26, 2023","Moffitt Cancer Center, Tampa, Florida, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Medical Center, New York, New York, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Rigshospitalet, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT01607892,1177.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1186,1187,NCT00045006,Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer,,Completed,No Results Available,Cancer,Drug: vorinostat,,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,,Other|NIH,Interventional,Primary Purpose: Treatment,MSKCC-01021|CDR0000256306|ATON-0101|NCI-G02-2099,2001-07-01,December 2005,2008-07-01,"January 27, 2003",,"May 30, 2013","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00045006,2557.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
1187,1188,NCT01353625,"Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.",,Completed,No Results Available,Glioblastoma Multiforme|Squamous Cell Carcinoma of Head and Neck|Prostate Cancer|Ewing's Osteosarcoma|Chronic Lymphocytic Leukemia|Neoplasm Metastasis,Drug: CC-115,Dose-Limiting Toxicity|Non-Tolerated Dose|Maximum Tolerated Dose|Maximum Observed Concentration in Plasma of CC-115|Area Under the Concentration-Time Curve for CC-115|Time to Maximum Concentration of CC-115|Terminal Half-Life for CC-115|Apparent Total Body Clearance of CC-115|Apparent Volume of Distribution of CC-115|Accumulation Index of CC-115|Pharmacodynamics|Anti-Tumor Efficacy,Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 1,118.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CC-115-ST-001,2011-04-25,"March 12, 2021",2021-03-12,"May 13, 2011",,"October 5, 2021","Cedars-Sinai Medical Center, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|University of California, San Francisco Comprehensive Cancer Center and Cancer Research Institiute, San Francisco, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Henry Ford Medical Center - New Center One, Detroit, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Sarah Cannon Research Institute Drug Development Unit, Nashville, Tennessee, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Gustave Roussy, Villejuif Cedex, France|Uniklinik Koln, Koeln, Germany|Universitatsklinikum Wurzburg, Würzburg, Germany|Hospital Val d'Hebron, Barcelona, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital de Donosti, San Sebastián (Guipuzcoa), Spain|Hospital Virgen del Rocio, Sevilla, Spain",,https://ClinicalTrials.gov/show/NCT01353625,3609.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1188,1189,NCT02046291,Safety of Romiplostim (Nplate®) Following UCBT,,Completed,No Results Available,Hematologic Malignancies,Drug: Romiplostim,Maximum tolerated dose of romiplostim|Platelet recovery|Thrombocytopenia|Bone marrow fibrosis,"Masonic Cancer Center, University of Minnesota",All,"18 Years and older   (Adult, Older Adult)",Phase 1,21.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2012LS089|MT2012-17R,2015-04-10,"December 12, 2020",2021-06-01,"January 27, 2014",,"June 8, 2021","University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02046291,2244.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Supportive Care
1189,1190,NCT00312429,Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer,,Completed,No Results Available,Hematologic Neoplasms,Procedure: Stem Cell Transplantation,Survival Rates,"Duke University|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,34.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2166|R01HL062095-06,2002-01-01,May 2008,2008-05-01,"April 10, 2006",,"April 3, 2012","Duke University, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00312429,2312.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1190,1191,NCT03082209,A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies,,Completed,No Results Available,Advanced Solid Tumors|Cancer|Hematologic Malignancies,Drug: ABBV-621|Drug: Venetoclax|Drug: Bevacizumab|Drug: FOLFIRI,Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) for ABBV-621|Area under the serum/plasma concentration time curve (AUC) of ABBV-621|Area under the serum/plasma concentration time curve (AUC) of Venetoclax|Maximum observed serum concentration (Cmax) of ABBV-621|Maximum observed serum concentration (Cmax) of Venetoclax|Time to Cmax (Tmax) of ABBV-621|Time to Cmax (Tmax) of Venetoclax|Terminal phase elimination rate constant (β) for ABBV-621|Terminal phase elimination rate constant (β) for Venetoclax|Terminal Phase Elimination Half-life (t1/2) of ABBV-621 in Plasma|Terminal Phase Elimination Half-life (t1/2) of Venetoclax in Plasma|QTcF Change from Baseline|Number of Participants with Dose-limiting Toxicities (DLTs),AbbVie,All,"18 Years and older   (Adult, Older Adult)",Phase 1,153.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M15-913|2016-003887-37,2017-03-20,"January 21, 2022",2022-01-21,"March 17, 2017",,"December 9, 2022","Yale University /ID# 158029, New Haven, Connecticut, United States|The University of Chicago Medical Center /ID# 158030, Chicago, Illinois, United States|Ingalls Memorial Hosp /ID# 171221, Harvey, Illinois, United States|Univ Michigan Med Ctr /ID# 207134, Ann Arbor, Michigan, United States|Rhode Island Hospital /ID# 171157, Providence, Rhode Island, United States|Vanderbilt University Medical Center /ID# 215000, Nashville, Tennessee, United States|MD Anderson Cancer Center /ID# 202187, Houston, Texas, United States|Millennium Oncology /ID# 214981, Houston, Texas, United States|South Texas Accelerated Research Therapeutics /ID# 160574, San Antonio, Texas, United States|Medical College of Wisconsin /ID# 171152, Milwaukee, Wisconsin, United States|National Cancer Center Hospital East /ID# 160596, Kashiwa-shi, Chiba, Japan|Yamagata University Hospital /ID# 200681, Yamagata-shi, Yamagata, Japan|Erasmus Medisch Centrum /ID# 160869, Rotterdam, Zuid-Holland, Netherlands|Universitair Medisch Centrum Groningen /ID# 169748, Groningen, Netherlands|Maastricht Universitair Medisch Centrum /ID# 214935, Maastricht, Netherlands|Universitair Medisch Centrum Utrecht /ID# 169747, Utrecht, Netherlands|Hospital Universitario Vall d'Hebron /ID# 170809, Barcelona, Spain|Hospital Universitario Fundacion Jimenez Diaz /ID# 200106, Madrid, Spain|Hospital Universitario HM Sanchinarro /ID# 165136, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03082209,1768.0,Industry Lead,Three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1191,1192,NCT02352558,"A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies",,Completed,No Results Available,Hematologic Malignancy,Drug: BBI608|Drug: Dexamethasone|Drug: Bortezomib|Drug: Imatinib|Drug: Ibrutinib,"Determination of the safety and tolerability of BBI608 administered as monotherapy and in combination with dexamethasone, bortezomib, imatinib or ibrutinib by assessing dose-limiting toxicities (DLTs)|Pharmacokinetic profile of BBI608 when administered in monotherapy and in combination with dexamethasone, bortezomib, imatinib or ibrutinib as assessed by maximum plasma concentration and area under the curve|Pharmacodynamic activity of BBI608 when administered in monotherapy and in combination with dexamethasone, bortezomib, imatinib or ibrutinib as assessed by biomarker analysis|Assessment of the preliminary anti-tumor activity by performing tumor assessments","Sumitomo Pharma Oncology, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BBI608-103HEME|BBI608-103HEM,2015-05-01,"December 14, 2018",2019-05-16,"February 2, 2015",,"April 5, 2022","Rocky Mountain Cancer Centers, Denver, Colorado, United States|Indiana University, Indianapolis, Indiana, United States|West Clinic, Germantown, Tennessee, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Cancer Care Centers of South Texas - HOAST, San Antonio, Texas, United States|Virginia Cancer Specialists, P.C., Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Northwest Cancer Specialists, PC, Vancouver, Washington, United States",,https://ClinicalTrials.gov/show/NCT02352558,1476.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1192,1193,NCT02061761,"A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies",,Completed,Has Results,Hematologic Neoplasms,Biological: BMS-986016|Biological: BMS-936558,"Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation|Number of Participants Who Died|Number of Participants With On-Treatment Laboratory Abnormalities in Specific Hepatics Tests|Objective Response Rate (ORR) - Part D|Duration of Response (DoR) - Part D|BMS-986016 Maximum Observed Serum Concentration (Cmax)|BMS-986016 Time of Maximum Observed Serum Concentration (Tmax)|BMS-986016 Area Under the Concentration-time Curve in One Dosing Interval (AUC(TAU))|BMS-986016 Concentration at the End of a Dosing Interval (Ctau)|BMS-986016 Effective Elimination Half-life That Explains the Degree of AUC Accumulation Observed (T 1/2eff AUC)|BMS-986016 Total Body Clearance (CL/T)|BMS-986016 Cmax Accumulation Index (AI_Cmax)|BMS-986016 Accumulation Index (AI_AUC)|BMS-986016 Ctau Accumulation Index (AI_Ctau)|BMS-986016 Average Concentration Over a Dosing Interval ([AUC(TAU)/Tau] (Css,Avg)|BMS-986016 Trough Observed Serum Concentration (Ctrough)|Number of Participants With Anti-BMS-986016 Antibodies (ADA)|Number of Participants With Anti-Nivolumab Antibodies (ADA)",Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,106.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA224-022,2014-03-13,"February 16, 2022",2022-02-16,"February 13, 2014","March 24, 2023","March 24, 2023","Local Institution - 0007, Baltimore, Maryland, United States|Local Institution - 0004, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Local Institution - 0010, Saint Louis, Missouri, United States|Weill Cornell Medical College, New York, New York, United States|Local Institution - 0002, Portland, Oregon, United States|Local Institution - 0006, Houston, Texas, United States|Local Institution - 0001, Seattle, Washington, United States|Local Institution - 0011, Vancouver, British Columbia, Canada|Local Institution - 0012, Toronto, Ontario, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02061761/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02061761,2897.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1193,1194,NCT02311998,Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML,,Completed,No Results Available,"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|CD22 Positive|Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive",Drug: Bosutinib|Biological: Inotuzumab Ozogamicin|Other: Laboratory Biomarker Analysis,Maximum tolerated dose of bosutinib defined as the highest dose level in which < 2 patients of 6 develop first course dose limiting toxicity (Phase I)|Major hematologic response for relapsed Philadelphia positive acute lymphoblastic leukemia (MaHR) (Phase II)|Complete response/complete response with incomplete bone marrow recovery for newly diagnosed Philadelphia positive acute lymphoblastic leukemia or chronic myeloid leukemia or chronic myeloid leukemia- lymphoid blast phase with age >= 60 (Phase II)|Overall major hematologic response (Phase I)|Duration of response (Phase I)|Overall survival (OS) (Phase I)|Incidence and severity of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Phase II)|Duration of response (Phase II)|Overall survival (Phase II),M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,23.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014-0435|NCI-2014-02606,2015-04-16,"March 23, 2022",2022-03-23,"December 9, 2014",,"April 5, 2022","M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02311998,2533.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1194,1195,NCT01445080,Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia,,Completed,Has Results,"Blastic Phase|Childhood Acute Promyelocytic Leukemia With PML-RARA|Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Childhood Solid Neoplasm|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Juvenile Myelomonocytic Leukemia|Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Disease",Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Sorafenib Tosylate,Number of Patients With Treatment-related Dose Limiting Toxicity in Cycle 1 by Dose Level|Number of Patients With Treatment-related Adverse Events|Area Under the Plasma Concentration Versus Time Curve (AUC) of Sorafenib|Clearance (Cl) of Sorafenib|Half-life of Sorafenib|Maximum Serum Concentration (Cmax) of Sorafenib|Number of Patients With Treatment-related Dose Limiting Toxicities in Later Cycles by Dose Level|Volume of Distribution at Steady State (Vss) of Sorafenib|Number of Patients Who Respond Using RECIST Criteria|Mean Concentration of VEGF2|Pharmacodynamics (PD) Blood Flow Part C|Number of Patients With DEMRI|Leukemia Mutations|Plasma Inhibitory Activity (PIA),National Cancer Institute (NCI),All,"2 Years to 21 Years   (Child, Adult)",Phase 1|Phase 2,70.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2009-00358|06-C-0233|CDR0000483040|COG-ADVL0413|NCI-06-C-0233|060233|ADVL0413|U01CA097452,2006-05-30,"March 16, 2012",2012-12-10,"October 3, 2011","February 2, 2021","February 2, 2021","University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Children's Hospital of Orange County, Orange, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Hospital for Sick Children, Toronto, Ontario, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01445080,2386.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1195,1196,NCT00702403,Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML,,Completed,Has Results,"Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase Chronic Myelogenous Leukemia|Philadelphia Positive Adult Acute Lymphoblastic Leukemia|Philadelphia Positive Childhood Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Relapsing Chronic Myelogenous Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia",Drug: nilotinib|Drug: imatinib mesylate|Other: pharmacological study,Number of Participants With Treatment Safety Failure|The Proportion of Patients at 1 Year With Treatment Efficacy Success|Survival|Patients Alive With Out Relapse|Relapse,Fred Hutchinson Cancer Center|National Cancer Institute (NCI),All,"Child, Adult, Older Adult",Phase 1|Phase 2,40.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2223.00|NCI-2010-00402|P30CA015704|P01CA018029,2008-08-14,December 2013,2013-12-01,"June 20, 2008","May 15, 2017","August 10, 2017","Stanford University Hospitals and Clinics, Stanford, California, United States|H Lee Moffitt Cancer Center and Research Institute Phase 2 Consortium, Tampa, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Oregon Health and Science University, Portland, Oregon, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00702403,1935.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1196,1197,NCT01914484,Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia,,Completed,No Results Available,Chronic Phase Chronic Myeloid Leukemia|Accelerated Phase Chronic Myeloid Leukemia|Blastic Phase Chronic Myeloid Leukemia|Philadelphia Positive Acute Lymphoblastic Leukemia|Resistant to Tyrosine Kinase Inhibitor Therapy,Drug: Nilotinib|Drug: Ruxolitinib,Phase I: Maximum Tolerated Dose (MTD)|Phase II: Major cytogenetic response|Phase I: complete hematologic response|Phase I: major cytogenetic response|Phase I: Safety and tolerability|Phase II: complete hematologic response,"University Health Network, Toronto|Novartis",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,4.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CAMN107ACA06T|OZM-051,2013-08-01,"December 31, 2018",2018-12-31,"August 2, 2013",,"November 2, 2020","Princess Margaret Hospital / University Health Network, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01914484,1978.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1197,1198,NCT01517035,Improving Blood Stem Cell Collection and Transplant Procedures,,Completed,No Results Available,Myelodysplastic Syndrome (MDS)|Chronic Myelogenous Leukemia|Acute Lymphoblastic Leukemia|CML (Chronic Myelogenous Leukemia|CLL (Chronic Lymphocytic Leukemia),Procedure: Stem Cell Transplantation,"The primary endpoint is all cause mortality at day 200, and the proportion of subjects who have survived at day 200 will be used to determine the sample size.|Cumulative incidence of relapse|Secondary Outcome Measure: Standard transplant outcome variables such as relapse, non-relapse mortality, neutrophil and platelet recovery kinetics, incidence and severity of acute GVHD and chronic GVHD. Technical success rates and the use of DLI...|Non Relapse Mortality|Days till ANC greater than 500/uL|Days till Platelet greater than 20 k/ul","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"2 Years to 80 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,43.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120028|12-H-0028,2012-01-13,"March 29, 2017",2017-03-29,"January 25, 2012",,"July 5, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01517035,1902.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1198,1199,NCT00109707,A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies,,Completed,Has Results,Chronic Myelogenous Leukemia|Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)|Hypereosinophilic Syndrome|Systemic Mastocytosis,Drug: Nilotinib,Number of Participants With Major Cytogenetic Response (MCyR)|Number of Participants Confirmed Overall Hematological Response (Phase II)|Number of Participants With Overall Major Cytogenetic Responses (Phase II)|Number of Participants With Complete Hematologic Response (Phase II)|Participants With (MMR) Major Molecular Response (Phase II)|Time to Progression (TTP) (Phase II)|Overall Survival (OS) (Phase II)|Number of Participants With Adverse Events and Serious Adverse Events to Evaluate Long Term Safety,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,507.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CAMN107A2101,2005-04-01,September 2012,2012-09-01,"May 3, 2005","June 29, 2021","June 29, 2021","City of Hope National Medical Center, Duarte, California, United States|Stanford University Medical Center, Stanford, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|H. Lee Moffitt Cancer Center & Research Institute Dept.of H. Lee Moffitt, Tampa, Florida, United States|University of Chicago Medical Center Dept. of U. of Chicago Hosp(3), Chicago, Illinois, United States|University of Illinois at Chicago Divisionof Hematology/Oncology, Chicago, Illinois, United States|Indiana Blood and Marrow Institute Dept of Indiana Blood&Mar (2), Beech Grove, Indiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Div.of Hematologic Malignancie, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Health System Clinical Trials Office, Ann Arbor, Michigan, United States|Wayne State University, Detroit, Michigan, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute Rosewell SC, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Oregon Health Sciences University, Portland, Oregon, United States|The Jones Clinic, Germantown, Tennessee, United States|Vanderbilt University Medical Center, Clinical Trials Center Investigational Drug Services, Nashville, Tennessee, United States|MD Anderson Cancer Center/University of Texas, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Novartis Investigative Site, St. Leonards, New South Wales, Australia|Novartis Investigative Site, Adelaide, South Australia, Australia|Novartis Investigative Site, Prahran, Victoria, Australia|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Haine-saint-Paul, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Vejle, Denmark|Novartis Investigative Site, HUS Helsinki, Finland|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, Créteil, France|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, Lille, France|Novartis Investigative Site, Limoges cedex, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Poitiers, France|Novartis Investigative Site, Rennes, France|Novartis Investigative Site, Vandoeuvre les Nancy, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Frankfurt/M, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Pokfulam, Hong Kong|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Pescara, PE, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Reggio Calabria, RC, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Orbassano, TO, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Hwasun-gun, Jeollanam-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Taegu, Korea, Republic of|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Grafton, Auckland, New Zealand|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Katowice, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Göteborg, Sweden|Novartis Investigative Site, Linköping, Sweden|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Genève, Switzerland|Novartis Investigative Site, Niaosong Township, Taiwan|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Cambridge, United Kingdom|Novartis Investigative Site, Glasgow - Scotland, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Newcastle upon Tyne, United Kingdom",,https://ClinicalTrials.gov/show/NCT00109707,2710.0,Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1199,1200,NCT02743351,Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies,,Completed,Has Results,Hematologic Malignancies|Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndromes|Chronic Myelogenous Leukemia|Acute Graft-versus-host Disease,Biological: ProTmune|Biological: Control Arm,"Percentage of Participants With Cumulative Incidence of Grade II to IV aGvHD Through Day +100 Based on Investigator Assessment|1-year GvHD-free, Relapse-free Survival (GRFS)|Percentage of Subjects Alive Without Relapse and Without Moderate or Severe cGvHD at Day +365 - mITT Population",Fate Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,96.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",PT-001,2016-12-20,"December 4, 2020",2021-11-05,"April 19, 2016","February 8, 2023","February 8, 2023","University of Alabama, Birmingham, Alabama, United States|City of Hope, Duarte, California, United States|University of California, San Diego (UCSD) Moores Cancer Center, San Diego, California, United States|University of Chicago, Chicago, Illinois, United States|Indiana Blood and Marrow Transplant, Indianapolis, Indiana, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Weill Cornell Medicine, New York, New York, United States|Jewish Hospital, Cincinnati, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Texas Transplant Institute, San Antonio, Texas, United States|Huntsman Cancer Institute (University of Utah), Salt Lake City, Utah, United States|Virginia Commonwealth University, Richmond, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02743351/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02743351/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02743351/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT02743351,1781.0,Industry Lead,More than three Conditions,Randomized,None-Crossover Assignment,Not Open Label,Other/Basic/Prevention
1200,1201,NCT00270881,Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies,,Completed,No Results Available,Acute Myelogenous Leukemia|Acute Lymphoblastic Leukemia|Chronic Myelogenous Leukemia|Myelodysplastic Syndrome,Procedure: Cord blood transplantation|Radiation: TBI|Drug: cyclophosphamide|Drug: cytarabine,Non-relapse mortality at 1 year|Engraftment|Disease free survival|Overall survival|Incidence of acute and chronic graft-versus-host disease|Incidence of infectious complication|Duration of hospitalization|Immune reconstitution after transplantation,Keio University,All,20 Years to 55 Years   (Adult),Phase 1|Phase 2,33.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KSGCT-CB2005,2006-01-01,January 2009,2011-01-01,"December 29, 2005",,"April 6, 2012","Keio University School of Medicine, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00270881,1826.0,Not Industry Lead,More than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1201,1202,NCT01816230,"Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM",,Completed,Has Results,Hematological Malignancies|Acute Lymphoblastic Leukemia (ALL)|Acute Myeloid Leukemia (AML)|Myelodysplastic Syndrome (MDS),Drug: NiCord®,Engraftment,Gamida Cell ltd,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,36.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GC P#03.01.020,2013-04-01,June 2017,2018-06-01,"March 22, 2013","September 21, 2020","October 22, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States|Loyola University, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States|University of Minnesota, Minneapolis, Minnesota, United States|Steven and Alexandra Cohen Children's Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Vanderbilt, Nashville, Tennessee, United States|Children Hospital Gaslini Scientific Institute, Genoa, Italy|University of Turin, Turin, Italy|University Medical Center Utrecht, Utrecht, Netherlands|National University Cancer Institute, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|University Hospital Vall d´Hebron, Barcelona, Spain|Hospital Universitario La Fe, Valencia, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT01816230/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01816230,1887.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1202,1203,NCT00881946,Repeat Dose Safety Study for Compound to Treat Hematologic Cancer,,Completed,No Results Available,Hematologic Malignancies,Drug: GSK21110183,Physical exam|Electrocardiogram (ECG)|Vital signs|Transthoracic Echocardiogram (TTE)/Multiple Gated Acquisition (MUGA) Scans|Clinical Laboratory assessments|ECOG Peformance Status|PK - Maximum observed plasma concentraion (Cmax)|PK - time to Cmax [tmax] (Maximum observed plasma concentration)|PK - Area under the plasma concentration-time curve (AUC(0-t))|PK - Apparent terminal phase elimination rate constant|PK - Apparent terminal phase half-life (t1/2)|PK - oral clearance (CL/F)|Metabolite Profiling,Accenture,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,73.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,PKB112835,2009-07-01,March 2012,2012-03-01,"April 15, 2009",,"April 4, 2012","Prince of Wales Hospital, Sydney, New South Wales, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Princess Margaret Hospital, Toronto, Ontario, Canada|Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00881946,974.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
1203,1204,NCT01167166,Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL),,Completed,No Results Available,Acute Myelocytic Leukemia|Acute Lymphocytic Leukemia|Myeloproliferative Disease|Chronic Myeloid Leukemia,Drug: rigosertib,"Dose Limiting Toxicity (DLT)|Change in bone marrow blast cell and peripheral blood counts at 5, 13 and 25 weeks|Concentration of ON 01910.Na in plasma","Onconova Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,04-19,2010-07-01,December 2013,2014-06-01,"July 22, 2010",,"June 26, 2017","University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01167166,1431.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1204,1205,NCT00052520,"Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation",,Completed,No Results Available,Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia|Essential Thrombocythemia|Polycythemia Vera|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia,Biological: therapeutic allogeneic lymphocytes|Biological: aldesleukin|Procedure: peripheral blood stem cell transplantation|Procedure: allogeneic bone marrow transplantation|Other: laboratory biomarker analysis|Genetic: gene expression analysis|Other: immunologic technique|Other: flow cytometry|Genetic: polymerase chain reaction|Genetic: cytogenetic analysis|Other: staining method,"Toxicity rate associated with infusing donor CD8+ CTL clones specific for WT1 in patients at high risk for post transplant relapse of CML, AML, or ALL|Relapse of disease",Fred Hutchinson Cancer Center|National Cancer Institute (NCI),All,"Child, Adult, Older Adult",Phase 1|Phase 2,37.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1655.00|NCI-2009-01471|P01CA018029,2002-09-01,April 2011,2013-06-01,"January 27, 2003",,"March 29, 2017","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00052520,3926.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1205,1206,NCT02569476,BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies,,Completed,Has Results,B-cell Lymphoid Malignancies,Drug: Zanubrutinib|Drug: Obinutuzumab,Part 1 : Number Of Participants Experiencing Adverse Events|Part 1: Number Of Participants With Clinical Laboratory Abnormalities|Part 1: Number Of Deaths|Part 1: Number Of Participants Experiencing Dose-limiting Toxicity (DLT)|Part 1 and Part 2: Number Of Participants Achieving A Best Response Of Partial Response|Part 1 and Part 2: Number Of Participants Achieving A Best Response Of Complete Response|Part 1 and Part 2: Progression-free Survival (PFS)|Part 1 and Part 2: Duration Of Response (DOR)|Part 1 and Part 2: Time To Response (TTR)|Part 1 and Part 2: Overall Survival (OS)|Part 1 and Part 2: Hematologic Improvement In Participants With CLL|Part 1: Area Under The Plasma Concentration-time Curve From Time 0 To The Time Of The Last Measurable Concentration (AUClast) Of Zanubrutinib|Part 1: Area Under The Plasma Concentration-time Curve From Time 0 To Infinity Time (AUC) Of Zanubrutinib|Part 1: Maximum Plasma Concentration (Cmax) Of Zanubrutinib|Part 1: Time To Maximum Plasma Concentration (Tmax) Of Zanubrutinib|Part 1: Terminal Elimination Half-life (t1/2) Of Zanubrutinib|Part 1: Apparent Clearance (CL/F) Of Zanubrutinib|Part 1: Apparent Volume Of Distribution (Vz/F) Of Zanubrutinib|Part 1 and Part 2: Steady State AUClast Of Zanubrutinib|Part 1 and Part 2: Steady State Cmax of Zanubrutinib|Part 1 and Part 2: Steady State Tmax Of Zanubrutinib|Part 2: Number Of Participants Experiencing Adverse Events|Part 2: Number Of Participants With Clinical Laboratory Abnormalities|Part 2: Number Of Deaths,BeiGene,All,"18 Years and older   (Adult, Older Adult)",Phase 1,119.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BGB-3111_GA101_Study_001,2016-01-13,"September 2, 2020",2020-09-02,"October 6, 2015","November 3, 2021","March 3, 2022","Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Tennessee Oncology, PLLC - Nashville, Nashville, Tennessee, United States|Border Medical Oncology, Albury, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Brisbane Clinic for Lymphoma, Myeloma and Leukaemia, Greenslopes, Queensland, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|St Vincent's Hospital Melbourne, East Melbourne, Victoria, Australia|University Hospital Geelong, Geelong, Victoria, Australia|St Frances Xavier Cabrini Hospital, Malvern, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02569476/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02569476/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02569476,1694.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1206,1207,NCT00521859,Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies,,Completed,No Results Available,Hematologic Malignancies,Drug: Cloretazine|Drug: Fludarabine,"To study the highest tolerable dose of VNP40101M that can be given to patients with a form of leukemia, MDS, lymphoma, or myeloma in preparation for an autologous stem cell transplant.",M.D. Anderson Cancer Center|Vion Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,5.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2005-0844,2007-08-01,December 2010,2010-12-01,"August 28, 2007",,"July 31, 2012","UT MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00521859,1218.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1207,1208,NCT01636622,"Study of Vemurafenib, Carboplatin, and Paclitaxel",,Completed,No Results Available,Advanced Cancers,Drug: Vemurafenib|Drug: Carboplatin|Drug: Paclitaxel,Maximum Tolerated Dose (MTD) of Vemurafenib with Carboplatin and Paclitaxel|Overall Response Rate,M.D. Anderson Cancer Center,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 1,21.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012-0394|NCI-2012-01221,2012-07-09,"April 21, 2020",2020-04-21,"July 10, 2012",,"June 18, 2020","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01636622,2843.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1208,1209,NCT02509156,Stem Cell Injection in Cancer Survivors,SENECA,Completed,Has Results,Cardiomyopathy Due to Anthracyclines,Biological: Allo-MSCs|Biological: Placebo,Proportion of Major Adverse Cardiac Events (MACE)|Proportion of Other Significant Clinical Events|Subjects With Events Precluding Their Receipt of Product|Subjects Who Receive Less Than 20 Injections During SPI|Subjects Who Did Not Receive the Study Product (Either 100 Million Cells or Placebo)|Subjects Who Have at Least One Cardiac MRI Endpoint Measure That is Uninterpretable|Subjects Who Fail to Complete Follow-up|Change From Baseline in Left Ventricular Ejection Fraction (LVEF)|Change From Baseline in Left Ventricular Ejection Fraction (LVEF)-Trajectory|Change From Baseline in Global Strain (HARP MRI)|Change From Baseline in Global Strain (HARP MRI)-Trajectory|Change From Baseline in Regional Strain (HARP MRI)|Change From Baseline in Regional Strain (HARP MRI)-Trajectory|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)-Trajectory|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)-Trajectory|Change From Baseline in Left Ventricular Sphericity Index|Change From Baseline in Left Ventricular Sphericity Index-Trajectory|Change From Baseline in Area of Injury|Change From Baseline in Area of Injury-Trajectory|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)-Trajectory|Change From Baseline in Minnesota Living With Heart Failure Questionnaire Score|Change From Baseline in Minnesota Living With Heart Failure Questionnaire Score-Trajectory|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)-Trajectory|Cumulative Days Alive and Out of Hospital for Heart Failure,"The University of Texas Health Science Center, Houston|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 1,46.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HSC-SPH-15-0443|5UM1HL087318,2016-08-01,November 2019,2020-04-20,"July 27, 2015","November 5, 2020","November 5, 2020","Stanford University School of Medicine, Stanford, California, United States|University of Florida-Department of Medicine, Gainesville, Florida, United States|University of Miami-Interdiciplinary Stem Cell Institute, Miami, Florida, United States|Indiana Center for Vascular Biology and Medicine, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|Texas Heart Institute, Houston, Texas, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02509156/ICF_001.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02509156/Prot_SAP_002.pdf",https://ClinicalTrials.gov/show/NCT02509156,1358.0,Not Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,Not Open Label,Treatment/Diagnostic
1209,1210,NCT01827579,Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT),ICAT,Completed,No Results Available,Haematological Malignancies,Biological: CD25/71 allodepleted donor T-cells,Circulating CD3+ve T cell count at 4 months post-SCT|Incidence of grade II-IV acute and chronic GVHD|Time to recovery of normal T-cell (>700/uL) and CD4 (>300/uL) counts and normal TCR diversity as assessed by Vb spectratyping|In vitro anti-viral responses of circulating PBMC|Transplant related mortality at 1 year post-SCT|Disease-free survival at 1 year post-SCT,"University College, London|Medical Research Council",All,"16 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,37.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,UCL/11/0519|2013-000872-14|MR/K007491/1,2014-07-01,January 2020,2020-01-01,"April 9, 2013",,"July 21, 2022","University College London Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT01827579,2010.0,Not Industry Lead,Less than three Conditions,Randomized,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
1210,1211,NCT00825487,Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies,,Completed,No Results Available,"Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies",Drug: ARQ 621,"To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 621 administered intravenously.|To determine the pharmacokinetic profile of ARQ 621.|To determine the pharmacodynamic profile (incl. biomarkers) of ARQ 621.|To assess the preliminary anti-tumor activity of ARQ 621.","ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)",All,"18 Years and older   (Adult, Older Adult)",Phase 1,50.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ARQ 621-101,2009-08-01,May 2011,2011-09-01,"January 21, 2009",,"October 19, 2011","Translational Genomics Institute, Phoenix, Arizona, United States|Premiere Oncology, Santa Monica, California, United States|Boston, Massachusetts, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States",,https://ClinicalTrials.gov/show/NCT00825487,761.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1211,1212,NCT00496860,Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies,,Completed,Has Results,Progressive Metastatic Malignancies,Biological: ALT-801,The Safety and Toxicity of ALT-801 in Patients With Progressive Metastatic Malignancies|The Maximum-tolerated Dose (MTD) of ALT-801|Clinical Antitumor Response to ALT-801|ALT-801 Induced Cell-mediated Immune Responses|Immunogenicity of ALT-801,Altor BioScience,All,"18 Years and older   (Adult, Older Adult)",Phase 1,26.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA-ALT-801-01-06,2007-05-01,October 2009,2009-10-01,"July 4, 2007","July 15, 2013","July 22, 2013","University of Colorado, Anschutz Cancer Pavillion, Aurora, Colorado, United States|MD Anderson Cancer Center Orlando, Orlando, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|University of Washington, Seattle Cancer Care Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00496860,884.0,Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1212,1213,NCT00375245,Rapamycin With Grapefruit Juice for Advanced Malignancies,,Completed,No Results Available,Tumors|Neoplasm Metastasis,Drug: Rapamycin (sirolimus)|Other: Grapefruit Juice,Pharmacokinetic interaction,University of Chicago,All,"18 Years and older   (Adult, Older Adult)",Phase 1,41.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14435B,2006-09-01,May 2009,2012-05-01,"September 12, 2006",,"January 17, 2014","University of Chicago Hospitals, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00375245,2069.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1213,1214,NCT00452374,"Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL",,Completed,Has Results,Leukemia,Drug: Cytarabine|Drug: Fludarabine|Drug: Oxaliplatin|Drug: Rituximab,Maximum Tolerated Dose (MTD) Oxaliplatin|Number of Participants With a Complete Response or Partial Response,M.D. Anderson Cancer Center|Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,48.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2004-0373,2004-11-01,January 2011,2011-01-01,"March 27, 2007","August 29, 2011","November 2, 2011","University of California-San Diego, La Jolla, California, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00452374,2252.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1214,1215,NCT01682746,Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors,,Completed,No Results Available,"Brain Tumor, Recurrent",Drug: Photofrin (porfimer sodium) & photodynamic therapy.,Maximum tolerable dose (MTD) of Photofrin® in pediatric subjects|Brain tumor response,"Harry T Whelan, MD|Pinnacle Biologics Inc.|Medical College of Wisconsin",All,"6 Months to 18 Years   (Child, Adult)",Phase 1,5.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,163588-1,2013-03-01,"June 29, 2018",2018-06-29,"September 11, 2012",,"February 25, 2019","Children's Hospital of Wisconsin, Wauwatosa, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01682746,1946.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1215,1216,NCT01344707,Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS),,Completed,No Results Available,Advanced Hematologic Malignancies,Drug: 4SC-202,Determination of Dose Limiting Toxicities of 4SC-202|Determination of Safety of 4SC-202|Determination of Pharmacokinetic Profile of 4SC-202|Determination of Maximum Tolerated Dose of 4SC-202|Determination of Tolerability of 4SC-202|Assessment of potential anticancer activity of 4SC-202|Histone deacetylase (HADAC) inhibition in peripheral mononuclear cells|Histone acetylation in peripheral mononuclear cells|Gene expression analysis in peripheral blood|Cytokine and miRNA levels in plasma,4SC AG,All,"18 Years and older   (Adult, Older Adult)",Phase 1,36.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4SC-202-1-2010,2011-03-01,March 2015,2015-03-01,"April 29, 2011",,"April 1, 2015","Universiätsklinikum Köln, Köln, Germany|Robert-Bosch-Krankenhaus, Stuttgart, Germany|Universitätsklinikum Würzburg, Würzburg, Germany",,https://ClinicalTrials.gov/show/NCT01344707,1461.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1216,1217,NCT01262235,A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients,,Completed,No Results Available,Cancer|Neuroendocrine Tumors|NET|Adrenocortical Carcinoma|ACC,Drug: TKM-080301,Safety and tolerability of treatment with TKM-080301|Determine dose-limiting toxicities and maximum tolerated dose of TKM-080301|Characterize the pharmacokinetics of TKM-080301|Assess preliminary evidence of anti-tumor activity,Arbutus Biopharma Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,68.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TKM-PLK1-001,2010-12-01,July 2015,2015-08-01,"December 17, 2010",,"January 16, 2019","Scottsdale Healthcare Research Institute, Scottsdale, Arizona, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|Moffitt Cancer Center, Tampa, Florida, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Westchase Oncology Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01262235,1704.0,Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1217,1218,NCT00048880,Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein,,Completed,No Results Available,Neoplasms,Drug: HeFi-1 Monoclonal Antibody,,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",Phase 1,9.0,NIH,Interventional,Primary Purpose: Treatment,030038|03-C-0038,2002-11-05,"July 2, 2008",2008-07-02,"November 11, 2002",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00048880,2066.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
1218,1219,NCT00654160,"Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer",,Completed,No Results Available,Anal Cancer|Carcinoma of the Appendix|Colorectal Cancer|Esophageal Cancer|Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Gastric Cancer|Gastrointestinal Carcinoid Tumor|Gastrointestinal Stromal Tumor|Liver Cancer|Pancreatic Cancer|Small Intestine Cancer,Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Other: pharmacogenomic studies|Other: pharmacological study,Maximum tolerated dose of genotype-based dosing of FOLFIRI with or without monoclonal antibody therapy|Response rate of genotype-based dosing in the subset of patients that has colorectal cancer,Mayo Clinic|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1,7.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment,CDR0000592931|P30CA015083|MC064G|NCI-2009-01216,2008-06-01,November 2010,2012-12-03,"April 7, 2008",,"May 25, 2017","Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00654160,1646.0,Not Industry Lead,More than three Conditions,Randomized,None-Crossover Assignment,N/A,Treatment/Diagnostic
1220,1221,NCT00003867,Irinotecan and Capecitabine in Treating Patients With Solid Tumors,,Completed,No Results Available,Cancer,Drug: capecitabine|Drug: irinotecan hydrochloride,,Montefiore Medical Center|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1,30.0,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000067031|P30CA013330|AECM-1199903068|NCI-V99-1541,1999-03-01,March 2003,2003-03-01,"February 16, 2004",,"September 10, 2018","Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT00003867,1461.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,N/A,Treatment/Diagnostic
1223,1224,NCT02175433,"A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies",,Completed,No Results Available,Relapsed Lymphoid Malignancy|Refractory Lymphoid Malignancy,Drug: AGS67E,"Incidence and nature of adverse events|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Concentration at the end of infusion (CEOI)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Maximum observed concentration (Cmax)|Pharmacokinetic parameter for Monomethyl Auristatin E (MMAE): Time to maximum concentration (Tmax)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Partial area under the serum concentration-time curve after first dose and as appropriate (AUC0-21)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Terminal or apparent terminal half-life (t1/2)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Systemic clearance (CL)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Volume of distribution at steady state (Vss)|Incidence of Anti-Drug Antibody (ADA) formation to the fully human monoclonal antibody (AGS67C) and antibody-drug conjugate (AGS67E)|Incidence of tumor response|Objective response rate (ORR)","Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",All,"18 Years and older   (Adult, Older Adult)",Phase 1,71.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AGS67E-14-1,2014-10-14,"October 29, 2019",2019-10-29,"June 26, 2014",,"December 1, 2020","Site US0006, Duarte, California, United States|Site US0002, Stanford, California, United States|Site US0004, Fairway, Kansas, United States|Site US0001, New York, New York, United States|Site CA0005, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT02175433,1841.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1224,1225,NCT04723602,"Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults",,Completed,No Results Available,Ebola Virus Disease|Marburg Virus Disease,Biological: cAd3-Marburg|Biological: cAd3-EBO-S,Safety of Ebola and Marburg vaccines assessed by clinical observation.|Safety of Ebola and Marburg vaccines assessed by change from baseline in levels of Complete Blood Count (CBC).|Safety of Ebola and Marburg vaccines assessed by change from baseline in levels of Creatinine.|Safety of Ebola and Marburg vaccines assessed by change from baseline in levels of Alanine Transaminase (ALT).|Safety of Ebola and Marburg vaccines assessed by adverse experiences.|Safety of Ebola and Marburg vaccines assessed by serious adverse experiences.|Evaluation of antibody response to cAd3-EBO-S and cAd3 Marburg vaccines|Collection of sufficient post-vaccination plasma to support further development of filovirus assays.,Albert B. Sabin Vaccine Institute|ICON plc|Oklahoma Blood Institute,All,18 Years to 50 Years   (Adult),Phase 1,32.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Sabin 001,2021-01-06,"December 14, 2021",2021-12-14,"January 26, 2021",,"August 3, 2022","Oklahoma Blood Institute (OBI), Oklahoma City, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT04723602,342.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Other/Basic/Prevention
1225,1226,NCT02145403,Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies,,Completed,Has Results,Hematologic Malignancies|Relapse|Graft-Versus-Host Disease,Drug: Carfilzomib|Drug: Tacrolimus,"Phase I: Maximum Tolerated Dose (MTD) of Carfilzomib|Phase II: Kaplan-Meier Estimate of the Percentage of Patients Who Are Alive and Have Not Developed Any ""Event""|Phase II: Kaplan-Meier Estimate for Progression/Relapse-free Survival Time|Phase II: Kaplan-Meier Estimate for Overall Survival Time|Number of Regimen Related Toxicities (RRTs)|Phase II: Cumulative Incidence of Acute GVHD|Phase II: Cumulative Incidence of Chronic GVHD|Phase II: Cumulative Incidence of Non-relapse Mortality",University of Michigan Rogel Cancer Center,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,53.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UMCC 2014.010|HUM00084170,2014-10-01,"November 26, 2018",2020-10-16,"May 22, 2014","January 6, 2020","January 3, 2022","University of Michigan Hospital, Ann Arbor, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02145403/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02145403,2207.0,Not Industry Lead,Three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1226,1227,NCT00506857,Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support,,Completed,Has Results,Hematologic Malignancies,Drug: Busulfan|Drug: Fludarabine,Maximum Tolerated Dose (MTD)|Number of Participants With Graft Versus Host Disease (GVHD),M.D. Anderson Cancer Center,All,"up to 75 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,82.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DM99-251,2003-11-01,August 2011,2011-08-01,"July 25, 2007","February 28, 2012","February 28, 2012","UT MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00506857,2830.0,Not Industry Lead,Less than three Conditions,N/A,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1227,1228,NCT00056966,Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases,,Completed,No Results Available,Hematologic Malignancy,Drug: ANTI-CD45|Drug: CAMPATH-1H|Drug: FK506|Drug: Fludarabine|Radiation: Total Body Irradiation|Procedure: Stem cell infusion,"Assess safety and feasibility of monoclonal abs directed to CD45 and CD52 antigens, Fludarabine and low dose TBI, as a non-myeloablative preparatory regimen for allo HSCT. This will be determined by 100d Non-relapse mortality and 100d Graft rejection|To obtain a preliminary estimate of the efficacy of this therapy as defined by: Complete remission at day 100 and One-year disease free survival.","Baylor College of Medicine|The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",All,"Child, Adult, Older Adult",Phase 1|Phase 2,24.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12472|ACHE,2002-11-01,May 2005,2006-12-01,"March 27, 2003",,"June 29, 2012","Texas Children's Hospital, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00056966,1491.0,Not Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
1228,1229,NCT00004911,Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction,,Completed,No Results Available,"Colorectal Cancer|Constipation, Impaction, and Bowel Obstruction|Gastric Cancer|Gastrointestinal Carcinoid Tumor|Gastrointestinal Stromal Tumor|Quality of Life|Small Intestine Cancer",Procedure: bowel obstruction management|Procedure: quality-of-life assessment,,Northwestern University|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,,Other|NIH,Interventional,Primary Purpose: Supportive Care,NU 98CC3|NU-98CC3|NCI-G00-1704,2000-01-01,February 2003,2003-02-01,"May 14, 2003",,"June 6, 2012","Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00004911,1127.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Supportive Care
1229,1230,NCT00004910,Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction,,Completed,No Results Available,"Colorectal Cancer|Constipation, Impaction, and Bowel Obstruction|Extrahepatic Bile Duct Cancer|Gastric Cancer|Gastrointestinal Carcinoid Tumor|Gastrointestinal Stromal Tumor|Pancreatic Cancer|Quality of Life|Small Intestine Cancer",Procedure: bowel obstruction management|Procedure: quality-of-life assessment,,Northwestern University|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,,Other|NIH,Interventional,Primary Purpose: Supportive Care,NU 98CC2|NU-98CC2|NCI-G00-1703,2000-01-01,February 2003,2003-02-01,"May 9, 2003",,"June 6, 2012","Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00004910,1127.0,Not Industry Lead,More than three Conditions,N/A,None-Crossover Assignment,N/A,Supportive Care
1230,1231,NCT01240720,A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer,,Completed,No Results Available,Cancer,Drug: 131I-F16SIP Radioimmunotherapy (RIT),"Phase I: Maximum tolerated Dose|Phase II: Antitumour activity|Phase I: Study of the variation of radioactivity of 131I or 124I in whole blood, at several time intervals (Pharmacokinetics)|Phase II: Adverse Events as a Measure of Safety|Phase II: Overall Response Rate (ORR)|Phase II: Progression free survival (PFS)|Phase II: Survival rate",Philogen S.p.A.|Eudax S.r.l.,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,65.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PH-F16SIPI131-06/07,2008-09-01,November 2011,2013-04-01,"November 15, 2010",,"February 25, 2014","University Hospital Pisa, Pisa, Tuscany, Italy|Policlinico S. Orsola-Malpighi- Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy|ASUR Zona Territoriale 9, Medicina Nucleare Ospedale di Macerata, Macerata, Italy|Irst - Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori - Meldola (Fc), Meldola, Italy|Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale Di Napoli, Napoli, Italy|Arcispedale Santa Maria Nuova Di Reggio Emilia, Reggio Emilia, Italy",,https://ClinicalTrials.gov/show/NCT01240720,1673.0,Industry Lead,Less than three Conditions,Non-Randomized,None-Crossover Assignment,None (Open Label),Treatment/Diagnostic
